2018 AAN Annual Meeting Science Program by American Academy of Neurology

â&#x20AC;&#x2030;ADVANCING NEUROLOGY. ADVANCING YOU.

2018 SCIENCE PROGRAM

EARLY REGISTRATION DEADLINE: MARCH 29, 2018

}Registration } }Annual } Meeting Schedule }Abstracts } AAN.com/view/AM18

MAKE THE MEETIN Your Single-registration Rate = Optimum Value and Flexibility

ADVANCING NEUROLOGY. ADVANCING YOU. 2

2018 AAN Annual Meeting

NG ALL YOUR OWN Register Early to Save Register once—no pre-registration required for most individual courses* Choose from 200+ expert-led courses and customize your schedule any way you want Explore courses, sessions, experiential learning areas—and even networking and social events—at your convenience Early Registration

(Before March 29, 2018)

Student Senior/Honorary Member Junior Member + Non-Neurologist Member † Member ‡ Nonmember

$0 $0 $245 $420 $720 $1,220

Late Registration

(After March 29, 2018)

$0 $0 $335 $570 $980 $1,660

Early Gold** Registration (Before March 29, 2018)

$199 $399 $444 $619 $1,119 $1,819

Late Gold** Registration (After March 29, 2018)

$199 $399 $534 $769 $1,379 $2,259

Junior Member: Junior, Intern Non-Neurologist Member: Advanced Practice Provider, Business Administrator, Researcher ‡ Member: Neurologist, Physician Affiliate †

*Some courses require pre-registration, may have a separate registration fee, and are subject to closure due to reaching maximum capacity. **Includes access to Annual Meeting On Demand

Early Registration Deadline March 29

AAN.com/view/AM18

CONTENTS “Best of” Scientific Platform Sessions . . . . . 91

INTRODUCTION Registration . . . . . . . . . . . . . . . . 6

ANNUAL MEETING OVERVIEWS Meeting-at-a-Glance Tear Out . . . . . . . . . 9 How to get the most from this Guide . . . . . 13 Annual Meeting Schedule Overview . . . . . 18 Saturday, April 21 . . . . . . . . . . 18 Sunday, April 22 . . . . . . . . . . . 20 Monday, April 23 . . . . . . . . . . . 22 Tuesday, April 24 . . . . . . . . . . . 24 Wednesday, April 25 . . . . . . . . . 27 Thursday, April 26 . . . . . . . . . . 29 Friday, April 27 . . . . . . . . . . . 31

Scientific Platform Sessions . . . . . . . . . 95 Sunday, April 22 . . . . . . . . . . 96 Monday, April 23 . . . . . . . . . . 100 Tuesday, April 24 . . . . . . . . . . 104 Wednesday, April 25 . . . . . . . . 108 Thursday, April 26 . . . . . . . . . 112 Friday, April 27 . . . . . . . . . . . 116 Poster Sessions . . . . . . . . . . . . . . 120 Poster Session I . . . . . . . . . . 122 Poster Session II . . . . . . . . . . 132 Poster Session III . . . . . . . . . . 142 Poster Session IV . . . . . . . . . . 152 Poster Session V . . . . . . . . . . 162 Poster Session VI . . . . . . . . . . 172

2018 Programs Listed By Topic . . . . . . .

70th Annual Meeting Exhibitors . . . . . . . 183

2018 Program Tracks . . . . . . . . . . . .

2018 Award Recipients . . . . . . . . . . . 184 2018 Research Program Recipients . . . . .

ANNUAL MEETING SESSIONS Plenary Sessions . . . . . . . . . . . . . Hot Topics Plenary Session . . . . . . 60 Presidential Plenary Session . . . . . . 61 Contemporary Clinical Issues Plenary Session . . . . . . . . . . . 62 Clinical Trials Plenary Session . . . . . . 63 Frontiers in Neuroscience Plenary Session 64 Controversies in Neurology Plenary Session 65 Neurology Year in Review: Emerging Therapies Plenary Session . . 66

HIGHLIGHTS AND FEATURES Experience Unique Opportunities for Students, Residents, and Fellows . . . . . . 190 Connect at Social Events . . . . . . . . . . 192 2018 Annual Meeting On Demand . . . . . . 194

ANNUAL MEETING INFORMATION General Information . . . . . . . . . . . . 196

Experiential Learning Areas . . . . . . . . . 67 HeadTalks . . . . . . . . . . . . . 68 Live Well: Taking Care of Your Patients Starts with Taking Care of You! . . . . . 70 Maximize Your Value / Advocacy to Action . 72 Navigating Your Career . . . . . . . . 74 Research Corner: Moving Neurology Forward . . . . . . . . . . . . . . 76 The Member Experience . . . . . . . 78 Neuroscience in the Clinic Sessions . . . . . Sunday, April 22 . . . . . . . . . . 80 Monday, April 23 . . . . . . . . . . . 82 Tuesday, April 24 . . . . . . . . . . . 82 Wednesday, April 25 . . . . . . . . . 83 Thursday, April 26 . . . . . . . . . . 84 Friday, April 27 . . . . . . . . . . . 85

Invited Science Sessions . . . . . . . . . .

Hotel and Reservations . . . . . . . . . .

2018 AAN Annual Meeting

201

Travel Information . . . . . . . . . . . . . 206 Meeting Information and Contacts . . . . .

March 2, 2018

Annual Meeting Hotel Reservation Deadline

March 29, 2018

Annual Meeting Early Registration Deadline

Location

Los Angeles Convention Center

Headquarter Hotel

JW Marriott Los Angeles L.A. LIVE

AAN.com/view/AM18

Current as of February 15, 2018. Program Subject to change

188

207

SPECIAL PRESENTATION Bennet Omalu, MBBS, MPH, MBA

Don’t Break the Rules, Change the Game: How Bennet Omalu SingleHandedly Changed American Football, Professional Sports, and How the World Perceives Traumatic Brain Injuries Tuesday, April 24, 1:00 p.m.–2:15 p.m. As chronicled in the 2015 film “Concussion,” Bennet Omalu’s story is one of triumph in the face of seemingly insurmountable odds. Born in eastern Nigeria during a civil war, Omalu and his family lived as refugees, yet he entered medical school at age 15 and became a physician by age 21. Steven DeKosky, MD, FAAN, FANA, FACP, is the Deputy Director of the McKnight Brain Institute in Gainesville, FL. In 2002, he was introduced to Dr. Omalu at the University of Pittsburgh. After looking at the case of the late Pittsburgh Steeler Mike Webster, they together confirmed the first case of dementia pugilistica/chronic encephalopathy in an American football player. Four more cases followed. As the first doctors to identify chronic brain damage as a major factor in the deaths of some professional athletes, DeKosky and Omalu withstood dismissals, backlash, and pressure from peers and the National Football League. Omalu’s new memoir, Truth Doesn’t Have a Side, will be available for purchase both before and after his presentation. Following Omalu’s presentation, he will be joined by DeKosky for a panel discussion.

April 21–27 • Los Angeles

Natalia S. Rost, MD, MPH, FAHA, FAAN Chair, Science Committee

To me, science is the most dynamic element of the Annual Meeting. It’s exciting. Cutting-edge. All-encompassing. Moreover, our vision for science at the Annual Meeting is to deliver it in an effective and engaging way, as to maximize our reach to the community of neurologists and neuroscientists we serve. And the 2018 Annual meeting promises to be the most exciting showcase of the best and the brightest in neurologic science yet! I am always excited about the meeting’s plenary sessions, which offer an unprecedented breadth and depth of science. We are thrilled to welcome NIH Director Dr. Francis Collins as this year’s Presidential lecturer, as he underlines the advances in neuroscience in the era of the BRAIN initiative, the importance of support for public research funding, the excitement of what’s yet to come in neurologic discoveries, and the promise of cures for our patients. The other plenary sessions cover every subspecialty on a daily basis and present a comprehensive array of the latest and groundbreaking developments in the field. I am also particularly proud of the Neuroscience in the Clinic (NIC) sessions, which first premiered in 2017 and received glowing reviews! The NICs were developed to encourage a dialogue between clinicians and scientists, the bi-directional flow of expertise and innovation, which brings meaning and purpose to the clinical applications of scientific discoveries—and, ultimately, benefits our patients. This type of exchange is only possible at the AAN Annual Meeting, where the clinical neurology and neuroscience worlds come together, and we hope you will join us for this unique experience! Finally, I am excited about the return of our Research Corner, one of the seven Experiential Learning Areas. (ELA) You have not fully experienced the Annual Meeting if you have not attended one of these most dynamic, motivating, and innovative “open” formats that the Annual Meeting has to offer! Our Research Corner ELA has been a particular hit with neurology trainees and junior faculty, who gained advice from our colleagues in the NINDS Career Development program, learned the tricks of grant writing, contemplated the complexity of the FDA regulations, and cheered on their colleagues presenting prize-winning abstracts. I will be stopping by Research Corner daily—and I encourage my colleagues to join us there as well!

SEE WHAT’S NEW! ■

Presidential Lecture by Francis S. Collins, MD, PhD, Director of National Institutes of Health:

■

This course will highlight dramatic changes in the management of acute ischemic stroke (AIS) that will impact the workforce, residency, staffing, and other aspects of the neurology profession and practice. These changes are based on the 2017 DAWN study, 2018 DEFUSE-3 study, and American Heart Association and the American Stroke Association’s new guidelines for early management of AIS, which the AAN recently affirmed, with recommendations to treat eligible patients for up to 24 with thrombectomy. Be sure to attend the Clinical Trials Plenary Session on Tuesday, April 25 to learn about the science behind the DEFUSE-3 study.

“California Dreaming: BRAIN and Precision Medicine in 2018”

■

Joint American Heart Association/American Stroke Association Session

A two-hour program will examine disparities in stroke care including bridging racial and ethnic disparities in the management of stroke and breakthroughs in engaging minority and rural communities in stroke studies.

■

BRAIN Initiative Session

This program will feature the latest findings from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, a large-scale effort aimed at revolutionizing our understanding of the human brain. Launched in 2013 by President Obama as a “moonshot to explore the frontiers of the mind,” this program seeks development of the technologies and insights to facilitate preventions, treatments, and cures of brain disorders.

Hot Topics in Stroke Education and Practice

■

Controversies in Neurology Plenary Session—Based on Member Suggestions!

For the first time, AAN members weighed in what they would like to see presented at this year’s session. Two memberchosen topics have been selected for presentation this year. Come hear about: Would You Let Your Child Play Contact Sports? and Should the Neurologist Be Primarily Responsible For Taking Care of Patients With Functional Disorders?

■

Expanded Use of Pulse Audience Response System

This popular, interactive response system will be making its way to the Hot Topics, Clinical Trials, and Controversies in Neurology Plenary Sessions, allowing audience members to submit questions directly to the moderators. In the Controversies in Neurology Plenary, audience members will be able to weigh in on which side of the debate they support.

■

New E-poster Set-up

Twelve semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for 12 different E-posters each day!

Special Presentation by Bennet Omalu, MBBS, MPH, MBA; and Steven DeKosky, MD, FAAN, FACP

As chronicled in the 2015 film “Concussion,” find out how Omalu and DeKosky changed American football, professional sports, and how the world perceives traumatic brain injury when together they confirmed the first case of dementia pugilistica/chronic encephalopathy in an American football player.

Anniversary Party

Secure Your Ticket(s) Before March 29! Join us on Sunday, April 22, from 7:00 p.m.to 11:00 p.m.at Universal Studios to celebrate 70 years of the AAN! A limited quantity of free tickets are available to the first 4,000 registered Annual Meeting attendees who reserve them in advance. Once free reserved tickets have been claimed you can still purchase a ticket for $115 each until March 29. Tickets include transportation to/ from the event, delicious food and beverages, and access to Universal Studios, including rides.

Reserve your ticket—and purchase additional tickets—before March 29 at AAN.com/view/AM18.

Tickets must be picked up at the Los Angeles Convention Center by 2:00 p.m. on Sunday, April 22; pre-reserved gratis tickets that are not picked up will be released for rush line.

REGISTRATION Plan Your Meeting Experience The 70th AAN Annual Meeting registration site makes planning your week as easy as 1-2-3:

Use the handy Meeting-at-a-Glance starting on page 9 » of this book to plan your week, incorporating your favorite education programs, scientific sessions, and other Annual Meeting social and informational events.

Show up and experience the excellence of the world’s largest and most vibrant gathering of neurologists!

WAYS TO REGISTER

REGISTRATION OPTIONS

Online

Annual Meeting Registration

AAN.com/view/register

The single meeting registration fee is mandatory for all registrants and is determined by AAN member type at the time of the meeting, not at registration.

Telephone US/Canada: (800) 676-4226 International: (415) 979-2283

Registration Deadline: March 29, 2018 Registrations received after March 29, 2018, will be processed at a higher rate.

Hotel Reservation Deadline: March 2, 2018 For questions go to aanam.cmrushelp.com To obtain a registration form to pay by check, please contact CMR. Registration forms will only be accepted for check payments.

To qualify for the member registration rate, your 2018 membership dues must be paid by April 21, 2018. Failure to do so will result in a balance due.

Gold Registration Upgrade your meeting registration to include access to Annual Meeting On Demand.

WAYS TO SAVE }} Renew your AAN membership or join the AAN for maximum registration savings. Visit AAN.com/view/membership. }} Register by the March 29, 2018, early registration deadline to avoid increased rates after this date.

Look for this seal to ensure you are booking through the AAN’s official housing vendor, CMR, and avoid fraudulent sites by only booking on sites where you see this seal.

2018 AAN Annual Meeting

ADDITIONAL INFORMATION

Kosher meals may be provided at any lunch and must be arranged on or before March 29, 2018, through the registration website or by contacting AAN Registration/CMR at aanam.cmrushelp.com, (800) 676-4226, or (415) 979-2283. There is a $50 surcharge per kosher meal. On-site requests cannot be accommodated. There are no refunds for kosher meals.

Cancelled or Closed Programs Programs may be closed due to reaching maximum capacity or cancelled due to insufficient enrollment. In the event of cancellation, registration for the cancelled course will be fully refunded for courses that have a separate registration fee. The AAN is not responsible for airfare, hotel, or other costs incurred by participants in the event of program or registration closure or cancellation.

Group Registration Deadline: March 29, 2018 Group registrations are those in which 10 or more individuals’ fees are paid for with one check or credit card. Special registration instructions are available online at AAN.com/view/register or by contacting CMR’s Group Registration at (800) 676-4226 (US/Canada) or (415) 979-2283 (International) or aanam.cmrushelp.com. See page 201 » for housing information.

Cancellations/Refunds of Registration Until March 29, 2018—Refund less $100 administrative fee March 30–April 14, 2018—Refund less $200 administrative fee After April 14, 2018—No refund •• All cancellations must be submitted in writing to aanam.cmrushelp.com or faxed to (415) 293-4071. •• No-shows will not receive a refund. •• Name substitutions are not permitted. •• No refunds will be processed for amounts of $20 or less.

What Is Not Included with Annual Meeting Registration? While the single registration rate provides an exceptional value, some courses require pre-registration, may have a separate registration fee, and are subject to closure due to reaching maximum capacity. For information on pricing please visit AAN.com/view/register.

Special Accommodations Deadline: March 29, 2018 The Los Angeles Convention Center and the AAN strive to accommodate all visitors. Information booths, designated parking, and assisted listening devices are available. If you require special accommodation to attend the Annual Meeting, submit your request while registering online or contact Jill Zelinsky no later than March 29, 2018, at JZelinsky@aan.com or (612) 928-6049.

REGISTRATION RATES Note: All prices in US dollars

Early Registration (Before March 29, 2018)

Late Registration (After March 29, 2018)

Early Gold Registration4 (Before March 29, 2018)

Late Gold Registration4 (After March 29, 2018)

Student

$199

Senior/Honorary Member

$399

Junior Member

$245

$335

$444

$534

Non-neurologist Member

$420

$570

$619

$769

Neurologist Member

$720

$980

$1,119

$1,379

Nonmember

$1,220

$1,660

$1,819

$2,259

1 2

1 Junior, Intern 2 Researcher, Advanced Practice Provider, Business Administrator 3 Neurologist, Physician Affiliate 4 Includes Access to Annual Meeting on Demand

AAN.com/view/AM18

BEGIN PLANNING YOUR 2018 ANNUAL MEETING EXPERIENCE NOW. Download the new AAN Conferences Mobile App now to put all the information you need for the 2018 Annual Meeting conveniently on your phone or tablet: • Access program details, speakers, and materials • Customize your program schedule • View the hotel map • Explore the Los Angeles City Guide • Find and connect with other conference attendees • Submit your evaluations and claim CME Available for iPhone ®, iPad ®, or Android ®

NEW AAN Conferences App

Sponsored by

TUESDAY April 24 11:30 a.m.–4:00 p.m.

WEDNESDAY April 25 11:30 a.m.–3:00 p.m.

INNOVATION HUB Located in the center of the Exhibit Hall, this new area will offer dynamic, interactive opportunities to expand your mind into new ways of thinking about your practice, your patients, and the future of neurology. Wine & Paint Sessions will take place daily to allow you to relax, interact, and learn in a novel way

SUNDAY April 22

12:00 p.m.–12:30 p.m.

Welcome to the Exhibit Hall

1:00 p.m.–2:00 p.m.

Korak Sarkar, MD The M3D Lab: 3d Printing, VR and AR in Medicine

2:00 p.m.–2:30 p.m.

Raghav Govindarajan, MD, FAAN Integrating Teleneurology into your Practice-a Hands on Training’

Teleneurology Displays will let you test with colleagues how telemedicine works—and decide if it is a good fit for your practice

1:00 p.m.–1:30 p.m.

Allen Gee, MD, PhD, FAAN Democratizing Technology in Healthcare

2:00 p.m.–2:30 p.m.

Jose Posas, MD Concussion: There’s an App for That

3:00 p.m.–3:30 p.m.

Jaime Hatcher-Martin, MD Telemovement: Using Telemedicine in an Outpatient Neurology Setting

4:30 p.m.–6:00 p.m.

Brainstorm: A Competition for the Innovator in All of Us!

Displays and Presentations from topic experts will showcase new ideas and new ways of thinking about neurology

12:00 p.m.–12:30 p.m.

David Evans, MBA Allison Weathers, MD, FAAN Using Technology to Enhance Patient Engagement

12:30 p.m.–1:00 p.m.

Allen Gee, MD, PhD, FAAN Back to the Future, Innovations Revisiting Neurohealth Space

1:00 p.m.–1:30 p.m.

Brad Klein, MD, MBA, FAAN Get Paid for Your Mental Status Exams... Use App Technology to Innovate What You Do

WEDNESDAY

11:30 a.m.–12:00 p.m.

Do you have an innovative idea that would transform the face of neurology through business, technology, education, or public health? Apply to pitch your idea at this Innovation Hub game show-style event! Finalists will be invited to present their ideas live to a panel of judges. The panel will provide feedback and finalists will get the unique opportunity to refine and improve their ideas for the future.

1:00 p.m.–1:30 p.m.

12:00 p.m.–12:30 p.m.

TUESDAY 11:30 a.m.–12:00 p.m.

1:30 p.m.–2:00 p.m.

3:00 p.m.–4:00 p.m.

Daniel Potts, MD, FAAN Hand in Hand with Art and Advocacy

MONDAY April 23

Jennifer Bickel, MD, FAAN Relaxation Tools: See One, Do One, Teach One Jack W. Tsao, MD, DPhil, FAAN Your Practice a Decade in the Future

12:30 p.m.–1:00 p.m.

Tanuja Chitnis, MD, FAAN Innovations for Multiple Sclerosis Monitoring and Care

April 24

David Evans, MBA Eric Cheng, MD, MS, FAAN Clinical Decision Support for Ordering of Diagnostic Imaging

April 25

11:30 a.m.–12:00 p.m.

Elaine Jones, MD, FAAN Balancing Business and Wellness: NonTraditional Work Settings

12:00 p.m.–12:30 p.m.

Anup Patel, MD, FAAN Utilizing Wearable Technology to Improve Neurological Care Lyell Jones, MD, FAAN Using Axon Registry to Improve Your Practice Jennifer Bickel, MD, FAAN Acupuncture FAQ

ANNUAL MEETING TOPIC LIST

2018 PROGRAMS LISTED BY TOPIC Aging, Dementia, Cognitive, and Behavioral Neurology

11:30 a.m.–7:00 p.m.

P2 Poster Session II

Behavioral and Cognitive Neurology: Genes, Environment, and Interventions

Saturday, April 21

7:00 a.m.–9:00 a.m.

Genetic and Basic Science Studies in Neurodegenerative Diseases

C1 Mild Cognitive Impairment: Implications for Clinicians

9:30 a.m.–11:30 a.m.

C10 More than Medicine: How to

Access Home Care, Support Caregivers, and Discuss Complex Situations in Advanced Neurologic Disease C13 Neuroimaging Biomarkers Across the Dementia Spectrum

4:15 p.m.–5:30 p.m.

Hot Topics Plenary Session: 4:35 p.m.–4:50 p.m. Brain Stimulation for Memory . 60

Sunday, April 22 7:00 a.m.–9:00 a.m.

C33 Clinicopathological Correlation Session in Dementia

11:30 a.m.–5:30 p.m.

Aging/Dementia/Cognitive

P1 Poster Session I

Clinical Issues in Dementia

P1.173–P1.180 . 125

Pathology Studies in Aging and Dementia

P1.181–P1.188 . 125

Vascular Risk Factors in Aging and Dementia

C80 Present and Future Biomarkers

How to Promote Healthy Cognitive Aging: What Should We Tell Our Patients and Ourselves? . . . . . . . . . 71

1:00 p.m.–3:00 p.m.

S2 Clinical Trials and

Therapeutic Approaches in Neurodegenerative Diseases . 96

Monday, April 23 7:00 a.m.–9:00 a.m.

C68 Cognitive Impairment Due to Alzheimer’s Disease: Using Old Skills and New Tools for Diagnosis and Treatment

34 2018 AAN Annual Meeting

7:00 a.m.–9:00 a.m.

C133 Higher Cortical Visual

Disorders: Case-based Review

C135 Neurocognitive Assessment for Neurologists

9:15 a.m.–11:30 a.m.

P4 Poster Session IV

2:00 p.m.–2:45 p.m.

Physical Exercise and Cognitive Training in Neurology: Application in Aging and Neurodegenerative Disease . . . . . . . . . . 71

3:30 p.m.–5:30 p.m.

C91 Chronic Traumatic

Encephalopathy: Update

Tuesday, April 24 7:00 a.m.–9:00 a.m.

11:30 a.m.–7:00 p.m.

P3 Poster Session III

Imaging Studies in Aging and Dementia

P3.173–P3.191 . 146

Language and Language Disorders

P3.192–P3.200 . 146

11:45 a.m.–12:35 p.m.

Aging and Dementia Poster Discussion Session P3.027–P3.036 143

1:00 p.m.–3:00 p.m.

N3 Neuroscience in the Clinic:

Challenges in Genetic Diagnosis in Neurology . . . . 82 C107 What Do I Do Now?: Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders C110 Neurologic Complications in Adults with Down Syndrome 3:30 p.m.–5:30 p.m.

C130 Disorders of Motor

Programming: The Apraxias and Action-Intentional Disorders Chalk Talk

Novel Biomarkers in Aging and Dementia

P4.173–P4.186 . 156

Biomarkers, Biology, Physiology

P4.187–P4.200 . 156

1:00 p.m.–3:00 p.m.

C145 Severe TBI: From ICU to Rehabilitation

C146 Non-Alzheimer’s Dementia I: Frontotemporal Dementias

3:30 p.m.–5:30 p.m.

S34 Behavioral and Cognitive

Neurology . . . . . . . . 110

C161 Non-Alzheimer’s Dementia

II: Lewy Body Dementias and Other Parkinsonian Dementias

C97 Vascular Cognitive Impairment and Dementia: Current Status and Future

Frontiers in Neuroscience Plenary Session: 9:35 a.m.–9:55 a.m. Does Connectomics Make Sense? . 64

11:30 a.m.–7:00 p.m.

in Dementia: A Case-based Approach

Behavioral and Cognitive Neurology: Other

12:00 p.m.–12:45 p.m.

Perception Is Reality: Are Neurologists Helping Patients Live Well with Dementia? . . . 71

1:00 p.m.–3:00 p.m.

P1.189–P1.196 . 125 P1.197–P1.200 . 126

P2.183–P2.200 . 136

12:25 p.m.–1:45 p.m.

1:30 p.m.–3:30 p.m.

C20 The Neurology of Social Behavior

P2.173–P2.182 . 136

Wednesday, April 25

Thursday, April 26 7:00 a.m.–9:00 a.m.

C181 Preventive Neurology: How

Neurologists Can Improve Outcomes That Matter to Patients

9:15 a.m.–11:30 a.m.

Controversies in Neurology Plenary Session: 9:15 a.m.–10:00 a.m. Should We Use Biomarkers Alone For Diagnosis of Alzheimer’s? . . 65

11:30 a.m.–7:00 p.m.

P5 Poster Session V

Cognitive Phenotypes in Aging and Dementia

P5.173–P5.193 . 165

Behavioral and Cognitive Neurology: Other II

P5.194–P5.200 . 166

1:00 p.m.–3:00 p.m.

C184 Behavioral Neurology I:

Network Anatomy of Behavior and Language C193 Assessment of Rapidly Progressive Dementias I: Overview, Prion Diseases, and Antibody-Mediated Rapidly Progressive Dementia

C198 Behavioral Neurology II:

Memory and Attention C208 Assessment of Rapidly Progressive Dementias II: Neurodegenerative Diseases and Infections Presenting as Rapidly Progressive Dementia

11:30 a.m.–5:30 p.m.

P1 Poster Session I

Neurology: Focus on Frontotemporal Degeneration

Friday, April 27 9:15 a.m.–11:30 a.m.

Neurology Year in Review: Emerging Therapies Plenary Session: 10:35 a.m.–10:55 a.m. Dementia . . 66

P1.210–P1.218 . 126

P1.219–P1.231 . 126

Intracerebral Hemorrhage

P1.232–P1.258 . 126

P6.173–P6.184 . 175

Healthcare and Caregiver Issues in Dementia

Behavioral and Cognitive Neurology: Other III

C66 Update on Medical

Management of Stroke

9:15 a.m.–11:30 a.m.

S48 Novel Biomarkers in Aging

and Dementia . . . . . . . 116

1:30 p.m.–3:30 p.m.

C22 Stroke in Young Adults and Women

Sunday, April 22 7:00 a.m.–9:00 a.m.

C30 Controversies in Stroke

Treatment and Prevention

8:00 a.m.–9:00 a.m.

S1 “Best of” Session:

Cerebrovascular Disease and Interventional Neurology . . . 92

Stroke Biomarkers and Animal Models

Cerebrovascular Genetics

Pre-Hospital, Telestroke and ED-Based Stroke Care II

1:00 p.m.–3:00 p.m.

Saturday, April 21

Outsmart Stress . . . . . . 71

Cerebrovascular Disease and Interventional Neurology

Stroke Epidemiology, Risk Factors, and Outcomes

P6.197–P6.200 . 176

based Approach

Ischemic Stroke . . . . . . 104

C116 Cerebrovascular Disease I: Prevention 3:30 p.m.–5:30 p.m.

C129 Cerebrovascular Disease II:

Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke

Wednesday, April 25 11:30 a.m.–7:00 p.m.

P4 Poster Session IV

Cerebrovascular Disease and Interventional Neurology I ePoster Session

P2.201–P2.223 . 136

P2.224–P2.240 . 136 P2.241–P2.250 . 137

P2.251–P2.258 . 137

1:00 p.m.–3:00 p.m.

S15 Cerebrovascular Disease

Epidemiology and Outcomes 101

C78 Therapeutic Temperature Modulation in the ICU

3:30 p.m.–5:30 p.m.

C94 Hot Topics in Stroke Education

and Practice . . . . . . . . 103

Tuesday, April 24 9:15 a.m.–11:30 a.m.

Clinical Trials Plenary Session: 9:30 a.m.–9:45 a.m. Expanding the Time Window for Thrombectomy: Results of the DEFUSE 3 Study . 63

11:30 a.m.–7:00 p.m.

P3 Poster Session III

Acute Stroke Imaging

P3.201–P3.214 . 146

P4.201–P4.229 . 156

P4.230–P4.258 . 157

P4.339–P4.344 . 159

Cerebrovascular Disease and Interventional Neurology II ePoster Session

11:45 a.m.–12:35 p.m.

Cerebrovascular Disease and Interventional Neurology Poster Discussion Session P4.027–P4.036 153

1:00 p.m.–3:00 p.m.

C151 Cerebrovascular Disease III:

Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke

3:30 p.m.–5:30 p.m.

C166 Cerebrovascular Disease IV: Telestroke

C244 Joint AAN and AHA/ASA Session

Thursday, April 26 11:30 a.m.–7:00 p.m.

P5 Poster Session V

Inpatient Stroke Care

P5.201–P5.213 . 166

Cerebrovascular Disease and Interventional Neurology: Large Artery Disease: Carotid, Basilar, Vertebral, Intracranial

P5.214–P5.233 . 166

P5.234–P5.248 . 167

X = Experiential Learning

P4.085–P4.090 . 154

Endovascular Treatment

TPA in Acute Ischemic Stroke

P2 Poster Session II

12:00 p.m.–12:45 p.m.

C238 Memory Disorders: A Case-

S21 Revascularization in Acute

Contemporary Clinical Issues Plenary Session: 9:15 a.m.–9:30 a.m. Retinal Microvasculature in Predicting Risk of Stroke Subtypes . . 62

P3.240–P3.258 . 147

1:00 p.m.–3:00 p.m.

11:30 a.m.–7:00 p.m.

P6.185–P6.196 . 175

3:30 p.m.–5:30 p.m.

P3.232–P3.239 . 147

Stroke Case Reports I

Stroke Clinic

Pre-Hospital, Telestroke and ED-Based Stroke Care III

P5.249–P5.258 . 167

AAN.com/view/AM18 35

Cerebrovascular/Interventional

Monday, April 23 7:00 a.m.–9:00 a.m.

P3.215–P3.231 . 146

Stroke Knowledge, Behavior, and Culture

P1.201–P1.209 . 126

3:30 p.m.–5:30 p.m.

Clinical Trials and Therapeutic Approaches in Neurodegenerative Diseases

P6 Poster Session VI

Pre-Hospital, Telestroke and ED-Based Stroke Care

Subarachnoid Hemorrhage and Intracranial Aneurysms

11:30 a.m.–5:30 p.m.

Subarachnoid Hemorrhage . . 99

C219 The Early-Onset Dementias

S10 Intracerebral and

7:00 a.m.–9:00 a.m.

Cerebral Venous Sinus Thrombosis (CVST)

C215 Case Studies in Behavioral

Post-Stroke Mood, Cognition, and Recovery

6:30 p.m.–9:30 p.m.

ANNUAL MEETING TOPIC LIST

3:30 p.m.–5:30 p.m.

ANNUAL MEETING TOPIC LIST

2018 PROGRAMS LISTED BY TOPIC 1:00 p.m.–3:00 p.m.

S40 Acute Stroke Care . . . . . . 112 C194 Actualización Sobre el Manejo del Ictus Cerebrovascular

Sunday, April 22 7:00 a.m.–9:00 a.m.

C28 Autism Spectrum Disorders

What We Know and Where We Are Going

3:30 p.m.–5:30 p.m.

C203 Endovascular Treatment

of Acute Stroke and Cerebrovascular Disease

9:15 a.m.–12:00 p.m.

Friday, April 27 7:00 a.m.–9:00 a.m.

C217 Current Management of

Incidental and Asymptomatic Cerebrovascular Lesions

9:15 a.m.–11:30 a.m.

Neurology Year in Review: Emerging Therapies Plenary Session: 10:55 a.m.–11:15 a.m. Finally, Some Closure on PFO Closure . . 66

11:30 a.m.–5:30 p.m.

P6 Poster Session VI

Stroke Case Reports II

Cerebrovascular and Cardiac Disease

P6.201–P6.235 . 176

P6.236–P6.249 . 176

Pre-Hospital, Telestroke and ED-Based Stroke Care IV

P1 Poster Session I

Neurogenetics and Metabolic Disease

Child Neurology

C19 Pediatric Neuro-

ophthalmology Update C22 Stroke in Young Adults and Women

Child Neurology - Staying on Track . . . . . . . . . . . 75

P2 Poster Session II

Child Neurology and Developmental Neurology ePoster Session

P2.085–P2.090 . 134

Child Neurology and Developmental Neurology: Epilepsy

P2.295–P2.305 . 138

Child Neurology and Developmental Neurology: Infectious, Inflammatory, and Autoimmune Disorders

P2.306–P2.321 . 138

Child Neurology and Developmental Neurology: Neuromuscular Disease

P2.322–P2.338 . 138

1:00 p.m.–3:00 p.m.

C73 Child Neurology II: Epilepsy and Neuromuscular

P3.302–P3.321 . 148

Child Neurology and Developmental Neurology: Neurodegenerative Disease

P3.322–P3.328 . 148

Clinical and Basic Science Observations

9:15 a.m.–11:30 a.m.

Contemporary Clinical Issues Plenary Session: 10:05 a.m.–10:20 a.m. Pediatric Brainstem Encephalitis Outbreak Investigation with Next-Generation Sequencing . . 62

P3.295–P3.301 . 148

Autism and Developmental Disabilities

Stroke, MS/Autoimmune

36 2018 AAN Annual Meeting

Acquired Brain Injury: Stroke, Traumatic Brain Injury

C64 Child Neurology I: Pediatric

11:30 a.m.–7:00 p.m.

1:30 p.m.–3:30 p.m.

P3 Poster Session III

7:00 a.m.–9:00 a.m.

Clinical Trials Plenary Session: 10:00 a.m.–10:15 a.m. Precision Medicine: Intracerebroventricular Enzyme Replacement Therapy with Cerliponase Alfa in Children with CLN2 Disease: Results from an Ongoing Multicenter Study . 63

11:30 a.m.–7:00 p.m.

Monday, April 23

Child Neurology and Developmental Neurology

Multiple Sclerosis in the Current Era

Autism Myth Busters . . . . 80

S54 Ischemic Stroke Prevention . . 118

C11 Treatment of Pediatric

9:15 a.m.–11:30 a.m.

P1.295–P1.313 . 128

11:30 a.m.–12:00 p.m.

9:30 a.m.–11:30 a.m.

Tuesday, April 24

N1 Neuroscience in the Clinic:

Ask Us Anything: Expert Panel on Stroke . . . . . . . . . 69

Saturday, April 21

TBI/Post-concussion

3:30 p.m.–5:30 p.m.

P6.250–P6.258 . 177

3:30 p.m.–5:30 p.m.

C86 Child Neurology III: Headache,

11:30 a.m.–5:30 p.m.

3:00 p.m.–4:00 p.m.

Presidential Plenary Session: 10:45 a.m.–11:15 a.m. Sidney Carter Award in Child Neurology: Spinal Muscular Atrophy Is a Treatable Neurodegenerative Disease . . 61

3:30 p.m.–5:30 p.m.

P3.329–P3.338 . 148

1:00 p.m.–3:00 p.m.

C110 Neurologic Complications in

Adults with Down Syndrome

3:30 p.m.–5:30 p.m.

C123 Child Neurology: A Casebased Approach

Wednesday, April 25 7:00 a.m.–9:00 a.m.

C141 Integrating Sleep Medicine Concepts into Your Child Neurology Practice

9:15 a.m.–11:30 a.m.

Frontiers in Neuroscience Plenary Session: 10:55 a.m.–11:15 a.m. Pediatric MS: A Unique Window into Environmental and Genetic Risk Factors for MS 64

1:00 p.m.–3:00 p.m.

S29 Child Neurology and

Developmental Neurology I . 108

3:30 p.m.–5:30 p.m.

S35 Child Neurology and

Developmental Neurology II . 110

Monday, April 23

9:15 a.m.–11:30 a.m.

7:00 a.m.–9:00 a.m.

Controversies in Neurology Plenary Session: 10:45 a.m.–11:30 a.m. Would You Let Your Child Play Contact Sports? 65

Friday, April 27

C67 Video EEG: Name That Spell

8:00 a.m.–9:00 a.m.

S11 “Best of” Session: Epilepsy/

Clinical Neurophysiology (EEG) . 92

11:30 a.m.–7:00 p.m.

P2 Poster Session II

9:15 a.m.–11:30 a.m.

Saturday, April 21 12:00 p.m.–4:00 p.m.

C17 Neurophysiologic

Intraoperative Monitoring Skills Workshop

Sunday, April 22 7:00 a.m.–9:00 a.m.

C32 Treatments for Drug-resistant Epilepsy: Surgery, Devices, and Other Updates

9:15 a.m.–12:00 p.m.

11:30 a.m.–5:30 p.m.

P1 Poster Session I

Clinical Epilepsy I

P1.259–P1.294 . 127

12:00 p.m.–12:50 p.m.

Epilepsy/Clinical Neurophysiology (EEG) Poster Discussion Session P1.027–P1.036 122

1:00 p.m.–3:00 p.m.

C42 Acute and Chronic Clinical

Epilepsy Update Explained in 6 Cases

3:30 p.m.–5:30 p.m.

S9 Epilepsy/Clinical

Neurophysiology (EEG) I . . . 98

Epilepsy: Basic Science and Genetics

Terapéuticas para la Epilepsìa Farmacorresistente

Thursday, April 26 7:00 a.m.–9:00 a.m.

C172 Clinical Epilepsy I: Basics

8:00 a.m.–9:00 a.m.

P2.259–P2.272 . 137 P2.273–P2.294 . 137

Epilepsy/Clinical Neurophysiology (EEG) ePoster Session

P2.339–P2.344 . 139

1:00 p.m.–1:30 p.m.

Subspecialty Sessions: IOM and cEEG . . . . . . . . . 75

11:30 a.m.–7:00 p.m.

P5 Poster Session V

3:30 p.m.–5:30 p.m.

S19 Epilepsy/Clinical

7:00 a.m.–9:00 a.m.

C96 Status Epilepticus

11:30 a.m.–7:00 p.m.

P3 Poster Session III

EEG and Imaging

P3.259–P3.294 . 147

1:00 p.m.–1:30 p.m.

Subspecialty Sessions: IOM and cEEG . . . . . . . . . 75

1:00 p.m.–3:00 p.m.

C106 Critical Care EEG Monitoring

C138 Clinical EEG I: Normal EEG,

Normal Variants, and How to Avoid The Common Pitfall of Over-reading

11:30 a.m.–7:00 p.m.

P4 Poster Session IV

Anti-epileptic Drugs and Epilepsy Surgery

Clinical Epilepsy III

Clinical Epilepsy IV

P5.259–P5.283 . 167 P5.284–P5.294 . 168

C182 Clinical Epilepsy II:

Considerations Across the Age Span Pediatrics, Pregnancy, and Elderly

3:30 p.m.–5:30 p.m.

C197 Clinical Epilepsy III: Advanced

(Status, Beyond AED, Video EEG)

Friday, April 27 7:00 a.m.–9:00 a.m.

C223 The Burden of Epilepsy:

Managing Comorbidities and Quality of Life

9:15 a.m.–11:30 a.m.

Wednesday, April 25 7:00 a.m.–9:00 a.m.

Anti-epileptic Drugs

1:00 p.m.–3:00 p.m.

Neurophysiology (EEG) II . . . 102

Tuesday, April 24

1:00 p.m.–3:00 p.m.

C77 Epilepsy Surgery Update

Enhancing Epilepsy Care in Your Practice: In-Person Digital Learning and Emotional for Self-Management, Education, and Community Supports from the National Epilepsy Education and Awareness Collaborative . . . 73

Neurology Year in Review: Emerging Therapies Plenary Session: 10:15 a.m.–10:35 a.m. Pediatric Epilepsy . . 66

11:30 a.m.–5:30 p.m.

P6 Poster Session VI

E pilepsy: Comorbidities, Psychosocial, Health Economics, Quality

P6.259–P6.294 . 177

1:00 p.m.–5:00 p.m.

C234 Epilepsy Skills Workshop: Focus on Treatment

P4.259–P4.279 . 157

1:30 p.m.–2:30 p.m.

P4.280–P4.294 . 158

3:30 p.m.–5:30 p.m.

1:00 p.m.–3:00 p.m.

C156 Clinical EEG II: Focal,

Diffuse, and Epileptiform Abnormalities in Adults

Live Intraoperative Monitoring . 69

S53 Epilepsy/Clinical

Neurophysiology (EEG) III . . . 118

3:30 p.m.–5:30 p.m.

C170 Clinical EEG III: Neonatal and Pediatric

X = Experiential Learning

AAN.com/view/AM18 37

Epilepsy (EEG)

Presidential Plenary Session: 10:15 a.m.–10:45 a.m. George C. Cotzias Lecture: How Early-Life Experiences Sculpt Your Brain: From Molecules to Circuits . . 61

Clinical Epilepsy II

Neurology Year in Review: Emerging Therapies Plenary Session: 10:15 a.m.–10:35 a.m. Pediatric Epilepsy . . 66

Epilepsy/Clinical Neurophysiology (EEG)

C171 Actualización Sobre Opciones

ANNUAL MEETING TOPIC LIST

Thursday, April 26

ANNUAL MEETING TOPIC LIST

2018 PROGRAMS LISTED BY TOPIC General Neurology

Sunday, April 22

Saturday, April 21

7:00 a.m.–7:45 a.m.

7:00 a.m.–9:00 a.m.

8:00 a.m.–9:00 a.m.

C2 Functional Neurologic

Disorders I: Movement, Seizures, and Multiple Sclerosis

7:00 a.m.–4:00 p.m.

C6 Neurology MOC Prep Course

X X

How to Network At the Annual Meeting: Strategies for Trainees . . . . . . . . 75

9:15 a.m.–10:00 a.m.

9:30 a.m.–11:30 a.m.

Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room C12 Functional Neurologic Disorders II: Life Experiences and Management of Functional Disorders

P1 Poster Session I

P1.118–P1.127 . 124

Cognitive Biases and Diagnostic Errors at Bedside . 75

P1.128–P1.132 . 124

Neuroepidemiology: Neuropathy, Neuromuscular Diseases, Demyelinating Diseases, and Other

Navigating the Annual Meeting App and Convention Center Tour . . . . . . . . 69

12:00 p.m.–12:45 p.m.

General Neurology

Neuroepidemiology: Cerebrovascular Disease and Epilepsy

Neuroepidemiology: Motor Neuron Disease, Cognitive Impairment, Sleep I

12:00 p.m.–12:30 p.m.

Presidential Plenary Session: 9:15 a.m.–10:15 a.m. Presidential Lecture: California Dreaming: BRAIN and Precision Medicine in 2018 . . 61

11:30 a.m.–5:30 p.m.

10:15 a.m.–10:45 a.m.

Challenges in Clinicogenetic Correlations: One Gene, Many Phenotypes; One Phenotype, Many Genes . . . . . . . . 77

9:15 a.m.–12:00 p.m.

Patient Centered Teaching . . 75

C8 Emergency Neurology:

Meditation for the Practicing Neurologist . . . . . . . . 71

8:00 a.m.–9:10 a.m.

9:15 a.m.–9:45 a.m.

Yoga (All-Levels Vinyasa) . . . 71

Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? . . . 71

P1.133–P1.146 . 125

General Neurology: Autoimmune Neurology

P1.314–P1.338 . 128

1:00 p.m.–1:30 p.m.

12:00 p.m.–1:00 p.m.

1:30 p.m.–3:30 p.m.

1:00 p.m.–1:45 p.m.

Statistics - Sample Size . . . 77

C23 Critical Care Consultations for Neurohospitalists

2:00 p.m.–2:45 p.m.

Cafe Talk: Narratives in Neurology: Creative Expression to Promote Resilience and Prevent Burnout . . . . . . . 71

X X

C35

2:15 p.m.–3:00 p.m.

C39

Rural Neurology . . . . . . .69 Teleneurology: Is this for me? Pre-hospital and Nontraditional Uses of Teleneurology . . . . 75

3:00 p.m.–3:45 p.m.

Acupuncture Demonstration: 4 Gates . . . . . . . . . . . 71

Solving Burnout . . . . . . . 71

S4 Neuroepidemiology:

2:00 p.m.–3:00 p.m.

Neurology Pictionary . . . . . 69

1:00 p.m.–3:00 p.m.

C40

Neurodegeneration, Epilepsy, Cerebrovascular Disease Risks . 97 General Neurology: Advances in Neurotherapeutics . . . . 97 Borderlands of Neurology and Internal Medicine: Chalk Talk Therapy in Neurology I: Headache and Stroke Autoimmune Neurology I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS

1:00 p.m.–5:30 p.m.

C48 Genomic Neurology Skills

Workshop: Developing Practical Knowledge of Tools and Concepts Through Case Studies

38 2018 AAN Annual Meeting

How Your Social Life Might Be Helping (or Harming) Your Brain . 71

3:00 p.m.–4:00 p.m.

Blind Spots: The Impact of Conscious and Unconscious Biases . . . . . . . . . . 69

3:15 p.m.–4:00 p.m.

Social Media for the Millennial Neurologist . . . . 75

3:30 p.m.–5:30 p.m.

C54 Therapy in Neurology II:

Epilepsy and Movement Disorders

C55 Autoimmune Neurology II

Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience

Monday, April 23 7:00 a.m.–7:45 a.m.

Yoga (All-Levels Vinyasa) . . . 71

7:00 a.m.–9:00 a.m.

C65 Clinical Pearls: Learning

from Complex Cases Simple Lessons that Apply to Everyday Problems

8:00 a.m.–8:45 a.m.

Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? . . . 71

8:10 a.m.–9:00 a.m.

P1.147–P1.172 . 125

General Neurology: Neurogenetics

3:00 p.m.–3:45 p.m.

Your CV is talking about you behind your back, and your LORs are too! . . . . . . . . 77

8:30 a.m.–9:00 a.m.

Tools to Transition from Trainee to Attending . . . . . 75

10:45 a.m.–11:15 a.m.

Choosing a Neurohospitalist Career . . . . . . . . . . 75

12:00 p.m.–1:00 p.m.

Is There a Neurologist on This Flight? . . . . . . . . . . 69

1:00 p.m.–1:30 p.m.

Office Hours: Creating Bridge Funding - How to Use NonNIH Funding . . . . . . . . 77

1:00 p.m.–3:00 p.m.

C71 Therapy in Neurology III:

Neurological Infectious Diseases and Neuroophthalmologic Disorders C74 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I C75 Safe and Appropriate Opioid Prescribing in Neurology

Office Hours: Statistics Sample Size . . . . . . . . 77

1:30 p.m.–2:30 p.m.

Eminence-based Medicine vs Evidence-based Medicine . . . 69

3:00 p.m.–3:45 p.m.

Introduction to Acupuncture I: Conceptual Framework and Mechanism of Action . . . . 71

3:00 p.m.–4:00 p.m.

Lifting the Curtain: Ask the AAN Publication Editors Anything! . . . . . . . . . 69

3:30 p.m.–5:30 p.m.

C84 Evidence Based Neurology

Foresights for Busy Clinicians

C112 Continuum ® Test Your

Knowledge: A Multiple-choice Question Review I

4:00 p.m.–4:45 p.m.

Striking the Balance - A Neurologist’s Personal Wellness Journey . . . . . . 71

Tuesday, April 24 7:00 a.m.–7:45 a.m.

Yoga (All-Levels Vinyasa) . . . 71

7:00 a.m.–9:00 a.m.

C99 Good Neurology in

Self-Management in Neurologic Disease . . . . . 71

11:30 a.m.–7:00 p.m.

P3 Poster Session III

General Neurology ePoster Session

Research Methodology ePoster Session

2:45 p.m.–3:30 p.m.

3:00 p.m.–4:00 p.m.

4:30 p.m.–5:30 p.m.

Controversies in Neurology: Is the Zombie Apocalypse Upon Us? Local Outbreaks, Bioterrorism or Bioengineering Run Amok… . . . . . . . . 69

4:45 p.m.–5:30 p.m.

Teaching During a Busy Clinic . 75

5:45 p.m.–7:15 p.m.

Emerging Science Session

7:00 a.m.–7:45 a.m.

Introduction to the 2018-2020 TRANSCENDS Scholars . . . 77 Treatment of Neuropathy Symptoms Without Medication . 71

Neurology Game Show: Localize the Lesion . . . . . 69

1:00 p.m.–3:00 p.m.

N3 Neuroscience in the Clinic:

Challenges in Genetic Diagnosis in Neurology . . . . 82

X = Experiential Learning

Yoga (All-Levels Vinyasa) . . . 71

7:00 a.m.–9:00 a.m.

C139 Neurologic Case Studies in Pregnancy

8:00 a.m.–8:45 a.m.

Acupuncture Demonstration: Auriculotherapy . . . . . . . 71

9:15 a.m.–11:30 a.m.

P4.006–P4.020 . 152

P4.021–P4.026 . 152

12:00 p.m.–12:30 p.m.

Recruiting Minorities . . . . 77

12:00 p.m.–12:45 p.m.

Neurology and Wellness Physician, Heal Thyself . . . . 71

12:00 p.m.–1:00 p.m.

X Neuro-Jeopardy:

Telencephalon Twisters . . . 69

12:30 p.m.–1:00 p.m.

C122 Multiple Sclerosis Overview III:

The Pathogenesis of Multiple Sclerosis and Mechanism of Action of Treatments for MS C125 Continuum ® Test Your Knowledge: A Multiple-choice Question Review II C131 Introduction to Integrative Neurology C132 Actualization Científica Durante el Congreso Anual I

P4.001–P4.005 . 152

General Neurology: Case Reports I

3:30 p.m.–5:30 p.m.

P3.339–P3.344 . 149

12:00 p.m.–1:00 p.m.

Biological and Chemical Neuroterrorism and Neurowarfare . . . . . . . 69

Wednesday, April 25

12:00 p.m.–12:45 p.m.

Training in Neurology While on a Visa: Challenges and Possible Solutions for Foreign Medical Graduates . . . . . 75

P3.085–P3.090 . 144

12:00 p.m.–12:30 p.m.

Neurological Exam Tips and Tricks . . . . . . . . . . . 69 Office Hours: Finding Collaborators . . . . . . . . 77

General Neurology: Neuroimaging

2:30 p.m.–3:00 p.m.

8:00 a.m.–8:45 a.m.

Neurology Practice and Outcomes

Office Hours: Navigating Uncommon Pathways in Academic Neurology: A Journey from Bedside to Bench . . . . 77

12:40 p.m.–1:10 p.m.

Neuroscience of Bias . . . . 77

1:00 p.m.–3:00 p.m.

C144 Neurology Update I: Epilepsy, Behavioral Neurology, and Neurologic Infections C148 LGBTQI Health in Neurology

2:00 p.m.–2:30 p.m.

Office Hours: Mentor-Mentee Relationships . . . . . . . . 77 Women in Neuroscience . . . 77

2:00 p.m.–2:45 p.m.

Resiliency for the Neurologist . 71

2:40 p.m.–3:10 p.m.

Patient-Reported Measures in Neurology . . . . . . . . . 77

3:00 p.m.–3:45 p.m.

Introduction to Acupuncture II: Evidence-based Applications for Acupuncture in the Treatment of Neurologic Conditions . . . . . . . . . 71

3:00 p.m.–4:00 p.m.

Health Care Disparities Among Underserved Populations . . . 69

3:30 p.m.–5:30 p.m.

C160 Neurology Update II:

Movement Disorders, Spine Disorders, and Sleep Disorders C168 CNS Toxicities

Frontiers in Neuroscience Plenary Session: 10:35 a.m.–10:55 a.m. BigBrain: A High Resolution 3D Digital Human Brain Atlas 64

AAN.com/view/AM18 39

General Neurology

Challenging Conditions: Lessons from Military Neurology

P4 Poster Session IV

1:30 p.m.–2:30 p.m.

C85 Therapy in Neurology IV:

Autoimmune PNS Synaptic Disorders and Neuro-Oncology C93 Advances in Neurogenetics

11:30 a.m.–7:00 p.m.

ANNUAL MEETING TOPIC LIST

1:30 p.m.–2:00 p.m.

ANNUAL MEETING TOPIC LIST

2018 PROGRAMS LISTED BY TOPIC 3:45 p.m.–4:30 p.m.

2:00 p.m.–2:45 p.m.

C240 Neuroimaging for the General

4:15 p.m.–5:00 p.m.

3:00 p.m.–3:45 p.m.

Global Health

X X

Navigating Fellowship in Neurology . . . . . . . . . . . . . 75

The Neurology of VooDoo . . . 69

5:15 p.m.–6:15 p.m.

Neurology Illustrated: The Neurology of Art . . . . . . 69

Thursday, April 26 Yoga (All-Levels Vinyasa) . . . 71

7:00 a.m.–9:00 a.m.

C180 Principles of Genomic

Medicine: Clinical Exome Sequencing in Neurologic Disease

8:00 a.m.–8:30 a.m.

How to Bridge to Careers in Industry . . . . . . . . . . 77

8:40 a.m.–9:10 a.m.

The Pathway to Become a Clinical Trialist . . . . . . . 77

9:15 a.m.–11:30 a.m.

Controversies in Neurology Plenary Session: 10:00 a.m.–10:45 a.m. Should the Neurologist Be Primarily Responsible For Taking Care of Patients With Functional Disorders? . . 65

11:30 a.m.–7:00 p.m.

P5 Poster Session V

Global Health

Neuroepidemiology: Motor Neuron Disease, Cognitive Impairment, Sleep II

General Neurology

Multiple Sclerosis, Neuroophthalmology, and Autoimmune Encephalopathies C202 Neuroimaging for the General Neurologist II: Spine and Peripheral Nerve C207 Mitochondrial Disorders in Neurology 6:30 p.m.–9:30 p.m.

C212 Case Studies: Test Your

Knowledge: A Case-based Approach to Neuroimaging

Friday, April 27 X

Teaching History and Exam with Teleneurology . . . . . 75 The Purpose Checkup: Find Meaning, Live Longer, Better . 71

Who Wants to be a Millionaire . 69

1:00 p.m.–2:30 p.m.

Invited Science: The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative . . . . . . 89

1:00 p.m.–3:00 p.m.

C185 Neurology Update III: Neuromuscular,

Headache, and Stroke C188 Neuroimaging for the General Neurologist I: Spine and Peripheral Nerve 1:30 p.m.–2:30 p.m.

The Value of the Neurologic Exam: Caring for your Patient for $500 or Less . . . . . . 69

40 2018 AAN Annual Meeting

Neurologist II: Brain

Monday, April 23 1:45 p.m.–2:30 p.m.

Tuesday, April 24 11:45 a.m.–12:30 p.m.

Yoga (All-Levels Vinyasa) . . . 71

C216 Neuroendocrine Update: Nuts

3:45 p.m.–4:30 p.m.

Wednesday, April 25 7:00 a.m.–9:00 a.m.

C134 Tuberculosis of the Central Nervous System

Neurologic Diseases

3:30 p.m.–4:15 p.m.

S33 Global Health . . . . . . . 110

Thursday, April 26

Neurologic Emergencies

11:30 a.m.–7:00 p.m.

11:30 a.m.–5:30 p.m.

P5 Poster Session V

P6 Poster Session VI

General Neurology: Vascular Neurology

P6.001–P6.011 . 172

General Neurology: Case Reports II

P6.012–P6.026 . 172

12:00 p.m.–12:30 p.m.

How to Bridge to Careers in Industry . . . . . . . . . . 77 Outsmart Stress . . . . . . 71

12:00 p.m.–1:00 p.m.

The Neurology of Creativity at the Keyboard . . . . . . . . 69

1:00 p.m.–3:00 p.m.

S50 Updates in General Neurology . 117 C228 Neuroimaging for the General Neurologist I: Brain C230 Neurologic Complications of Medical and Surgical Therapies C233 Simposio Español: Actualización Científica Durante el Congreso Anual II

3:30 p.m.–5:30 p.m.

C237 Neurologic Complications of Medical Disease

Infectious Disease and Global Health I ePoster Session

P5.085–P5.090 . 164 Global Health

P5.154–P5.163 . 165

2:45 p.m.–3:30 p.m.

12:00 p.m.–12:45 p.m.

International Members: What Can the AAN Do For You? . . . 75

and Bolts of What You Need to Know

C220 Drugs and Toxin-induced

Foreign Medical Graduates Adjustment Skills . . . . . . 75

C154 The Global Burden of

7:00 a.m.–9:00 a.m.

Creating a Career in Global Health with Design Thinking . 75

1:00 p.m.–3:00 p.m.

7:00 a.m.–7:45 a.m.

P5.317–P5.338 . 168

12:00 p.m.–1:00 p.m.

Consejos Prácticos para un Buen Examen Neurológico . . 69

3:30 p.m.–5:30 p.m.

P5.164–P5.172 . 165

12:00 p.m.–12:45 p.m.

Magnifying Your Life Through Poetry . . . . . . . . . . 71

3:00 p.m.–4:00 p.m.

11:45 a.m.–12:30 p.m.

Cafe Talk: Communication in Neurology Practice . . . . . 71

C199 Neurology Update IV:

7:00 a.m.–7:45 a.m.

O Funding, Where Art Thou? How to Develop a Full-Time Academic Career in Global Neurology . . . . . . . . . 75

Headache

Saturday, April 21 12:45 p.m.–1:45 p.m.

Ask Us Anything: Expert Panel on Headache and Facial Pain . 69

Sunday, April 22 3:30 p.m.–5:30 p.m.

C50 Low and High Pressure

Headache: Clinical Presentation and Approach to Evaluation and Management

9:15 a.m.–11:30 a.m.

Contemporary Clinical Issues Plenary Session: 11:10 a.m.–11:30 a.m. Non-invasive Neuromodulation . . 62

1:00 p.m.–3:00 p.m.

C79 Comprehensive Migraine

Education Program I: Diagnosis, Risk Factors, and Neurobiology

11:30 a.m.–7:00 p.m.

P4 Poster Session IV

Education Program II: Behavioral and Psychological Approaches, and Preventive and Acute Treatment Advances

Tuesday, April 24 8:00 a.m.–9:00 a.m.

S20 “Best of” Session: Headache . 92

11:30 a.m.–7:00 p.m.

Thursday, April 26

7:00 a.m.–9:00 a.m.

1:00 p.m.–3:00 p.m.

C195 Practical Training in Injection Techniques in the Treatment of Headache Disorders Skills Workshop

3:30 p.m.–5:30 p.m.

S43 Migraine . . . . . . . . . 114

6:30 p.m.–9:30 p.m.

C214 Case Studies: Challenging Headache Cases

Friday, April 27 9:15 a.m.–11:30 a.m.

Headache: Imaging, Neurophysiology, and Research Methods

P3.091–P3.100 . 144

The Less Common Headaches

P3.101–P3.122 . 144

P3.123–P3.149 . 145

Headache Diagnosis, Burden and Co-Morbidity

1:00 p.m.–3:00 p.m.

C108 Introduction to Primary

3:30 p.m.–5:30 p.m.

C121 Introduction to Primary

Headache Disorders II: Trigeminal Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches

Wednesday, April 25 7:00 a.m.–9:00 a.m.

C137 What Do I Do Now?:

Emergency and Inpatient Management of Migraine and Other Headache Disorders

X = Experiential Learning

Neurology Year in Review: Emerging Therapies Plenary Session: 9:55 a.m.–10:15 a.m. Headache Medicine 2018: Year In Review . . 66

1:00 p.m.–3:00 p.m.

C232 Hot Topics in Headaches and

Related Disorders I: Migraine Pathophysiology, Brain Imaging, and Therapeutic Advances

3:30 p.m.–5:30 p.m.

C243 Hot Topics in Headaches and

Related Disorders II: Unusual Headaches, Childhood Headaches, and Concussion Management

Infectious Disease

C134 Tuberculosis of the Central Nervous System

Thursday, April 26 7:00 a.m.–9:00 a.m.

C177 So You’ve Diagnosed Your

Patient with a Neuroinfectious Disease, Now What? Practical Pearls in the Treatment and Management of Neuroinfectious Diseases

11:30 a.m.–7:00 p.m.

P5 Poster Session V

Infectious Disease and Global Health I ePoster Session

Neurologic Infections: Treatments and Outcomes

Neurologic Infections: Unusual Presentations

P5.085–P5.090 . 164 P5.091–P5.107 . 164 P5.108–P5.143 . 164

Neurological Infections: Diagnostics and Animal Models

P5.144–P5.153 . 165

Infectious Disease and Global Health II ePoster Session

P5.339–P5.344 . 169

1:00 p.m.–3:00 p.m.

S41 Neurologic Infections . . . . 113

3:30 p.m.–5:30 p.m.

C201 Differential Diagnosis of Neurologic Infections

Sunday, April 22

Friday, April 27

12:00 p.m.–12:30 p.m.

7:00 a.m.–9:00 a.m.

Office Hours: Finding/Working with Epidemiologists on Your Grant . . . . . . . . . . . 77

Monday, April 23 9:15 a.m.–11:30 a.m.

Contemporary Clinical Issues Plenary Session: 10:05 a.m.–10:20 a.m. Pediatric Brainstem Encephalitis Outbreak Investigation with Metagenomic Next-Generation Sequencing . . 62

C218 Infections of the Nervous

System I: Diagnostic Testing of Neurological Infections

1:00 p.m.–3:00 p.m.

C226 Infections of the Nervous

System II: Neuro-ID Emergencies

3:30 p.m.–5:30 p.m.

C239 Infections of the Nervous

System III: Advanced Topics in Infectious Neurology

AAN.com/view/AM18 41

Infectious Disease

Headache Disorders I: Migraine and Other Primary Headaches Including TensionType, Hypnic, Primary Stabbing and Nummular Headache Syndromes, Epicrania Fugax and Retinal Migraine

Infecciones del Sistema Nervioso Central y la Medicina Tropical

Wednesday, April 25

S32 Headache: Therapeutics . . . 109

P3 Poster Session III

P4.091–P4.153 . 154

C95 Actualización Sobre las

1:00 p.m.–3:00 p.m.

3:30 p.m.–5:30 p.m.

C90 Comprehensive Migraine

Headache Therapeutics

3:30 p.m.–5:30 p.m.

ANNUAL MEETING TOPIC LIST

Monday, April 23

ANNUAL MEETING TOPIC LIST

2018 PROGRAMS LISTED BY TOPIC Leadership

Saturday, April 21 7:00 a.m.–4:00 p.m.

C7 L Women in Leadership

12:00 p.m.–12:45 p.m.

Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? . . . 71

12:00 p.m.–4:00 p.m.

C16 L Leadership Challenges in Practice

1:00 p.m.–4:00 p.m.

C18 L Educators’ Leadership Program

1:15 p.m.–2:00 p.m.

Interviewing Skills: Medical Students and Residents . . . 75

3:15 p.m.–4:15 p.m.

Women in Neurology: Crafting Your Leadership Career: Lessons from Leaders . . . . 69

Sunday, April 22 8:30 a.m.–9:00 a.m.

Giving and Receiving Feedback for Medical Students and Residents . . . 75

10:45 a.m.–11:15 a.m.

C45 L Being a Resilient Leader:

How Do You Lead the Change? C46 L The Most Important Tool in Your Black Bag: Gallup StrengthsFinders™ Assessment

Leadership

2:00 p.m.–2:30 p.m.

Breaking Down Silos: Using Simulation for Interprofessional Team Education to Enhance Clinical Outcomes in Neurology . . . 73

2:15 p.m.–3:00 p.m.

Education Administrator Building Blocks: Navigating the Role of the Administrator and Taking Your Role to the Next Level . . . . . . . . . 75

3:15 p.m.–3:45 p.m.

How to Get Into Leadership in Professional Societies . . . . 75

Monday, April 23 8:00 a.m.–8:45 a.m.

Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? . . . 71

42 2018 AAN Annual Meeting

How to be “Useful” on Rotations: Tips for Medical Students . . . . . . . . . 75

1:00 p.m.–3:00 p.m.

C69 L Continuing Your Leadership

Movement Disorders

Saturday, April 21 7:00 a.m.–9:00 a.m.

C4 Hyperkinetic Movement

Disorders: Videodiagnosis and Treatment

Journey: Uncharted Waters

1:00 p.m.–4:00 p.m.

C81 L Mitigating the Impact of

Unconscious Bias Workshop

4:15 p.m.–5:00 p.m.

Foundations for Success in the AAN . . . . . . . . . . . 69

4:45 p.m.–5:30 p.m.

Career Development for Medical Educators . . . . . 75

Tuesday, April 24 8:15 a.m.–9:00 a.m.

Career Development for Clinician Educators . . . . . 75

9:30 a.m.–11:30 a.m.

C14 Parkinson’s Disease Update

1:30 p.m.–3:30 p.m.

C24 Diagnosis and Treatment of

Functional Movement Disorders

Sunday, April 22 7:00 a.m.–9:00 a.m.

C25 Hot Topics and Controversies in Parkinson’s Disease

11:30 a.m.–5:30 p.m.

P1 Poster Session I

8:30 a.m.–9:00 a.m.

Career Stories: Nuts and Bolts of Academic Leadership Strategies I Have Learned in My Career . . . . . . . . . 75

1:00 p.m.–3:00 p.m.

C105 L Mentoring…Growing the

Next Generation of Neurologist

C118 L Leadership in the Era of

Burnout: A Practical Approach to Becoming a True Physician Leader

So You Want to Be a Residency Program Director? . 75

1:00 p.m.–5:00 p.m.

Interviewing Skills: Negotiation . 75

9:15 a.m.–9:45 a.m.

10:00 a.m.–10:30 a.m.

3:00 p.m.–3:45 p.m.

StrengthsFinder Social Hour . . 71

Wednesday, April 25 1:00 p.m.–5:00 p.m.

C157 L Advanced Leadership

Training: Preparing for Your Career’s Insurmountable Opportunities C158 L Leadership Strengths in Neurology: The Data, Tools and Practical Application of Strengths for Leadership, Team Building, and Personal Development 2:45 p.m.–3:30 p.m.

Pursing a Career in Healthcare Administration . . . . . . . 75

Thursday, April 26 1:45 p.m.–2:30 p.m.

Interviewing Skills . . . . . . 75

Parkinson’s Disease: Non-Motor Manifestations

P1.037–P1.056 . 123

Ataxias I

P1.057–P1.084 . 123

1:00 p.m.–3:00 p.m.

S3 Movement Disorders:

Parkinson’s Disease: Genetics, Biomarkers, and Diagnosis . . 96 C37 Nonmotor Manifestations of Parkinson’s Disease I 1:45 p.m.–2:15 p.m.

Career Stories: Challenges for the Physician Scientist . . . . 75

3:30 p.m.–5:30 p.m.

C52 Nonmotor Manifestations of Parkinson’s Disease II

4:30 p.m.–5:30 p.m.

What is that Twitch? . . . . . 69

Monday, April 23 7:00 a.m.–9:00 a.m.

C60 Balance and Gait Disorders C67 Video EEG: Name That Spell

11:30 a.m.–7:00 p.m.

P2 Poster Session II

Parkinson’s Disease: Therapeutics

P2.037–P2.048 . 133

P2.049–P2.084 . 133

Parkinson’s Disease: Phenomenology, Epidemiology and Rating Scales

1:00 p.m.–3:00 p.m.

C70 Evaluating Tremor in the Office

3:30 p.m.–5:30 p.m.

S18 Movement Disorders: Ataxia

and Tremor . . . . . . . . 102

7:00 a.m.–9:00 a.m.

11:30 a.m.–7:00 p.m.

C102 Movement Disorders for the

11:30 a.m.–7:00 p.m.

P3 Poster Session III

Parkinson’s Disease: Surgical Management

Movement Disorders: Tardive Dyskinesia

Dystonia, Chorea, and other Disorders . . . . . . . . . 109

C159 Clinical Uses of Botulinum

Thursday, April 26

P3.064–P3.084 . 143

Complementary Therapies in Parkinson’s Disease . . . . . 71

1:00 p.m.–3:00 p.m.

Invited Science: Movement Disorders . . . . . . . . . 88 N3 Neuroscience in the Clinic: Challenges in Genetic Diagnosis in Neurology . . . . 82 C115 Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia

2:00 p.m.–2:45 p.m. 3:30 p.m.–5:30 p.m.

S26 Movement Disorders:

Parkinson’s Disease Clinical Trials . . . . . . . . . . 106 C123 Child Neurology: A Casebased Approach C128 Movement Disorders for the General Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypies, and Tics

Wednesday, April 25 7:00 a.m.–9:00 a.m.

C140 Paroxysmal Movement Disorders

8:00 a.m.–9:00 a.m.

S27 “Best of” Session: Movement

Disorders . . . . . . . . . 93

Movement Disorders II ePoster Session

P6.068–P6.084 . 173

P6.085–P6.090 . 174 P6.339–P6.344 . 178

Movement Disorders Poster Discussion Session P6.027–P6.036 172

1:00 p.m.–3:00 p.m.

C229 Deep Brain Stimulation

I: Basic Principles and Programming in Movement Disorders

3:30 p.m.–5:30 p.m.

7:00 a.m.–9:00 a.m.

C176 The Dystonia: Diagnosis,

C241 Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders

Treatment and Update on Etiologies

11:30 a.m.–7:00 p.m.

P5 Poster Session V

Dystonia: Phenomenology and Therapeutics

Parkinson’s Disease: Therapeutics II

Ataxias II

Movement Disorders I ePoster Session

Top Ten Clinical, Educational and Leadership Pearls . . . . 75

P6.054–P6.067 . 173

11:45 a.m.–12:35 p.m.

Parkinson Disease: Raising Your Game . . . . . . . . . 69

Atypical Parkinsonism

P5.037–P5.063 . 163

MS and CNS Inflammatory Disease

P5.064–P5.076 . 163

Saturday, April 21

P5.077–P5.084 . 164

9:30 a.m.–11:30 a.m.

1:00 p.m.–3:00 p.m.

C187 Cerebellar and Afferent Ataxias: Diagnosis and Management

3:30 p.m.–5:30 p.m.

S45 Movement Disorders:

Parkinsonian Disorders, Basic Science, and Imaging . . . . 114 C209 Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop 6:30 p.m.–9:30 p.m.

C213 Case Studies: Unusual

C11 Treatment of Pediatric

Multiple Sclerosis in the Current Era

4:15 p.m.–5:30 p.m.

Sunday, April 22 7:00 a.m.–9:00 a.m.

C34 Multiple Sclerosis in the

Trenches: Controversy and Consensus in Clinical Decision-Making

Movement Disorders

Friday, April 27 7:00 a.m.–9:00 a.m.

C222 Therapy of Movement

Hot Topics Plenary Session: 5:05 p.m.–5:20 p.m. Monitoring Multiple Sclerosis Using Blood Neurofilament Light Protein . . 60

10:00 a.m.–10:30 a.m.

Autoimmune Neurology . . . 75

Disorders: A Case-based Approach

X = Experiential Learning L = Leadership University

AAN.com/view/AM18 43

MS & CNS Disease

Dancing with Parkinson’s . . . 71

1:00 p.m.–5:30 p.m.

Toxin for Dystonia Skills Workshop

Movement Disorders: Essential and other Tremor Syndromes

S30 Movement Disorders:

P6.037–P6.053 . 173

1:00 p.m.–3:00 p.m.

Parkinson’s Disease: Imaging

P3.049–P3.063 . 143

P4.074–P4.084 . 154

4:45 p.m.–5:30 p.m.

F unctional Movement Disorders and Other Hyperkinetic Movement Disorders

P4.052–P4.073 . 153

Parkinson’s Disease: Animal Models and Biomarkers

P3.037–P3.048 . 143

P6 Poster Session VI

P4.037–P4.051 . 153

1:30 p.m.–2:30 p.m.

1:00 p.m.–1:45 p.m.

Parkinson’s Disease: Wearable Sensors and Remote Monitoring Technology

Huntington’s Disease and other Chorea

9:15 a.m.–11:30 a.m.

Clinical Trials Plenary Session: 9:15 a.m.–9:30 a.m. Effects of IONIS-HTTRx in Patients with Early Huntington’s Disease, Results of the First HTT-Lowering Drug Trial . 63

General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson’s Disease

11:30 a.m.–5:30 p.m.

P4 Poster Session IV

ANNUAL MEETING TOPIC LIST

Tuesday, April 24

ANNUAL MEETING TOPIC LIST

2018 PROGRAMS LISTED BY TOPIC 11:30 a.m.–5:30 p.m.

P1 Poster Session I

MS and CNS Inflammatory Disease ePoster Session

P1.085–P1.090 . 124

Neuroinflammatory and Other Autoimmune Disorders I

P1.345–P1.350 . 129

P1.351–P1.382 . 129

Comparative Efficacy of Disease Modifying Therapies Biomarkers and Experimental Studies for Multiple Sclerosis

P1.383–P1.414 . 130

MS and CNS Inflammatory Disease: Quality of Life, Symptoms, and Symptomatic Therapy I

3:30 p.m.–5:30 p.m.

C87 Neuro-rheumatology:

Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II C95 Actualización Sobre las Infecciones del Sistema Nervioso Central y la Medicina Tropical

S8 Progressive MS Therapies and

C98 Multiple Sclerosis Overview I: Clinical Pearls

9:15 a.m.–11:30 a.m.

P3 Poster Session III

P2 Poster Session II

MS Modifiable Risk Factors

MS Diagnosis, Mimickers, and Phenotypes

MS & CNS Disease

P2.345–P2.361 . 139 P2.362–P2.374 . 139

MS Epidemiology and Genetics

P2.375–P2.400 . 139

MS Animal Models

P2.401–P2.414 . 140

MS and CNS Inflammatory Disease: Quality of Life, Symptoms, and Symptomatic Therapy II

P2.415–P2.428 . 140

1:00 p.m.–3:00 p.m.

S13 Neuromyelitis Optica

Spectrum Disorder and other Autoimmune Disorders . . . 100 C74 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I

44 2018 AAN Annual Meeting

P4.345–P4.354 . 159

Pregnancy and Multiple Sclerosis

P4.355–P4.372 . 159

P4.373–P4.408 . 159

P4.409–P4.428 . 160

T ools and Outcome Measures for MS Trials and Clinical Tracking MS and CNS Inflammatory Disease: Quality of Life, Symptoms, and Symptomatic Therapy III

1:00 p.m.–3:00 p.m.

C147 Multiple Sclerosis Therapy:

Disease-modifying Treatment II

3:30 p.m.–5:30 p.m.

S36 MS Therapeutics and Clinical

Research . . . . . . . . . 111

C162 Multiple Sclerosis Therapy: Symptom Management

4:00 p.m.–4:45 p.m.

MS and CNS Inflammatory Disease: Neuroimaging: Novel Techniques

Thursday, April 26

P3.345–P3.376 . 149

P3.377–P3.392 . 149

MS Therapeutics in Development

P3.393–P3.408 . 150

MS Therapeutics I

P3.409–P3.417 . 150

Neuroinflammatory and Other Autoimmune Disorders II

C175 Clinical Pearls in Autoimmune Neurology: Real World Cases

11:30 a.m.–7:00 p.m.

P5 Poster Session V

P3.418–P3.428 . 150

Clinical Advances

3:30 p.m.–5:30 p.m.

S24 MS Outcome Measures and

Wednesday, April 25

Disease-modifying Treatment I

9:15 a.m.–11:30 a.m.

Frontiers in Neuroscience Plenary Session: 10:55 a.m.–11:15 a.m. Pediatric MS: A Unique Window into Environmental and Genetic Risk Factors for MS . 64

P5.345–P5.380 . 169

P5.381–P5.406 . 169

Neuroinflammatory and Other Autoimmune Disorders III

P5.407–P5.424 . 170

MS Therapeutics II

P5.425–P5.428 . 170

11:45 a.m.–12:35 p.m.

7:00 a.m.–9:00 a.m.

C136 Multiple Sclerosis Therapy:

MS Therapies: MOA, Safety and Complications

MS and CNS Inflammatory Disease: Encephalities and Encephalopathies

C109 Multiple Sclerosis Overview II:

Biomarkers . . . . . . . . 106 C122 Multiple Sclerosis Overview III: The Pathogenesis of Multiple Sclerosis and Mechanism of Action of Treatments for MS

Diets and Supplements in MS: What’s the Evidence Thus Far? . 71

7:00 a.m.–9:00 a.m.

1:00 p.m.–3:00 p.m.

Pediatric Multiple Sclerosis

MS and CNS Inflammatory Disease: Neuroimaging

9:15 a.m.–11:30 a.m.

11:30 a.m.–7:00 p.m.

Monday, April 23 Contemporary Clinical Issues Plenary Session: 10:50 a.m.–11:10 a.m. Biosimilars and Non-biologic Complex Drugs . . 62

Clinical Trials Plenary Session: 10:30 a.m.–10:45 a.m. A Phase II Trial of Ibudilast in Progressive Multiple Sclerosis . 63

11:30 a.m.–7:00 p.m.

Age-Dependent Factors in MS Therapy . . . . . . . . . . 98 C59 Actualización Sobre el Tratamiento de la Esclerosis Múltiple

7:00 a.m.–9:00 a.m.

1:00 p.m.–3:00 p.m.

3:30 p.m.–5:30 p.m.

P4 Poster Session IV

Tuesday, April 24

P1.415–P1.428 . 130

S6 MS Neuroimaging . . . . . . 97

11:30 a.m.–7:00 p.m.

MS and CNS Inflammatory Disease Poster Discussion Session P5.027–P5.036 . 64

1:00 p.m.–3:00 p.m.

N5 Neuroscience in the Clinic:

Treatment of Progressive Multiple Sclerosis . . . . . . 84

2:00 p.m.–3:00 p.m.

Using your Patients as Resources: Group Medical Visits for Improved Wellness and Efficiency . . . . . . . 73

S44 MS Risk Factors,

Susceptibility, Diagnosis, and Cognitive Impairment . . . . 114

Friday, April 27 8:00 a.m.–9:00 a.m.

S47 “Best of” Session: MS and

CNS Inflammatory Diseases . . 93

11:30 a.m.–5:30 p.m.

P6 Poster Session VI

MS Therapeutics III

MS Therapeutics: Extension Studies

P6.345–P6.361 . 178

P6.362–P6.396 . 179

MS and CNS Inflammatory Disease: Neuromyelitis Optica and Related Disorders

3:30 p.m.–5:30 p.m.

C53 Neurological Intensive Care III: Vascular Diseases

1:00 p.m.–3:00 p.m.

C72 Sports Neurology: Enhancing Athletic Performance

Tuesday, April 24

9:15 a.m.–11:30 a.m.

S51 Pediatric MS . . . . . . . . 117 C224 Neuromyelitis Optica S52 MS and CNS Inflammatory

Disease: Basic Science . . . . 118

4:30 p.m.–5:30 p.m.

Ask Us Anything: Expert Panel on Multiple Sclerosis . . . . 69

Neuro Trauma, Critical Care, and Sports Neurology

Saturday, April 21

3:30 p.m.–5:30 p.m.

C127 Concussion Management:

Chronic Sequelae and Symptom Targeted Treatment in the Acute, Subacute and Chronic Phase After Concussion

Wednesday, April 25

C38 Neurological Intensive Care

II: Acute Brain and Spinal Cord Injury and Acute Neuromuscular Dysfunction

X = Experiential Learning

Neurocritical Care I

P4.295–P4.338 . 158

Cerebrovascular Disease and Interventional Neurology II ePoster Session

P4.339–P4.344 . 159

C211 Case Studies in the ICU

Friday, April 27 11:30 a.m.–5:30 p.m.

P6 Poster Session VI

8:00 a.m.–8:45 a.m.

Sleep and Performance in Elite Athletes . . . . . . . . 71

Sports Neurology

Neurocritical Care II

P6.295–P6.321 . 177 P6.322–P6.338 . 178

1:00 p.m.–3:00 p.m.

S49 Neuro Trauma and Sports

Neurology . . . . . . . . 116

Neuromuscular and Clinical Neurophysiology (EMG)

Saturday, April 21 9:30 a.m.–11:30 a.m.

C9 Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies

1:30 p.m.–3:30 p.m.

C21 Evaluation and Management

of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia

Sunday, April 22 7:00 a.m.–9:00 a.m.

C31 Peripheral Neuropathy

I: Anatomical Basis and Acquired Demyelinating Neuropathies

C145 Severe TBI: From ICU to

Thursday, April 26

1:00 p.m.–3:00 p.m.

Rehabilitation

Invited Science: Neuro Trauma . 90

6:30 p.m.–9:30 p.m.

9:15 a.m.–12:00 p.m.

Presidential Plenary Session: 10:45 a.m.–11:15 a.m. Sidney Carter Award in Child Neurology: Spinal Muscular Atrophy Is a Treatable Neurodegenerative Disease . . 61

AAN.com/view/AM18 45

Neuromuscular (EMG)

7:00 a.m.–9:00 a.m.

1:00 p.m.–3:00 p.m.

3:30 p.m.–5:30 p.m.

P4 Poster Session IV

Neurohospitalists

The Essentials

How to Perform a Brain Death Evaluation, Avoid Pitfalls and Convey the News to the Family

11:30 a.m.–7:00 p.m.

C23 Critical Care Consultations for

C27 Neurological Intensive Care I:

Choosing a Career in Neurocritical Care . . . . . . 75

Fluid and Imaging Biomarkers, Diagnosis, and Treatment of Post-Concussion Headache

1:30 p.m.–3:30 p.m.

Sunday, April 22

Clinical Trials Plenary Session: 10:45 a.m.–11:00 a.m. Brain Oxygen Optimization in Severe Traumatic Brain Injury (BOOST) Phase 2 trial: Towards Evidence-Based in the Neurological Intensive Care Unit . 63

C106 Critical Care EEG Monitoring C114 Concussion: Pathogenesis,

ophthalmology

Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room

C196 Brain Death Skills Workshop:

1:00 p.m.–3:00 p.m.

C3 Emergency Room NeuroC8 Emergency Neurology:

1:00 p.m.–5:30 p.m.

10:00 a.m.–10:30 a.m.

7:00 a.m.–9:00 a.m.

9:30 a.m.–11:30 a.m.

S42 Neurocritical Care . . . . . . 113

C104 Sports Concussion Skills

Workshop: Event Coverage Foundational Skills and Sport Specific Pearls

Controversies in Neurology Plenary Session: 10:45 a.m.–11:30 a.m. Would You Let Your Child Play Contact Sports? . . 65

1:00 p.m.–3:00 p.m.

7:00 a.m.–9:00 a.m.

1:00 p.m.–3:00 p.m.

3:30 p.m.–5:30 p.m.

Monday, April 23

P6.397–P6.428 . 180

Spectrum Disorders

9:15 a.m.–11:30 a.m.

ANNUAL MEETING TOPIC LIST

3:30 p.m.–5:30 p.m.

ANNUAL MEETING TOPIC LIST

2018 PROGRAMS LISTED BY TOPIC 11:30 a.m.–5:30 p.m.

9:15 a.m.–11:30 a.m.

P1 Poster Session I

Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session

P1.339–P1.344 . 129

Neuropathy

P1.429–P1.467 . 131

1:00 p.m.–3:00 p.m.

C41 Peripheral Neuropathy

II: Diabetic and Inherited Neuropathies

11:30 a.m.–7:00 p.m.

C49 Neuromuscular Ultrasound

3:30 p.m.–5:30 p.m.

C63 Therapy of Neuromuscular

Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis

11:30 a.m.–7:00 p.m.

P2 Poster Session II

Autonomic Disorders: Autonomic Neuropathies

Autonomic Disorders: Other

P2.109–P2.116 . 134 P2.117–P2.124 . 135 Neuropathy II

P2.429–P2.453 . 141

Neuromuscular Diagnostics, Genetics, and Biomarkers

P2.454–P2.467 . 141

11:45 a.m.–12:35 p.m.

Neuromuscular (EMG)

Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion Session P2.027–P2.036 133

1:00 p.m.–2:15 p.m.

S12 Autonomic Disorders . . . . 100

1:00 p.m.–3:00 p.m.

C76 Clinical Approach to Muscle

Disease I: Role of Antibodies, Muscle Imaging and Genetic Testing

3:30 p.m.–5:30 p.m.

N2 Neuroscience in the Clinic:

Antisense Oligonucleotide (ASO) Therapy . . . . . . . 82 C89 Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology

Tuesday, April 24 46 2018 AAN Annual Meeting

Practice of NCS and Needle EMG

8:00 a.m.–9:00 a.m.

S38 “Best of” Session:

Clinical Trial Updates in Neuromuscular Disorders . . . 93

11:30 a.m.–7:00 p.m.

P5 Poster Session V

P3.435–P3.462 . 151

P3.463–P3.465 . 151

ALS I

Treatment of Neuropathy Symptoms Without Medication . 71

1:00 p.m.–3:00 p.m.

N3 Neuroscience in the Clinic:

Challenges in Genetic Diagnosis in Neurology . . . . 82 S22 Advances in Muscular Dystrophy and Congenital Myopathy . . . . . . . . 104

3:30 p.m.–5:30 p.m.

S25 Advances in Amyotrophic

Lateral Sclerosis . . . . . . 106

Neuromuscular Junction Testing and Quantitative EMG

3:30 p.m.–5:30 p.m.

S46 Advances in Spinal Muscular

Atrophy . . . . . . . . . . 115

C206 Clinical EMG III: Nerve

Conduction Criteria and Electrodiagnostic Approaches

6:30 p.m.–9:30 p.m.

C210 Case Studies: Unusual

Diagnostic and Management of Cases in Neuromuscular Disease

Friday, April 27 8:00 a.m.–9:10 a.m.

Wednesday, April 25 7:00 a.m.–9:00 a.m.

C142 Mastering EMG Waveform

Recognition Skills in Just Two Hours!

11:30 a.m.–7:00 p.m.

P4 Poster Session IV

ALS II

P4.429–P4.450 . 161

ALS, SMA, and other Neuromuscular Disorders II

P4.451–P4.465 . 161

1:00 p.m.–3:00 p.m.

S31 Therapeutics, Phenotypes,

and Biomarkers in Neuromuscular Disorders . . 109 C155 Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System 3:30 p.m.–5:30 p.m.

C169 Small Fiber Neuropathies:

Sensory, Autonomic, and Both II: Focus on Sensory Nervous System

Thursday, April 26

P5.459–P5.464 . 171

C192 Clinical EMG II:

1:00 p.m.–5:30 p.m.

C119 EMG Skills Workshop: Basic

P5.429–P5.458 . 170

1:00 p.m.–3:00 p.m.

12:00 p.m.–12:45 p.m.

Muscular Dystrophy

LS, SMA, and other Neuromuscular A Disorders III

P3.429–P3.434 . 150

C56 Peripheral Neuropathy III:

7:00 a.m.–9:00 a.m.

C179 Clinical EMG I: Principles and

ALS, SMA, and other Neuromuscular Disorders I

Myopathy

Skills Workshop

Monday, April 23

7:00 a.m.–9:00 a.m.

P3 Poster Session III

1:00 p.m.–5:30 p.m.

Genetic Testing and Next Generation Sequencing

Clinical Trials Plenary Session: 9:45 a.m.–10:00 a.m. Patisiran, a RNAi Therapeutic, to Improve Outcomes in Hereditary Transthyretin Mediated (hATTR) Amyloidosis with Polyneuropathy . 63

Role of Placebo in Neuromuscular Clinical Trials and in Management of NM Disorders . . . . . . . . . 77

9:15 a.m.–11:30 a.m.

Neurology Year in Review: Emerging Therapies Plenary Session: 9:15 a.m.–9:35 a.m. A Year in Review of Neuromuscular Diseases: Making Treatments Great Again . . 66

11:30 a.m.–5:30 p.m.

P6 Poster Session VI

Myasthenia Gravis

P6.429–P6.459 . 180 ALS III

P6.460–P6.466 . 181

1:00 p.m.–3:00 p.m.

C225 Neuromuscular Junction

Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia

C236 Neuromuscular Junction

Disorders II: Toxins, LambertEaton Syndrome and Less Common Disorders of Neuromuscular Transmission

Neuro-oncology

Sunday, April 22 9:15 a.m.–12:00 p.m.

Presidential Plenary Session: 11:15 a.m.–11:45 a.m. Robert Wartenberg Lecture: Neuro-Oncology: How Cancer and the Nervous System Interact . . 61

Tuesday, April 24 7:00 a.m.–9:00 a.m.

C100 Basic Principles of Brain

Tumors: For Practice and for Certification

1:00 p.m.–3:00 p.m.

S23 Biologic and Clinical Discoveries

in Neuro-oncology . . . . . . 105

3:30 p.m.–5:30 p.m.

C124 The Palliative Care Guide in

Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders

Wednesday, April 25 11:30 a.m.–7:00 p.m.

P4 Poster Session IV

T herapeutics in Neuro-oncology: From Laser Ablation to Immunotherapy I

P4.154–P4.163 . 155

1:00 p.m.–3:00 p.m.

C149 What Do I Do Now?:

3:30 p.m.–5:30 p.m.

C164 What Do I Do Now?:

Neurologic Consultations in Cancer Patients II

Thursday, April 26 7:00 a.m.–9:00 a.m.

C178 Neuro-oncology in 2018:

Navigating Current Trends

1:00 p.m.–3:00 p.m.

N6 Neuroscience in the Clinic:

Neurologic Complications of Cancer Immunotherapy: A New Frontier in NeuroInflammation . . . . . . . . 84

9:15 a.m.–11:30 a.m.

Neurology Year in Review: Emerging Therapies Plenary Session: 9:35 a.m.–9:55 a.m. Neuro-Oncology Year in Review: Progress, Breakthroughs and Future Directions . . 66

11:30 a.m.–5:30 p.m.

P6 Poster Session VI

Case based Neuro-oncology: the Art and Power of Clinical Observation

P6.091–P6.127 . 174

P6.128–P6.137 . 174

T herapeutics in Neuro-oncology: From Laser Ablation to Immunotherapy II

7:00 a.m.–9:00 a.m.

C62 Neuro-ophthalmology: Overview and Update

9:15 a.m.–11:30 a.m.

Friday, April 27

Monday, April 23

Neuro-oncology: Genes, Biomarkers, Patient Care and Outcomes

P6.138–P6.172 . 174

Neuro-ophthalmology/Neurootology

Saturday, April 21 7:00 a.m.–9:00 a.m.

C3 Emergency Room Neuroophthalmology

1:30 p.m.–3:30 p.m.

C19 Pediatric Neuro-

ophthalmology Update

Sunday, April 22 7:00 a.m.–9:00 a.m.

C26 Neuro-ophthalmology I: Visual Loss, Optic Neuropathies, and Papilledema

1:00 p.m.–3:00 p.m.

C44 Neuro-ophthalmology II: Optic Neuritis, Visual Fields, and Anisocoria

3:30 p.m.–5:30 p.m.

C58 Neuro-ophthalmology III:

Contemporary Clinical Issues Plenary Session: 9:15 a.m.–9:30 a.m. Retinal Microvasculature in Predicting Risk of Stroke Subtypes . . 62

11:30 a.m.–7:00 p.m.

P2 Poster Session II

Neuro-Ophthalmology/ Neuro-Otology

P2.136–P2.172 . 135

1:00 p.m.–3:00 p.m.

S16 Neuro-Ophthalmology/

Neuro-Otology . . . . . . . 101

1:00 p.m.–5:30 p.m.

C83 Neuro-ophthalmology and

Neurovestibular Exam Lab Skills Workshop

Tuesday, April 24 7:00 a.m.–9:00 a.m.

C103 Now You See It, Now You Know It: Pathognomonic Neuro-ophthalmology Examination Findings

Wednesday, April 25 7:00 a.m.–9:00 a.m.

C133 Higher Cortical Visual

Disorders: Case-based Review

1:00 p.m.–3:00 p.m.

C152 Nystagmus and Saccadic Intrusions Made Simple

3:30 p.m.–5:30 p.m.

C167 Eye Movement Disorders: A

Systematic Approach to the Evaluation of Diplopia

Thursday, April 26 1:00 p.m.–3:00 p.m.

C191 Neuro-otology I: The Common

Peripheral Vestibular Disorders

3:30 p.m.–5:30 p.m.

C205 Neuro-otology II: Diagnosis and Treatment of Nuanced Causes of Dizziness

Diplopia, Ocular Motility Disorders, and Nystagmus

C190 Neuro-oncologic Predicaments in the Hospital Setting

X = Experiential Learning

AAN.com/view/AM18 47

Neuro-ophthalmology

Neurologic Consultations in Cancer Patients I

3:30 p.m.–5:30 p.m.

ANNUAL MEETING TOPIC LIST

3:30 p.m.–5:30 p.m.

ANNUAL MEETING TOPIC LIST

2018 PROGRAMS LISTED BY TOPIC Neuro-rehabilitation

Pain and Palliative Care

Tuesday, April 24

Saturday, April 21

3:30 p.m.–5:30 p.m.

9:30 a.m.–11:30 a.m.

C120 Lumbar Radiculopathy, Lumbar

Spinal Stenosis, Low Back Pain, and Failed Back Syndrome

C143 Evaluation and Treatment of

Access Home Care, Support Caregivers, and Discuss Complex Situations in Advanced Neurologic Disease

12:45 p.m.–1:45 p.m.

Common Spine Disorders

9:15 a.m.–11:30 a.m.

Frontiers in Neuroscience Plenary Session: 9:15 a.m.–9:35 a.m. The Dynamics of the Unconscious Brain under General Anesthesia . 64

S37 Neurorehabilitation . . . . . 111

Thursday, April 26 C174 Rehabilitation in Neurology P5 Poster Session V

1:00 p.m.–3:00 p.m.

C186 Myelopathies I: Recognizing

and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes

Using your Patients as Resources: Group Medical Visits for Improved Wellness and Efficiency . . . . . . . 73

3:30 p.m.–5:30 p.m.

C200 Myelopathies II: Approaches

Neuro-rehabilitation

to Rehabilitation and Psychosocial Challenges

Friday, April 27 3:30 p.m.–5:30 p.m.

9:15 a.m.–11:30 a.m.

Contemporary Clinical Issues Plenary Session: 10:30 a.m.–10:50 a.m. Neuropalliative Care . . 62

11:30 a.m.–7:00 p.m.

P2 Poster Session II

Pain and Palliative Care

P2.091–P2.108 . 134

N4 Neuroscience in the Clinic:

Opioid Use and Abuse: The Overlapping Neurobiology of Pain and Addiction, and the Path Toward Better Treatments . 83

Thursday, April 26 1:00 p.m.–1:45 p.m.

C195 Practical Training in Injection Techniques in the Treatment of Headache Disorders Skills Workshop

Friday, April 27 3:30 p.m.–5:30 p.m.

C235 Neck Pain, Cervical

Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy

Prescribing in Neurology

3:30 p.m.–5:30 p.m.

C88 Core Concepts in Pain

Management: Refractory Neuropathic Pain Practical Pharmacologics, Advances in Neuromodulation, and a Balanced Look at Cannabinoids

3:45 p.m.–4:30 p.m.

Teaching Communication Skills: From Good to Great . . 75

Tuesday, April 24 1:00 p.m.–3:00 p.m.

C111 Enhancing Your Career and Practice Through Neuropalliative Care

3:20 p.m.–3:50 p.m.

Pain Research Funding Opportunities, Clinical and Basic . 77

C120 Lumbar Radiculopathy, Lumbar

Spinal Stenosis, Low Back Pain, and Failed Back Syndrome

Medical Marijuana: What do Neurologists Need to Know? . 71

1:00 p.m.–3:00 p.m.

C75 Safe and Appropriate Opioid

3:30 p.m.–5:30 p.m.

48 2018 AAN Annual Meeting

Common Spine Disorders

3:30 p.m.–5:30 p.m.

1:00 p.m.–3:00 p.m.

C235 Neck Pain, Cervical

Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy

Cafe Talk: Is that an Emotional or Cognitive Question? Navigating Difficult Conversations with Communication Skills . . . . . 71

Monday, April 23

2:00 p.m.–3:00 p.m.

C143 Evaluation and Treatment of

4:00 p.m.-4:45 p.m.

Neuro-rehabilitation

P5.001–P5.026 . 162

7:00 a.m.–9:00 a.m.

S7 Pain and Palliative Care . . . 98

7:00 a.m.–9:00 a.m.

11:30 a.m.–7:00 p.m.

Wednesday, April 25

3:30 p.m.–4:30 p.m.

C145 Severe TBI: From ICU to

4:30 p.m.–5:30 p.m.

Ask Us Anything: Expert Panel on Headache and Facial Pain . 69

Sunday, April 22

1:00 p.m.–3:00 p.m.

Rehabilitation

Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders

C10 More than Medicine: How to

Wednesday, April 25 7:00 a.m.–9:00 a.m.

C124 The Palliative Care Guide in

Practice, Policy, and Ethics

Saturday, April 21 9:30 a.m.–10:00 a.m.

What is the Axon Registry? . . 73

11:15 a.m.–12:00 p.m.

Choosing a Career in Clinical Practice . . . . . . . . . . 75

12:00 p.m.–4:00 p.m.

C16 L Leadership Challenges in Practice

2:00 p.m.–2:30 p.m.

Paths for Success in the Quality Payment Program . . . 73

2:30 p.m.–3:00 p.m.

Ask the Expert: Paths for QPP Success . . . . . . . . . . 73

3:00 p.m.–3:30 p.m.

Clinical Decision Support for Ordering of Diagnostic Imaging . 73

Social Media for Clinicians . . 75

3:30 p.m.–4:00 p.m.

Growing Research in Medical Marijuana . . . . . . . . . 73

2:00 p.m.–2:30 p.m.

4:00 p.m.–4:30 p.m.

TBI in Domestic Violence Victims: Care for Those Who Need it Most . . . . . . . . 73

Sunday, April 22 8:00 a.m.-9:00 a.m.

How Can the Axon Registry Improve My Practice? . . . . 73

12:00 p.m.–1:00 p.m.

Pursuing a Career in Clinical Informatics . . . . . . . . 73

1:00 p.m.–2:00 p.m.

Meet and Greet with the California Neurological Society . 73

1:00 p.m.–3:00 p.m.

C36 Clinical Neurology for

Advanced Practice Providers I

1:15 p.m.–2:00 p.m.

Measuring Success: Quality Improvement 101 . . . . . . 75

2:00 p.m.–2:30 p.m.

Breaking Down Silos: Using Simulation for Interprofessional Team Education to Enhance Clinical Outcomes in Neurology . . . 73

2:30 p.m.–3:00 p.m.

Ask the Expert: Teaching through Simulation . . . . . 73

3:00 p.m.–3:30 p.m.

Tip of the Iceberg: Ultra-High Cost Neurology Drugs . . . . 73

3:30 p.m.–5:30 p.m.

C51 Clinical Neurology for

Advanced Practice Providers II

4:00 p.m.–4:30 p.m.

X X

Transitioning from Private Practice to Academics . . . . 75 Why are Drug Prices So High? And What Can We Do About It? . 73

What Does BrainPAC Do for Me? . 73

Monday, April 23 7:00 a.m.–9:00 a.m.

C61 Starting a Practice From the

Ground Up: A Guide for Early Career Neurologists

12:00 p.m.–1:00 p.m.

Practice Models for Advanced Practice Providers . . . . . . 73

X = Experiential Learning

Can Aviation Accidents Teach Neurologists Patient Safety and Error Management? . . . 73

The Encompassing Value of the Patient-Physician Relationship . . . . . . . . 75

2:00 p.m.–2:30 p.m.

Caring for Telemedicine Patients . 73

2:30 p.m.–3:30 p.m.

3:00 p.m.–3:30 p.m.

1:45 p.m.–2:30 p.m.

Safety and Quality Awards . . 73

What is the AAN Doing for Small and Solo Practitioners? . 73

3:30 p.m.–4:00 p.m.

3:45 p.m.–4:30 p.m.

3:30 p.m.–5:30 p.m.

Wednesday, April 25

What Does the AAN’s Latest Guideline Mean for My Practice? . 73

C84 Evidence Based Neurology

Foresights for Busy Clinicians

C92 What Keeps You Up at Night?

Addressing Mistakes and Injuries, In-n-Out-Patient Transition, and Building a Team to Support You C94 Hot Topics in Stroke Education and Practice . . . . . . . . 103 4:00 p.m.–4:30 p.m.

Streamlining Clinic Scheduling and Access . . . . . . . . 73

4:30 p.m.–5:00 p.m.

Knowing Your Value: How to Negotiate to Get What You’re Worth . . . . . . . . . . . 73

Tuesday, April 24 10:45 a.m.–11:15 a.m.

Staying on an Academic Clinical Track . . . . . . . . 75

8:00 a.m.–9:00 a.m.

P4 Poster Session IV

Practice, Policy and Ethics I

P3.150–P3.172 . 145

12:00 p.m.–1:00 p.m.

Communicating via EHR . . . 73

12:15 p.m.–12:45 p.m.

1:00 p.m.–2:00 p.m.

Understanding Axon Registry and Using it to Improve Your Value . . . . . . . . . . . 73

1:00 p.m.–3:00 p.m.

C148 LGBTQI Health in Neurology

3:00 p.m.–4:00 p.m.

Health Care Disparities Among Underserved Populations . . . 69

3:30 p.m.–5:30 p.m.

C163 How to Run a Practice:

Business Strategies for Neurology Private Practices, Academic Centers, and the Future

Thursday, April 26 8:00 a.m.–9:00 a.m.

1:00 p.m.–1:30 p.m.

What Do I Need to Know About Coding in My Practice? . 73

1:00 p.m.–3:00 p.m.

C189 Business Strategies for Payer Negotiations and/or How to Go off the Grid

C111 Enhancing Your Career and Practice Through Neuropalliative Care

So You Want to Work for a Hospital? . . . . . . . . . 73

S28 Practice, Policy, and Ethics . . 108

Neurohospitalists 2.0, How to Craft a Satisfying and Sustainable Career . . . . . 75 Choosing Teleneurology as a Career . . . . . . . . . . 75

P4.164–P4.172 . 156

1:00 p.m.–2:00 p.m.

12:45 p.m.–1:30 p.m.

Practice, Policy and Ethics II

1:00 p.m.–1:30 p.m.

P3 Poster Session III

Step Away from the Desktop! Recapturing the Joy in Practice . 73

11:30 a.m.–7:00 p.m.

International Members: What Can the AAN Do For You? . . . 75

1:30 p.m.–2:30 p.m.

The Value of the Neurologic Exam: Caring for your Patient for $500 or Less . . . . . . 69 AAN.com/view/AM18 49

Practice/Policy/Ethics

4:30 p.m.–5:00 p.m.

Using EHR for Better Communication with Patients and Colleagues . . . . . . . 73

ANNUAL MEETING TOPIC LIST

3:15 p.m.–4:00 p.m.

ANNUAL MEETING TOPIC LIST

2018 PROGRAMS LISTED BY TOPIC 2:00 p.m.–3:00 p.m.

Using your Patients as Resources: Group Medical Visits for Improved Wellness and Efficiency . . . . . . . 73

3:30 p.m.–5:30 p.m.

12:15 p.m.–1:00 p.m.

12:20 p.m.–12:50 p.m.

C204 Making Sure You Get Paid

Under the New Health Care Laws

Friday, April 27 Incorporating a SemiConcierge Model into your Own Neurology Practice . . . 73

1:00 p.m.–3:00 p.m.

C231 ICD-10-CM: How to Optimize for Accurate Diagnosis and Reimbursement

3:30 p.m.–5:30 p.m.

C242 Coding 101: It’s Not Your Father’s Oldsmobile

Research Methodology, Education, and History

Saturday, April 21 7:00 a.m.–12:30 p.m.

C5 Clerkship and Program

Clinical Trials Methodology Course - Information Session with William Meurer MD, MS, CTMC Principal Investigator . . 77

C29 Faculty Development:

Enhancing Your Role in Student and Resident Training

Research in Residency: How to Choose the Right Project . . 75

K is for Career Development: Tips From Successful Applications for NIH Career Development Awards . . . . 75

Office Hours: The Researcher Pipeline: The Benefits of Participating in Academic Medicine, Research and Clinical Trials as a Medical Student or Resident . . . . . 77

11:30 a.m.–5:30 p.m.

P1 Poster Session I

Education: Patients

Education: Nursing, APPs, and Others

Education: Needs Analysis and Novel Fields

9:20 a.m.–9:50 a.m.

Work Life Balance in Research . 77 How to Successfully Publish Quality Improvement Projects . 77

10:00 a.m.–10:50 a.m.

Investigator Panel: How I Launched My Career with NIH Funding, Private Funding, AAN Research Program Funding and/or Government Funding . . 77

Research/Education/History

11:30 a.m.–12:00 p.m.

Office Hours: Research Careers in Industry . . . . . 77

Office Hours: Writing a Great AAN Research Program Proposal . . . . . . . . . . 77

12:00 p.m.–4:00 p.m.

C15 Resident Basic Science I: Neuropharmacology

50 2018 AAN Annual Meeting

P1.008–P1.014 . 122 P1.015–P1.026 . 122

Office Hours: Surviving as a Clinician Researcher . . . . . 77

1:00 p.m.–1:30 p.m.

Being a Great Chief Resident . 75

1:00 p.m.–3:00 p.m.

C43 Developing the Treatments of

Tomorrow I: Taking Molecules from Lab to Man

12:00 p.m.–12:30 p.m.

C57 Developing the Treatments of Tomorrow II: Clinical Trials in Neurology

1:00 p.m.–5:30 p.m.

C47 Resident Basic Science II: Neuropathology

1:20 p.m.–1:50 p.m.

So You Have a Research Idea—How Do You Turn it into a Project? . . . . . . . 77

Introduction to the Fascinating World of Movement Disorders . 75

4:30 p.m.–5:00 p.m.

How to Start a Career in Clinical Trials . . . . . . . . 77

4:45 p.m.–5:15 p.m.

Everything You Wanted to Know About the R&F Section of Neurology . . . . . . . . 75

5:00 p.m.–5:30 p.m.

Statistics and Study Design: Pearls and Pitfalls . . . . . . 77

Monday, April 23 7:30 a.m.–8:00 a.m.

Defining and Managing Your Message as An Early Career Researcher . . . . . . . . 77

7:45 a.m.–8:15 a.m.

P1.001–P1.007 . 122

12:30 p.m.–1:00 p.m.

Breaking Down Silos: Using Simulation for Interprofessional Team Education to Enhance Clinical Outcomes in Neurology . . . 73

3:30 p.m.–5:30 p.m.

10:00 a.m.–10:30 a.m.

8:15 a.m.–9:00 a.m.

8:25 a.m.–9:10 a.m.

2:00 p.m.–2:30 p.m.

7:45 a.m.–8:15 a.m.

Hall of Presidents: Using Past Experience to Solve the Futures Problems . . . . . . 69

4:15 p.m.–5:00 p.m.

7:00 a.m.–9:00 a.m.

7:30 a.m.–8:15 a.m.

Are You My Mentor? How to Select a Good Mentor for Your Research Career . . . . . . 77

Sunday, April 22

Directors Conference: Demonstrating Your Impact as a Medical Educator

How to Find Training: The Best Clinical Research and Methodology Training Options . 77

1:30 p.m.–2:30 p.m.

1:40 p.m.–2:10 p.m.

12:00 p.m.–12:30 p.m.

What I Learned About Research— An Early Career Perspective . . . 75

Using the R&F Section of Neurology for your Residents and Residency . . . . . . . 75

8:15 a.m.–9:00 a.m.

Choosing An Academic Career in Neurology: Perspectives for Early Career Investigators and Foreign Medical Graduates . . 75

11:30 a.m.–7:00 p.m.

P2 Poster Session II

Undergraduate Medical Education: Assessment and Curricular Design I

Undergraduate Medical Education: Novel Formats

Health Services Research and Methodologies

Education: Career Choice and Attitudes

P2.001–P2.005 . 132 P2.006–P2.011 . 132 P2.012–P2.016 . 132

P2.017–P2.026 . 132

Finding Your Niche in Neurology: Perspectives from an Epileptologist and Educator . 75

12:00 p.m.–12:30 p.m.

Office Hours: Working with an Epidemiologist . . . . . . . 77

12:45 p.m.–1:30 p.m.

Transitioning From a Clinical Research Career to an Educational and Clinical Focused Career . . . . . . . 75

1:00 p.m.–3:00 p.m.

S14 Education and Patient

Outcomes Research . . . . 101

1:00 p.m.–5:30 p.m.

C82 Resident Basic Science III:

Neuroanatomy: All the Lesions

12:30 p.m.–1:00 p.m.

12:40 p.m.–1:10 p.m.

Office Hours: Defining and Managing Your Message As An Early Career Scientist . . . 77

Up Your Game as a Medical Educator in Neurology . . . . 75

5:15 p.m.–6:15 p.m.

Practicing Neurology in the 1960s and 1970s . . . . . . 69

Tuesday, April 24 8:00 a.m.–8:30 a.m.

Welcome to NINDS Day/ Overview of NIH Funding with NINDS Director and NINDS Deputy Director . . . . . . . 77

8:40 a.m.–9:10 a.m.

Research and Methods

1:20 p.m.–1:50 p.m.

Graduate Medical Education: Assessment and Curricular Design II

P3.001–P3.007 . 142

P3.008–P3.014 . 142

Graduate Medical Education: Burnout and Professionalism Graduate Medical Education: Novel Formats

P3.015–P3.026 . 142

Research Methodology ePoster Session

P3.339–P3.344 . 149

2:00 p.m.–2:30 p.m.

NINDS Clinical Trials (new NIH definition) and networks, NeuroNEXT, StrokeNET, SIREN . 77

2:30 p.m.–3:00 p.m.

How to Start a Career in Neurology Education . . . . . 75

2:40 p.m.–3:10 p.m.

Pain Research Funding Opportunities, Clinical and Basic . 77

Training in Neurology While on a Visa: Challenges and Possible Solutions for Foreign Medical Graduates . . . . . 75

3:15 p.m.–3:45 p.m.

Staying on Track: A Career as a Clinical Researcher . . . . . 75

3:20 p.m.–3:50 p.m.

Pain Research Funding Opportunities, Clinical and Basic . 77

4:00 p.m.–4:30 p.m.

Your Grant Proposal Was Rejected: Now What? Turning a Feedback Into a Successful Project . . . . . . . . . . 77

Wednesday, April 25 8:00 a.m.–9:10 a.m.

Office Hours: How to Get a K-Award . . . . . . . . . . 77

How to Write and Publish Research Papers, Reviews and Other Scientific Communications . . . . . . . 77

8:15 a.m.–9:00 a.m.

X = Experiential Learning

12:00 p.m.–12:30 p.m.

Office Hours: Recruiting Difficult and Underrepresented Populations in Research . . . . . . . . 77

12:45 p.m.–1:30 p.m.

Clinical Research in the Area of Practice, Quality and Patient Safety . . . . . . . 75

1:00 p.m.–1:50 p.m.

Community Education in Minority Population . . . . . 77

1:00 p.m.–3:00 p.m.

C150 Where is the Lesion? A History of Neurological Investigations Part I

3:00 p.m.–3:30 p.m.

Office Hours: Research Careers in Industry . . . . . 77

3:30 p.m.–5:30 p.m.

C165 Where is the Lesion? A History of Neurological Investigation Part II

3:45 p.m.–4:30 p.m.

Navigating Fellowship in Neurology . . . . . . . . . 75

Thursday, April 26 11:30 a.m.–7:00 p.m.

P5 Poster Session V

2:45 p.m.–3:30 p.m.

12:00 p.m.–12:30 p.m.

Academic Career Panel: Find out How to Get Your Career Started . . . . . . . . . . 75

Office Hours: Selecting an AAN Research Program Mentor . . . 77

History of Neurology

P5.295–P5.316 . 168

12:45 p.m.–1:30 p.m.

Effective Neurology Residency Program . . . . . . . . . . 75

1:00 p.m.–1:30 p.m.

Office Hours: Early Career Research Funding and Career Development . . . . . . . . 77

1:00 p.m.–2:15 p.m.

S39 History of Neurology . . . . . 112

4:30 p.m.–5:00 p.m.

Grantwriting 101: Getting Started . . . . . . . . . . 77

4:30 p.m.–5:30 p.m.

Neurology History: Weaving Past with Present . . . . . . 69

Friday, April 27 12:30 p.m.–1:00 p.m.

Office Hours: Making the Transition from Research Fellow to Clinical Research Faculty . . . . . . . . . . 77

How to Give Effective Feedback . 75 AAN.com/view/AM18 51

Research/Education/History

Office Hours: Clinical Research Recommendations for Residents and Fellows . . .77

1:45 p.m.–2:15 p.m.

11:30 a.m.–7:00 p.m.

P3 Poster Session III

NIH Grant Review Process . . 77

1:30 p.m.–2:00 p.m.

K Awards and Training Programs . 77

Reviewer to Editorial Board to Editor . . . . . . . . . . 75

Office Hours: VA Research Funding: Career Development Awards . . . . . . . . . . 77

C117 Introduction to Clinical

11:30 a.m.–12:00 p.m.

1:00 p.m.–3:00 p.m.

2:45 p.m.–3:30 p.m.

NIH Funding and Professional Development Opportunities for Diverse Researchers . . . 77

8:30 a.m.–9:00 a.m.

1:00 p.m.–1:30 p.m.

2:30 p.m.–3:00 p.m.

Office Hours: Bridge Funding . 77

ANNUAL MEETING TOPIC LIST

11:45 a.m.–12:30 p.m.

ANNUAL MEETING TOPIC LIST

2018 PROGRAMS LISTED BY TOPIC 12:40 p.m.–1:10 p.m.

3:30 p.m.–5:30 p.m.

2:40 p.m.–3:10 p.m.

Tuesday, April 24

How to Put Together an Effective Research Presentation . . . . . 77 Recruiting Minorities . . . . 77

4:00 p.m.–4:30 p.m.

S17 Sleep . . . . . . . . . . 102

C101 Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist

10:00 a.m.–10:30 a.m.

Sleep: Why You Should Spend Your Career Helping People Do It Right . . . . . . . . . . 75

Sunday, April 22 11:30 a.m.–5:30 p.m.

P1 Poster Session I

Sleep: Neurology and Sleep-Disordered Breathing/Sleep Apnea

Sleep: Too Much, Too Little, Abnormal Timing, and Parasomnias

P1.103–P1.117 . 124

9:15 a.m.–11:30 a.m.

C113 Sleep for the Practicing

Neurologist I: Is it Narcolepsy or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence

3:30 p.m.–5:30 p.m.

C126 Sleep for the Practicing

Neurologist II: Night Fighting: Sleep Related Hypermotor Epilepsy, Sleepwalking, and Dream Enactment

Sleep: A Frequently Forgotten Part of Your Patient’s Day . . . 75

Monday, April 23 Contemporary Clinical Issues Plenary Session: 9:40 a.m.–9:55 a.m. Predictors of Neurodegeneration in Idiopathic REM Sleep Behavior Disorder: A Multicenter Cohort Study . . 62

Clinical Trials Plenary Session: 10:15 a.m.–10:30 a.m. A Randomized, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Solriamfetol (JZP-110) for the Treatment of Excessive Sleepiness (ES) in Participants with Narcolepsy Types 1 and 2 (NT1/2) . 63

1:00 p.m.–3:00 p.m.

P1.091–P1.102 . 124

12:15 p.m.–1:00 p.m.

C141 Integrating Sleep Medicine Concepts into Your Child Neurology Practice

9:15 a.m.–11:30 a.m.

Saturday, April 21 X

7:00 a.m.–9:00 a.m.

Historical Perspective on Treating Epilepsy . . . . . . 77

Sleep

Wednesday, April 25

4:00 p.m.–4:45 p.m.

The Sleep Mythbuster!: Illuminating the Facts and Fiction Towards Achieving the Sleep Healthy Neurologist . . 71

Frontiers in Neuroscience Plenary Session: 9:55 a.m.–10:15 a.m. Biology of Bedtime: Understanding Circadian Rhythms and Sleep . 64

1:00 p.m.–3:00 p.m.

C153 Circadian Rhythm Disorders: Implications for Neurology

3:30 p.m.–5:30 p.m.

Invited Science: Sleep . . . . 89

Thursday, April 26 7:00 a.m.–9:00 a.m.

C173 Using Sleep Medicine to Help

Solve Difficult Neurologic Cases

8:00 a.m.–8:45 a.m.

Sleep and Performance in Elite Athletes . . . . . . . . 71

1:00 p.m.–3:00 p.m.

C183 Hot Topics in Sleep Neurology

Friday, April 27 7:00 a.m.–9:00 a.m.

C221 REM Sleep Behavior Disorder

3:30 p.m.–5:30 p.m.

N7 Neuroscience in the Clinic:

REM Sleep Behavior Disorder: Past, Present, Future . . . . . 85

2019 ANNUAL MEETING COURSE PROPOSAL SUBMISSIONS Sleep

The AAN is seeking submissions for course proposals for the 2019 Annual Meeting. The submission deadline is May 18, 2018. Please visit aan.com/view/courseproposals for additional information and guidelines.

52 2018 AAN Annual Meeting

Business of Neurology Track We’ve curated audience-focused programming into select tracks to make navigating the meeting easier than ever. This lineup was created specifically for those starting a new practice, as well as anyone who wants to learn the fundamentals of neurology business.

Saturday, April 21 12:00 p.m.–4:00 p.m.

C16 L Leadership Challenges in Practice

2:00 p.m.–2:30 p.m.

Paths for Success in the Quality Payment Program . . . 73

2:30 p.m.–3:00 p.m.

Ask the Expert: Paths for QPP Success . . . . . . . . . . 73

3:00 p.m.–3:30 p.m.

Clinical Decision Support for Ordering of Diagnostic Imaging . 73

Sunday, April 22 3:00 p.m.–3:30 p.m.

Tip of the Iceberg: Ultra-High Cost Neurology Drugs . . . . 73

3:30 p.m.–4:00 p.m.

How to Increase Investments in Neuroscience Research . . 73

Monday, April 23 3:30 p.m.–4:00 p.m.

What Does the AAN’s Latest Guideline Mean for My Practice? . 73

4:00 p.m.–4:30 p.m.

Streamlining Clinic Scheduling and Access . . . . . . . . 73

4:30 p.m.–5:00 p.m.

Knowing Your Value: How to Negotiate to Get What You’re Worth . . . . . . . . . . . 73

Tuesday, April 24 12:00 p.m.–1:00 p.m.

Communicating via EHR . . . 73

1:00 p.m.–2:00 p.m.

Understanding Axon Registry and Using it to Improve Your Value . . . . . . . . . . . 73

2:30 p.m.–3:30 p.m.

What is the AAN Doing for Small and Solo Practitioners? . 73

X = Experiential Learning

Wednesday, April 25 8:00 a.m.–9:00 a.m.

Step Away from the Desktop! Recapturing the Joy in Practice . 73

1:00 p.m.–1:30 p.m.

So You Want to Work for a Hospital? . . . . . . . . . 73

3:30 p.m.–5:30 p.m.

C163 How to Run a Practice:

Business Strategies for Neurology Private Practices, Academic Centers, and the Future

Thursday, April 26 1:00 p.m.–3:00 p.m.

C189 Business Strategies for Payer Negotiations and/or How to Go off the Grid

3:30 p.m.–5:30 p.m.

C204 Making Sure You Get Paid

Under the New Health Care Laws

Friday, April 27 1:00 p.m.–3:00 p.m.

C231 ICD-10-CM: How to Optimize for Accurate Diagnosis and Reimbursement

3:30 p.m.–5:30 p.m.

C242 Coding 101: It’s Not Your Father’s Oldsmobile

C23 Critical Care Consultations for Neurohospitalists

Sunday, April 22 7:00 a.m.–9:00 a.m.

C27 Neurological Intensive Care I: The Essentials

1:00 p.m.–3:00 p.m.

C36 Clinical Neurology for

Advanced Practice Providers I

C39 Therapy in Neurology I: Headache and Stroke

C40 Autoimmune Neurology

I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS

1:00 p.m.–5:30 p.m.

C47 Resident Basic Science II: Neuropathology

3:30 p.m.–5:30 p.m.

C50 Low and High Pressure

Headache: Clinical Presentation and Approach to Evaluation and Management C51 Clinical Neurology for Advanced Practice Providers II C54 Therapy in Neurology II: Epilepsy and Movement Disorders

Monday, April 23 7:00 a.m.–9:00 a.m.

Foundations in Clinical Neurology Track For Advanced Practice Providers who are new to neurology, this track will help lay the foundation for success as a new care team member

Saturday, April 21 7:00 a.m.–9:00 a.m.

C1 Mild Cognitive Impairment: Implications for Clinicians

C2 Functional Neurologic

Disorders I: Movement, Seizures, and Multiple Sclerosis

9:30 a.m.–11:30 a.m.

C14 Parkinson’s Disease Update

12:00 p.m.–4:00 p.m.

C15 Resident Basic Science I: Neuropharmacology

1:30 p.m.–3:30 p.m.

C22 Stroke in Young Adults and Women

C66 Update on Medical

Management of Stroke

C68 Cognitive Impairment Due to Alzheimer’s Disease: Using Old Skills and New Tools for Diagnosis and Treatment

1:00 p.m.–3:00 p.m.

C70 Evaluating Tremor in the Office C75 Safe and Appropriate Opioid Prescribing in Neurology

C79 Comprehensive Migraine

Education Program I: Diagnosis, Risk Factors, and Neurobiology

1:00 p.m.–5:30 p.m.

C82 Resident Basic Science III:

Neuroanatomy: All the Lesions

3:30 p.m.–5:30 p.m.

C86 Child Neurology III: Headache, TBI/Post-concussion

C90 Comprehensive Migraine

Education Program II: Behavioral and Psychological Approaches, and Preventive and Acute Treatment Advances

AAN.com/view/AM18 53

PROGRAM TRACKS

2018 PROGRAM TRACKS

PROGRAM TRACKS

2018 PROGRAM TRACKS Tuesday, April 24 7:00 a.m.–9:00 a.m.

C98 Multiple Sclerosis Overview I:

Clinical Pearls C101 Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist C102 Movement Disorders for the General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson’s Disease 1:00 p.m.–3:00 p.m.

C108 Introduction to Primary

Headache Disorders I: Migraine and Other Primary Headaches Including Tension-Type, Hypnic, Primary Stabbing and Nummular Headache Syndromes, Epicrania Fugax and Retinal Migraine C109 Multiple Sclerosis Overview II: Clinical Advances C116 Cerebrovascular Disease I: Prevention 3:30 p.m.–5:30 p.m.

C121 Introduction to Primary

Headache Disorders II: Trigeminal Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches C123 Child Neurology: A Casebased Approach C129 Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke

Wednesday, April 25 7:00 a.m.–9:00 a.m.

C135 Neurocognitive Assessment

for Neurologists C136 Multiple Sclerosis Therapy: Disease-modifying Treatment I C137 What Do I Do Now?: Emergency and Inpatient Management of Migraine and Other Headache Disorders 1:00 p.m.–3:00 p.m.

C144 Neurology Update I: Epilepsy, Behavioral Neurology, and Neurologic Infections C146 Non-Alzheimer’s Dementia I: Frontotemporal Dementias

54 2018 AAN Annual Meeting

C147 Multiple Sclerosis Therapy:

Disease-modifying Treatment II

3:30 p.m.–5:30 p.m.

C160 Neurology Update II:

Movement Disorders, Spine Disorders, and Sleep Disorders C161 Non-Alzheimer’s Dementia II: Lewy Body Dementias and Other Parkinsonian Dementias

Thursday, April 26 7:00 a.m.–9:00 a.m.

C172 Clinical Epilepsy I: Basics C175 Clinical Pearls in Autoimmune Neurology: Real World Cases

1:00 p.m.–3:00 p.m.

C182 Clinical Epilepsy II:

Considerations Across the Age Span Pediatrics, Pregnancy, and Elderly C185 Neurology Update III: Neuromuscular, Headache, and Stroke C193 Assessment of Rapidly Progressive Dementias I: Overview, Prion Diseases, and Antibody-Mediated Rapidly Progressive Dementia 1:00 p.m.–5:30 p.m.

C196 Brain Death Skills Workshop:

How to Perform a Brain Death Evaluation, Avoid Pitfalls and Convey the News to the Family

3:30 p.m.–5:30 p.m.

C199 Neurology Update IV:

Multiple Sclerosis, Neuroophthalmology, and Autoimmune Encephalopathies C208 Assessment of Rapidly Progressive Dementias II: Neurodegenerative Diseases and Infections Presenting as Rapidly Progressive Dementia 6:30 p.m.–9:30 p.m.

C211 Case Studies in the ICU C214 Case Studies: Challenging

Headache Cases C215 Case Studies in Behavioral Neurology: Focus on Frontotemporal Degeneration

Friday, April 27 7:00 a.m.–9:00 a.m.

C217 Current Management of

Incidental and Asymptomatic Cerebrovascular Lesions C219 The Early-Onset Dementias

C223 The Burden of Epilepsy:

Managing Comorbidities and Quality of Life

1:00 p.m.–3:00 p.m.

C225 Neuromuscular Junction

Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia C226 Infections of the Nervous System II: Neuro-ID Emergencies C228 Neuroimaging for the General Neurologist I: Brain 3:30 p.m.–5:30 p.m.

C240 Neuroimaging for the General Neurologist II: Brain C243 Hot Topics in Headaches and Related Disorders II: Unusual Headaches, Childhood Headaches, and Concussion Management

Neurohospitalist Track Created specifically for neurohospitalists whose primary focus is inpatient care, or for anyone who would like to learn more about the care of hospitalized patients, this lineup of programming will cover the gamut from prevention, telestroke, critical care monitoring and consultations, and issues encountered in the ICU.

Saturday, April 21 7:00 a.m.–9:00 a.m.

C3 Emergency Room Neuroophthalmology

9:30 a.m.–11:30 a.m.

C8 Emergency Neurology:

Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room

1:30 p.m.–3:30 p.m.

C22 Stroke in Young Adults and Women C23 Critical Care Consultations for Neurohospitalists

Sunday, April 22 7:00 a.m.–9:00 a.m.

C27 Neurological Intensive Care I: The Essentials

1:00 p.m.–3:00 p.m.

C38 Neurological Intensive Care

II: Acute Brain and Spinal Cord Injury and Acute Neuromuscular Dysfunction

I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS

3:30 p.m.–5:30 p.m.

C53 Neurological Intensive Care III: Vascular Diseases C55 Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience

Monday, April 23 7:00 a.m.–9:00 a.m.

C66 Update on Medical

Management of Stroke

1:00 p.m.–3:00 p.m.

C78 Therapeutic Temperature Modulation in the ICU

3:30 p.m.–5:30 p.m.

C95 Actualización Sobre las

Infecciones del Sistema Nervioso Central y la Medicina Tropical

Tuesday, April 24 7:00 a.m.–9:00 a.m.

C96 Status Epilepticus

1:00 p.m.–3:00 p.m.

C106 Critical Care EEG Monitoring C116 Cerebrovascular Disease I: Prevention

3:30 p.m.–5:30 p.m.

C124 The Palliative Care Guide in

Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders C129 Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke

Wednesday, April 25 7:00 a.m.–9:00 a.m.

3:30 p.m.–5:30 p.m.

C166 Cerebrovascular Disease IV: Telestroke

Thursday, April 26 7:00 a.m.–9:00 a.m.

C177 So You’ve Diagnosed Your

Patient with a Neuroinfectious Disease, Now What? Practical Pearls in the Treatment and Management of Neuroinfectious Diseases

1:00 p.m.–3:00 p.m.

C190 Neuro-oncologic Predicaments in the Hospital Setting C194 Actualización Sobre el Manejo del Ictus Cerebrovascular

1:00 p.m.–5:30 p.m.

C196 Brain Death Skills Workshop:

How to Perform a Brain Death Evaluation, Avoid Pitfalls and Convey the News to the Family

3:30 p.m.–5:30 p.m.

C201 Differential Diagnosis of

Neurologic Infections C203 Endovascular Treatment of Acute Stroke and Cerebrovascular Disease 6:30 p.m.–9:30 p.m.

C211 Case Studies in the ICU

Friday, April 27

Spanish Language Track We’re expanding our Spanish-language curriculum! Look for education courses and experiential learning area talks on a variety of topics, including MS, epilepsy, stroke, CNS infection and tropical medicine, and more— taught entirely in Spanish.

Sunday, April 22 3:30 p.m.–5:30 p.m.

C59 Actualización Sobre el

Tratamiento de la Esclerosis Múltiple

Monday, April 23 3:30 p.m.–5:30 p.m.

C95 Actualización Sobre las

Infecciones del Sistema Nervioso Central y la Medicina Tropical

Tuesday, April 24 3:30 p.m.–5:30 p.m.

C132 Actualization Científica

Durante el Congreso Anual I

Wednesday, April 25 3:30 p.m.–5:30 p.m.

C171 Actualización Sobre Opciones

Terapéuticas para la Epilepsìa Farmacorresistente

7:00 a.m.–9:00 a.m.

C218 Infections of the Nervous

System I: Diagnostic Testing of Neurological Infections C220 Drugs and Toxin-induced Neurologic Emergencies 1:00 p.m.–3:00 p.m.

C226 Infections of the Nervous

System II: Neuro-ID Emergencies C230 Neurologic Complications of Medical and Surgical Therapies 3:30 p.m.–5:30 p.m.

C239 Infections of the Nervous

System III: Advanced Topics in Infectious Neurology

Thursday, April 26 1:00 p.m.–3:00 p.m.

C194 Actualización Sobre el Manejo del Ictus Cerebrovascular

3:00 p.m.–4:00 p.m.

Consejos Prácticos para un Buen Examen Neurológico . . 69

Friday, April 27 1:00 p.m.–3:00 p.m.

C233 Simposio Español:

Actualización Científica Durante el Congreso Anual II

C137 What Do I Do Now?:

Emergency and Inpatient Management of Migraine and Other Headache Disorders

1:00 p.m.–3:00 p.m.

C145 Severe TBI: From ICU to Rehabilitation

C151 Cerebrovascular Disease III:

Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke

X = Experiential Learning

AAN.com/view/AM18 55

PROGRAM TRACKS

C40 Autoimmune Neurology

Industry Therapeutic Updates

Saturday, April 21 | Monday, April 23 | Tuesday, April 24 Registration is free and open to registered Annual Meeting attendees. Representatives from the following companies invite you to an informational session on therapeutic updates. This program provides you the opportunity to learn about current therapies and projects in the industry pipeline.

Saturday, April 21 Amgen & Novartis Pharmaceuticals Corp. Enhanced Conversation with the Migraine Patient... Assessment, Diagnosis and Management Location: JW Marriott LA Live Diamond Salon 5

GE Healthcare Location: JW Marriott LA Live Platinum Ballroom A-C

Monday, April 23 CSL Behring Location: Hotel Indigo Los Angeles Orpheum Ballroom

Ionis Pharmaceuticals Location: Westin Bonaventure Hotel Beaudry Ballroom B

Genentech, A Member of the Roche Group Industry Therapeutic Update from Genentech Location: JW Marriott LA Live Platinum Ballroom A – D

Mitsubishi Tanabe Pharma America Location: JW Marriott LA Live Gold Ballroom 3 Novartis Pharmaceuticals Corp. Location: Westin Bonaventure Hotel Palos Verdes Ballroom

Sunovion Pharmaceuticals Inc. A Spotlight on Parkinson’s Disease and Innovation Location: JW Marriott LA Live Platinum Ballroom F – J Teva CNS Location: JW Marriott LA Live Gold Ballroom 1

RSVP is recommended for these events. No CME will be given by any accredited organization for the Industry Therapeutic Updates, and the AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

| Wednesday, April 25 | Starting at 7:00 p.m.

Tuesday, April 24 Abbott Location: Hotel Indigo Los Angeles Orpheum Ballroom B Adamas Pharmaceuticals, Inc. Location: Westin Bonaventure Hotel San Jose and San Diego Ballroom

Biogen Navigating an Early Diagnosis of Alzheimer’s Disease: A Call for Action Location: JW Marriott LA Live Diamond Salon 1 - 4 Biogen Location: JW Marriott LA Live Platinum Ballroom C

Alnylam Pharmaceuticals, Inc. Advancing the Care of Patients with hATTR Amyloidosis: Diagnostic Biogen Challenges and Potential New Therapies Location: JW Marriott LA Live Location: Westin Bonaventure Hotel Platinum Ballroom H - J San Francisco Ballroom

Biogen Location: JW Marriott LA Live Gold Ballroom 4 Sarepta Therapeutics Location: Hotel Indigo Los Angeles Metropolitan Ballroom Teva CNS Location: JW Marriott LA Live Gold Ballroom 2

Wednesday, April 25 EMD Serono, Inc. Location: JW Marriott LA Live Platinum Ballroom

Sanofi Genzyme Predicting Patient Trajectory in MS: How Advanced Prognostic Measures Can Support More Informed Treatment Decisions Location: JW Marriott LA Live Gold Ballroom 3 & 4

Please visit AAN.com/view/ITU for more information.

Los Angeles Friday April 20, 2018 10:00 a.m.–4:00 p.m. LA CONVENTION CENTER

See How We’re Giving Back to the Los Angeles Community Designed to connect neurology patients, families, caregivers, and students throughout the Los Angeles area to local and national experts to learn the latest research advances and get their toughest questions answered.

Encourage Your Patients to Attend The Brain Health Fair is a free public event! If you have patients in the area, let them know about this fun-filled, educational event—everyone’s welcome!

Seeking Physician Volunteers While this event is designed for the public, we are looking for volunteers—including Spanish-speaking physicians— to help out during the event in many different ways. Contact wvokaty@aan.com if you’re interested.

Learn more at BrainHealthFair.com

PLENARY SESSIONS

hese daily not-to-be-missed premier sessions offer a unique opportunity to hear from some of the most inspiring and innovative thought leaders in the field of neurology.

Hot Topics Plenary Session

Saturday, April 21 4:15 p.m.–5:30 p.m. . . . . .

Presidential Plenary Session

Sunday, April 22 9:15 a.m.–12:00 p.m. . . . . .

60 61

Contemporary Clinical Issues Plenary Session Monday, April 23 9:15 a.m.–11:30 a.m. . . . . .

Clinical Trials Plenary Session

Tuesday, April 24 9:15 a.m.–11:30 a.m. . . . . .

Frontiers in Neuroscience Plenary Session Wednesday, April 25 9:15 a.m.–11:30 a.m. . . .

63 64

Controversies in Neurology Plenary Session

Thursday, April 26 9:15 a.m.–11:30 a.m. . . . . . 65

Neurology Year in Review: Emerging Therapies Plenary Session

Friday, April 27 9:15 a.m.–11:30 a.m. . . . . . . 66

AAN.com/view/AM18 59

PLENARY SESSIONS

HOT TOPICS PLENARY SESSION

Saturday, April 21 4:15 p.m.–5:30 p.m.

This session features translational research related to clinical issues of importance. Four outstanding physicianscientists provide summaries of their recent research findings and describe the clinical implications of the results. This plenary session will feature audience response technology to create an interactive attendee experience. Please look for more details during this session at the Annual Meeting.

Moderator Eric Klawiter, MD

Member, Science Committee

Coming of Age: Clinical Implementation of Metagenomics for Diagnosis in Meningitis and Encephalitis Michael R. Wilson, MD

Opioid Receptor Modulation of Headache Amynah Pradhan, PhD

University of Illinois at Chicago, Chicago, IL

niversity of California San Francisco, San U Francisco, CA

Saturday

Brain Stimulation for Memory Faculty

Monitoring Multiple Sclerosis Using Blood Neurofilament Light Protein Jens Kuhle, MD

Universitätsspital Basel, Oberwil, Switzerland

60 2018 AAN Annual Meeting

Sunday, April 22 9:15 a.m.–12:00 p.m.

This session features the AAN’s premier lecture awards for clinically relevant research and a presentation by a leading lecturer. Top researchers speak on some of the most significant findings in neurology in 2018.

Moderator Natalia S. Rost, MD, MPH, FAAN, FAHA

PLENARY SESSIONS

PRESIDENTIAL PLENARY SESSION

Chair, Science Committee

Presidential Lecture California Dreaming: BRAIN and Precision Medicine in 2018 Francis S. Collins, MD, PhD

irector of National Institutes of Health, D Bethesda, MD

Richard S. Finkel, MD

George C. Cotzias Lecture How Early-Life Experiences Sculpt Your Brain: From Molecules to Circuits

Robert Wartenberg Lecture Neuro-oncology: How Cancer and the Nervous System Interact

Tallie Z. Baram, MD, PhD

Lisa M. DeAngelis, MD, FAAN

Nemours Children’s Hospital, Orlando, FL

emorial Sloan-Kettering Cancer Center, M New York, NY

AAN.com/view/AM18 61

Sunday

University of CA-Irvine, Irvine, CA

Sidney Carter Award in Child Neurology Spinal Muscular Atrophy Is a Treatable Neurodegenerative Disease

PLENARY SESSIONS

CONTEMPORARY CLINICAL ISSUES PLENARY SESSION G Monday, April 23

9:15 a.m.–11:30 a.m.

This session highlights issues most critical to practicing neurologists, including abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments. Commentary and discussion follow each presentation.

Moderator Randolph S. Marshall, MD, FAAN Vice Chair, Science Committee Retinal Microvasculature in Predicting Risk of Stroke Subtypes Presenter:

Neuropalliative Care

Michelle P. Lin, MD

Maisha T. Robinson, MD, MS

J ohns Hopkins University School of Medicine, Baltimore, MD

Mayo Clinic, Jacksonville, FL

Discussant:

Valerie Biousse, MD Atlanta, GA

Predictors of Neurodegeneration in Idiopathic REM Sleep Behavior Disorder: A Multicenter Cohort Study Presenter:

Biosimilars and Non-biologic Complex Drugs

Ronald Postuma, MD

Jeffrey Allan Cohen, MD

ontreal General Hospital, M Montreal, QC, Canada

Cleveland Clinic, Cleveland, OH

Discussant:

leksandar Videnovic, A MD, MSc, FAAN

Monday

GH Neurological Clinical Research M Institute, Boston, MA

Pediatric Brainstem Encephalitis Outbreak Investigation with Metagenomic Next-Generation Sequencing Presenter:

Kristoffer Edgar Leon niversity of California San U Francisco, San Francisco, CA

Discussant:

Shibani Mukerji, MD

assachusetts General Hospital, M Boston, MA

62 2018 AAN Annual Meeting

Non-invasive Neuromodulation eborah I. Friedman, MD, D MPH, FAAN

niversity of Texas Southwestern Medical U Center, Dallas, TX

Tuesday, April 24 9:15 a.m.–11:30 a.m.

This session covers important clinical topics identified from other society meetings that affect patient care. The latest updates within several clinical trials conducted over the course of the last year will be presented. This plenary session will feature audience response technology to create an interactive attendee experience. Please look for more details during this session at the Annual Meeting.

Moderators Deborah Hall, MD, PhD, FAAN Member, Science Committee

Holly E. Hinson, MD, MCR Member, Science Committee

Natalia S. Rost, MD, MPH, FAAN, FAHA

PLENARY SESSIONS

CLINICAL TRIALS PLENARY SESSION

Chair, Science Committee

Effects of IONIS-HTTRx in Patients with Early Huntington’s Disease, Results of the First HTT-Lowering Drug Trial Sarah J. Tabrizi

niversity of College London U London, United Kingdom

A Randomized, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Solriamfetol (JZP-110) for the Treatment of Excessive Sleepiness (ES) in Participants with Narcolepsy Types 1 and 2 (NT1/2) Michael J. Thorpy, MD

Montefiore Medical Center, Bronx, NY

Expanding the Time Window for Thrombectomy: Results of the DEFUSE 3 Study

A Phase II Trial of Ibudilast in Progressive Multiple Sclerosis

Gregory W. Albers, MD

Cleveland Clinic, Cleveland, OH

Robert J. Fox, MD, FAAN

Stanford University, Stanford, CA

Brain Oxygen Optimization in Severe Traumatic Brain Injury (BOOST) Phase 2 Trial: Towards Evidence-Based in the Neurological Intensive Care Unit

David D. Adams

amon R. Diaz-Arrastia, MD, R PhD, FAAN

A PHP, Le Kremlin-Bicetre, France

P enn Presbyterian Medical Center, Philadelphia, PA

Precision Medicine: Intracerebroventricular Enzyme Replacement Therapy with Cerliponase Alfa in Children with CLN2 Disease: Results from an Ongoing Multicenter Study Emily C. De Los Reyes, MD

Nationwide Childrens Hospital, Columbus, OH

= Abstract of Distinction

AAN.com/view/AM18 63

Tuesday

Patisiran, a RNAi Therapeutic, to Improve Outcomes in Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy

PLENARY SESSIONS

FRONTIERS IN NEUROSCIENCE PLENARY SESSION G Wednesday, April 25

9:15 a.m.–11:30 a.m.

This plenary session features basic and translational research related to clinical issues of importance. Six outstanding physician-scientists provide summaries of their recent research findings and describe the clinical implications of the results.

Moderator Paul M. George, MD, PhD, MSE Member, Science Committee

The Dynamics of the Unconscious Brain Under General Anesthesia Emery Brown, MD, PhD

Combining Patient-Derived Cell and Animal Models to Uncover Epilepsy Mechanisms and Precision Therapies

assachusetts Institute of Technology, M Cambridge, MA

Jack M. Parent, MD

Does Connectomics Make Sense?

BigBrain: A High Resolution 3D Digital Human Brain Atlas

Jeff Lichtman, MD, PhD

University of Michigan, Ann Arbor, MI

Wednesday

Harvard University, Cambridge, MA

Alan Evans, PhD

Biology of Bedtime: Understanding Circadian Rhythms and Sleep

Pediatric MS: A Unique Window into Environmental and Genetic Risk Factors for MS

Amita Sehgal, PhD

University of Pennsylvania, Haverford, PA

64 2018 AAN Annual Meeting

McGill University, Montreal, QC, Canada

Emmanuelle Waubant, MD, FAAN UCSF MS Center, San Francisco, CA

9:15 a.m.–11:30 a.m.

This session features experts discussing the most current and controversial issues in neuroscience. It is set up as a debate format in which two speakers argue one side of a single topic, followed by a rebuttal. This plenary session will feature audience response technology to create an interactive attendee experience. Please look for more details during this session at the Annual Meeting.

Moderators Aleksandar Videnovic, MD, MSc, FAAN Member, Science Committee

PLENARY SESSIONS

CONTROVERSIES IN NEUROLOGY PLENARY SESSION G Thursday, April 26

Amy R. Brooks-Kayal, MD, FAAN Member, Science Committee

Should We Use Biomarkers Alone For Diagnosis of Alzheimer’s?

Would You Let Your Child Play Contact Sports?

Yes:

Faculty

J ack W. Tsao, MD, DPhil, FAAN

No:

Maria Glymour, ScD, MS niversity of California, San U Francisco, San Francisco, CA

Memphis, TN

No:

Christopher Giza, MD CLA, Dept of Neurosurgery, U Los Angeles, CA

Should the Neurologist Be Primarily Responsible for Taking Care of Patients with Functional Disorders? Yes:

David L. Perez, MD

assachusetts General Hospital, M Boston, MA

No:

Andrea Leigh Haller, MD F ort Wayne Neurological Center, Fort Wayne, IN

Thursday

AAN.com/view/AM18 65

PLENARY SESSIONS

NEUROLOGY YEAR IN REVIEW: EMERGING THERAPIES PLENARY SESSION

Friday, April 27 9:15 a.m.–11:30 a.m.

This session will feature six speakers, each focusing on the latest research that has happened in the last year within a specific subspecialty topic.

Moderator Antonio M. P. Omuro, MD Member, Science Committee

A Year in Review of Neuromuscular Diseases: Making Treatments Great Again Ericka P. Simpson, MD, FAAN

Pediatric Epilepsy Kelly G. Knupp, MD

Children’s Hospital Colorado, Aurora, CO

Methodist Hospital, Houston, TX

Neuro-oncology Year in Review: Progress, Breakthroughs, and Future Directions Antonio M. P. Omuro, MD

Dementia Liana Apostolova, MD, FAAN I ndiana University School of Medicine, Indianapolis, IN

niversity of Miami Miller School of Medicine, U Miami, FL

Headache Medicine 2018: Year in Review Matthew S. Robbins, MD, FAAN Montefiore Headache Center, Bronx, NY

Friday 66 2018 AAN Annual Meeting

Finally, Some Closure on PFO Closure teven R. Messé, MD, S FAAN, FAHA

ospital of the University of Pennsylvania, H Philadelphia, PA

EXPAND YOUR HORIZONS WITH EXPERIENTIAL LEARNING AREAS

e’re taking learning outside the traditional classroom, every day of the meeting, with dynamic and interactive areas that will offer a variety of real-world experiences to engage you intellectually, emotionally, and socially and offer you fresh ideas to help you personally and professionally.

2. Live Well: Taking Care of Your Patients Starts with Taking Care of You! Start each day with a guided yoga session to refresh your mind and body. Return to the Kentia Foyer throughout the week for thought-provoking sessions revolving around better self-care practices for both you and your patients.

1. HeadTalks Discover transformational experiences in this unconventional platform. Nontraditional neurology topics will be discussed in an energizing format that transports you to another time and place.

3. Maximize Your Value and Advocacy to Action Learn the best business practices for neurology and leave with ready-to-apply strategies. Find out how to make your voice heard for you, your patients, and the future of neurology.

6 West Lobby

2 wn Do

5 4

EN TR AN CE

South Lobby

5. Research Corner: Moving Neurology Forward 4. Navigating Your Career Receive comprehensive information regarding professional development at every career stage. Panel presentations and small group mentoring options throughout the week provide many opportunities to get your questions answered.

ENTRANCE

6. The Member Experience: Personalize Your Journey Connect and be recognized as a valued AAN member. Learn how to personalize your experience and get the most out of your Academy.

See the importance of research on neurology’s future and its impact on patient care. Find your inspiration in research presentations and award winners.

AAN.com/view/AM18 67

Experiential Learning Areas

So uth Ex hib it

Ha ll

West Exhibit Hall

Those Other Sessions Feed Your Brain.

We’ll Fuel Your Spirit.

Visit the HeadTalks area for transformational experiences In this unconventional platform, non-traditional neurology topics include: • Gamification of Neurology • Zombie Apocalypse • Is There a Neurologist on This Flight? • The Impact of Conscious and Unconscious Biases

Wind down at the end of the day with a glass of wine during the presentations.

See following pages for full program listing

Saturday, April 21

Monday, April 23

Wednesday, April 25

12:00 p.m.–12:30 p.m.

12:00 p.m.–1:00 p.m.

Navigating the Annual Meeting App and Convention Center Tour Speaker: Carlayne E. Jackson, MD, FAAN

12:45 p.m.–1:45 p.m.

Ask Us Anything: Expert Panel on Headache and Facial Pain Speakers: Deborah I. Friedman, MD, MPH, FAAN Peter Goadsby, MD, PhD

2:00 p.m.–3:00 p.m.

Rural Neurology Speakers: Dario Beltran, MD, FAAN Michael Stitzer, MD

3:15 p.m.–4:15 p.m.

Women in Neurology: Crafting Your Leadership Career: Lessons from Leaders Speakers: Allison Brashear, MD, MBA, FAAN Cynthia L. Comella, MD, FAAN Helena C. Chui, MD Merit E. Cudkowicz, MD, MSC Mona Bahouth, MD Barbara G. Vickrey, MD, MPH, FAAN

Sunday, April 22 12:00 p.m.–1:00 p.m.

Neurology Pictionary Speaker: Bert B. Vargas, MD, FAAN

1:30 p.m.–2:30 p.m.

3:00 p.m.–4:00 p.m.

Blind Spots: The Impact of Conscious and Unconscious Biases Speakers: Jeffrey C. McClean, II, MD, FAAN Laraine Kaminsky Charles C. Flippen II, MD, FAAN

4:30 p.m.–5:30 p.m.

What is that Twitch? Speakers: Leonard Verhagen Metman, MD, PhD Susan B. Bressman, MD, FAAN

1:30 p.m.–2:30 p.m.

Eminence-based Medicine vs Evidence-based Medicine Speaker: Martin A. Samuels, MD, MACP, FAAN

3:00 p.m.–4:00 p.m.

Lifting the Curtain: Ask the AAN Publication Editors Anything! Speakers: Joseph E. Safdieh, MD, FAAN Orly Avitzur, MD, MBA, FAAN Robert A. Gross, MD

4:15 p.m.–5:00 p.m.

Foundations for Success in the AAN Speakers: Jeffrey C. McClean, II, MD, FAAN Terrence L. Cascino, MD, FAAN Christine E. Phelps

5:15 p.m.–6:15 p.m.

Practicing Neurology in the 1960s and 1970s Speakers: Martin A. Samuels, MD, MACP, FAAN Thomas R. Swift, MD, FAAN Austin J. Sumner, MD, FAAN Sandra F. Olson, MD, FAAN

Tuesday, April 24 12:00 p.m.–1:00 p.m.

Neurology Game Show: Localize the Lesion Speaker: Luis F. Torres, MD

1:30 p.m.–2:30 p.m.

Neurological Exam Tips and Tricks Speakers: Kapil D. Sethi, MD, FRCP (UK), FAAN Thomas R. Swift, MD, FAAN Christopher H. Hawkes, MD, Bsc, FRCP

3:00 p.m.–4:00 p.m.

Biological and Chemical Neuroterrorism and Neurowarfare Speaker: Thomas P. Bleck, MD, FAAN

4:30 p.m.–5:30 p.m.

Controversies in Neurology: Is the Zombie Apocalypse Upon Us? Local Outbreaks, Bioterrorism or Bioengineering Run Amok… Speakers: Bert B. Vargas, MD, FAAN Joseph I. Sirven, MD, FAAN Constantine Moschonas, MD, FAAN Jennifer Bickel, MD, FAAN

Neuro-Jeopardy: Telencephalon Twisters Speakers: Laurice T. Yang, MD, MHA Veronica E. Santini, MD

1:30 p.m.–2:30 p.m.

Parkinson Disease: Raising Your Game Speakers: Janis Miyasaki, MD, FAAN Cynthia L. Comella, MD, FAAN Oksana Suchowersky, MD, FAAN

3:00 p.m.–4:00 p.m.

Health Care Disparities Among Underserved Populations Speakers: Holly E. Hinson, MD, MCR Charles C. Flippen II, MD, FAAN Lisa M. Shulman, MD, FAAN Temitayo Oyegbile, MD, PhD

4:15 p.m.–5:00 p.m.

The Neurology of VooDoo Speaker: Ann H. Tilton, MD, FAAN

5:15 p.m.–6:15 p.m.

Neurology, Illustrated: The Neurology in Art Speaker: David E. Thaler, MD, PhD

Thursday, April 26 12:00 p.m.–1:00 p.m.

Who Wants to be a Millionaire Speakers: Jose H. Posas, MD

1:30 p.m.–2:30 p.m.

The Value of the Neurologic Exam: Caring for your Patient for $500 or Less Speaker: Donn Dexter, MD, FAAN

3:00 p.m.–4:00 p.m.

Consejos Prácticos para un Buen Examen Neurológico Speakers: Jose Biller, MD, FAAN, FACP, FAHA Vladimir Hachinski, MD, DSc, FAAN

4:30 p.m.–5:30 p.m.

Neurology History: Weaving Past with Present Speaker: Christopher Goetz, MD, FAAN

Friday, April 27 12:00 p.m.–1:00 p.m.

The Neurology of Creativity at the Keyboard Speaker: Phillip L. Pearl, MD, FAAN

1:30 p.m.–2:30 p.m.

Live Intraoperative Monitoring Speaker: Constantine Moschonas, MD, FAAN

3:00 p.m.–4:00 p.m.

Ask Us Anything: Expert Panel on Stroke Speakers: Natalia S. Rost, MD, MPH, FAAN, FAHA Jose Biller, MD, FAAN, FACP, FAHA Italo Linfante, MD

4:30 p.m.–5:30 p.m.

Ask Us Anything: Expert Panel on Multiple Sclerosis Speakers: John W. Rose, MD, FAAN John Corboy, MD, FAAN

AAN.com/view/AM18 69

HeadTalks

Hall of Presidents: Using Past Experience to Solve the Future’s Problems Speakers: Ralph L. Sacco, MD, MS, FAHA, FAAN Terrence L. Cascino, MD, FAAN Robert C. Griggs, MD, FAAN Francis I. Kittredge, Jr., MD,FAAN Roger N. Rosenberg, MD, FAAN Stanley Fahn, MD, FAAN Stephen M. Sergay, MB BCh, FAAN Thomas R. Swift, MD, FAAN Sandra F. Olson, MD, FAAN Timothy A. Pedley, MD, FAAN

Is There a Neurologist on This Flight? Speaker: Joseph I. Sirven, MD, FAAN

EXPERIENTIAL LEARNING AREAS

X HeadTalks

Your Wellness is Not One Dimensional.

Neither is the Live Well Experiential Learning Area.

Taking better care of your patients starts with taking better care of you. Get inspired, motivated, refreshed, and educated about the importance of taking care of the three most important dimensions of your well-being through more than 50 highly interactive opportunities throughout the week.

Physical

Beginner Friendly Yoga - Vinyasa Acupuncture Demonstration 4 Gates and Auriculotherapy The Sleep Mythbuster!: Illuminating the Facts and Fiction Towards Achieving the Sleep Healthy Neurologist

Mental

Meditation for the Practicing Neurologist The Purpose Checkup: Find Meaning, Live Longer,Better Guided Meditation Session

Professional

Perception is Reality: Are Neurologists Helping Patients Live Well with Dementia? Café Talk: Burnout Mitigation—What’s In Your Toolbox? Communication in Neurology Practice

SEE FOLLOWING PAGES FOR FULL PROGRAM LISTING.

Taking Care of Your Patients Starts with Taking Care of You!

Saturday, April 21

Tuesday, April 24

Thursday, April 26

12:00 p.m.–12:45 p.m.

7:00 a.m.–7:45 a.m.

8:00 a.m.–8:45 a.m.

Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? Speakers: Janis Miyasaki, MD, FAAN Kathrin LaFaver, MD, FAAN Elaine C. Jones, MD, FAAN

2:00 p.m.–2:45 p.m.

Cafe Talk: Narratives in Neurology: Creative Expression to Promote Resilience and Prevent Burnout Speaker: Sneha Mantri, MD

3:00 p.m.–3:45 p.m.

Acupuncture Demonstration: 4 Gates Speaker: Jennifer Bickel, MD, FAAN

Sunday, April 22

Yoga (All-Levels Vinyasa) Speaker: Sarah Bird Nelson, JD Self-Management in Neurologic Disease Speakers: Barbara C. Jobst, MD, FAAN Lisa M. Shulman, MD, FAAN

12:00 p.m.–12:45 p.m.

Treatment of Neuropathy Symptoms Without Medication Speaker: Janice F. Wiesman, MD, FAAN

1:00 p.m.–1:45 p.m.

Complementary Therapies in Parkinson’s Disease Speaker: Veronica E. Santini, MD

7:00 a.m.–7:45 a.m.

2:00 p.m.–2:45 p.m.

8:00 a.m.–9:00 a.m.

3:00 p.m.–3:45 p.m.

Yoga (All-Levels Vinyasa) Speaker: Ann Marie Collier, MD Meditation for the Practicing Neurologist Speaker: Sarah Mulukutla, MD, MPH

12:00 p.m.–12:45 p.m.

How to Promote Healthy Cognitive Aging: What Should We Tell Our Patients and Ourselves? Speaker: Kirk R. Daffner, MD, FAAN

1:00 p.m.–1:45 p.m.

Solving Burnout Speaker: Neil A. Busis, MD, FAAN

3:00 p.m.–3:45 p.m.

How Your Social Life Might Be Helping (or Harming) Your Brain Speaker: Joel Armando Salinas, MD

4:00 p.m.–4:45 p.m. Cafe Talk: Is that an Emotional or Cognitive Question? Navigating Difficult Conversations with Communication Skills Speaker: Tara Cook, MD

Monday, April 23 7:00 a.m.–7:45 a.m.

Yoga (All-Levels Vinyasa) Speaker: Jamie L. Heath, MD Cafe Talk: Burnout Mitigation: What’s in Your Toolbox? Speakers: Janis Miyasaki, MD, FAAN Kathrin LaFaver, MD, FAAN Elaine C. Jones, MD, FAAN Amy Hessler, DO Divya Singhal, MD

12:25 p.m.–1:45 p.m.

Perception Is Reality: Are Neurologists Helping Patients Live Well with Dementia? Speakers: Daniel C. Potts, MD, FAAN Neelum T. Aggarwal, MD

2:00 p.m.–2:45 p.m.

Physical Exercise and Cognitive Training in Neurology: Application in Aging and Neurodegenerative Disease Speaker: Ergun Y. Uc, MD

StrengthsFinder Social Hour Speakers: Keri Bischoff Julie Anderson

4:00 p.m.–4:45 p.m.

The Sleep Mythbuster!: Illuminating the Facts and Fiction Towards Achieving the Sleep Healthy Neurologist Speaker: Charlene Gamaldo, MD, FAAN

5:00 p.m.–5:30 p.m.

Guided Meditation Speaker: Divya Singhal, MD

Wednesday, April 25

Sleep and Performance in Elite Athletes Speaker: Scott J. Kutscher, MD

12:00 p.m.–12:45 p.m.

The Purpose Checkup: Find Meaning, Live Longer, Better Speaker: Richard Leider

1:00 p.m.–1:45 p.m.

Medical Marijuana: What Do Neurologists Need to Know? Speaker: Jessica Robinson Papp, MD, FAAN

2:00 p.m.–2:45 p.m.

Cafe Talk: Communication in Neurology Practice Speakers: Jessica Robinson Papp, MD, FAAN Shanna Patterson, MD

3:00 p.m.–3:45 p.m.

Magnifying Your Life Through Poetry Speaker: Michael L. Wynn, DO

Friday, April 27 7:00 a.m.–7:45 a.m.

Yoga (All-Levels Vinyasa) Speaker: Jamie L. Heath, MD

12:00 p.m.–12:45 p.m.

Outsmart Stress Speaker: Marie E. Pasinski, MD

7:00 a.m.–7:45 a.m.

Yoga (All-Levels Vinyasa) Speaker: Ann Marie Collier, MD

8:00 a.m.–8:45 a.m.

Acupuncture Demonstration: Auriculotherapy Speaker: Jennifer Bickel, MD, FAAN

12:00 p.m.–12:45 p.m.

Neurology and Wellness - Physician, Heal Thyself Speakers: Jennifer Rose Molano, MD, FAAN Divya Singhal, MD

2:00 p.m.–2:45 p.m.

Resiliency for the Neurologist Speaker: Justin T. Jordan, MD, MPH

Live Well

8:00 a.m.–8:45 a.m.

Dancing with Parkinson’s Speaker: Diviya Kaul, MD

Yoga (All-Levels Vinyasa) Speaker: Jamie L. Heath, MD

3:00 p.m.–3:45 p.m.

Introduction to Acupuncture II: Evidence-based Applications for Acupuncture in the Treatment of Neurologic Conditions Speaker: Alexandra Dimitrova, MD

4:00 p.m.–4:45 p.m.

Diets and Supplements in MS: What’s the Evidence Thus Far? Speaker: Vijayshree Yadav, MD

5:00 p.m.–5:30 p.m.

Guided Meditation Speaker: Divya Singhal, MD

3:00 p.m.–3:45 p.m.

Introduction to Acupuncture I: Conceptual Framework and Mechanism of Action Speaker: Alexandra Dimitrova, MD

4:00 p.m.–4:45 p.m.

Striking the Balance—A Neurologist’s Personal Wellness Journey Speaker: Neil A. Busis, MD, FAAN

EXPERIENTIAL LEARNING AREAS

X Live Well:

AAN.com/view/AM18 71

EMPOWER YOURSELF, YOUR PRACTICE, YOUR PROFESSION Practice management and advocacy are not mutually exclusive—and neither are this year’s experiential learning areas. These two popular Annual Meeting destinations will share the stage to provide the most powerful and effective tips and tools to arm you for success. A desire to improve our profession’s economic, clinical practice, and regulatory environment can inspire advocacy. And advocacy can lead to the changes necessary to ensure your practice’s success, your patients’ success, and the success of the neurology profession.

Maximize Your Value

When you succeed, your patients succeed.

Advocacy to Action

When neurology succeeds, we all succeed.

Hear from experts about the latest AAN guidelines and quality measurement sets

Learn about neurologists’ compensation and increase your own revenue through coding and technology

Learn more and provide input on the AAN’s important legislative priorities

Find out how you can initiate your own advocacy efforts

Visit the Polling Station to tell us what matters most to you—your voice can make a difference! Meet with staff from the AAN’s Axon Registry® and technical vendor FIGMD to learn how this quality improvement tool can work for you

Attend talks on some of the most controversial topics impacting your practice today—like marijuana, telemedicine, and patient portals

Bow Tie Tuesday! Wear your green bow ties and scarves. Learn about Neurology on the Hill

Network with experienced AAN advocates and alumni of the Palatucci Advocacy Leadership Forum Learn about the Quality Payment Program (QPP)

See following pages for full program listing.

Snap a photo at our selfie station and upload it to social media to promote #AANadvocacy

Improve Your Neurology Practice

Empowering Patients and Physicians

Saturday, April 21

Monday, April 23

Wednesday, April 25

9:30 a.m.–10:00 a.m.

12:00 p.m.–1:00 p.m.

8:00 a.m.–9:00 a.m.

What is the Axon Registry? Speaker: Sarah M. Benish, MD, FAAN

2:00 p.m.–2:30 p.m.

Paths for Success in the Quality Payment Program Speaker: Lyell K. Jones, MD, FAAN

2:30 p.m.–3:00 p.m.

Ask the Expert: Paths for QPP Success Speaker: Lyell K. Jones, MD, FAAN

3:00 p.m.–3:30 p.m.

Clinical Decision Support for Ordering of Diagnostic Imaging Speakers: David A. Evans, MBA Eric M. Cheng, MD, MS, FAAN

3:30 p.m.–4:00 p.m.

Growing Research in Medical Marijuana Speaker: Anup D. Patel, MD, FAAN

4:00 p.m.–4:30 p.m.

TBI in Domestic Violence Victims: Care for Those Who Need it Most Speaker: Glynnis Zieman, MD

Sunday, April 22 8:00 a.m.-9:00 a.m.

How Can the Axon Registry Improve My Practice? Speakers: Katie Hentges Tim Parr

12:00 p.m.–1:00 p.m.

Pursuing a Career in Clinical Informatics Speakers: Allison L. Weathers, MD, FAAN Eric M. Cheng, MD, MS, FAAN Allan Ding Wu, MD Melissa Yu, MD

1:00 p.m.–2:00 p.m.

Meet and Greet with the California Neurological Society Speaker: Erik Perkins, MD, FAAN

2:00 p.m.–2:30 p.m.

2:30 p.m.–3:00 p.m.

Ask the Expert: Teaching through Simulation Speakers: Barbara A. Dworetzky, MD, FAAN Tracey A. Milligan, MD, FAAN

3:00 p.m.–3:30 p.m.

Using EHR for Better Communication with Patients and Colleagues Speakers: Allison L. Weathers, MD, FAAN Allan Ding Wu, MD Melissa Yu, MD Radhika Sampat, DO

2:00 p.m.–2:30 p.m.

Can Aviation Accidents Teach Neurologists Patient Safety and Error Management? Speakers: Rohit Das, MD, FAAN Amy E. Sanders, MD, FAAN

3:00 p.m.–3:30 p.m.

Safety and Quality Awards Speakers: Anup D. Patel, MD, FAAN Amy E. Sanders, MD, FAAN

3:30 p.m.–4:00 p.m.

What Does the AAN’s Latest Guideline Mean for My Practice? Speaker: Gregory S. Day, MD, MSc

4:00 p.m.–4:30 p.m.

Streamlining Clinic Scheduling and Access Speakers: Melissa Yu, MD Radhika Sampat, DO

4:30 p.m.–5:00 p.m.

Knowing Your Value: How to Negotiate to Get What You’re Worth Speaker: Eva K. Ritzl, MD, FAAN

Tuesday, April 24 12:00 p.m.–1:00 p.m.

Communicating via EHR Speakers: Allison L. Weathers, MD, FAAN Melissa Yu, MD Radhika Sampat, DO

1:00 p.m.–2:00 p.m.

Understanding Axon Registry and Using it to Improve Your Value Speakers: Lyell K. Jones, MD, FAAN Anup D. Patel, MD, FAAN

Step Away from the Desktop! Recapturing the Joy in Practice Speakers: Allison L. Weathers, MD, FAAN Allan Ding Wu, MD Melissa Yu, MD

1:00 p.m.–1:30 p.m.

So You Want to Work for a Hospital? Speaker: J. Todd Barnes, MBA

1:00 p.m.-2:00 p.m.

Scientific Platform Session S28 Practice, Policy, and Ethics

Thursday, April 26 8:00 a.m.–9:00 a.m.

12:00 p.m.-12:30 p.m.

How to Increase Investments in Neuroscience Research Speaker: David Q. Beversdorf, MD, FAAN

1:00 p.m.–1:30 p.m.

What Do I Need to Know About Coding in My Practice? Speaker: Bruce H. Cohen, MD, FAAN

2:00 p.m.–3:00 p.m.

Using Your Patients as Resources: Group Medical Visits for Improved Wellness and Efficiency Speakers: Mary R. Rensel, MD, FAAN Nancy B. Isenberg, MD, MPH, FAAN

Friday, April 27 12:00 p.m.–12:30 p.m.

Incorporating a Semi-Concierge Model into your Own Neurology Practice Speaker: Teryn B. Clarke, MD

Maximize Your Value Advocacy to Action

Breaking Down Silos: Using Simulation for Interprofessional Team Education to Enhance Clinical Outcomes in Neurology Speakers: Barbara A. Dworetzky, MD, FAAN Tracey A. Milligan, MD, FAAN Charles Pozner, MD

Practice Models for Advanced Practice Providers Speaker: Calli Leighann Cook, FNP-C

2:00 p.m.–2:30 p.m.

Caring for Telemedicine Patients Speaker: Raghav Govindarajan, MD, FAAN

2:30 p.m.–3:30 p.m.

What is the AAN Doing for Small and Solo Practitioners? Speaker: Elaine C. Jones, MD, FAAN

Tip of the Iceberg: Ultra-High Cost Neurology Drugs Speaker: Nicholas Elwood Johnson, MD, FAAN

4:00 p.m.–4:30 p.m.

Why are Drug Prices So High? And What Can We Do About It? Speaker: Brian Callaghan, MD

4:30 p.m.–5:00 p.m.

What Does BrainPAC Do for Me? Speaker: Mike Amery

EXPERIENTIAL LEARNING AREAS

aximize Your Value: X M Advocacy to Action:

AAN.com/view/AM18 73

Get on Track...

No matter where you are in your professional journey, you’ll want to stop by the Navigating Your Career Experiential Learning Area for essential tips, tools, and resources to get you on the right track to make your professional journey a huge success. Take advantage of one-on-one and small-group mentoring sessions with experts, and congratulate recipients of the 2018 Faculty and Trainee Awards. FOR MEDICAL STUDENTS A Giving and Receiving Feedback for Medical Students and Residents A How to Be “Useful” on Rotations: Tips for Medical Students A Why Choose a Career in Neurology?

FOR RESIDENTS A Being a Great Chief Resident A Research in Residency: How to Choose the Right Project A Navigating Fellowship in Neurology

FOR EDUCATORS A Education Administrator Building Blocks: Navigating the Role of the Administrator and Taking Your Role to the Next Level A Patient Centered Teaching A Up Your Game as a Medical Educator in Neurology

FOR THE JOB SEARCHER A Interviewing Skills A Academic Career Panel: How to Get Your Career Started A Negotiation Skill: You Do Not Get What You Deserve, You Get What You Negotiate

Saturday, April 21 9:15 a.m.–9:45 a.m.

How to Network at the Annual Meeting: Strategies for Trainees Speaker: Safiullah Shareef, MD

9:15 a.m.–10:00 a.m.

Patient Centered Teaching Speaker: Raghav Govindarajan, MD, FAAN

10:00 a.m.–10:30 a.m.

Sleep: Why You Should Spend Your Career Helping People Do It Right Speaker: Logan D. Schneider, MD

10:15 a.m.–10:45 a.m.

Cognitive Biases and Diagnostic Errors at Bedside Speaker: Raghav Govindarajan, MD, FAAN

11:15 a.m.–12:00 p.m.

Choosing a Career in Clinical Practice Speaker: James C. Stevens, MD, FAAN

12:15 p.m.–1:00 p.m.

What I Learned About Research—An Early Career Perspective Speaker: Logan D. Schneider, MD

1:15 p.m.–2:00 p.m.

Interviewing Skills: Medical Students and Residents Speaker: Ezgi Tiryaki, MD, FAAN

2:15 p.m.–3:00 p.m.

Teleneurology: Is this for me? Pre-hospital and Nontraditional Uses of Teleneurology Speaker: Nina J. Solenski, MD

3:15 p.m.–4:00 p.m.

Social Media for Clinicians Speaker: Pearce Korb, MD, FAAN

Sunday, April 22 7:45 a.m.–8:15 a.m.

Research in Residency: How to Choose the Right Project Speaker: Roy E. Strowd, III, MD

8:15 a.m.–9:00 a.m.

K is for Career Development: Tips From Successful Applications for NIH Career Development Awards Speaker: Logan D. Schneider, MD

8:30 a.m.–9:00 a.m.

9:15 a.m.–9:45 a.m.

Giving and Receiving Feedback for Medical Students and Residents Speaker: Ezgi Tiryaki, MD, FAAN

10:00 a.m.–10:30 a.m.

Autoimmune Neurology Speaker: Pooja Santosh Raibagkar, MD

10:45 a.m.–11:15 a.m.

So You Want to Be a Residency Program Director? Speaker: Neil E. Schwartz, MD, PhD

12:15 p.m.–1:00 p.m.

Sleep: A Frequently Forgotten Part of Your Patient’s Day Speaker: Anne M. Morse, DO

1:00 p.m.–1:30 p.m.

Being a Great Chief Resident Speaker: Roy E. Strowd, III, MD

Measuring Success: Quality Improvement 101 Speaker: Justin P. Martello, MD

1:45 p.m.–2:15 p.m.

Career Stories: Challenges for the Physician Scientist Speaker: Mark Hallett, MD, FAAN

2:15 p.m.–3:00 p.m.

Education Administrator Building Blocks: Navigating the Role of the Administrator and Taking Your Role to the Next Level Speakers: Crys Draconi, C-TAGME Shannon H. Darrah

3:15 p.m.–3:45 p.m.

How to Get Into Leadership in Professional Societies Speaker: Mark Hallett, MD, FAAN

3:15 p.m.–4:00 p.m.

Social Media for the Millennial Neurologist Speaker: Safiullah Shareef, MD

4:00 p.m.–4:30 p.m.

Transitioning from Private Practice to Academics Speaker: Neil A. Busis, MD, FAAN

4:15 p.m.–5:00 p.m.

Introduction to the Fascinating World of Movement Disorders Speakers: Shilpa Chitnis, MD, PhD, FAAN, FANA Svjetlana Miocinovic, MD, PhD

4:45 p.m.–5:15 p.m.

Everything You Wanted to Know About the R&F Section of Neurology Speakers: Roy E. Strowd, III, MD John J. Millichap, MD

Monday, April 23 7:45 a.m.–8:15 a.m.

Using the R&F Section of Neurology for your Residents and Residency Speakers: Roy E. Strowd, III, MD John J. Millichap, MD

8:15 a.m.–9:00 a.m.

Choosing An Academic Career in Neurology: Perspectives for Early Career Investigators and Foreign Medical Graduates Speakers: Deepak Kumar Gupta, MBBS Ciro Ramos Estebanez, MD

8:30 a.m.–9:00 a.m.

Tools to Transition from Trainee to Attending Speaker: Safiullah Shareef, MD

10:00 a.m.–10:30 a.m.

How to be “Useful” on Rotations: Tips for Medical Students Speaker: Ezgi Tiryaki, MD, FAAN

10:45 a.m.–11:15 a.m.

Choosing a Neurohospitalist Career Speaker: S. Andrew Josephson, MD, FAAN

11:30 a.m.–12:00 p.m.

Child Neurology—Staying on Track Speaker: Warren D. Lo, MD

11:45 a.m.–12:30 p.m.

Finding Your Niche in Neurology: Perspectives from an Epileptologist and Educator Speaker: Chad Carlson, MD

12:45 p.m.–1:30 p.m.

Transitioning From a Clinical Research Career to an Educational and Clinical Focused Career Speaker: Chad Carlson, MD

1:00 p.m.–1:30 p.m.

Subspecialty Sessions: IOM and cEEG Speaker: Eva K. Ritzl, MD, FAAN

1:45 p.m.–2:30 p.m.

Creating a Career in Global Health with Design Thinking Speaker: Nirali Vora, MD

2:45 p.m.–3:30 p.m.

Mejora Tu Desempeño Como Educador Médico Speaker: Rachel Marie E. Salas, MD, FAAN

3:45 p.m.–4:30 p.m.

Teaching Communication Skills: From Good to Great Speaker: Tara Cook, MD

4:45 p.m.–5:30 p.m.

Career Development for Medical Educators Speaker: Ralph F. Józefowicz, MD, FAAN

Tuesday, April 24 8:15 a.m.–9:00 a.m.

Career Development for Clinician Educators Speaker: Allison Brashear, MD, MBA, FAAN

8:30 a.m.–9:00 a.m.

Career Stories: Nuts and Bolts of Academic Leadership - Strategies I Have Learned in My Career Speakers: Deborah Hall, MD, PhD, FAAN Cynthia L. Comella, MD, FAAN

10:00 a.m.–10:30 a.m.

Choosing a Career in Neurocritical Care Speaker: Matthew B. Maas, MD

10:45 a.m.–11:15 a.m.

Staying on an Academic Clinical Track Speaker: John Probasco, MD

11:30 a.m.–12:00 p.m.

Reviewer to Editorial Board to Editor Speaker: Mark Hallett, MD, FAAN

11:45 a.m.–12:30 p.m.

Foreign Medical Graduates Adjustment Skills Speaker: Ehtesham Khalid, MBBS

12:15 p.m.–12:45 p.m.

Neurohospitalists 2.0, How to Craft a Satisfying and Sustainable Career Speaker: David J. Likosky, MD, SFHM, FAAN, FAHA, FACP

12:45 p.m.–1:30 p.m.

Choosing Teleneurology as a Career Speaker: Eric Anderson, MD, PhD

1:00 p.m.–1:30 p.m.

Subspecialty Sessions: IOM and cEEG Speaker: Eva K. Ritzl, MD, FAAN

1:45 p.m.–2:15 p.m.

Academic Career Panel: Find out How to Get Your Career Started Speakers: Joseph E. Safdieh, MD, FAAN Jennifer Rose Molano, MD, FAAN

2:30 p.m.–3:00 p.m.

How to Start a Career in Neurology Education Speaker: Joseph E. Safdieh, MD, FAAN

2:45 p.m.–3:30 p.m.

Training in Neurology While on a Visa: Challenges and Possible Solutions for Foreign Medical Graduates Speaker: Ahmed Z. Obeidat, MD, PhD

3:15 p.m.–3:45 p.m.

Staying on Track: A Career as a Clinical Researcher Speaker: Rebecca F. Gottesman, MD

3:45 p.m.–4:30 p.m.

International Members: What Can the AAN Do For You? Speakers: Jerome H. Chin, MD, PhD, MPH, FAAN Christi Kokaisel, MBA, CAE

4:45 p.m.–5:30 p.m.

Teaching During a Busy Clinic Speaker: Raghav Govindarajan, MD, FAAN

Wednesday, April 25 8:15 a.m.–9:00 a.m.

How to Give Effective Feedback Speakers: Laurice T. Yang, MD, MHA Veronica E. Santini, MD

12:45 p.m.–1:30 p.m.

Clinical Research in the Area of Practice, Quality and Patient Safety Speakers: Mona Bahouth, MD Justin T. Jordan, MD

2:45 p.m.–3:30 p.m.

Pursing a Career in Healthcare Administration Speaker: Laurice T. Yang, MD, MHA

3:45 p.m.–4:30 p.m.

Navigating Fellowship in Neurology Speaker: Ahmed Z. Obeidat, MD, PhD

4:45 p.m.–5:30 p.m.

Top Ten Clinical, Educational and Leadership Pearls Speaker: Steven Galetta, MD, FAAN

Thursday, April 26 11:45 a.m.–12:30 p.m.

Teaching History and Exam with Teleneurology Speaker: Raghav Govindarajan, MD, FAAN

12:45 p.m.–1:30 p.m.

Effective Neurology Residency Program Speaker: Ralph F. Józefowicz, MD, FAAN

1:45 p.m.–2:30 p.m.

Interviewing Skills Speaker: Ralph F. Józefowicz, MD, FAAN

2:45 p.m.–3:30 p.m.

O Funding, Where Art Thou? How to Develop a Full-Time Academic Career in Global Neurology Speaker: Omar Siddiqi, MD

1:45 p.m.–2:30 p.m.

The Encompassing Value of the PatientPhysician Relationship Speaker: Stephen M. Sergay, MB BCh, FAAN

AAN.com/view/AM18 75

Navigating Your Career

Interviewing Skills: Negotiation Speaker: Allison Brashear, MD, MBA, FAAN

1:15 p.m.–2:00 p.m.

EXPERIENTIAL LEARNING AREAS

X Navigating Your Career

The Research You Do Today Could Be the Cure of Tomorrow. We Can Help. No matter where you’re at in your neurology research career—be it simply considering, early, expert, or late— the Research Corner Experiential Learning Area is your opportunity to get in and discover how you can shape the future. Improve your knowledge and skills through practical tools and resources you won’t find anywhere else at the Annual Meeting. And be the future that you and patients with neurologic disease want to see.

Burning Questions

Get invaluable face-to-face time with expert leaders in any research topic of your choice.

Show Me the Money

Get all the tips and tricks from key decision makers in federal research funding and AAN Research Program grant funding on how to get your proposal funded.

Celebrity Sightings

Get star struck when the biggest names in research take to the stage to present the hottest topics and most recent breakthroughs.

Walk of Fame

Check out the AAN’s 2018 scientific award winners and AAN Research Program grant recipients.

Inspire Others

Inspire your colleagues to get in and join the research movement, too! Snap a selfie for our Faces of Research Wall and tell us what research means to you.

See following pages for full program listing.

Saturday, April 21 7:30 a.m.–8:15 a.m.

Are You My Mentor? How to Select a Good Mentor for Your Research Career Speaker: Deborah Hall, MD, PhD, FAAN

8:25 a.m.–9:10 a.m.

Work Life Balance in Research Speaker: Amanda C. Peltier, MD, MS

9:20 a.m.–9:50 a.m.

How to Successfully Publish Quality Improvement Projects Speakers: Anup D. Patel, MD, FAAN Rohit Das, MD, FAAN

10:00 a.m.–10:50 a.m.

Investigator Panel: How I Launched My Career with NIH Funding, Private Funding, AAN Research Program Funding and/or Government Funding Speakers: An Hong Do, MD Nicoline Schiess, MD Daniel O. Claassen, MD

11:30 a.m.–12:00 p.m.

Office Hours: Research Careers in Industry Speaker: Brandy R. Matthews, MD, FAAN

12:00 p.m.–12:30 p.m.

Office Hours: Writing a Great AAN Research Program Proposal Speaker: Jeffrey Marc Gelfand, MD, MAS, FAAN

12:20 p.m.–12:50 p.m.

How to Find Training: The Best Clinical Research and Methodology Training Options Speaker: Nicole A. Chiota-McCollum, MD

1:00 p.m.–1:30 p.m.

Statistics - Sample Size Speaker: William Joseph Meurer, MD

1:40 p.m.–2:10 p.m.

Clinical Trials Methodology Course— Information Session with William Meurer MD, MS, CTMC Principal Investigator Speaker: William Joseph Meurer, MD

Sunday, April 22 8:00 a.m.–9:10 a.m.

Challenges in Clinicogenetic Correlations: One Gene, Many Phenotypes; One Phenotype, Many Genes Speakers: Kailash P. Bhatia, MD, FAAN Roy Alcalay, MD

10:00 a.m.–10:30 a.m.

12:00 p.m.–12:30 p.m.

Office Hours: Finding/Working with Epidemiologists on Your Grant Speaker: Caroline M. Tanner, MD, PhD, FAAN

12:30 p.m.–1:00 p.m.

Office Hours: Surviving as a Clinician Researcher Speaker: Lisa C. Silbert, MD, FAAN

1:20 p.m.–1:50 p.m.

So You Have a Research Idea—How Do You Turn it into a Project? Speaker: Edward H. Bertram, MD, FAAN

3:30 p.m.-4:30 p.m.

1:00 p.m.-2:15 p.m.

4:30 p.m.–5:00 p.m.

1:00 p.m.–1:30 p.m.

5:00 p.m.–5:30 p.m.

1:20 p.m.–1:50 p.m.

Monday, April 23

1:30 p.m.–2:00 p.m.

Scientific Platform Session S7 Pain and Palliative Care How to Start a Career in Clinical Trials Speaker: Aleksandar Videnovic, MD, MSc, FAAN Statistics and Study Design: Pearls and Pitfalls Speaker: Senan Ebrahim

7:30 a.m.–8:00 a.m.

Defining and Managing Your Message as An Early Career Researcher Speaker: Corey R. Fehnel, MD

8:10 a.m.–9:00 a.m.

Your CV is Talking About You Behind your Back, and your LORs Are Too! Speaker: Na Tosha N. Gatson, MD, PhD

12:00 p.m.–12:30 p.m.

Office Hours: Working with an Epidemiologist Speaker: Kelly Sullivan, PhD

1:00 p.m.–1:30 p.m.

Office Hours: Creating Bridge Funding How to Use Non-NIH Funding Speaker: Lidia Maria Veras Rocha Moura, MD

1:30 p.m.–2:00 p.m.

Office Hours: Statistics—Sample Size Speaker: Jordan J. Elm

2:30 p.m.–3:00 p.m.

Office Hours: Defining and Managing Your Message As An Early Career Scientist Speaker: Christopher D. Anderson, MD, PhD

4:00 p.m.–4:45 p.m.

Cafe Talk: Is that an Emotional or Cognitive Question? Navigating Difficult Conversations with Communication Skills Speaker: Tara Cook, MD

Tuesday, April 24 8:00 a.m.–8:30 a.m.

Welcome to NINDS Day/Overview of NIH Funding With NINDS Director and NINDS Deputy Director Speakers: Walter J. Koroshetz, MD, FAAN Nina F. Schor, MD, PhD, FAAN

8:40 a.m.–9:10 a.m.

K Awards and Training Programs Speakers: Adam L. Hartman, MD Nina F. Schor, MD, PhD, FAAN

12:00 p.m.–12:30 p.m.

Introduction to the 2018–2020 TRANSCENDS Scholars Speaker: Bruce I. Ovbiagele, MD, MSc, FAAN Office Hours: How to Get a K-Award Speaker: Michael Levy, MD, FAAN

12:30 p.m.–1:00 p.m.

Office Hours: Bridge Funding Speaker: Randolph S. Marshall, MD, FAAN

12:40 p.m.–1:10 p.m.

NIH Funding and Professional Development Opportunities for Diverse Researchers Speaker: Michelle Jones-London, PhD

Scientific Platform Session S12 Autonomic Disorders Office Hours: VA Research Funding: Career Development Awards Speaker: Beth Leeman-Markowski, MD, MA NIH Grant Review Process Speakers: Adam L. Hartman, MD Shanta Rajaram, PhD Office Hours: Clinical Research Recommendations for Residents and Fellows Speaker: Benjamin David Tolchin, MD

2:00 p.m.–2:30 p.m.

NINDS Clinical Trials (new NIH definition) and networks, NeuroNEXT, StrokeNET, SIREN Speaker: Clinton B. Wright, MD

2:30 p.m.–3:00 p.m.

Office Hours: Finding Collaborators Speaker: Mia T. Minen, MD

2:40 p.m.–3:10 p.m.

Pain Research Funding Opportunities, Clinical and Basic Speakers: Clinton B. Wright, MD Michael Oshinsky, PhD

3:20 p.m.–3:50 p.m.

Pain Research Funding Opportunities, Clinical and Basic Speaker: Kenneth H. Fischbeck, MD, FAAN

4:00 p.m.–4:30 p.m.

Your Grant Proposal Was Rejected: Now What? Turning a Feedback Into a Successful Project Speaker: Amy R. Brooks-Kayal, MD, FAAN

Wednesday, April 25 8:00 a.m.–9:10 a.m.

How to Write and Publish Research Papers, Reviews and Other Scientific Communications Speakers: Mark Hallett, MD, FAAN Francois Boller, MD, PhD, FAAN Michael J. Aminoff, MD, DSc, FAAN

2:00 p.m.–2:30 p.m.

Office Hours: Mentor-Mentee Relationships Speaker: Nicte I. Mejia, MD Women in Neuroscience Speaker: Amy R. Brooks-Kayal, MD, FAAN

2:40 p.m.–3:10 p.m.

Patient-Reported Measures in Neurology Speaker: Lidia Maria Veras Rocha Moura, MD

3:00 p.m.–3:30 p.m.

Office Hours: Research Careers in Industry Speaker: Brandy R. Matthews, MD, FAAN

3:30 p.m.-4:15 p.m.

Scientific Platform Session S33 Global Health

4:30 p.m.-5:30 p.m.

Scientific Platform Session S37 Neurorehabilitation

Thursday, April 26 8:00 a.m.–8:30 a.m.

How to Bridge to Careers in Industry Speaker: Alfred W. Sandrock, MD, PhD

8:40 a.m.–9:10 a.m.

The Pathway to Become a Clinical Trialist Speaker: James F. Meschia, MD, FAAN

1:00 p.m.–1:30 p.m.

Office Hours: Early Career Research Funding and Career Development Speaker: Ryan R. Walsh, MD, PhD, FAAN

1:00 p.m.-2:15 p.m.

Scientific Platform Session S39 History of Neurology

4:30 p.m.–5:00 p.m.

Grantwriting 101: Getting Started Speaker: Logan D. Schneider, MD

Friday, April 27 8:00 a.m.–9:10 a.m.

Role of Placebo in Neuromuscular Clinical Trials and in Management of NM Disorders Speakers: Aziz I. Shaibani, MD, FAAN Richard J. Barohn, MD, FAAN

8:30 a.m.–9:00 a.m.

12:00 p.m.–12:30 p.m.

12:30 p.m.–1:00 p.m.

Office Hours: Selecting an AAN Research Program Mentor Speaker: Brian Edlow, MD Office Hours: Recruiting Difficult and Underrepresented Populations in Research Speaker: Jessica Robinson Papp, MD, FAAN Recruiting Minorities Speaker: Temitayo Oyegbile, MD, PhD

12:30 p.m.–1:00 p.m.

Office Hours: Navigating Uncommon Pathways in Academic Neurology: A Journey from Bedside to Bench Speaker: Carolina B. Maciel, MD

12:40 p.m.–1:10 p.m.

Neuroscience of Bias Speaker: Jose H. Posas, MD

1:00 p.m.–1:50 p.m.

Community Education in Minority Population Speaker: Olajide Abiodun Williams, MD

How to Bridge to Careers in Industry Speaker: Jose E. Cavazos, MD, PhD, FAAN Office Hours: Making the Transition from Research Fellow to Clinical Research Faculty Speaker: Benzi Kluger, MD, FAAN

12:40 p.m.–1:10 p.m.

How to Put Together an Effective Research Presentation Speaker: Enrique C. Leira, MD, MS, FAAN

2:40 p.m.–3:10 p.m.

Recruiting Minorities Speaker: Bernadette Boden-Albala, MPH

4:00 p.m.–4:30 p.m.

Historical Perspective on Treating Epilepsy Speaker: Gregory K. Bergey, MD, FAAN

AAN.com/view/AM18 77

Research Corner

Office Hours: The Researcher Pipeline: The Benefits of Participating in Academic Medicine, Research and Clinical Trials as a Medical Student or Resident Speaker: Laurie Gutmann, MD, FAAN

Moving Neurology Forward

EXPERIENTIAL LEARNING AREAS

X Research Corner:

MEMBERSHIP

FAAN AAN.COM

SYNAPSE

It’s all about you We our members. And at the Member Experience: Personalize Your Journey Experiential Learning Area, we’re ready to show you all the steps we’ve taken to help you connect, engage, and personalize your member experience to make it all your own.

GET UP TO SPEED

•

Take a look at the new AAN.com and see how it’s personalized just for you

•

Get a new profile picture

•

Join Synapse™ Online Communities

•

Compete with your colleagues to see who can find their way around the new site

GET RECOGNIZED

•

See if you qualify to elevate your membership status to the premier Fellow of the American Academy of Neurology (FAAN)

•

Check out our recognition wall to congratulate your deserving colleagues!

NEUROSCIENCE IN THE CLINIC SESSIONS

two-hour session featuring a mix of scientists and clinicians actively engaged in lively case discussion to integrate scientific research with clinical application. Scientists will introduce and provide background on a case and clinicians will apply the case to a patient. Sessions will feature abstract presentations related to the topic. Sessions end with a panel discussion.

Sunday, April 22 3:30 p.m.–5:30 p.m.

N1 Neuroscience in the Clinic:

Autism Myth Busters . . . . . . . . . . . . . . . 80

Monday, April 23 3:30 p.m.–5:30 p.m.

N2 Neuroscience in the Clinic:

Antisense Oligonucleotide (ASO) Therapy . . . . . . . 82

Tuesday, April 24 1:00 p.m.–3:00 p.m.

N3 Neuroscience in the Clinic:

Challenges in Genetic Diagnosis in Neurology . . . . . 82

Thursday, April 26 1:00 p.m.–3:00 p.m.

N5 Neuroscience in the Clinic:

Treatment of Progressive Multiple Sclerosis . . . . . . 84

3:30 p.m.–5:30 p.m.

N6 Neuroscience in the Clinic:

NeurologicComplications of Cancer Immunotherapy: A New Frontier in Neuro-Inflammation . . . . . . . . 84

Friday, April 27

3:30 p.m.–5:30 p.m.

N7 Neuroscience in the Clinic:

REM Sleep Behavior Disorder: Past, Present, Future . . 85

Wednesday, April 25 3:30 p.m.–5:30 p.m.

N4 Neuroscience in the Clinic:

Opioid Useand Abuse: The Overlapping Neurobiology of Painand Addiction, and the Path Toward Better Treatments . . . . . . . . . . . 83

AAN.com/view/AM18 79

NEUROSCIENCE IN THE CLINIC

Sunday, April 22

A two-hour session featuring a mix of scientists and clinicians actively engaged in lively case discussion to integrate scientific research with clinical application. Scientists will introduce and provide background on a case and clinicians will apply the case to a patient. Sessions will feature abstract presentations related to the topic. Sessions end with a panel discussion.

N1 Neuroscience in the Clinic: Autism Myth Busters Directors: Sarah J. Spence, MD, PhD; and Shafali Jeste, MD

Program Description Rapid advances in our understanding of the underlying neurobiology of autism spectrum disorder (ASD) has prompted more accurate and informed diagnoses, detailed prognostication, and the development of targeted treatment trials. However, these scientific achievements often become overshadowed by community practices that lack evidence or a scientific foundation, leaving patients and caregivers uncertain about best practices. The goal of this symposium is to provide neurologists with clinically relevant scientific updates on autism spectrum disorders (ASD), in order to facilitate more informed dialogues with their patients. We will begin with a representative clinical case, followed by three presentations with paired abstracts on key topics in the autism field, including prediction and diagnostic biomarkers, clinical trials and therapeutics, and advances in genetics. Upon Completion Participants should become familiar with insights on early signs of ASD gained from studies of infants at risk for ASD; the definition of a biomarker and an understanding of the types of biomarkers investigated in ASD; challenges around clinical trial design and implementation in ASD; evidence around pharmacological interventions for ASD and updates from clinical drug trials; and updates on autism genetics, from recommended diagnostic practices to implications for management.

3:30 p.m.–5:30 p.m.

3:30 p.m.–3:45 p.m. Clinical Vignette: Autism Spectrum Disorders Sarah J. Spence, MD, PhD, Boston, MA 3:45 p.m.–4:00 p.m. Biomarkers of ASD: From Screening to Clinical Stratification to Quantitative Outcomes Shafali Jeste, MD, Los Angeles, CA 4:00 p.m.–4:10 p.m. N1.001: The Broader Autism Phenotype in Tuberous Sclerosis Complex Jamie K. Capal, MD, Cincinnati, OH 4:10 p.m.–4:25 p.m. Clinical Trials and Treatments in ASD: What Works and Why Trials Fail Evdokia Anagnastou, MD, Toronto, ON, Canada 4:25 p.m.–4:35 p.m. N1.002: Sulforaphane Treatment of Children with Autism Spectrum Disorder (ASD) – A Progress Report Andrew W. Zimmerman, MD, FAAN, Worcester, MA 4:35 p.m.–4:50 p.m. Updates in Autism Genetics: Clinical and Scientific Implications for Precision Medicine Faculty 4:50 p.m.–5:00 p.m. N1.003: Multi-Gene Panels vs. Diagnostic Exome Sequencing: A Comparison of Genetic Testing Options for Neurodevelopmental Disorders Jing Wang, MD, Aliso Viejo, CA 5:00 p.m.–5:30 p.m. Panel Discussion Faculty

2019 ANNUAL MEETING COURSE PROPOSAL SUBMISSIONS The AAN is seeking submissions for course proposals for the 2019 Annual Meeting. The submission deadline is May 18, 2018. Please visit aan.com/view/courseproposals for additional information and guidelines.

80 2018 AAN Annual Meeting

Frontiers in Child Neurology: Cultivating Careers, Networking, and Exploring a Neurologic Disorder Through a Lifespanâ&#x20AC;&#x201D;Focus on Autism Sunday, April 22

12:30 p.m.â&#x20AC;&#x201C;6:00 p.m.

This exciting afternoon starts with a luncheon for medical students, residents, and fellows who are new to the field of child neurology. Afterwards, join leaders in child neurology for a Neuroscience in the Clinic session focused on autism, with presentations covering hot topics in the field to help clinicians have more informed discussions with their patients regarding biomarkers, clinical trials/treatments, and genetics. End the day with a networking reception for child neurologists before heading to the Opening Party.

Highlights

Careers in Child Neurology Luncheonâ&#x20AC;&#x201D; Ask the Experts

Neuroscience in the Clinic: Autism Mythbusters

Co-chairs: Ann H. Tilton, MD, FAAN, and Rujuta Bhatt, MD

Directors: Shafali Jeste, MD, and Sarah Spence, MD, PhD

Medical students and residents who are considering a career as a child neurologist will get a unique opportunity to meet with the experts and have their questions answered regarding a career as a child neurologist. Items discussed will include how different fellowships work, strategies for child neurology research, research funding, careers in child neurology education, and a discussion regarding careers in child neurology inthe community. This event is invite only.

Rapid advances in our understanding of the underlying neurobiology of autism spectrum disorder (ASD) has prompted more accurate and informed diagnoses, detailed prognostication, and the development of targeted treatment trials. However, these scientific achievements often become overshadowed by community practices that lack evidence or a scientific foundation, leaving patients and caregivers uncertain about best practices. The goal of this

session is to provide neurologists with clinically relevant scientific updates on autism spectrum disorders (ASD), in order to facilitate more informed dialogues with their patients. We will begin with a representative clinical case, followed by three presentations with paired abstracts on key topics in the autism field, including prediction and diagnostic biomarkers, clinical trials and therapeutics, and advances in genetics. Networking Reception The program will conclude with a wine and cheese reception allowing attendees an opportunity to network and talk with presenters.

NEUROSCIENCE IN THE CLINIC

NEUROSCIENCE IN THE CLINIC in the Clinic: N2 Neuroscience Antisense Oligonucleotide (ASO) Therapy Directors: John W. Day, MD, PhD; and Richard S. Finkel, MD

Program Description Ongoing clinical research has already identified the genetic cause of hundreds of distinct disorders, most notably in the area of neuromuscular neurology. While knowing the underlying genetic cause provides a clear target for course-modifying treatments, the ability to successfully and safely modify genes in the clinical world has remained difficult until very recently. After decades of development, technologies are now being successfully used to modify pathogenic mutations using antisense technologies. The faculty will discuss the range of antisense technologies now in clinical investigation, and the multiple methods by which they can alter expression of disease-causing mutations, focusing on current successes such as for spinal muscular atrophy, and future targets. Specific cases will be discussed to show how antisense technologies are being used clinically and how they will impact current and future care of neuromuscular disorders. Upon Completion Participants will be able to identify different antisense oligonucleotide chemistries and their relative values. They will understand the biodistribution and pharmacokinetics of some antisense oligonucleotides, and the various ways in which antisense oligonucleotides can impact normal and pathogenic gene expression. They will get an update on recently approved antisense treatments that are now commercially available, as well as those that are currently in development.

in the Clinic: N3 Neuroscience Challenges in Genetic Diagnosis in Neurology Directors: Guy A. Rouleau, MD, PhD; and Massimo Pandolfo, MD, FAAN

82 2018 AAN Annual Meeting

3:30 p.m.–5:30 p.m.

3:30 p.m.–3:35 p.m. Introduction John W. Day, MD, PhD, Palo Alto, CA 3:35 p.m.–3:50 p.m. Scientific Content on ASOs Frank Bennett, PhD, Carlsbad, CA 3:50 p.m.–4:05 p.m. Case Presentation Richard S. Finkel, MD, Orlando, FL 4:05 p.m.–4:20 p.m. Case Presentation John W. Day, MD, PhD, Palo Alto, CA 4:20 p.m.–4:30 p.m. Scientific Wrap-up of Case Presentation Treatments Frank Bennett, PhD, Carlsbad, CA 4:30 p.m.–4:45 p.m. N2.001: Safety and Efficacy of Inotersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NEURO-TTR) Morie A. Gertz, MD, Rochester, MN 4:45 p.m.–5:00 p.m. N2.002: Stereopure Antisense Oligonucleotides Preferentially Knockdown G4C2 Repeat-Containing C9ORF72 Transcripts: A Potential Therapeutic Approach for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) Yuanjing Liu, PhD, Cambridge, MA 5:00 p.m.–5:30 p.m. Panel Discussion and Audience Q&A Faculty

NEUROSCIENCE IN THE CLINIC

Program Description Genetic testing is becoming increasingly prevalent and interpretation sometimes difficult. The program will consist of a presentation of a complex case, followed by discussion that will illustrate the science that led to the current state of the art, where it is expected to move, how this impacted practice, what are the unmet needs in the clinic. Upon Completion Participants should become familiar with the issues involved in the interpretation of genetic testing results, including the assessment of the potential pathogenicity of the identified genetic variants and their correlation with phenotype.

Monday, April 23

Tuesday, April 24

1:00 p.m.–3:00 p.m.

1:00 p.m.–1:10 p.m. Case Presentation Stefan M. Pulst, MD, FAAN, Salt Lake City, UT 1:10 p.m.–1:35 p.m. Clinical Discussion Stefan M. Pulst, MD, FAAN, Salt Lake City, UT 1:35 p.m.–2:00 p.m. Scientific Discussion Brent L. Fogel, MD, PhD, FAAN, Los Angeles, CA 2:00 p.m.–2:15 p.m. N3.001: Integrated Whole Exome Sequencing and Chromosomal Microarray in Familial Parkinson’s Disease Laurie Robak, MD, PhD, Houston, TX 2:15 p.m.–2:30 p.m. N3.002: Expanding the Genetic Spectrum of Congenital Sensory and Autonomic Neuropathies with Whole Exome Sequencing Jose-Alberto Palma, MD, PhD, New York, NY 2:30 p.m.–3:00 p.m. Panel Discussion Faculty

Wednesday, April 25

in the Clinic: Opioid Use N4 Neuroscience and Abuse: The Overlapping Neurobiology of Pain

and Addiction, and the Path Toward Better Treatments Directors: Jessica Robinson Papp, MD, FAAN; and Walter J. Koroshetz, MD, FAAN

Program Description Chronic pain and substance use disorders frequently co-exist and neurologists often feel ill-equipped to treat patients with these complex disorders. In this session we will travel from bench to bedside and beyond, exploring the neurobiology underlying pain and addiction, and the hope it brings for better treatments; hearing the patient’s perspective; and learning about governmental policy designed to improve the care of chronic pain patients while working to ameliorate the U.S. opioid epidemic. Upon Completion Participants will become familiar with central nervous system mechanisms underlying chronic pain and addiction and how knowledge of these mechanisms can inform drug discovery. Participants will also understand changes in public policy which effect neurologists and their patients with chronic pain, with a focus on the U.S. National Pain Strategy.

3:30 p.m.–5:30 p.m.

3:30 p.m.–3:35 p.m. Introduction Jessica Robinson Papp, MD, FAAN, New York, NY 3:35 p.m.–3:50 p.m. Patient Presentation: Use of Opioids in Complex Disease Elyse J. Singer, MD, Los Angeles, CA 3:50 p.m.–4:10 p.m. Neurobiology of Pain and Addiction Catherine Cahill, PhD, Los Angeles, CA 4:10 p.m.–4:30 p.m. N4.001: Association of OPRM1, OPRK1 and COMT Genes with Opioid Response Is Opioid and Pain Modality Specific Kwo Wei David Ho, MD, Gainesville, FL 4:25 p.m.–4:40 p.m. Clinical Follow-up and Discussion of National Pain Strategy Walter J. Koroshetz, MD, FAAN, Bethesda, MD 4:40 p.m.–4:55 p.m. N4.002: Provider Perspectives On Patient-Provider Communication Related to Opioid Use for Chronic Pain Allison P. Navis, MD, New York, NY 4:55 p.m.–5:10 p.m. Scientific Wrap-up and Link to Therapeutics Jessica Robinson Papp, MD, FAAN, New York, NY 5:10 p.m.–5:30 p.m. Panel Discussion, Questions and Answers, and Closing Remarks Faculty

AAN.com/view/AM18 83

NEUROSCIENCE IN THE CLINIC

NEUROSCIENCE IN THE CLINIC in the Clinic: N5 Neuroscience Treatment of Progressive Multiple Sclerosis Directors: Ellen M. Mowry, MD, FAAN; and Eric Klawiter, MD

Program Description Advances in the understanding of multiple sclerosis have opened up potential therapeutic targets, addressing a great need in progressive MS. Following a case presentation, faculty will discuss disease pathogenesis, biomarker development, and the latest clinical trial results with a focus of relating the recent discoveries in neuroscience in this area back to the bedside. Upon Completion Participants should become familiar with the pathogenesis of progressive multiple sclerosis and how to assess progressive multiple sclerosis. They should be equipped to improve their management of patients with progressive multiple sclerosis.

A New Frontier in Neuro-Inflammation

Directors: Andreas Felix Hottinger, MD; and Antonio M. P. Omuro, MD

84 2018 AAN Annual Meeting

1:00 p.m.–3:00 p.m.

1:00 p.m.–1:15 p.m. Progressive MS Case Presentation Faculty 1:15 p.m.–1:35 p.m. From Pathology to Pathogenesis of Progressive MS Gabriele C. De Luca, MD,PhD, Oxford, United Kingdom 1:35 p.m.–1:45 p.m. A Clinician’s Perspective of Progressive MS Jiwon Oh, MD, Toronto, ON, Canada 1:45 p.m.–2:00 p.m. Progress in Progressive MS Faculty 2:00 p.m.–2:15 p.m. N5.001: Continuous Wrist-Worn Accelerometry Captures Change in Average Daily Step Count in People with Multiple Sclerosis Over One Year Valerie A J Block, San Francisco, CA 2:15 p.m.–2:30 p.m. N5.002: Disease-specific Atrophy in Alzheimer’s Disease; An Approach to Identify Grey Matter Regions Linked to Neurodegeneration in MS Daniel Pelletier, MD, Los Angeles, CA 2:30 p.m.–3:00 p.m. Progressive MS Panel Discussion Faculty

in the Clinic: Neurologic N6 Neuroscience Complications of Cancer Immunotherapy: Program Description The use of anti-cancer immunotherapies has become widespread in oncology, and multiple agents spanning a variety of mechanisms of action are currently approved, including immune checkpoint inhibitors (anti-CTLA-4, PD-1 and PD-L1 antibodies), CAR-T cells therapy and dendritic cell vaccines. Many of these agents disrupt mechanisms involved in prevention of auto-immunity and maintenance of selftolerance, or have pro-inflammatory properties. As a result, a wide spectrum of neurologic inflammatory complications have emerged as potential, and at times life-threatening side effects, posing diagnostic and therapeutic challenges that neurologists will be required to address. In this course, the most common immunotherapy complications involving both the CNS and peripheral nervous system will be reviewed, including encephalitis, myelitis, peripheral neuropathies, radiculopathies, neuromuscular junction disorders and myopathy. The mechanisms underlying these side effects, as well as principles governing immune responses within the nervous system will be discussed, integrated with a review on diagnosis and clinical management. Upon Completion Participants should be able to recognize and treat neurologic complications of anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies and CAR-T cell therapies and understand the mechanisms of action of such agents, how they can translate into injury to the nervous system and how they can be reversed.

Thursday, April 26

3:30 p.m.–5:30 p.m.

3:30 p.m.–3:35 p.m. Introduction on Cancer Immunotherapy Antonio M. P. Omuro, MD, Miami, FL 3:35 p.m.–3:40 p.m. Case Presentation Bianca Santomasso, MD, New York, NY 3:40 p.m.–4:10 p.m. Neuroscience Background: The Peripheral and CNS Immune System: Physiology and Effects of Anti-Cancer Immunotherapies David A. Hafler, MD, FAAN, New Haven, CT 4:10 p.m.–4:30 p.m. Clinical Implications Bianca Santomasso, MD, New York, NY 4:30 p.m.–4:40 p.m. Future Directions Antonio M. P. Omuro, MD, Miami, FL 4:40 p.m.–4:55 p.m. N6.001: Neurologic Immune Related Adverse Events (irAEs) in Patients with Metastatic Solid Tumors Treated with Immune Checkpoint Inhibitors: A Single Institution Retrospective Analysis Rachna Malani, MD, New York, NY 4:55 p.m.–5:10 p.m. N6.002: Immune-mediated Necrotizing Myositis in Patients Receiving Immune Checkpoint Inhibitors: Clinical and Histopathological Features, Treatment and Outcome Mehdi Touat, Paris, France 5:10 p.m.–5:25 p.m. Abstracts Discussion and Implications for Clinical Practice Andreas Felix Hottinger, MD, Lausanne, Switzerland 5:25 p.m.–5:30 p.m. Panel Discussion/Questions and Answers Faculty

Friday, April 27

in the Clinic: N7 Neuroscience REM Sleep Behavior Disorder: Past, Present, Future Directors: Aleksandar Videnovic, MD, MSc, FAAN; and Phyllis C. Zee, MD, PhD

Program Description REM sleep behavior disorder (RBD) is a parasomnia characterized by dream enactment in the context of loss of physiological atonia during REM sleep. RBD is of particular importance to neurosciences as it is one of the earliest manifestations of α-synuclein related neurodegeneration. Over 80% of patients with idiopathic RBD eventually develop Parkinson’s disease, dementia with Lewy body or multiple system atrophy. This program with highlight clinical aspects of the disorder, its historical perspective, as well as novel findings related to the pathophysiology of the disorder and its relationship with neurodegenerative disorders. Upon Completion Participants should be able to recognize clinical characteristics, diagnosis, differential diagnosis, and treatment of RBD; understand novel advances in the pathophysiology of RBD; and discuss the association between RBD and α-synucleinopathies.

3:30 p.m.–5:30 p.m.

3:30 p.m.–3:35 p.m. Introduction Aleksandar Videnovic, MD, MSc, FAAN, Boston, MA 3:35 p.m.–3:45 p.m. Case Presentation Roneil Malkani, MD, Chicago, IL 3:45 p.m.–4:00 p.m. RBD – Historical Perspective Carlos H. Schenck, MD, Minneapolis, MN 4:00 p.m.–4:15 p.m. RBD – Diagnostic and Treatment Challenges Aleksandar Videnovic, MD, MSc, FAAN, Boston, MA 4:15 p.m.–4:30 p.m. RBD – Control of Muscle Tone Across the Sleep-Wake Cycle and in Narcolepsy Jerome Siegel, PhD, Los Angeles, CA 4:30 p.m.–4:45 p.m. N7.001: Diagnostic Yield of REM Sleep Muscle Activity for Presumed Synucleinopathy Neurodegeneration Stuart McCarter, MD, Rochester, MN 4:45 p.m.–5:00 p.m. N7.002: Nocturnal REM Sleep Without Atonia is a Diagnostic Biomarker of Pediatric Narcolepsy Kiran Prasad Maski, MD, Boston, MA 5:00 p.m.–5:30 p.m. Panel Discussion Faculty

AAN.com/view/AM18 85

NEUROSCIENCE IN THE CLINIC

NEW AT 2018 ANNUAL MEETING

New for 2018 Medical Student Symposium: Careers in Neurology Sunday, April 22, 2018 12:30 p.m.–5:30 p.m.

Attend this half-day event to explore the exciting opportunities that a career in neurology can offer. This program is specifically designed for medical students to attend and discover their career potential as well as network with other students.

Young Investigators Programming Saturday, April 21–Monday, April 23, 2018

Support your budding career in research with training and mentoring specifically for medical students and residents. Components include training, mentoring, and networking designed to address the specific needs of pre- and early-career researchers.

Visit www.aan.com/view/StudentsRF to learn more about these programs.

INVITED SCIENCE SESSIONS

n AAN platform session featuring authors giving encore presentations of top abstracts previously presented at a subspecialty meeting.

Tuesday, April 24 1:00 p.m.–3:00 p.m.

Invited Science: Movement Disorders . . . . . . . . . . . 88

Wednesday, April 25 3:30 p.m.–5:30 p.m.

Invited Science: Sleep . . . . . . . . . . . . . . . . . 89

Thursday, April 26 1:00 p.m.–2:30 p.m.

Invited Science: The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative . . . . . . . . . . . . . . . . . . . 89 3:30 p.m.–5:30 p.m.

Invited Science: Neuro Trauma . . . . . . . . . . . . . . 90

AAN.com/view/AM18 87

INVITED SCIENCE SESSIONS

INVITED SCIENCE SESSIONS Invited Science: Movement Disorders Tuesday, April 24 1:00 p.m.–3:00 p.m.

Top abstracts previously presented at the Movement Disorders Society Annual Meeting will be presented by their authors. Select abstracts from their “best of” lineups emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of movement disorders with the overall goal of developing more effective prevention and treatment. This session is being presented in partnership with the International Parkinson and Movement Disorder Society. 1:00 p.m.–1:20 p.m.

2:00 p.m.–2:20 p.m.

Tissue Engineered Nigrostriatal Pathway for Treatment of Parkinson’s Disease John E. Duda, MD

Results From A Phase 1b Multiple Ascending-dose Study of prx002, An Anti–alpha-synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease Joseph Jankovic, MD, FAAN

Veterans Affairs Medical Center, Philadelphia, PA

1:20 p.m.–1:40 p.m.

Baylor College of Medicine, Houston, TX

Which Clinical Features Predict Progressive Supranuclear Palsy Pathology? A Clinicopathological Study on 437 Autopsy Cases and A Literature Review Gesine Respondek, MD

2:20 p.m.–2:40 p.m.

1:40 p.m.–2:00 p.m.

2:40 p.m.–3:00 p.m.

Skin Nerve Phosphorylated a-synuclein Deposits in Idiopathic REM Sleep Behavior Disorder Elena Antelmi, MD

Exercise Alters Response of Reward Anticipation in the Ventral Striatum of Subjects with Parkinson’s Disease Matthew Sacheli

Technische Universität München, Munich, Germany

University of Bologna, Bologna, Italy

88 2018 AAN Annual Meeting

The Effect of Early STN-DBS in PD Patients on Axial Symptoms: a 2-year Randomized Controlled Trial (EARLYSTIM-Gait Analysis) Michael Barbe, MD University Hospital Köln, Köln, Germany

Pacific Parkinson’s Research Centre, Vancouver, BC, Canada

Wednesday, April 25 3:30 p.m.–5:30 p.m.

Top abstracts previously presented at the American Academy of Sleep Medicine/Sleep Research Society Annual Meeting will be presented by their authors. Select abstracts from their “best of” lineups emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of sleep disorders with the overall goal of developing more effective prevention and treatment. This session is being presented in partnership with the American Academy of Sleep Medicine and the Sleep Research Society. 3:30 p.m.–3:50 p.m.

4:30 p.m.–4:50 p.m.

Recurrent Circuitry for Balancing Sleep Need Jeffrey Donlea, PhD

Sleep Loading Improves Visual Search Response Time and Reduces Fatigue in Professional Baseball Players Cheri D. Mah, MS

UCLA, David Geffen School of Medicine, Los Angeles, CA

3:50 p.m.–4:10 p.m.

A Circuit For the Circadian Control of Aggression W illiam D. Todd, PhD Beth Israel Deaconess Medical Center, Boston, MA

4:10 p.m.–4:30 p.m.

Direct Electrical Stimulation to the Human Amygdala Enhances Recognition Memory Following Sleep Jon T. Willie, MD, PhD Emory University, Atlanta, GA

niversity of California San Francisco Human Performance Center, San U Francisco, CA

4:50 p.m.–5:10 p.m.

S leep While On-Call Overnight Does Not Restore Performance Among First-Year Resident Physicians Melissa A. St. Hilaire, PhD Brigham and Women’s Hospital, Boston, MA

5:10 p.m.–5:30 p.m.

The Role of Nightly Zopiclone on Obstructive Sleep Apnea Severity and Symptoms in People with Low to Moderate Respiratory Arousal Thresholds: A Randomized, Double-Blind, Placebo-Controlled Trial Sophie Carter NeuRA, Randwick, Australia

Invited Science: The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative Thursday, April 26 1:00 p.m.–2:30 p.m.

This program will feature the latest findings from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, a large-scale effort aimed at revolutionizing our understanding of the human brain. Launched in 2013 by President Obama as a “moonshot to explore the frontiers of the mind,” this program seeks development of the technologies and insights to facilitate treatment, cure, and prevention of brain disorders. This session is being presented in partnership with the National Institutes of Health. 1:05 p.m.–1:25 p.m.

1:45 p.m.–2:05 p.m.

Full-scale Neuronal Network Modeling of Spatial Learning and Memory in Hippocampus Ivan Soltesz, PhD

Defining Cell Types, Lineage, and Connectivity in Developing Human Cortex Faculty

Stanford University School of Medicine, Stanford, CA

1:25 p.m.–1:45 p.m.

Non-degenerate multiphoton microscopy for deep brain imaging Anna Devor, PhD University of California, San Diego, San Diego, CA

2:05 p.m.–2:25 p.m.

Using Tissue Clearing and Optogenetics to Dissect the Circuitry Underlying Neurological Disorders Viviana Gradinaru, PhD California Institute of Technology, Pasadena, CA

AAN.com/view/AM18 89

INVITED SCIENCE SESSIONS

Invited Science: Sleep

INVITED SCIENCE SESSIONS

INVITED SCIENCE SESSIONS Invited Science: Neuro Trauma

Thursday, April 26 3:30 p.m.–5:30 p.m.

Key talks previously given at the National Neurotrauma Society Annual Meeting will be presented during this session. Speakers will emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of neurotrauma with the overall goal of developing more effective treatments. This session is being presented in partnership with the National Neurotrauma Society. 3:30 p.m.–4:10 p.m.

4:50 p.m.–5:10 p.m.

Operation Brain Trauma Therapy Consortium Patrick M. Kochanek, MD, MCCM

The Invisible Wounds of War: Combat Concussions Christine MacDonald, PhD

4:10 p.m.–4:30 p.m.

5:10 p.m.–5:30 p.m.

The Glymphatic System: Role in Post-TBI Edema? Miranda M. Lim, MD, PhD

Intestinal Dysfunction Following TBI: Lessons from Drosophila David Wassarman, PhD

University of Pittsburgh, Pittsburgh, PA

Washington University School of Medicine, Saint Louis, MO

Oregon Health & Science University, Portland, OR

University of Wisconsin-Madison, Madison, WI

4:30 p.m.–4:50 p.m.

Hormonal Alterations and Sleep Following Brain Injury Faculty

MEM: 17 Membership Continuum Ad—Half Page Horizontal> AN Placed in AANnews, Early 8.25 x 5.25 +0.125 bleed, 4C

Essential Education. Incomparable Support. That’s AAN Membership. Only an AAN membership provides a single source for all the tools and resources you need to thrive throughout your professional lifetime.

See the full listing of exclusive member benefits and apply or renew AAN.com/membership

“BEST OF” SCIENTIFIC PLATFORM SESSIONS

platform session that brings together the top four scoring abstracts in a topic, as rated by the topic reviewers. Interact with the authors in a smaller, more intimate setting at the conclusion of the session. These “Best of” sessions are the perfect lead-in to the plenary sessions that immediately follow.

Sunday, April 22 8:00 a.m.–9:00 a.m.

S1 “Best of” Session: Cerebrovascular Disease and

Interventional Neurology . . . . . . . . . . . . . 92

Monday, April 23 8:00 a.m.–9:00 a.m.

S11 “Best of” Session: Epilepsy/Clinical Neurophysiology (EEG)92

Tuesday, April 24 8:00 a.m.–9:00 a.m.

S20 “Best of” Session: Headache . . . . . . . . . . . . 92

Wednesday, April 25 8:00 a.m.–9:00 a.m.

S27 “Best of” Session: Movement Disorders . . . . . . . . 93

Thursday, April 26 8:00 a.m.–9:00 a.m.

S38 “Best of” Session: Clinical Trial Updates

in Neuromuscular Disorders . . . . . . . . . . . . 93

Friday, April 27

8:00 a.m.–9:00 a.m.

S47 “Best of” Session: MS and CNS Inflammatory Diseases . 93

AAN.com/view/AM18 91

“BEST OF” SCIENTIFIC PLATFORM SESSIONS

“BEST OF” SCIENTIFIC PLATFORM SESSIONS Sunday, April 22

Monday, April 23

Tuesday, April 24

8:00 a.m.–9:00 a.m.

S1 “Best of” Session: Cerebrovascular

Disease and Interventional Neurology

8:00 a.m.

S1.001

Minocycline Protects against Delayed Cerebral Ischemia after Subarachnoid Hemorrhage via Matrix Metalloproteinase-9 Inhibition —Glenn Harris, Ananth

Vellimana, Meng-Liang Zhou, Itender Singh, Diane Aum, James Nelson, Umeshkumar Athiraman, ByoungJun Han, Gregory Zipfel

8:08 a.m.

S1.002

Genome-Wide Association Study of Hematoma Volume Identifies 17p12 as a Novel Susceptibility Locus for Severity and Outcome in Intracerebral Hemorrhage —Sandro Marini, William J. Devan, Farid Radmanesh,

Laura Miyares, Timothy Poterba, Bjorn Hansen, Bo Norrving, Eva Giralt-Steinhauer, Jordi Jimenez-Conde, Roberto Elosua, Elisa Cuadrado-Godia, Carolina Soriano, Jaume Roquer Gonzalez, Christina Kourkoulis, Alison Ayres, Kristin Schwab, David Tirschwell, Magdy Selim, Devin Brown, Scott Silliman, Bradford Worrall, James Meschia, Chelsea Kidwell, Joan Montaner, Israel Fernandez-Cadenas, Pilar Delgado, Steven Greenberg, Arne Lindgren, Charles Matouk, Kevin Sheth, Daniel Woo, Christopher Anderson, Jonathan Rosand, Guido Falcone

8:16 a.m.

S1.003

Association of prothrombin complex concentrates administration and hematoma enlargement in NOACrelated intracerebral hemorrhage —Stefan Gerner, Stefan Schwab, Hagen Huttner

8:24 a.m.

S1.004

Left Atrial Endothelial Dysfunction, Inflammation and Fibrosis Induced by Selective Insular Cortex Ischemic Stroke in Rats —Brittany Balint, Victoria Thorburn, Victoria Jaremek, Maryse Paquet, Shawn Whitehead, Luciano Sposato

8:32 a.m. Panel Discussion/Meeting the Investigators

92 2018 AAN Annual Meeting

S11 “Best of” Session: Epilepsy/Clinical Neurophysiology (EEG)

8:00 a.m.

S11.001

Maintaining Seizure Freedom during Pregnancy and Postpartum: Findings from the MONEAD Study —Page

Pennell, Jacqueline French, Ryan May, Elizabeth Gerard, Laura Kalayjian, Evan Gedzelman, Patricia Penovich, Jennifer Cavitt, Sean Hwang, Alison Pack, Maria Sam, Eugene Moore, Dominic Ippolito, Kimford Meador

8:08 a.m.

S11.002

A Practical Risk Score for EEG Seizures in Hospitalized Patients —Aaron Struck, Berk Ustun, Andres Rodriguez-Ruiz,

Jong Lee, Suzette LaRoche, Lawrence Hirsch, Emily Gilmore, Jan Vlachy, Hiba Haider, Cynthia Rudin, M. Westover

8:16 a.m.

S11.003

Seizure Semiologies and Effects of Anti-epileptic Drugs in Patients with Leucine-rich glioma-inactivated-1 ligand antibody (LGI1-Ab) Autoimmune Epilepsy —Christopher Lamb,

Jeffrey Britton, Sean Pittock, Avi Gadoth, Andrew McKeon, Christopher Klein, Anteneh Feyissa

8:24 a.m.

S11.004

Interictal Spike Rates Are Correlated with Verbal Memory in Patients with Mesial Temporal Lobe Epilepsy —Kimford Meador, David Loring, Tara Crowder Skarpaas, Martha Morrell

8:32 a.m. Panel Discussion/Meet the Investigators

S20 “Best of” Session: Headache

8:00 a.m.

S20.001

Primary Results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Episodic Migraines —Joel Saper, Richard Lipton, David Kudrow, Joe Hirman, David Dodick, Stephen Silberstein, George Chakhava, Jeff Smith

8:08 a.m.

S20.002

Alterations in regional cerebral blood flow during the premonitory stage of nitroglycerin-triggered migraine attacks, assessed with arterial spin-labelled fMRI —Nazia Karsan, Pyari Bose, Fernando Zelaya, Peter Goadsby

8:16 a.m.

S20.003

Untangling the burden of menstrual migraine from headache day frequency: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study —Jelena Pavlovic, Michael Reed, Kristina Fanning, Sagar Munjal, Aftab Alam, Todd Schwedt, David Dodick, Dawn Buse, Richard Lipton

8:24 a.m.

S20.004

Efficacy of Galcanezumab in Patients Who Failed to Respond to Preventives Previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN Studies —Qi Zhang, Dustin Ruff, Eric Pearlman, Sriram Govindan, Sheena K. Aurora

8:32 a.m. Panel Discussion/Meet the Investigators

Thursday, April 26

Friday, April 27

8:00 a.m.–9:00 a.m.

S27 “Best of” Session: Movement Disorders

8:00 a.m.

S27.001

Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations —Charles Adler, Thomas

Beach, Nan Zhang, Holly Shill, Erika Driver-Dunckley, John Caviness, Shyamal Mehta, Marwan Sabbagh, Geidy Serrano, Lucia Sue, Christine Belden, Jessica Powell, Sandra Jacobson, Edward Zamrini, David Shprecher, Kathryn Davis, Brittany Dugger, Joseph Hentz

8:08 a.m.

S27.002

Exenatide Modulates Neuronal Insulin Signalling in Parkinson’s Disease —Dilan Athauda, Seema Gulyani, Hanuma

Karnati, Yazhou Li, David Tweedie, Simon Skene, Kashfia Chowdhury, Nigel Greig, Dimitrios Kapogiannis, Thomas Foltynie

8:16 a.m.

S27.003

Sensitivity and Specificity of Clinical Criteria for 4-Repeat Tauopathies in Autopsy-Confirmed Cases —Jessica

Weinstein, David Irwin, John Trojanowski, Pouya Khankhanian, Murray Grossman, Corey McMillan

8:24 a.m.

S27.004

Multiple Ascending Dose Study of the Tau-Directed Monoclonal Antibody BIIB092 in Patients with Progressive Supranuclear Palsy —Adam Boxer, Irfan Qureshi, Michael Grundman, Giridhar S. Tirucherai, Clifford Bechtold, Michael Ahlijanian, Gerry Kolaitis, Lawrence Golbe, Lawrence Honig, Stuart Isaacson, Murray Grossman, Nikolaus McFarland, Irene Litvan, David Geldmacher, Tao Xie, Yvette Bordelon, Paul Tuite, Padraig O’Suilleabhain, Theresa Zesiewicz

S38 “Best of” Session: Clinical Trial

Updates in Neuromuscular Disorders

8:00 a.m.

S38.001

Preliminary Results from a Phase 2 Study to Evaluate ACE-083, a Local Muscle Therapeutic, in Patients with Facioscapulohumeral Muscular Dystrophy —Jeffrey

Statland, Anthony Amato, Elena Bravver, Craig Campbell, Lauren Elman, Nicholas Johnson, Nanette Joyce, Chafic Karam, John Kissel, Lawrence Korngut, Erin O’Ferrall, Georgios Manousakis, Alan Pestronk, Perry Shieh, Alrabi Tawil, Ashley Leneus, Barry Miller, Matthew Sherman, Chad E Glasser, Kenneth Attie

8:08 a.m.

S38.002

NurOwn® Phase 2 ALS Trial: ALSFRS-R Improvement is Reflected in Subscale Domains —Ralph Kern, Merit Cudkowicz, James Berry, Anthony Windebank, Nathan Staff, Margaret Owegi, Chaim Lebovits, Yael Gothelf, Robert Brown

8:16 a.m.

S38.003

Long-Term Efficacy and Safety of Bimagrumab in Inclusion Body Myositis: 2 Years Results —Anthony Amato, Lixin ZhangAuberson, Michael Hanna, Umesh Badrising, Merrilee Needham, Hector Chinoy, Masashi Aoki, Barbara Koumaras, Laszlo Tanko, Min Wu, Dimritris Papanicolaou, Olivier Benveniste

8:24 a.m.

S38.004

Randomized Phase 2B trial of NP001, a Novel Immune Regulator, in ALS —Robert Miller, Jonathan Katz, Gilbert Block, NP001-10-003 Study Group

8:32 a.m. Panel Discussion/Meet the Investigators

S47 “Best of” Session: MS and

CNS Inflammatory Diseases

8:00 a.m.

S47.001

Longitudinal Changes in Quantitative Spinal Cord MRI in Multiple Sclerosis Patients: Results of a 5-year

Study —Jiwon Oh, Kateryna Cybulsky, Min Chen, Suradech

Suthiphosuwan, Estelle Seyman, Aaron Carass, Marie Diener-West, Peter Van Zijl, Jerry Prince, Daniel Reich, Peter Calabresi

8:08 a.m.

S47.002

Effect of Age at Puberty on Risk of Multiple Sclerosis: A Mendelian Randomization Study —Adil Harroud, John

A. Morris, Vincenzo Forgetta, Ruth Mitchell, George Davey Smith, Stephen Sawcer, J. Brent Richards

8:16 a.m.

S47.003

Longitudinal assessment of rates of brain and retinal atrophy in African American versus Caucasian American patients with Multiple Sclerosis —Natalia Gonzalez Caldito,

Shiv Saidha, Elias Sotirchos, Blake Dewey, Norah Cowley, jeffrey Glaister, Kathryn Fitzgerald, James Nguyen, Alissa Rothman, Esther Ogbuokiri, Dorlan Kimbrough, Teresa Frohman, Elliot Frohman, Laura Balcer, Ciprian Crainiceanu, Dzung Pham, Jerry Prince, Peter Calabresi

8:24 a.m.

S47.004

Meta-Analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments —Ann Weideman, Marco Tapia-Maltos, Kory Johnson, Mark Greenwood, Bibiana Bielekova

8:32 a.m. Panel Discussion/Meet the Investigators

= Abstract of Distinction

AAN.com/view/AM18 93

“BEST OF” SCIENTIFIC PLATFORM SESSIONS

Wednesday, April 25

Annual Meeting Edition

Earn 10 free self-assessment CME credits and receive help planning your 2018 Annual Meeting itinerary Post-test

Pre-test Annual Meeting Take pre-test before

Take post-test before

April 21, 2018

July 27, 2018

Attend Annual Meeting

April 21â&#x20AC;&#x201C;27, 2018

Assess your strengths and compare your performance to other neurologists with this ABPN-approved programâ&#x20AC;&#x201D; available on the Annual Meeting App!

AAN.com/view/NeuroSAEAM

SCIENTIFIC PLATFORM SESSIONS

hese popular sessions feature a group of abstracts covering a similar topic presented in an oral format. Format will feature eight-minute presentation followed by four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.

Sunday, April 22 1:00 p.m.–3:00 p.m.

S2 Clinical Trials and Therapeutic Approaches in S3 S4 S5 S6

3:30 p.m.–4:30 p.m.

S7 Pain and Palliative Care . . . . . . . . . . . . . . 98 3:30 p.m.–5:30 p.m.

S8 Progressive MS Therapies and Age-Dependent

Factors in MS Therapy . . . . . . . . . . . . . . 98 S9 Epilepsy/Clinical Neurophysiology (EEG) I . . . . . . . 98 S10 Intracerebral and Subarachnoid Hemorrhage . . . . . 99

Monday, April 23 1:00 p.m.–2:15 p.m.

S12 Autonomic Disorders . . . . . . . . . . . . . . . 100 1:00 p.m.–3:00 p.m.

S13 Neuromyelitis Optica Spectrum Disorder and Other

Autoimmune Disorders . . . . . . . . . . . . . . 100

S14 Education and Patient Outcomes Research . . . . . . 101 S15 Cerebrovascular Disease Epidemiology and Outcomes . 101 S16 Neuro-ophthalmology/Neuro-otology . . . . . . . . 101 3:30 p.m.–5:30 p.m.

S17 Sleep . . . . . . . . . . . . . . . . . . . . . 102 S18 Movement Disorders: Ataxia and Tremor . . . . . . 102 S19 Epilepsy/Clinical Neurophysiology (EEG) II . . . . . . 102

Tuesday, April 24 1:00 p.m.–3:00 p.m.

S21 Revascularization in Acute Ischemic Stroke . . . . . 104 S22 Advances in Muscular Dystrophy and Congenital

Myopathy . . . . . . . . . . . . . . . . . . . 104 S23 Biologic and Clinical Discoveries in Neuro-oncology . . 105 3:30 p.m.–5:30 p.m.

S24 MS Outcome Measures and Biomarkers . . . . . . . 106 S25 Advances in Amyotrophic Lateral Sclerosis . . . . . 106 S26 Movement Disorders: Parkinson’s Disease Clinical Trials 106

Wednesday, April 25 1:00 p.m.–2:00 p.m.

S28 Practice, Policy, and Ethics . . . . . . . . . . . . 108 1:00 p.m.–3:00 p.m.

S29 Child Neurology and Developmental Neurology I . . . 108 S30 Movement Disorders: Dystonia, Chorea, and other Disorders . . . . . . . . . . . . . . . . . . . 109

S31 Therapeutics, Phenotypes, and Biomarkers in

Neuromuscular Disorders . . . . . . . . . . . . . 109

S32 Headache: Therapeutics . . . . . . . . . . . . . 109 3:30 p.m.–4:15 p.m.

S33 Global Health . . . . . . . . . . . . . . . . . . 110 3:30 p.m.–5:30 p.m.

S34 Behavioral andCognitive Neurology . . . . . . . . . 110 S35 Child Neurology and Developmental Neurology II . . . 110 S36 MS Therapeutics and Clinical Research . . . . . . . 111 4:30 p.m.–5:30 p.m.

S37 Neurorehabilitation . . . . . . . . . . . . . . . 111

Thursday, April 26 1:00 p.m.–2:15 p.m.

S39 History of Neurology . . . . . . . . . . . . . . . 112 1:00 p.m.–3:00 p.m.

S40 Acute Stroke Care . . . . . . . . . . . . . . . . 112 S41 Neurologic Infections . . . . . . . . . . . . . . 113 S42 Neurocritical Care . . . . . . . . . . . . . . . . 113 3:30 p.m.–5:30 p.m.

S43 Migraine . . . . . . . . . . . . . . . . . . . 114 S44 MS Risk Factors, Susceptibility, Diagnosis, and Cognitive Impairment . . . . . . . . . . . . . . 114 S45 Movement Disorders: Parkinsonian Disorders, Basic Science, and Imaging . . . . . . . . . . . . . . 114 S46 Advances in Spinal Muscular Atrophy . . . . . . . . 115

Friday, April 27

1:00 p.m.–3:00 p.m.

S48 S49 S50 S51

Novel Biomarkers inAging and Dementia . . . . . . 116 Neuro Trauma andSports Neurology . . . . . . . . 116 Updates in General Neurology . . . . . . . . . . . 117 Pediatric MS . . . . . . . . . . . . . . . . . . 117

3:30 p.m.–5:30 p.m.

S52 MS and CNS Inflammatory Disease: Basic Science . . 117 S53 Epilepsy/Clinical Neurophysiology (EEG) III . . . . . . 118 S54 Ischemic Stroke Prevention . . . . . . . . . . . . 118

AAN.com/view/AM18 95

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC PLATFORM SESSIONS 8:00 a.m.–9:00 a.m. S1 “Best of” Session: Cerebrovascular

Disease and Interventional Neurology

Titles and authors of these abstracts are listed in “Best of” Scientific Platform Sessions on page 92 »

1:00 p.m.–3:00 p.m.

S2 Clinical Trials and Therapeutic Approaches in Neurodegenerative Diseases

1:00 p.m.–3:00 p.m.

1:00 p.m. Potamkin Prize for Research in

Pick’s, Alzheimer’s, and Related Diseases T his award recognizes major contributions to the understanding

of the cause, prevention, treatment of, and ultimately the cure for Pick’s, Alzheimer’s, and related diseases.

Recipient:

David A. Bennett, MD Chicago, IL

1:24 p.m.

S2.003

Aducanumab titration dosing regimen: 24-month analysis from PRIME, a randomized, double-blind, placebocontrolled Phase 1b study in patients with prodromal or mild Alzheimer’s disease —Sebastian Von Rosenstiel, Sarah Gheuens, Tianle Chen, John O’Gorman, Ping Chiao, Guanfang Wang, Christian Von Hehn, LeAnne Skordos, Christoph Hock, Roger Nitsch, Samantha Budd Haeberlein, Alfred Sandrock

1:36 p.m.

S2.004

Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease —Samantha Budd Haeberlein, Sarah Gheuens, Tianle Chen, John O’Gorman, Sebastian Von Rosenstiel, Ping Chiao, Guanfang Wang, Christian Von Hehn, LeAnne Skordos, Christoph Hock, Roger Nitsch, Alfred Sandrock

1:48 p.m.

S2.005

Higher Dose Gantenerumab leads to Significant Reduction in Amyloid Plaque Burden - Results for the Marguerite and Scarlet Road Open Label Extension Studies —Gregory Klein,

Paul Delmar, Carsten Hofmann, Mirjana Adjelkovic, Danielle Abi-Saab, Smiljana Milosavljevic-Ristic, Monika Baudler, Paulo Fontoura, Rachelle Doody

2:00 p.m.

S2.006

Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-lowering Antisense Oligonucleotide, in Patients With Alzheimer Disease —Laurence Mignon, Holly Kordasiewcz, Roger

Sunday

Lane, Anne Smith, Timothy Miller, Padma Narayanan, Eric Swayze, Daniel Norris, Bethany Fitzsimmons, Frank Bennett

2:12 p.m.

S2.007

SIAXI: Efficacy and safety of Xeomin (incobotulinumtoxinA) for the treatment of sialorrhea in Parkinson’s disease (PD) and other neurological conditions: Results of a Phase III, placebo-controlled, randomized, double-blind study —

S3 Movement Disorders: Parkinson’s Disease: Genetics, Biomarkers, and Diagnosis

1:00 p.m.

S3.001

Validation of the MDS Clinical Diagnostic Criteria for Parkinson’s Disease —Ronald Postuma, Werner Poewe, Irene

Litvan, Simon Lewis, Anthony Lang, Glenda Halliday, Christopher Goetz, Piu Chan, Elizabeth Slow, Klaus Seppi, Eva Schaeffer, Daniela Berg, Silvia Rios Romenets, Taomian Mi, Corina Maetzler, Yuan Li, Beatrice Heim, Ian Bledsoe

1:12 p.m.

S3.002

Application of the Movement Disorder Society Prodromal Criteria in healthy G2019S-LRRK2 carriers —Anat Mirelman, Rachel Saunders-Pullman, Roy Alcalay, Shiran Shustak, Avner Thaler, Deborah Raymond, Helen Mejia Santana, Martha Orbe-Reilly, Laurie Ozelius, Lorraine Clark, Mali Gana-Weiss, Anat Bar-Shira, Avi OrrUrtreger, Susan Bressman, Karen Marder, Nir Giladi

1:24 p.m.

S3.003

Features of GBA-associated Parkinson’s disease at presentation in the United Kingdom Tracking Parkinson’s study —Naveed Malek, Rimona Weil, Catherine Bresner, Lawton

Michael, Katherine Grosset, Manuela Tan, Nin Bajaj, Roger Barker, David Burn, Thomas Foltynie, John Hardy, Nicholas Wood, Yoav BenShlomo, Nigel Williams, Donald Grosset, Huw Morris

1:36 p.m.

S3.004

Genetic risk variants for Parkinson’s disease (PD) and cognitive impairment in four clinical PD subtypes —Angela

Deutschlander, Takuya Konno, Alexandra Soto-Ortolaza, Maryam Ossi, Audrey Strongosky, Michael Heckman, Ryan Uitti, Jay Van Gerpen, Owen Ross, Zbigniew Wszolek

1:48 p.m.

S3.005

Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia —Fernando Pagan, Michaeline Hebron, Yasar TorresYaghi, Abigail Keys, James Starr, Elizabeth Mundel, Nadia Yusuf, Myrna Arellano, Barbara Wilmarth, Charbel Moussa

2:00 p.m.

S3.006

Tear Proteins as Possible Biomarkers for Parkinson’s Disease —Danielle Feigenbaum, Mark Lew, Srikanth Janga, Mihir Kunjeshkumar Shah, Wendy Mack, Curtis Okamoto, Sarah HammAlvarez

2:12 p.m.

S3.007

Automatic Detection of ON/OFF states in Parkinson Disease Patients Using Wearable Sensor Technology —Vibha Anand,

Wolfgang Jost, Andrzej Friedman, Olaf Michel, Birgit Flatau-Baque, Janos Csikós, Andrew Blitzer

Erhan Bilal, Vesper Ramos, Melissa Naylor, Charmaine Demanuele, Hao Zhang, Stephen Amato, Paul Wacnik, Farhan Hameed, Tairmae Kangarloo, Bryan Ho, Michael Erb, Daniel Karlin

2:24 p.m.

S2.008

The Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL) North American Rare Disease Clinical Research Consortium: Progress and Participant Characterization —Adam Boxer, Howard Rosen, Bradley

Boeve, Hilary Heuer, Murray Grossman, Giovanni Coppola, Bradford Dickerson, Brian Appleby, Yvette Bordelon, Danielle Brushaber, Christina Dheel, Kimiko Domoto-Reilly, Kelley Faber, Howard Feldman, Julie Fields, Jamie Fong, Tatiana Foroud, Nupur Ghoshal, Neill GraffRadford, Ging-Yuek Hsiung, Edward Huey, David Irwin, Kejal Kantarci, Daniel Kaufer, Diana Kerwin, Alex Klein, David Knopman, John Kornak, Irene Litvan, Codrin Lungu, Ian R.A. Mackenzie, Mario Mendez, Bruce Miller, Chiadi Onyike, Alexander Pantelyat, Madeline Potter, Rosa Rademakers, Eliana Marisa Ramos, Katya Rascovsky, Erik Roberson, Margaret Sutherland, Carmela Tartaglia, Nadine Tatton, Arthur Toga, Sandra Weintraub, Zbigniew Wszolek

2:35 p.m.

96 2018 AAN Annual Meeting

Sunday, April 22

Discussion

S3.008

Glucose dysregulation in Parkinson’s disease: a controlled cross-sectional study —Ana Marques, Frédéric Dutheil, Elodie Durand, Isabelle Rieu, Aurelien Mulliez, Maria Livia Fantini, Yves Boirie, Franck Durif

2:35 p.m.

Discussion

S4 Neuroepidemiology: Neurodegeneration, Epilepsy, Cerebrovascular Disease Risks

1:00 p.m.–3:00 p.m.

1:00 p.m. Bruce S. Schoenberg

International Award in Neuroepidemiology I n tribute to Dr. Schoenberg’s career in training neurologists

internationally in epidemiologic methods, this award salutes a young investigator selected from a developing country or Eastern Europe.

Recipient:

Fred Sarfo, MD, PhD Kumasi , Ghana

1:24 p.m.

S4.003

Pre-diagnostic Plasma Polyunsaturated Fatty Acids and the Risk of Amyotrophic Lateral Sclerosis —Eilis

O’Reilly, Kjetil Bjornevik, Marjorie McCullough, Larry Kolonel, Loic Le Marchand, JoAnn Manson, Alberto Ascherio

1:36 p.m.

S4.004

The influence of genetic mutations on the multistep process in ALS —Adriano Chio, Andrea Calvo, Letizia Mazzini, Sandra D’Alfonso, Maura Brunetti, Marco Barberis, Orla Hardiman, James Rooney, Jan Veldink, Neil Pearce, William Sproviero, Leonard Van den Berg, Ammar Al-Chalabi

1:48 p.m.

S4.005

S5 General Neurology:

Advances in Neurotherapeutics

1:00 p.m.

1:12 p.m.

Michael Kennemer, Thomas Winder, Perry Shieh

1:24 p.m.

2:12 p.m.

S4.007

Association of JNC-8 and SPRINT Systolic Blood Pressure Levels and Regional White Matter Lesion Load: the Northern Manhattan Study (NOMAS) —Michelle Caunca,

Marialaura Simonetto, Chuanhui Dong, Hannah Gardener, Ken Cheung, Noam Alperin, Consuelo McLaughlin, Mitchell Elkind, Tatjana Rundek, Ralph Sacco, Clinton Wright

Gerard Vockley, Amel Karaa

1:36 p.m.

S4.008

Readmission After Epilepsy Discharge in a Nationally Representative Sample —Leah Blank, Dylan Thibault, James Crispo, Kathryn Davis, Allison Wright Willis

2:35 p.m.

Discussion

S5.004

Modulation of Transcriptomic Changes in Alzheimer Disease by Ethnicity —Sathesh Sivasankaran, Anthony J.

Griswold, Olivia Gardner, Farid Rajabli, Brian Kunkle, Kara Hamilton, James Jaworski, William S. Bush, Eden Martin, Gary Beecham, Goldie S. Byrd, Jonathan Haines, Margaret Pericak-Vance

S5.005

Canagliflozin Associated with MELAS Pseudoexacerbation —Ramita Dewan, Christopher Stack, John

2:00 p.m.

S5.006

Inotersen Improves Norfolk Quality of Life-Diabetic Neuropathy Measures in Patients With Hereditary Transthyretin Amyloidosis with Polyneuropathy in the Phase 3 Study NEURO-TTR —Michael Polydefkis, Teresa

Coelho, Marcia Waddington Cruz, Peter Dyck, Morton Scheinberg, Violaine Plante-Bordeneuve, John Berk, Fabio Adrian Barroso, David Adams, Thomas Brannagan, Carol Whelan, Giampaolo Merlini, Brian Drachman, Stephen B. Heitner, Isabel Conceicao, Hartmut Schmidt, Giuseppe Vita, Josep Campistol, Josep Gamez, Edward Gane, Peter Gorevic, Acary Oliveira, Brett Monia, Steven hughes, Jesse Kwoh, Bradley W. McEvoy, Brenda F. Baker, Elizabeth Ackermann, Morie A. Gertz, Merrill Benson, Annabel Wang

2:12 p.m.

S5.007

Variation of Penetrance estimates in a wide spectrum of TTR-FAP families: implication for management of carriers —Farida Gorram, Malin Olsson, Flora Alarcon, Bérénice Hébrard, Benoit Funalot, Gregory Nuel, Ole Suhr, Violaine PlanteBordeneuve

2:24 p.m.

S5.008

Glycemic Control Boosts Glucosylated Nanocarrier Crossing the BBB into the Brain —Hiroya Kuwahara,

Yasutaka Anraku, Kazunori Kataoka, Takanori Yokota

2:35 p.m.

Discussion

S6 MS Neuroimaging

1:00 p.m.

S6.001

Association Between Abnormal Functional Connectivity of Thalamic Sub-Regions and Clinical Disability in CIS Patients: A Longitudinal Study —Milagros Hidalgo de la Cruz,

Maria Rocca, Alessandro Meani, Sarlota Mesaros, Jelena Dackovic, Irena Dujmovic Basuroski, Jelena Drulovic, Massimo Filippi

1:12 p.m.

S6.002

Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the OpenLabel Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis —Douglas Arnold, Ludwig Kappos, Stephen Hauser, Xavier Montalban, Anthony Traboulsee, Jerry Wolinsky, Victoria Levesque, Pablo Villoslada, Shibeshih Belachew, Fabian Model, Stanislas Hubeaux, Amit Bar-Or

1:24 p.m.

S6.003

Brain and Spinal Cord Imaging Features in Neuromyelitis Optica Spectrum Disorders —Laura Cacciaguerra, Maria Rocca, Sarlota Mesaros, Marta Radaelli, Jacqueline Palace, Jelena Drulovic, Elisabetta Pagani, Vittorio Martinelli, Lucy Matthews, Irena Dujmovic Basuroski, Giancarlo Comi, Massimo Filippi

1:36 p.m.

S6.004

Corpus callosum axon diameter and axon density from highgradient diffusion MRI are related to cognitive dysfunction and disability in multiple sclerosis —Natalya K. Machado, BS, Susie Y. Huang, MD, PhD, J. Daniel Bireley, BA, Andrew Russo, Sean Tobyne, Qiuyun Fan, Aapo Nummenmaa, PhD, Thomas Whitzel, PhD, Eric Klawiter

1:48 p.m.

S6.005

Baseline cerebellar volume as short-term predictor of clinical disability in Multiple Sclerosis: MRI Findings from the CombiRx trial —Maria Petracca, Sirio Cocozza, Leorah

Freeman, John Kangarlu, Amgad Droby, Stephen Krieger, Gary Cutter, Jerry Wolinsky, Fred Lublin, Matilde Inglese

2:00 p.m.

S6.006

Comparison of Methods for Whole-Brain and Grey Matter Atrophy Assessment in Multiple Sclerosis —Loredana Storelli, Maria Rocca, Elisabetta Pagani, Wim Van Hecke, Mark Horsfield, Nicola De Stefano, Alex Rovira, Jaume Sastre-Garriga, Jacqueline Palace, Diana Sima, Dirk Smeets, Massimo Filippi

2:12 p.m.

S6.007

Dentate nucleus T1 hyperintensity in early relapsingremitting multiple sclerosis patients is associated with cumulative gadopentetate dimeglumine (Gd-DTPA) administration —Robert Zivadinov, Jesper Hagemeier, Niels Bergsland, Deepa Ramasamy, Channa Kolb, Bianca WeinstockGuttman, David Hojnacki

2:24 p.m.

S6.008

Leptomeningeal inflammation is related to cortical thinning in relapsing-remitting multiple sclerosis —Niels Bergsland, Deepa Ramasamy, David Hojnacki, Bianca Weinstock-Guttman, Robert Zivadinov

2:35 p.m.

= Abstract of Distinction

Discussion

AAN.com/view/AM18 97

Sunday

2:24 p.m.

S5.003

Effects of Elamipretide in Adults with Primary Mitochondrial Myopathy: a Phase 2 Double-Blind, Randomized, Placebo-Controlled Crossover Trial (MMPOWER-2) —Bruce Cohen, Richard Haas, Amy Goldstein,

Cole

Bennett, Martha C. Morris

S5.002

Quantitative Determination of SMN2 Copy Number using Next Generation Sequencing and Correlation to Disease Severity —Jody Westbrook, Daniel Kvitek, Erik Gafni, Joshua Paul,

2:00 p.m.

S4.006

S5.001

Maria Rodriguez, John Ravits

1:48 p.m.

Association of Carotenoids, Vitamin E and Vitamin C intake with Parkinsonism and Progression of Parkinsonian signs in Older Adults —Puja Agarwal, Yamin Wang, Aron Buchman, David

Characterization of Atxn2 in ALS Patient Samples and Insight into ASO Therapy —Amy Taylor, Sandra Diaz Garcia,

Amyotrophic lateral sclerosis and exposure to diesel exhaust in Denmark —Aisha Dickerson, Johnni Hansen, Ole Gredal, Marc Weisskopf

1:00 p.m.–3:00 p.m.

SCIENTIFIC PLATFORM SESSIONS

1:00 p.m.–3:00 p.m.

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC PLATFORM SESSIONS 3:30 p.m.–4:30 p.m. S7 Pain and Palliative Care

3:30 p.m.–5:30 p.m.

This session will be presented at the Research Corner Experiential Learning Area located in the South Lobby of the Los Angeles Convention Center 3:30 p.m. Mitchell B. Max Award for

Neuropathic Pain T his award recognizes an individual for outstanding work in the field of neuropathic pain for either a single contribution or for lifetime achievement.

Recipient:

David M. Simpson, MD, FAAN New York, NY

3:42 p.m.

S7.002

Effects of Opioids on Causal Relationships Between Intrinsic Connectivity Brain Networks in Patients with Chronic Low Back Pain - A Resting-State fMRI Study — Behnaz Jarrahi, Sean Mackey

3:54 p.m.

S7.003

Characteristics of Surrogate Decision Makers Selecting Life-sustaining Therapy for Severe Intracerebral Hemorrhage Patients: a Neuropalliative Care Survey of the US Population —David Hwang, Andrea Knies, Douglas White, Robert Holloway, Kevin Sheth, Liana Fraenkel

4:06 p.m.

S7.004

Reversal of allodynia and neurophysiological outcomes by CX-8998, a potent, selective T-type calcium channel modulator, in a model of bortezomib induced peripheral neurotoxicity —Margaret Lee, Yuri Maricich, Guido Cavaletti, Spiridon Papapetropoulos

S8 Progressive MS Therapies and

Age-Dependent Factors in MS Therapy

Sunday, April 22

3:30 p.m.–5:30 p.m.

3:30 p.m. John Dystel Prize for

Multiple Sclerosis Research T his prize recognizes outstanding contributions to research in the

S9 Epilepsy/Clinical Neurophysiology (EEG) I

3:30 p.m. Alliance Awards: Founders

This award is designed to encourage clinical and translational

understanding, treatment, or prevention of multiple sclerosis.

research in neuroscience by physicians in clinical neurology training programs.

Recipient:

Frederik Barkhof, MD, PhD Amsterdam, Netherlands

3:54 p.m.

S8.003

ARPEGGIO: a placebo-controlled trial of oral laquinimod in primary progressive multiple sclerosis —Gavin Giovannoni,

Frederik Barkhof, Hans-Peter Hartung, Bruce Cree, Stephen Krieger, Xavier Montalban, Maria Pia Sormani, Antonio Uccelli, Bernard Uitdehaag, Timothy Vollmer, Ayelet Reshef, Thomas Li, Peter Feldman, Aaron Tansy, Joshua Steinerman

4:06 p.m.

S8.004

Long-Term Outcomes in Patients With Progressive Forms of Relapsing MS Treated With Teriflunomide: Real-World Evidence —Flavia Nelson, Christine Lebrun-Freney, Alexey Boyko,

Karthinathan Thangavelu, Matthew Mandel, Steven Cavalier, Philippe Truffinet, Jinjun Liang, Regina Berkovich

4:18 p.m.

S8.005

Uncoupling the Impact on Relapses and Disability Progression: Siponimod in Relapsing and Non-relapsing Patients With Secondary Progressive Multiple Sclerosis in the Phase III EXPAND Study —Bruce Cree, Robert Fox,

Gavin Giovannoni, Patrick Vermersch, Amit Bar-Or, Ralf Gold, Baldur Magnusson, Nicolas Rouyrre, Daniela Piani Meier, Davorka Tomic, Goeril Karlsson, Frank Dahlke, Ludwig Kappos

4:30 p.m.

S8.006

Siponimod Reduces Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients — Jens Kuhle, Harald Kropshofer, Christian Barro, Rolf Meinert, Dieter Haering, David Leppert, Davorka Tomic, Frank Dahlke, Ludwig Kappos

4:42 p.m.

S8.007

Early versus Later Treatment Start in Multiple Sclerosis - A Register Based Cohort Study —Thor Chalmer, Melinda Magyari,

Sunday

Lisbeth M. Baggesen, Mette Nørgaard, Nils Koch-Henriksen, Per Solberg Sorensen

4:54 p.m.

S8.008

Discontinuation of Disease Modifying Therapies in Stable MS Patients is Associated with Disability Progression Regardless of Age. —Bianca Weinstock-Guttman, Katelyn

Kavak, Caila Vaughn, Andrew Goodman, Patricia Coyle, Lauren Krupp, Malcolm Gottesman, Keith Edwards, Michael Lenihan, Allan Perel, Robert Zivadinov

5:05 p.m.

Discussion

Ezequiel Gleichgerrcht, MD Charleston, SC

3:42 p.m.

S9.002

Pediatric to Adult Transition Care Gaps for Youth with Epilepsy with Comorbid Intellectual or Developmental Disability —Christine Baca, Frances Barry, Alice Kuo, Cornelia Drees, Kelly Knupp

3:54 p.m.

S9.003

Normalizing mTOR Activity Has Dose-Dependent Bidirectional Effects on Acute Epileptic Extensor Spasms in the Ts65Dn Mouse Model —O. Snead, Susan dong, krutika joshi, Miguel Cortez

4:06 p.m.

S9.004

Adjunctive Everolimus in Patients with Treatmentrefractory Seizures Associated with Tuberous Sclerosis Complex (TSC): Analysis of Exposure-efficacy and Exposure-safety Relationships in the Randomized, Phase 3, EXIST-3 Trial —Jacqueline French, Paolo Curatolo, John Lawson, Zuhal Yapici, Hiroko Ikeda, Tilman Polster, Rima Nabbout, Petrus de Vries, Dennis Dlugos, Jenna Fan, Neva Coello, Diana Pelov, Maurizio Voi, David Franz

4:18 p.m.

S9.005

Periodic Focal Epileptiform Discharges during Awake Craniotomy —William Tatum, Anteneh Feyissa, Karim ReFaey, Tito Vivas-Buitrago, Alfredo Quinones-Hinojosa

4:30 p.m.

S9.006

Predicting Epilepsy Surgery Outcomes from Presurgical Temporal Lobe Network Architecture —Ezequiel Gleichgerrcht, Sonal Bhatia, Jonathan Edwards, William A. Vandergrift, Ruben Kuzniecky, Leonardo Bonilha

4:42 p.m.

S9.007

Efficacy and Safety of Everolimus Based on Prior and Concomitant Antiepileptic Drugs in Patients with Tuberous Sclerosis Complex (TSC)-Associated Treatment-Refractory Seizures: A Subanalysis of the Phase 3 EXIST-3 Study — David Franz, John Lawson, Zuhal Yapici, Hiroko Ikeda, Tilman Polster, Rima Nabbout, Paolo Curatolo, Petrus de Vries, Dennis Dlugos, Bijoyesh Mookerjee, Jenna Fan, Antonia Ridolfi, Fabian Herbst, Jacqueline French

4:54 p.m.

S9.008

Impact of Mutation Status on Seizure Outcomes in Patients with Tuberous Sclerosis Complex (TSC) Treated in the EXIST-3 Study —Zuhal Yapici, David Franz, John Lawson, Hiroko

Ikeda, Tilman Polster, Rima Nabbout, Paolo Curatolo, Petrus de Vries, Dennis Dlugos, Bijoyesh Mookerjee, Jenna Fan, Antonia Ridolfi, Fabian Herbst, Jacqueline French

5:05 p.m.

98 2018 AAN Annual Meeting

Discussion

S10 Intracerebral and

Subarachnoid Hemorrhage

3:30 p.m. Michael S. Pessin

Stroke Leadership Prize T his prize is awarded to emerging neurologists who have a strong interest in, and have demonstrated a passion for, learning and expanding the field of stroke research.

Recipient:

Glen Jickling, MD Edmonton, AB, Canada

3:42 p.m.

S10.002

Intracranial Hemorrhage in Infective Endocarditis: Underlying Arterial and Parenchymal Disease —Jean Khoury, Sung Cho, Cory Rice, Lucy Zhang, Dolora Wisco, Ken Uchino

3:54 p.m.

S10.003

Stress and Risk of Intracerebral Hemorrhage in the Ethnic/ Racial Variation of Intracerebral Hemorrhage (ERICH) Study —Tyler Behymer, Elisheva Coleman, Padmini Sekar, Ashby Turner, Charles Moomaw, Jennifer Osborne, Misty Wethington, Daniel Woo

4:06 p.m.

S10.004

Global Variation and Burden of Hemorrhagic Stroke —Steve O’Donnell, David Tirschwell, Rizwan Kalani, Valery Feigin, Catherine Johnson, Gregory Roth

4:18 p.m.

S10.005

Secular increases in spontaneous subarachnoid hemorrhage during pregnancy —Kaustubh Limaye, Achint Patel,

Sourabh Lahoti, Cynthia Kenmuir, Ashutosh Jadhav, Edgar Samaniego, Santiago Ortega-Gutierrez, James Torner, David Hassan, Colin Derdeyn, Tudor Jovin, Harold Adams, Enrique Leira

4:30 p.m.

S10.006

Spontaneous Intracerebral Hemorrhage in the Elderly Population —Rachel Beekman, Stacy Chu, Samuel Sommaruga,

Join Neurology’s Global Conversation! Connect with neurologists and neuroscience professionals in your area of interest.

SCIENTIFIC PLATFORM SESSIONS

3:30 p.m.–5:30 p.m.

Zachary King, Hooman Kamel, Charles Matouk, David Hwang, Kevin Sheth, Guido Falcone

4:42 p.m.

S10.007

Audrey Leasure, Opeolu Adeoye, Fu-Dong Shi, Steven Kittner, Carl Langefeld, Achala Vagal, Kevin Sheth, Daniel Woo

4:54 p.m.

S10.008

Impact of Pre-existing Dementia on Intracerebral Hemorrhage Outcomes —Eunji Yim, Padmini Sekar, Charles

Moomaw, Jennifer Osborne, Sharyl Martini, Li Xiong, Alessandro Biffi, Jonathan Rosand, Daniel Woo

5:05 p.m.

Discussion

= Abstract of Distinction

Get started at AAN.com/Synapse Sunday

Race/Ethnicity Influences Outcomes in Young Adults with Intracerebral Hemorrhage —Laura Miyares, Guido Falcone,

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC PLATFORM SESSIONS 8:00 a.m.–9:00 a.m. S11 “Best of” Session: Epilepsy/Clinical Neurophysiology (EEG)

Titles and authors of these abstracts are listed in “Best of” Scientific Platform Sessions on page 92 »

1:00 p.m.–2:15 p.m.

S12 Autonomic Disorders

1:00 p.m.–3:00 p.m.

This session will be presented at the Research Corner Experiential Learning Area located in the South Lobby of the Los Angeles Convention Center 1:00 p.m. Irwin Schatz Award for

Autonomic Disorders T his award recognizes young investigators who have advanced

the field of autonomic disorders, or senior investigators that have made major contributions to the field.

Recipient:

David S. Goldstein, MD, PhD Bethesda, MD

1:12 p.m.

S12.002

Intrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System Atrophy Results in Growth Factor Spike —Wolfgang Singer, Ann Schmeichel, Karla Minota, Anita Zeller, James Schmelzer, Tonette Gehrking, David Sletten, Jade Gehrking, Allan Dietz, Phillip Low

1:24 p.m.

S12.003

A double blind-placebo controlled trial of IVIG in the treatment of AAG: Results, Implications and Lessons Learned —Christopher Gibbons, Sharika Rajan, Jenniffer Garcia

Perez, David Robertson, Italo Biaggioni, Horacio Kaufmann, Amanda Peltier, Steven Vernino, Phillip Low, Roy Freeman

1:36 p.m.

S12.004

The Heart of PD is the Heart: Lewy Body Diseases as Neurocardiologic Disorders —David Goldstein, Risa Isonaka, Patti Sullivan, Courtney Holmes, Yehonatan Sharabi

1:48 p.m.

Monday, April 23

S12.005

The Quantitation of Cutaneous Neurovascular Density —

Christopher Gibbons, Eun Hee Sohn, Bum Chun Suh, Ningshan Wang, Roy Freeman

S13 Neuromyelitis Optica Spectrum Disorder and Other Autoimmune Disorders

1:00 p.m.

S13.001

Developing Evidence-Based Guidelines for the Diagnosis and Treatment of NMOSD in Alberta, Canada —Jodie Burton, Fiona Costello

1:12 p.m.

S13.002

Clinical Characteristics of MOG and AQP associated Neuromyelitis Optica Spectrum Disorder (NMOSD) in Adults —Marco Alfonso Narduc Capobianco, Arianna Sala, Fabiana Marnetto, Paola Valentino, Simona Malucchi, Maria Malentacchi, Francesca Sperli, Marianna Lo Re, Antonio Bertolotto

1:24 p.m.

S13.003

Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients —Daniel

Whittam, Alvaro Cobo-Calvo, Alfonso Lopez, Santiago Pardo, James Dodd, Alexander Brandt, Klaus Berek, Thomas Berger, Grace Gombolay, Luana Micheli Oliveira, Dagoberto Callegaro, Kimihiko Kaneko, Tatsuro Misu, Bruno Brochet, Bertrand Audoin, Guillaume Mathey, David Laplaud, Eric Thouvenot, Mikael Cohen, Ayman Tourbah, Elisabeth Maillart, Jonathan Ciron, Romain Deschamps, Damien Biotti, Marcelo Matiello, Jacqueline Palace, Ming Lim, Kazuo Fujihara, Ichiro Nakashima, Jeffrey Bennett, Lekha Pandit, Tanuja Chitnis, Brian Weinshenker, Brigitte Wildemann, Douglas Sato, Su-Hyun Kim, Ho Jin Kim, Markus Reindl, Michael Levy, Sven Jarius, Silvia Tenembaum, Friedemann Paul, Sean Pittock, Romain Marignier, Anu Jacob

1:36 p.m.

S13.004

The Mayo Clinic Glial Autoimmunity study: Persistence of MOG-IgG seropositivity predicts relapse after ADEM in both children and adults —Alfonso Lopez, Masoud Majed,

James Fryer, Andrew McKeon, Eoin Flanagan, Jan-Mendelt Tillema, John Chen, Divyanshu Dubey, Naga Kothapalli, Jessica Sagen, Avi Gadoth, Brian Weinshenker, Dean Wingerchuk, Mark Keegan, Claudia Lucchinetti, Vanda Lennon, Sean Pittock

1:48 p.m.

S13.005

Autoimmune GFAP Astrocytopathy: Prospective Evaluation of 90 Patients in 1 year —Divyanshu Dubey, Shannon Hinson, Anastasia Zekeridou, Eoin Flanagan, Sean Pittock, Eati Basal, Daniel Drubach, Daniel Lachance, Vanda Lennon, Andrew McKeon

2:00 p.m.

S13.006

Monday

Glial Fibrillary Acid Protein Immunoglobulin G (GFAP-IgG) Related Myelitis: Characterization and Comparison with Aquaporin-4-IgG Myelitis —Elia Sechi, Padraig Morris, Andrew McKeon, Sean Pittock, Shannon Hinson, Brian Weinshenker, Allen Aksamit, Evan Jolliffe, Anastasia Zekeridou, Dean Wingerchuk, Eoin Flanagan

2:12 p.m.

S13.007

The Mayo Clinic Glial Autoimmunity Study: AQP4/MOG-IgG serostatus and outcomes in 228 patients presenting with recurrent optic neuritis —Jiraporn Jitprapaikulsan, John Chen, James Fryer, Brian Weinshenker, Andrew McKeon, Vanda Lennon, Jacqueline Leavitt, Eoin Flanagan, W. Tobin, Alfonso Lopez, Mark Keegan, Claudia Lucchinetti, Orhun Kantarci, Jessica Sagen, Sean Pittock

2:24 p.m.

S13.008

It’s Not All Transverse Myelitis: The Differential Diagnosis of Spinal Cord Myelopathy —Maureen Mealy, Laura Munoz-

Arcos, Paula Barreras, Maria Garcia, Daniel Becker, Scott Newsome, Philippe Gailloud, Michael Levy, Carlos Pardo-Villamizar

2:35 p.m.

100 2018 AAN Annual Meeting

Discussion

S14 Education and Patient Outcomes Research

1:00 p.m.

1:00 p.m.–3:00 p.m.

S14.001

Breaking the curve: moving from normative to criterion-based grading on neurology clerkship —E.

S15 Cerebrovascular Disease

Epidemiology and Outcomes

1:00 p.m.

1:00 p.m.–3:00 p.m.

S15.001

Clinical Care and Outcomes of Asian-American Acute Ischemic Stroke Patients —Sarah Song, Li Liang, Gregg

S16 Neuro-ophthalmology/Neuro-otology

1:00 p.m.

S16.001

Optical Coherence Tomography Angiography in pre-clinical Alzheimer’s disease —Gregory Van Stavern,

Alexandra Brown, Nina Garga, Megan Richie, Nilika Singhal, Audrey Foster-Barber, Vanja Douglas

Fonarow, Eric Smith, Deepak Bhatt, Roland Matsouaka, Ying Xian, Lee Schwamm, Jeffrey Saver

Rajendra Apte, Nathan Kung, Bliss O’Bryhim, Dean Coble

1:12 p.m.

Ocular Motor Abnormalities and Reading Difficulties in Different Neuro-Ophthalmic Diseases —Angela Oh,

S14.002

Neurology Clerkship - Predictors of OSCE and Shelf Exam Performance —Ajay Sampat, Gerald Rouleau, Cindy Zadikoff 1:24 p.m.

S14.003

What’s the Right Blend? Identifying the optimal blend of classroom and eLearning to promote immediate and longterm retention in the neurology clerkship —Michael Halstead, Rachel Marie Salas, Mona Bahouth, Deanna Saylor, Bernadette Clark, Charlene Gamaldo, Roy Strowd

1:36 p.m.

S14.004

Utilization of Ultrasound Guided Lumbar Puncture to Improve the Efficacy and Outcome in an Overweight Patient Population: A Resident Driven Quality Improvement Project —Yi Li, Swetha Ade, Kate Daniello 1:48 p.m.

S14.005

A Quality Improvement Curriculum for Neurology Residents —Rebecca Miller-Kuhlmann, Lironn Kraler, Nina Bozinov, Alexander Frolov, Michael Mlynash, Carl Gold, Kathryn Kvam

2:00 p.m.

S14.006

A Resident-driven Intervention To Decrease Door-to-needle Time And Increase Resident Satisfaction In A Resourcelimited Setting —Alexandra J. Lloyd-Smith Sequeira, Michael Fara, John McMenamy, Monica Chan, Koto Ishida, Jose Torres, Cen Zhang, Albert Favate, Anuradha Singh, Ting Zhou, Sara Rostanski

2:12 p.m.

S14.007

Validation of a Uniform, Standardized Testing Model for Emergency Neurological Life Support (ENLS) —Christopher

Robinson, Teddy Youn, Marc-Alain Babi, Carolina Maciel, Jacqueline Baron-Lee, Christa Ochoa, Katharina Busl

2:24 p.m.

S14.008

Stroke Severity and Cognitive Impairment as Predictors of Near-Term Mortality in the Mayo Clinic Florida Familial Cerebrovascular Diseases Registry —Tasneem Hasan, Kevin

2:35 p.m.

Discussion

Temporal Trends in Sex and Age Disparities in Acute Ischemic Stroke Treatment and Outcomes in the United States from 2004 to 2014 —Vasu Saini, Fadar Otite, Priyank Khandelwal, Dileep Yavagal, Seemant Chaturvedi, Amer Malik

1:24 p.m.

Gender disparities in cognitive, motor and mood outcomes: preliminary data from the Bugher Foundation’s Combined Aerobic and Resistance Exercise Training (CARET) program and Cognitive Training Intervention (CTI) Study. —Marialaura Simonetto, Chuanhui Dong, Carolina M. Gutierrez, Clinton Wright, David Loewenstein, Ralph Sacco, Sebastian Koch, Tatjana Rundek

1:36 p.m.

= Abstract of Distinction

S15.004

Effect of Obesity on Inpatient Mortality of Patients with Ischemic Stroke —Sahil Gupta, Mina Lobbous, Frank Benesh, Angela Hays Shapshak

1:48 p.m.

S15.005

Cerebral microbleeds associated with white matter and deep gray matter atrophy in community-dwelling populations —Ning Su, Xin-Yu Liang, Lixin Zhou, Ming Yao, Quan

Wang, Fei Han, Jiang-Tao Zhang, Dong-Hui Ao, Ming-Li Li, Zheng-Yu Jin, Shu-Yang Zhang, Li-Ying Cui, Gao-Lang Gong, Yi-Cheng Zhu, Jun Ni

2:00 p.m.

S15.006

Regulation of HMGB1 inflammation in patients with ischemic stroke by microRNA —Glen Jickling, Bradley Ander, Boryana Stamova, DaZhi Liu, Frank Sharp

2:12 p.m.

S15.007

Frequency of brain death in acute cerebrovascular disease related mortality. —Rakesh Khatri, Alberto Maud, Anantha Vellipuram, Mohammad-Rauf Afzal, Mohtashim Qureshi, Ihtesham Qureshi, Paisith Piriyawat, Darine Kassar, Salvador Cruz-Flores, Gustavo Rodriguez

2:24 p.m.

S15.008

Risk of Transient Ischemic Attack and Stroke in Patients with Herpes Zoster: 2007 - 2014 US Claims Data Analysis —Brandon Patterson, Debora Rausch, Debra Irwin,

S16.002

Mohammad Shariati, Naz Jehangir, Caroline Yu, Tiffany Chen, Rosa Yu, Y. Joyce Liao

1:24 p.m.

S16.003

Mobile Universal Lexicon Evaluation System (MULES) in MS: Evaluation of a New Visual Test of Rapid Picture Naming —Meagan Seay, Omar Akhand, Lucy Cobbs, Lisena

Hasanaj, Prin Amorapanth, John-Ross Rizzo, Rachel Nolan, Liliana Serrano, Barry Jordan, Janet Rucker, Steven Galetta, Laura Balcer

1:36 p.m.

S16.004

Relation of Quantitative Eye Movements with Cognitive Dysfunction in Patients with Concussion —Doria Gold, John

Martone, Yuen Shan Christine Lee, Amanda Childs, Yuka Matsuzawa, Felicia Fraser, Joseph Ricker, Wei-Wei Dai, John-Ross Rizzo, Todd Hudson, Ivan Selesnick, Steven Galetta, Laura Balcer, Janet Rucker

1:48 p.m.

S16.005

2:00 p.m.

S16.006

Long term Reversal of Visual Loss by Mitochondrial Gene Transfer in a Mouse Model of Leber Hereditary Optic Neuropathy —John Guy, Hong Yu Low- and Medium-Dose Gene Therapy in Patients with Prior Unilateral LHON Does Not Prevent Further Visual Loss in the Treated Eye —John Guy, William Feuer, Janet Davis, Vittorio Porciatti, Byron Lam, Huijuan Yuan, Rajeshwari Koilkonda, Phillip Gonzalez

2:12 p.m.

S16.007

Abnormal Visuo-vestibular Interactions in Vestibular Migraine —Marta Casanovas Ortega, Nadja F. Bednarczuk, AnneSophie Fluri, John Chan, Heiko Rust, Fabiano Peixoto, Diego Kaski, Barry M. Seemungal, Adolfo Bronstein, Qadeer Arshad

2:24 p.m.

S16.008

Self-monitoring visual function in Neurology —Nicolas

Dubuisson, Matthew Laws, Adam Paterson, Benjamin Turner, Alison Thomson, Mark Westcott, Gavin Giovannoni

2:35 p.m.

Discussion

Michael Liang, Songkai Yan, Barbara Yawn

2:35 p.m.

S15.003

1:12 p.m.

Discussion

AAN.com/view/AM18 101

Monday

Barrett, Thomas Brott, Elizabeth R. Lesser, David O. Hodge, James Meschia

S15.002

SCIENTIFIC PLATFORM SESSIONS

1:00 p.m.–3:00 p.m.

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC PLATFORM SESSIONS 3:30 p.m.–5:30 p.m. S17 Sleep

3:30 p.m.–5:30 p.m.

3:30 p.m. Alliance Awards: S. Weir Mitchell

This award is designed to encourage basic research in

neuroscience by physicians in clinical neurology training programs.

Recipient:

Eric C. Landsness, MD, PhD St. Louis, MO

3:42 p.m. Wayne A. Hening

Sleep Medicine Investigator Award T his award recognizes scientific contributions in sleep from

promising young investigators. The goal of this award is to reward productive young investigators and to emphasize the essential role of neurology in sleep medicine.

Recipient:

Yo-El Ju, MD, MSCI Saint Louis, MO

3:54 p.m. Sleep Science Award

This award is intended to recognize distinguished academic

contributions by neurologists to the field of sleep medicine or the contributions of non-neurologists to the interface area of sleep neurology.

Recipient:

Bradley F. Boeve, MD Rochester, MN

4:18 p.m.

S17.005

Subcortical Basis of Cognitive Impairment in Idiopathic Rapid Eye Movement Sleep Behavior Disorder —Shady

Rahayel, Ronald Postuma, Jacques Montplaisir, Malo Gaubert, Daphne Genier-Marchand, Frédérique Escudier, Pierre-Alexandre Bourgouin, Julie Carrier, Oury Monchi, Sven Joubert, Jean-Francois Gagnon

4:30 p.m.

S17.006

NREM sleep spindles predict impaired memory consolidation in children with OSA —Kiran Maski, Erin Steinhart, Robert Stickgold

4:42 p.m.

S17.007

A Double-Blind, Placebo-Controlled, RandomizedWithdrawal, Multicenter Study of the Efficacy and Safety of Sodium Oxybate (SXB) in Pediatric Participants with Narcolepsy Type 1 (NT1) —Chad Ruoff, Giuseppe Plazzi, Michel

Monday

Lecendreux, Yves Dauvilliers, Carol Rosen, MD, Jed Black, Rupa Parvataneni, Diane Guinta, Y. Grace Wang, Emmanuel Mignot

4:54 p.m.

S17.008

Adverse Childhood Experiences and Insufficient Sleep: Persistent Association Through Life —Kelly Sullivan, Diane Donley

5:05 p.m.

Discussion

102 2018 AAN Annual Meeting

S18 Movement Disorders: Ataxia and Tremor

3:30 p.m.–5:30 p.m.

3:30 p.m. Movement Disorders Research Award

This award recognizes an individual for outstanding work in the

field of Parkinson’s disease or other movement disorders for either a single, outstanding contribution or for lifetime achievement.

Recipient:

Irene Litvan, MD, FAAN La Jolla, CA

3:54 p.m.

S18.003

Unilateral Versus Bilateral Ventral Intermediate Nucleus Deep Brain Stimulation for Axial Essential Tremor Symptoms —Kyle Mitchell, Delea Peichel, Robert Wharen, Michael Okun, Barton Guthrie, Ryan Uitti, Paul Larson, Harrison Walker, Rajesh Pahwa, Khashayar Dashtipour, Joseph Jankovic, Kelly Foote, Jason Schwalb, Blair Ford, Richard Simpson, Fenna Phibbs, Joseph Neimat, R. Malcolm Stewart, Frederick Marshall, Jill Ostrem

4:06 p.m.

S18.004

Deep Cerebellar Stimulation to Treat Degenerative Cerebellar Ataxias —Collin Anderson, Stefan Pulst 4:18 p.m.

S18.005

Spinocerebellar Ataxia Type 2 (SCA2) Spinal Cord Transcriptome Sequencing Informs Understanding on ALS —Daniel Scoles, Warunee Dansithong, Lance Pflieger, Sharan Paul, Karla Figueroa, Matthew Schneider, Frank Rigo, Frank Bennett, Stefan Pulst

4:30 p.m.

Monday, April 23

S18.006

S19 Epilepsy/Clinical Neurophysiology (EEG) II

3:30 p.m. Dreifuss-Penry Epilepsy Award

The intent of this award is to recognize physicians in the

early stages of their careers who have made an independent contribution to epilepsy research.

Recipient:

Kathryn A. Davis, MD, MS, FAES Philadelphia, PA

3:42 p.m.

S19.002

Epilepsy Technotherapy - Results of a 1 Year Pilot Study — Rupert Page, Michelle Knight, Karen Symon

3:54 p.m.

S19.003

Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE5) —Ian Miller, Orrin Devinsky, Rima Nabbout, Linda Laux, Marta Zolnowska, Stephen Wright, Claire Roberts

4:06 p.m.

S19.004

: Spectrographic Seizure Detection Using Deep Learning With Convolutional Neural Networks —Peter Yan, Fei Wang,

Zachary Grinspan

4:18 p.m.

S19.005

Efficacy and Tolerability of Adjunctive Cenobamate Therapy in Different Types of Partial-Onset Seizures —Gregory Krauss, Marc Kamin

Characterization of a Murine Model of Spinocerebellar Ataxia 13 —Swati Khare, Jerelyn Nick, Stephanie Niemczyk,

4:30 p.m.

4:42 p.m.

Privitera, Hari Bhathal, Matthew Wong, J. Helen Cross, Kenneth Sommerville

Kristina Sanborn, Jada Lewis, Harry Nick, Michael Waters

S18.007

Longitudinal analysis of low-contrast acuity in Friedreich ataxia —Ali Hamedani, Lauren Hauser, Susan Perlman, Katherine

Mathews, George Wilmot, Theresa Zesiewicz, S Subramony, Tetsuo Ashizawa, Martin Delatycki, Alicia Brocht, David Lynch

4:54 p.m.

S18.008

Longitudinal change of gait and balance in individuals with Friedreich ataxia —Sarah Milne, Seok Kim, Anna Murphy, Theresa

S19.006

Cannabidiol (CBD) Treatment Effect and Adverse Events (AEs) by Time in Patients with Lennox-Gastaut Syndrome (LGS): Pooled Results from 2 Trials —Elaine Wirrell, Michael

4:42 p.m.

S19.007

Resting State Functional Connectivity between Thalamic Nuclei and Hippocampal Subfields in Epilepsy Using 7 T MRI —Prantik Kundu, Lara Marcuse, Rebecca Feldman, Madeline Fields, Priti Balchandai

Zesiewicz, Mary Danoudis, Jessica Shaw, Ritchie Malapira, Eppie Yiu, Nellie Georgiou-Karistianis, Martin Delatycki, Louise Corben

4:54 p.m.

5:05 p.m.

Sean Pittock, Maftuna Gafurova, Ember Eldridge, Raymond Dingledine

Discussion

S19.008

Pathogenesis of Seizures in Anti-NMDA Receptor Encephalitis: a Mouse Model —Olha Taraschenko, Howard Fox, 5:05 p.m.

Discussion

C94: Hot Topics in Stroke

Education and Practice

Monday, April 23, 3:30 p.m. – 5:30 p.m.

Director: Pierre Fayad, MD, FAHA, FAAN, Omaha, NE The management of acute ischemic stroke has witnessed a dramatic transformation over the past decades. More recently, the evidence-based introduction of thrombectomy in 2015, as a powerful and effective treatment for patients with intracranial large vessel occlusion (LVO) for up to 6 hours from symptom-onset, with or without intravenous thrombolysis with tPA, accelerated such changes. To translate these findings into clinical settings, acute stroke teams reorganized their screening processes, to evaluate emergently patients with CT or MR angiography and widen the window of screening and treatment from 4.5 hours for IV tPA to 6 hours for IV tPA and thrombectomy. Neurointerventionalists mobilized to perform thrombectomy emergently for eligible patients. Neurointensivists, Vascular Neurologists and Neuro-Hospitalists mobilized to provide the skills, the acute care needed before, during and following the interventions. In 2017, further revolutionary events impacted knowledge and practice. The DAWN study demonstrated that thrombectomy is highly effective at improving outcomes and preventing disability when applied for up to 24 hours from symptom-onset in eligible patients based on neurologic deficits, LVO and presence of “salvageable brain tissue,” based on imaging criteria from cerebral diffusion and perfusion studies based on the RAPID software analysis. In 2018, the DEFUSE-3 study, showed similarly demonstrated dramatic effectiveness of thrombectomy for up to 16 hours from symptom-onset in eligible patients based on variations of the DAWN criteria. These powerful findings were already incorporated in the American Heart Association Guidelines update for the management of acute ischemic stroke, whose values were endorsed by the AAN, with recommendations to treat patients for up to 24 hours with thrombectomy according to the eligibility criteria of both trials. These seismic changes, will have a massive impact on the organization and delivery of acute stroke care services in terms of human, organizational and financial costs in the years to come. Expanding the window of emergent care for up to 24 hours, will require immediate implementation, placing major strains on stroke systems of care, but most importantly on the neurologist and neurology subspecialists, who generally carry the largest burden of screening, evaluating, and treating such patients. This session will explore those changes and potential ways to meet them. Neurological education and training need to incorporate such changes in order to prepare our residents’ readiness for their future practice, once they graduate. Strong knowledge and skills in evaluating and treating stroke will undoubtedly be an essential skill of any neurologic practice, in any setting, in the future. The Roundtable and Q/A Session at the end of the session will discuss the potential impact on neurology training.

Timeline 3:30 p.m.– 3:35 p.m. Welcome and Session Introduction Pierre Fayad, MD, FAHN, FAAN 3:35 p.m.– 3:50 p.m. Major Findings in DAWN and DEFUSE-3 Faculty 3:50 p.m.– 4:05 p.m. Highlights From 2018 ASA/AHA Guidelines for Acute Ischemic Stroke Alejandro Rabinstein, MD, FAAN

4:05 p.m.–4:20 p.m. Role of Advanced Acute Stroke Imaging for the Neurologist Gregory Albers, MD

4:35 p.m.– 4:50 p.m. Potential Strategies to Meet Challenges of The 24-Hours Window For Acute Stroke Lawrence Wechsler, MD, FAAN

4:50 p.m. –5:30 p.m. 4:20 p.m.– 4:35 p.m. Roundtable Discussion with Question & Stroke Training During Neurology Residency Answer Participants and Fellowships: Present and Future Sunil Sheth, MD

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC PLATFORM SESSIONS 8:00 a.m.–9:00 a.m. S20 “Best of” Session: Headache

Titles and authors of these abstracts are listed in “Best of” Scientific Platform Sessions on page 92 »

1:00 p.m.–3:00 p.m.

S21 Revascularization in Acute Ischemic Stroke

1:00 p.m.

1:00 p.m.–3:00 p.m.

S21.001

Thrombolysis in Ischemic Stroke: Predictors of Thrombolysis Utilization from a National Database —Frank Benesh, Sahil Gupta, Mina Lobbous, Angela Hays Shapshak

1:12 p.m.

S21.002

Region Based Disparities in tPA Utilization in the United States: An Analysis of Nationwide Inpatient Sample Database —Sahil Gupta, Mina Lobbous, Frank Benesh, Margi Patel, Angela Hays Shapshak

1:24 p.m.

S21.003

Frequency, Determinants, and Outcomes of Distal Emboli Related to Mechanical Thrombectomy for Acute Ischemic Stroke —Gregory Wong, Reza Jahan, Viktor Szeder, David

Liebeskind, Latisha Sharma, Gary Duckwiler, Satoshi Tateshima, May Nour, Jin Lee, Sidney Starkman, Jeffrey Saver

1:36 p.m.

S21.004

Decreases in Blood Pressure During Endovascular Stroke Therapy are Common and Associated with Poor Functional Outcome —Anson Wang, David Mampre, Kevin Sheth, Can Tan, Ryan Hebert, Charles Matouk, Nils Petersen

1:48 p.m.

S21.005

Laterality is an independent predictor of endovascular thrombectomy in patients with lower NIHSS Score — Shashvat Desai, Tudor Jovin, Ashutosh Jadhav

2:00 p.m.

S21.006

Systemic Review of Intravenous tPA for Patients with Central Retinal Artery Occlusion. —Mohammed Alkuwaiti,

Connie Bongiorno, Christopher Logue, Shailesh Male, Rwoof Reshi, Benjamin Miller, Kevin Engel, Victor Urrutia, Christopher Streib

2:12 p.m.

S21.007

Safety of Repeated Use of Intravenous Thrombolysis for Recurrent Acute Ischemic Stroke —Yahya Atalay, Alexander Merkler

2:24 p.m.

S21.008

Autoregulation-based Blood Pressure Optimization After Large-vessel Ischemic Stroke using Non-invasive Nearinfrared Spectroscopy Monitoring —Anson Wang, Kevin Sheth, Randolph Marshall, David Mampre, Ryan Hebert, Charles Matouk, Nils Petersen

2:35 p.m.

Discussion

Tuesday, April 24

S22 Advances in Muscular Dystrophy and Congenital Myopathy

1:00 p.m.

S22.001

Golodirsen Induces Exon Skipping Leading to Sarcolemmal Dystrophin Expression in Duchenne Muscular Dystrophy Patients With Mutations Amenable to Exon 53 Skipping —

Francesco Muntoni, DE Frank, Valentina Sardone, Jenny Morgan, F Schnell, JS Charleston, Cody Desjardins, Rahul Phadke, Caoline Sewry, Linda Popplewell, Michela Guglieri, Kate Bushby, Pierre Carlier, Chris Clark, George Dickson, Jean-Yves Hogrel, Volker Straub, Eugenio Mercuri, Thomas Voit, Edward Kaye, Laurent Servais

1:12 p.m.

S22.002

Targeted Next Generation Sequencing (NGS) for Analysis of Splicing Biomarkers of Myotonic Dystrophy Type 1 (DM1) — Charles Thornton, Wenli Wang, Ami Mankodi, S Subramony, Tetsuo Ashizawa, John Day, Jeffrey Statland, William Arnold, John Kissel, on behalf of Myotonic Dystrophy Clinical Research Network

1:24 p.m.

S22.003

First-in-human Study of ATB200/AT2221 in Patients with Pompe Disease: Preliminary Results From the ATB200-02 Trial —Tahseen Mozaffar, Drago Bratkovic, Barry Byrne, Paula

Clemens, Tarekegn Geberhiwot, Ozlem Goker-Alpan, Priya Kishnani, Xue Ming, Mark Roberts, Peter Schwenkreis, Kumaraswamy Sivakumar, Ans Van Der Ploeg, Jacquelyn Wright, Franklin Johnson, Sheela Das, Jay Barth, Swati Sathe, Benedikt Schoser

1:36 p.m.

S22.004

Disease progression in Myotonic Dystrophy Type 1 during a non-interventional multicenter study —Ami Mankodi, Jeffrey Statland, Katy Eichinger, Jeanne Dekdebrun, John Day, S Subramony, John Kissel, Tetsuo Ashizawa, Charles Thornton, On behalf of Myotonic Dystrophy Research Network

1:48 p.m.

S22.005

Cardiac atrophy: a Novel Mechanism for Duchenne Muscular Dystrophy (DMD)-Associated Cardiomyopathy — Shaida Khan, Daniel Cheeran, Pradeep Mammen

2:00 p.m.

S22.006

Myo18b-related nemaline myopathy null mutation causes dysfunctional sarcomere contractility —Edoardo Malfatti, Barbara Joureau, Josine de winter, Johann Bohm, Jocelyn Laporte, Norma Romero, Coen AC Ottenheijm

2:12 p.m.

S22.007

Cardiac troponin T as biomarker of cardiac dysfunctions in skeletal muscle from myotonic dystrophy type 1 and type 2 patients —Giovanni Meola, Francesca Bosè, Laura Renna, Barbara Fossati, Elisa Brigonzi, Michele Cavalli, Rosanna Cardani

2:24 p.m.

S22.008

Tuesday

Development of the histone deacetylases inhibitor Givinostat in Duchenne Muscular Dystrophy —Giacomo

Comi, Enrico Bertini, Giuseppe Vita, Eugenio Mercuri, Stefania Petrini, Maurizio Moggio, Paolo Bettica, Alessandra Govoni, Barbara Gatti, Sara Cazzaniga

2:35 p.m.

104 2018 AAN Annual Meeting

Discussion

SCIENTIFIC PLATFORM SESSIONS

1:00 p.m.–3:00 p.m. S23 Biologic and Clinical Discoveries in Neuro-oncology

1:00 p.m. Neuro-oncology Investigator Award

This award recognizes young investigators who have advanced the field of neuro-oncology.

Recipient:

Milan Chheda, MD Saint Louis, MO

1:12 p.m.

Neuro-oncology Scientific Award This award recognizes an individual from any discipline and of

any academic rank for a singular scientific achievement that has advanced the field of neuro-oncology.

Recipient:

Scott R. Plotkin, MD, PhD Boston, MA

1:24 p.m.

S23.003

Bone Marrow is a Critical Mediator of Central Nervous System Regeneration after Radiation Injury —Jorg Dietrich,

Ninib Baryawno, Naema Nayyar, Yannis Valtis, Betty Yang, Ina Ly, Antoine Besnard, Nicolas Severe, Karin Gustafsson, Ovidiu Andronesi, Tracy Batchelor, Amar Sahay, David Scadden

1:36 p.m.

S23.004

Multicenter, phase 2 study of bevacizumab in children and adults with neurofibromatosis 2 and progressive vestibular schwannomas: an NF Clinical Trials Consortium study — Scott Plotkin, James Tonsgard, Nicole Ullrich, Jeffrey Allen, Jaishri Blakeley, Tena Rosser, David Clapp, Jian Campion, Michael Fisher, Gary Cutter, Bruce Korf, Roger Packer, Coretta Thomas, Matthias Karajannis

1:48 p.m.

S23.005

Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis —Adrienne Boire,

Yilong Zou, Jason Shieh, Danilo Macalinao, Elena Pentsova, Joan Massagué

2:00 p.m.

S23.006

Toca 511 & Toca FC: Evaluation of Durable Response Rate in the Post-Resection Setting and Association with Survival in Patients with Recurrent High Grade Glioma —Timothy

Cloughsey, Joseph Landolfi, Michael Vogelbaum, Derek Ostertag, Bradley Elder, Bob Carter, Clark Chen, Steven Kalkanis, Santosh Kesari, Albert Lai, Ian Lee, Linda Liau, Phioanh Nghiemphu, David Piccioni, William Accomando, Oscar Diago, Daniel Hogan, Douglas Jolly, Katie Wood, Thian Kheoh, Harry Gruber, Asha Das, Tobias Walbert

2:12 p.m.

S23.007

Tuesday

The Prevalence and Impact of Sleep Disturbance on Patients with Primary Brain Tumors —Neha Garg, Fang-Chi

Hsu, Rachel Marie Salas, Charlene Gamaldo, Peter Dziedzic, Glenn Lesser, Roy Strowd

2:24 p.m.

S23.008

Neurotoxicity Associated with CD19-specific Chimeric Antigen Receptor T cell Therapy for Adult Acute Lymphoblastic Leukemia (B-ALL) —Bianca Santomasso, Jae

Hong Park, Isabelle Riviere, Elena Mead, Daniel Li, Brigitte Senechal, Terrence Purdon, Elizabeth Halton, Claudia Diamonte, Michel Sadelain, Renier Brenjens

2:35 p.m.

Discussion

= Abstract of Distinction

AAN.com/view/AM18 105

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC PLATFORM SESSIONS 3:30 p.m.–5:30 p.m. S24 MS Outcome Measures and Biomarkers

3:30 p.m.

3:30 p.m.–5:30 p.m.

S24.001

OCTiMS Study: A 3-Year Longitudinal Assessment of RNFL Thickness Measured by Optical Coherence Tomography in Patients with Relapsing-Remitting Multiple Sclerosis — Peter Calabresi, Frederik Barkhof, Ari Green, Randy Kardon, Friedemann Paul, Jaume Sastre-Garriga, Sven Schippling, Patrick Vermersch, Catherine Agoropoulou, Ervin Carolyn Marie, Diego Silva, Axel Petzold

3:42 p.m.

S24.002

Interim Analysis of the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Study in Multiple Sclerosis (MS) — Amit Bar-Or, Jeffrey Gelfand, Damian Fiore, Christopher Harp, Ann Herman, Bruno Musch, Hanzhe Zheng, Anne Cross

3:54 p.m.

S24.003

Serum Neurofilament Light (NfL): Towards a Blood Test for Prognosis and Disease/Treatment Monitoring in Multiple Sclerosis Patients —Peter Calabresi, Douglas Arnold, Revere

Kinkel, Carol Singh, Dipen Sangurdekar, Carl DeMoor, Bob Engle, Aaron Deykin, Elizabeth Fisher, Alfred Sandrock, Richard Rudick, Bernd Kieseier, Tatiana Plavina

4:06 p.m.

S24.004

Long-term Prognosis of Disease Evolution and Evidence for Sustained Fingolimod Treatment Effect by Blood Neurofilament Light in RRMS Patients —Jens Kuhle, Jeffrey

S25 Advances in

Amyotrophic Lateral Sclerosis

contributions in research in the search for the cause, treatment, prevention, and cure for amyotrophic lateral sclerosis (ALS).

Recipient:

Timothy M. Miller, MD, PhD Saint Louis, MO S25.003

Extra-Motor Pathology in ALS-FTD: Looking Beyond C9orf72 —Eoin Finegan, Rangariroyashe Chipika, Taha Omer,

S24.006

Link between vascular risk factors and grey matter cortical thickness in early MS and the moderating influence of sex —Ilana Katz Sand, Michelle Fabian, Victoria Leavitt, Patrizia

Frank Rigo, Jeffrey Rothstein

4:18 p.m.

S25.005

Modulation of CSF miRNAs in ALS Phase 2 Study Participants Treated with MSC-NTF Cells (NUROWN®) —

Revital Aricha, Haggai Kaspi, Merit Cudkowicz, James Berry, Anthony Windebank, Nathan Staff, Margaret Owegi, Yossef Levy, Chaim Lebovits, Robert Brown, Yael Gothelf, Ralph Kern

S25.006

Tuesday

S24.008

NeurEx: App-based documentation of neurological exam eliminates noise in current disability scales and provides a new scale with enhanced sensitivity —Peter Kosa, Mary Sandford, Alison Wichman, Bibiana Bielekova

5:05 p.m.

Discussion

106 2018 AAN Annual Meeting

S26.002

Interim Clinical Assessment of a Neural Stem Cell Based Therapy for Parkinson’s Disease —Russell Kern, Ibon

S26.003

Efficacy and safety of subcutaneous L-dopa/carbidopa (ND0612H) infusion in fluctuating PD patients —C. Olanow, Fabrizio Stocchi, Werner Poewe, Aaron Ellenbogen, Ruth Djaldetti, Tamar Rachmilewitz, Yael Cohen, Sheila Oren, Karl Kieburtz

4:06 p.m.

S26.004

Inhaled Levodopa Administered With Oral Carbidopa/ Levodopa for Early Morning OFF Symptoms in Patients With Parkinson’s Disease: Exploratory Efficacy Analysis —Stuart Isaacson, Aaron Ellenbogen, Robert Hauser, Beth Safirstein, Daniel Truong, Steven Komjathy, Deena Kegler-Ebo, Ping Zhao

4:42 p.m.

Robert Hauser, Stuart Isaacson, Beth Safirstein, Daniel Truong, Ping Zhao, Steven Komjathy, Charles Oh

S25.007

Sit to Stand (STS) Vs. Stair Climbing (SC) as a Measure of Lower Extremity (LE) Function In Ambulatory Patients with Amyotrophic Sclerosis (ambALS). —Mohammed Sanjak, Cody

Mabe, Scott Holsten, Nigel Rozario, Elena Bravver, William Bockenek, Benjamin Brooks

4:54 p.m.

S25.008

iPSC-derived M2-like ALS macrophages suppress proInflammatory phenotype of M1-like macrophages —Weihua

5:05 p.m.

4:54 p.m.

3:42 p.m.

4:18 p.m.

4:42 p.m.

Maria Pia Sormani, Ludwig Kappos, Dieter Haering, Harald Kropshofer, Christian Barro, David Leppert, Davorka Tomic, Jens Kuhle

Brys, Aaron Ellenbogen, Laura Fanning, Natasha Penner, Minhua Yang, Mackenzie Welch, Erica Koenig, Eric David, Tara Fox, Shavy Makh, Jason Aldred, Ira Goodman, Danielle Graham, Andreas Weihofen, Jesse Cedarbaum

TP73 Is an Amyotrophic Lateral Sclerosis Candidate Risk Gene —Jon Downie, Summer Gibson, Spyridoula Tsetsou, Matthew

Zhao, David Beers, Jason Thonhoff, Loren Ornelas, Clive Svendsen, Stanley Appel

S24.007

S26.001

Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease —Miroslaw

3:54 p.m.

S25.004

Strand-specific antisense oligonucleotides for C9ORF72ALS/FTD —Lindsey Hayes, Alyssa Coyne, Paymaan Jafar-Nejad,

Casaccia, James Sumowski

Including Blood Neurofilament Light Chain in the NEDA Concept in Relapsing-Remitting Multiple Sclerosis Trials —

3:30 p.m.

4:06 p.m.

Keefe, Kristi Russell, Karla Figueroa, Mark Bromberg, Charles Murtaugh, Stefan Pulst, Joshua Bonkowsky, Lynn Jorde

4:30 p.m.

Parkinson’s Disease Clinical Trials

Garitaonandia, Rodolfo Gonzalez, Glenn Sherman, Alexander Noskov, Dylan Cardiff, Christiansen-Weber Trudy, Andrey Semechkin, Emma Braine, Azmin Shahrul, Girish Nair, Andrew Evans

4:18 p.m.

Sormani, Mark Freedman, Julie Aldridge, Kurt Marhardt, Nicola De Stefano

S26 Movement Disorders:

Mark A Doherty, Alice Vajda, Russell McLaughlin, Niall Pender, Orla Hardiman, Peter Bede

4:30 p.m.

S24.005

Research This award recognizes an individual who has made significant

Cohen, Harald Kropshofer, Rolf Meinert, Christian Barro, Martin Bernhard Merschhemke, Dieter Haering, David Leppert, Davorka Tomic, Ludwig Kappos

Disease Activity as Assessed by the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) Score Predicts Long-Term Clinical Disease Activity (CDA)-Free Status and Disability Progression in Patients Treated with Subcutaneous Interferon beta-1a (scIFN?-1a) —Maria Pia

3:30 p.m.–5:30 p.m.

3:30 p.m. Sheila Essey Award: An Award for ALS

3:54 p.m.

Tuesday, April 24

Discussion

S26.005

Inhaled Levodopa Administered With Oral Carbidopa/ Levodopa for Early Morning OFF Symptoms in Patients With Parkinson’s Disease: Safety Assessment —Aaron Ellenbogen,

4:30 p.m.

S26.006

Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study —Donald Grosset,

Rohit Dhall, Tanya Gurevich, Jan Kassubek, Werner Poewe, Olivier Rascol, Monika Rudzinska-Bar, Jennifer Cormier, Alexander Sedkov, Charles Oh

4:42 p.m.

S26.007

Effect of NP002, a centrally acting cholinergic agent, in reducing dyskinesia, freezing of gait, and falls in patients with Parkinson’s disease —Abraham Lieberman, Thurmon Lockhart, Markey Olson, Victoria Smith, Christopher Frames

4:54 p.m.

S26.008

Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects With Motor Fluctuations: a Phase 3 Open-Label Randomized Study —Donald Grosset, Rohit Dhall,

Tanya Gurevich, Jan Kassubek, Werner Poewe, Olivier Rascol, Monika Rudzinska-Bar, Jennifer Cormier, Alexander Sedkov, Charles Oh

5:05 p.m.

Discussion

Thank You

2O18 Industry Roundtable Members* The American Academy of Neurology and the Industry Roundtable collaborate on opportunities to support neurology and serve patients with neurologic disease.

$50,000

$40,000

$25,000

Acorda Therapeutics Greenwich Biosciences, Inc. IPSEN Biopharmaceuticals, Inc.

Abbott Adamas Pharmaceuticals, Inc. Allergan Alnylam Pharmaceuticals, Inc. Eisai Inc.

$10,000 GE Healthcare Medtronic Neurocrine Biosciences Sarepta Therapeutics UCB Inc.

CSL Behring Ionis Pharmaceuticals

*commitments as of January 19, 2018

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC PLATFORM SESSIONS 8:00 a.m.–9:00 a.m. S27 “Best of” Session: Movement Disorders

Titles and authors of these abstracts are listed in “Best of” Scientific Platform Sessions on page 93 »

1:00 p.m.–2:00 p.m.

S28 Practice, Policy, and Ethics

Wednesday, April 25

1:00 p.m.–3:00 p.m.

S29 Child Neurology and

Developmental Neurology I

This session will be presented at the Maximize Your Value Experiential Learning Area located in the South Lobby of the Los Angeles Convention Center

1:00 p.m.

Telephonic follow for chronic childhood neurological disorders: A Teach and Treat Initiative —Shefalli Gulati, Shruthi N M, Ramesh Konanki, Manoj Singh, Lokesh Saini, Vishal Sondhi, Prashant Jauhari, Biswaroop Chakrabarty, R M Pandey

Jerry Mendell, Samiah Al-Zaidy, Richard Shell, William Arnold, Louise Rodino-Klapac, Thomas Prior, Linda Lowes, Lindsay Alfano, K Berry, Kathleen Church, John Kissel, Sukumar Nagendran, James L’Italien, Douglas M. Sproule, Courtney Wells, Arthur Burghes, Kevin D. Foust, Kathrin Meyer, Shibi Likhite, Brian Kaspar

1:12 p.m.

S28.001

S28.002

Routine and Urgent TeleNeurology consultations improve access to neurological care and decreases length of stay — Robert McCormick, Juan Estrada, Cynthia Whitney, Adam Cohen, Lee Schwamm, Marcelo Matiello

S29.001

AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Continued Event Free Survival and Achievement of Developmental Milestones —

S29.002

AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Patients Treated Early with the Proposed Therapeutic Dose Were Able to Sit Unassisted at a Younger Age —Lindsay Alfano, Linda Lowes, Samiah Al-Zaidy, Richard Shell,

1:24 p.m.

S28.003

Safety of lumbar puncture performed on dual antiplatelet therapy —Ivan Carabenciov, Maximiliano Hawkes, Sara Hocker

William Arnold, Louise Rodino-Klapac, Thomas Prior, Katherine Berry, Kathleen Church, John Kissel, Sukumar Nagendran, James L’Italien, Douglas M. Sproule, Courtney Wells, Arthur Burghes, Kevin D. Foust, Kathrin Meyer, Shibi Likhite, Brian Kaspar, Jerry Mendell

1:36 p.m.

S28.004

1:24 p.m.

Variability of Safety Policies Related to Prion Disease Among Top Neurological Institutions —Katherine

Werbaneth, Praveen Tummalapalli, Lironn Kraler, Carl Gold

S29.003

AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Continued Independence from Nutritional and Ventilatory Support in Patients Dosed Early in Disease Progression —Richard Shell, Samiah Al-Zaidy, William Arnold, Louise Rodino-Klapac, Thomas Prior, Linda Lowes, Lindsay Alfano, K Berry, Kavitha Kotha, Kathleen Church, John Kissel, Sukumar Nagendran, James L’Italien, Douglas M. Sproule, Courtney Wells, Arthur Burghes, Kevin D. Foust, Kathrin Meyer, Shibi Likhite, Brian Kaspar, Jerry Mendell

1:36 p.m.

S29.004

AVXS-101 Trial Experience: CHOP-INTEND Detects Early Improvements in Infants with SMA Type 1 but is not Sensitive to Continued Advances in Motor Function —Linda Lowes, Lindsay Alfano, Megan Iammarino, Natalie Miller, Melissa Menier, Jessica Cardenas, Douglas M. Sproule, Sukumar Nagendran, Samiah Al-Zaidy, Jerry Mendell

1:48 p.m.

S29.005

A Subset of Axonal and Synaptic Genes with Altered Expression/Splicing in SMA-MNs Harbours a Common Motif that Interacts with SMN/SYNCRIP Complex —

Federica Rizzo, Monica Nizzardo, Shikha Vashisht, Valentina Melzi, Irene Faravelli, Sabrina Salani, Monica Bucchia, Michela Taiana, Andreina Bordoni, Nereo Bresolin, Uberto Pozzoli, Giacomo Comi, Stefania Corti

2:00 p.m.

S29.006

MoveDMD®: Positive Effects of Edasalonexent, an NF-κB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy in Phase 2 Study with an Open-Label Extension —Richard Finkel, Krista H. Elvire Vandenborne, H. Lee

Wednesday

Sweeney, Erika Finanger, Gihan Tennekoon, Perry Shieh, Rebecca J. Willcocks, Sean C. Forbes, William Triplett, Sabrina Yum, Maria Mancini, Angelika Fretzen, Joanne Donovan

2:12 p.m.

S29.007

Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Pediatric Lower Limb Spasticity: Primary Results —Heakyung Kim, Jill Meilahn, Chengcheng Liu, Henry G. Chambers, Rozalina Dimitrova

2:24 p.m.

S29.008

Gene Therapy in Children with AADC Deficiency with AGIL-AADC Leads to De Novo Dopamine Production and Sustained Improvement in Motor Milestones over 5 Years —Yin-Hsiu Chien, Ni-Chung Lee, Sheng-Hong Tseng, Chun-

Hwei Tai, Anne Marie Conway, Kirsten Gruis, Mark Pykett, Wuh-Liang Hwu

2:35 p.m.

108 2018 AAN Annual Meeting

Discussion

S30 Movement Disorders:

Dystonia, Chorea, and other Disorders

1:00 p.m.–3:00 p.m.

1:00 p.m. Jon Stolk Award in Movement Disorders

for Young Investigators T his award recognizes young investigators who have made

significant contributions to movement disorders research. The award is named for Dr. Jon Stolk, a driving force in the drug development field for Parkinson’s disease.

Nandakumar Narayanan, MD, PhD Iowa City, IA S30.002

Establishing Preclinical Proof-of-Concept of Gene Therapy for Huntington Disease —Melvin Evers 1:24 p.m.

S30.003

Perinatal insults and neurodevelopmental disorders may impact age of diagnosis of Huntington’s disease —Filipe B

Rodrigues, Melinda Barkhuizen, David G Anderson, Edward Wild, Boris W Kramer, Danilo Gavilanes

1:36 p.m.

S30.004

Brain Structural Changes in Focal Dystonia—What About Task Specificity? A Multimodal Imaging Study —Elisabetta Sarasso, Federica Agosta, Alexandra Tomic, Nataþa Dragaþevic, Marina Svetel, Elisa Canu, Vladimir Kostic, Massimo Filippi

1:48 p.m.

S30.005

Disease onset in X-linked Dystonia-Parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1 —D. Cristopher Bragg, Nichita Kulkarni, Christine A. Vaine, Rachita Yadav, Mai-Linh Ton, Patrick Acuna, Criscely Go, Trisha Multhaupt-Buell, Ulrich Muller, Xandra Breakefield, Laurie Ozelius

2:00 p.m.

S30.006

Functional Neuroimaging of Functional Movement Disorders (FMD) Before and After a Rehabilitation Program —Kathrin LaFaver, Leonard Faul, Alexandra Jacob, Brendan Depue

2:12 p.m.

S30.007

SIAXI: IncobotulinumtoxinA for sialorrhea in Parkinson’s disease, stroke, and other etiologies-Phase 3 Results —Olaf Michel, Andrew Blitzer, Andrzej Friedman, Birgit Flatau-Baqué, János Csikós, Wolfgang Jost

2:24 p.m.

S30.008

Association analysis of single nucleotide polymorphisms near the DYT3 locus to dystonic symptoms in X-linked dystonia-parkinsonism —Gerard Raimon Saranza, Derick Erl Sumalapao, Aloysius Domingo, Paul Matthew Pasco, Lillian Lee, Roland Dominic Jamora, Ana Westenberger, Christine Klein

1:00 p.m.

Discussion

S31.002

Michael Reed, Steve H. Kawahara, Robert Cowan, Firas Dabbous, Karen Campbell, Riya Pulicharam, Hema Viswanathan, Richard Lipton

Clinical Phenotypes of Pure Primary Lateral Sclerosis —

Shivam Mittal, William Hu, Keith Josephs, J. Ahlskog, Eric Sorenson, Anhar Hassan

S31.003

Evaluation of Quality of Life and Disability in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy Following Treatment with Patisiran, An Investigational RNAi Therapeutic: Results from the Phase 3 APOLLO Study —David Adams, Alejandra Gonzalez-

Duarte, William O’Riordan, Chih-Chao Yang, Taro Yamashita, Arnt Kristen, Ivaylo Tournev, Hartmut Schmidt, Teresa Coelho, John Berk, Kon-Ping Lin, Peter Dyck, Pritesh Gandhi, Marianne Sweetser, Jihong Chen, Sunita Goyal, Jared Gollob, Ole Suhr

S31.004

More than just fun and games: ACTIVE Workspace volume video game quantifies upper extremity function in individuals with neuromuscular disease —Lindsay Alfano,

Natalie Miller, Megan Iammarino, Margaret Dugan, Melissa MooreClingenpeel, John Kissel, Samiah Al-Zaidy, Kevin Flanigan, Jerry Mendell, Linda Lowes

1:48 p.m.

S31.005

Sporadic Late-Onset Nemaline Myopathy —Elie Naddaf,

Margherita Milone, Ankit Kansagra, Francis Buadi, Taxiarchis Kourelis

2:00 p.m.

S31.006

RA101495, A Subcutaneously Administered Peptide Inhibitor of Complement Component 5 (C5) for the Treatment of Generalized Myasthenia Gravis (gMG): Phase 1 Results and Phase 2 Design —James Howard, Henry Kaminski, Richard Nowak, Gil Wolfe, Michael Benatar, Alonso Ricardo, Michelle D Hoarty, Steven J DeMarco, Ramin Farzaneh-Far, Petra Duda

2:12 p.m.

S31.007

Autologous Hematopoietic Stem Cell Transplantation May Be Highly Effective Treatment for Severe, Treatment Refractory Stiff Person Syndrome —George Georges, Peter McSweeney, James Bowen, Michael Pearlman, Annette Wundes, Gloria Von Geldern, George Kraft, Michael Weiss, Joel Sytsma, Bernadette McLaughlin, Richard Nash

2:24 p.m.

S31.008

Small Fiber Polyneuropathy in Patients with Neurofibromatosis, Type 1 —Vera Bril, Alon Abraham, Raymond

H Kim, Catherine Maurice, Tayir Alon, Paul Kongkham, Gelareh Zadeh, Carolina Barnett Tapia

2:35 p.m.

Discussion

= Abstract of Distinction

S32.001

Migraine Treatment Patterns and Opioid Use Among Chronic and Episodic Migraine Patients Identified by a Clinician-Administered Semi-Structured Diagnostic Interview —Jelena Pavlovic, Justin S. Yu, Stephen Silberstein,

1:12 p.m.

S32.002

Increased Migraine-Free Intervals With Eptinuzumab Were Associated With Improved Health-Related Quality-of-Life Outcomes Through Week 12: Results From the Phase 3 PROMISE-1 Trial —Richard Lipton, David Kudrow, Eric Kassel, Joe Hirman, Roger Cady

1:24 p.m.

S32.003

In Vitro Characterization of Agonist Binding and Functional Activity at a Panel of Serotonin Receptor Subtypes for Lasmiditan, Triptans and Other 5-HT Receptor Ligands and Activity Relationships for Contraction of Human Isolated Coronary Artery —Antoinentte Maassen Van Den Brink, Alejandro

Labastida-Ramirez, Antoon van den Bogaerdt, Ad Bogers, Eric Zanelli, Laurent Meeus, Alexander Danser, Kirk Johnson, Joe Kovalchin, Carlos Villalon, Eloisa Rubio-Beltran

1:36 p.m.

S32.004

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients with Stable Angina —Christophe Depre, Lubomir Antalik, Amaal Starling, Michael Koren, Osa Eisele, Yumi Kubo, Robert Lenz, Daniel Mikol

1:48 p.m.

S32.005

Efficacy of Two Dose Regimens of Subcutaneous Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine —Stephen Silberstein, Ernesto Aycardi, Marcelo Bigal, Paul Yeung, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma, MS, David Dodick, Peter Goadsby

2:00 p.m.

S32.006

Efficacy of Erenumab for the Treatment of Patients With Chronic Migraine With and Without Aura —Messoud Ashina, David Dodick, Peter Goadsby, David Kudrow, Uwe Reuter, Stewart Tepper, Sunfa Cheng, Dean Leonardi, Robert Lenz, Daniel Mikol

2:12 p.m.

S32.007

The Positive Impact of Fremanezumab on Work Productivity and Activity Impairment in Patients with Chronic Migraine —Richard Lipton, Sanjay Gandhi, Timothy Fitzgerald, MA, PhD, Paul Yeung, Josh Cohen, Ronghua Yang, Ernesto Aycardi

2:24 p.m.

S32.008

Lasmiditan Inhibits CGRP Release in the Mouse Trigeminovascular System —Antoinentte Maassen Van Den

Brink, Eloisa Rubio-Beltran, Ingrid Garrelds, Kristian Haanes, Kayi Chan, Joe Kovalchin, Kirk Johnson, Alexander Danser, Carlos Villalon, Alejandro Labastida-Ramirez

2:35 p.m.

1:00 p.m.

Mathieu

1:36 p.m.

S31.001

The natural history of impairments and disabilities in Oculopharyngeal Muscular Dystrophy: a large retrospective study —Jean-Denis Brisson, Cynthia Gagnon, Bernard Brais, Jean

1:24 p.m.

S32 Headache: Therapeutics

Discussion

AAN.com/view/AM18 109

Wednesday

2:35 p.m.

Biomarkers in Neuromuscular Disorders

1:12 p.m.

Recipient:

1:12 p.m.

S31 Therapeutics, Phenotypes, and

1:00 p.m.–3:00 p.m.

SCIENTIFIC PLATFORM SESSIONS

1:00 p.m.–3:00 p.m.

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC PLATFORM SESSIONS 3:30 p.m.–4:15 p.m. S33 Global Health

3:30 p.m.–5:30 p.m.

This session will be presented at the Research Corner Experiential Learning Area located in the South Lobby of the Los Angeles Convention Center 3:30 p.m.

S33.001

LTA4H Genotype is Not Associated with Mortality in Zambian Patients with Tuberculous Meningitis —

Shawn Love, Igor Koralnik, Xin Dang, Kalo Musukuma, Eugene Mubanga, Clayton Buback, Gretchen Birbeck, Masharip Atadzhanov, Omar Siddiqi

3:42 p.m.

S33.002

The Impact of Changes in Health Expenditures Per Capita, Population Growth, and Aging on Ischemic Stroke Deaths by Country, 1995-2014 —Kafi Hemphill, Anthony Kim

S34 Behavioral and

Cognitive Neurology

3:30 p.m.–5:30 p.m.

3:30 p.m. Norman Geschwind Prize in Behavioral

Neurology This prize is awarded to an individual for outstanding research

in the field of behavioral neurology. Applicants should have a strong desire to expand the field of behavioral neurology through research.

Zachary Miller, MD San Francisco, CA S34.002

Characterisation of basal ganglia pathology in frontotemporal dementia: a connectivity-based multimodal neuroimaging study —Peter Bede, Eoin Finegan,

Rangariroyashe Chipika, Taha Omer, Niall Pender, Siobhan Hutchinson, Orla Hardiman

3:54 p.m.

S34.003

The Neuroimaging Profile of Primary Progressive Aphasia —Eoin Finegan, Rangariroyashe Chipika, Taha Omer, Siobhan Hutchinson, Mark A Doherty, Alice Vajda, Russell McLaughlin, Orla Hardiman, Peter Bede

4:06 p.m.

S34.004

Network Localization of Disordered Free Will Perception — Richard Darby, Matthew Burke, Michael Fox

4:18 p.m.

S34.005

Gerstmann like Parietal Dysfunction in a Family with Congenital Mirror Movements with a Novel Missense Variant in RAD51 Gene —Adit Friedberg, Merav Kedmi, Shay Ben-Shachar, Avi Orr-Urtreger, Nir Giladi, Iftah Biran

4:30 p.m.

S34.006

A High Prevalence Rate of a Positive Screen for Neurocognitive Dysfunction in Patients with Chronic Hepatitis C infection in an Irish Clinic. —Damien Ferguson, Orla Strahan, Robert Coen, Susan McKiernan, Colm Bergin, Paul Dockree, Colin Doherty, Suzanne Norris

4:42 p.m.

Developmental Neurology II

3:30 p.m.

S34.007

S35.001

Natalizumab treatment for highly active children and juveniles multiple sclerosis patients : An Israeli collaborative study —Shay Menascu, Ron Milo, David Magalashvili, Mark Dolev, Anat Achiron

S35.002

A New Rodent Model of Dystonic Cerebral Palsy —Bhooma Aravamuthan, Anne Young, Seward Rutkove

3:54 p.m.

S35.003

Safety of mTOR Inhibitors in Infants with Tuberous Sclerosis Complex (TSC): Multicenter Clinical Experience —Darcy Krueger, Jamie Capal, Paolo Curatolo, Orrin Devinsky, Sergiusz Jozwiak, Petrus de Vries, Michael Wong, Stephanie Bruns, David Franz

4:06 p.m.

S35.004

Seizures at presentation are predictors of relapsing disease in children presenting with acute disseminated encephalomyelitis —Tom Rossor, Sukhvir Wright, Sophie Duignan, Olga Ciccarelli, Krishna Das, Evangeline Wassmer, Ming Lim, Cheryl Hemingway, Yael Hacohen

4:18 p.m.

S35.005

Implications of the International Paediatric Multiple Sclerosis Study Group Consensus Criteria for Paediatric Acute Disseminated Encephalomyelitis: a Nationwide Validation Study —Magnus Spangsberg Boesen, Melinda

Magyari, Nils Koch-Henriksen, Lau Thygesen, Peter Uldall, Morten Bjorn Blinkenberg, Alfred Peter Born

4:30 p.m.

S35.006

Dietary Therapy In Epilepsy Treatment (DIET-Trial): A Randomised Non-Inferiority Trial Comparing KD, MAD & LGIT for Drug Resistant Epilepsy —Vishal Sondhi, Anuja

Agarwala, Biswaroop Chakrabarty, Prashant Jauhari, Rakesh Lodha, R M Pandey, G S Toteja, Vinod K Paul, Shefalli Gulati

4:42 p.m.

S35.007

Understanding Divergent Trajectories in Pediatric Patients with Moderate to Severe Traumatic Brain Injury —Faisal

Resting State Functional Connectivity Correlates of Fatigue Following Mild Traumatic Brain Injury —Jeffrey Lewis, Kristine Knutson, Stephen Gotts, Eric Wassermann

Rashid, Emily Dennis, Monica Ellis-Blied, Talin Babikian, Jeffrey Alger, Julio Villalon-Reina, Yan Jin, Alexander Olsen, Richard Mink, Christopher Babbitt, Jeffrey Johnson, Christopher Giza, Paul Thompson, Robert Asarnow

4:54 p.m.

S34.008

Cerebellar Functional Neuroanatomy: Recent Developments, Outstanding Questions, and Future Directions. —Xavier Guell, John Gabrieli, Jeremy Schmahmann, Satrajit Ghosh

5:05 p.m.

Wednesday 110 2018 AAN Annual Meeting

S35 Child Neurology and

3:42 p.m.

Recipient:

3:42 p.m.

Wednesday, April 25

Discussion

S35.008

DNA methylation in autism brains supports epigeneticmediated effects in GABA signaling. —Jeffery Vance, Juan young, Anthony Griswold, Cheryl Brandenburg, Margaret PericakVance, John Hussman, Gene Blatt

5:05 p.m.

Discussion

S36 MS Therapeutics and Clinical Research

3:30 p.m.

4:30 p.m.–5:30 p.m.

S36.001

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis —Stephen Hauser, Ludwig Kappos, Xavier Montalban, Harold Koendgen, Carrie Li, Carole Marcillat, Ashish Pradhan, David Wormser, Jerry Wolinsky

3:42 p.m.

S36.002

Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis —Amit Bar-Or, Daniela Stokmaier, Kevin

Winthrop, Cathy Chognot, Joanna Evershed, Marianna Manfrini, John McNamara

3:54 p.m.

S36.003

Alemtuzumab-Treated Patients Experienced Decreased MRI Disease Activity and Slowing of Brain Volume Loss Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS I (TOPAZ Study) —Alex Rovira, Michael Barnett, Giancarlo Comi, Kunio Nakamura, Daniel Pelletier, Sven Schippling, Anthony Traboulsee, David Margolin, Maria Melanson, Nadia Daizadeh, Douglas Arnold

4:06 p.m.

SCIENTIFIC PLATFORM SESSIONS

3:30 p.m.–5:30 p.m.

S36.004

Non-myeloablative hematopoietic stem cell transplantation (HSCT) is superior to disease modifying drug (DMD) treatment in highly active Relapsing Remitting Multiple Sclerosis (RRMS): interim results of the Multiple Sclerosis International Stem cell Transplant (MIST) Randomized Trial —Richard K Burt, Roumen Balabanov, John Snowden, Basil

S37 Neurorehabilitation

This session will be presented at the Research Corner Experiential Learning Area located in the South Lobby of the Los Angeles Convention Center 4:30 p.m.

S37.001

Chronic Nerve Health Following Implantation of Nerve Cuff Electrodes Designed for the Proximal Femoral Nerve —Max Freeberg, Gilles Pinault, Dustin Tyler, Ronald Triolo, Rahila Ansari

4:42 p.m.

S37.002

Structural and Functional MRI Correlates of Hand Motor Performance in Patients with Multiple Sclerosis —Claudio Cordani, Claudio Piazza, Marco Roselli, Federica Esposito, Marta Radaelli, Bruno Colombo, Paolo Preziosa, Giancarlo Comi, Massimo Filippi, Maria Rocca

4:54 p.m.

S37.003

Using Intracortical Microstimulation to Deliver Instructional Information: Towards Neural Rehabilitation Solutions — Kevin Mazurek, Marc Schieber

5:06 p.m.

S37.004

Pre-existing White Matter Disease Burden Impacts Cognitive Outcome after Inpatient Rehabilitation for Ischemic Stroke —Heather Heiser, Laurel Packard, Nathan Bernicchi, Muhib Khan

Sharrack, Maria-Carolina Oliveira, Joachim Burman

4:18 p.m.

S36.005

Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, ActiveControlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) —Ludwig Kappos, Krzysztof Selmaj, Amit Bar-Or, Giancarlo Comi, Douglas Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Havrdova, James Sheffield, Kartik Raghupathi, Bruce Cree, Jeffrey Cohen

4:30 p.m.

S36.006

Safety of Ozanimod Versus Interferon β-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) —Bruce Cree, Amit Bar-Or, Giancarlo Comi, Krzysztof Selmaj,

Douglas Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Havrdova, James Sheffield, Kartik Raghupathi, Ludwig Kappos, Jeffrey Cohen

4:42 p.m.

S36.007

Wednesday

A Randomized Controlled Pilot Trial of Aspirin to Improve Exercise Performance in Persons with Multiple Sclerosis — Victoria Leavitt, Adam Blanchard, Chu-Yueh Guo, Eva Gelernt, James Sumowski, Claire Riley, Joel Stein

4:54 p.m.

S36.008

Risk of Stroke in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon beta-1a (scIFNβ-1a) —

Meritxell Sabidó Espin, Saritha Venkatesh, Julie Aldridge, Alan Gillett

5:05 p.m.

Discussion

= Abstract of Distinction

AAN.com/view/AM18 111

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC PLATFORM SESSIONS 8:00 a.m.–9:00 a.m. S38 “Best of” Session: Clinical Trial Updates in Neuromuscular Disorders

Titles and authors of these abstracts are listed in “Best of” Scientific Platform Sessions on page 93 »

1:00 p.m.–2:15 p.m.

S39 History of Neurology

Thursday, April 26

1:00 p.m.–3:00 p.m.

This session will be presented at the Research Corner Experiential Learning Area located in the South Lobby of the Los Angeles Convention Center 1:00 p.m. Lawrence C. McHenry Award: An Award

S40 Acute Stroke Care

1:00 p.m.

S40.001

Automated Detection of Facial Weakness Using Machine Learning —Omar Uribe, Mark McDonald, Yan Zhuang, Iris Lin,

Daniel Arteaga, William Dalrymple, Bradford Worrall, Gustav Rohde, Andrew Southerland

for the History of Neurology S elected by the Lawrence C. McHenry Award Workgroup,

1:12 p.m.

Recipient:

Wu, Anne-Katrin Giese, Arne Lauer, Gregoire Boulouis, Brittany Mills, Lisa Cloonan, Kathleen Donahue, William Copen, Pamela Schaefer, Natalia Rost

this award recognizes excellence in research in the history of neurology.

Bart TH Lutters, BSc Utrecht , Netherlands

1:24 p.m.

S39.003

Lymphatics of the Central Nervous System: Forgotten first descriptions. —Daniel Moreno-Zambrano, David

Santana, David Avila, Rocio Santibanez

1:36 p.m.

S39.004

Evolving models of pseudobulbar affect: historical accounts, controversies, localisation —Peter Bede, Eoin Finegan, Rangariroyashe Chipika, Orla Hardiman

1:48 p.m.

S39.005

“These Cases Are So Dramatic That They Could Never Be Overlooked:” A History of Pediatric Neuromyelitis Optica — Alison Christy

S40.002

White Matter Integrity is Associated with Early Neurologic Improvement After Ischemic Stroke —Mark Etherton, Ona

1:24 p.m.

S40.003

Impaired cerebral autoregulation after endovascular stroke therapy is associated with hemorrhagic transformation — Nils Petersen, Anson Wang, Randolph Marshall, David Mampre, Can Ozan Tan, Kevin Sheth

1:36 p.m.

S40.004

Long-term Consequences of Further Post-stroke Disability in Patients with Pre-morbid Disability: Potential for Acute Stroke Therapies —Aravind Ganesh, Sarah T Pendlebury, Rose M Wharton, Ramon Luengo-Fernandez, Peter Rothwell, on behalf of the Oxford Vascular Study

1:48 p.m.

S40.005

CT Brain Calcium Score Predicts Recurrent Transient Ischaemic Attack or Stroke in Patients with First Presentation of Transient Ischaemic Attack —Wan Yee Kong,

Eide Sterling, Nicholas JH Ngiam, Christine CH Yuan, Deborah YC Tan, Han Yang Ong, Sunny Sibi, Benjamin Yong Qiang Tan, Vijay Sharma, Bernard PL Chan, Leonard Yeo

2:00 p.m.

S40.006

Is the Slope of Optic Nerve Sheath Diameter Change in Malignant Middle Cerebral Artery Stroke Associated with Mortality Outcomes? —Grace Kuo, Steven Cen, Ling Zheng, Alejandro Vazquez, John Margetis, Jess Holguin, Kellyn Trummer, Benjamin Emanuel, May Kim-Tenser, Sebina Bulic

2:12 p.m.

S40.007

Sex and Race-Ethnic Disparities in Door-to-CT Time in Acute Ischemic Stroke in the FL-PR CReSD —Enmanuel Perez, Kefeng Wang, Maria Ciliberti-Vargas, Carolina M. Gutierrez, Sofia Oluwole, Chuanhui Dong, Ralph Sacco, Tatjana Rundek

2:24 p.m.

S40.008

Neighborhood differences in stroke knowledge, selfefficacy, and barriers to calling 9-1-1 in Chicago —Sarah

Song, Soyang Kwon, Erin Wymore, Namratha Kandula, Jen Brown, Amy Eisenstein, Christopher Richards, Maryann Mason, Heather Beckstrom, Peggy Jones, Knitasha Washington, Neelum Aggarwal, Shyam Prabhakaran

2:35 p.m.

Thursday 112 2018 AAN Annual Meeting

Discussion

S41 Neurologic Infections

1:00 p.m.

1:00 p.m.–3:00 p.m.

S41.001

Clinical performance of the BioFire FilmArray Meningitis/ Encephalitis panel in Korean adult patients with central nervous system infection —Eunjin Kwon, So Yeon Kim, Ji Yun,

Sook Young Roh, Dohyun HAN, Jee Jeong, Kee-Duk Park, Moon-Woo Seong

1:12 p.m.

S41.002

FilmArray Meningitis/Encephalitis Multiplex Polymerase Chain Reaction Performance and Clinical Impact —Sara

Radmard, Prajwal Ciryam, Savina Reid, Nhan Ho, Alexandra Boubour, Jason Zucker, Dean Sayre, Benjamin Miko, Marcus Pereira, Susan Whittier, Daniel Green, Kiran Thakur

1:24 p.m.

S41.003

Rabies Virus Causes Acute Neurological Disease by Inducing Mitochondrial Dysfunction and Oxidative Stress: Critical Role of the Rabies Virus Phosphoprotein —Alan Jackson, Wafa Kammouni, Heidi Wood, Paul Fernyhough

1:36 p.m.

S41.004

Treating Progressive Multifocal Leukoencephalopathy With Expanded Third Party BK Virus Specific Cytoxic T Cells In Acute Myeloid Leukemia Patient Following Cord Blood Transplantation —Sudhakar Tummala, Katy Rezvani 1:48 p.m.

S41.005

A Human derived 3D Brain Microphysiological System as a Model to study Progressive Multifocal Leukoencephalopathy —Paula Barreras, David Pamies, Maria Chiara Monaco, Laura Munoz-Arcos, Xiali Zhong, Eugene Major, Helena Hogberg, Thomas Hartung, Carlos Pardo-Villamizar

2:00 p.m.

S41.006

Long-term Outcomes of West Nile Neuroinvasive Disease. —Maximiliano Hawkes, Ivan Carabenciov, Eelco Wijdicks, Alejandro Rabinstein

2:12 p.m.

S41.007

Aging-Associated Proteins in CSF of Persons Living with HIV —Bryan Smith, Katrina Geannopoulos, Chuen-Yen Lau, Ulisses Santamaria, Robert G. Deiss, Anuradha Ganesan, Brian K. Agan, Avindra Nath

2:24 p.m.

S41.008

The effects of JAK inhibitors in a mouse model of HIV neurocognitive disorders —William Tyor, Woldeab Haile,

Christina Gavegnano, Heather Bimonte-Nelson, Rajeth Koneru, Raymond Schinazi

2:35 p.m.

Discussion

SCIENTIFIC PLATFORM SESSIONS

1:00 p.m.–3:00 p.m.

S42 Neurocritical Care

1:00 p.m.

S42.001

Dynamic Changes In EEG Coherence During Cardiac Arrest And Resuscitation In A Rodent Model That Mimics A NeuroIntensive Care Unit —Yama Akbari, Danny Siu, Donald Lee, Lauren Lee, Afsheen Bazrafkan, Juan Alcocer, Niki Maki, Maryam Hosseini, Robert Wilson, Beth Lopour

1:12 p.m.

S42.002

Differential Outcomes in Cardiac Arrest Due to Drug Overdose —Cora Ormseth, Laura Miyares, Sonya Zhou, Mary Barden, Rachel Beekman, Carolina Maciel, David Greer

1:24 p.m.

S42.003

A Multimodal Optical Imaging Platform that Predicts Neurological Recovery after Cardiac Arrest in an “Animal Neuro-Intensive Care Unit” —Robert Wilson, Christian Crouzet, Mohammad Torabzadeh, Afsheen Bazrafkan, Dishant Donga, Shuhab Zaher, Juan Alcocer, Bernard Choi, Bruce Tromberg, Yama Akbari

1:36 p.m.

S42.004

Acute serum GFAP, NF-L, Tau, and UCH-L1 predict CT pathology and 3-month outcome in TBI —Jamie Podell,

Frederick Korley, John Yue, David Wilson, Adam Ferguson, Esther Yuh, Pratik Mukherjee, Kevin Wang, Alex Valadka, Ava Puccio, David Okonkwo, Geoffrey Manley, Ramon Diaz-Arrastia

1:48 p.m.

S42.005

Somatic death and Asystole after brain death diagnosis; duration of circulatory survival in the intensive care unit — Omar Ayoub, Areej Bushnag, Ahmed Abdelaal, Alhassan Ghodeif

2:00 p.m.

S42.006

Data-Driven Comparison Of Acute Imaging Biomarkers For Spinal Cord Injury: A Prospective TRACK-SCI Pilot Study —J. Russell Huie, Jason Talbott, Vineeta Singh, Xuan Duong

Fernandez, Rachel Tsolinas, Lisa Pascual, Jonathan Pan, Nikolaos Kyritsis, Dolores Torres, Michael Beattie, Jacqueline Bresnahan, Adam Ferguson, Sanjay Dhall, William Whetstone

2:12 p.m.

S42.007

Restarting Therapeutic Anticoagulation in Patients with Intracerebral Hemorrhage and Mechanical Heart Valves. —Joji Kuramatsu, Jochen Sembill, Stefan Schwab, Hagen Huttner, Retrace Investigators

2:24 p.m.

S42.008

Racial Variation in Comfort Measures Only Status in Patients with Intracerebral Hemorrhage —Cora Ormseth,

Guido Falcone, Sara Jasak, David Mampre, Audrey Leasure, Laura Miyares, David Hwang, Michael James, Fernando Testai, Kyra Becker, David Tirschwell, Carl Langefeld, Daniel Woo, Kevin Sheth

2:35 p.m.

Discussion

Thursday

= Abstract of Distinction

AAN.com/view/AM18 113

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC PLATFORM SESSIONS 3:30 p.m.–5:30 p.m. S43 Migraine

3:30 p.m.–5:30 p.m.

3:30 p.m. Harold Wolff-John Graham Award: An

Award for Headache/Facial Pain Research T his award recognizes individuals who have submitted research results in the field of headache and facial pain.

Recipient:

William R. Renthal, MD, PhD Boston, MA

3:42 p.m.

S43.002

Factors Associated with Acute Medication Overuse in Persons with Migraine: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study —Todd

Schwedt, Aftab Alam, Michael Reed, Kristina Fanning, Sagar Munjal, David Dodick, Dawn Buse, Richard Lipton

3:54 p.m.

S43.003

Evaluation of the Identify Chronic Migraine (ID-CM) Screener in a Large Medical Group —Justin S. Yu, Jelena

Pavlovic, Stephen Silberstein, Michael Reed, Steve H. Kawahara, Robert Cowan, Firas Dabbous, Karen Campbell, Riya Pulicharam, Hema Viswanathan, Richard Lipton

4:06 p.m.

S43.004

The King-Devick test (KDT) and visual contrast sensitivity test (VCS) in migraine: the effect of migraine attack on rapid eye movements and visual sensitivity —Chia-Chun Chiang, Amaal Starling, David Dodick, Juliana VanderPluym

4:18 p.m.

S43.005

Randomized Controlled Study of Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Treatment of Migraine: The PRESTO Trial —Cristina Tassorelli, Licia Grazzi, Marina De Tommaso, Giulia Pierangeli, Paolo Martelletti, Innocenzo Rainero, Pierangelo Geppetti, Anna Ambrosini, Paola Sarchielli, Eric Liebler, Piero Barbanti

4:30 p.m.

S43.006

Cell type-specific expression of migraine associated genes in the CNS and peripheral nociceptors —Angeliki Vgontzas, William Renthal

4:42 p.m.

S43.007

The Relationship Between Sleep Disorders and Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study —Dawn Buse, Jeanetta C. Rains, Kristina Fanning, Michael Reed, Aubrey Manack Adams, Jelena Pavlovic, Richard Lipton

S44 MS Risk Factors, Susceptibility,

Diagnosis, and Cognitive Impairment

3:30 p.m.

3:30 p.m.–5:30 p.m.

S44.001

MS in immigrants to Canada in the McDonald era: Increasing prevalence and risk factors —Dalia Rotstein,

Ruth-Ann Marrie, Sima Gandhi, Kinwah Fung, Colleen Maxwell, Jack Tu, Karen Tu

3:42 p.m.

Thursday, April 26

S44.002

Fish, Fatty Acid Biosynthesis Genes, and Multiple Sclerosis Susceptibility —Annette Langer-Gould, Lucinda Black, Jun Wu,

S45 Movement Disorders: Parkinsonian

Disorders, Basic Science, and Imaging

3:30 p.m.

S45.001

3:42 p.m.

S45.002

Defining the pathologic contribution of glia to alphasynucleinopathies —Abby Olsen, Mel Feany Regional Distribution of α-Synuclein and Alzheimer’s Disease pathology in Lewy Body Disorders —David Coughlin,

Jessica Smith, Edlin Gonzales, Lisa Barcellos, Anny Xiang, Robyn Lucas

Mendy Liang, Andrew Williams, Sharon Xie, Daniel Weintraub, Andrew Siderowf, David Wolk, John Duda, Edward Lee, Murray Grossman, John Trojanowski, David Irwin

3:54 p.m.

S44.003

Symptoms of Hypermobility Spectrum Disorder May Mimic Multiple Sclerosis —Kelsey Riggs, Lauren Babcock, Vernon Rowe, John Hunter, Doug Schell, Arlene O’Shea, Dorsey Paul, Gloria OrtizGuerrero, James Barnett

4:06 p.m.

S44.004

Impact of Siponimod on Cognition in Patients With Secondary Progressive Multiple Sclerosis: Results From Phase 3 EXPAND Study —Ralph Benedict, Bruce Cree, Davorka Tomic, Robert Fox, Gavin Giovannoni, Amit Bar-Or, Ralf Gold, Patrick Vermersch, Harold Pohlmann, Goeril Karlsson, Frank Dahlke, Ludwig Kappos

4:18 p.m.

S44.005

S45.003

Tau Pathology within Fetal Graft Tissue at Autopsy: A case report —Abbie Ornelas, Charles Adler, Geidy Serrano, Jasmine Curry, Holly Shill, Oleg Kopyov, Thomas Beach

4:06 p.m.

S45.004

In Vitro Seeding of Endogenous α-Synuclein in Primary Oligodendroglial Cells May Potentially Delineate the Cellular Pathogenesis of Multiple System Atrophy —Seiji

Kaji, Takakuni Maki, Hisanori Kinoshita, Norihito Uemura, Takashi Ayaki, Yuichi Ono, Takahiro Furuta, Makoto Urushitani, Xiaobo Mao, Ted Dawson, Ryosuke Takahashi

4:18 p.m.

S45.005

Alpha Galactosidase A Activity in Parkinson Disease —Roy

Time to Cognitive Worsening in Patients With Relapsing Multiple Sclerosis in Ocrelizumab Phase III Trials —Stanley Cohan, Ralph Benedict, Jerome De Seze, Stephen Hauser, Ludwig Kappos, Jerry Wolinsky, Laura Julian, Pablo Villoslada, Jian Han, Ashish Pradhan, Aaron Miller

Alcalay, Oren Levy, Cheryl Waters, Stanley Fahn, Blair Ford, Sheng-Han Kuo, Nora Vanegas-Arroyave, Hiral Shah, Christopher Liong, Sushma Narayan, Michael Pauciulo, William Nichols, Ziv Gan-Or, Guy Rouleau, Wendy Chung, Pavlina Wolf, Petra Oliva, Joan Keutzer, Karen Marder, Xiaokui Zhang

4:30 p.m.

S44.006

Word Finding Deficits in Early Multiple Sclerosis: A Behavioral and Neuroimaging Investigation —Rachel

Brandstadter, Michelle Fabian, Stephen Krieger, Victoria Leavitt, Christina Lewis, Gabrielle Pelle, James Sumowski

4:42 p.m.

S44.007

Benchmarks of Cognitive Performance in a Large, Representative Patient Population —Carl DeMoor, Richard Rudick, James Williams, Lauren Krupp, Carrie Hersh, Stephen Rao

4:54 p.m.

S44.008

Preservation of Functional Connectivity Moderates the Impact of White Matter Tract Disruption on Cognition in Multiple Sclerosis —Tom Fuchs, Ralph Benedict, Sanjeevani

S45.006

Pharmacokinetic/Pharmacodynamic Analysis of Amantadine for Levodopa-Induced Dyskinesia: Correlation of Therapeutic Plasma Concentrations from Multiple Species with Humans —Elizabeth Brigham, Tom Johnston, Carl

Brown, Jonathon Holt, Susan Fox, Patrick Howson, Jonathan Brotchie, Jack Nguyen

4:42 p.m.

S45.007

Bidirectional longitudinal changes in regional cerebral covariance of vesicular acetylcholine transporter binding in Parkinson disease: Evidence for dynamic regional cerebral compensatory mechanisms —Nicolaas Bohnen, Siamak NejadDavarani, Roger Albin, William Dauer, Martijn Muller

Choudhery, Xian Li, Keith Carolus, Matthew Mallory, Alexander Bartnik, Devon Oship, Faizan Yasin, Deepa Ramasamy, Dejan Jakimovski, Bianca Weinstock-Guttman, Robert Zivadinov, Michael Dwyer

4:54 p.m.

5:05 p.m.

Fanning, Sagar Munjal, Aftab Alam, Dawn Buse, Todd Schwedt, Richard Lipton

ROCHA, Ines Debove, Clarissa Yasuda, Rachel Guimaraes, Felipe Bergo, Anelyssa D’Abreu, Kathleen Poston, Roland Wiest, Fernando Cendes, Paul Thompson, Ysbrand van der Werf, for the ENIGMA Parkinson’s Disease Working Gr

5:05 p.m.

4:54 p.m.

S43.008

Predictors of Allodynia in Persons with Migraine: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study —David Dodick, Michael Reed, Kristina

Discussion

Thursday 114 2018 AAN Annual Meeting

Discussion

S45.008

Widespread Cortical Thinning in Parkinson’s Disease: Findings from the ENIGMA-Parkinson’s Disease Working Group —Boris Gutman, Joanna Bright, Christian Rummel, CRISTIANE

Discussion

SCIENTIFIC PLATFORM SESSIONS

3:30 p.m.–5:30 p.m. S46 Advances in Spinal Muscular Atrophy

3:30 p.m.

S46.001

Nusinersen Efficacy in Adults with Spinal Muscular Atrophy —John Day, Connie Wolford, Chelsea MacPherson, William Martens, Michael McDermott, Basil Darras, Darryl De Vivo, Zarazuela Zolkipli-Cunningham, Richard Finkel, Jacinda Sampson, Tina Duong

3:42 p.m.

S46.002

A Long-Term, Open-Label Follow-Up Study of Olesoxime in Patients with Type 2 or Non-Ambulatory Type 3 Spinal Muscular Atrophy who Participated in a Placebo-Controlled Phase 2 Trial —Francesco Muntoni, Jeppe Buchbjerg, Enrico Bertini, Eric Dessaud, Eugenio Mercuri, Jan Kirschner, Carol Reid, Anna Lusakowska, Giacomo Comi, Jean-Marie Cuisset, Jean-Louis Abitbol, Bruno Scherrer, Eduardo Paulo Morawski Vianna, Ludo Van Der Pol, Carole Vuillerot, Ksenija Gorni, Paulo Fontoura

3:54 p.m.

S46.003

Preliminary Evidence for Pharmacodynamics Effects of RG7916 in JEWELFISH, a Study in Patients with Spinal Muscular Atrophy who Previously Participated in a Study with Another SMN2-Splicing Targeting Therapy —Claudia Chiriboga, Eugenio Mercuri, Dirk Fischer, Dominik Kraus, Monika Alexander, Gillian Armstrong, Heidemarie Kletzl, Marianne Gerber, Yumi Cleary, Tobias Bergauer, Ksenija Gorni, Omar Khwaja

4:06 p.m.

S46.004

Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Feasibility for Individuals with Severe Spinal Muscular Atrophy II —

Elizabeth Kichula, Tina Duong, Allan Glanzman, Amy Pasternak, Basil Darras, Richard Finkel, Darryl De Vivo, Zarazuela Zolkipli-Cunningham, John Day

4:18 p.m.

S46.005

Evaluation of lean mass through DXA scanning and the correlation to functional outcomes in adults with SMA. —

Arun Nagaraj, William Arnold, Wendy King, John Kissel, Bakri Elsheikh

4:30 p.m.

S46.006

Nusinersen treatment for adults with Spinal Muscular Atrophy; a single center experience —Bakri Elsheikh, William Arnold, Louisa Mezache, John Kissel

4:42 p.m.

S46.007

Relationship Between Central and Peripheral SMN Protein Increase Upon Treatment with RO7034067 (RG7916) — Agnès Poirier, M. Weetall, Hasane Ratni, Katja Heim, Nikolai Naryshkin, S. Paushkin, Lutz Mueller

4:54 p.m.

S46.008

Pervasive Neuromuscular Deficits in Adults with Nephropathic Cystinosis —Reza Sadjadi, Stacey Sullivan, Rachel Duong, Camille Corre, Peter James, Florian Eichler

5:05 p.m.

Discussion

Thursday

= Abstract of Distinction

AAN.com/view/AM18 115

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC PLATFORM SESSIONS 8:00 a.m.–9:00 a.m. S47 “Best of” Session: MS and CNS Inflammatory Diseases

Titles and authors of these abstracts are listed in “Best of” Scientific Platform Sessions on page 93 »

1:00 p.m.–3:00 p.m.

S48 Novel Biomarkers in

Aging and Dementia

1:00 p.m.

1:00 p.m.–3:00 p.m.

S48.001

Plasma Tau Corresponds to Preclinical Alzheimer’s Disease and is a Strong Predictor of Future Dementia —Matthew Pase, Alexa Beiser, Jayandra Himali, Claudia Satizabal, Hugo Javier Aparicio, Charles DeCarli, Sudha Seshadri

1:12 p.m.

S48.002

CSF non-Beta-Amyloid, non-Tau Biomarkers for Clinical Alzheimer’s Disease Stages —Umesh Gangishetti, J. Christina Howell, Richard Perrin, John Morris, John Trojanowski, Anne Fagan, Steven Arnold, William Hu

1:24 p.m.

S48.003

Cardiovascular Risk Factors and the Risk of Dementia in the Oldest Old —Farah Mozaffar, Maria Corrada, Claudia Kawas 1:36 p.m.

S48.004

Association of Circulating Fibroblast Growth Factor 23 with Incident Dementia: The Framingham Heart Study —Emer McGrath, Jayandra Himali, Daniel Levy, Carmela Abraham, Sarah Connor, Alexa Beiser, Paul Courchesne, Claudia Satizabal, Matthew Pase, Vasan Ramachandran, Sudha Seshadri

1:48 p.m.

S48.005

Biomarkers of Cerebral Small Vessel Endotheliopathy — Fanny Elahi, Marie Altendahl, Adam Staffaroni, Kaitlin Casaletto, Pauline Maillard, John Neuhaus, Jason Hinman, Charles DeCarli, Edward Goetzl, Joel Kramer

2:00 p.m.

S48.006

Immunological Signatures Distinguish FTLD-TDP from FTLD-tau Disorders Across Clinically Defined, Genetic, and Pathologically Proven Cohorts. —Zachary Miller, Wendy Shwe,

S49 Neuro Trauma and Sports Neurology

1:00 p.m.

S49.001

Vascular reactivity and microstructural changes association with neurocognitive symptoms in chronic traumatic brain injury —Sarah Woodson, Margalit Haber, Franck

Amyot, Kelley Fleshner, Erika Silverman, Kimbra Kenney, Carol Moore, Yi-Yu Chou, Dzung Pham, Michael Sangobowale, Ramon Diaz-Arrastia

1:12 p.m.

S49.002

Neurofilament Light and Tau in the Aftermath of Human Repetitive Concussive Traumatic Brain Injury —Pashtun Shahim, Yelverton Tegner, Kaj Blennow, Henrik Zetterberg

1:24 p.m.

S49.003

Behavioral and Brain Imaging Changes in Patients Receiving Bright Light Therapy Following a Mild Traumatic Brain Injury (mTBI) —Bradley Shane, Johnny Vanuk, Sahil Bajaj, Melissa Millan, William Killgore

1:36 p.m.

S49.004

Longitudinal Changes in Depression and Cognition in Professional Fighters with Baseline Structural Imaging: The Role of Depression in Cognitive Change and Structural Differences. —Bern Lee, Lauren Bennett, Charles Bernick, Sarah Banks

1:48 p.m.

S49.005

The Association of Reported Cognitive Symptoms and Objective Cognitive Performance in Patients with Prolonged Post-Concussion Symptoms —Douglas Polster, Aliyah Snyder, Alma Martinez, Collin Blout, Christopher Giza, Talin Babikian

2:00 p.m.

S49.006

David Perry, Virginia Sturm, Susanna Kwok, Shoshannah Rubin, Robin Ketelle, Reilly Dever, Hilary Heuer, Nicholas Olney, Anna Karydas, Jennifer Yokoyama, Eliana Marisa Ramos, Giovanni Coppola, Daniel Geschwind, Rosa Rademakers, Dennis Dickson, Neill Graff-Radford, Salvatore Spina, Eric Huang, Lea Grinberg, Katherine Rankin, Howard Rosen, Bradley Boeve, Adam Boxer, Maria Gorno Tempini, William Seeley, Bruce Miller

ENIGMA Military Brain Injury: A Preliminary Meta-Analysis of Diffusion MRI Measures —Emily Dennis, Elisabeth Wilde,

2:12 p.m.

S48.007

Clinical Dementia Rating Score 0.5 Predicts Clinical Decline in Familial Frontotemporal Dementia —Salvatore Spina, Adam Staffaroni, Luke Bonham, Nicholas Olney, Suneth Attygalle, Yann Cobigo, Kevin Chang, Richard Binney, Jennifer Yokoyama, John Kornak, Adam Boxer, Bruce Miller, Suzee Lee, Bradley Boeve, Howie Rosen

2:24 p.m.

S48.008

Genetic Screening of CSF1R in Familial Ischemic Stroke — Takuya Konno, Takeshi Miura, Andrea Harriott, Naomi Mezaki, Emily Edwards, Rosa Rademakers, Owen Ross, James Meschia, Takeshi Ikeuchi, Zbigniew Wszolek

2:35 p.m.

Friday 116 2018 AAN Annual Meeting

Friday, April 27

Discussion

Randall Scheibel, Maya Troyanskaya, Carmen Velez, Benjamin Wade, Ann Marie Drennon, Gerald York, Erin Bigler, Tracy Abildskov, Brian Taylor, Carlos Jaramillo, Blessen Eapen, Heather Belanger, Mary Newsome, Harvey Levin, Sidney Hinds, William Walker, Paul Thompson, David Tate

S49.007

Geriatric Traumatic Brain Injury: Unique Considerations for Presentation and Outcome —Raquel Gardner, Sourabh Sharma, John Yue, Allison Kaup, Geoffrey Manley

2:24 p.m.

S49.008

Large-Scale Frontotemporal Limbic Networks in TBI: Vulnerability and Response to Non-Invasive Brain Stimulation —Kevin Bickart, Keith Main, Anna-Clare Milazzo, Megan Newsom, Chandler Sours, J. Wesson Ashford, Maheen Adamson

2:35 p.m.

Discussion

S50 Updates in General Neurology

1:00 p.m.

1:00 p.m.–3:00 p.m.

S50.001

A Neurology Practice Based Research Network for Quality Improvement and Practice Based Research Using the EMR —Kelly Simon, Payal Gupta, Laura Hillman, Christine Boutwell, Ihtsham Haq, Steven Meyers, Matthew Rizzo, James Wymer, Monika Szela, Roberta Frigerio, Demetrius Maraganore

1:12 p.m.

S50.002

Burnout Prevention Measures - Do They Meet the Needs of Women Neurologists? —Lauren Moore, Kathrin LaFaver, Divya Singhal, Craig Ziegler, Amy Hessler

S51 Pediatric MS

1:00 p.m.

3:30 p.m.–5:30 p.m.

S51.001

Development of Clinically Isolated Syndrome after Vaccination, A CDC/FDA Vaccine Adverse Event Reporting System (VAERS) Study, [1985-2017]. —Moamina Fakher Eddin, Janaki Patel, Abdul Rahman Alchaki, Nizar Souayah

1:12 p.m.

S51.002

Oligoclonal Bands in Spinal Fluid Improve the Specificity of Different MRI Criteria for Dissemination in Space to Predict a First Clinical Event in Children with the Radiologically Isolated Syndrome —Naila Makhani, Christine Lebrun-Freney,

Woodward, Jon Reimers

Aksel Siva, Sona Narula, Evangeline Wassmer, James Brenton, David Brassat, Clarisse Carra-Dalliere, Jerome De Seze, Francoise Durand Dubief, Megan Langille, Rinze F Neuteboom, Jean Pelletier, Daniela Pohl, Daniel Reich, Juan Ignacio Rojas, Veronika Shabanova, Eugene Shapiro, Robert Thompson-Stone, Silvia Tenembaum, Mar Tintoré, Ugur Uygunoglu, Wendy Vargas, Sunita Venkateswaran, Orhun Kantarci, Darin Okuda, Daniel Pelletier, Observatoire Francop (OFSEP), Société Francophone (SFSEP), Radiologically Isola (RISC), Pediatric Radiologic Consortium (PARIS)

1:48 p.m.

1:24 p.m.

S50.003

Validation of a Porcine Model for White Matter Developmental Trajectories —Kelsey Cacic, John Sladky, Stephen McGuire

1:36 p.m.

S50.004

Pineal cysts: a long term follow-up —Sarah Wright, Zoe S50.005

LGI1 Limbic Encephalitis after Interleukin-2 Therapy —Bahar Beaver, Sarah Burbank, Emily Tharp, Aimee Szewka

2:00 p.m.

S50.006

Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis: Crest-2 —James Meschia,

Brajesh Lal, George Howard, Gary Roubin, Robert Brown, Kevin Barrett, Seemant Chaturvedi, Marc Chimowitz, Bart Demaerschalk, Virginia Howard, John Huston, Ronald Lazar, Wesley Moore, Claudia Moy, Tanya Turan, Jenifer Voeks, Thomas Brott

2:12 p.m.

S50.007

Baseline cognitive function among participants in the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (Crest-2) —Ronald

Lazar, Virginia Wadley, Randolph Marshall, George Howard, Virginia Howard, James Meschia, Jenifer Voeks, Ya Yuan, Brajesh Lal, Donald Heck, Michael Jones, Thomas Brott

2:24 p.m.

S50.008

Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan Compared to Placebo for Acute Treatment of Migraine — Linda Wietecha, Bernice Kuca, Josephine Asafu-Adjei, Sheena K. Aurora

2:35 p.m.

Discussion

S51.003

MRI Contributions to the Diagnosis of Multiple Sclerosis in Children —Giulia Fadda, Robert Brown, Giulia Longoni, Denise

Castro, Julia O’Mahony, Leonard Verhey, Helen Branson, Amit Bar-Or, Ruth-Ann Marrie, E. Ann Yeh, Sridar Narayanan, Douglas Arnold, Brenda Banwell

1:36 p.m.

S51.004

Patterns of Use and Safety of Newer Disease-modifying therapies in Pediatric Multiple Sclerosis in the US —Kristen

Krysko, Jennifer Graves, Mary Rensel, Gregory Aaen, Leslie Benson, Tanuja Chitnis, Mark Gorman, Manu Goyal, Yolanda Harris, Lauren Krupp, Timothy Lotze, Soe Mar, Manikum Moodley, Moses Rodriguez, John Rose, Teri Schreiner, Bianca Weinstock-Guttman, Michael Waltz, Theron Casper, Emmanuelle Waubant

1:48 p.m.

S51.005

Effects of Fingolimod on MRI Outcomes in Patients with Pediatric Onset Multiple Sclerosis: Results from Phase 3 PARADIGMS Study —Douglas Arnold, Brenda Banwell, Amit Bar-

S52 MS and CNS Inflammatory Disease: Basic Science

3:30 p.m.

S52.001

Antibodies specific for myelin proteolipid protein can inhibit remyelination in vivo. —Bridget Bagert, Judith Greer, Hannah Savage, Shannon Beasley, Gracy Juba, Michael Pender

3:42 p.m.

S52.002

Immune Cell Profiling during Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of non-T Cell Populations into the CSF - Results from the ToFingo Successor Study —Lisa Lohmann, Claudia Janoschka, Andreas

Schulte-Mecklenbeck, Svenja Klinsing, Timo Wirth, Tilman SchneiderHohendorf, Nicholas Schwab, Catharina Groß, Maria Eveslage, Sven Meuth, Heinz Wiendl, Luisa Klotz

3:54 p.m.

S52.003

Anti-CD20 Antibodies Ofatumumab and Ocrelizumab Have Distinct Effects on Human B-cell Survival —Thalia Pacheco-

Fernandez, Ismahane Touil, Celine Perrot, Gaelle Elain, David Leppert, Anis Mir, Gisbert Weckbecker

4:06 p.m.

S52.004

Immunopathology of Neurosarcoidosis: an Uncommon but Significant Neuroinflammatory Disorder —Lucia Sablich, Laura Munoz-Arcos, Fausto Rodriguez, Carlos Pardo-Villamizar

4:18 p.m.

S52.005

Neuronal Intermediate Filament Autoimmunity —Eati Basal,

Thomas Kryzer, Divyanshu Dubey, Yong Guo, Shannon Hinson, Masoud Majed, Eduardo Benarroch, Claudia Lucchinetti, Sean Pittock, Vanda Lennon, Andrew McKeon

4:30 p.m.

S52.006

NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody —Manish Malviya, Sumanta Barman, Kristin Golombeck, Kim Kristin Falk, Jesús Planagumà, Francesco Mannara, Nathalie Strutz-Seebohm, Guiscard Seebohm, Frank Leypoldt, Sven Meuth, Heinz Wiendl, Hans-Peter Hartung, Josep Dalmau, Nico Melzer, Norbert Goebels

4:42 p.m.

S52.007

Or, Angelo Ghezzi, Benjamin Greenberg, Emmanuelle Waubant, Gavin Giovannoni, Jerry Wolinsky, Jutta Gaertner, Kevin Rostasy, Lauren Krupp, Marc Tardieu, Wolfgang Brueck, Tracy Stites, Yu Chen, Martin Merschhemke, Tanuja Chitnis

Cladribine for the Effective Control of Multiple Sclerosis via Memory B Cell Depletion —Bryan Ceronie, Nicolas Dubuisson,

2:00 p.m.

4:54 p.m.

WITHDRAWN

5:05 p.m.

Discussion

S51.006

Educational Achievement Data is a Patient-Relevant Outcome in Pediatric Multiple Sclerosis —Wendy Vargas,

SCIENTIFIC PLATFORM SESSIONS

1:00 p.m.–3:00 p.m.

Benjamin Jacobs, Zhifeng Mao, Francesca Ammoscato, Helen Lock, Hilary Longhurst, Gavin Giovannoni, David Baker, Klaus Schmierer

Victoria Leavitt, James Sumowski, Hannah Street, Gabriella Tosto, Ji Lee, Brenda Banwell, Philip De Jager

2:12 p.m.

S51.007

The Impact of Occipital Cortical Mantle Thinning on Visual Processing in Pediatric Multiple Sclerosis —Amy Waldman, Jack Sollee, Amy Lavery, Krystle Karoscik, Geraldine Liu, Russell Shinohara, Brenda Banwell, Ritobrato Datta

2:24 p.m.

S51.008

Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) associated disease —Yael Hacohen, Wong Yuyi,

2:35 p.m.

= Abstract of Distinction

Friday

Christian Lechner, Maciej Jurynczyk, Sukhvir Wright, Bahadir Konuskan, Anne lisa Poulat, Helene Maurey, Evangeline Wassmer, Cheryl Hemingway, Eva Maria Hennes, Maria Leite, Olga Ciccarelli, Banu Anlar, Rogier Hintzen, Romain Marignier, Jacqueline Palace, Matthias Baumann, Kevin Rostasy, Rinze F Neuteboom, Kumaran Deiva, Ming Lim

Discussion

AAN.com/view/AM18 117

SCIENTIFIC PLATFORM SESSIONS

SCIENTIFIC PLATFORM SESSIONS 3:30 p.m.–5:30 p.m. S53 Epilepsy/Clinical Neurophysiology (EEG) III

3:30 p.m.

3:30 p.m.–5:30 p.m.

S53.001

BDNF rs6265 Met and COMT rs4680 Val are Associated with Psychiatric Symptomatology in Pharmacoresistant Epilepsy —Christine Doherty, Olivia Hogue, Jessica Altemus, Imad Najm, Charis Eng, Robyn Busch

3:42 p.m.

S53.002

Alternative Trial Methodology in Pediatric Epilepsy Clinical Trials - Time to “Nth” Seizure Analysis in Children with Partial Onset Seizures Treated With Pregabalin —Jeremias Antinew, Lloyd Knapp, Mary Almas, Jing Liu, Joseph Scavone, B. Parsons

3:54 p.m.

S53.003

Fracture Risk and Bone Health in Veterans Treated for Epilepsy —Anne Van Cott, Robert Adler, Kathy Tortorice, Mary Jo Pugh, Barry Gidal, Diane Dong, Francesca Cunningham

4:06 p.m.

S53.004

Antiseizure properties of cannabidiol (CBD) are attenuated in the absence of transient receptor potential vanilloid 1 (TRPV1) receptors —Benjamin Whalley, Royston A. Gray, Colin Stott, Nicholas Jones

4:18 p.m.

S53.005

Antisense Oligonucleotide Therapy for Lafora Disease —

Saija Ahonen, Tamar Grossman, Julie Turnbull, Holly Kordasiewcz, Melanie Katz, Michael McCaleb, Peixiang Wang, Xiaochu Zhao, Berge Minassian

4:30 p.m.

S53.006

Dynamic Causal Modeling Reveals Altered Effective Connectivity Between Contralateral Hippocampus and Default Mode Network in Temporal Lobe Epilepsy —

Mariana Vallim, Tamires Zanão, Akari Ishikawa, Jose Carlos Moreira, Matheus Zabin, Danielle Garcia, Fernando Cendes, Aluisio Pinheiro, Clarissa Yasuda

S54 Ischemic Stroke Prevention

3:30 p.m.

S54.001

Effect of Extended Thromboprophylaxis with Non-Vitamin K Antagonist Oral Anticoagulant on the Risk of Stroke and Major Bleeding in Acutely Ill Hospitalized Medical Patients: A Meta-Analysis of Randomized Controlled Trials —Jolanta

Marszalek, Adeel Jamil, Umer Jamil, Sunny Kumar, Farima Kahe, Zahra Karimi, Gerald Chi

3:42 p.m.

S54.002

Interarm Systolic and Diastolic Blood Pressure Difference Is Diversely Associated With Cerebral Atherosclerosis in Noncardioembolic Stroke Patients —Yoonkyung Chang, Soo Mee Lim, Yong-Jae Kim, Tae-Jin Song

3:54 p.m.

S54.003

4:06 p.m.

S54.004

Systematic Review and Meta-Analysis of Randomized Control Trials Examining Efficacy of CPAP for Prevention of Stroke in Patients with Moderate to Severe Obstructive Sleep Apnea —Nida Faheem, Suzanne Stevens Are SNPs associated with large artery disease in Caucasians also significant in intracranial atherosclerotic disease? —Thomas Leung, Elvis Dong, Bonaventure Ip, Hing Lung Ip, Yannie Soo, Ronald CW Ma, Ricard KW Choy

4:18 p.m.

S54.005

Influence of on-going Treatment with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker on the Outcome of Patients treated with Intravenous rt-PA for Ischemic Stroke —Sixtine GILLIOT, Igor

Sibon, Jean-Louis Mas, Thierry Moulin, Yannick Bejot, Charlotte Cordonnier, Maurice Giroud, Pascal ODOU, Regis Bordet, Denis Vivien, Didier Leys

4:30 p.m.

S54.006

Electrographic Correlates of Clinical Seizures —Sharanya

Left Atrial Dilatation: A Cohort Analysis With Strong Implications For Future Atrial Fibrillation And Stroke Monitoring. —Muhammad Affan, Sumul Modi, Lonni Schultz,

4:54 p.m.

4:42 p.m.

S53.007

Desai, Thomas Tcheng, Martha Morrell

S53.008

Sleep in Patients with Psychogenic Non-Epileptic Seizures: Time to raise the red flag —Veronique Latreille, Gaston Baslet, Rani Sarkis, Milena Pavlova, Barbara Dworetzky

5:05 p.m.

Discussion

Abhimanyu Mahajan, Daniel Miller

S54.007

Device closure of patent foramen ovale reduces the risk of stroke compared to medical therapy in patients with cryptogenic ischaemic stroke and PFO: a meta-analysis — Yao Feng Victor Chong, Bernard Chan

4:54 p.m.

S54.008

Therapeutic Regimen of L-arginine for Patients with MELAS: 9-year, Prospective, Multicentre, Clinical Research Integrating the Data from Two 2-year Clinical Trials with 7-year Follow-up —Yasutoshi Koga, Nataliya Povalko, Eisuke Inoue, Hidefumi Nakamura, Akiko Ishii, Yasuhiro Suzuki, Makoto Yoneda, Fumio Kanda, Masaya Kubota, Hisashi Okada, Katsunori Fujii

5:05 p.m.

Friday 118 2018 AAN Annual Meeting

Discussion

Friday, April 27

Joint AAN/AHA/ASA Session Wednesday, April 25, 3:30 p.m. – 5:30 p.m. Bridging Racial and Ethnic Disparities in the Management of Stroke

Breakthroughs in Engaging Minority and Rural Communities in Stroke Studies

3:30 p.m. – 3:45 p.m.

4:30 p.m. – 4:45 p.m.

State of Racial and Ethnic Disparities in Stroke

3:45 p.m. – 4:00 p.m. hat More Can Be Done to Address Racial and Ethnic Disparities W in Stroke?

4:00 p.m. – 4:15 p.m. Avenues to Engage in Stroke Disparities Research

4:15 p.m. – 4:30 p.m. bstacles and Opportunities in Stroke Care Access Among Racial O and Ethnic Minorities

L earning About Your Community (and Establishing a Community Advisory Board)

4:45 p.m. – 5:00 p.m. Captivating the Community and Sustaining Ties

5:00 p.m. – 5:15 p.m. Building Trust with Your Community Through Communication

5:15 p.m. – 5:30 p.m. Dissemination of Results and Presenting Information

AAN.com/view/AM18 119

POSTER SESSION FLOOR PLAN AND SCHEDULE Poster Session I Sunday, April 22, 11:30 a.m.–5:30 p.m. Presenters Stand by Posters 4:00 p.m.–5:30 p.m. Poster Session II Monday, April 23, 11:30 a.m.–7:00 p.m. Presenters Stand by Posters 5:30 p.m.–7:00 p.m. Poster Session III Tuesday, April 24, 11:30 a.m.–7:00 p.m. Presenters Stand by Posters 5:30 p.m.–7:00 p.m. Poster Session IV Wednesday, April 25, 11:30 a.m.–7:00 p.m. Presenters Stand by Posters 5:30 p.m.–7:00 p.m. Poster Session V Thursday, April 26, 11:30 a.m.–7:00 p.m. Presenters Stand by Posters 5:30 p.m.–7:00 p.m. Poster Session VI Friday, April 27, 11:30 a.m.–5:30 p.m. Presenters Stand by Posters 4:00 p.m.–5:30 p.m.

9 28 0 29 1 29 2 29 3 29 4 29

20 20 20 20 20 20 1 2 3 4 5 6 21 21 21 20 20 20 2 1 0 9 8 7 21 21 21 21 21 21 3 4 5 6 7 8 22 22 22 22 22 21 4 3 2 1 0 9 22 22 22 22 22 23 23 5 6 7 8 9 0 1 23 23 23 23 23 23 23 8 7 6 5 4 3 2 23 24 24 24 24 9 0 1 2 3 24 24 24 24 24 8 7 6 5 4 24 25 25 9 0 1 25 25 25 4 3 2 25 25 5 6 25 25 8 7

8 28 7 28 6 28 5 28 4 28 3 28

17 17 17 16 16 16 2 1 0 9 8 7 16 16 16 16 16 16 1 2 3 4 5 6 16 15 15 15 15 15 0 9 8 7 6 5 14 15 15 15 15 15 9 0 1 2 3 4 14 14 14 14 14 14 8 7 6 5 4 3 13 13 13 14 14 14 7 8 9 0 1 2 13 13 13 13 13 13 6 5 4 3 2 1 12 12 12 12 12 13 5 6 7 8 9 0 12 12 12 12 12 11 4 3 2 1 0 9 11 11 11 11 11 11 3 4 5 6 7 8 11 11 11 10 10 10 2 1 0 9 8 7 10 10 10 10 10 10 6 5 4 3 2 1 10 9 9 9 9 0 9 8 7 6 91 92 93 94 95

7 27 8 27 9 27 0 28 1 28 2 28

8 33 7 33 6 33 5 33 4 33 3 33 2 33 1 33 0 33 9 32 8 32

340 339

342

7 31 8 31 9 31 0 32 1 32 2 32 3 32 4 32 5 32 6 32 7 32

b1 g1 a1 88

343

ePosters

344

32 36 35 34 33 31 27 28 29 30

9 60 4 0 59 5 1 58 5 2 57 5 3 56 5 4 55 5 7 48 3 8 47 3 9 46 3 0 45 4 1 44 4 2 43 4

24 20

16 19 15 17 10 14 18 9 11 13 8 12 4 7 3 5 2 6 1

25 23

34 34 34 34 8 7 6 5 34 35 35 35 9 0 1 2 35 35 35 35 35 35 8 7 6 5 4 3 35 36 36 36 36 36 9 0 1 2 3 4 37 37 37 36 36 36 36 36 2 1 0 9 8 7 6 5 37 37 37 37 37 37 37 38 3 4 5 6 7 8 9 0 38 38 38 38 38 38 38 38 8 7 6 5 4 3 2 1 38 39 39 39 39 39 39 39 9 0 1 2 3 4 5 6 40 40 40 40 40 39 39 39 4 3 2 1 0 9 8 7 40 40 40 40 40 41 41 41 5 6 7 8 9 0 1 2 42 41 41 41 41 41 41 41 0 9 8 7 6 5 4 3 42 42 42 42 42 42 42 42 1 2 3 4 5 6 7 8

Poster Discussion

1 72 6 2 71 6 3 70 6 4 69 6 5 68 6 6 67 6

120 2018 AAN Annual Meeting

6 27 5 27 4 27 3 27 2 27 1 27

6 31 5 31 4 31 3 31 2 31 1 31 0 31 9 30 8 30 7 30 6 30

341

3 84 7 4 83 7 5 82 7 6 81 7 7 80 7 8 79 7

F G

5 29 6 29 7 29 8 29 9 29 0 30 1 30 2 30 3 30 4 30 5 30

ePosters

5 26 6 26 7 26 8 26 9 26 0 27

4 26 3 26 2 26 1 26 0 26 9 25

197 188 196 198 187 189 195 199 194 200 178 186 190 177 179 185 191 193 176 180 184 192 175 181 183 174 182 173

434 439 433 440 432 454 457 453 441 431 458 452 442 430 443 429 469 459 451 470 468 460 450 444 471 467 461 449 462 438 477 472 466 445 437 478 476 473 465 446 479 475 474 436 456 463 455 447 435 480 448 464

POSTER SESSIONS

e are once again grouping topic-related posters together into “neighborhoods” to enhance your discussions and make the posters easier to navigate. Please see floor plan on the previous page.

Check out the interactive, touchscreen e-posters at the virtual hall kiosk for another great opportunity to view scientific posters. And if you can’t get enough cutting-edge science, join the quick lunchtime Poster Discussion Session! A group of 10 abstracts will be presented as both a data blitz and a poster with a moderator leading stimulating discussion on the content of the selected posters.

Poster Session I

Sunday, April 22 . . . . . . . . . . . . . . 122

Poster Session II

Monday, April 23 . . . . . . . . . . . . . . 132

Poster Session III

Tuesday, April 24 . . . . . . . . . . . . . . 142

Poster Session IV

Wednesday, April 25 . . . . . . . . . . . .

Poster Session V

Thursday, April 26 . . . . . . . . . . . . .

152 162

Poster Session VI

Friday, April 27 . . . . . . . . . . . . . . . 172

AAN.com/view/AM18 121

POSTER SESSIONS

POSTER SESSION I

EDUCATION: PATIENTS

P1.010 Teaching Psychiatrists Neurology

P1.001 Development and Preliminary

Nuri Jacoby, Neel Dixit, Daniel Shalev

Results of a Community-Partnered Stroke Preparedness Intervention in Chicago —

Neelum Aggarwal, Sarah Song, Soyang Kwon, Erin Wymore, Namratha Kandula, Jen Brown, Amy Eisenstein, Christopher Richards, Maryann Mason, Peggy Jones, Heather Beckstrom, Knitasha Washington, Shyam Prabhakaran

P1.002 Headache and Arts Program:

Headache and Concussion Education in High School Visual Arts Classes —Alexandra Boubour, Mia Minen

P1.003 Readability assessment of

online Essential Tremor patient educational resources —Keerthana Nalamada, Amar Patel

P1.004 Professional Art Therapy and

Visuospatial Exploration in Parkinson’s Disease: An Experimental Protocol and Preliminary Feasibility Data. —Alberto Cucca, Daniella F Mania, Ikuko Acosta, Marygrace Berberian, Hilary C Bertish, Todd Hudson, Amy Lemen, John-Ross Rizzo, Milton Biagioni, Alessandro Di Rocco

P1.005 Youth Stroke Education Series —

Lucy Fell, Nicte Mejia

through E-Learning: A Model Curriculum —

P1.011 Understanding Resident Workflow and Educational Experience to Implement Advanced Practice Clinicians Into Neurology Residency Training Programs —

173–200

ePosters

085–090

P1.012 A Pilot Neurology Curriculum To

Train Advanced Practice Clinicians Joining An Inpatient Stroke Service At A Busy Tertiary Care Center —Anna Pace, Laura Stein,

037–084

Stephen Krieger, Mandip Dhamoon

P1.013 Developing a Comprehensive

Pre-Residency Acclimatizing Program for International Medical Graduates —Raghav Govindarajan, Penny McQueen, Pradeep Bollu, Pradeep Sahota

P1.014 Impact on Education and Quality

of Care of a Neurology Free Clinic in Bogota, Colombia —Jaime Toro, Manuel Yepes, Fabián

Cortés, Camilo Diaz-Cruz, Saul Reyes, Maria ReyesMantilla, David Cuellar Giraldo, Lisseth Burbano, Jorge Patiño, Alejandra Duque Ramirez

P1.006 Internet Search Behavior Trends

Saeed Ansari, Rashi Krishnan, Sarah Ganji, Vida Abedi, Katherine Nearing, Andrie Alexandrov, Ramin Zand

P1.015 Integrative Medicine in Child Neurology: What do providers think and what do they need to learn? —Amanda Sandoval Karamian, Ann Ming Yeh, Courtney

P1.007 Clinics as classrooms: Assessing Wusthoff patient knowledge and satisfaction following P1.016 Improving Resident Knowledge of stroke video education —Sarah Tisel, Abigail Rieman, Matthew Hodges, Rishi Desai, M. Ryan Haynes, Kelly Gwathmey

Healthcare Business and Policy through the Development of a High-yield and Dynamic Educational Series —John Legge, Scott Vota

EDUCATION: NURSING, APPS, AND OTHERS

P1.017 Autism Spectrum Disorder (ASD) knowledge variation and gaps in adult neurology residents —Surabhi Kaul, Pauline

Sunday

P1.008 Analysis of Early Post-Training Research Activity: The Effect of the Critical Years on Later Success of PhysicianScientists —Wyatt Bensken, Alexandra Hansen,

091–172

Laura Stein, Anna Pace, Mandip Dhamoon, Stephen Krieger

EDUCATION: NEEDS ANALYSIS AND NOVEL FIELDS

for Public Education in Neurology Field —

Sunday, April 22 11:30 a.m.–5:30 p.m.

Filipek

P1.018 Knowledge of Genetics and

Genetic Testing In an Academic Neurology

Gina Norato, John Heiss, Avindra Nath, Omar Khan Setting —Sami Bajwa, Anthony Geraci, Laura Ragoonanan P1.009 Improving Confidence in

Nurses When Performing a Neurological P1.019 Targeted Needs Assessment Assessment —Scott Le, Leigh Allen, Jeffrey Clark for a Competency-Based “Boot Camp” Curriculum for First-Year Neurology

201–258

b1 g1 339–344 a1 ePosters

Poster Discussion

027–036

001–026

259–294

295–338

345–428

429–480

Poster Session 1 A. Research Methodology, Education, and History: 001 – 026

a1. Epilepsy/Clinical Neurophysiology (EEG) Poster Discussion Session: 027 – 036 B. Movement Disorders: 037 – 084

b1. MS and CNS Inflammatory Disease ePoster Session: 085 – 090 C. D. E. F. G.

Sleep; Neuroepidemiology; General Neurology: 091 – 172 Aging, Dementia, Cognitive, and Behavioral Neurology: 173 – 200 Cerebrovascular Disease and Interventional Neurology: 201 – 258 Epilepsy/Clinical Neurophysiology (EEG): 259 – 294 General Neurology: 295 – 338

g1. Neuromuscular/Clinical Neurophysiology (EMG) ePoster Session: 339 – 344 H. MS and CNS Inflammatory Disease: 345 – 428 I. Neuromuscular/Clinical Neurophysiology (EMG): 429 – 480

Residents —Seraj Makkawi, Michael Yeung, Alexandra Harrison, Lara Cooke

P1.020 A single institutional study

of neurology residents to evaluate the advantages of neuro-oncology didactics during training and understand field-specific attitudes —Aubree Bruhnding, Elizabeth Neil

P1.021 Awakening European

Neurology—Sleep Education in Neurology

(SEN) survey —Martin Rakusa, Mariusz

Sieminski, Fabio Pizza, Sofia Gak, Cristian FalupPecurariu, Ulf Kallweit

P1.022 NA P1.023 NA P1.024 NA P1.025 NA P1.026 NA

Epilepsy/Clinical Neurophysiology (EEG) Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below.

Posters displayed 11:30 a.m.-5:30 p.m. • Data blitz 12:00 p.m.-12:50 p.m. • Presenters Stand by Posters 4:00 p.m.-5:30 p.m. Data Blitz: 12:00 p.m.–12:05 p.m.

P1.027 Safety, tolerability, and cognitive

Zachary Stowe, D. Jeffrey Newport, James Ritchie, of Refractory Epilepsy on Health-Related Page Pennell Quality of Life (HRQoL) —Menno Vergeer, Wendela L. de Ranitz-Greven, Maureen Neary, Data Blitz: 12:15 p.m.–12:20 p.m. Raluca Ionescu-Ittu, Bruno Emond, Mei-Sheng P1.030 Response to Pharmaceutical Duh, Bernard Zonnenberg

and behavioral effects of long-term adjunctive lacosamide in children and adolescents with focal seizures —Brian Potter, Formulation of Purified Cannabidiol (CBD) in Data Blitz: 12:30 p.m.–12:35 p.m. Cynthia Beller, Simon Borghs, Ali Bozorg, Nancy Pediatric and Adult Patients with TreatmentYuen, Tony Daniels Refractory Epilepsy —Jerzy Szaflarski, E Bebin, P1.033 Automated and Manual Diffusion Tyler Gaston, Leslie Perry Grayson, Yuliang Liu, Tractography in the Presurgical Evaluation of Data Blitz: 12:05 p.m.–12:10 p.m. Gary Cutter Patients with Temporal Lobe Epilepsy —Iren P1.028 Risk of Spontaneous Abortion Orosz, Vishal Patel, Hajime Yokota, Shennan Data Blitz: 12:20 p.m.–12:25 p.m. in Women with Epilepsy: Where do Newer Weiss, Davis Woodworth, Stephanie Moy, Edgar Antiepileptic Drugs Stand? —Madhukar P1.031 Predictors of Response to A. Rios Piedra, Itzhak Fried, Anatol Bragin, Richard Trivedi, Manna Jose, Helen Simson Babyratnam, Staba, Jerome Engel, Gary Mathern, Noriko Placebo in Phase III Trials of Adjunctive Sankara Sarma, Sanjeev Thomas Eslicarbazepine Acetate (ESL) —JungAh Jung, Salamon David Blum, Todd Grinnell, Hailong Cheng Data Blitz: 12:10 p.m.–12:15 p.m. Data Blitz: 12:35 p.m.–12:40 p.m. Data Blitz: 12:25 p.m.–12:30 p.m. P1.029 Levetiracetam, Oxcarbazepine P1.034 Surgical Success After Epilepsy and Topiramate Clearance Changes During P1.032 Tuberous Sclerosis Complex (TSC) Re-operations —Ruta Yardi, James Bena, Pregnancy —Paula Voinescu, Suna Park, Li Chen, and Epilepsy Manifestations: The Impact

122 2018 AAN Annual Meeting

Imad Najm, Jorge Gonzalez-Martinez, William Bingaman, Shannon Morrison, Lara Jehi

Data Blitz: 12:40 p.m.–12:45 p.m.

P1.035 Towards Improved Diagnosis

in Epilepsy —Robert Yao, Lidia Csernak, Edgar

Salinas, Neel Mehta, Erin Okazaki, Joseph Sirven

Data Blitz: 12:45 p.m.–12:50 p.m.

P1.036 A Common Data Language for

Clinical Research Studies: The National Institute of Neurological Disorders and Stroke Updates to Epilepsy Common Data Element Recommendations —Joy Esterlitz,

Muniza Sheikh, Joan Austin, Jacqueline French, Nicholas Barbaro, Daniel Lowenstein, Sherita Alai, Sarah Tanveer, Vicky Whittemore

PARKINSON’S DISEASE: NONMOTOR MANIFESTATIONS

P1.037 Heart Rate Variability (HRV)

from a 10-second Electrocardiogram (ECG) in Parkinson’s Disease (PD) and Control —

Samuel Goldman, Ahro Kim, Chen Meng, Kathleen Comyns, Helen Petrovitch, Caroline Tanner, Robert Abbott, Web Ross

P1.038 Non-motor Symptoms (NMS)

Improvement is Positively Correlated with Baseline NMS Burden and Improved Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-carbidopa Intestinal Gel: A Post-hoc Analysis from the GLORIA Registry —Werner Poewe, Lars Bergmann, Angelo Antonini, Kallol Chaudhuri

P1.049 Bilateral downward finger

displacement in Parkinson disease may be a sign of worsening dementia and a bedside test to distinguish it from Alzheimer’s disease —Aman Deep, Abraham Lieberman, Talal Aboud, Rohit Dhall, Jiong Shi

P1.059 Calcium derangement and

P1.070 Multimodal Neuroimaging

Paul, Warunee Dansithong, Karla Figueroa, Daniel Scoles, Stefan Pulst

Piccinin, Thiago Rezende, Patrick Dion, Guy Rouleau, Marcondes Franca, Orlando Barsottini, Jose Luiz Pedroso

STAU1-dependent ER stress in an in vitro model of SCA2 —Mariana Gandelman, Sharan

P1.060 Evaluation Of Various Movement

Disorders In Patients Of Genetically Proven Spino Cerebellar Ataxia (SCA) : Study From disease patients with and without Visual Hallucinations: A Retrospective Case Control A Tertiary Care Center In Northern India — Divya MR, Vinay Goyal, Achal Srivastava, Garima study —Dharampreet Singh, Guy Schwartz

P1.050 EEG findings in Parkinson

P1.051 No Postural Stability Differences

Shukla, Madhuri Behari

P1.061 Characterization of The between Asymptomatic and Symptomatic Brazilian ARSACS Phenotype: Clinical, Neurological Orthostatic Hypotension in Parkinson’s disease—A Pilot Study —Victoria Ophthalmological, Neuroimaging, and Genetic Features of Fourteen Cases. —Flavio Smith, Christopher Frames, Markey Olson, Thurmon Lockhart, Abraham Lieberman

Rezende Filho, Jose Luiz Pedroso, Juliana Maria Sallum, Fernando Kok, Marcondes Franca, Ingrid De Vasconcellos, Wilson Marques, Charles Lourenco, Paola Giunti, Orlando Barsottini

P1.039 Effects of ADS-5102 on non-

P1.052 Increased Frequency of Suicide

Mehta, Rajesh Pahwa, Caroline Tanner, Robert Hauser, Reed Johnson, Lily Llorens, Rajiv Patni

Anat Mirelman, Roy Alcalay, Sonya Elango, Deborah Raymond, Mark Groves, Nir Giladi, Karen Marder, Susan Bressman, Rachel SaundersPullman

P1.062 A Longitudinal Assessment of

P1.053 A Multivariate Analysis of the

P1.063 TRIO Gene Segregation in a

motor symptoms (NMS) in Parkinson’s disease patients with dyskinesia —Shyamal

P1.040 Clinical Experience with

Pimavanserin for Treatment of Parkinson’s Disease Psychosis —Jessie Sellers, Richard Darby, Daniel Claassen

P1.041 Color vision and contrast

sensitivity in Parkinson Disease —Gupta

Harsh, Nan Zhang, Thomas Beach, Charles Adler

P1.042 A Network Meta-analysis of

Droxidopa and Midodrine for the Treatment of Neurogenic Orthostatic Hypotension —

Jack Chen, Jonathan Tang, Khashayar Dashtipour

P1.043 Cognitive performance and

In First Degree Relatives of LRRK2 G2019S Mutation Parkinson Disease —Robert Ortega,

Effects of Physical Activity and Cognition on Resting-State Brain Networks in Parkinson’s Patients with and without Mild Cognitive Impairment —Behnaz Jarrahi, Andrew Petkus,

Kristen Sundvick, Jiayue Cai, Daryl Wile, Adam Book, Z.J. Wang, Martin McKeown, Silke Cresswell

Huether, Sarah Matcha, Tanya Harlow, Danelle Staebler, Jau-Shin Lou

ATAXIAS I Symptoms of Dysphonia and Dysphagia in P1.057 Prevalence of spinocerebellar Movement Disorder Patients at an Academic ataxia 36 in a US population —Juliana Valera, Medical Center —Mary Finger, Mustafa Tatyana Diaz, Lauren Petty, Beatriz Quintáns,

P1.045 Prevalence of Patient-Reported

Siddiqui, Jessica Tate, Ihtsham Haq, Lyndsay L. Madden

and The Risk of Cerebellar Ataxias: A Systematic Review and Meta-analysis —ChiYing Lin, Min-Jung Wang, Winona Tse, Rachel Pinotti, Sheng-Han Kuo

P1.072 Sleep and Fatigue in Friedreich’s

Ataxia —Addie Patterson, Leonardo Almeida, Erin Hastings, Jen Farmer, S Subramony

P1.073 Lack of Placebo Effect in Fragile X-associated Tremor/Ataxia Syndrome —

Emily Hill, Bichum Ouyang, Randi Hagerman, Jennifer Cogswell, Patrick Adams, Deborah Hall

Family with Cerebellar Ataxia —Rana Hanna AL-Shaikh, Audrey Strongosky, Mavis Matthew, Paldeep Atwal, Ryan Uitti, Zbigniew Wszolek

P1.064 A comparative study of the

P1.065 Quality of life in Spinocerebellar Ataxia type 10 —Nathália Bergamasco,

Napierala

P1.075 Strong correlations observed

among four measures of disease progression in Friedreich’s ataxia —Harry Saal, Frederic Heerinckx, Rezi Zawadzki, Omid Omidvar, Marcus Kilpatrick, Theresa Zesiewicz

P1.076 Spinocerebellar ataxia type 2:

The second most frequent dominant ataxia in Peru —Erick Figueroa-Ildefonso, Karina Milla-

Neyra, Miguel Inca-Martinez, Victoria Marca, Olimpio Ortega-Davila, Elison Sarapura Castro, Maryenela Illanes-Manrique, Maria-Luiza SaraivaPereira, Laura Jardim, Mario Cornejo Olivas

Laudiane Santos, Marise Zonta, Ana Carolina P1.077 Progressive motor and balance Macedo, Francisco Germiniani, Helio Afonso Teive, impairment in Spinocerebellar Ataxia type Tetsuo Ashizawa 10 —Nathalia Bergamasco, Katia Konno, Marise P1.066 Quantitative oculomotor Zonta, Gustavo Ribas, Francisco Germiniani, Tetsuo Ashizawa, Helio Afonso Teive assessment and non-motor biomarkers

in late-onset Tay-Sachs and Sandhoff disease —Christopher Stephen, David Balkwill,

P1.078 Cerebellar Degeneration and

P1.067 Spinocerebellar Ataxias—

Thiago Vale, Jose Luiz Pedroso, Gustavo Ribas, Júlio Kristochik, Maria Cristina Domingues da Silva Fink, Augusto Cesar Penalva de Oliveira, Helio Afonso Teive, Orlando Barsottini

Rodrigues, Fernando Castilho Pelloso, Salmo Raskin, Helio Afonso Ghizoni Teive

P1.079 Nocturnal Hyperkinetic Spells

Peter James, Kenneth Sassower, Jeremy Schmahmann, Richard Lewis, Florian Eichler

Genotypical and Phenotypical Evaluation of 213 Brazilian Families —Vinicius Oliveira Rocha

Progressive Ataxia Associated With HIVVirus Infection —Maria Thereza Drumond Gama,

in Dentatorubral Pallidoluysian Atrophy —

P1.068 Fragile X Low Normal Alleles are Deepmala Nandanwar, Edwin George, Maysaa not associated with Cognitive Dysfunction in Basha

Zuleima Yáñez, Eric Boerwinkle, Donna Muzny, an Elderly Community Population —Deborah Dmitry Akhmedov, Rebecca Berdeaux, Maria Jesus Hall, Aisha Ali, David Bennett, Lili Zhou, Elizabeth Sobrido, Richard Gibbs, James Lupski, Daniel Berry-Kravis P1.046 The Prevalence and Geschwind, Susan Perlman, Piper Below, Brent Characteristics of Probable REM behavior P1.069 Relevance of Superior Vertical disorder in Thai Parkinson Patients. —Patama Fogel Ophthalmoparesis in the Diagnosis of Gomutbutra P1.058 Omaveloxolone Increases Spinocerebellar Ataxia type 3 —Bruno Carniatto Marques Garcia, Fabio Nascimento, P1.047 Is Excessive Daytime Sleepiness Nrf2 Activity, Reduces Inflammation, And Improves Mitochondrial Function In Cultured Francisco Germiniani, Marcia Olandoski, Helio Related to Nocturnal Sleep in Parkinson’s Cell Models Of Friedreich’s Ataxia. —Brandon Afonso Teive Disease? —Aliya Sarwar, Suzanne Moore, Max Probst, Lyndsey McCauley, Deborah Ferguson, Hirshkowitz Christian Wigley

P1.080 Autoimmune Cerebellar Ataxia Associated With Anti-GRAF1 Antibody — Chaitanya Amrutkar, Erik Burton

P1.081 WITHDRAWN P1.082 NA P1.083 NA P1.084 NA

P1.048 WITHDRAWN

AAN.com/view/AM18 123

Sunday

symptoms of anxiety, depression, and apathy Jessika Suescun, Richard Castriotta, Timothy in Parkinson’s patients with and without mild Ellmore cognitive Impairment. —Andrew Petkus, J. P1.055 Somatic items on the Beck Vincent Filoteo, Dawn Schiehser, Megan Gomez, Depression Inventory-II do not affect selfJennifer Hui, Behnaz Jarrahi, Sarah McEwen, reported depression severity in Parkinson’s Giselle Petzinger disease —Veronica Ramirez, Taylor R. Hendershott, Nazlie Faridi, Delphine Zhu, Lu Tian, P1.044 Patterns of responses on Kathleen Poston the Montreal Cognitive Assessment in Parkinson’s Disease Associated Mild P1.056 Defining Clinically Significant Cognitive Impairment —Melissa Mackenzie, Fatigue in Parkinson’s Disease —Asenath

P1.071 Serum Anti-Gliadin Antibodies

P1.074 Upregulation of Mitochondrial Aldehyde Dehydrogenase Activity Inhibits Spinocerebellar Ataxia types 1, 2, 3, 6 and 17 Lipid Peroxidation in Friedreich’s Ataxia in Taiwan. —Yicheng Lin, Yi-Chung Lee, Yi-Chu Cells —Jill Napierala, Yu-Yun Chen, Marek Liao, Bing-Wen Soong

Megan Gomez, J. Vincent Filoteo, Dawn Schiehser, clinical and electrophysiological features Jennifer Hui, Giselle Petzinger, Sarah McEwen between Friedreich ataxia and Ataxia with isolated vitamin E deficiency in Tunisia — P1.054 Preliminary evidence for an altered relationship between uric acid levels Cyrine Jridi, Haifa Kharrat, Jihene Sassi, Fatma Nabli, Samir Blel, Faycal Hentati and resting state functional connectivity in

REM sleep behavior disorder —Mya Schiess,

Analysis in Brazilian Patients with SYNE1 Ataxia —Maria Thereza Drumond Gama, Camila

POSTER SESSIONS

Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.

POSTER SESSIONS

POSTER SESSION I

b1 C

Sunday, April 22 11:30 a.m.–5:30 p.m.

MS and CNS Inflammatory Disease ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P1.085 Is the neuroradiological

differentiation between M. Fabry and MS possible? —Paulus Rommer, Oliva Fösleitner,

Compared to Multiple Sclerosis and Healthy Control Subjects —Lisa Eunyoung Lee, Jillian

Adriana Delgado, Jayawant Mandrekar, Kenton Kaufman, Lawrence Berglund

Chan, Anthony Traboulsee, Shannon Kolind, Robert P1.088 Effective treatment of CLIPPERS Jakob Rath, Lukas Haider, Gere Sunder-Plassmann, Carruthers with long-term use of rituximab —Veronica Daniela Prayer, Gregor Kasprian P1.087 McArdle’s sign: A specific sign of Penyak Cipriani, Nancy Arndt, Peter Pytel, Anthony P1.086 Quantitative Myelin multiple sclerosis —Brian Weinshenker, Filippo Reder, Adil Javed Measurement in Brain White Matter Tracts Savoldi, Zahra Nasr, Wei Hu, Nathan Schilaty,

of Rare Progressive Solitary Sclerosis,

SLEEP: NEUROLOGY AND SLEEPDISORDERED BREATHING/SLEEP APNEA

Questionnaire —Hye-Jin Moon, Jong-Ho Byun,

P1.112 Drosophila Myc is Involved in Fly Zheng, Amita Sehgal, Chi Dang

P1.091 The Impact of Co-Morbid Sleep

P1.102 Expediting the Diagnosis of

Obstructive Sleep Apnea by Increasing Awareness of the Sleep Laboratory Scheduling Process —Micaela Nannery, Lisa

Apnea and Stroke on the Cost of Health Care —Majaz Moonis, Baqar Husaini

Young Sun Lee, Yong Won Cho

P1.092 Screening for Sleep Apnea in

Park, Chantale Branson, Marianne Kelly, Yelena Pyatkevich, Sanford Auerbach

Irfan

SLEEP: TOO MUCH, TOO LITTLE, ABNORMAL TIMING, AND PARASOMNIAS

Patients with Ischemic Stroke: A Quality Improvement Project —Abby Metzler, Muna

P1.093 Prevalence of High Risk

Obstructive Sleep Apnea and Insomnia P1.103 Improved primary CNS Ascertained by STOP and Insomnia Severity hypersomnia diagnosis with statistical Index in Neurological Populations —Thapanee machine learning —Lan Jiang, Joe Cheung,

Circadian Behavior —Annie Hsieh, Xiangzhong

P1.095 Treatment of Obstructive Sleep

Apnea with Positive Airway Pressure in Mild Cognitive Impairment —Aarushi Suneja, Virginia Skiba, Marina Novikova, Lonni Schultz, Beth McLellan

Sunday

P1.096 A Motivational and Educational

Assessment of Sodium Oxybate (SXB) on Functioning, Productivity, and HealthRelated Quality of Life in Participants With Narcolepsy —Michael Thorpy, Kathleen F. Villa, Jed Black, Shay Bujanover, Miriam G. Cisternas, David J. Pasta, Maurice Ohayon

P1.106 The Nexus Narcolepsy Registry: Toolkit to Improve CPAP Therapy Adherence: Factors Associated With Use of Different Feasibility of Organizational System Medications and Discontinuation Rates in Implementation —Jamie Slettedahl, Andrew Participants With Narcolepsy —Kathleen F. Yantes, Jean Tsai

P1.097 Text Message Reminders and

Intensive Education Improves Positive Airway Pressure Compliance and Cognition in Veterans with Traumatic Brain Injury and Obstructive Sleep Apnea: ANNIE Pilot Study —Lynn Kataria, Cynthia Sundahl, Lauren Skalina, Medha Shah, Michael Pfeiffer, Marshall Balish, Julie Chapman

P1.098 Serotonin Reuptake Inhibitors in Obstructive Sleep Apnea with Depression: Associations in People With and Without Epilepsy —Jocelyn Cheng

P1.099 Polysomnography is Crucial to

the Diagnosis of Sleep Disordered Breathing Syndromes in Patients with Hypermobility Spectrum Disorder —Lauren Babcock, Kelsey

Villa, David J. Pasta, Jed Black, Shay Bujanover, Miriam G. Cisternas, Maurice Ohayon, Michael Thorpy

call for the elderly at a tertiary care centre in Islamabad, Pakistan —Neha Siddiqui, Rahy

Farooq, Salman Mansoor, Maimoona Siddiqui, Shoab Saadat, Zain Ahmad Javed, Arooj Fatimah Shah

P1.109 The Role of Prescription Drugs

P1.123 Insight into the Burden of Opioids on Stroke Patient Outcomes in the United States —Leila Parand, Asad Ikram, Maryam

Contraception in Women with Epilepsy —

P1.124 Changing Trends for

P1.114 Eveningness Chronotype is

Andrew Herzog, Hannah Mandle, Devon MacEachern

Associated with Sleep Disturbances and Depressive Mood in Korean Working Adults —Hye-Jin Moon, Yeong Seon Lee, Yong Won Cho

P1.115 Defining the Pattern of the

Arousal-Related Motor-Behavioral Episodes (AMBEs) in Agrypnia Excitata (AE)-Limbic Autoinmune Encephalopathy (AE-LAE). — Arturo Garay, Susana Blanco

Suescun, Luca Giancardo, Timothy Ellmore, Laura Ocasio, Arash Kamali, Roy Riascos-Castaneda, Mya Schiess

P1.117 Sleep Duration and Cognitive

P1.125 A Neuroepidemiological Review of Childhood Epilepsy in a Children’s Hospital —Arayamparambil Anilkumar, Jeff Swarz

P1.126 The Incidence of First Seizures, New Diagnosis of Epilepsy and Seizure Mimics in County Cork, Ireland; An Epidemiologic Protocol —Eimer Maloney, Daniel Costello

P1.127 Prevalence of Seizures in Patients with Systemic Lupus Erythematosus in Western Mexico. —Adrian Rodriguez

Hernandez, Valeria Diaz-Rizo, Paloma RiveroMoragrega, Ana Paulina Davalos-delaCruz, Alberto Daniel Rocha-Muñoz

Function: Associations in a Nationally Representative U. S. Sample —Dominique

NEUROEPIDEMIOLOGY: MOTOR NEURON DISEASE, COGNITIVE IMPAIRMENT, SLEEP I

NEUROEPIDEMIOLOGY: CEREBROVASCULAR DISEASE AND EPILEPSY

P1.128 Alcohol consumption and

Low, Mark Wu, Adam Spira

P1.118 Let’s Talk About Stroke: A

Retrospective Descriptive Study —Isabel

Pellicer Espinosa, Juan Antonio Iniesta Valera, Noelia García Lax, José Ángel Motos García, María P1.107 Performance of the Patient Global Palao Rico, Eliot Gómez López, Jose Marin, María Luisa Martínez Navarro, Begoña Palazón Cabanes, Impressions—Severity Scale as a SelfJose Manuel Rodriguez Garcia, M.Purificacion reported Patient Assessment of Insomnia Severity —William Herring, Ellen Snyder, Peining Salmeron Ato, Antonio Díaz Ortuño Tao, Vladimir Svetnik, Christopher Lines P1.119 Identification of Potential

P1.108 Poor Sleep Quality: A wake up

Peter Pytel, Anthony Reder, Adil Javed

Thomas Ferree, Shai Gozani, John Winkelman

P1.116 Longitudinal connectome-base metric (STREAM) aids in discerning central biomarker from Diffusion Tensor Imaging disorders of hypersomnolence —Brynn Dredla, for REM Sleep Behavior Disorder —Jessika Joseph Burns, Ronald Chervin, Cathy Goldstein P1.105 The Nexus Narcolepsy Registry:

antibody encephalomyelitis in an adult man —Veronica Penyak Cipriani, Nancy Arndt,

Zulfiqar, Fares Qeadan, Owen Owens, Atif Zafar

P1.094 Performance Characteristics

Somboon, Jay Alberts, Susan Linder, Lu Wang, James Bena, Nancy Foldvary-Schaefer

P1.090 Treatment-refractory anti-MOG

Classification by Leg-Worn Actigraphy —

Emmanuel Mignot, Logan Schneider

of Sleep Apnea Screening Instruments in Former Professional Athletes —Thapanee

of an Unusual Presentation of NMO with Aquaporin Cross Reactivity to Cryptococcus spp. —Steven Xian, Howard Geyer, Isaac Molinero

P1.113 Pilot Study of Sleep/Wake

Somboon, Harneet Walia, Tyler G. Kinzy, Irene Katzan, Nancy Foldvary-Schaefer

P1.104 Supra-threshold EMG activity

P1.089 Pigeonholed: Misdiagnosis

Triggering Factors for the Occurrence of Stroke: A case-crossover study —Manya

probable REM sleep behavior disorder: A community-based study —Chaoran Ma, Milena Pavlova, Junjuan Li, Ying Liu, Yujie Sun, Zhe Huang, Shouling Wu, Xiang Gao

P1.129 Brain volumes and longitudinal cognitive change: A population-based study —Deepti Vibha, Henning Tiemeier, Saira Mirza, Hieab Adams, Wiro Niessen, Albert Hofman, Kameshwar Prasad, Aad Van Der Lugt, Meike Vernooij, Mohammad Ikram

P1.130 Syphilis screening in Mild

Cognitive Impairment: Is it worth it? —

Prasad

Catarina Assuncao, Cassio Henrique Taqu Martins, Eduardo Hummelgen

P1.120 Identifying predictors of stroke

P1.131 Relationship between central and

preparedness among a high risk churchgoing urban population: Findings from The Tailored Approaches to Stroke Health Education (TASHE) trial —Mark Cort, James

peripheral presbycusis and mild cognitive impairment in a population-based study of Southern Italy: The “Great Age Study” —

Rodolfo Sardone, Petronilla Battista, Rosanna Tortelli, Marco Piccininni, Francesco Coppola, Vito Guerra, Daniela Isabel Abbrescia, Alessandra Riggs, Vernon Rowe, John Hunter, Arlene O’Shea, P1.110 Gr8 Expectations: The Efficacy of Grasso, Maria Barulli, Cristina Didio, Madia Doug Schell, Dorsey Paul, Mark Varona, Shelia BioBoosti 8 Minute Electromagnetic Cycles P1.121 A Striking Preponderance of Lozupone, Davide Seripa, Francesco Panza, Nicola Miller, James Barnett, Snehal Kadia for the Treatment of Insomnia —Nirajan Puri, Hemorrhagic Strokes Among Young Africans: Quaranta, Giancarlo Logroscino P1.100 Polysomnographic Veronique Latreille, Paul Mathew, Milena Pavlova Evidence from the SIREN study. —Fred Characterization of Sleep Disturbance in Sarfo, Bruce Ovbiagele, Mulugeta Gebregziabher, P1.132 Exploring the Potential Risk Factors of Neurodegenerative Disease in Kevin Armstrong, Onoja Akpa, Kolawole Wahab, Angelman Syndrome: A Case Series —Jordan P1.111 Melatonin Promotes Sleep by Inhibiting Orexinergic Neurons in Perifornical Mayowa Owolabi Autopsy Cases —Patricia Henegan, Tanya Butt, Broman-Fulks, Yael Shiloh-Malawsky, Bradley Lateral Hypothalamus —Mahesh Thakkar, Rishi Jessica Crothers, Brenda Waters, Elijah Stommel Vaughn, Zheng Fan P1.122 Association between Sharma, Pradeep Sahota

P1.101 Patients’ Estimates of Their

First Night Effects during in-Laboratory Polysomnography Using a Morning

124 2018 AAN Annual Meeting

in REM Sleep —Elahhe Afkhamnejad, Sandhya Kumar

Noble, Joseph Eimicke, Jeanne Teresi, Olajide Williams

Hospital Teaching Status and Iatrogenic Cerebrovascular Hemorrhage or Infarct — Taylor Johnson, Sheetal Hegde, Ali Seifi

NEUROEPIDEMIOLOGY: NEUROPATHY, NEUROMUSCULAR DISEASES, DEMYELINATING DISEASES, AND OTHER

P1.133 Effectiveness of a

Multidisciplinary Neuropathy Clinic in Diagnosis and Treatment of Peripheral Neuropathy —Martha Cruz, Fang Bai, Lawrence Zeidman

P1.134 The Relationship Between Facial Nerve Palsy and Vaccination —Venkatraman Thulasi, Thomas Savage, Nizar Souayah, Erin Feinstein

P1.135 Title: Does Neurology Have a

Role? Chemotherapy-Induced Peripheral Neuropathy from the Perspective of Breast Cancer Survivors —Barbara Gordon, Gustavo Patino, Ishmael Jaiyesimi

P1.136 Lumbosacral Radiculoplexus

P1.144 Differences in Comorbidity

P1.159 A Tale of Two Thalami: A Case Phenotypes in Afghanistan and Iraq War of Lupus Presenting as Central Neuropathic Veterans with mild and no TBI: A Chronic Pain —Denise Chen, Nikolaos Spilias, Lorenzo Effects of Neurotrauma Consortium Study — Difrancesco Mary Jo Pugh, Alicia Swan, Roxana Delgado, Megan Amuan, David Tate, Chen-Pin Wang

P1.145 Trends of mortality in West

Nile Neuroinvasive Disease (WNND) from 2005-2014 in a US hospital cohort. —Monika Manchanda, Saqib Abbasi, Richard Dubinsky

P1.146 Machine Learning Tools

for Improving the Efficiency of Drug Development Clinical Trials in Neurodegenerative Diseases —David Ennist, Danielle Beaulieu, Samad Jahandideh, Albert Taylor

GENERAL NEUROLOGY: AUTOIMMUNE NEUROLOGY

P1.147 Neurological Complications of

Neuropathy—Incidence and the association Monoclonal Antibodies —Pritikanta Paul, Boyd with Diabetes Mellitus. —Peng Soon Ng, Peter Koffman Dyck, Prabin Thapa, Ruple Laughlin, P. James B. Dyck

P1.137 Ischemic Optic Neuropathies: A

Case Series Study —José Ángel Motos García, María Palao Rico, Isabel Pellicer Espinosa, Eliot Gómez López, Noelia García Lax

P1.138 The Danish National

Epidemiology of Neuromyelitis Optica Spectrum Disorders Based On the 2015 International Panel for NMO Diagnosis (IPND) Criteria —Viktoria Papp, Zsolt Illes,

Melinda Magyari, Nils Koch-Henriksen, Matthias Kant, Monika Góra, Lars Kristian Storr, Claudia Pfleger, Shanu Roemer, Michael Jensen, Lene Rosendahl, Linda Locht, Zsolt Mezei, Tove Christensen, Annett Petersen, Kristina Bacher Svendsen, Helle Hvilsted Nielsen, Jette Lautrup Frederiksen Battisti, Finn Sellebjerg, Egon Stenager, Thor Petersen

P1.139 Interaction of alcohol

Syndrome and Important MalignancyRelated Considerations —Gabriela Gilmour, Alexander Arnold, Marcus Koch

P1.149 A Case of Gait Ataxia and Ophthalmoparesis —Fang Bai, Andrew Christiana, Qin Li Jiang

P1.150 Systemic Lupus Erythematosus Presenting as Rhombencephalitis —Shafaq

Mansoor, Adrian Moritz, Iftekhar Ahmed, Graham Lee

P1.151 Guillain-Barré Syndrome in a

Patient with Shingles Following Multiple Myeloma Treatment —Sean Kennedy, Aldo Mendez Ruiz, Teri Thomsen

P1.152 Anti-Ma-2 Encephalitis causes

Obstructive Hydrocephalus —Stephen English, Mark Keegan, Eoin Flanagan, W. Tobin, Nicholas Zalewski

P1.153 Efficacy and Safety of

Intravenous Immunoglobulin (IVIG) IgPro10 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): The PRIMA and P1.140 Epidemiology of multiple sclerosis PATH studies —Orell Mielke, Ivo Van Schaik, Jean-Marc Leger, Vera Bril, Nan van Geloven, in the United States —Kanika Sharma, Frank Domizia Vecchio, Paola Naldi, Sandra D’Alfonso, Massimiliano Copetti, Maurizio Leone

Hans-Peter Hartung, Richard Lewis, Gen Sobue, John-Philip Lawo, Billie Durn, Jan De Bleecker, P1.141 Mitochondrial disease David Cornblath, Claudia Sommer, Wim phenotypes of 999 patients in the North Robberecht, Mika Saarela, Jerzy Kamienowski, American Mitochondrial Disease Consortium Zbigniew Stelmasiak, Bjorn Tackenberg, Ingemar Merkies (NAMDC) —Emanuele Barca, Victoria Cooley, Robert Schoenaker, Valentina Emmanuele, P1.154 Steroid-responsive Salvatore DiMauro, Bruce Cohen, Amel Karaa, Encephalopathy Associated with Georgirene Vladutiu, Richard Haas, Johan Van Autoimmune Thyroiditis: A Case Report — Hove, Fernando Scaglia, Sumit Parikh, Jirair Andres De Leon Benedetti, Daniel Garbin Di Luca, Bedoyan, Suzanne DeBrosse, Ralitza Gavrilova, Sishir Mannava, Mohan Kottapally, Leticia Tornes Russell Saneto, Gregory Enns, Peter Stacpoole, Jaya Ganesh, Austin Larson, Zarazuela ZolkipliP1.155 Acute immune-mediated Cunningham, Marni Falk, Amy Goldstein, Mark polyneuropathies: The Royal North Shore Tarnopolsky, Kathryn Camp, Danuta Krotoski, Kristin Engelstad, Xiomara Rosales, Joshua Kriger, Hospital experience —Stephanie Barnes, Geoffrey Herkes Richard Buchsbaum, John Thompson, Michio Hirano P1.156 A case of Autoimmune Bittner, John Kamholz

P1.142 Psychology: A Truth in Neglect

in Neuromuscular Clinics. A Meta-analysis of Mood Disorders in Myasthenia Gravis Clinics. —Sankar Bandyopadhyay, Alair Altiero

P1.143 Epidemiology of War-related

Spinal Cord Injury among Soldiers: A systematic Review —Julio Furlan, Sivakumar Gulasingam, B. Catharine Craven

Glial Fibrillary Acidic Protein Astrocytopathy(GFAP) Meningo encephalomyelitis —Ambihai Sivalingam

Han Yuan, Barbara Carlson, Johnny O’Keeffe, Lei Ding, Michael Wenger, Linda Hershey

P1.160 Multiple antibody positive

P1.180 Attitudes towards research

Sharmeen Hussaini, Sherif Elwan, Gobind Singh, Laura Simionescu, Robert Beach

Gerson Hernandez, Angélica Zuno Reyes, Mellissa Withers, Yaneth Rodriguez, Esmeralda Matute, Lon Schneider, John Ringman

autoimmune encephalomyelitis; Role of immunosuppression in relapsing disease —

P1.161 Anti-CASPR2 Associated

Encephalitis, A Case Report —Nazaret Peláez, Carlos Sanchez, Raquel Portillo Rivero, Ángela Ortega, Dennis Dunlop

in persons of Mexican origin at-risk for autosomal dominant Alzheimer’s disease —

PATHOLOGY STUDIES IN AGING AND DEMENTIA

P1.181 Abnormal Nighttime Behaviours P1.162 WITHDRAWN along the Spectrum of Alzheimer’s Pathology P1.163 Effect of Coexisting Autoimmune Load —David Munoz, Ka Yi Koo, Tom Schweizer, Disorders on Clinical Outcome in GuillainBarre syndrome: An Analysis from National Inpatient Database —Mohammed Qureshi,

Corinne Fischer

P1.164 WITHDRAWN P1.165 Inflammatory Pseudotumor

Kim, Tom Schweizer, Corinne Fischer

Malik Adil, Daniel Larriviere

P1.182 Structural Basis of Psychosis

in Cognitively Intact Subjects with Severe Alzheimer’s Pathology —David Munoz, Julia

P1.183 Neuropathological and neuropsychological associations in of Skull Base with Intracranial Extension Mimicking Temporal Arteritis —Mausaminben hippocampal sclerosis of ageing; the 90+ Hathidara, Shuchi Chaudhary, David Gordon study —S. Ahmad Sajjadi, Maria Corrada, John P1.166 Primary Angiitis of the Central

Nervous System (PACNS): A 12-year singlecenter review —Tan Guan Zhong, Wai-Yung Yu, Soke Miang Chng, Hwee Yee Lee, Carol Tham, Xuling Lin

P1.167 Case Series of Polineuropathy

and Monoclonal Gammopathy (POEMS) — Nathane Rezende, Yuri Macedo, Camila Pupe, Osvaldo Nascimento

P1.168 Intravenous Immunoglobulin

Use In Treatment Of Central Pontine Myelinolysis: A Case Report —Margi Patel, Manmeet Kaur, Sahil Gupta, Mahvish Ayman, Angela Hays Shapshak

P1.169 Cruciate Paralysis: A Rare

Brainstem-Cord Syndrome —Jeanna WestMiles, Tyler Koehn, Thomas Duginski

P1.170 NA P1.171 NA P1.172 NA CLINICAL ISSUES IN DEMENTIA

P1.173 The Left Parietal or “Acalculia”

Robinson, Ron Kim, John Trojanowski, Claudia Kawas

P1.184 Post-Mortem and In Vivo

Assessment of Catecholaminergic Innervation and Alpha-Synuclein Deposition by Multi-Protein Immunofluorescence Microscopy —Risa Isonaka, Patti Sullivan, Courtney Holmes, David Goldstein

P1.185 Divergent Bi-hemispheric

Patterns of FTLD-TDP and FTLD-Tau Neuropathologies in Primary Progressive Aphasia —Lucia Giannini, Mendy Liang, Corey

McMillan, Andrew Williams, Charles Jester, Katya Rascovsky, David Wolk, Sharon Ash, Edward Lee, John Trojanowski, Murray Grossman, David Irwin

P1.186 The Pathology of Rapid Cognitive Decline in Clinically Reported Alzheimer’s Disease —Christin Nance, Aaron Ritter, Justin Miller, Sarah Banks

P1.187 Higher Circulating VEGF is

Associated with Higher Burden of Neuritic Plaques in APOE ε4- Older Adults in the Framingham Study —Mekala Raman, Jayandra Himali, Sarah Conner, Thor Stein, Ann

Variant of Early-Onset Alzheimer’s Disease — McKee, Bertrand Huber, Victor Alvarez, Vasan Negar Moheb, Randy Desarzant, Diana Chavez, Elvira Jimenez, Edmond Teng, Mario Mendez

P1.174 Early-Onset Progressive

Dementia with Persistent Extensive Cortical Diffusion Restriction —Juebin Huang, Mark Cohen, Jiri Safar, Alexander Auchus

P1.175 Peripheral Neuropathy in Patients

Ramachandran, Alexa Beiser, Sudha Seshadri

P1.188 Grey Matter Atrophy as a Marker for Increasing Pathological Burden in TDP-43 Proteinopathies —Pilar M. Ferraro, Christopher

Olm, Katerina Placek, David Irwin, Lauren Elman, Leo McCluskey, Corey McMillan, Edward Lee, John Trojanowski, Murray Grossman

with Prion Disease —Han Wang, Mark Cohen, Jiri Safar, Brian Appleby

VASCULAR RISK FACTORS IN AGING AND DEMENTIA

P1.176 Representation of ethnic

P1.189 Definite Cerebral Amyloid

minorities in dementia trials: A systematic review and meta-analysis —Manav Vyas,

Pranali K. Raval, Jennifer Watt, David Tang-Wai

Angiopathy related granulomatous inflammation in a middle-aged man with Homozygous alleles for ApoE4. —Yan Hou,

P1.177 Posterior Cortical Atrophy with

Aparna Vaddiparti, Xianyuan Song, Lawrence Hudson

P1.157 Rheumatoid Meningitis

Alicia Parker, Leila Saadatpour, Leilani Doty, Kenneth Heilman

P1.190 fMRI Surrogate of Cerebral

McKenna, Simon Cronin

P1.178 Hashimoto’s Encephalitis

presenting as Cough Headache —Mary Clare

P1.158 Steroid-Responsive Hashimoto

Encephalopathy and its association with von-Willebrand disease —Roohi Katyal, Divya Singhal

sleep in aMCI patients & healthy controls —

Quadrantic Spatial Neglect —Usama Tariq,

Presenting as Normal Pressure Hydrocephalus —Ellen Chang, May Kim-Tenser, Benjamin Emanuel, Sebina Bulic, John Ringman, Helena Chui

Vascular Reactivity is Impaired in Cerebral Amyloid Angiopathy but Not Alzheimer’s Disease —Aaron Switzer, Ikreet Cheema, Cheryl

McCreary, Saima Batool, Angela Zwiers, Anna Charlton, Charlotte Zerna, Randall Stafford, Richard Frayne, Bradley Goodyear, Eric Smith

AAN.com/view/AM18 125

Sunday

consumption and smoking on Multiple Sclerosis severity course: A cross-sectional study —Andrei Ivashynka, Simona Arcuti,

P1.148 Four Patients with Numb Chin

P1.179 EEG frequency changes during

POSTER SESSIONS

Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.

POSTER SESSIONS

POSTER SESSION I

P1.191 Poststroke Mild Cognitive

Hypertension: A Systematic Review of the Literature —Brandon Bond, Kamila Bond, Chike Impairment and Dementia: A meta-analysis. Prominent role of criterion of cognitive deficit — Ilorah, Jorge Kattah Olivier Godefroy, Momar Diouf, Martine Roussel, P1.204 An Observational Study, On Low Mélanie Barbay, Grecogvasc study group Molecular Weight Heparin (LMWH) Versus P1.192 Endothelial CTACK associated Unfractionated Heparin (UFH) Therapy In with an altered cerebral vasoreactivity in The Treatment Of Cerebral Venous Sinuses Alzheimer Disease. —Juan Gongora Rivera, Thrombosis (CVST) —Sai Sripada Koneru, Vijay Xochitl Ortiz, Eduardo Garza-Villarreal, Antonio Anaya-Escamilla, Meztli Espinoza, Alejandro Gonzalez Aquines, Nancy Garza-Garcia, Carlos Medina, Hector Villarreal, Mario Carmona

P1.193 24-hour ambulatory blood

pressure, cognitive performance, and cerebral microbleeds in the elderly —Annlia

Paganini-Hill, David Floriolli, Natalie Bryant, Dana Greenia, Maria Corrada, Claudia Kawas, Mark Fisher

P1.194 Dementia and vascular risk

Chandran, Sankar Gorthi, Aravind Prabhu

P1.205 Cerebral Venous Thrombosis in

Older Patients —Yvonne Zuurbier, Sini Hiltunen, Erik Lindgren, Suzanne Silvis, Katarina Jood, Sharon Devasagayam, Timothy Kleinig, Frank Silver, Daniel Mandell, Jukka Putaala, Turgut Tatlisumak, Jonathan Coutinho

P1.206 Cerebral Venous Sinus

Thrombosis: Clinical Outcomes in Medical Management and Mechanical Thrombectomy —Quang Vu, Amy Guzik, Bryan

scores in an aging population: An association Neth with cognitive and sensory impairment — Rosanna Tortelli, Marco Piccininni, Petronilla Battista, Luca Di Lena, Daniela Isabel Abbrescia, Maria Rosaria Barulli, Rosa Capozzo, Francesco Coppola, Madia Lozupone, Francesco Panza, Rodolfo Sardone, Nicola Quaranta, Giancarlo Logroscino

P1.195 Elucidating Subtypes and Risk

Factors of Brain Arteriolosclerosis —Eseosa

P1.207 Suspicion of cerebral venous

thrombosis based on the patient’s headache characteristics —Vanessa Rizelio, Paulo Sérgio Faro Santos, Matheus Kahakura Franco Pedro, Pedro Kowacs

P1.208 Cerebral Venous Sinus

Thrombosis: Predictors of Poor Clinical

Outcomes —Bryan Neth, Quang Vu, Amy Guzik Ighodaro, Erin Abner, Sarah Monsell, Walter Kukull, Janna Neltner, Vanessa Smith, David Fardo, P1.209 Trans- Venous Aphasias — Peter Nelson Balasubramanian Samivel, Lakshmi Ranganathan, Harish Jayakumar, Shanmuga Sundaram N, P1.196 Blood pressure and the risk Thamilpavai Natarajan, Venkateswaran Kuttuva of dementia: A systematic review and dose-response meta-analysis of prospective Jeyarman, P Lenin Sankar, Pratheep Kumar S studies —Wei Xu BEHAVIORAL AND COGNITIVE NEUROLOGY: OTHER

P1.197 Features Can Be Bound in

Blindsight Without Consciousness —Chaipat Chunharas, Vilayanur Ramachandran

P1.198 Capgras Syndrome in a 20-Year-

PRE-HOSPITAL, TELESTROKE, AND ED-BASED STROKE CARE

P1.210 Characteristics of Prehospital

Acute Stroke Care in an Urban Setting: Pilot Data from the Pre-hospital Rapid Evaluation via Ambulance Lead Emergency Remote Telemedicine (PRE-ALERT) Study —Mariko Hanson, Michelle Stockner, Elizabeth Aradine,

Sunday, April 22 11:30 a.m.–5:30 p.m. P1.215 Then and Now: Temporal

P1.227 Diabetic Patients with Non-

Sheikhi, Naresh Mullaguri, Andrew Buletko, Jason Mathew, Tapan Thacker, John Nocero, Andrew Reimer, Rasmussen Peter, Andrew Russman, Muhammad Hussain, Ken Uchino

Joshua Santucci, Lance Ford, Kimberly Hollabaugh, Bappaditya Ray

Evolution of a Mobile Stroke Unit —Lila

P1.216 Pre-Hospital Stroke Diagnosis

Aneurysmal Subarachnoid Hemorrhage—A Single Center Perspective —Amna Sohail,

P1.228 The Rise of Non Aneurysmal

Subarachnoid Hemorrhages in the United Accuracy: Cross Sectional comparison States: Analysis of Nationwide Inpatient 2010/11 & 2016 —Michael Schneck, Paula De la Sample from 2006 to 2014 —MohammadPena, Sean Ruland, Camilo Gomez, Mark Cichon, Jose Biller

Rauf Afzal, Omar Saeed, Saqib Chaudhry, Adnan Qureshi

P1.217 Door-to-CT time: A Novel Tool

P1.229 Natural History of Infectious to Assess Effect of Prehospital Notification Intracranial Aneurysms Undergoing of Acute Stroke Patients in a High Volume Antibiotic Treatment —Cory Rice, Sung Cho, Comprehensive Stroke Center. —Arpita Hazra, Lucy Zhang, Jean Khoury, Prateek Thatikunta, Anisha Chaudhry, Erin Hollis, Paul Wright, Elliott Salamon, Rohan Arora

Dolora Wisco, Muhammad Hussain, Ken Uchino

Stroke education: A Model to Increase EMS Prehospital Notification for Acute Ischemic Stroke. —Arpita Hazra, Erin Hollis, Anisha

imaging finding for perioperative neurologic complications? —Lucy Zhang, Cory Rice, Jean

P1.230 Sulcal SAH in patients with P1.218 College Student Led One-on One infective endocarditis : A predictive

Chaudhry, Joe Landers, Tammy Haber, Paul Wright, Rashmeet Gujral, Jeffrey Katz, Rohan Arora

SUBARACHNOID HEMORRHAGE AND INTRACRANIAL ANEURYSMS

P1.219 Anatomical variations

circle Willis, aneurisms correlation, and relationship with subarachnoid haemorrhage —Kledisa Shemsi, Edlira Shemsi, Elton Cekaj, Ferid Domi, Arsen Seferi

P1.220 Convexity Subarachnoid

Hemorrhage: Clinical Features and Etiology of an Argentinian Cohort —Anibal Chertcoff,

Miguel Saucedo, Lucrecia Bandeo, Fatima Pantiu, Luciana Vanesa Leon Cejas, Maria Pacha, Marcela Uribe Roca, Pablo Bonardo, Manuel Fernandez Pardal, Ricardo Reisin

P1.221 Defining clinical and radiological features of nontraumatic convexal subarachnoid hemorrhage in a cohort of 60 Argentinean patients —Federico Eberbach,

Khoury, Sung Cho, Ken Uchino, Dolora Wisco

P1.231 Procedures requiring general

anesthesia in patients with unruptured intracranial aneurysms. —Vijayaleskhmi Nair,

Adekorewale Odulate-Williams, Sameer Sharma, Hesham Masoud

INTRACEREBRAL HEMORRHAGE

P1.232 Microhemorrhages and Cerebral Amyloid Angiopathy: Worth Counting? —

Joseph Carrera, Prachi Mehndiratta, Shareena Rahman, Andrew Southerland, Bradford Worrall

P1.233 Transient Focal Neurological

Episodes with Subsequent Catastrophic Intracerebral Hemorrhage Due To Cortical Superficial Siderosis and Amyloid Angiopathy —Davida Goltz, Derek Cheng, Karen Black, Elliott Salamon, Paul Wright

P1.234 Clinical Characteristics of 100

patients with Angiography-confirmed Lowflow Spinal Arteriovenous Fistulas —Olwen

Sunday

Old Woman with DiGeorge Syndrome and Jamie Ricks, Rashon Britt, Sherita Chapman Diffuse Brain Calcifications —Julien Cavanagh, P1.211 Rapid Arterial Occlusion Ilana Lasner, Hyeyoung Seol, Roderick Alfonso, Evaluation Score Agreement Between Nathan Farkas, Weijun Jin, Arnold Eggers Emergency Medical Services Providers and P1.199 What Day is Today? A Case Stroke Specialized Neurologists —Rahul of a Patient who Developed Significant Rahangdale, Muhammad Adeel Saleemi, Chris Anterograde Amnesia with Abnormal Signal Hackett, Jack Protetch, Sandeep Rana, David Intensity in the Medial Temporal Lobes on Wright, Robert Fishman, Ashis Tayal Brain Magnetic Resonance Imaging (MRI) P1.212 Using the RE-AIM Framework in the Setting of Substance Abuse. —Dena in Formative Evaluation/Planning of a Little, Eric Nagele, Michael Gallagher, Michael Mobile Prehospital Telestroke Intervention Weston in an Urban Setting: Pilot Data for the P1.200 Unusual Amnestic Syndrome Prehospital Rapid Evaluation via Ambulance Associated with Combined Fentanyl and Lead Emergency Remote Telemedicine Cocaine Overdose —Quynh Vo, Uzoma Duru, (PRE-ALERT) Study —Michelle Stockner, Tsion

Veronica Bruno, Hernan Chaves, Sebastian Ameriso

Murphy, Carlos Pardo-Villamizar, Philippe Gailloud

P1.222 Change in outpatient post-

on outcomes after ruptured arteriovenous malformation: A Nationwide Inpatient Sample analysis —Rakesh Khatri, Mohammad-

CEREBRAL VENOUS SINUS THROMBOSIS (CVST)

Norma Castillo, Fernando Testai

Gauri Pawar

P1.201 Timing Of Anticoagulation In

Patients With Cerebral Venous Thrombosis Requiring Neurosurgery: Case Series —

Russell Bartt, Kristin Salottolo, Kathryn McCarthy, Rebecca van Vliet, Amy Nieberlein, Judd Jensen, David Bar-Or

P1.202 Cerebral Venous Thrombosis

(CVT) presenting symptoms in Native Americans and Hispanics. —Saif Bushnaq,

Asad Ikram, Saji Bushnaq, Fares Qeadan, Andrew Carlson

P1.203 Endovascular Venous Sinus

Stenting for Refractory Idiopathic Intracranial

126 2018 AAN Annual Meeting

Habtamu, Joshnamaithili Seelam, Shwetha Hara Sridhar, Mirinda Gormley, Alfred Brown, Pamela Brown, Sherita Chapman

P1.213 Predictors for prehospital time

delay in patients with acute stroke in Germany —Katja Kolpatzik, Stelios Grigoriadis,

Hassan Belamkadem, Xenia Stasinaki, Iris Adelt, Zaza Katsarava

P1.214 Air Transport Shortens Arrival Times and May Increase Thrombectomy Rates —Nitish Kumar, Reyanna Massaquoi,

Randall Edgell, Aninda Acharya, Abhay Kumar, Ryan Murphy

discharge clinic follow-up for aneurysmal subarachnoid hemorrhage patients over 5-year period—a single center perspective —Danny Samkutty, Swathy

Chandrashekhar, Joshua Santucci, Lance Ford, Kimberly Hollabaugh, Brad Bohnstedt, Bappaditya Ray

P1.223 Increased Rate of Subarachnoid

P1.235 Aspirin and anticoagulant usage

Rauf Afzal, Mohtashim Qureshi, Ihtesham Qureshi, Anantha Vellipuram, Darine Kassar, Paisith Piriyawat, Alberto Maud, Salvador Cruz-Flores, Gustavo Rodriguez

P1.236 Cerebral Hemangiomas: 53

Times More Likely To Bleed —Dinesh Jillella,

Hemorrhage and Aneurysm Size in Patients with Obstructive Sleep Apnea —Sebastian

Fares Qeadan, Asad Ikram, Christopher Calder, Leila Parand, Maryam Zulfiqar, Piotr Bzdyra, Leslie Morrison, Atif Zafar

P1.224 Early Inflammation as a

P1.237 Intracranial Hemorrhage in

Zaremba, Luca Albus, Erdem Güresir

Predictor of Vasospasm after Subarachnoid Hemorrhage —Muhammad Rizwan Husain,

Familial Cerebral Cavernous Malformation: Clinical presentation vs. incidental MRI findings in the follow-up Imaging —Nazeem

P1.225 Serum lactate and cerebral

Arsalan, Leslie Morrison, Asad Ikram, Atif Zafar, Helen Kim, Jeffrey Nelson, Blaine L Hart

Purón-González

Zafar, Puja Mathur, Asad Ikram, Leslie Morrison

P1.226 Subarachnoid Hemorrhage in

P1.239 Risk factors associated with

vasospasm in subarachnoid hemorrhage. Sequential transcranial doppler in a Hispanic P1.238 Role of Lamotrigine in cohort. A preliminary study —Leticia Alejandra Management of Commonly Encountered Olguín-Ramírez, Hector Martinez, Joan Stephanie Symptoms in Patients with Cerebral Celis Jasso, Norma Lizeth Alvarado-Franco, Emma Cavernous Malformations —Piotr Bzdyra, Atif

the Setting of Electroconvulsive Therapy in a Patient with an Unsecured Cerebral Aneurysm: A Case Report and Review of the Literature —James Gugger, Lauren Dunn

acute symptomatic seizures in patients with intracerebral hemorrhage: A case-control study —Ting Wu, Maria Stefanidou, Jose Romero, Helena Lau

P1.240 Validating the role of Prophylactic P1.254 Evaluation of Prothrombin Antiepileptic Drugs (AEDs) in Cortical Intracranial Hemorrhage in a Large Urban Hospital. —Anusha Boyanpally, Rajanigandhi

Complex Concentrate on Oral Anticoagulation Associated Intracerebral Hemorrhage —Thuy Nguyen, Sophie Samuel,

Hanumanthu, Matthew Sumicad, Francisco Gomez, Sujan Teegala Reddy, Adeola Olowu, Hope Moser, Machteld Hillen Nicole Gonzales

P1.241 Distal Brain Alteration and

P1.255 Modifiable Factors are a Major Delayed Cognitive Impairment Following Cause of Non-traumatic Intracerebral Intracerebral Hemorrhage —Elaine Shi, Kai-Bin Hemorrhage in Young Adults —Matthew Shi, Shenfeng Qiu, Jie Wu, Kevin Sheth, Andrew Ducruet

P1.242 The Impact of Left versus

Broderick, Luca Rosignoli, Abhishek Lunagariya, Supreet Kaur, Teddy Youn, Alexis Simpkins, Anna Khanna, Christina Wilson, Nandakumar Nagaraja

P1.256 A Decade of Intracerebral Right Sided Strokes on Intracerebral Hemorrhage —Russell Bartt, Jan Leonard, Kristin Hemorrhage in the United States: The Salottolo, Amy Nieberlein, David Bar-Or Impact of Teaching Institutions —Sheetal P1.243 Role of Flat Panel Cone Beam

Computed Tomography in Detecting ICH: Single Center Study —Amrinder Singh, Ashish

Kulhari, Siddhart Mehta, Briana DeCarvalho, Anna Barminova, Spozhmy Panezai, Jawad Kirmani

P1.244 Primary Intracerebral

Hemorrhage and Perihematomal Edema Volumes in Diabetics on Sulfonylureas: A Case-Control Study —Hannah Irvine, Shailesh

P1.258 Intracranial Injuries in the Burn

Intensive Care Unit —Brian Stephens, Anthony Frattalone, Kevin Chung, Leopoldo Cancio

CLINICAL EPILEPSY I

P1.245 Multifocal Hemorrhagic Brain

P1.259 Extrapolation of Adjunctive

Parand, Atif Zafar

P1.246 Acute Hyperglycemia is

Efficacy and Safety Data from Phase III Partial Epilepsy Trials to Evaluate Perampanel as Monotherapy —Scott Mintzer, Jacqueline French, Betsy Williams, Anna Patten, Antonio Laurenza

P1.260 Clinical Factors Associated Associated with Larger AntithromboticRelated Intracerebral Hemorrhage Volume — with a Major Response (=75% Reduction Himanshu Gupta, Simon Beshara, Tushar Patil, in Seizure Frequency/28 Days) in Phase III Ashkan Shoamanesh Trials of Adjunctive Perampanel in Patients with Partial Seizures: Post Hoc Multivariate P1.247 Characterization of Atrial Analysis —Elinor Ben-Menachem, Gregory Fibrillation in Antithrombotic-Related Krauss, Robert Wechsler, Anna Patten, Betsy Intracerebral Hemorrhage —Simon Beshara, Himanshu Gupta, Tushar Patil, Ashkan Shoamanesh

P1.248 Elevated Serum Troponin Levels Fernando Testai

P1.249 Thromboelastography with

Platelet Mapping (TEG-PM) in Patients with Spontaneous Intracerebral Hemorrhage on Antiplatelet Therapy-Validity and application of Testing —Premkumar Nattanmai Chandrasekaran, Christopher Newey, Keerthivaas Premkumar, Sharmila Suri Mohanram

P1.250 Benign Intracerebral

Hemorrhage: Proposal for a New Definition and Association with Functional Independence —Qi Li, Xiao Wei, Wen-Song

P1.267 Retrospective, Phase IV Study

of Perampanel in Real-World Clinical Care of Patients with Epilepsy: An Interim Analysis —Robert Wechsler, James Wheless, Katherine Moretz, Betsy Williams, Antonio Laurenza, Anna Patten, Manoj Malhotra

P1.268 Assessment of the Long-Term

Efficacy and Safety of Adjunctive Perampanel in Adolescent Patients: Post Hoc Analysis of Open-Label Extension (OLEx) Studies —Jesus

Williams, Antonio Laurenza

P1.261 Effect of Common Concomitant

Antiepileptic Drugs (AEDs) During Adjunctive Treatment with Perampanel: Post Hoc Analysis from the Open-Label Extension (OLEx) of a Phase III Study in Patients with Idiopathic Generalized Epilepsy (IGE) — Terence O’Brien, Francesco Bibbiani, Anna Patten, Antonio Laurenza, Betsy Williams

P1.262 One-year Retention Study

of Adjunctive Perampanel Treatment in Epilepsy Patients —Dayoung Kim, Dong Wook Kim, Jeeyoung Oh

P1.263 Pharmacokinetic Evaluations of ADS-4101 (Lacosamide) Modified Release Capsules versus Lacosamide IR in Two Phase 1 Studies up to 600 mg —Rajiv Patni,

P1.270 Time to Pre-randomization

P1.278 Functional Connectivity of

Idiopathic Generalized Epilepsy Patients vs Frontal Epilepsy Patients using Magnetoencephalography (MEG) —Sira

Carrasco, Laura Burriel, Guiomar Niso, Fernando Maestu, Julia Vaamonde Gamo

P1.279 Altered Frontal Lobe Network

Function in Temporal Lobe Epilepsy Revealed by Graph Theory Analysis —Shankar Iyer, Jedidiah Mathis, Candida Ustine, Veena Nair, Megan Rozman, Taylor McMillan, Peter Kraegel, Dace Almane, Courtney Forseth, Gyujoon Hwang, Andrew Nencka, Rasmus Birn, Douglas Ward, Vivek Prabhakaran, Rama Maganti, Lisa Conant, Bruce Hermann, Colin Humphries, Edgar DeYoe, Manoj Raghavan, Mary Meyerand, Jeffrey Binder

P1.280 ECG reporting in the first seizure

clinic: Are we missing an opportunity? —Xuya Huang, Naveed Malek, Joanne Simpson, Dheeraj Kalladka, Francis Dunn, John Paul Leach

P1.281 Surface EMG from the Brain

Sentinel® Monitoring and Alerting System for classification of seizure events —Jose

Monthly Seizure Count for Perampanel in Cavazos, Damon Cardenas, Kristen Malloy, Luke Patients with Primary Generalized TonicWhitmire Clonic (PGTC) Seizures: A Potential New Clinical Endpoint —Jacqueline French, Christian P1.282 Provider and Patient SUDEP-7 Brandt, Emilia Bagiella, Francesco Bibbiani, Anna Scoring: A Prospective Pilot Study —Allison Patten, Betsy Williams, Antonio Laurenza

P1.271 Exposure-Response Analysis

of Cannabidiol (CBD) Oral Solution for the Treatment of Lennox-Gastaut Syndrome — Gilmour Morrison, Maria Luisa Sardu, Christian Hove Rasmussen, Kenneth Sommerville, Claire Roberts, Graham E Blakey

P1.272 Post Hoc Analysis of Rufinamide Study 303: Seizure-Free Days in Patients with Lennox-Gastaut Syndrome (LGS) —

Stéphane Auvin, Betsy Williams, Rob McMurray, Dinesh Kumar, Carlos Perdomo, Manoj Malhotra

Kiernan, Keerthi Jaliparthy, Anwar Chahal, Anna Myburgh, Tanya Bredesen, Paul Timm, Jeffrey Britton, Gregory Cascino, Gregory Worrell, Elson So, Virend Somers, Erik St. Louis

P1.283 On the Feasibility of Natural

Language Processing for Standardized Data Extraction from Electronic Medical Records of Epilepsy Patients —Pouya Khankhanian,

Nikitha Kosaraju, Jay Pathmanathan, Colin Ellis, Ingo Helbig, Brian Litt, John Pollard, Kathryn Davis

P1.284 Reliability of Patient-Reported

Peri-Ictal Behavior to Identify Psychogenic Nonepileptic Seizures —Wesley Kerr, Andrea

P1.273 Efficacy and Safety of Adjunctive Chau, Emily Janio, Chelsea Braesch, Justine Le, Rufinamide in Lennox-Gastaut Syndrome (LGS): Results from Studies 022, 022E, 303, 304, and 305 —Alexis Arzimanoglou, Gerhard

Jessica Hori, Akash Patel, Norma Gallardo, Janar Bauirjan, Eric Hwang, Emily Davis, Albert Buchard, David Torres-Barba, Shannon D’Ambrosio, Mona Al Kluger, Arnd Müller, Yoko Ohtsuka, Betsy Williams, Banna, Andrew Cho, Jerome Engel, Mark Cohen, John Stern Francesco Bibbiani, Carlos Perdomo, Manoj Malhotra

P1.274 Seizure Outcome After Lesional Epilepsy Surgery: A Report of the First Comprehensive Epilepsy Surgery Program in Iran —Shervin Badihian, Jafar Mehvari

Habibabadi, Houshang Moein, Reza Basiratnia, Bagher Zaki, Navid Manouchehri, Mohammad Zare, Majid Barekatain, Elham Rahimian, Amirali Mehvari Habibabadi, Payam Moein, Yahya AghaKhani, Shahram Amina, Samden Lhatoo

P1.275 Seizure Outcome after Epilepsy

Surgery in a Developing Country using a Non

P1.285 PAP Therapy is Challenging for Epilepsy Patients —Veronique Latreille, Ellen Bubrick, Milena Pavlova

P1.286 Association of

Photoplethysmography (PPG) signals and seizures in patients with epilepsy —Fatemeh Mohammadpour Touserkani, Elelonora Tamilia, Francesca Coughlin, Sarah Hammond, Boram Kim, Jack Connolly, Sheryl Manganaro, Christos Papadelis, Kush Kapur, Tobias Loddenkemper

P1.287 Utilization of Continuous Video

Electroencephalogram and Predictors of Poor Sangita Ghosh, William Wargin, April Ruby, Oriana Invasive Presurgical Evaluation Protocol — Yang, Rui Li, Lan Deng, Peng Xie Outcomes in Non-Convulsive Epilepsy. — Lewallen, Lily Llorens, Jack Nguyen Jayanthi Mani, Sunita Iyer, Pradnya Gadgil, Abhaya Urvish Patel, Ram Mohan Sankaraneni, Anusha P1.251 Comparison of Clinical and Kumar P1.264 Long-term Safety and Efficacy of Lekshminarayanan, Abhishek Lunagariya, Vishal Radiological Characteristics of Warfarin Cannabidiol (CBD) in Patients with LennoxJani, Sanjay Singh P1.276 Magnetoencephalography in versus Novel Oral Anticoagulant Related Gastaut Syndrome (LGS): Results from Epilepsy surgery: Concordance and Yield — P1.288 Reversible Complete Blindness Intracerebral Hemorrhages —Malgorzata Open-label Extension Trial (GWPCARE5) — Arunmozhimaran Elavarasi, P. Sarat Chandra, Ajay Miller, Nils Henninger due to Bilateral Status Epilepticus Jonathan Halford, Eric Marsh, Maria Bronislawa Garg, Vibhin Viswanathan, Kamal Bharti, Chandra Amauroticus Secondary to Hyperglycemia — P1.252 Remote Cerebellar Hemorrhage: Mazurkiewicz-Beldzin, Boudewjin Gunning, Daniel Sekhar Bal, Madhavi Tripathi, Mehar Chand Dennis Chuang, Faisal Alsallom, Pitcha Checketts, Claire Roberts, Elizabeth Thiele Report of Two Cases and Systematic Sharma, Ravindra Pandey, Deepa Dash, Senthil Chompoopong, Trisha Dickey, Fajun Wang, Literature Review —Guilherme Torezani, Kumaran, Pravat Mandal, Arpan Banerjee, Manjari P1.265 Acute Treatment of Prolonged Nataliya Pyatka, Michael Devereaux, Hesham Barbara Diniz, Joao Marcos Ferreira, Pedro Tripathi and Repetitive Seizures in Adults Using Abboud Macedo, Yuri Macedo, Karoline Medeiros, Rodrigo Sublingual Administration of Lorazepam P1.277 Utilization of epilepsy surgery in Sperling Torezani, Gabriel De Freitas Intensol 2 mg/ml Solution —Charlotte Kwok, the United States, 2009–2014 —Ahyuda Oh, P1.289 First Reported Case of Alice in Wonderland Syndrome Due to an P1.253 The Spot Sign in Intraventricular Erie Gonzalez, Gregory Krauss Hyunmi Kim, Joshua Chern Arteriovenous Malformation —Veeresh Kumar Hemorrhage: Prevalence and Relation to Nanjangud Shivamurthy, Prateeka Koul, Jonathan Hematoma Expansion —Mohammad Hamed, P1.266 A randomized, double-blind, placebo-controlled, crossover study to Lim, Jeffrey Kornitzer, David Marks Omar Hussein, Khalid Sawalha, Michel Torbey, evaluate the abuse potential of purified Archana Hinduja

AAN.com/view/AM18 127

Sunday

Predict Worse Outcome After Intracerebral Hemorrhage —Gabriela Trifan, Alex Guman,

Tilden Etges, Naama Levy-Cooperman, Catherine Mills, Edward Sellers, Beatrice Setnik, Isabella Szeto, Kenneth Sommerville

Pina-Garza, Vicente Villanueva, William Rosenfeld, Harumi Yoshinaga, Francesco Bibbiani, Anna Patten, P1.257 Improving appropriate use of DVT Betsy Williams, Antonio Laurenza prophylaxis in spontaneous ICH patients — P1.269 Third-Line Antiepileptic Aparna Prabhu, Sridhara Yaddanapudi, Anusha Treatment Outcomes in Refractory Status Edara, Jalyoung Joe, Dilip Kumar Jayaraman, Steven Yang Epilepticus —Steven Ellis, Lola Morgan Hegde, Taylor Johnson, Ali Seifi

Male, Jetter Robertson, Caitlin Bell, Christopher Streib

Lesions and Leukoencephalopathy Due to Acute Disseminated Intravascular Coagulation —Andrew Lin, Dinesh Jillella, Leila

cannabidiol (CBD) in subjects with a history of recreational polydrug use —Kerri Schoedel,

POSTER SESSIONS

Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.

POSTER SESSIONS

POSTER SESSION I P1.290 The Importance of Early

Immunotherapy in patients with Faciobrachial Dystonic Seizures —Julia

Zealanders with neurodevelopmental disorders —Rosamund Hill, Whitney Whitford,

Sunday, April 22 11:30 a.m.–5:30 p.m. P1.316 Neurological Therapeutic goals in P1.326 A Refined Brain Database Fabry Disease: European Expert Consensus

to Study Transcriptomic Changes in

Brendan Swan, Juliet Taylor, Klaus Lehnert, Russell Recommendations —Max Hilz, Ralf Baron, Perry Neurological Disease —Ashkaun Razmara, Snell, Jessie Jacobsen Thompson, Mian Bi, Mateusz Makuch, Andrew Elliott, Dominique Germain, Marco Spada, Miguel Leonardo Collado-Torres Murchison, Christian Bien, Kon Chu, Pue Farooque, Viana-Baptista, Christoph Wanner, Alessandro P1.305 Insights Into a Rare Genetic P1.327 Blood Volatile Organic Jeffrey Gelfand, Michael Geschwind, Ernest Burlina Disease: Unique Behavioral Phenotype Compounds Related to Oxidative Stress Somerville, Bethan Lang, Angela Vincent, Maria P1.317 Fatal Familial Insomnia in a in PURA-related Neurodevelopmental as Potential Biomarkers for Huntington’s Leite, Patrick Waters, Sarosh Irani Canadian family —Nathaniel Bendahan, Sean Disorders —Christina Chrisman, Perry Shieh disease —Hongquan Jiang, Ming Ren, Jing P1.291 NA Taylor, Lysa Boissé Lomax Wang, Changsong Wang, Xiang Yin, Shuyu Wang, P1.306 Recessive mutations in SLC13A5 Tianhang Wang, Xudong Wang, Guangtao Dong, P1.292 NA P1.318 Potential role of gut microbiota result in a loss of citrate transport and Yueqing Yang, Enyou Li, Honglin Feng P1.293 NA

P1.294 NA NEUROGENETICS AND METABOLIC DISEASE

P1.295 Thermolabile Carnitine

Palmitoyltransferase II (CPT2) variant susceptibility in influenza-associated encephalopathy—a case report —Wing Cheong Lee

P1.296 WITHDRAWN P1.297 Pitt-Hopkins Syndrome: A

cause refractory epilepsy/status epilepticus, in Amyotrophic Lateral Sclerosis (ALS) pathogenesis —Fabiola De Marchi, Letizia developmental delay and progressive microcephaly —Abdul Aziz Al Ghamdi, Saad Al Mazzini, Luca Mogna, Angela Amoruso, Marco Shahwan, Faisal Alshibani, Brahim Melaiki

P1.307 Clinical phenotypic data is a

key factor necessary to improve molecular interpretation of de novo alterations in neurodevelopmental genetic testing — Rhonda Lassiter

P1.308 Diagnostic Exome Sequencing in Adolescents with Neurological and Neurodevelopmental Disorders —Kirsten

Blanco, Zoe Powis, Kelly D.F. Hagman, Elaine C.

23-Patient Case Series —Kimberly Goodspeed, Weltmer, Sha Tang Cassandra Newsom, Mary Ann Morris, Craig Powell, Patricia Evans, Sailaja Golla

P1.298 GTPBP3 Mutation Leading

Recurrent Lactic Acidosis Associated with Vomiting and Headache —Gozde Erdemir, Neil Friedman, Sumit Parikh

P1.299 Intra-familial variability

P1.309 Quantitative Measures of Motor Function in children with Duplications of 15q11.3-13.1 (Dup15q Syndrome) and Typically Developing (TD) Children —Rujuta Wilson, Abigail Dickinson, Carly Hyde, Sumana Rallipalli, Katie Dahlerbruch, Carolyn Rocha, Shafali Jeste

associated with recessive mutations in P1.310 Expanding the phenotype of MTO1 gene. —Valentina Emmanuele, Christiane ATP1A3 mutations with newly described De Araujo Martins Moreno, Francine Testa, Emily abnormalities on brain MRI —Janet Elgallab,

Pane, Irene Aloisio, Nicole Cionci, Francesca Gaggìa, Ausiliatrice Lucenti, Enrica Bersano, Roberto Cantello, Diana DI Gioia, Giovanni Mogna

P1.328 Human systems analysis

implicates disturbed pathways associated with cognitive dysfunction in Williams Syndrome and shared in Autism —Ursula Bellugi

P1.319 To Study Clinical, Histological

P1.329 VPS35 and Hydrocephalus of the And Radiological Features In Neurological Developing Mouse Brain. —HyunJin Song, Lu Mitochondrial Disorders —Nishita Singh, Achal Zhao, Fulei Tang, Wen-Cheng Xiong Srivastava, Awadh Pandit, Deepti Vibha, Garima Shukla, Kameshwar Prasad

P1.320 ANXA11 mutations prevail

in Chinese amyotrophic lateral sclerosis patients with and without cognitive dementia —Kang Zhang, Qing Liu, Keqiang Liu,

P1.330 Cerebellar Ataxia Renal-failure

Neuropathy with Encephalopathy (mtCARNE): A New Mitochondrial Syndrome Identified by Sequencing Frozen Nerve and Kidney Tissue DNA —Peng Soon Ng, Jadee

Neff, Edward Highsmith, Chenjing Sun, Marcus Dongchao Shen, Hongfei Tai, Shi Shu, Qingyun Pinto, Min Xu, Samantha Roellinger, Linda Hasadri, Ding, Hanhui Fu, Shuangwu Liu, Zhili Wang, Mary Fidler, Ralitza Gavrilova, Christopher Klein Xiaoguang LI, Mingsheng Liu, Xue Zhang, Liying Cui

P1.321 Transcriptional profiling of

P1.331 Burden of Hereditary

Transthyretin Amyloidosis With Primary Progressive Multiple Sclerosis Polyneuropathy in Patients Enrolled in patients identifies Fast and Slow progression the Phase 3 Study NEURO-TTR —John patterns —Michael Gurevich, Carolina Legarda, Berk, Annabel Wang, Teresa Coelho, Marcia Rina Falb, David Magalashvili, Mark Dolev, Anat Achiron

Sunday

Waddington Cruz, Michael Polydefkis, Peter Dyck, Morton Scheinberg, Violaine Plante-Bordeneuve, Fabio Adrian Barroso, David Adams, Thomas Li, Saba Tadesse, Kristin Engelstad, Robert Lesser, P1.322 Niemann Pick Disease (NPD) Kara Anstett, Heather Lau, Lauren Krupp Brannagan, Carol Whelan, Brian Drachman, Michio Hirano presenting as cortical venous sinus Stephen B. Heitner, Isabel Conceicao, Hartmut P1.311 Novel Phenotype of ATP1A3 thrombosis: A rare presentation —Leenu P1.300 Compound Heterozygotes with Schmidt, Giuseppe Vita, Josep Campistol, Josep Mutation Starting in Infancy —Jason Richards, Gupta, Jeyaraj Pandian Three Disparate Orphan Diseases: Pyridoxine Marie McDonald, Allyn McConkie-Rosell, Vandana Gamez, Edward Gane, Peter Gorevic, Acary Dependent Epilepsy, Ataxia Telangiectasia, Shashi, Mohamad Mikati P1.323 Gaboxadol Normalizes Behavioral Oliveira, Brett Monia, Steven hughes, Jesse Kwoh, and Tay Sachs Disease —Richard Young, Peter Abnormalities in a Mouse Model of Fragile X Bradley W. McEvoy, Brenda F. Baker, Elizabeth P1.312 Acroparesthesia may be Davis, Mark Schomer, Joseph Tucker Syndrome —Patricia Cogram, Robert J. Deacon, Ackermann, Spencer Guthrie, Asia Sikora Kessler, of Mitochondrial Origin —Jose-Rafael Melanie J. von Schimmelmann, Matthew During, Morie A. Gertz, Merrill Benson, Giampaolo Merlini P1.301 Defective mitochondrial rRNA Zuzuarregui, H Hutchison Brett Abrahams P1.332 Clinical and Molecular

methyltransferase MRM2 causes MELASlike clinical syndrome —Caterina Garone,

Aaron R D’Souza, Cristina Dallabona, Tiziana Lodi, Pedro Rebelo-Guiomar, Joanna Rorbach, Alice Donati, Elena Procopio, Martino Montomoli, Renzo Guerrini, Massimo Zeviani, Sarah Calvo, Vamsi Mootha, Salvatore DiMauro, Iliana Ferrero, Michal Minczuk

P1.302 The Role of Autophagy

Dysfunction and Mitochondrial Depolarization in Neuronal Death in hiPSCderived Niemann-Pick Type C1 Neurons — Emma Wu, M. Paulina Ordoñez, John Steele, Lawrence Goldstein

P1.303 Yield of Genetic Testing

P1.313 Clinical utility of next generation

sequencing in pediatric neurology —Priyanka Madaan, Biswaroop Chakrabarty, Prashant Jauhari, Ankita Pal, Vishal Sondhi, Shefalli Gulati

GENERAL NEUROLOGY: NEUROGENETICS

P1.314 Argentinian Clinical Genomics

in a Leukodystrophies and Genetic Leukoencephalopathies cohort: Diagnostic yield in our first nine years —Leila Cohen,

Analisa Manin, Nancy Medina, Sergio Rodriguez Quirofa, Dolores Moron, Julieta Rosales, Hernan Amartino, Norma Specola, Marta Cordoba, Marcelo Kauffman, Patricia Vega

P1.324 Open Label Extension of the

Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis —Thomas Brannagan, Annabel

Wang, Teresa Coelho, Marcia Waddington Cruz, Michael Polydefkis, Peter Dyck, Morton Scheinberg, Violaine Plante-Bordeneuve, John Berk, Fabio Adrian Barroso, David Adams, Carol Whelan, Giampaolo Merlini, Brian Drachman, Stephen B. Heitner, Isabel Conceicao, Hartmut Schmidt, Giuseppe Vita, Josep Campistol, Josep Gamez, Peter Gorevic, Brett Monia, Steven hughes, Jesse Kwoh, Bradley W. McEvoy, Brenda F. Baker, Elizabeth Ackermann, Merrill Benson, Morie A. Gertz

Including Targeted Gene Panel in a Clinical Population of Children with Autism Spectrum P1.315 Clinicoradiological Improvement P1.325 In vivo Safety and Efficacy of a Disorder —Louisa Kalsner, Jennifer Twachtman- in MELAS after L-Arginine Therapy —Dominic 3rd generation Antisense Oligonucleotide Bassett, Laurie Derynioski, Stormy Chamberlain Hovsepian, Alexandra Galati, Robert Chong, targetting TGF-ßRII to treat Amyotrophic Mazumder, Catherine Yim, Shrikant Lateral Sclerosis —Sebastian Peters, Eva P1.304 Exome and genome sequencing Rajarshi Mishra, Christopher DeGiorgio Zitzelsperger, Sabrina Kuespert, Rosmarie Heydn, results refine diagnoses and provide Sven Korte, Tim-Henrik Bruun, Ulrich Bogdahn treatment options in a cohort of New

128 2018 AAN Annual Meeting

Characterization of Hereditary Spastic Paraplegias: A Next-Generation Sequencing Panel Approach —Daniela Burguez, Pablo Winckler, Marcia Polese Bonatto, Lais Alves Jacinto Scudeiro, Ingemar Bjorkhem, Ludger Schols, Laura Jardim, Ursula Matted, Maria-Luiza Saraiva-Pereira, Marina Sieber, Jonas Saute

P1.333 MiR-218 as a candidate of

biomarker for early diagnosis of ALS. —

Sandra Diaz Garcia, Giancarlo Costaguta, Amy Taylor, Maria Rodriguez, Samuel Pfaff, Eran Hornstein, John Ravits

P1.334 NA P1.335 NA P1.336 NA P1.337 NA P1.338 NA

g1 H

Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P1.339 A Portable Wireless Motion

Polyneuropathy (CIDP): Identifying P1.342 Characterization of Amyotrophic Ultrasonographic Features for Diagnosis and Lateral Sclerosis (ALS) Seen in the Prognosis —Nicholas Crump, Michael Cartwright Medical University of South Carolina ALS Adam Bruetsch, Melissa Currence, Laura Herbelin, Clinic —Jayson Rodriguez, P1.341 Is high-resolution fascicular nerve Multidisciplinary Mary Paulter, Carenina Trujillo, Melissa McIntire, Pramod Chopade, I-Hweii Chen ultrasound an upcoming obligation in the Mazen Dimachkie, Jeffrey Statland, Nicholas P1.343 Prevalence and Incidence Rates neurological diagnostic algorithm? —Anna Johnson Grisold, Elisabeth Lindeck-Pozza, Wolfgang Grisold, of Autonomic Disorders among U.S. Military P1.340 A Retrospective Study of Patients Stefan Meng Healthcare System Beneficiaries Never with Chronic Inflammatory Demyelinating Capture System for Patients with Myotonic Dystrophy —Tekalign Burka, Jessie Huisinga,

NEUROINFLAMMATORY AND OTHER AUTOIMMUNE DISORDERS I

P1.345 The clinical features and

pathophysiology of ataxic form of Hashimoto’s encephalopathy —Makoto

Yoneda, Akiko Matsunaga, Masamichi Ikawa, Yasunari Nakamoto, Hiroshi Mitoma

P1.346 Primary Angiitis of the Central

P1.354 A Panel Survey Analysis of

Nervous System with Unusual Imaging Characteristics —Adam Margolius, Margaret Yu, Niels Bergsland, Jeffrey Chavin, Karthinathan Edward Manno

Thangavelu, Matthew Mandel, Stanley Cohan

P1.347 Neurological spectrum of

P1.356 WITHDRAWN P1.357 Effect of previous therapies

diseases associated with autoimmune thyroid disease: A case series to recognize diagnostically helpful signs. —Ehad Afreen, Mohammad Humayun, Ajaz Sheikh

P1.348 Neurosurgical Awakening of

on treatment retention and satisfaction in patients randomized to fingolimod or injectable disease-modifying therapies in PREFERMS —Florian Thomas, Samuel Hunter,

Cerebral Adrenoleukodystrophy: Phenotypes, Xiangyi Meng, Lesley Schofield, Scott Kolodny, Predictors, and Prevention —Na Tosha Gatson, Nadia Tenenbaum, Bruce Cree Sankeerth Challagundla, Atom Sarkar, Ann Kahler, Syed AJ Kazmi, Ruben Bonilla-Guerrero, Gino Mongelluzzo

P1.349 Neurosarcoidosis Flare with

Multifocal Restricted Diffusion: Stroke, Inflammation, or Both? —Elizabeth Spurgeon,

Justin Abbatemarco, Richard Prayson, Mary Willis

CASPR2 Antibody Syndrome with Optical Coherence Tomography (OCT) —Clarice Zhou, Vy Le, BA, Margaret Kellogg, Jacqueline Bernard

COMPARATIVE EFFICACY OF DISEASE MODIFYING THERAPIES

P1.351 Propensity Score Matched

Comparative Effectiveness Analysis of Dimethyl Fumarate Relative to Interferon, Glatiramer Acetate, or Teriflunomide Treated RRMS Outpatients in the German NeuroTransData Registry —Arnfin Bergmann,

P1.358 Observational, retrospective

study in relapsing-remitting multiple sclerosis to compare the effectiveness of second line treatments Fingolimod and Natalizumab in Spanish clinical practice —

Francisco Javier Ricart, Carmen Duran Herrera, Sergio Martinez-Yelamos, Teresa Ayuso, Miguel Angel Hernandez Perez, Nicolas Herrera, Angel Sempere, Eli Garcia, Jose Meca Lallana

P1.359 WITHDRAWN P1.360 Peginterferon Beta-1a

Demonstrated Better Clinical Outcomes Than Teriflunomide in Newly Diagnosed Relapsing Multiple Sclerosis (RMS) Patients: A Matching-Adjusted Comparison of Phase 3 Trial Data —Scott Newsome, Jang Yun, Carmen Castrillo-Viguera, Maria Naylor

Cohen, Florence Bucciarelli, Jonathan Ciron, beatrice pignolet, David Laplaud, Sandrine Wiertlewski, Laure Michel, Bruno Brochet, Aurelie Ruet, Gilles Defer, Nathalie Derache, Patrick Vermersch, Helene Zephir, Marc Debouverie, Guillaume Mathey, Eric Berger, Pierre Labauge, Jerome De Seze, Lydiane Mondot, Caroline Ranc, David Brassat, Christine Lebrun Frenay

P1.353 Relapse in Patients with Multiple

P1.362 Delayed-release Dimethyl

Fumarate Demonstrated No Difference in Clinical Outcomes Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Real-World EFFECT Study —Jacob Sloane, J. Theodore Phillips, Jonathan Calkwood, Anneke Van Der Walt, Jinny Min, Fan Wu, Catherine Miller

P1.363 Comparative Effectiveness and

Discontinuation of Dimethyl Fumarate and Sclerosis Newly Initiating scIFN?1a Compared Fingolimod in Two Large Academic Medical with Oral Disease-Modifying Drugs: A RealCenters at 24-Month Follow-Up: Sub-Group World Assessment —James Bowen, Chris K. Analyses —Carrie Hersh, Brandi Vollmer, Anasua Kozma, Megan Grosso, Amy Phillips

P1.365 Comparative effectiveness of

Bandyopadhyay, Samuel Cohn, Kavita Nair, Stefan

P1.344 Whipple’s disease—an unusual

etiology for neurologic disease —Mohammad Kabir, Naveen Addagatla, Sumaiya Khondker, Michael Collins

Rozsa, Cavit Boz, Raymond Hupperts, Vincent Van Pesch, Celia Oreja-Guevara, Vilija Jokubaitis, Tomas Kalincik, Helmut Butzkueven

P1.370 Integrated Transcriptomic

and Physicochemical Characterization of Glatiramer Acetate Products (Copaxone and Glatopa) Available in the United States — Arthur Komlosh, Daphna Laifenfeld, Sarah Kolitz, Kevin Fowler, Tal Hasson, Attila Konya, Shlomo Bakshi, Benjamin Zeskind, Jenny Zhang, Kevin Wells-Knecht, Tatiana Molotsky, Revital Krispin, Galia Papir, Dalia Pinkert, Helena Cooperman, Vera Weinstein, Yousif Sahly, Pippa Loupe, Sigal Melamed-Gal, Iris Grossman, Michael Hayden

dimethyl fumarate and fingolimod using fully P1.371 Confirmed Disability Progression automated algorithms to assess effects on in Different Subgroups of Patients With brain atrophy and T2-lesion volume —Jenny Relapsing Multiple Sclerosis Who Received Ocrelizumab or Interferon Beta-1a in the Feng, Kunio Nakamura, Carrie Hersh, Daniel Phase III OPERA I and OPERA II Studies — Ontaneda

P1.366 Annualized Relapse Rate

and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis —Stephen Hauser, Bruno

Benjamin Turner, Bruce Cree, Johannes Lorscheider, Xavier Montalban, Caroline Papeix, Regine Buffels, Donna Masterman, Jian Han, Victoria Levesque, Jerry Wolinsky

P1.372 Time to treatment failure

following initiation of fingolimod versus teriflunomide for the treatment of multiple sclerosis: A retrospective U.S. claims Brochet, Xavier Montalban, Robert Naismith, Jerry study —Cecilia Vieira da Silva, Devon Conway,

Wolinsky, Marianna Manfrini, Monika Garas, Pablo Gina Cox, James Signorovitch, Miranda Peeples, Arielle Bensimon, Vivian Herrera Villoslada, Fabian Model, Stanislas Hubeaux, Ludwig Kappos P1.373 Propensity Score Matched

P1.367 Efficacy of Delayed-Release

Dimethyl Fumarate in Newly Diagnosed and Other Early Multiple Sclerosis Patients, and Patients Switching from Interferon or Glatiramer Acetate, in Routine Medical Practice: Interim Results from ESTEEM — Kathryn Giles, Jerome Hanna, Fan Wu, Catherine Miller, Konstantin Balashov, Richard Macdonell,

P1.361 Demonstration of Equivalence of Joerg Windsheimer, Nicholas Everage Generic Glatiramer Acetate (GA) Produced by Mylan to Copaxone® —Peter Lipsky, Patrick P1.368 Safety and efficacy of IV

Stefan Braune, Sarah Grimm, Philip van Hövell, Ulrich Vallano, Jeffrey Smith, Viswanath Bandaru, Yunfu Freudensprung, Robert Hyde, NTD Study Group Sun, Ross Wallingford, Joseph Duncan, Joshua P1.352 Comparing Efficacy between Lewis, Jason Southall, Azeem Ansari

Natalizumab and Fingolimod: Radiological Findings from BEST-MS Study —Mikael

Zhang, Isobel Pearson, Michael Tempest, Ulrich Freudensprung, Carlos Acosta, Robert Hyde, Timothy Spelman, Helmut Butzkueven

Christina Shibley, Ernest Williams

Comparative Effectiveness Analysis of Dimethyl Fumarate Relative to FingolimodTreated RRMS Outpatients in the German NeuroTransData Registry —Stefan Braune, Sarah Grimm, Philip van Hövell, Ulrich Freudensprung, Robert Hyde, Arnfin Bergmann, NTD Study Group

P1.374 Comparative Effectiveness of

Dimethyl Fumarate Versus Fingolimod and Teriflunomide on the Risk of Relapse in MS cladribine versus alemtuzumab in aggressive Patients Switching from First-Generation Platform Therapies in the US —Jacqueline multiple sclerosis: A retrospective cohort study —Gauruv Bose, Mark Freedman, Carolina Nicholas, Matthew Carraro, Daniel Ontaneda, Jia Rush, Marjorie Bowman, Harold Atkins

P1.369 A comparative effectiveness

analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: Patients switching within first-line agents or to either natalizumab or fingolimod in active relapsingremitting multiple sclerosis (RRMS) —Timothy Spelman, Eva Havrdova, Dana Horakova, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo Ayuso, Pierre Grammond, Pierre Duquette, Raed Alroughani, Eugenio Pucci, Franco Granella, Jeannette Lechner-Scott, Patrizia Sola, Diana Ferraro, Francois Grand-Maison, Murat Terzi, Csilla

Zhou, Qiang Hou, Jaanai Babb, Katherine Riester, Jason Mendoza, Terrie Livingston, Mehul Jhaveri

P1.375 Injectable disease-modifying

therapies cycling versus switching to fingolimod: A retrospective U.S. claims study of risk of MS related relapses —Cecilia Vieira da Silva, Li Yunfeng, Xiangyi Meng, Huanxue Zhou, Olivia Wenxian Piao, Christen Kutz, Devon Conway

P1.376 Characterization and Comparison

of the Gene Expression Profiles of Copaxone® and Mylan Glatiramer Acetate — Jeffrey Smith, Chun-Nan Hsu, Peter Lipsky

P1.377 Patterns of Regional Gray Matter and White Matter Atrophy in Patients

AAN.com/view/AM18 129

Sunday

P1.350 Quantifying Retinal Layers in

Sillau, Robert Bermel, John Corboy, Robert Fox,

Timothy Vollmer, Jeffrey Cohen, Daniel Ontaneda, Adherence in Patients with Multiple Sclerosis Treated with scIFNβ1a or Dimethyl Enrique Alvarez Fumarate —Amy Perrin Ross, Chris K. Kozma, P1.364 A cost-effectiveness analysis Shaloo Gupta, Amy Phillips using real-world data from the MSBase registry: Comparing natalizumab to P1.355 Comparative Effectiveness of fingolimod in patients with inadequate Teriflunomide and Dimethyl Fumarate in response to disease-modifying therapies Patients With Relapsing Forms of MS in the Real-World Teri-RADAR Study —Robert in relapsing-remitting multiple sclerosis Zivadinov, Chakkarin Burudpakdee, Michael Dwyer, (RRMS) in Scotland —William Herring, Yuanhui

Diagnosed with Diabetes —Glen Cook,

POSTER SESSIONS

Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.

POSTER SESSIONS

POSTER SESSION I

Sunday, April 22 11:30 a.m.–5:30 p.m.

Starting Fingolimod or Natalizumab: A 2-Year Aquaporin-4 and Myelin Oligodendrocyte Retroviral Type W Elements (pHERV-W-ENV) MS AND CNS INFLAMMATORY Tensor-Based Morphometry Study —Paolo Glycoprotein Antibody Status —Sara Mariotto, is Specifically Extracted from Demyelinating DISEASE: QUALITY OF LIFE, Preziosa, Maria Rocca, Mariaemma Rodegher, Livia Hofer, Sergio Ferrari, Ruggero Capra, Chiara MS Lesions. —Benjamin Charvet, Rianne Gorter, SYMPTOMS, AND SYMPTOMATIC Lucia Moiola, Andrea Falini, Giancarlo Comi, Mancinelli, Adriana Bonora, Roberto Bombardi, kevin reant, Justine Pierquin, Sandra Amor, Herve THERAPY I Massimo Filippi

Salvatore Monaco, Alberto Gajofatto, Markus Reindl Perron

P1.378 Cytokine changes induced

P1.390 Investigating Immune Phenotype P1.402 Effects of Cladribine Tablets

Zanganeh, Sean Selva, Kavita Nair, Joseph M Machtinger, Timothy Vollmer, Enrique Alvarez

Amit Bar-Or, Bruce Cree, Yang Mao-Draayer, May

by antiCD20 Infusions: A Comparison of Rituximab Versus Ocrelizumab —Nassim

Biomarker Changes in Patients with Relapsing MS Treated with Fingolimod 0.5 mg/day: The FLUENT Study —Jeffrey Cohen,

Barry Singer, Ann Jannu, Scott Kolodny, P1.379 Patients switching to Fingolimod Han, Xiangyi Meng, Ryan Winger from other oral DMTs and different P1.391 Recent Advances in Flow treatment frequencies in daily clinical

routine: Results from PANGAEA 2.0 —Tjalf Ziemssen, Christian Cornelissen

Cytometry Reveal Cellular Immune Dysregulation in MS and NMOSD —Makoto

Matsui, Hiroshi Sugiyama, Nobuaki Uchida, Ukichiro

P1.380 Early versus Delayed Natalizumab Kawai, Miki Oono, Michiyo Nakata, Megumi for Multiple Sclerosis —Devon Conway

Nakanishi, Mitsuru Sanada, Nagayama Shigemi

P1.381 Treatment Experiences of

P1.392 Low Levels of Alpha-Synuclein Patients with MS: Results From the Global in Peripheral Tissues are Related to Clinical vsMS™ Survey —Ann Bass, Bart Van Wijmeersch, Relapse in Relapsing-Remitting Multiple Aaron Boster, Lori Mayer, Matthew Mandel, Kersten Sclerosis —Manuel Mejia Torres, Ildefonso Sharrock, Colin Mitchell, Barry Singer

P1.382 Comparison of Rituximab

vs Fingolimod, Dimethyl Fumarate and Natalizumab in the Treatment of Multiple Sclerosis: Two Year Experience —Brandi

Vollmer, Kavita Nair, Stefan Sillau, John Corboy, Timothy Vollmer, Enrique Alvarez

BIOMARKERS AND EXPERIMENTAL STUDIES FOR MULTIPLE SCLEROSIS

P1.383 Serum neurofilament light chain levels are increased at the onset of PML in natalizumab treated MS patients —Gloria

Rodriguez-Leyva, Fernando Cortés-Enríquez, Erika Chi, Diana Portales-Perez, Miguel Angel MacíasIslas, Maria Jimenez-Capdeville

significance of IgG, IgA, and IgM antibodies against the NMDA receptor —Makoto Hara,

Sunday

Eugenia Martinez-Hernandez, Helena Arino, Thais Armangue, Marianna Spatola, Mar Petit-Pedrol, Albert Saiz, Myrna Rosenfeld, Francesc Graus, Josep Dalmau

Olaf Stuve, Per Soerensen, Yann Hyvert, Doris Damian, Ursula Boschert

Alamri, abdullmgeed Asiri, Reem Alqahtany, Adel Alfaifi

P1.403 Relative Bioavailability of

P1.416 Association of cognitive

Miao Yu, Richard Leigh-Pemberton, Lisa von Moltke

Russell, Geraldine Nolan, Niall Tubridy, Michael Hutchinson, John Garvey, Christopher McGuigan

Monomethyl Fumarate after Administration of ALKS 8700 and Dimethyl Fumarate in Healthy Subjects —Angela Wehr, Marjie Hard,

P1.404 Immune-related microRNAs are

differentially regulated in the cerebrospinal fluid of Multiple Sclerosis patients according to disease activity and their profile mirrors neuroinfectious diseases —Vincent Van Pesch,

Hong Anh Dang, Océane Perdaens, Ludovic D’auria

P1.405 Effects of MS Donor-Derived

Ambrosius, Jeremias Motte, Kalliopi Pitarokoili, Ralf Gold

P1.387 Analysis of lymphocyte counts

and infection rates with fingolimod in patients with primary progressive multiple sclerosis over the INFORMS trial —Edward Fox, Fred Lublin, Jerry Wolinsky, Jeffrey Cohen, Xiangyi Meng, Marina Ziehn, Scott Kolodny, Norman Putzki, Bruce Cree

P1.388 Mesenchymal Stem Cells

from Patients with Secondary Progressive Multiple Sclerosis Show Deficient Immunomodulatory Activity towards Homologous Immune Cells —Cris

P1.396 CCL18 plasma levels are

increased in progressive MS patients and associated with MRI outcomes of tissue injury —Nicole Ziliotto, Giovanna Marchetti,

P1.398 Inhibition of FGFR1/2 decreases oligodendrocyte proliferation through ERK signaling in vitro —Vinothkumar Rajendran, Ranjithkumar Rajendran, Martin Berghoff

Mohammad Fouladvand, Steven Galetta

P1.408 WITHDRAWN P1.409 The Impact of Hard Drug

Abuse as Risk Factor Prognosis in the Clinical Evolution of Patients with Multiple Sclerosis —Maria Curbelo, Judith Steinberg,

Guido Vazquez, Alejandro Thomson, Adriana Carra

Disease Severity in Relapsing Remitting

P1.412 Early disease stage of Multiple Sclerosis in Chilean patients: cognitive impairment is a key domain and does not relate to MRI measures —Carlos Guevara

Oliva, Melissa Martinez, Jose de Grazia, Patricia Orellana, Katya Bulatova, Wendy Soruco, Cristian Methionine Levels are Decreased in Multiple Garrido, Gabriel Abudinen, Carlos Silva, Violeta Diaz Sclerosis Patients —Matthew Mendelsohn, Brian Lyudmer, Fozia Mir, Saud Sadiq

P1.400 Physicochemical and Biological

Characterization of both Copaxone and the European Follow-On Glatiramer Acetate Product —Bracha Timan, Arthur Komlosh, Olga

Constantinescu, Nanci Frakich, Sarah Thevathas, Radu Tanasescu, Bruno Gran, Ian Spendlove, Cherry Chang, Rhodri Jones

P1.389 Comparison of IL6 Levels in

P1.401 An Hexameric Soluble Form the

130 2018 AAN Annual Meeting

scales in assessment of fatigue in patients with multiple sclerosis —Gorana Vukorepa, Tereza Gabelic, Magdalena Krbot Skoric, Biljana Dapic, Mario Habek

P1.418 Depression in Low Income

Wolinsky, Hanzhe Zheng, Shibeshih Belachew, Laura Julian, Pablo Villoslada, Fred Lublin

P1.421 “Real world” experience

of medical marijuana in symptomatic management of multiple sclerosis and transverse myelitis —Tirisham Gyang, Megan Hyland, Lawrence Samkoff, Andrew Goodman

P1.422 The Impact of Cervical Spinal P1.410 Retinal Structure Reflects Clinical Cord Atrophy on Quality of Life in Multiple

P1.399 Cerebrospinal Fluid S-Adenosyl

Beriozkin, Attila Konya, Kevin Wells-Knecht, Vera Weinstein, Yousif Sahly, Adrian Gilbert, Oren BarIlan, Jenny Zhang, Jason Funt, Tal Hasson, Daphna Laifenfeld, Sarah Kolitz, Benjamin Zeskind, Sigal Melamed-Gal, Pippa Loupe, Iris Grossman, Ralph Laufer, Michael Hayden

CNS Inflammatory Conditions according to

P1.417 Evaluation of different fatigue

Population with Multiple Sclerosis —Britany Mesenchymal Stem Cell-Neural Progenitors Klenofsky, Nigar Dargah-Zada, Debra Shabas (MSC-NP) on Microglial Polarization —Gillian Connectome in Patients with Systemic Lupus Carling, Shayna Zanker, Saud Sadiq, Violaine Harris P1.419 Evaluation of a Spasticity Management Program for People with Erythematosus and Multiple Sclerosis: A Multiple Sclerosis: Full-scale Study Graph Theory Study —Paolo Preziosa, Giuseppe P1.406 Immune-regulatory Role of A. Ramirez, Enrica Bozzolo, Patrizia Rovere-Querini, Mucosal-associated Invariant T cells (MAIT) Protocol —Lucinda Hugos, Michelle Cameron in MS: A Follow-up Study. —Jorge Correale, Angelo Manfredi, Massimo Filippi, Maria Rocca P1.420 Impact of Ocrelizumab on Junior Carnero, Mauricio Farez Cognition in Patients at Increased Risk of P1.394 Cerebrospinal Fluid IgA Levels P1.407 The Search for the Missing Progressive Disease —Ralph Benedict, Jerome Correlate with Disease Activity in Patients Antibody —Jessica Lin, Jacob Pellinen, De Seze, Stephen Hauser, Ludwig Kappos, Jerry with Multiple Sclerosis; A Novel Finding —

Dejan Jakimovski, Marcello Baroni, Niels Multiple Sclerosis Patients —Melody Gilroy, Bergsland, Bianca Weinstock-Guttman, Paolo Samuel Lichtman-Mikol, Sara Razmjou, Carla Zamboni, Francesco Bernardi, Murali Ramanathan, Santiago-Martinez, Evanthia Bernitsas, Navid P1.385 Lipoic Acid Stimulates cAMP Robert Zivadinov Seraji-Bozorgzad Production in Healthy Control and Secondary P1.397 Elevated LGI1-IgG CSF index Progressive MS Subjects —Sarah Fiedler, P1.411 FTY720 promotes cellular Vijayshree Yadav, Amelia Kerns, Catherine Tsang, predicts worse neurological outcome — pathways involved in myelination and antiAnastasia Zekeridou, Avi Gadoth, Christopher Sheila Markwardt, Edward Kim, Rebecca Spain, oxidant system in the brain cortex —Mehdi Klein, Colton Thoreson, Masoud Majed, Eoin Dennis Bourdette, Sonemany Salinthone Flanagan, Andrew McKeon, Sarah Jenkins, Vanda Mirzaei, Vivek Gupta, Alexander Klistorner, Stuart Graham P1.386 Capsaicin Increases the AntiLennon, Sean Pittock

inflammatory Potential of Myelinating Schwann Cells —Thomas Grüter, Bjorn

impairment in Multiple Sclerosis with polysomnographic measurement of sleep disorders —Nuala McNicholas, Audrey

P1.393 Impaired Structural Brain

Alexandra Tse, Antara Finney-Stable, Jerry Lin, Dalla Costa, Vittorio Martinelli, Annamaria Finardi, Saud Sadiq Francesca Sangalli, Bruno Colombo, Lucia Moiola, Paola Cinque, Eva-Maria Kolb, Aiden Haghikia, Ralf P1.395 Laboratory Assessment Of Mitochondrial Dysfunction In Patients With Gold, Roberto Furlan, Giancarlo Comi Multiple Sclerosis —Ahmed Mohamed

P1.384 Clinical and pathogenic

P1.415 Insomnia And Disability Severity Among Multiple Sclerosis Patients In Saudi on CD4+ T-cell Subsets in the ORACLEArabia —Adel Ali Alhazzani, Mohammed MS Study: Results from an Analysis of Alqahtani, Mohammed Alahmari, Shahad Lymphocyte Surface Markers —Thomas Leist, Alkhashrami, Leen Sarhan, Mohannad Assiri, Noof

P1.413 Establishment of Optimal

Bioanalytical Parameters for Measuring Neurofilament Light Chain (Nf-L) in Multiple Sclerosis (MS) Subjects from Clinical Trial Cohorts. —Akash Datwani, Christopher Harp,

Bruno Musch, Damian Fiore, Ann Herman, Robert Hendricks

P1.414 Dimethyl Fumarate Treatment

Sclerosis —Jonathan Zurawski, Bonnie Glanz, Brian Healy, Shahamat Tauhid, Fariha Khalid, Tanuja Chitnis, Howard Weiner, Rohit Bakshi

P1.423 Anxiety and Diabetes Adversely

Affect Cognition in Multiple Sclerosis —RuthAnn Marrie, Ronak Patel, James Marriott, Chase Figley, Jennifer Kornelsen, Lesley Graff, James Bolton, Charles Bernstein, John Fisk

P1.424 Let’s raise the awareness of MS specialists concerning the frequency and impact of RLS in MS and consequently the life quality of patients with MS: Striking results of the ‘RELOMS-T’ Study —Serhan

Sevim, Meltem Demirkiran, Murat Terzi, Nur Yüceyar, Bahar Tasdelen, Egemen Idiman, Murat Kurtuncu, Cavit Boz, Deniz Tuncel, Rana Karabudak, Aksel Siva, A. Cemal Ozcan, Münife Neyal, Basak Karakurum Goksel, Mehmet Balal, Sedat Sen, Özgül Ekmekçi, Derya Kara, Turkish Multiple Scl Study Group

P1.425 Prevalence and Characteristics of the Pseudobulbar Affect in a Large Population of People with Multiple Sclerosis —Kathryn Fitzgerald, Amber Salter, Tuula Tyry, Robert Fox, Gary Cutter, Ruth-Ann Marrie

alters T Cell Metabolism in Multiple P1.426 NA Sclerosis —Marie Liebmann, Claudia Janoschka, P1.427 NA Alexander Herrmann, Andreas SchulteMecklenbeck, Nicholas Schwab, Catharina Groß, P1.428 NA

Pathogenic Protein from Human Endogenous Sven Meuth, Heinz Wiendl, Luisa Klotz

NEUROPATHY

P1.429 Clinical Meaning and

Responsiveness of Skin Biopsy abnd Corneal Confocal Microscopy to Diabetic Neuropathy Progression —A. Gordon Smith, Brittany Thurgood, Cathy Revere, Peter Hauer, Adrienne Aperghis, J. Singleton

P1.430 Schwann Cells Express

Melanocortin Receptor Subtypes: Activation by ACTH 1-39 and Alpha-MSH Enhances Proliferation —Robert Lisak, Beverly Bealmear, Liljana Nedelkoska, Joyce Benjamins

P1.431 Comparative Study for the

Effects of Several Angiotensin Receptor Blockers on Immune-mediated Experimental Neuritis —Toshiki Fujioka, Hideo Kihara, Wataru Hagiwara, Masashi Inoue, Hisao Kitazono, Shingo Konno, Hideki Sugimoto

P1.432 Multi-parametric MRI of the

Proximal and Distal Nerves of the Leg: Longitudinal Findings in Patients with Inherited Neuropathies —Michael Pridmore, Megan Simmons, Jun Li, Richard Dortch

P1.433 Electrophysiological Testing

in Patients with Chronic Inflammatory Demyelinating Polyneuropathy Treated with Subcutaneous Immunoglobulin: The PATH Study —Vera Bril, Ivo Van Schaik, Nan van

Geloven, Hans-Peter Hartung, Richard Lewis, Gen Sobue, John-Philip Lawo, Orell Mielke, Billie Durn, David Cornblath, Ingemar Merkies

P1.440 Lumbosacral Radiculoplexopathy P1.454 Quantitative Ultrasound to

NEUROSCIENCE RESEARCH Quantify Neurogenic Change in Hand PRIZE RECIPIENTS Muscles in Ulnar and Median Neuropathy — P1.468 Behavioral lateralization and Yuebing Li MD Maria Martucci, Alison Poussaint, Kristin Qi, scototaxis unaltered by near future ocean Seward Rutkove P1.441 The Temporal Profiles of Changes acidification conditions in Poecilia latipinna P1.455 Clinical and Electrodiagnostic in Nerve Excitability Indices in Familial (Sailfin Molly) —Alex Remnitz Findings in Neuropathy with Anti-Fibroblast Amyloid Polyneuropathy —Ming-Jen Lee, P1.469 Utilizing Drug Intervention Hsing Jung Lai, Ya-Wen Chiang, Chih-Chao Yang, Growth Factor Receptor 3 Antibodies — to Inhibit Delayed Neuronal Death by Sung-Tsang Hsieh, Chi-Chao Chao, Chung-Chin Kuo Carmen Boessen, Tammy Mulcahey, Raghav Migrainous Spreading Depolarizations — Govindarajan P1.442 Suprascapular Neuropathy: A Jackie Stochel P1.456 A comparison of different review of 87 cases —Anza Memon, Braydon Dymm, Richard Smith, Bashiruddin Ahmad, Lonni laboratory and clinical findings in Small fiber P1.470 Exacerbated Alzheimer’s Disease Schultz, Arun Chandok neuropathy (SFN) —Reyanna Massaquoi, Jafar Pathology in Female Hippocampus and Kafaie, Atul Kumar, Pin-Win Chen, Ayesha Naeem Frontal Cortex of Tg6799 Mice and Humans P1.443 Neuralgic Amyotrophy in Relative to Males —Sarah Hoffman Children —Fouad Alghamdi, Partha Ghosh P1.457 Elevated Soluble ICAM in Patients with Peripheral Demyelination — CEREBROVASCULAR DISEASE P1.444 WITHDRAWN Adam Andrzey Niezgoda, Slawomir Michalak, as the Initial Presentation of Lymphoma: A Report of Four Cases —Robert Marquardt,

P1.445 Abnormal spontaneous activity

on electromyographic study of intrinsic foot muscles in patients with painful distal small fiber neuropathy. —Prachi Parikh, Steven MacDonald, David Polston, Yuebing Li MD

P1.446 Quality Improvement and

Practice-Based Research in Peripheral Neuropathy Using the Electronic Medical Record —Octavia Kincaid, Alexandru Barboi,

David Randall, Lisette Garduno, Monika Szela, Samuel Tideman, Laura Hillman, Don Macapinlac, Roberta Frigerio, Kelly Claire Simon, Demetrius Maraganore

P1.447 Variability of fasting plasma

Jacek Losy, Wojciech Kozubski

P1.471 Understanding the tPA Gap: The P1.458 Worsening Chronic Inflammatory Role of Socioeconomics in Acute Stroke Demyelinating Polyneuropathy After Pembrolizumab Treatment of Metastatic Melanoma: A Case Report —Shoichi Shimamoto, Anthony Allen, Goran Rakocevic

P1.459 Expanding the Phenotype

of SEPT9 Gene Mutations in Hereditary Neuralgic Amyotrophy: Slowly Progressive and Painless Bilateral Brachial Plexopathies —Rocio Vazquez Do Campo, Eric

DYNC1H1 mutations in Brazilian Patients —

Burnor, Amit Bar-Or, Eric Lancaster

P1.448 Utility of Genetic Testing to

P1.461 Immune-Mediated

Identify Individuals Suspected of Having Hereditary ATTR (hATTR) Amyloidosis —

Neuropathy: Comparison of treatment in real Jordanna Mora, Rebecca Truty, Ruthvik Malladi, life situations (PAIN-CONTRoLS) —Richard Nathan Cheng, Angela Partisano Barohn, Byron Gajewski, Mamatha Pasnoor, Lexie Brown, Laura Herbelin, Kim Kimminau, Omar Jawdat, Tina Liu, Chad Parks, Pam Shlemon, Mazen Dimachkie, PAIN-CONTRoLs Study Team

with anti-myelin associated glycoprotein antibodies responsive to lenalidomide in combination with rituximab —Tiffany Lee, Donika Patel, Jinny Tavee

onset Chronic Inflammatory Demyelinating P1.450 Obinutuzumab (GAZYVA), a Polyneuropathy (A-CIDP) and Acute Inflammatory Demyelinating Polyneuropathy Potent Anti-B Cell Agent, in the Treatment of Rituximab- Unresponsive IgM Anti-Myelin(AIDP) in adult patients. —Lucas Alessandro, Jose Pastor, Miguel Wilken, Luis Querol, Mariano Associated-Glycoprotein (MAG)-MediatedMarrodan, Alberto Rivero, Fabio Adrian Barroso, Neuropathy —Goran Rakocevic, Ubaldo Mauricio Farez

Martínez, Marinos Dalakas

P1.437 Correlation Between Nerve

P1.451 Clinical and Genetic Features in

Krishnan

Parman, Hacer Durmus, Ayse Candayan, Halil Ibrahim Akcay, Gulshan Yunisova, Cagri Ulukan, Piraye Serdaroglu, Feza Deymeer, Esra Battaloglu

Ultrasound and Excitability Parameters in Diabetic Neuropathy —Adeniyi Borire, Arun

P1.438 Peripheral neuropathy in wild

type transthyretin amyloidosis. —Fernanda

X-Linked Charcot-Marie-Tooth Neuropathy (CMT-X) Patients from Turkey —Fatma Yesim

Wajnsztajn, Arreum Kim, Amelia Boehme, Mathew P1.452 Guillain Barre Syndrome Maurer, Thomas Brannagan Following Stem Cell Transplant: A Single

P1.439 Recovery of Sensory Modalities

Institution Five -Year Retrospective Study — Nicholas Metrus, Karin Woodman, Na Tosha

after Peripheral Nerve Lesions at Forearm Gatson, Clement Pillainayagam Level Associated with Mechanoreceptor and Sensory Nerve Fiber Function —Christian P1.453 Quantitative MRI of Nerve Pathology in Mouse Models of CMT1A and Krarup, Birgitta Rosen, Michel Boeckstyns, Allan Ibsen, Göran Lundborg, Mihai Moldovan, Simon HNPP —Isaac Manzanera, Megan Simmons, Archibald

P1.472 Higher Score on Prehospital Los Angeles Motor Scale Predicts Likelihood of Mechanical Thrombectomy After Acute Ischemic Stroke. —Latha Ganti, Paul Banerjee

Eduardo Uchoa Cavalcanti, Savana Camilla Santos, Denise Freitas, Maria Cristina Freitas, Osvaldo Nascimento

Polyradiculopathy in a Patient with Melanoma Responsive to IVIG —Christopher Doughty, Amanda Guidon

P1.462 Diagnostic Challenge of 12 cases of Hereditary Neuropathy with Liability to Pressure Palsy (HNPP) —Lise Phan, Said Beydoun

Sunday

P1.436 Differences between Acute-

P1.449 Demyelinating polyneuropathy

Paul Baneejee

P1.460 Phenotypic Spectrum of

P1.434 Mechanisms of autoantibodies

P1.435 Patient Assisted Intervention for

Care —Latha Ganti, Jessalyn Landeta, Thor Stead,

Goldstein, Devon Rubin

glucose increased risks of painful diabetic peripheral neuropathy in patients with type 2 diabetes —Ming-hong Chang

to neurofascins in acquired demyelinating neuropathies —Kristina Patterson, Elisabeth

POSTER SESSIONS

Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.

P1.463 FGFR3 Antibodies in Neuropathy. What to do with them? —Verena Samara, Jacinda Sampson, Srikanth Muppidi

P1.464 Clinical, Laboratory and

Electrodiagnostic Features of Peripheral Neuropathy in Copper Deficiency and Copper Toxicity —Jennifer Haynes, Jin Luo, Favio Bumanlag

P1.465 Differential Effects of Statins on Motor and Sensory Compared with Cortical Gene Expression Patterns —Beth Hogans, Ethan B. Murinson, Merav Shor

P1.466 Vascular factors to be correlated with diabetic polyneuropathy —Kyong Jin Shin, Byungin Lee, Seong-il Oh

P1.467 EGR2 Mutations in Brazilian

Patients—a Clinical, Electrophysiological and Genetic Profile —Eduardo Uchoa Cavalcanti, Savana Camilla Santos, Maria Cristina Freitas, Denise Freitas, Osvaldo Nascimento

Daniel Moiseev, Bo Hu, Jun Li, Richard Dortch

AAN.com/view/AM18 131

POSTER SESSIONS

POSTER SESSION II UNDERGRADUATE MEDICAL EDUCATION: ASSESSMENT AND CURRICULAR DESIGN I

P2.001 Common difficulties medical

HEALTH SERVICES RESEARCH AND METHODOLOGIES

Ganesh, Georgirene Vladutiu, Richard Haas, Charles Hoppel, Douglas Kerr, Russell Saneto, P2.004 Published Headache OSCEs Have Bruce Cohen, Johan Van Hove, Fernando Scaglia, Xiomara Rosales, Emanuele Barca, Richard Excellent Inter-rater Reliability —Maryam Shakir, Sheryl Strasser, David Solomon, Samantha Buchsbaum, John Thompson, Salvatore DiMauro, Michio Hirano, North American Mitoc (NAMDC) Syms, Fauzia Nausheen, Diana Barratt Pradeep Sahota

feedback? —Doris Kung

UNDERGRADUATE MEDICAL EDUCATION: NOVEL FORMATS

P2.006 Movement Disorders Video

Curriculum for Neurology Clerkships and Residency Programs —Sagari Bette, Jason

Margolesky, Corneliu Luca, Henry Moore, Carlos Singer, Yolanda Reyes-Iglesias

P2.007 Assessment Of The Difficult

Components Of Neurological Exam Performance In Medical Students —Yi Li, Lan Qin

P2.008 Animated Neurological Exam Videos in PBL Cases —J. Douglas Miles

P2.009 Student Neurology Clerkship Improvement Project (“SNIP”) —Victoria Cannon, Emily Nonnemacher, Amanda Witt

P2.010 Incorporating Formal Nutrition

P2.014 Streamlining Clinical Research

in Sports-Related Concussion: The National Institute of Neurological Disorders and Stroke (NINDS)/National Institutes of Health (NIH), and Department of Defense (DOD) Sport-Related Concussion Common Data Elements (CDEs) —Kristen Joseph, Sherita Alai, Joy Esterlitz, Katelyn Gay, Patrick Bellgowan

P2.015 Registration status of clinical

trials published in core neurology journals: A cross-sectional study —Jose Merino, Rebecca Burch, Melissa Rayhill

P2.016 A Common Language for Clinical

Research Studies: The National Institute of Neurological Disorders and Stroke (NINDS) and Centers for Disease Control and Prevention (CDC) Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) Common Data Elements (CDEs) —Robin Feldman, Katelyn Gay, Sherita Alai, Joy Esterlitz, Muniza Sheikh, Sarah Tanveer, Kristen Joseph, Elizabeth Unger, Vicky Whittemore

Monday

Education into a Medical School Curriculum: A Student-Initiated Lecture Series —Vanessa EDUCATION: CAREER CHOICE AND Baute, Amelia Carr, Jacob Blackwell, Estelle ATTITUDES Wilson, Michael Cartwright

P2.011 Expert Patient Tutors: The

Eradication of Neurophobia —Gina Hadley,

Laurice Yang, Veronica Santini, Gabriele De Luca

P2.017 Headache interest in US

academic neurology leadership: A crosssectional study —Matthew Robbins, Noah Rosen

P2.018 Neurology Residency Websites: A Critical Evaluation. —Adeel Memon, Rabia

Jamy, Raima Memon, Bilal Pasha, Manmeet Kaur, Marissa Natelson Love

132 2018 AAN Annual Meeting

P2.012 Common Data Elements

(CDEs) for Biomechanical Devices used students have with the neurological physical in Blunt Head Impact and Blast Exposure exam are identified by direct observation. — Dynamics: The National Institute of Juliana Coleman, Chad Hoyle, Jacquelyne Cios, Neurological Disorders and Stroke (NINDS), Adam Quick National Institutes of Health (NIH) and Department of Defense (DOD) Version 1.0 P2.002 Evaluation of a Single Year Competency-Based Clerkship Alternative to Recommendations —Kristen Joseph, Katelyn Gay, Adam Bartsch, David Camarillo, Carol TaylorEffectively Navigate a Fourth-Year to Third Burds, Sherita Alai, Joy Esterlitz, Patrick Bellgowan Year Curricular Transition —Jeff Kraakevik, Meredith Frederick, Nicole Ryan, Patricia Carney P2.013 Development of diagnostic criteria to facilitate research in P2.003 Developing a Student-Centric/ mitochondrial disorders: A proposal from Student Responsive Four Week Neurology the North American Mitochondrial Disease Clerkship —Raghav Govindarajan, Penny McQueen, Susanta Bandyopadhyay, Brandi French, Consortium. —Valentina Emmanuele, Jaya

P2.005 Why aren’t you giving

Monday, April 23 11:30 a.m.–7:00 p.m.

091–172

173–200

ePosters

b1 g1 339–344 a1 ePosters

085–090

037–084

201–258

Poster Discussion

027–036

001–026

259–294

295–338

345–428

429–480

Poster Session 2 A. Research Methodology, Education, and History: 001 – 026

a1. Neuromuscular/Clinical Neurophysiology (EMG) Poster Discussion Session: 027 – 036 B. Movement Disorders: 037 – 084

b1. Child Neurology and Developmental Neurology ePoster Session: 085 – 090 C. Pain and Palliative Care; Autonomic Disorders; Neuroophthalmology/Neuro-otology: 091 – 172 D. Aging, Dementia, Cognitive, and Behavioral Neurology: 173 – 200 E. Cerebrovascular Disease and Interventional Neurology: 201 – 258 F. Epilepsy/Clinical Neurophysiology (EEG): 259 – 294 G. Child Neurology and Developmental Neurology: 295 – 338

g1. Epilepsy/Clinical Neurophysiology (EEG) ePoster Session: 339 – 344 H. MS and CNS Inflammatory Disease: 345 – 428 I. Neuromuscular/Clinical Neurophysiology (EMG): 429 – 480

P2.019 The Rutgers-NJMS Experience:

P2.022 The Impact of Early Medical

Machteld Hillen

Aghajan, Sean Evans

Why Are Our Medical Students Increasingly Applying to Adult Neurology? —Jessy Walia,

P2.020 Changing the Image of

Neurology —Yolanda Reyes-Iglesias, Michelle Caunca, Ramses Ribot

P2.021 The Importance of Neurology as a Required Third-Year Clerkship: A Medical Student Survey —Enmanuel Perez, Michelle Caunca, Damianie Montero , Yolanda ReyesIglesias

School Exposure to Clinical Neurology on Career Interest in Neurology —Yasmin

P2.023 NA P2.024 NA P2.025 NA P2.026 NA

Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below.

Posters displayed 11:30 a.m.-5:30 p.m. • Data blitz 12:00 p.m.-12:50 p.m. • Presenters Stand by Posters 5:30p.m.-7:00 p.m. Data Blitz: 11:45 a.m.–11:50 a.m.

P2.027 Machine-learning in

Data Blitz: 12:00 p.m.–12:05 p.m.

Activation in Amyotrophic and Primary

ALS-at-home study —Seward Rutkove, Jeremy

Longitudinal Study —Mohamad J. Alshikho,

Data Blitz: 12:25 p.m.–12:30 p.m.

P2.030 The Long Exercise Test in Primary Lateral Sclerosis: Cross Sectional and

neurodegeneration: Evaluation, optimisation Periodic Paralysis: A Bayesian Analysis — Daniel Simmons, Julie Lanning, James Cleland, and validation of MRI-based diagnostic Araya Puwanant, Paul Twydell, Robert Griggs, methods —Peter Bede, Eoin Finegan, Rangariroyashe Chipika, Orla Hardiman

Alrabi Tawil, Eric Logigian

Data Blitz: 11:50 a.m.–11:55 a.m.

Data Blitz: 12:05 p.m.–12:10 p.m.

Nicole R. Zürcher, Marco Loggia, Paul Cernasov, Beverly Reynolds, Olivia Pijanowski, Daniel Chonde, David Izquierdo Garcia, Caterina Mainero, Ciprian Catana, James Chan, Suma Babu, Sabrina Paganoni, Jacob Hooker, Nazem Atassi

P2.028 Skeletal Muscle Interstitial

P2.031 Congenital Myasthenic

Data Blitz: 12:15 p.m.–12:20 p.m.

Amyloid in Anoctaminopathy-5: Does it Matter? —Charenya Anandan, Margherita Milone, Teerin Liewluck

Data Blitz: 11:55 a.m.–12:00 p.m.

P2.029 Egr2-dependent microRNA-138 is Dispensable for Peripheral Nerve Myelination —Hsin-Pin Lin, Idil Oksuz, John Svaren, Rajeshwar Awatramani

PARKINSON’S DISEASE: THERAPEUTICS

P2.037 Effects of Probiotics on

Constipation, Neurological Symptoms, and Quality of Life Associated with Parkinson’s Disease —Duarte Machado, Lucy Honeycutt

P2.038 Exploratory risk analysis

for motor complications and non-motor symptoms: Observations in a registry of a tertiary Parkinson’s disease center in Brasilia, Brazil —Talyta Grippe, Natalia Cunha,

Danilo Pereira, Marcelo Lobo, Flavio Pereira, Pedro Manzke, Pedro Renato Brandao

P2.039 A Phase 2 study of Isradipine as

Syndromes (CMS) Due to Impaired Principal P2.033 Undiagnosed Congenital Coupling Pathway in the ε Subunit of Muscle Myasthenic Syndromes in Adult Acetylcholine Receptor (AChR) —Xin Ming Neuromuscular Practice: A Long Road to Shen, Joan Brengman, Shelley Shen, Hacer Durmus, Preethish Kumar Veeramani, Nur Yuceyar, Diagnosis and Treatment. —Justin Kao, Steven Sine, Andrew Engel

Data Blitz: 12:10 p.m.–12:15 p.m.

Andrew Engel, Teerin Liewluck

Data Blitz: 12:20 p.m.–12:25 p.m.

P2.032 Integrated MRI and [11C]-PBR28

P2.034 ALS progression over short time

PET Imaging to Characterize In vivo Glial

intervals: Early insights from the ongoing

ND0612 infusion given as adjunct treatment to oral levodopa in fluctuating PD —Karl

P2.051 Item Response Theory Analysis

Kieburtz, C. Olanow, Tamar Rachmilewitz, Yael Cohen, Sheila Oren

P2.045 A Phase 3 Study of Tozadenant

(TOZ-PD) as a Maintenance Therapy for Patients With Parkinson’s Disease Experiencing Motor Fluctuations: Characterization of Study Population —Karl

of the Unified Dyskinesia Rating Scale Items —Christopher Goetz, Sheng Luo, Glenn Stebbins

in Primary Periodic Paralysis: Pooled-Data Analysis of Two Phase 3 Clinical Trials —Perry Shieh, Fredric Cohen, Richard Barohn, Robert Griggs

Data Blitz: 12:30 p.m.–12:35 p.m.

P2.036 Decreased EEG Spectral Power

Bahman Nasseroleslami, Michael Broderick, Kieran Mohr, Christina Schuster, Brighid Gavin, Russell McLaughlin, Mark Heverin, Alice Vajda, Parameswaran Iyer, Niall Pender, Peter Bede, Edmund Lalor, Orla Hardiman

cohort study in Olmsted County, MN (19912010) —Pierpaolo Turcano, Michelle Mielke, James Bower, Joseph Parisi, J. Ahlskog, Rodolfo Savica

P2.052 A Clinically Important Difference P2.060 A Real-World Inquiry of the (CID) for the Unified Dyskinesia Rating Scale (UDysRS) Total Score Change in Parkinson’s Disease (PD) Patients with Dyskinesia —

Rajesh Pahwa, Caroline Tanner, Robert Hauser, Kieburtz, C. Olanow, Jayshree Krishnaswami, Chris Stuart Isaacson, Reed Johnson, Larissa Felt, Rajiv Resburg, Fred Kerwood, Andrew Glass, Christopher Patni, Lily Llorens Kenney

P2.053 Smoking and Coffee

So-Called Parkinsonian Personality -Comparing No-Show Rates of the Neurology Outpatients with and without Parkinson’s disease (PD) —Jeremiah Bell, Yingxing Wu, Ann Sollinger, Ronex Muthukattil, Joseph Ferrara

P2.061 Parkinson’s Diagnostic

Accuracy- What diagnoses cause the most

P2.046 Safety and Efficacy of Levodopa- Consumption Preceding Clinically-diagnosed diagnostic-switches by Movement Disorder Carbidopa Monotherapy in Patients with Synucleinopathies: A Case-control Study in Advanced Parkinson’s Disease —James Boyd, Olmsted County MN (1991-2005). —Jinna Yu, Martin Peter, Michelle Mielke, James Bower, Pierpaolo Turcano, Rodolfo Savica

P2.040 Optimizing Delivery of

Snyder, Erik Barr, Melissa Armstrong, Joseph Savitt, F. Rainer Von Coelln, Stephen Reich, Ann Gruber-Baldini, Lisa Shulman

Intestinal Gel Treatment in Advanced Parkinson’s Disease Patients Receiving ≥ 2000 mg Daily Dose of Levodopa —Cindy

Zadikoff, James Boyd, Stephanie Dubow, Lars Bergmann, Weining Robieson, Horia Ijacu, Janet Benesh

Specialists? —Marzieh Keshtkarjahromi, Danielle Abraham, Ann Gruber-Baldini, Erik Barr, Katrina Schrader, Stephen Reich, Joseph Savitt, F. Rainer Von Coelln, Lisa Shulman

P2.054 Predictors of Disability in

P2.062 Barriers to Vaccination in Parkinson Disease: Motor vs. Cognitive Homebound and Non-Homebound People Impairment Using MMSE vs. MoCA —Allison with Parkinson’s Disease —Jori Fleisher,

P2.055 Communication Regarding Off

Patrick Drummond, Talia Meisel, Naomi Friede, Alessandro Di Rocco, Joshua Chodosh

P2.063 Traumatic brain injury and

P2.041 Objective Evaluation of Levodopa Comparing Levodopa-Carbidopa Intestinal

erectile dysfunction preceding clinically Time with People with Parkinsons and their diagnosed alpha-synucleinopathies: A Caregivers: Qualitative Analysis of Physician case-control study in Olmsted County, MN Interviews —Tara Rastgardani, Connie Marras, (1991-2010). —Shemonti Hasan, James Bower,

Fowler, Summer Gernon, Rajesh Pahwa, Kelly Lyons

Anna Gagliardi, Melissa Armstrong

Michelle Mielke, Rodolfo Savica

P2.056 Foundations for a Patient-

P2.064 Objective Markers of Turning

Michael Gendreau, Jeffrey Meckler

Response on Gait and Balance —Alexandra

P2.042 Effect of PD medication on

disease progression as measured by rate of change in MDS_UPDRS in PPMI study — Zhen Xiao, Jesse Cedarbaum, Minhua Yang

P2.043 Pharmacokinetics of ADS-5102

(amantadine) Extended Release Capsules Administered Once-Daily at Bedtime for the Treatment of Dyskinesia —Robert Hauser,

P2.048 Rationale and Design of an

Open-Label, Randomized, 26-Week Study

Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease - INSIGHTS Study —Kallol Chaudhuri, Daniel Weintraub, Angelo Antonini, Weining Robieson, Mei Li, Krai Chatamra, Janet Benesh, Maurizio Facheris

Reported Natural History of Parkinson Disease: Cross-sectional Analysis of the MJFF Fox Insight (FI) Platform —Lakshmi

PARKINSON’S DISEASE: PHENOMENOLOGY, EPIDEMIOLOGY, AND RATING SCALES

P2.057 Stumbling, Near-falls, Freezing

P2.049 Dry facts are not always

Rajesh Pahwa, William Wargin, Cindy Souza-Prien, inviting: An analysis of Korean videos about Parkinson’s disease on YouTube —Beomseok Natalie McClure, Rajiv Patni Jeon, Ryul Kim, Hye-Young Park, Han Kim, Aryun P2.044 The iNDiGO study: A multicenter, Kim, Mi-Hee Jang

randomized, double-blind, placebo-controlled clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous

in Idiopathic Parkinson’s Disease —Lakshmi Pillai, Kunal Shah, Tuhin Virmani

P2.065 Changes in motor subtypes in

Arbatti, Andrew Nguyen, Lauren McLaughlin, Luba a Mexican Parkinson’s disease cohort — Smolensky, Catherine Kopil, Emily Flagg, Carol Robert Eisinger, Amin Cervantes-Arriaga, Mayela Christopher, Ira Shoulson Rodriguez Violante, Daniel Martinez-Ramirez

or Postural Instability: What Predicts Falling Best in Parkinson Disease? —Zahra Rezvani, Erik Barr, Ann Gruber-Baldini, Joseph Savitt, F. Rainer Von Coelln, Stephen Reich, Lisa Shulman

P2.066 Prevalence and patterns of rest, postural and action tremor in drug-naive Parkinson’s disease —Deepak Gupta, ShengHan Kuo

P2.067 Experiences, impact, and Disorders Subspecialty Consultations at a VA communication of “off” periods in P2.050 Clinical factors associated with Hospital —Brandon Barton Parkinson’s disease: Qualitative experiences clinician certainty in diagnosis of idiopathic of patients and carepartners —Tara Parkinson’s disease —Kishan Ughreja, Sam Wu, P2.059 Levodopa-induced dyskinesias in Rastgardani, Melissa Armstrong, Anna Gagliardi, Parkinson disease: A population basedConnie Marras Fernando Cubillos, Peter Schmidt, Danny Bega P2.058 Diagnostic Impact of Movement

AAN.com/view/AM18 133

Monday

Carbidopa/Levodopa via the Accordion Pill™: Comparative PK and Safety From 2 Randomized Crossover Studies in Healthy Volunteers —Nadav Navon, Zeev Weiss, R.

P2.035 Efficacy of Dichlorphenamide

and Increased Cortico-Cortical Connectivity Correlate with Structural MRI Changes in Seena Vengalil, Atchayaram Nalini, Feza Deymeer, Margherita Milone, Duygu Selcen, Xin Ming Shen, Amyotrophic Lateral Sclerosis —Stefan Dukic,

a disease modifying agent in patients with Cindy Zadikoff, Janet Benesh, Jorge Zamudio, Weining Robieson, Pavnit Kukreja early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update — P2.047 Safety of Levodopa-Carbidopa Tanya Simuni, Robert Holloway, David Oakes, Kevin Biglan, Codrin Lungu

Shefner

POSTER SESSIONS

Presenters Stand by Posters 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION II P2.068 Characteristics of Patients with

Parkinson Disease in Pakistan: Prospective Multicenter Cross-sectional Study —Wagma

Shahzad, Saba Aslam, Kiran Waqar, Muslim Lakhiar, Nabeel Syed, Farheen Niazi, Safia Bano, Waqas Arshad, Manzoor Lakhair, Muhammad Javed, Nadir Syed, Arsalan Ahmad, Zikria Saleem, John Bertoni, Danish Bhatti

P2.069 Predictors of health-related quality of life in Parkinson’s disease —

Gregory Kuhlman, Matthew Barrett, Flanigan Joseph

P2.070 Prenatal Exposure to Chlorpyrifos

P2.072 Characterizing Types of Falls in

Shelby DeCardenas, Jonathan Clark, Robert Watson, Charles Maitland

Thurmon Lockhart, Markey Olson, Victoria Smith, Christopher Frames

P2.077 Development of a Parkinson’s

Parkinson’s Disease —Abraham Lieberman,

P2.071 Primary Care Knowledge and

American Patients with Parkinson’s Disease : Cindy Zadikoff A Comprehensive Literature Review and Call P2.078 Sex Disparities in Health and to Action —Shivani Naik, Kathrin LaFaver Health Care Utilization after Parkinson Diagnosis: Rethinking PD Associated P2.074 Deeply Phenotyped Control Cohort for Studies of Parkinson’s Disease — Disability —Michelle Fullard, Dylan Thibault, Rana Hanna AL-Shaikh, Angela Deutschlander, Owen Ross, Zbigniew Wszolek

Margolesky, Sagari Bette, Danielle Shpiner, Tatjana Rundek, Corneliu Luca, Henry Moore, Carlos Singer

Referral Practices Based on Early Symptoms P2.076 Instructed Arm Swing Improves of Parkinson’s Disease —Stephanie Walking Performance and Decreases Fall Bissonnette, Juan Peng, Punit Agrawal Risk in Individuals with Parkinsonism —Evan Fitzgerald, Ranbir Ahluwalia, Brooke Hartenstein,

b1 C

Disease-Specific Admission Order Set —

P2.073 Healthcare Disparities in African- Danielle Larson, Yasaman Kianirad, Mitra Afshari,

P2.075 The Prevalence of Tandem Gait and Parkinson’s risk: A prospective adolescent cohort evaluation —Sarah O’Shea, Abnormality in Parkinson’s Disease —Jason Virginia Rauh, Roy Alcalay

Monday, April 23 11:30 a.m.–7:00 p.m. P2.080 Presentation of Parkinson’s

disease in patients originating of different geographical altitudes —Kelly Meza Capcha, Armando Pezo Pezo, Carlos Cosentino, Luis Eduardo Torres Ramirez

P2.081 Differences in Quality of Life

Between Men and Women with Parkinson’s Disease —Medha Gudavalli, Jiangxia Wang, Catherine Bakker, Nadine Yoritomo, Alexander Pantelyat, Ted Dawson, Liana Rosenthal

Veronica Todaro, Susan Foster, Lori Katz, Robin P2.082 Predictors of Clinically Morgan, Drew Kern, Jason Schwalb, Enrique Meaningful Change in PDQ-39 in Parkinson’s Urrea-Mendoza, Lisa Shulman, Nabila Dahodwala, Disease —Adam Margolius, Fernando Cubillos, Allison Wright Willis Samuel Wu, Peter Schmidt, Tanya Simuni

P2.079 Characterization of variants in

P2.083 Use of a modified STROOP test genes associated with Parkinson’s disease to help with diagnosis in early idiopathic and parkinsonism in the African American Parkinson’s disease —Rebekah Langston, Tuhin population using exome sequencing —Angela Virmani Deutschlander, Alexandra Soto-Ortolaza, Ronald Walton, Joseph Reddy, Audrey Strongosky, Minerva Carrasquillo, Mark LeDoux, Nilufer Taner, Owen Ross, Zbigniew Wszolek

P2.084 NA

Child Neurology and Developmental Neurology ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P2.085 A splice-site mutation in USMG5 Posthemorrhagic Hydrocephalus Treated causes Leigh Syndrome due to lack of ATP synthesis —Emanuele Barca, Marti Juanola-

P2.088 Iron and ferritin levels in patients P2.090 Striatal Changes on MRI in Young

Mary Leppert, Elizabeth Cristofalo, Edward Ahn

with ADHD —Shreya Agarwal, Siddharth Gupta, Children with NMDAR: A Single Center Keith Pecor, Daniel Oh, Jeffrey Kornitzer Experience —Michael Nelson, Monica Marcus,

P2.087 Clinical profile and outcome of

P2.089 Unusual Presentation of

Outcomes in Preterm Infants with

Sondhi, Biswaroop Chakrabarty, Prashant Jauhari, Aparajita Gupta, Shefalli Gulati

Parikh

PAIN AND PALLIATIVE CARE

Chronic Pelvic Pain —Barbara Karp, Hannah

P2.105 The Effectiveness of Spinal Cord P2.112 Dysautonomia in Charcot-Marie-

P2.091 Gluten Neuropathy: Prevalence

Tandon, Ninet Sinaii, Jay Shah, Jackie Aredo, Pamela Stratton

P2.097 WITHDRAWN P2.098 Botulinum Toxin Treatment

P2.106 Efficacy and Safety of Repetitive

Ptolemaios Sarrigiannis, Marios Hadjivassiliou

Ninet Sinaii, Jay Shah, Pamela Stratton

J. do N. Freitas, Jessika Thais da Silva Maia, Marcelo Rodrigues Zacarkim, Juliéli N. Teixeira, Nilson Nogueira Mendes Neto

Falgarona, Valentina Emmanuele, Saba Tadesse, Marcello Ziosi, Orhan Akman, Kurenai Tanji, Wendy Chung, Michio Hirano

P2.086 Long-term Neurodevelopmental

of Pain and the Role of Gluten-Free Diet. —Panagiotis Zis, Dasappaiah Ganesh Rao,

P2.092 The Effectiveness of Injectable

Monday

Extended Release Naltrexone versus daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical trial. — Kristin Solli, Arild Opheim, Zill-E-Huma Latif, Nikolaj Kunoe, Lars Tanum

P2.093 ALS Patient Perspectives on

Physician Assisted Death After Recent Passage of End of Life Options Act —Nicole Heinl, Carol Tran, Elizabeth Lindenberger, Y-Nhy Duong, Catherine Lomen-Hoerth

P2.094 Prognostic Factors and

Effectiveness of Percutaneous Balloon Compression in the Treatment of Trigeminal Neuralgia: An Experience of 222 patients — Sergio Adrian Fernandes Dantas, Juliano Jose da Silva, Daniel Duarte Rolim, Marcelo Rodrigues Zacarkim, Jessika Thais da Silva Maia, Nilson Nogueira Mendes Neto

P2.095 Evaluation of Pain Reproduction

and other Predictive Factors of Selective Lumbar Nerve Block Efficacy for the Diagnosis and Palliative Treatment of Chronic Low Back Pain: A Retrospective Cohort Study —Yi Tong, Nadia Demko, Thierry Gagné, Maia Del Pilar Cortes

P2.096 Widespread Myofascial

Dysfunction and Regional Sensitization in Women with Endometriosis-associated

134 2018 AAN Annual Meeting

with Temporizing Devices —Lydia Bernhardt,

children with Lennox Gastaut Syndrome: Retrospective single centre cohort —Vishal

of Chronic Pelvic Pain in Women with Endometriosis —Barbara Karp, Hannah Tandon,

P2.099 Evaluation of Clinical Symptom

and Signs Related to Histological and Functional Properties of Small Fiber Neuropathy in Diabetic Neuropathic Pain Patients —Isin Unal-Cevik, Diclehan Orhan, Pınar Acar

P2.100 Polarity-specific Modulation

of Central Pain Processing by Transcranial Direct Current Stimulation —Steffen Naegel, Nina Theysohn, Adrian Ringelstein, Christoph Kleinschnitz, H. Diener, Zaza Katsarava, Mark Obermann, Dagny Holle

Stimulation (SCS) In Reduction of Oral Opioid Tooth Disease and Correlations with PatientUse —Derek Yuan, Patricia Tsui Reported Disability —Sindhu Ramchandren, Transcranial Magnetic Stimulation for the Treatment of Fibromyalgia: An open label clinical trial —Levi Higino Jales Junior, Waleska

P2.113 Small Fiber Neuropathy and

Multiple Endocrinopathies with COX6A1 Gene Deletion —Glen Cook, Michael Crimmins, Clesson Turner

P2.114 Characterizing the spectrum

of autonomic impairment in neurologic disorders with calcium channel antibodies —

Falah, Eman Al-Ghawi, Eslam Shosha, Ali Al-Hilly, Moiz Bakhiet

P2.115 Autonomic description in patients

Refractory Trigeminal Neuralgia with Sphenopalatine Ganglion Block —Mohamed

P2.108 Inflamed Brain: A Neuro-

Palliative Approach —Justin Voorhees, Joel

Julie Khoury, Charlene Hoffman-Snyder, Brent Goodman

with very early TTR amyloidosis (Familial Amyloid Polyneuropathy). —Maria Alejandra

Phillips, Brandon Francis

Gonzalez Duarte, Carlo Enrico Bañuelos, Karen García, Omar Fueyo, Carolina Dominguez, Karla Cardenas-Soto

AUTONOMIC DISORDERS: AUTONOMIC NEUROPATHIES

P2.116 The effect of vagal dysfunction

fibromyalgia syndrome combined with small treatment for melanoma —Kyle Kern, Peony fiber pathology. —Walter Maier-Janson Pak, Rajarshi Mazumder, Dylan Alegria, Phioanh Nghiemphu, Lucas Restrepo

Service for Patients with Spinocerebellar Ataxia Type 1. —Patama Gomutbutra, Megan

P2.110 A Case of Paraneoplastic

P2.104 Evaluation of Berberin- a Nrf2

Perero, Gita Harapannahally

Brandeland

Carolyn Tirella

P2.107 Successful Treatment of

P2.101 WITHDRAWN P2.109 Autoimmune polyneuropathy P2.102 Biotin-deficiency in patients with with severe dysautonomia after ipilimumab P2.103 ‘Triggers’ for a Palliative Care

Mered Parnes, Sarah Risen, Eyal Muscal

Wilson Disease in a Pediatric Patient: Case Report —Michael DiSano, Neil Friedman, Sumit

Dysautonomia and Small Fiber Neuropathy —Jacob Didion, Mayra Montalvo

Activator, on Paclitaxel-Induced Neuropathic P2.111 Diagnostic Utility of Sweat Pain Model in Rat —Amitava Chakrabarti, jagjit Gland Nerve Fiber Density in Small Fiber singh, lekha saha, alka bhatia Neuropathy —Peter Novak, Lan Qin

on cytokine networks in HIV —Elizabeth

Pedowitz, Alexandra Nmashie, Emma Benn, Mary Catherine George, Sandeep Sharma, Jacinta Murray, Josef Machac, Sherif Heiba, Saurabh Mehandru, Seunghee Kim-Schulze, Allison Navis, Isabel Elicer, Susan Morgello, Jessica Robinson Papp

AUTONOMIC DISORDERS: OTHER

P2.117 Healthcare Related Costs

of Autonomic Disorders in MHS Beneficiaries —Agata Bogacki, Ernest Willams, Glen Cook

P2.118 Progressive Multiple Sclerosis

Patients Have a Higher Burden of Autonomic

Dysfunction Compared to Relapsing Remitting Phenotype —Ivan Adamec, Luka Crnosija, Magdalena Krbot Skoric, Anamari Junakovic, Mario Habek

Ivan Adamec, Magdalena Krbot Skoric, Anamari Junakovic, Mario Habek

P2.133 Running-Induced Vertigo in

P2.119 Psychosis in Multiple System

an Adolescent: A Treatable Orthostatic Vestibular Migraine Variant —Imad Jarjour

Lucy Norcliffe-Kaufmann, Horacio Kaufmann

P2.134 Elevated Paraneoplastic Markers:

Atrophy —Jose-Alberto Palma, Jose Martinez,

P2.120 Long-term Fingolimod therapy

An Uncommon Finding in Orthostatic Intolerance and Postural Orthostatic Tachycardia —Charlene Hoffman-Snyder, Julie

increases sympathetic cardiovascular modulation —Ruihao Wang, Max Hilz, Sankanika Khoury, Brent Goodman Roy, Mao Liu, Carmen de Rojas Leal, Katharina Hosl, Klemens Winder, De-Hyung Lee, Ralf Linker

P2.121 Cognitive impairment correlates

with autonomic dysfunction in patients with a history of traumatic brain injury —Max Hilz, Carmen de Rojas Leal, Sankanika Roy, Mao Liu, Katharina Hosl, Klemens Winder, Ruihao Wang

P2.122 Seasonal Hypothermia,

Hypersomnolence, Encephalopathy, and Hypoventilation Following Hypothalamus Injury—A Case of Human Hibernation? — Leighton Mohl, Michael Howell

P2.123 Three Shapiro Syndrome cases :

P2.124 Autonomic Dysfunction

in Patients with Down Syndrome and Alzheimer Disease —Eric Huttler, Michal Shauly-Aharonov, Joseph Jeret

AUTONOMIC DISORDERS: ORTHOSTATIC HYPOTENSION AND ORTHOSTATIC INTOLERANCE

The Stanford experience —Safwan Jaradeh, Srikanth Muppidi, Mitchell Miglis, Dong in Sinn, Irina Krugomova, Thomas Prieto

NEURO-OPHTHALMOLOGY/NEUROOTOLOGY in Pregnancy —Noelia García Lax, Ana Esther

Baidez Guerrero, Rocio Hernandez Clares, José Ángel Motos García, Gabriel Valero López, María Palao Rico, Isabel Pellicer Espinosa, Eliot Gómez López

Mingyang Meah Gao, David Chan

Hypotension in Parkinson Disease Patients in a Neurology Resident Continuity Clinic — Elisabeth Golden, Tran Le, Larry Brown, Steven Vernino, Pravin Khemani

Hypotension Burden of Illness Patient and Caregiver Survey: Impact of Symptoms —

of Pediatric Monophasic and Recurrent Idiopathic Optic Neuritis —Soren Jonzzon,

Janace Hart, Andrew Yousef, Leena Suleiman, Emmanuelle Waubant, Jennifer Graves

Sclerosis Patients in Jordan: A Case-Control Study. —Mohammad Alkhoujah, Khader AbdulBaqi, Margaret Zuriekat, Oday Halhouli, Omar Qudah, Murad Alkharabsheh, Baeth Alrawashdeh

Ahmed, Fatih Bushara, Basheer Mohamed, Afraa Musa

P2.152 Venous Sinus Stenting

Improves Visual Fields and Cerebrospinal Fluid Opening Pressures in Patients with Idiopathic Intracranial Hypertension —Evan Schloss, Athos Patsalides, Cristiano Oliveira, Jessica Wilcox, Marc Dinkin

Hyperemesis Gravidarum —Pria Anand, Daniel Gold

P2.139 A Case of Severe Wernicke

rTMS —Benjamin Chipper Doudican, Diamond Urbano, Yoon-Hee Cha

P2.154 ‘Sandbagging’ a Vision Test for Encephalopathy with Bilateral Sensorineural Concussion-based Sideline Assessment: Hearing Loss —Michael Hansen, Alireza Bozorgi, An Eye Movement Investigation Objectively Sindhu Richards, Thananan Thammongkolchai, Reveals the ‘Gamers’ Strategies —Janet Michael Devereaux Rucker, Lisena Hasanaj, John-Ross Rizzo, Todd Hudson, Wei-Wei Dai, John Martone, Yash Chaudhry, Oluchi Ihionu, Ivan Selesnick, Laura Balcer, Steven Galetta

P2.141 Hypereosinophilia and

P2.155 Field testing the ICHD 3 beta

Woon Chow, John Bond

Mark Obermann, Daria Lippegaus, Eva Bock, Zaza Katsarava, Dagny Holle

Neuro-ophthalmological manifestations in Lymphoma —Ehtesham Khalid, Alexandra May,

diagnostic criteria of vestibular migraine —

Oculomotor Nerve —Laszlo Mechtler, Sarthak Mittal

P2.143 Horner’s Syndrome as the

Doudican, Yoon-Hee Cha

P2.129 Persistence of Droxidopa

P2.145 Unilateral proptosis, scleral

Experiences With the Diagnosis of Neurogenic Orthostatic Hypotension —

Treatment in Patients With Neurogenic Orthostatic Hypotension —Jan Basile, Steven Kymes, Kenneth Jackson, Michelle Widolff Cyr

P2.130 Management and Treatment of

injection and superior gaze diplopia secondary to spontaneous ophthalmic artery to superior ophthalmic vein fistula—Case report and review of literature —Subin

Neurogenic Orthostatic Hypotension: Results Mathew, Dhara Murray-Frank, Maria Martucci, Pirouz Piran, Nestor Galvez-Jimenez, Michal Obrzut From a Survey of Patients and Caregivers — Lawrence Hewitt, Charles Adler, Daniel Claassen, P2.146 Development of Optic Neuritis Christopher Gibbons, Satish Raj after Vaccination, A CDC/FDA Vaccine Adverse Event Reporting System (VAERS) P2.131 Short-Term Outcome in Study, 1990-2017. —Janaki Patel, Abdul Children and Adolescents with Orthostatic Rahman Alchaki, Moamina Fakher Eddin, Nizar Intolerance and Postural Tachycardia Souayah Syndrome —Imad Jarjour, Adriana Hernandez, Laila Jarjour P2.147 Chronic Relapsing Inflammatory P2.132 Joint Hypermobility is Related to Optic Neuropathy —Chaitanya Amrutkar, Erik Pathological Finding on Tilt Table Testing —

Menaka Thounaojam, Amany Tawfik, Diana Gutsaeva, Manuela Bartoli

coherence tomography in non-inflammatory models of retinal neurodegeneration — Michael Dietrich, Andrea Issberner, Christina Hecker, Zippora Kohne, Hans-Peter Hartung, Philipp Albrecht

P2.164 Mkk4 and Mkk7 are Important

for Both Retinal Development and Axonal Injury-Induced Retinal Ganglion Cell Death — Stephanie Syc, Rebecca Rausch, Kimberly Fernandes, Richard Libby

P2.165 Correlation of Visual Field Loss

with MRI Findings in Patients with Pituitary Tumours —Christian Lueck, Emily Kane, Kate Reid, David Ashton

P2.166 Impact of cataract surgery

on cognitive functions in elderly patients presenting to a tertiary care center in Islamabad. —Faleha Zafar, Fiza Shaheen, Javeria Muid, Farooq Afzal

P2.167 Saccadic Intrusions Are Rare

In Multiple Sclerosis —Lisa DePledge, Pavle

Repovic, James Bowen, Peiqing Qian, Bobbie Severson, Steven Hamilton, Bonnie Keung, Eugene May

P2.168 Correlative Enhancement: Evaluation of a new postprocessing Individuals with Mal de Debarquement Syndrome —Diamond Urbano, Benjamin Chipper algorithm for diagnosis of optic neuritis. —

Lawrence Hewitt, Charles Adler, Daniel Claassen, Christopher Gibbons, Satish Raj

P2.128 Patient and Caregiver

Releasing Hormone (GHRH) Protects Retinal Ganglion Cells in a Model of Traumatic Optic Neuropathy —Christian Kim, Ornella Oluwole,

P2.142 Intraorbital Perineural Cyst of the P2.156 Psychological Measures of

Presenting Symptom in Giant Cell Arteritis — P2.157 Vestibular Perceptual Threshold and Motion Sensitivity in Vestibular Stephanie Figueira, Benjamin Farley, Brooke Migraine and Persistent Postural-Perceptual Hartenstein, Charles Maitland Dizziness —Felix Wurthmann, Steffen Naegel, P2.144 Diplopia as the Presenting Miriam Roesner, Christoph Kleinschnitz, H. Diener, Symptom of Systemic T Cell Prolymphocytic Mark Obermann, Dagny Holle Leukemia with Infiltration of the Superior Rectus Muscle. —Humaira Khan, Yu-Ting Chen, P2.158 Erlotinib-Induced Dandy’s Syndrome: Case Report —Kristen Steenerson, Betul Gundogdu

Daniel Claassen, Charles Adler, Christopher Gibbons, Lawrence Hewitt

P2.162 Agonist of Growth Hormone

Burton

Terry Fife

P2.159 Short-Term Memory Loss in

Vestibular Patients can Arise Independently of Psychiatric Impairment, Fatigue and Sleeplessness —S.S. Surenthiran, Laura Smith,

Leanne Stunkel, Amber Salter, Matthew Parsons, Aseem Sharma, Gregory Van Stavern

P2.169 The New MULES: A Sideline-

Friendly Test of Rapid Picture Naming for Concussion —Omar Akhand, Matthew Galetta,

Lisena Hasanaj, Lucy Cobbs, Nikki Webb, Julia Brandt, Prin Amorapanth, John-Ross Rizzo, Liliana Serrano, Rachel Nolan, Janet Rucker, Arlene Silverio, Barry Jordan, Steven Galetta, Laura Balcer

P2.170 NA P2.171 NA P2.172 NA

David Wilkinson, Rowena Bicknell, Mayur Bodani

P2.160 Optimal Inter-Eye Difference

Thresholds in Retinal Nerve Fiber Layer and Ganglion Cell Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis: An International Collaborative Study —Rachel Nolan, Omar Akhand, Peter

Calabresi, Friedemann Paul, Elena MartinezLapiscina, Axel Petzold, Alexander Brandt, Shiv Saidha, Pablo Villoslada, Abdullah Abu Al-Hassan, Raed Behbehani, Elliot Frohman, Teresa Frohman, Joachim Havla, Bernhard Hemmer, Hong Jiang, Benjamin Knier, Thomas Korn, Letizia Leocani,

AAN.com/view/AM18 135

Monday

P2.127 Neurogenic Orthostatic

Knier, Timm Oberwahrenbrock, Janina Behrens, Catherina Pfuhl, Llian Aly, Miriam Kaminski, MunaMiriam Hoshi, Svenja Specovius, Rene Giess, Michael Scheel, Mark Mühlau, Judith BellmannStrobl, Klemens Ruprecht, Bernhard Hemmer, Thomas Korn, Friedemann Paul, Alexander Brandt

P2.149 Clinical Features and Outcomes

P2.153 Long-term Symptom Reduction P2.138 Wernicke’s Encephalopathy After of MdDS Rocking Vertigo with Theta Burst

P2.140 Objective Evidence of HyperNeurogenic Orthostatic Hypotension: Results rapid Olfactory Adaptation in Cranial Nerve I From a Survey of Patients and Caregivers — Dysfunction —Khurram Janjua, Alan Hirsch P2.126 Addressing Orthostatic

Schatz, John Guy

P2.151 Idiopathic Intracranial P2.163 Evaluation of neuroprotective Hypertension (IIH): An Aggressive Disease P2.136 Isolated Sixth Cranial Nerve Palsy in Sudanese Patients —Ammar Ahmed, Hadab properties of dimethylfumarate by optical

P2.125 Understanding the Symptoms of Satish Raj, Daniel Claassen, Charles Adler, Christopher Gibbons, Lawrence Hewitt

Athina Papadopoulou, Marco pisa, Hanna

Zimmermann, Steven Galetta, Laura Balcer treatment in the management of corticosteroid unresponsive optic neuritis: A P2.161 Retinal Ganglion Cell Layer retrospective case series of 15 cases —Yu and Disease Activity in Clinically Isolated Zhao, Angela Herro, William Feuer, Norman Syndrome —Hanna Zimmermann, Benjamin

P2.135 Postural Orthostatic Tachycardia: P2.150 Audiological Profile of Multiple

Diagnostic challenge of clinical spectrum of P2.137 A case of optic neuropathy due the spontaneous paroxysmal hypothermia to cat scratch disease (CSD) and syphilis cosyndrome —Rubens Salomão, Jose Luiz Pedroso, infection with characteristic MRI findings — Orlando Barsottini

P2.148 Intravenous immunoglobulin

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION II

Disease —Olivia Gardner, Anthony Griswold, BEHAVIORAL AND COGNITIVE NEUROLOGY: GENES, ENVIRONMENT, Sathesh Sivasankaran, Farid Rajabi, Brian Kunkle, Kara Hamilton, James Jaworski, William AND INTERVENTIONS

P2.173 Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype —John

Parker, Tahseen Mozaffar, Ashlynn Messmore, Joshua Deignan, Virginia Kimonis, John Ringman

P2.174 Huntington’s disease across four generations in a Mexican family: Westphal variant with female predominance —Jazmin

Bush, Eden Martin, Gary Beecham, Goldie Byrd, Jonathan Haines, Margaret Pericak-Vance

P2.186 Genetic Basis of Motoric

P2.179 Dietary Approaches to Stop

Hypertension (DASH) Diet Associated with Lower Rates of Depression —Laurel Cherian, Yamin Wang, Thomas Holland, Puja Agarwal, Neelum Aggarwal, Martha Clare Morris

P2.180 An Exploratory Analysis of

Lifetime Surgical History and Cognition — James Bateman, Christopher Filley, Brianne Bettcher

P2.181 Neurostimulation for Functional

Monday

Weakness: A Longitudinal Evaluation of Cortical Neurophysiology —Matthew Burke,

Reina Isayama, Gaayathiri Jegatheeswaran, Carolyn Gunraj, Anthony Feinstein, Anthony Lang, Robert Chen

P2.182 ‘Just Google It’—The Effect of

Media Events on Patterns of Public Interest in the ‘Vaccines Cause Autism’ Fallacy from 2004-2017 —Shehryar Sheikh, Carol Swetlik, Robert Wilson DO

GENETIC AND BASIC SCIENCE STUDIES IN NEURODEGENERATIVE DISEASES

P2.183 Characterization of Regulatory

T Lymphocytes in the progression of Alzheimer’s Disease —Alirexa Faridar, Aaron

Thomas, Neha Pal, Belen Pascual, Weihua Zhao, David Beers, Joseph Masdeu, Stanley Appel

P2.184 Age-Dependent White Matter Inflammation and Cognitive Impairment in the TgAPP21 Rat Model of Alzheimer Disease —Alexander Levit, Brian L. Allman,

Shaykh

Intranuclear Inclusion Disease —Monique

Montenegro, Brian Crum, Joseph Parisi, John Chen, Ralitza Gavrilova, Keith Josephs, Devin Mackay, Timothy Kaufmann, William Mantyh, Eoin Flanagan

Konno, Hiroaki Nozaki, Osamu Onodera, Takeshi Ikeuchi

Daiello, Cyrus Kosar, Richard Jones, Karen Furie

P2.212 Aphasia at Presentation Predicts Poor Functional Outcome After Acute Ischemic Stroke —Kathleen L. Donahue, Anne-

Katrin Giese, Mark Etherton, Ona Wu, Natalia Rost

P2.213 Cancer and Stroke— cognitive decline in a patient with deletion of Presentations and Problems —David Collas, exons 5-17 —Elizabeth Coffee, Hassan Fathallah- Aishah Azam, Manpreet Dhillon P2.199 NA P2.200 NA

P2.214 Stroke in Teens —

STROKE EPIDEMIOLOGY, RISK FACTORS, AND OUTCOMES

Chandramouleeswaran Venkatraman, Pratheep Kumar S, Balasubramanian Samivel, Venkatraman Karthikeayan, Kannan Vellaichamy, Harish Jayakumar, N. Shanmugasundaram, Lakshmi Ranganathan

P2.201 Characterizing Stroke in

P2.215 Development and Validation

Transgender Adults—a San Francisco General Hospital Study —Sara LaHue, Dolores Torres, Nicole Rosendale, Vineeta Singh

P2.202 The Role of Acute versus Ever

Use of Cocaine in Ischemic Stroke of Young Adults —Sleiman El Jamal, Mohsen Pirastehfar, Carl-Hans Blanchard, Bauman Kristie, Gabriella Garcia, Victoria Cantoral, Paul Katz

Tamao Tsukie, Toshiyasu Ogata, Toru Baba, Takeshi P2.203 Code 420: A case series Miura, Takanobu Ishiguro, Hiroaki Nozaki, Kensaku of accidental marijuana ingestion Kasuga, Yoshio Tsuboi, Etsuro Mori, Osamu masquerading as acute stroke —Katherine Onodera, Takeshi Ikeuchi Werbaneth, Tarini Goyal, Eric Beriner, Nirali Vora

P2.204 Recreational Use Of Marijuana

and Stroke: A Nationwide Outcome Study —Urvish Patel, Anam Habib, Aparna Saha, Gull Mahvish, Salma Yousuf, Priti Poojary, Liseth Lavado, Abhishek Lunagariya, Tapan Kavi, Vishal Jani

P2.205 Impact of Cocaine Use on Acute

of Graphical Displays for Reporting Acute Stroke Trials that Use a Patient-Centered Disability Outcome Primary Endpoint —Ivie Tokunboh, Jeffrey Saver

P2.216 Classical Crossed Medullary

Syndromes in Patients with Lateral Medullary Infarction —Guillermo Delgado-

Garcia, Fabiola Serrano-Arias, Monica Chavarria, Jose Merino, Antonio Arauz

P2.217 Etiologies, risk factors and

functional outcomes of young stroke in a Taiwanese cohort —Chun-Yu Chen, Ruei-Wun

Syu, Li-Hsin Chang, Jui-Yao Tsai, Hui-Chi Huang, Chun-Jen Lin, Chih-Wei Tang, Yung-Yang Lin, I-Hui Lee

P2.218 Prevalence of HIV Infection

Among Stroke Patients and its Association with Mortality in Southwestern Uganda —

Amir Abdallah, Sam Olum, Cumara O’Carroll, Bart Demaerschalk, Mark Siedner, Samson Okello

BRCA1 lead to reduced neuronal plasticity in Alzheimer’s disease —Tatsuo Mano, Takashi

Ischemic Stroke Patients: Insights from Nationwide Inpatient Sample in the United P2.219 Incidence of Ischemic and States —Zabeend Mahuwala, Chintan Rupareliya, Hemorrhagic Stroke Amongst Asians in the United States —Antonio Moya, Babak Navi, Rupak Desai, Upenkumar Patel, Sandeep Singh,

P2.192 Measuring the Contributions of

and Smoking Predicts Recurrence Rate of Ischemic Stroke in the Young —Muhammad

P2.191 Tau-related dysfunction of

Nonaka, Airi Tarutani, Tadafumi Hashimoto, Shigeo Manan Shah, Rikinkumar Patel, Smit Patel Murayama, Masato Hasegawa, Takeshi Iwatsubo, P2.206 History of Diabetes, Drug Abuse Atsushi Iwata

Hooman Kamel, Santosh Murthy

P2.220 Leukoaraiosis & Metabolic

Syndrome In Middle Age Egyption Ischemic Stroke Patients —Wael Amer, Mahmoud

Heritable and Non-Heritable Risk Factors Ahmed, Haris Kamal, Charlie Zhang, Robert to Alzheimer Disease Age-at-Symptomatic- Sawyer Onset in Adult Children of Affected Parents —Gregory Day, Carlos Cruchaga, Thomas P2.207 Continued Nationwide decline in Stroke related In-Hospital Mortality Wingo, Dean Coble, John Morris in United States —Mohammad-Rauf Afzal, P2.193 Clinical and neuropsychological Mohtashim Qureshi, Ihtesham Qureshi, Darine features of a family with a novel PSEN-1 Kassar, Paisith Piriyawat, Anantha Vellipuram, Alberto Maud, Salvador Cruz-Flores, Gustavo variant (I416T) —Laura Ramírez-Aguilar, Sonia

AbdelSayed, Tarik Menecie, Sayed El zayat, Mohamed Abdel Mouaty, Mohamed AbdAlsalam

P2.194 Genome-wide Association Study P2.208 Clinical Characteristics of Stroke

Mustapha Danesi

Moreno, Sara Henao, Laura Osorio, Mario Parra

Rodriguez, Rakesh Khatri

Patients with Essential Thrombocytosis Based on A/T/N System Identifies New Susceptibility Loci for Alzheimer’s Disease — according to JAK2 mutation —Joung-Ho Rha, Chenchen Tan, Jin-Tai Yu, Lan Tan

P2.195 African Haplotypic Background

Mitigates the Effect of APOE e4 Risk Allele in Alzheimer Disease —Farid Rajabli, Briseida

Hee-Kwon Park, Cindy Yoon, Byung-Nam Yoon, Eun-Kee Bae, Seong Choi, Woochang Chun, Haein Bak, Sang Won Lee, Dan Oh

P2.209 Trauma due to Acute Ischemic

Feliciano-Astacio, Katrina Celis, Kara Hamilton, Patrice Whitehead, Larry D. Adams, Parker L. Bussies, Jacob McCauley, Heriberto Acosta, Angel Chinea, Alejandra Rodriguez Betancourt, Goldie S. Byrd, Eden Martin, Christiane Reitz, Lindsay Farrer, Gerard Schellenberg, Richard Mayeux, Jeffery Vance, Michael L. Cuccaro, Jonathan Haines, Badri Vardarajan, Gary Beecham, Margaret PericakVance

Stroke: A Case Series —Kevin Yeboah, Aakash

P2.196 TREM2 P.Arg47His Is Not

P2.211 Level of Consciousness at

Nagalingam Rajakumar, Vladimir Hachinski, Shawn Associated With Late-Onset Alzheimer’s Whitehead Disease In A Tunisian Population —Mouna P2.185 Case Control Study of RNA Ben Djebara, Zied Landoulsi, Amira Nasri, Saloua Mrabet, Rym Kefi, Sonia Abdelhak, Amina Gargouri Editing in Blood Reveals Decreased Global Ep Berrechid, Riadh Gouider Levels of A-to-I Editing in Alzheimer’s

136 2018 AAN Annual Meeting

Gundimeda, Anat Boehm-Cagan, Jan Johansson, Helena Chui, Michael Harrington, Daniel Michaelson, Hussein Yassine

P2.187 Familial Adult-onset Neuronal

Ayers, Joe Verghese

Leucoencephalopathy with brainstem and spinal cord involvement and lactate elevation P2.190 Identification and Functional Assay of Novel CSF1R Mutations in Patients (LBSL) —Michael Doyle, John Lynch with Adult-onset Leukoencephalopathy with P2.178 Correlation Between Exercise Axonal Spheroids and Pigmented Glia — and Motor Skills with Elderly Patients Takeshi Miura, Naomi Mezaki, Takanobu Ishiguro, Takayoshi Tokutake, Kensaku Kasuga, Takuya Cognition —Cassio Henrique Taqu Martins, Catarina Assuncao

fluid studies implicate decreased ABCA-1 activity with APOE4 —Varun Rawat, Usha

P2.198 Case Report: SPG4-related

Elk-1 SUMOylation Mediate Endogenous P2.175 Fahr’s disease due to a novel Neuroprotection against Amyloid-beta SLC20A2 gene mutation in a Canadian patient: Early Neurocognitive, Structural and Toxicity —Shau-Yu Liu, Yun-Li Ma, Hsiao-Yuan Metabolic changes —Leila Sellami, Louis Verret, Lee Stephane Poulin, Robert Laforce P2.189 Mutational Analysis of AARS2 P2.176 Two Distinct Clinical Phenotypes in Japanese Patients with Adult-Onset Leukoencephalopathy Lacking CSF1R in a Family with ALSP Caused by a Novel Mutation —Naomi Mezaki, Norikazu Hara, CSF-1R Mutation. —Ryan Taylor, Basma

P2.177 A Case of AARS2

P2.197 In vitro, In vivo and cerebrospinal Linda Wendell, Ali Mahta, Nicholas Potter, Lori

Cognitive Risk Syndrome in Health and Retirement Study —Sanish Sathyan, Emmeline

G. Sotelo-Hernandez, Laura DeLeón-Flores, Ingrid Estrada-Bellman, Beatriz E Chavez-Luevanos, Adriana C Cantu-Salinas, Salvador Vazquez, Jessica Merino-Caballero, Nelly M NavaRodriguez, Belen Avila-Montanez, Ricardo Pinales- P2.188 Amyloid-beta Induction of Razo, Christopher Cerda-Contreras PIAS1 Ser-503 Phosphorylation and

Alyamany, Sachin Pandey, Andrew Kertesz, Lee Cyn Ang, Elizabeth Finger

Monday, April 23 11:30 a.m.–7:00 p.m.

Bodhit, Ali Al Balushi, Erik Krause, Abhay Kumar

P2.210 Only hepatic fibrosis,

not steatosis, assessed on transient elastography is an independent predictor of long-term mortality in patients with ischemic stroke. —Minyoul Baik, Hyo Suk Nam, Ji Hoe Heo, Seung Up Kim, Young Dae Kim

Discharge and Associations with Outcome After Ischemic Stroke —Michael Reznik, Shadi Yaghi, Mahesh Jayaraman, Ryan McTaggart, Morgan Hemendinger, Brian Mac Grory, Tina Burton, Shawna Cutting, Bradford Thompson,

P2.221 Impact of Reactive

Hyperglycemia on Stroke Severity and Outcome in Lagos, Nigeria —Osigwe Agabi, Mustapha Danesi

P2.222 Predictors of Stroke

Recurrence at Lagos University Teaching Hospital,Nigeria. —Osemwegie Nosakhare,

P2.223 Clinical characteristics

of borderzone infarction in Egyptian population —Nevine EL Nahas, Hossam Farag,

M Abdulghani, Magd Zakaria, Adel Taha Kamel, Nagia Fahmi, Naglaa Khayat, Aly Shalash, Ahmed El Basiony, Ramez Reda, Sherine Farag, Ihab Abdelbaset, Hany Aref

STROKE BIOMARKERS AND ANIMAL MODELS

P2.224 Neurovascular Protective Effects

of Remote Ischemic Preconditioning in Acute Ischemic Stroke Model —Farris Taha

P2.225 Functional Remapping of the

Mouse Somatosensory Cortex After Ischemic Stroke —William Zeiger, Mate Marosi, Cynthia He, Gengming Liu, Sheyda Mesgarzadeh, Michael Le, Cindy Chen, Carlos Portera-Cailliau

P2.226 Multimodal Imaging of White Matter Inflammation in a Rat Model of

Striatal Ischemic Stroke —Alexander Levit, Matthew S. Fox, Qi Qi, Vladimir Hachinski, Jonathan D. Thiessen, Shawn Whitehead

P2.227 Blockade of Soluble Epoxide Hydrolase Attenuates Post-Ischemic Neuronal Hyperexcitation and Confers Resilience Against Stroke with TrkB Activation —Li-Hsin Chang, Hui-Ching Lin,

Shiang-Suo Huang, I-Chih Chen, Kai-Wen Chu, Chun-Lien Chih, Yao-Wen Liang, Yi-Chung Lee, You-Yin Chen, Yi-Hsuan Lee, I-Hui Lee

P2.228 Characterizing the

Neuroinflammatory Response of Focal Ischemic Stroke in the Rat Insular Cortex —

P2.239 Role of Blood Based Biomarkers for Predicting Outcome after Spontaneous Intracerebral Hemorrhage: Findings from a Multi-Centric Prospective Cohort Study — Kameshwar Prasad, Amit Kumar, Shubham Misra, Ram Sagar, Bhavna Kaul, Surekha Dabla, SP Gorthi, Chandrashekhar Agrawal, Ajay Garg, Kuljeet Anand, Samander Kaushik

P2.240 A Combination of Three

Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Ischemic Stroke —I-Chen Yu, Ping-Chang Kuo,

Jui-Hung Yen, Hallel Paraiso, Benecia Hong-Goka, Robert Sweazey, Fen-Lei Chang

Victoria Thorburn, Brittany Balint, Victoria Jaremek, Maryse Paquet, Luciano Sposato, Shawn CEREBROVASCULAR GENETICS Whitehead P2.241 Molecular Genetic Features Of

PRE-HOSPITAL, TELESTROKE AND ED-BASED STROKE CARE II

P2.265 Impact of Seizures in Temporal

P2.251 Safety and Feasibility of

Hackett, Rahul Rahangdale, Ashis Tayal, Sandeep Rana, Robert Fishman, Jack Protetch, David Wright, Eric Schmidt, Rebekah Pratt

Mathis, Veena Nair, Megan Rozman, Taylor McMillan, Courtney Forseth, Dace Almane, Bruce Hermann, Neelima Tellapragada, Onyekachi Nwoke, Cole Cook, Andrew Nencka, Rasmus Birn, Elizabeth Felton, Aaron Struck, Rama Maganti, Lisa Conant, Colin Humphries, Edgar DeYoe, Manoj Raghavan, Vivek Prabhakaran, Jeffrey Binder, Mary Meyerand

P2.252 Pre-arrival RACE Score-Based

P2.266 Clinical Significance of Bilateral

Sitara Koneru, Samar Sheriff, Jaclyn Mueller, Syed Zaidi

Suchita, David Gonzalez, Lola Morgan, Kameel Karkar, Octavian Lie, Samiya Rashid, Campbell Sullivan, Alexander Papanastassiou, Charles Szabo

Telestroke in the Prehospital Emergency Medical Services Setting—The REACHOUT Project —Muhammad Adeel Saleemi, Chris

Hospital Bypass Protocol Improves Treatment Time Efficiencies —Shazli Khan,

Lobe Epilepsy on Cognitive Functions and Imaging Features —Gyujoon Hwang, Jedidiah

Failures on Wada Memory Testing —Iffat Ara

P2.267 Seizure-induced Behavioral and Autonomic Arousal Localizes to the Anterior and documentation of neurologic deficit by EMS and ED of patients with acute ischemic Cingulate Gyrus: Network Dynamics and Polymorphism Of The Gene Col4a1 Rs605143 P2.229 Association of plasma D-dimer Underlying Mechanism —Harshad Ladha, stroke —Haitham Hussein, Lauren Erickson, G / A In The Development Of Pathological and B-type natriuretic peptide levels with Bhavani Kashyap, Mitchelle Clayton, Mary Fennig, Adeel Memon, Sandipan Pati stroke mechanism, severity, and outcome — Deformations Of Cerebral Vessels In Patients Vesselina Pearsall, Carol Droegemueller, Sandi P2.268 Does A Drug Refractory Epilepsy With Migraine —Gulnora Rahmatullaeva Hyun-Wook Nah Wewerka, Aaron Burnett, Leah Hanson (DRE) diagnosis impact time to seizures in the P2.242 The Cerebral Straight and P2.230 Role Of Blood Biomarkers P2.254 A Prospective Validation of Epilepsy Monitoring Unit (EMU) —Brian Toh, Narrow: A Case Illustration of Moyamoya In Differentiating Ischemic Stroke and Stroke Network Of Wisconsin (SNOW) William Duong, Mary Porter, Leah Loewenstein, Syndrome in the Setting of the ACTA-2 Gene Scale —Kessarin Panichpisal, Maureen Hess, Intracerebral Hemorrhage —Rohit Bhatia, Frank Bertone, Sunita Dergalust Anand Warrier, Prerna Bali, Pranjal Sisodia, Anchal Mutation —Malcolm McDonald, Patrick Reynolds Reji Babygirija, Maharaj Singh, Paul Vilar, Thomas P2.269 The Role Of Immunoreactivity Gupta, Sreenivas Vishnubhatla, S Vivekanadhan, P2.243 Rare Presentation of Malignant Wolfe, Rehan Sajjad, Amin Kassam, Richard Rovin Of Neurotropic Autoantibodies And Padma Hadakasira, Kameshwar Prasad Myxomatous Aneurysms with PRKAR1A P2.255 Safety of intravenous Neuromediators In The Pathogenesis Of P2.231 Circulating inflammatory gene mutation —Usman Shehzad, Alexander Ou, thrombolysis in telestroke and impact of Symptomatic And Idiopathic Epilepsy — biomarkers are related to cerebrovascular Patricia Coyle, Agnes Kowalska an acute stroke training curriculum —Tarun Maruf Salokhiddinov, Rano Azizova disease in a non-demented elderly Girotra, Disha Kohli, Ellen Debenham, Christine P2.270 Epilepsy as a Dynamic population —Nicole Schupf, Jose Gutierrez, Irene P2.244 Molecular - Genetic Features Of The Gene Of Vasculoendothelial Growth Holmstedt, Chirantan Banerjee Disease: Modeling Seizure Burden Based Meier, Vanessa Guzman, Jennifer Manly, Adam Factor (C634G VEGFA) In The Deformations P2.256 NA Brickman, Richard Mayeux On Transitions Between Seizure Risk Of Cerebral Vessels —Gulnora Rahmatullaeva P2.257 NA States —Sharon Chiang, Marina Vannucci, Daniel P2.232 Diapedetic Potential of Goldenholz, Robert Moss, John Stern P2.245 PAI-1 polymorphism and stroke in P2.258 NA Monocytes in Complexes with Platelets pregnancy —Mary Hollist, Yogesh Gujrati, Stacie P2.271 Effect of Anesthesia on Correlates with Clinical Outcome after CLINICAL EPILEPSY II Demel Electrocorticography for localization of Stroke —Maria Lukasik, Radoslaw Kazmierski, Natalia Andrzejewska, Jacek Aniola, Maria P2.246 Ring-enhancing lesions, stroke P2.259 Baroreflex Sensitivity in Patients Epileptic Focus: Literature Review and Future Kamieniarz, Justyna Rosinska, Maciej Directions —Ayse Bayram, Shilpa Rao, Dennis and vascular retinopathy associated with a with Intractable Generalized Tonic Clonic Boruczkowski, Magdalena Frydrychowicz, Robert novel TREX1 mutation —Marcus Cimino, Sylvia Spencer, Mhd Alkawadri Seizures versus Partial Seizures —Behnaz Narozny, Grzegorz Dworacki, Wojciech Kozubski Soo, Mark Morrow Esmaeili, Farhad Kaffashi, Wanchat Theeranaew, P2.272 Can We Predict the prognosis in Aman Dabir, Samden Lhatoo, Kenneth Loparo P2.233 Multiple Biomarkers for the patients with Acute Symptomatic Seizure? P2.247 Systemic Response to Rupture Prediction of Stroke Outcomes: Findings A Prognostic model: A Retrospective study of Intracranial Aneurysms Analyzed with P2.260 Evaluation of Dual Pathology from a Cohort of 792 Patients with Ischemic Whole-transcriptome Sequencing —Joanna Among Drug Resistant Epileptic Patients from a developing nation —Gopal Dash, Stroke in a University Teaching Hospital — Jignesh parajapati, Amitkumar Patanvadiya Pera, Michal Korostynski, Marcin Piechota, Dzesika With Hippocampal Sclerosis —Peyman Zuolu Liu, Kwan Ng

Predicting Outcomes After Acute Stroke —

Hoinkis, Slawomir Golda, Magdalena Zygmunt, Tomasz Dziedzic, Rafal Morga, Marek Moskala, Agnieszka Slowik

Divya MR, Anand Warrier, Rohit Bhatia, Prerna P2.248 Association of Transforming Bali, Pranjal Sisodia, Anchal Gupta, Mohd growth Factor-β1 gene C509T, G800A and Sharique, Padma Srivastava, Kameshwar Prasad, V T869C Polymorphisms with Intracerebral Sreenivas, S Vivekanadhan

P2.235 Marked Leukocytosis on

Presentation with Acute Ischemic Stroke -- What Does it Mean? —Matthew Broderick, Tiffany Sheehan, Katharina Busl, Teddy Youn

Anne-Katrin Giese, Arooshi Kumar, Cathy Zhang, Sarah Nelson, Kelsey Shideler, Lisa Cloonan, Allison Kanakis, Kaitlin Fitzpatrick, Karen Furie, Fanny Herisson, Ona Wu, Natalia Rost

P2.237 Can S100b, IL 6 And BNP

Predict Functional Neurological Outcome In Intracerebral Hemorrhage? —Mohammed

El-Sherif, Abeer Mosbah, Hany Eldawoody, Ashraf Zaher, Mohamed Abdelbary

P2.238 Role of Copeptin as a Biomarker for Predicting Outcome after Spontaneous Intracerebral Hemorrhage: A Prospective Cohort Study —Shubham Misra, Amit Kumar, Pradeep Kumar, Pumanshi Talwar, Dheeraj Mohania, Deepti Vibha, Kameshwar Prasad

P2.261 A New Database Platform

for Clinical and Genetic Investigation Hemorrhage in North Indian Population: A of Epilepsies and the New ILAE Case-Control Study —Shubham Misra, Pradeep Classification —David Discua, Reyna Duron, Kumar, Amit Kumar, Pumanshi Talwar, Kameshwar Prasad

P2.249 Role Of Pharmacogenetics and

Pharmacodynamics On The Antiplatelet count is associated with stroke severity and Effect Of Clopidogrel In North Indian outcome independent of acute infarct size — Ischemic Stroke Patients —Dheeraj Khurana,

P2.236 Admission white blood cell

Gookizadeh, Jafar Mehvari Habibabadi, Shervin Badihian, Nasim Tabrizi, Navid Manouchehri, Reza Basiratnia, Majid Barekatain, Houshang Moein, Amirali Mehvari Habibabadi, Payam Moein

Jitender Gairolla, Rupinder Kler, Jasmina Ahluwalia, Madhu Khullar, Manish Modi, Bikash Medhi

P2.250 Association between Tumor

Iris Martinez, Viet-Huong Nguyen, Christopher Patterson, Julia Bailey, Miyabi Tanaka, Adriana Ochoa, Aurelio Jara-Prado, Maria Alonso, Minerva Lopez Ruiz, Marco Medina, Laura Guilhoto, Elza Targas Yacubian, René Silva, Carlos Arias, Antonio Delgado-Escueta

P2.273 Characterization of a Novel

Knock-in Mouse Model of KCNT1 Epileptic Encephalopathy —Lisseth Burbano, Melody

Li, Nikola Jancovski, Kay Richards, Elena Gazina, Snezana Maljevic, Christopher Reid, Steven Petrou

P2.274 NLRP1 Inflammasome is

Activated in Patients with Medial Temporal Lobe Epilepsy and Contributes to Neuronal Pyroptosis in Amygdala Kindling- induced Rat Model —Chenchen Tan, Jin-Tai Yu, Lan Tan

P2.262 Initial Presentations and Surgical P2.275 Autophagy in Juvenile Myoclonic Epilepsy (JME) —Miyabi Tanaka, Iris MartinezOutcomes of Pediatric Patients with Neurovascular Lesions —Janani Kassiri, Thilinie Juarez, Reyna Duron, Viet-Huong Nguyen, Adriana Rajapakse, D Sinclair

P2.263 Comparing the Clinical Profile

necrosis factor-alpha (-308G/A, +488G/A, -857C/T and -1031 T/C) gene polymorphisms and Seizure Control between Focal and Generalized Seizures in Adult Nigerian and risk of ischemic stroke in north Indian population: A case-control study —Pumanshi Patients with Epilepsy. —Chindo Mallum, Talwar, Shubham Misra, Pradeep Kumar, Amit Kumar, Kameshwar Prasad

EPILEPSY: BASIC SCIENCE AND GENETICS

Adedunni Olusanya, Olubunmi Omojowolo, Mustapha Danesi

P2.264 A Fatal Case of Mistaken

Identity: Brugada Syndrome Masquerading as Seizure Disorder —Claribel Wee, Julius Latorre

Ochoa, Aurelio Jara-Prado, Maria Alonso, Minerva Lopez Ruiz, Marco Medina, Laura Guilhoto, Elza Targas Yacubian, Rene Silva, Christopher Patterson, Julia Bailey, Antonio Delgado-Escueta

P2.276 NADPH oxidase inhibitor

attenuated increased seizure susceptibility after systemic inflammation —Wan-Yu Huang, Hung-Ming Wu

P2.277 A role of GPR55 in the

antiepileptic properties of cannabidiol (CBD) —Benjamin Whalley, Michael Bazelot, Evan Rosenberg, Richard Tsien

AAN.com/view/AM18 137

Monday

P2.234 Role Of Blood Biomarkers In

P2.253 Correlation between evaluation

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION II P2.278 Variation in Cortical Impact

Augments Epileptogenesis in Rat Model of Traumatic Brain Injury. —Shammy Chandel, Bikash Medhi

P2.279 Protective effects of

protocatechuic acid against seizure-induced neuronal death in the pilocarpine-induced status epilepticus rat model —Dong Jin Shin, Hongki Song, Sang Won Suh

CHILD NEUROLOGY AND DEVELOPMENTAL NEUROLOGY: EPILEPSY

P2.295 EEG Patterns in Routine

Polysomnography in Childhood and Risk of Epilepsy —Robert Stowe, Daniel Glaze

P2.296 New Onset Refractory Status

Epilepticus in Pediatric Population: A Single Tertiary Center Experience —Khalil Husari,

P2.280 Association Between Occurrence Katherine Labiner, Rana Said of Hippocampal Spindles and Hippocampal Interictal Spiking. —Kseniia K. Kriukova, Anatol P2.297 Cognitive, Linguistic and Bragin, Evgenia Alexandrova, Lin Li

P2.281 Majority of Epilepsy

Mutations are in Genes with Therapeutic Associations —Elaine Weltmer, Heather Newman, Amal Yussuf, Jing Wang

P2.282 Genotype and Phenotype

Correlation in Patients with Comorbid Epilepsy and Intellectual Disability — Mohamed Taha

P2.283 Screening of PI3K-AKT-mTOR

pathway genes in focal cortical dysplasias in a clinical setting —Andrea Accogli, Judith

Behavioral Characteristics of Children with Comorbid Autism Spectrum Disorder and Epilepsy —Louisa Kalsner, Jennifer TwachtmanBassett, Hudin Jackson, Laurie Derynioski

Monday, April 23 11:30 a.m.–7:00 p.m. P2.307 Cerebrospinal fluid (CSF)

P2.321 Chiari malformations associated Neurofilament and CXCL-13 Levels in with transverse myelitis: Are these Children with Demyelinating Disease —Maria myelopathies truly inflammatory? —Eliza

Galardi, Rachel Butler, Alyssa Lui, Jordan Cole, Gordon-Lipkin, Laura Munoz-Arcos, Paula Barreras, Robert Mikesell, Amber Salter, Laura Piccio, Soe Mar Maria Castaneda, Philippe Gailloud, Carlos PardoVillamizar

P2.308 Pediatric and Adult MS: A

Longitudinal Multimodal MRI Study to Explore the Substrates of the Different Clinical Courses —Ermelinda De Meo,

Alessandro Meani, Lucia Moiola, Bruno Colombo, Mariaemma Rodegher, Angelo Ghezzi, Giancarlo Comi, Andrea Falini, Massimo Filippi, Maria Rocca

P2.309 Chitinase 3-like 1 and

Neurofilament Light Chain Predict Pediatric Demyelination —Magnus Spangsberg Boesen, Poul Erik Hyldgaard Jensen, Melinda Magyari,

Peter Born, Peter Uldall, Morten Bjorn P2.298 Evaluation of new onset seizures Alfred Blinkenberg, Finn Sellebjerg

presenting to the Pediatric Emergency Department(ED). A quality improvement study based on the AAN, CNS and AES practice parameters (2010). —Nitish

Chourasia, Chritie Becu, Liang Zhu, Robert Lapus, Gretchen Von Allmen

P2.299 Cognitive Outcomes In Children With Infantile Spasms: Successful

Eva Chow, rasmus Kiehl, Timo Krings, Anne Bassett, Danielle Andrade

P2.285 STXBP1 is associated with bruxism in awake patients —Arezoo

Rezazadeh, Victor Lira, Alexandra Silberberg, Shelly Weiss, Elizabeth Donner, Maria Zak, Laura Bradbury, Muhammed Uddin, Stephen Scherer, O. Snead, Alfonso Fasano, Danielle Andrade

P2.286 Prevalence and Impact of

Consanguinity in Patients with Mesial Temporal Sclerosis in Saudi Population —

Khalid Alqadi, Saba Rammal, Ashwaq Alshahrani, Mosaab Alam, Saleh Baeesa, Youssef Al Said, Edward Cupler, Husam Kayyali

Prashant Jauhari, Biswaroop Chakrabarty, Vishal Sondhi, Shobha Sharma, Shefalli Gulati

Cases During 2015-2016 Zika Outbreak: A Cohort Study —Tabata De Alcantara, Angelle

Desiree LaBeaud, David Aronoff, Marcelo Rodrigues Zacarkim, Jessika Thais da Silva Maia, Kalyana E. Fernandes, Nilson Nogueira Mendes Neto

P2.302 Rectal Administration of

Vigabatrin Achieves Higher Plasma Concentration than Oral Administration. — Mohammad Hamed, Omar Hussein, Khalid Sawalha, Arun Asha Kalra

P2.303 Utilizing Quality Improvement

Monday

P2.306 The Spectrum of Myelopathies in Children: Beyond Idiopathic Transverse Myelitis —Laura Munoz-Arcos, Eliza Gordon-

Lipkin, Paula Barreras, Maria Jimena CastanedaValderrama, Maureen Mealy, Wendy Piedra, Olwen Murphy, Michael Levy, Daniel Becker, Scott Newsome, Carlos Pardo-Villamizar

P2.313 Autoimmune encephalitis in

Dunaway, Elena Mazzone, Amy Pasternak, Allan Glanzman, Richard Finkel, Basil Darras, Francesco Muntoni, Eugenio Mercuri, Darryl De Vivo, Kathie Bishop, Eugene Schneider, Frank Bennett, Richard Foster, Wildon Farwell

abobotulinumtoxinA (Dysport®) for lower limb spasticity: Pooled analysis of controlled clinical trials —Ann Tilton, Dennis Matthews,

Mark Gormley, Gustavo Suarez-Zambrano, Philippe Picaut, Mauricio Delgado

P2.324 Safety and Efficacy of

Nusinersen in Infants/Children with Spinal Muscular Atrophy (SMA): Part 1 of the Phase 2 EMBRACE Study —Perry Shieh, Gyula Acsadi, Wolfgang Mueller-Felber, Thomas Crawford, Randal Richardson, Nina Natarajan, Diana Castro, Sarah Gheuens, Ishir Bhan, Giulia Gambino, Peng Sun, Wildon Farwell, Sandra Reyna

Peter Riebling, Edward O’Mara, G. Elfring, Xiaohui Luo, Panayiota Trifillis, Joseph McIntosh, Claudio Santos, Julie Parsons, Perry Shieh, Susan Apkon, Craig Campbell, Craig McDonald

children: Clinical profile and outcome from a single tertiary care centre in India —Shefalli

P2.326 Pediatric Myasthenia Gravis

P2.314 Radiological Findings and

Rajanigandhi Hanumanthu, Nirav Sanghani, Shreya Shah, Nizar Souayah

Gulati, Vishal Sondhi, Biswaroop Chakrabarty, Prashant Jauhari, Rachana Dubey

Neurological Disorders in Microcephaly Cases Related to Zika Virus: A Cohort Study —Tabata De Alcantara, Jessika Thais da

Silva Maia, David Aronoff, Daniel Duarte Rolim, Marcelo Rodrigues Zacarkim, Angelle Desiree LaBeaud, Kalyana E. Fernandes, Nilson Nogueira Mendes Neto

After Vaccination in the United States. A Report from the CDC/FDA Vaccine Adverse Event Reporting System. (1990-2017) —

P2.327 Evaluation of Childhood

Weakness: Utilization of a Web-Based Educational Tool childmuscleweakness. org —Ann Martin, Holly Peay, Jen Ely, Erin O’Rourke, Katherine Mathews

P2.328 Predicting Ambulatory Aid Needs attention and information processing speed with Disease Progression in Charcot-Mariein adolescents with multiple sclerosis —Shay Tooth Disease —Sindhu Ramchandren, Jacob P2.315 Gait variability is related to

Menascu, Alon Kalron, Lior Frid, Anat Achiron

Moore, Joseph Hornyak

P2.316 A Case of Cognitive and

P2.329 Design of a Phase 3 Trial to

Behavioral Decline leading to Onset of Pediatric Onset Multiple Sclerosis —Janet Elgallab, Leigh Charvet, Lauren Krupp

Evaluate the Long-Term Efficacy and Safety of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy —

P2.317 A Case Series of Acute Flaccid

Panayiota Trifillis, Peter Riebling, Edward O’Mara, Xiaohui Luo, Joseph McIntosh

Jayne Ness

P2.330 Assessment of Practice Patterns

Myelitis in Pediatric Patients —Lydia Marcus,

P2.318 Imaging of the Mechanisms

of Thalamic Damage in Pediatric Multiple Sclerosis —Ermelinda De Meo, Lucia Moiola,

Angelo Ghezzi, Pierangelo Veggiotti, Ruggero Capra, Giancarlo Comi, Andrea Falini, Massimo Filippi, Maria Rocca

and Knowledge of Pathophysiology for Spinal Muscular Atrophy Among Neurologists —John Maeglin, Thomas Finnegan

P2.331 Slope Analysis of 6-Minute

Walk Dstance as an Alternative Method to Determine Treatment Effect in Trials in Duchenne Muscular dystrophy —Panayiota

P2.319 Miller Fisher Syndrome in a Case Trifillis, Peter Riebling, Marcio Souza, Gary Elfring, of Identical Twins —Tayyba Anwar, Juma

Mbwana, Katie Kundrat, Anne Vasiliadis, William Suslovic, Elizabeth Wells, Diana Bharucha-Goebel

P2.320 Pediatric Acute Flaccid Myelitis: A Case Series —Alison Christy, Yoon-Jae Cho

138 2018 AAN Annual Meeting

in nusinersen-treated children with spinal muscular atrophy. —Jacqueline Montes, Sally

neurologic syndromes, intellectual disability, P2.325 Meta-Analysis of Deflazacort vs abnormal behavior and sleep related Prednisone/Prednisolone in Patients with problems in HIV infected children —Rajni Farmania, Rakesh Lodha, Biswaroop Chakrabarty, Duchenne Muscular Dystrophy —Basil Darras,

Pediatric Epilepsy: A Review Of Literature. — Pandey, S K Kabra, Shefalli Gulati

Strategies to Increase Continuous EEG Monitoring in Critically Ill Pediatric Patients P2.287 Refractory Status Epilepticus and with Persistent Encephalopathy Following Chronic Kidney Disease in a Large Pedigree Status Epilepticus —Asri Yuliati, Nina Laudato, Katherine Cashen, Amanda Weber Due to a Variant in the Mitochondrial Encoded tRNA Phenylalanine (MT-TF) P2.304 Expanding the clinical spectrum Gene —James Ellis, Katie Mayne, Carina of the rare epilepsy syndrome of Benign Imburgia, Russell Butterfield Infantile Focal Epilepsy with Midline Spikes P2.288 Analysis of 234 Epilepsy Genes (BIMSE) —Reema Butt, Jules Constantinou, Muhammad Salim Khan for Sequence and Copy Number Variants Using Next Generation Sequencing — P2.305 Drug-Resistant Epilepsy Zhenyuan Wang, Marc Meservey, Izabela Karbassi, and Neurodevelopmental Disabilities in Sat Dev Batish, Glen Maston, Michele McCarthy, Randomized Controlled Trials of Therapeutic Joseph Higgins Devices —Lydia Bernhardt, John Powers, Rory Petteys, Rosemary Powers P2.289 Genetic Testing has taken out Guesswork: Cases of Familial and Nonfamilial Benign Infantile Epilepsy Associated CHILD NEUROLOGY AND DEVELOPMENTAL NEUROLOGY: with PRRT2 gene mutations. —Yoshimi INFECTIOUS, INFLAMMATORY, AND Hisamoto, Sonam Verma, Joan Cracco, Radha AUTOIMMUNE DISORDERS Giridharan

P2.290 NA P2.291 NA P2.292 NA P2.293 NA P2.294 NA

P2.312 To determine the prevalence of

P2.301 Long-Term Prognostic Patterns In Prashant Jauhari, Savita Sapra, Atin Kumar, R M Kushal Naik, Susan McCallum, Ton DeGrauw

P2.322 Ambulatory function and fatigue

P2.310 CT Scan Findings in Microcephaly P2.323 Safety profile of

St-Onge, Nassima Addour, Roy Dudley, Jean-Pierre Treatment Response Is Beneficial Regardless P2.311 Use of Induction Immunotherapy Farmer, Jeffrey Atkinson, Chantal Poulin, Francois Of Etiology —Nonita Mittal, Miya Asato, Yoshimi Plus Rituximab for the Treatment of Pediatric Dubeau, Joel Lafond Lapalme, Bernard Rosenblatt, Opsoclonus-Myoclonus Syndrome —Colin Sogawa Steffen Albrecht, Jean-Baptiste Riviere, Myriam Srour Wilbur, Carmen Yea, christoph licht, Meredith P2.300 The clinical and Irwin, E. Ann Yeh P2.284 Characteristics of periventricular

electroencephalographic spectrum of ESES nodules in patients with 22q11. 2 deletion (Encephalopathy with status epilepticus in syndrome —Arezoo Rezazadeh, Eduard Bercovici, sleep) in Indian children —Priyanka Madaan,

CHILD NEUROLOGY AND DEVELOPMENTAL NEUROLOGY: NEUROMUSCULAR DISEASE

Xiaohui Luo, Joseph McIntosh, Stuart Peltz

P2.332 Tolerability of Eteplirsen for

Duchenne Muscular Dystrophy in the Youngest Reported Patient Treated With This Therapy —Sonam Bhalla, Arpita Lakhotia

P2.333 Cervical Puncture to Deliver

P2.334 A unique presentation of rapidly Nusinersen in Patients with Spinal Muscular fluctuating symptoms in a child diagnosed Atrophy and no Lumbar Access —Aravindhan with Congenital Myasthenic Syndrome due Veerapandiyan, Ria Pal, Stephen DAmbrosio, Iris to RAPSN mutation. —Ashutosh Kumar, Sheila Young, Katy Eichinger, Erin Collins, Per-Lennart Westesson, Jennifer Kwon, Emma Ciafaloni

g1 H

Asghar, Robert Kavanagh, Matthew Wicklund

P2.335 Focal Myositis of the Iliopsoas

in a Young Girl with Recurrent Symptoms: A Case Report —Stephanie Manberg, Saunder Bernes

P2.336 Unexpected Neuromuscular

Diagnoses from Chromosomal Microarrays —Rebecca Luke, Sumit Verma

P2.337 NA P2.338 NA

Epilepsy/Clinical Neurophysiology (EEG) ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P2.339 Seizure Risk From Intraoperative Motor Evoked Potential Stimulation —Viet

Nguyen, Breanna Sandoval, Brian Ahuja, Leslie Lee, S. Charles Cho, Scheherazade Le, Jaime Lopez

Albalawi, Khalid Alqadi, Saleh Baeesa, Khalil Kurdi, Disease patient: A Case Report —Alexis Hosam Al-Aradati, Edward Cupler, Youssef Al Said Taylor, Victor Gonzalez-Montoya

P2.344 Analyzing Phenotypes Using

Artificial Intelligence Tools in Subgroups of

P2.341 Long Term Effects of Vagal Nerve P2.343 EEG Cap Placement for Expedited Absence and Myoclonic Epilepsies —Reyna Stimulation on Seizure Control and Quality of

M. Duron, Carlos Arias, Iris Martinez, Christopher

masks undiagnosed epilepsy in a Parkinson’s

Escueta

Identification of Non-Convulsive Status Patterson, Julia Bailey, Miyabi Tanaka, Adriana P2.340 Mesial Temporal Sclerosis (MTS) Life —Justin Abraham, Antoaneta Balabanov Epilepticus —Jake McKay, Caitlin D’Souza, Ugur Ochoa, Aurelio Jara-Prado, Maria Alonso, Marco Undetected by MRI of the Brain —Miad Sener, Christopher Smelick, Anteneh Feyissa, Medina, Viet-Huong Nguyen, Antonio DelgadoP2.342 Unilateral deep brain stimulation William Tatum

MS MODIFIABLE RISK FACTORS

P2.345 Hypertension and heart

disease are independently associated with development of brain atrophy in multiple sclerosis patients. A 5-year longitudinal study —Dejan Jakimovski, Sirin Gandhi, Ivo Paunkoski, Niels Bergsland, Jesper Hagemeier, Deepa Ramasamy, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman, Robert Zivadinov

P2.353 Longer Sleep Duration is Linked

MS DIAGNOSIS, MIMICKERS, AND PHENOTYPES

Victoria Leavitt, Maria Petracca, Matilde Inglese, James Sumowski

P2.362 Sarcoidosis Presenting as

to Preserved Cortical Gray Matter Volume in Early MS —Michelle Fabian, Ilana Katz Sand,

P2.354 Risk Factors Associated with

Multiple Sclerosis in Bogotá, Colombia. —

Intramedullary Spinal Cord Lesions —Prateek Thatikunta, Jude Khatib, Joseph Baar

P2.363 When It’s Not Multiple Sclerosis:

Jaime Toro, Fabián Cortés, Camilo Diaz-Cruz, Saul Reyes, Maria Reyes-Mantilla, Alejandra Duque Ramirez, Jorge Patiño, Camilo Torres, Jorge Ríos, David Cuellar Giraldo

Progressive White Matter Lesions with Inflammation —Julia Bucklan, Mary Willis,

Allen-Philbey, Sebastian Suarez, Özlem Yildiz, Benjamin Turner, Sharmilee Gnanapavan, Klaus Schmierer, Monica Marta, Joela Mathews, Grace Anjorin, Freya Edwards, Cherry Jain, Gavin Giovannoni

Multiple Sclerosis Patients Compared to Controls. —Raffaella Umeton, Evdokia

Increased Mortality —Anja Thormann, Per

P2.347 Vitamin D and physical activity

P2.356 Fecal Microbial Transplantation

P2.346 The Impact of Socioeconomic

Yuebing Li MD

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

P2.372 Retinal Vasculopathy with

Cerebral Leukoencephalopathy (RVCL): A Rare Familial Mimic of Tumefactive Multiple Sclerosis (MS) —Asaff Harel, Jenelle Raynowska, Dhanashri Miskin, Bidyut Pramanik, Saeed Asiry, Todd Anderson, John Boockvar, Souhel Najjar

P2.373 An Extremely Aggressive case of Marburg’s Disease —Jose Avila-Ornelas, Laura Surillo Dahdah, Eduardo Labat, Gishlaine Alfonso,

P2.364 Comorbidity in Multiple Sclerosis Carmen Serrano, Franchesca Fiorito Torres Status on Treatment Choice in Patients with is associated with Diagnostic Delays and P2.355 The Gut Microbiome in Relapsing P2.374 Spectrum of Peripheral Facial Multiple Sclerosis. —Saul Reyes, Kimberley Eleftheriou, Simona Nedelcu, Lauren Hall, Ana Luisa Maldonado-Contreras, Doyle Ward, Beth McCormick, Carolina Ionete

Solberg Sorensen, Nils Koch-Henriksen, Bjarne Laursen, Melinda Magyari

P2.365 Population-Based Prospective

Cohort of RRMS Patients Who Declined or Delayed Disease-Modifying Therapy —

Abdulaziz Al Sultan, Helene Parpal, Dina Lavorato, Jamie Greenfield, Luanne Metz

in multiple sclerosis —Florian Deisenhammer,

in Multiple Sclerosis: Trial design. —Ana

Angelika Bauer, Ivan Lechner

Cristina Dos Santos, Marcelo Kremenchutzky

P2.348 Depression Severity Among

P2.357 Gut microbiota and metagenomic P2.366 Assessment of Relative

Multiple Sclerosis Patients In Saudi ArabiaCross Sectional Study —Adel Ali Alhazzani,

P2.349 Vitamin B12 and its impact on Multiple Sclerosis Type and Severity —

Shymaa Hussain, Omar Salih, Fahad Ali, Reem Bunyan, Talal Harbi, Eman Nassim Ali

P2.350 Cesarean delivery and artificial

lactation are associated with an earlier age of disease onset in multiple sclerosis — Vittorio Martinelli, Gloria Dalla Costa, Marzia Romeo, Francesca Sangalli, Bruno Colombo, Lucia Moiola, Marta Radaelli, Federica Esposito, Giancarlo Comi

P2.351 Distinct Effects of Obesity and Vitamin D on Risk of Multiple Sclerosis: A Mendelian Randomization Study —Adil

Harroud, John A. Morris, Despoina Manousaki, Vincenzo Forgetta, Ruth Mitchell, George Davey Smith, Stephen Sawcer, J. Brent Richards

P2.352 Vitamin D Levels and Clinical

and OCT measures in Progressive Multiple Sclerosis —Justin Abbatemarco, Robert Bermel, Hong Li, Robert Fox, Daniel Ontaneda

Simona Rolla, Ilario Ferrocino, Valentina Bardina, Manfredi Ferraro, Alessandra Cianflone, Roberta Lanzillo, Stefania De Mercanti, Luca Cocolin, Marinella Clerico

P2.358 A Paleolithic Diet-Based

Intervention Decreases Multiple Sclerosis Fatigue via Lipid Profile Changes —Murali

Ramanathan, Kelly Fellows, Terry Wahls, Richard Browne, Babita Bisht, Linda Snetselaar, Bianca Weinstock-Guttman

P2.359 Stress-induced Brain Activity,

Brain Atrophy, and Clinical Disability in Multiple Sclerosis —Lil-Antonia Meyer-Arndt,

Martin Weygandt, Janina Behrens, Katharina Wakonig, Judith Bellmann-Strobl, Kerstin Ritter, Michael Scheel, Alexander Brandt, Stefan Hetzer, Stefan Gold, John Dylan Haynes, Friedemann Paul

P2.360 Case Series of Four High School Football Players with Multiple Sclerosis —

Cynthia Wang, Lana Harder, Benjamin Greenberg

P2.361 Nutrition in the First Year

MS EPIDEMIOLOGY AND GENETICS

P2.375 Impact of age at relapse on

recovery: An EDSS-recovery model for clinical trials —Burcu Zeydan, Brittani Conway, Elizabeth Atkinson, Carmen Castrillo-Viguera,

Importance of Disease Modifying Treatment Orhun Kantarci (DMT) Attributes in Multiple Sclerosis (MS) P2.376 Predictors of Vocational Status Patients —Tobias Sejbaek, Mette Bøgelund, Jens Among Persons with Multiple Sclerosis — Leander, Klaus Madsen

P2.367 Late Onset Fabry Disease: A

Mimicker of CNS Demyelinating Disease — Subhendu Rath, Ninad Desai, Lucas Meira Benchaya, Matthew Imperioli

P2.368 The phenotype of Argentinean Multiple Sclerosis patients is similar to Multiple Sclerosis patients from other regions and has remained stable over the past decade. —Mariano Marrodan, Negrotto Laura, Mauricio Farez, Jorge Correale

Sarah Morrow, Dhwanil Bhatty, Mervin Blair, Swati Mehta, Sascha Gill

P2.377 Relevance of Age and

Cerebrospinal Fluid Measures in Multiple Sclerosis associated with seizures —Shitiz

Sriwastava, Kalyan Yarraguntla, Maysaa Basha, Rohit Marawar, Deepti Zutshi, Evanthia Bernitsas

P2.378 Bone Microarchitecture and Bone Mineral Density in Multiple Sclerosis —Anna Olsson, Annette Bang Oturai, Helle Soendergaard, Finn Sellebjerg, Peter Oturai

P2.369 Impact of Gender on 30-day

P2.379 Impact of multiple comorbidities Readmission After Primary Admissions on EDSS at presentation in patients with for Multiple Sclerosis: A Nationwide multiple sclerosis: A cross-sectional study. — Readmission Database Analysis —Smit Patel, Faisal Alsallom, Sophia Woodson, Farren Briggs, Rupak Desai, Sandeep Singh, Upenkumar Patel, Alessandro Serra, Hesham Abboud Neel Patel, Shubhi Jain, Ninad Desai, Tapan Mehta

P2.370 Residual disability of acute

severe multiple sclerosis relapses —Anat Following the Diagnosis of Multiple Achiron, Shay Menascu, Ida Sarova-Pinhas, David Sclerosis —Yujie Wang, Kevin Alschuler, Annette Magalashvili, Mark Dolev, Michael Gurevich Wundes, Gloria Von Geldern

Jorge Kattah

P2.380 Estimated prevalence of

secondary progressive multiple sclerosis in the USA and Europe: Results from a systematic literature search —Vivek Khurana, Harsh Sharma, Jennie Medin

P2.371 Clinical and Immunologic

P2.381 Erdheim-Chester Disease in Characterization of MRI-Defined Phenotypes the Brainstem Mimicking Tumefactive in Multiple Sclerosis: A Longitudinal Study — Demyelination. —Maria Prieto Eibl, Javier Christopher Hemond, Brian Healy, Shahamat Gonzalez Tauhid, Maria Antonietta Mazzola, Roopali Ghandi, Howard Weiner, Rohit Bakshi

AAN.com/view/AM18 139

Monday

Mohammed Alqahtani, Hassan Ogran, Osamah Abuhawi, Abdulrahman Asiri, Ali Al-hanash, abdullmgeed Asiri, Reem Alqahtany, Adel Alfaifi, Mohannad Assiri

diversity in Clinical Isolated Syndrome —

Involvement in Central Demyelinating Diseases —Elias Samaha, Oscar Mancera Páez,

POSTER SESSIONS

POSTER SESSION II

P2.382 Differential Expression of

P2.393 Predictors of Conversion to Alternative Splicing Variants in Individuals Secondary Progressive Multiple Sclerosis in with Relapsing-Remitting Multiple Patients With Relapsing-Remitting Multiple Sclerosis —Michael Hecker, Annelen Rüge, Nina Sclerosis —Davorka Tomic, Ludwig Kappos, Boxberger, Brit Fitzner, Dirk Koczan, Ina Schroder, Hans-Jurgen Thiesen, Uwe Zettl

Daniela Piani Meier, Dieter Haering, Rolf Meinert, Gavin Giovannoni, Tanuja Chitnis

P2.383 Development of Multiple

P2.394 Predicting Physical and Mental

Sclerosis relapse flare after Vaccination, A CDC/FDA Vaccine Adverse Event Reporting System (VAERS) Study, [1987-2017]. — Moamina Fakhera Eddin, Janaki Patel, Abdul Rahman Alchaki, Nizar Souayah

P2.384 Employment Situation in

Brazilian Patients Diagnosed with Multiple Sclerosis —Denis Bichuetti, Carolina Martines

P2.395 New versus old: Implications of diagnostic criteria for Relapsing Remitting Multiple Sclerosis —Nuala McNicholas,

Estrutti, Gustavo San Martin E Cardoso, Enedina Oliveira

P2.385 Impact of Age on 30-day

P2.396 Familial Multiple Sclerosis:

Rupak Desai, Upenkumar Patel, Sandeep Singh, Neel Patel, Shubhi Jain, Allan Zhang, Ninad Desai

P2.386 The Prevalence and Special

Characteristic of Multiple Sclerosis that Begins in Older Adults —Gabriel Valero López,

Ana Esther Baidez Guerrero, Jose Diaz Perez, Luna Fuentes Rumi, Jose Maria Cabrera Maqueda, Rocio Hernandez Clares, Ester Carreon Guarnizo, Jose Meca Lallana

P2.387 Does Co-morbidity with Familial

An Epidemiological Study in Pontevedra, Spain. —Ana Rodriguez Regal, Luis Anibarro

Garcia, Macarena Soto Dopazo, María del Campo Amigo Jorrín

P2.397 Increased Risk of Ischemic

Stroke Associated with Untreated Multiple Sclerosis: A Nationwide Case-Control Population-Based Study. —Asad Ikram,

Christopher Calder, Fares Qeadan, Dinesh Jillella, Piotr Bzdyra, Maryam Zulfiqar, Joel NunezGonzalez, Tobias Kulik, Corey Ford, Atif Zafar

P2.388 Protective role of Multiple

Sclerosis in Stroke; Analysis of a large national data base —Maryam Zulfiqar, Fares

Qeadan, Christopher Calder, Asad Ikram, Dinesh Jillella, Piotr Bzdyra, Corey Ford, Atif Zafar

MS AND CNS INFLAMMATORY with Demyelination, Brain Atrophy and DISEASE: QUALITY OF LIFE, SYMPTOMS, AND SYMPTOMATIC Motor Impairment in a Model of Multiple Sclerosis —Maria Karamita, Richard Nicholas, Lili THERAPY II Kokoti, Sophia Rizou, Dimos Dimitrios Mitsikostas, Vassilis Gorgoulis, Lesley Probert, Dimitrios Papadopoulos

Zhang, Nazanin Kiapour, Sahil Kapoor, Joseph Merrill, Yongjuan Xia, Woomi Ban, Stephanie Cohen, Bentley Midkiff, Yen-Yu Ian Shih, Silva Markovic Plese

Care and Research in Multiple Sclerosis — Fox, Lori Mayer, Michael Racke

Neutrophils’ Migration to CNS in Passive Transfer RREAE —Nazanin Kiapour, Sahil Kapoor, Xin Zhang, Silva Markovic Plese

P2.408 Teriflunomide (Aubagio®)

decreases microglial density in Theiler’s Murine Encephalomyelitis Virus model of demyelination: Histological approach in combination with neuroimaging —Suyog

Pol, Claire Modica, Ferdinand Schweser, Michele Sveinsson, Michelle Sudyn, Nicola Bertolino, Marilena Preda, Michael Dwyer, Jesper Hagemeier, Danielle Siebert, Robert Zivadinov

activity-regulated oligodendrogenesis — Anna Geraghty, Michelle Monje

P2.410 Effect of Subcutaneous vs

P2.399 Long-term disability outcomes in Intravenous Chronic Treatment with an relapsing-remitting multiple sclerosis: A 10- Anti-CD20 Antibody on B-, T- and Myeloid year follow-up study —Jelena Drulovic, Tatjana Lymphocyte Subsets in Blood, Lymph Nodes and Spleen of C57BL/6 Mice —Anna Schubart, Pekmezovic, Sarlota Mesaros, Irena Dujmovic Basuroski, Vanja Martinovic, Jovana Ivanovic, Kerstin Hellwig

P2.415 Neurocognitive Correlates of

Impaired Perceptual Decision-Making in MS and their Link to Quality of Life —Martin

Weygandt, Janina Behrens, Jelena Brasanac, Eveline Soeder, Katharina Wakonig, Kerstin Ritter, Lil-Antonia Meyer-Arndt, Alexander Brandt, Judith Bellmann-Strobl, Stefan Gold, John Dylan Haynes, Friedemann Paul

P2.416 Treatment satisfaction and illness perception in MS patients —Jarrett Leech, Stefan Sillau, Valdez Brooke, Timothy Vollmer,

P2.407 IL-11-stimulated Encephalitogenic Enrique Alvarez, Luis Medina CD4+ Cells Induce Aggressive RREAE, P2.417 Pain Network and Mediated via Th17, CD8+, CD19+ Cells and

P2.398 The North American Registry for P2.409 BDNF is necessary for neuronal

Mediterranean Fever change the course of Anne Cross, Kottil Rammohan, David Jones, June Multiple Sclerosis? —Aksel Siva, Melih Tutuncu, Halper, Sara Murphy, Lisa Patton Perry, Edward Ugur Uygunoglu, Mustafa Erdogan, Serdal Ugurlu, Bihter Ozcan, Mesude Ozerden, Sabahattin Saip, Ayse Altintas, Emire Seyahi, Huri Ozdogan

P2.405 Cellular Senescence Correlates

Disability in Patients with Multiple Sclerosis: P2.406 IL-11 antagonist suppresses A Longitudinal Analysis of Electronic Health Th17 cells-mediated neuroinflammation and demyelination in a mouse model of Records. —Farren Briggs, Nicholas Thompson, Devon Conway relapsing-remitting multiple sclerosis —Xin

Andrew Lockhart, Siew Mei Yap, Karen O’Connell, Niall Tubridy, Michael Hutchinson, Christopher McGuigan

Readmission After Primary Admission for Multiple Sclerosis: A Nationwide Readmission Databse Analysis —Smit Patel,

Monday, April 23 11:30 a.m.–7:00 p.m.

Gaelle Elain, Cindy Schmid, Julien Perdoux, Catherine Huck, David Leppert, Anis Mir, Gisbert Weckbecker

Neuropsychological Profile in Multiple Sclerosis and Migraine Patients —Claudio

Gobbi, Emanuele Pravatà, Gianna Riccitelli, Chiara Zecca

P2.418 Neuroanatomical Correlates of

Latent Variables Speed and Memory in Early Multiple Sclerosis —Ilena George, Christian Habeck, Christina Lewis, Gabrielle Pelle, Victoria Leavitt, James Sumowski

P2.419 Exploring Cannabis use by

Patients with Multiple Sclerosis in a state where Cannabis is legal —Laura J Weinkle, Ian Shelton, Stefan Sillau, Christopher Domen, Kavita Nair, Enrique Alvarez

P2.420 Screening of cognitive

impairment in patients with multiple sclerosis (MS): The BICAMS short version for patient-centered care in small neurological institutions —Iris Katharina Penner, Melanie Filser, Alina Renner, Sebastian Ullrich, Chrstoph Lassek, Sharon Baetge

P2.421 A new electronic and brief

Monday

neuropsychological scale to detect cognitive impairment (CI) in patients with multiple P2.389 A Whole-Exome Sequencing Discontinuing Disease Modifying Therapies sclerosis (MS): Validation study of the MSSigns and Synergism of the Combination Study In Multiple Sclerosis Multiplex in the NARCOMS Registry —Marisa McGinley, COG-e scale —Jose Meca Lallana, Jose Maria Ponesimod-dimethyl Fumarate in Rat Models Philip Cola, Robert Fox, Deborah Miller Families —Elisabetta Mascia, Andrea Zauli, Prieto Gonzalez, Isabel Jimenez Martín, Judith of Multiple Sclerosis —Laetitia Pouzol, Paul Clara Guaschino, Melissa Sorosina, Silvia Santoro, Jimenez Veiga, Rafael Carles Diez, Francisco Javier Brian, Martine Clozel Donatella Biancolini, Silvia Bonfiglio, Dejan MS ANIMAL MODELS Olascoaga Urtaza, Gabriel Valero López, Rocio Lazarevic, Giovanni Meola, Vittorio Martinelli, Hernandez-Clares, Ester Carreon Guarnizo, Ioana P2.412 Cerebrospinal Fluid Derived Giovanni Tonon, Giancarlo Comi, Federica Esposito, P2.401 Astrocyte Transciptomics in Croitoru, Eva Costa Arpin, Maria cerdan, Andone from Primary Progressive MS Delays EAE Lead to Cholesterol Homeostasis as a Filippo Martinelli Boneschi Sistiaga Berrondo Remyelination after Lysolecithin-induced New Treatment Target —Noriko Itoh, Yuichiro Demyelination —Nathan Kung, Serena P2.390 The Saudi Arabian National P2.422 Effects of Live-Online Education Itoh, Alessia Tassoni, Michael Sofroniew, Rhonda Shimshak, Jamie Wong, Saud Sadiq Multiple Sclerosis Registry (NMSR): Initial on Multiple Sclerosis Disease Management: Voskuhl Results Saudi MS Registry Study Changes in Patient Experience, Clinical P2.413 Dietary Conjugated Linoleic P2.402 Longitudinal Diffusion Group* —Mohammed Al-Jumah, Reem Bunyan, Practice, Provider Knowledge and Acid Supplementation Modulates CNS Tensor Imaging in Theiler’s Murine Hessa Alotaibi, Edward Cupler, S. Ishak, S. Competence —Anne Roc, Wendy Turell, Patricia Autoimmunity —Ann-Katrin Fleck, Stephanie Encephalomyelitis Virus Driven Mouse Shami, Abid Kareem, Mamdouh Kalakatawi, Ghadah Altowaijri, Mousa Almejally, Hussein Al Gahtani, Saad Alrajeh, Ali Al-Mubarak, Sadaga Alawi, Shireen Al-Qureshi, Abdulrahman Almalki, Adel Alhazzani, A.M. Noor, I. Althubaiti, Nasser Alzahrani, Jameela Saeedi

P2.391 Demyelination and

Neurodegeneration along the Visual Pathway are more prominent in Secondary Progressive than Primary Progressive Multiple Sclerosis. —Simone Guerrieri, Marco pisa, Giovanni Di Maggio, Lucia Moiola, Vittorio Martinelli, Giancarlo Comi, Letizia Leocani

P2.392 Regional thalamic volumes

preferentially correlate with extra-thalamic white matter injury and clinical disability in multiple sclerosis subtypes —Kedar Mahajan, Kunio Nakamura, Jeffrey Cohen, Bruce Trapp, Daniel Ontaneda

140 2018 AAN Annual Meeting

P2.400 Patient Perspectives on

P2.411 Complete Resolution of Clinical

Hucke, Marvin Hartwig, Flavio Teipel, Martin Herold, Kerstin Berer, Marie Liebmann, Ivan Kuzmanov, Berit Grützke, Angelos Sagredos, Venkatpavanni Punugu, Michelle Sudyn, Ferdinand Maria Eveslage, Catharina Groß, Gurumoorthy Schweser, Claire Modica, Nicola Bertolino, Krishnamoorthy, Ulrich Dobrindt, Tanja Kuhlmann, Marilena Preda, Michael Dwyer, Robert Zivadinov Heinz Wiendl, Luisa Klotz

Model of MS Reveals White Matter Change —Ely Cuberos Paredes, Suyog Pol,

P2.403 Interaction of Normal and

Antineuronal IgGs with Neurons in Rat Brain Slice Cultures: Comparison of IgG Uptake, Clearance, Intraneuronal Binding to Target Antigens, and Production of Neuronal Death —John Greenlee, Susan Clawson, Kenneth Hill, Blair Wood, Suzanne Liu, Stacey Clardy, Noel Carlson

P2.404 Estrogen Receptor β Ligand

Acts on Two Pathways Within the CNS to Mediate Neuroprotection in the MS Model —Roy Kim, Darian Mangu, Noriko Itoh, Rhonda Voskuhl

P2.414 Passive transfer of human

aquaporin-4 IgG autoantibodies causes complement-independent spinal cord immunopathologies in mice —Koon Ho Chan, Kevin Leung Wah Yick

Coyle, Fred Lublin

P2.423 Cognitive reserve is consistently

related to cognitive performance in Multiple Sclerosis —Alvino Bisecco, Gabriella Santangelo, Luigi Trojano, Rosaria Sacco, Mattia Siciliano, Alessandro d’Ambrosio, Marida Della Corte, Luigi Lavorgna, Simona Bonavita, Gioacchino Tedeschi, Antonio Gallo

P2.424 Impact of Multiple Sclerosis

on Employment and its Association with Anxiety, Depression, Fatigue and Sleep Disorders —Junior Carnero, Pablo Lopez, María Balbuena Aguirre, Veronica Tkachuk

P2.425 NA P2.426 NA P2.427 NA P2.428 NA

NEUROPATHY II

P2.429 Skin coldness and painful cold:

P2.444 Novel Mutation in KIF5A

Causing Hereditary Spastic Paraplegia with Axonal Sensorimotor Neuropathy —Mathieu

The common symptom in patients with Cuchanski, Kelly Baldwin clinically suspected small fiber neuropathy in Korea —Eun Bin Cho, Jin Myoung Seok, Ki-Jong P2.445 Eosinophilic Vasculitic Neuropathy As A Presentation Of ChurgPark, Ju-Hong Min, Bum Chun Suh, Byoung-Joon Strauss Syndrome —Sandeep Devarapalli, Kim

P2.457 Smart Somatotopic Quantitative Sensory Testing findings in hATTR with Polyneuropathy —Marcus Vinicius Pinto, Linde

Gove, Brian McCauley, P. James B. Dyck, Elizabeth Ackermann, Marcia Waddington Cruz, Peter Dyck

P2.468 Functional neurological disorders in Parkinson disease —Benjamin Wissel

P2.469 Ghost in the Machine: Historical

P2.430 Is There A Relationship Between B. Dyck Exacerbated Diabetic Peripheral Neuropathy And Metformin? —Mohammed El-Sherif, Manal P2.446 Outcome comparison of

Aspects of Irreversible Brain Injury and Brain hereditary neuropathy —Ernesto Alonso-Labori, Death — Yi Tong Mazen Dimachkie, Omar Jawdat, Jeffrey Statland, P2.470 Discovery of novel recessive Tekalign Burka, Anai Hamasaki, Richard Barohn, Melanie Glenn, Laura Herbelin, Melissa Currence, genes in a consanguineous cohort using genotype-phenotype correlations —Kirsten Bhavana Sharma, Constantine Farmakidis, Duaa

P2.431 Brachial plexopathy after

P2.459 Correlation of supranormal

Hashem, Abdelfattah Nassar, Ahmed Esmael

influenza vaccination in adults in the USA. A report from the CDC/FDA Vaccine Adverse Event Reporting System (1990-2017) — Shreya Shah, Nirav Sanghani, Rajanigandhi Hanumanthu, Nizar Souayah

P2.432 Neuropathy with Dysarthria and Ophthalmoparesis —Tekalign Burka, Mamatha Pasnoor, Omar Jawdat, Melanie Glenn, Duaa Jabari

P2.433 Use of Intravenous

Immunoglobulin in Small Fiber Neuropathy associated with FGFR3 —Ajal Dave, Jonathan Smith

Pariwat Thaisetthawatkul, Rana Zabad, P. James

mechanically ventilated Guillain-Barre Syndrome versus Myasthenia Gravis in US Hospitals —Anantha Vellipuram, Rakesh

P2.458 Genetics in patients with

Jabari, Mamatha Pasnoor, Jasti Swetha

Khatri, Mohtashim Qureshi, Ihtesham Qureshi, Mohammad-Rauf Afzal, Paisith Piriyawat, Darine Kassar, Alberto Maud, Salvador Cruz-Flores, Gustavo Rodriguez

sensory nerve action potential amplitudes (supraSNAPs) with sensory nerve “hyperexcitable” symptoms —Philip Tipton,

P2.447 Guillain-Barre Syndrome as a

P2.460 The Role of Needle

Eduardo De Sousa

Laughlin

Rare Initial Presentation of Systemic Lupus Erythematosus. —Swathy Chandrashekhar,

P2.448 Rapidly Progressive POEMS

Syndrome with Absent M protein in Serum or Urine, Normal Bone Survey, and Normal Non-targeted Bone Marrow Biopsy —Payam Soltanzadeh, Jason Valent

Martin

Devon Rubin

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

Electromyography in the Evaluation of Carpal Tunnel Syndrome —Cory Kogelschatz, Ruple

P2.461 Morphometry of dorsal

rootlets using immunofluorescent confocal microscopy —Adam Loavenbruck, Samuel Roiko, Brian McAdams, Frank Symons

P2.462 Utility of Neuromuscular

P2.434 Isolated external

P2.449 Modifying Hyperglycemic

Porambo, Kaye Sedarsky, Emily Elliott, Brett Theeler, Jonathan Smith

Marca, Hiroshi Takashima, Pilar Mazzetti Soler, Mario Cornejo Olivas

Omer Suhaib, Gozde Demiralp, Eduardo De Sousa

(AMAN) presenting with truncal and appendicular ataxia —Ashmanie Mahatoo,

Bhadola, Kate Daniello

Ultrasound in the Evaluation of Proximal ophthalmoplegia associated with IgG Median Neuropathies: A Case Series —Elina Peripheral Nerve Injury —Mark Stecker anti-GQ1b antibody —Sunhee Kim, Muhammad Zakin, Susan Shin P2.450 Rare Case of Ulnar Neuropathy — Rizwan Husain, Lawrence Zeidman P2.463 Why do we repeat Anai Hamasaki, Mazen Dimachkie, Mamatha P2.435 A case of remission from Pasnoor, Melanie Glenn, Richard Barohn, Omar electrodiagnostic studies? And, does it make multifocal motor neuropathy following Jawdat, Laura Herbelin, Brian Everist, Duaa Jabari a difference? —Shivakrishna Kovi, David Avila rituximab —Natalia Gonzalez, Vern Juel, Sasha P2.451 Ustekinumab related CIDP in a P2.464 Ultrasound Guided Open Muscle Zivkovic patient with psoriatic arthritis —Gamaleldin Biopsy —Shumaila Sultan, Kymberly Gyure, P2.436 Late Onset TTR-related Familial Osman, Kavit Shah, Muhammad Salim Khan, Kara Cheryl Smith Steijlen, Naganand Sripathi Amyloid Polyneuropathy (FAP) in Two P2.465 Clinic and Lab Based Respiratory Patients with Acquired Demyelinating P2.452 Proximal Motor Sensory Testing in Patients with Myasthenia Features —Nazila Rad, Said Beydoun Hereditary Neuropathy (HMSN-P) in a Gravis —Hans Katzberg, Carolina Barnett Tapia, Peruvian Family with Japanese Ancestry — Vera Bril P2.437 A Novel Report of NivolumabElison Sarapura Castro, Darko Quispe, Maryenela Induced Parsonage-Turner Syndrome P2.466 Comparison of Train of Four with Associated with Hourglass-like Constriction Illanes-Manrique, Karina Milla-Neyra, Miguel Repetitive Nerve Stimulation in the ICU — of the Anterior Interosseous Nerve —Michael Inca-Martinez, Erick Figueroa-Ildefonso, Victoria

P2.438 Acute Intermittent Porphyria: Macedo, Raisa Saron Murari, Barbara Diniz, Pedro Macedo, Joao Marcos Ferreira, Guilherme Torezani, Karoline Medeiros, Leonardo Modenezi, Fabio Martins, Leonardo Araujo, Eduardo Davidovich, Camila Pupe, Osvaldo Nascimento

P2.439 Ganglioside Antibodies in

Monday

Sometimes DIfficult to Diagnose —Yuri

P2.467 Should We Refer Patients with P2.453 Acute Motor Axonal Neuropathy Pain for Electromyography? —Shivkumar Karan Topiwala, Amre Nouh, Yan Zhang, Isaac Silverman, Annie Daniel

NEUROMUSCULAR DIAGNOSTICS, GENETICS, AND BIOMARKERS

Acute Inflammatory Demyelinating P2.454 Needle ImpedancePolyradiculoneuropathy (AIDP) and its Electromyography (I-EMG): A New Technique Variants —Mithila Fadia, Ratna Bhavaraju-Sanka for the Electrodiagnostic Laboratory —

P2.440 Cognitive Biases at Bedside

Resulting in Diagnostic Error of GuillainBarré Syndrome —Rohit Gummi, Chakrapani

Pathikonda, Pradeep Bollu, Fang Zhang, Spurthi Surpur, Raghav Govindarajan

P2.441 Heterozygous Mutations of

SH3TC2 as a Cause of HNPP —Devin Prior, Victoria Lawson

P2.442 Reduction in Idiopathic

Peripheral Neuropathy Diagnoses Using a Comprehensive EMR-based Laboratory Order Set —Fang Bai, Martha Cruz, Dilip Pandey, Lawrence Zeidman

P2.443 Brachial Plexopathy Post

Seward Rutkove, Hyeuknam Kwon, Benjamin Sanchez

P2.455 Feasibility and Validation of

Modified Oculobulbar Facial Respiratory Score (mOBFRS) in Amyotrophic Lateral Sclerosis —Marie Wencel, Nadia Araujo, Lishi

Zhang, Eileen Medina, Tahseen Mozaffar, Namita Goyal

P2.456 A New Method to Detect

Potential Causative Genes for Spastic Paraplegia Utilizing Aggregate Data of Whole Exome Sequencing —Masaki Tanaka, Hiroyuki Ishiura, Jun Mitsui, Kishin Koh, Yuta Ichinose, Yoshihisa Takiyama, Shoji Tsuji

Transcatheter Arterial Chemoembolization — Kavneet Kaur, Anila Thomas, Jin Li

AAN.com/view/AM18 141

POSTER SESSIONS

POSTER SESSION III G GRADUATE MEDICAL EDUCATION: ASSESSMENT AND CURRICULAR DESIGN II

P3.001 Effectiveness of Blended

Learning for Resident Education in Neurology: Experience from Movement Disorder Course —Danish Bhatti, John Bertoni, Faye Haggar, Linda Love, Ryan Brennan, Peggy Moore, Sachin Kedar, Diego Torres-Russotto

P3.002 Predictors of Strong Performance during Neurology Residency and Beyond — Deborah Bradshaw, Cheryl Roe, Mary Phelan

P3.003 Graduation competencies: What

Tuesday, April 24 11:30 a.m.–7:00 p.m.

P3.010 Developing a Successful

Wellness Program for Child Neurology Residents —Aimee Sato, Sandra Cushner

P3.011 Assessing and Enhancing

Neurology Resident Education on Interpersonal Communication and Professionalism —Arielle Kurzweil, Ariane

091–172

Lewis, Perrin Pleninger, Sara Rostanski, Aaron Nelson, Koto Ishida, Laura Balcer, Steven Galetta

P3.012 Improving Resilience Among Neurology Residents —Adrienne Keener, Brenda Bursch, PhD

Gewirtz, Mercedes Jacobson, Sarah Zubkov, Ivan Cuesta Isabel, Jennifer Haynes

Iqbal, Muhammad Taimur Malik

P3.004 Impact of a Novel Clinic Block

Licensure Actions Involving ABPN Diplomates —Larry Faulkner, Dorthea Juul

Laura Donovan, Barbara Almeida, Christina Ulane

P3.005 Evaluation of Resident Physician Exposure and Patient Access in Outpatient Continuity Clinic —Neeraj Singh, Philip Yeung

P3.006 Implementing a Formal

Faculty-Resident Feedback Protocol for NYU Neurology Residency —Scott Grossman, Alexandra Lloyd-Smith, Cen Zhang, Harold Weinberg, Arielle Kurzweil

P3.007 The development of the National In-training examination for Canadian Pediatric Neurology Residents (NITECaP) —

P3.014 Neurologists in Trouble:

P3.008 Autonomy and Praise from

Co-Residents May Protect Against Burnout in Neurology Residents —Jeffrey Ratliff,

Ted Weissfeld, Christopher Skidmore, Andrew Southerland, Cormac O’Donovan, Joseph Carrera, Vicki Shanker

P3.009 Residents’ Perceptions of

Tuesday

Inappropriate Consults: Expectations of Expertise Among Neurology and Medicine Residents as a Barrier to Interdisciplinary Collaboration —Stephen Krieger, Erik Bortnick

142 2018 AAN Annual Meeting

ePosters

037–084

b1 g1 339–344 a1 ePosters

Poster Discussion

027–036

001–026

B. Movement Disorders: 037 – 084

P3.016 Code Stroke Simulation Training

Benefits Junior Neurology Residents —Linda Wendell, Michael Reznik, David Lindquist, Ali Saad, Jonathan Cahill, Tina Burton, Shawna Cutting, Brian Mac Grory, Ali Mahta, Matthew Siket, Shadi Yaghi, Mahesh Jayaraman, Bradford Thompson, Karen Furie

Neurology Residency In-Service Training Examination (RITE) Scores —Alyssa-Rae

259–294

295–338

345–428

429–480

A. Research Methodology, Education, and History: 001 – 026

P3.015 Resident Education through Adult Shoirah, Achillefs Ntranos, Rachel Brandstadter, Elisha Medina-Gallagher, Yangbo Liu, Jamie Kwan, Stephen Krieger

Poster Session 3 a1. Aging and Dementia Poster Discussion Session: 027 – 036

Learning: Two Years of Experience —Hazem

201–258

GRADUATE MEDICAL EDUCATION: NOVEL FORMATS

Sunita Venkateswaran, Serena Orr, Timothy Wood, P3.017 Intensive Neuroanatomy Boot Debra Pugh, Susan Humphrey-Murto, David Callen Camp Curriculum Demonstrates Improved

GRADUATE MEDICAL EDUCATION: BURNOUT AND PROFESSIONALISM

173–200

085–090

P3.013 Burnout, resident satisfaction, does a future Neurology resident need and well-being among neurology residents to know at medical school graduation to prepare for Neurology residency? —Alexandra with different service models —Muhammad

Schedule on Resident Satisfaction and Continuity of Care in the adult neurology resident clinic at Columbia University Medical Center —Andrew Taylor, William Roth,

Weinstein, James Reese, Amy Kao

b1. General Neurology ePoster Session: 085 – 090 C. D. E. F. G.

Headache; Practice, Policy, and Ethics: 091 – 172 Aging, Dementia, Cognitive, and Behavioral Neurology: 173 – 200 Cerebrovascular Disease and Interventional Neurology: 201 – 258 Epilepsy/Clinical Neurophysiology (EEG): 259 – 294 Neuro Trauma, Critical Care, and Sports Neurology; Child Neurology and Developmental Neurology: 295 – 338

g1. Research Methodology ePoster Session: 339 – 344 H. MS and CNS Inflammatory Disease: 345 – 428 I. Neuromuscular/Clinical Neurophysiology (EMG): 429 – 480

Novroski, Kelly Baldwin, Cynthia Correll, Anthony Noto, David Avila

P3.018 Effectiveness of a Video-Based

P3.020 Flipped Classroom: Applications P3.023 Feasibility of Online Resident Lecture (VBL) EEG Curriculum for Incoming in Teaching EEG —Alyssa-Rae Novroski, Cynthia Education in Pakistan with international Neurology Residents —Rachael Benson, Eliezer Correll collaborations: Implementing Blended Sternberg, Jeremy Moeller, Michelle Bell learning —Danish Bhatti, Nadir Syed, P3.021 Increasing Knowledge and Muhammad Javed, Muhammad Ilyas, John P3.019 Medical Simulation as the Comfortability in the Management of Standard for Acute Stroke Education: Review Pediatric Status Epilepticus —Jeffrey Kornitzer, Bertoni, Arsalan Ahmad of the Literature and Recommendations Jessica Tu P3.024 NA for Future Implementation —Frances Chow, P3.025 NA P3.022 Stroke Code Simulation Has Nerses Sanossian, Gene Sung, Roy Poblete Sustained Benefit on Neurology Resident P3.026 NA Education and Preparedness for Stroke Call —Catherine Legault, Nirali Vora

Aging and Dementia Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below.

Posters displayed 11:30 a.m.-5:30 p.m. • Data blitz 12:00 p.m.-12:50 p.m. • Presenters Stand by Posters 5:30p.m.-7:00 p.m. Data Blitz: 11:45 a.m.–11:50 a.m.

P3.027 Plasma Biomarkers in Early

Neurodegenerative Disease Stages —Fanny

Elahi, Kaitlin Casaletto, Adam Staffaroni, John Neuhaus, Yann Cobigo, Emily Fox, Samantha Walters, Marie Altendahl, Ryan Fitch, Anna Karydas, Jason Hinman, Charles DeCarli, Adam Boxer, Gil Rabinovici, Howard Rosen, Bruce Miller, Joel Kramer

Data Blitz: 11:50 a.m.–11:55 a.m.

Feingold, Corlier Fabian, Nicki Mostowfi, Paul Thompson, Meredith Braskie

Steven Horton, John Umhau, Helena Chui, Lon Schneider, Michael Harrington, Alfred Fonteh

Mayo Clinic —Vijay Ramanan, David Jones,

Data Blitz: 12:00 p.m.–12:05 p.m.

Data Blitz: 12:15 p.m.–12:20 p.m.

Data Blitz: 12:30 p.m.–12:35 p.m.

P3.030 Multisensory Impairment

P3.033 Changes in Functional and

P3.036 Characteristics and Progress on

Kristine Yaffe

Agosta, Silvia Basaia, Elisa Canu, Francesca imperiale, Giuseppe Magnani, Monica Falautano, Giancarlo Comi, Andrea Falini, Massimo Filippi

is Associated with Increased Risk of Dementia —Willa Brenowitz, Allison Kaup, Data Blitz: 12:05 p.m.–12:10 p.m.

P3.031 Sense-encoded poly-GR

Structural Brain Connectome Along the Alzheimer’s Disease Continuum —Federica

Data Blitz: 12:20 p.m.–12:25 p.m. dipeptide repeat proteins correlate to P3.034 In Vivo [18F]-AV-1451 Tau-PET neurodegeneration and uniquely co-localize levels are associated with risk of Mild Imaging in Sporadic Creutzfeldt-Jakob Cognitive Impairment among individuals with with TDP-43 in dendrites of repeat expanded Disease —Gregory Day, Brian A Gordon, Richard and without low CSF amyloid-beta —Michelle C9orf72 amyotrophic lateral sclerosis —

P3.028 Elevated CSF neurofilament

Mielke, Jeremy Syrjanen, Kaj Blennow, Henrik Zetterberg, Ingmar Skoog, Clinton Hagen, Argonde Van Harten, David Knopman, Clifford Jack, Ronald Petersen, Silke Kern

Data Blitz: 11:55 a.m.–12:00 p.m.

P3.029 VEGF’s Relationship to Brain Aging Biomarkers —Meral Tubi, Franklin

Shahram saberi, Jennifer Stauffer, Jie Jiang, Sandra Garcia, derek schulte, Takuya Ohkubo, Cheyenne Schloffman, Marcus Maldonado, michael baughn, Maria Rodriquez, Donald Pizzo, Don Cleveland, John Ravits

Data Blitz: 12:10 p.m.–12:15 p.m.

P3.032 Role of ABCA-1 Activity in Brain

Perrin, Nigel Cairns, Helen Beaumont, Katherine Schwetye, Cole Ferguson, Namita Sinha, Bob Bucelli, Erik Musiek, Nupur Ghoshal, Maria R Ponisio, Benjamin Vincent, Shruti Mishra, Kelley Jackson, John Morris, Tammie Benzinger, Beau Ances

Data Blitz: 12:25 p.m.–12:30 p.m.

DHA Metabolism in Carriers of APOE4 —

P3.035 Transient Epileptic Amnesia: A

PARKINSON’S DISEASE: WEARABLE SENSORS AND REMOTE MONITORING TECHNOLOGY

P3.043 Developing a Self-Administered

PARKINSON’S DISEASE: ANIMAL MODELS AND BIOMARKERS

P3.037 Using Objective Measurement

Shyamal Patel, Bryan Ho, Paul Wacnik, Hao Zhang, Tairmae Kangarloo, Vesper Ramos, Stephen Amato, Dmitri Volfson, Peter Bergethon, Michael Erb

alpha-synuclein toxicity in a rat model of Parkinsonism —Nikolaus McFarland, Mayur

P3.044 Accelerometry-Based

P3.050 Cytosolic glucocerebrosidase

Via Wearable Sensors To Evaluate Realworld Effectiveness Of Carbidopa/Levodopa Enteral Suspension For Managing Motor Fluctuations: PROviDE Study Design And Baseline Characteristics —Rajesh Pahwa, E. Ray Dorsey, Irene Pan, Stephanie van Norman, Thomas Marshall, Dustin Heldman, Yash Jalundhwala

P3.038 Virtual research visits in

Instrumented Motor Exam for Home-based Parkinson’s Disease Assessment Using Wearable Sensors —Charmaine Demanuele,

Quantitative Analysis of Mobility in Parkinson Disease —Jia Zhen Cheng, Rainer

von Coelln, Katrina Schrader, Erik Barr, Ann Gruber-Baldini, Joseph Savitt, Stephen Reich, Lisa Shulman

individuals with Parkinson disease enrolled in a clinical trial: REACT-PD Study —Christopher P3.045 Clinical Experience with Personal KinetiGraph Before and After Deep Brain Tarolli, Kelly Andrzejewski, Grace Zimmerman, Michael Bull, Steven Goldenthal, Michael O’Brien, Stimulation for Parkinson’s Disease — Tanya Simuni, Kevin Biglan, E. Ray Dorsey

P3.039 Objective Data in Parkinson’s

Summer Gernon, Alexandra Fowler, Kelly Lyons, Rajesh Pahwa

Horne

P3.040 Using Wireless Wearable

Sensors to Estimate the Severity of Rest Hand Tremor in PD —Md Nafiul Alam, Asenath Huether, Abby Aymond, Tamanna Tabassum Kha Munia, Colin Combs, Reza Fazel-Rezai, Sarah Matcha, Tanya Harlow, Jau-Shin Lou

P3.041 Wearable Motion Quantification

Florian Lipsmeier, Kirsten I. Taylor, Timothy Kilchenmann, Detlef Wolf, Alf Scotland, Jens Schjodt-Eriksen, Wei-Yi Cheng, Igancio Fernandez Garcia, Juliane Siebourg-Polster, Liping Jin, Jay Soto, Lynne Verselis, Meret Martin Facklam, Frank Boess, Martin Koller, Michael Grundman, Andreas Monsch, Ronald Postuma, Anirvan Ghosh, Thomas Kremer, Christian Czech, Christian Gossens, Michael Lindemann

312 Subjects in the Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) Protocol —Bradley Boeve,

Howard Rosen, Adam Boxer, Danielle Brushaber, Giovanni Coppola, Christina Dheel, Bradford Dickerson, Kelley Faber, Julie Fields, Jamie Fong, Tatiana Foroud, Ralitza Gavrilova, Nupur Ghoshal, Jill Goldman, Jonathan Graff-Radford, Neill Graff-Radford, Murray Grossman, Hilary Heuer, John Hsiao, Ging-Yuek Hsiung, Edward Huey, David Irwin, David Jones, Kejal Kantarci, Anna Karydas, David Knopman, John Kornak, Joel Kramer, Walter Kukull, Maria Lapid, Ian R.A. Mackenzie, Bruce Miller, Leonard Petrucelli, Madeline Potter, Rosa Rademakers, Katherine Rankin, Margaret Sutherland, Jeremy Syrjanen, Joanne Taylor, Arthur Toga, Sandra Weintraub, Zbigniew Wszolek

Retrospective Analysis of Cases from the

P3.049 Rab8a protects against

Parmar, Hyo-Jin Park, Daniel Ryu, Lyndsee Powell, Rachel Foels, Sofia Anagnostis

P3.057 Support for the Spreading

Hypothesis: Pathologically Proven Alphasynuclein Peripheral Neuropathy 20 years Before Development of Parkinsonism — Olwen Murphy, Jacques Noel, Michael Farrell, Timothy Lynch

P3.058 Role of a-Synuclein in the GFAP. HMOX1 mouse model of PD —Laurianne Garabed, Hyman Schipper

impairs alpha-synuclein degradation P3.059 Alpha-synuclein Protein by blockade of chaperone-mediated autophagy —Sheng-Han Kuo, Inmaculada Tasset, Homeostasis and Oligomerization in Ironoverloaded Cells Expressing Mutant HFE — Ana Maria Cuervo, David Sulzer

P3.051 Evaluation of Glucosylceramide Synthase (GCS) Inhibition for GBAAssociated Parkinson’s Disease —Tanya

Fischer, S. Pablo Sardi, Lamya Shihabuddin, Dan Rudin, Jyoti Bala Sharma, Roberto Araujo, Jian Li, M. Judith Peterschmitt

P3.052 A comparative plasma alpha-

synuclein concentration and metabolic profiling study in Parkinson’s disease and essential tremor —Esther Cubo Delgado,

Olimpio Montero-Domingo, Silvia Albillos, Sara Calvo, Jose Trejo, Berta Solano, Sandra Delgado, Sara Casais

P3.053 Dendritic cells, CD4+ T cells, and

Yunsung Kim, James Connor, Mark Stahl

P3.060 Pilot Assessment of Salivary

Cortisol Levels as a Marker for Depression in Patients with Parkinson Disease —Jared Sweeney, Julia Prusik, Eric Molho

P3.061 Fundamental limit of alpha-

synuclein pathology in gastrointestinal biopsy as a pathologic biomarker of Parkinson’s disease: Comparison with surgical specimens —Beomseok Jeon, Chae

Won Shin, Sung-Hye Park, Ji Yun, Jung Hwan Shin, Guangxun Shen, Yoon Kim, Han-Kwang Yang, Hyuk-Joon Lee, Seong-Ho Kong, Yun-Suhk Suh, Han Kim

α synuclein triangle fuels neuroinflammation P3.062 Neuroprotective Effect of Parkin on Mitochondria in Central Dopaminergic in Parkinson’s disease —Daniel Magnusen, Neurons —Hae-young Hawong, Joseph Tsitsi Nyamajenjere, Jillian Rapien, Mary Mckay, Albert Magnusen, Manoj Pandey

Patterson, Keith Lookingland, John Goudreau

and Electronic Diaries for Long-Term Monitoring of Parkinson’s Disease —Aaron

P3.047 Hypomimia detection with a

P3.054 Patients with Alpha-

P3.063 Modulation of CaMKIIa-NR2B

Carol Zimmerman, Joseph Giuffrida, Zoltan Mari, Michelle Burack, Ilia Itin, Fredy Revilla, Dustin Heldman

Seliverstov, Dmitrii Diagovchenko, Michael Kravchenko, Mikhail Babin, Ekaterina Fedotova, Mikhail Belyaev

Csencsits-Smith, Shivika Chandra, Qianmiao Gao, Hongyu Miao, Mya Schiess

Wen Wang, Si-Yan Chen, Cheng-Long Xie

P3.042 Machine learning algorithms

the Pedunculopontine Tegmental Nucleus as P3.064 Progression of Parkinson’s P3.048 Clinician-Input Study (CIS-PD): a Rat Model of Parkinson’s Disease —Anam Disease: 2-Year Longitudinal Study of How the Fox Wearable Companion Clinical and MRI Changes in Patients at Application can influence treatment and care Syed, Phillip Baker, Michael Ragozzino in Parkinson’s disease —Margaret Daeschler, P3.056 Salivary Alpha-Synuclein a new Different Stages of the Disease —Massimo Jordan Elm, Erin Klintworth, Michal Afek, Shira tool for the diagnosis of Parkinson’s disease? Filippi, Elisabetta Sarasso, Noemi Piramide, Tanya Stojkovic, Vladana Pica, Iva Stankovic, Lazar, Tanya Simuni PARKSYN study —Cecile Aertz, Victoria

smartphone camera as a possible selfHadley, Enrique Urrea-Mendoza, Nicola Mennucci, screening tool for Parkinson disease —Yury

applied to digital biomarker data (iMotor) discriminate Parkinson’s motor status — Ioannis Tsoulos, Athanassios Stavrakoudis, Georgia Mitsi, Spiridon Papapetropoulos

synucleinopathies Display Distinct Chemokine Profiles —Jessika Suescun, Keri

P3.055 The Effect of NMDA Lesions in

interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson’s rats —WenPARKINSON’S DISEASE: IMAGING

Silvia Basaia, Andrea Fontana, Igor Petrovic, Elka Gonzalez, Christophe Hirtz, Sylvain Lehmann, Marie Stefanova, Vladimir Kostic, Federica Agosta Deverdal, Laurent Collombier, Giovanni Castelnovo

AAN.com/view/AM18 143

Tuesday

P3.046 Remote patient testing with Disease: A description of over 10,000 Parkinsons symptom scores across the world smartphones provides reliable, valid and using the Personal KinetiGraph (PKG) —Peter sensitive measures of motor symptom severity in Parkinson’s disease patients — Lynch, Rajesh Pahwa, Filip Bergquist, Malcolm

Jonathan Graff-Radford, Rodolfo Savica

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION III G P3.065 Functional Brain Connectome

Tuesday, April 24 11:30 a.m.–7:00 p.m.

P3.070 Longitudinal Cortical Thickness Architecture in a Large Cohort of Parkinson’s Changes in Early Parkinson’s Disease Disease Patients —Silvia Basaia, Federica Patients with Impulsive Compulsive Agosta, Homa Zahedmanesh, Tanya Stojkovic, Behaviors —Francesca imperiale, Federica

P3.075 Functional Magnetic Resonance

P3.066 Combining Metabolomics and

P3.076 White Matter Tract Alterations

Vladana pica, Iva Stankovic, Igor Petrovic, Elka Stefanova, Vladimir Kostic, Massimo Filippi

Agosta, Vladana pica, Iva Stankovic, Paola Valsasina, Igor Petrovic, Elisabetta Sarasso, Vladimir Kostic, Massimo Filippi

Neuroimaging in mid-stage Parkinson’s P3.071 Zonisamide Co-treatment Slows Disease. A Proof of Concept for CrossReduction of Striatal Dopamine Transporter Fertilization. —Jean-Pierre Trezzi, Andrea Greuel, in Patients with Parkinson’s Disease —Ken Enrico Glaab, Zdenka Hodak, Lars Timmermann, Christian Jaeger, Nico Diederich, Carsten Eggers

P3.067 Longitudinal Cortical Thickness

Changes in GBA-Positive Relative to GBANegative Parkinson’s Disease Patients with Hemiparkinsonism —Francesca imperiale,

Federica Agosta, Vladana pica, Iva Stankovic, Elisabetta Sarasso, Paola Valsasina, Igor Petrovic, Vladimir Kostic, Massimo Filippi

Ikeda, Masaru Yanagihashi, Ken Miura, Yuichi Ishikawa, Takehisa Hirayama, Takanori Takazawa, Osamu Kano, Kiyokazu Kawabe, Sunao Mizumura, Yasuo Iwasaki

P3.072 Cortical Surface Analysis

in Parkinson Disease Patients —Rachel

Guimaraes, Luiza Piovesana, Paula Azevedo, Clarissa Yasuda, Jose Moreira, Daniela Garcia, Anelyssa D’Abreu, Fernando Cendes

P3.068 Domain-specific impact of cerebral P3.073 Microstructural Changes in Balance white matter hyperintensities on Parkinson’s disease cognitive functioning —Patricia

Control Centers, as Measured by Diffusion Tensor Imaging, Correlate with the Ability to Use Somatosensory Information to Maintain Balance in Parkinson’s Disease —Jacob Surkont, Wayne

Imaging-Based Neurofeedback Training in Patients with Parkinson’s Disease —Ayse

P3.080 Pattern Analysis of FDG PET

in Atypical Parkinsonism—an Innovative Approach —Balakrishnan Shankar, Karthikeyan

Tinaz, Keerthana Nalamada, Mine Sezgin, Ana Soundarpandian Vives-Rodriguez, Kiran Para, Dustin Scheinost, Elan P3.081 A CT-Based Diagnostic Index Louis, Michelle Hampson

in Drug-naive Parkinson’s Disease Patients with Impulse Control Disorders —Mahtab Mojtahed Zadeh, Mohammad Hadi Aarabi

P3.077 Analysis of Tc-99m TRODAY

to differentiate between Progressive Supranuclear Palsy and Parkinson’s disease: A potential application for DaT-SPECT/CT. —

Bhumika Balgobin, Rajesh Gupta, Chuan Huang, Vivekanand Tatineni, Robert Matthews, Dinko Franceschi, Karl Spuhler, Tim Duong, Guy Schwartz

study in patients with Parkinsonism —Yu-Wei P3.082 Hyperechogenicity of the Lin, Han-Cheng Wang substantia nigra in non-mutation-carrying family members of LRRK2 PD —Mariel P3.078 Transcranial sonography in real clinical practice: Differential diagnosis between idiopathic Parkinson’s disease, atypical parkinsonism and essential tremor —Talyta Grippe, Nasser Allam, Pedro Renato Brandao, Danilo Pereira, Ana Carolina Aguilar, Natalia Cunha, Iruena Kessler

Pullman, Roberto Ortega, Amanda Glickman, Andres Deik Acosta Madiedo, Deborah Raymond, Karen Marder, Nir Giladi, Susan Bressman, Johann Hagenah, Norbert Bruggemann, Rachel SaundersPullman

P3.083 White Matter Changes in

P3.079 Substantia Nigra

Parkinson’s Disease Mapped with a Novel Tract Mapping Algorithm —Conor Corbin,

Reisin

Çevik, Orhan Sümbül, Semiha Kurt

Hyperechogenicity in Parkinson’s Disease Vikash Gupta, Julio Villalon-Reina, Talia Nir, Faisal and Essential Tremor and Its Association Rashid, Sophia Thomopoulos, Neda Jahanshad, P3.069 Microstructural Changes in the Martin, Marguerite Wieler, Myrlene Gee, Cari-Ann with Premotor Symptoms of Parkinson’s Paul Thompson Thalamus and Putamen, as Measured by Disease. —Marcela Uribe Roca, Anibal Chertcoff, Cooke, Richard Camicioli, Fang Ba P3.084 The Evaluation of the Ganglion Diffusion Tensor Imaging, Correlate with Gait Lucrecia Bandeo, Miguel A. Saucedo, Fatima Abnormalities in Parkinson’s Disease —Jacob P3.074 DAT-SPECT Imaging in Cases of Pantiu, Laura De Francesco, Luciana Vanesa Leon Cell Layer-Inner Plexiform Layer Complex Surkont, Wayne Martin, Marguerite Wieler, Myrlene Drug-Induced Parkinsonism in a Specialty Cejas, Maria Pacha, Galeno Rojas, Gabriel Napoli, Thickness in Early Parkinson’s Disease — Movement Disorders Practice —Jacob Gee, Cari-Ann Cooke, Richard Camicioli, Fang Ba Pablo Bonardo, Manuel Fernandez Pardal, Ricardo Durdane Aksoy, Selim Demir, Hüseyin Ortak, Betül Linortner, Taylor Hendershott, Kathleen Poston

Yomtoob, Kimberly Koloms, Danny Bega

b1 C

General Neurology ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P3.085 Ambulatory Computerized

Tippetts, Blake Zimmerman, Alfred Van Hoek,

Sarang Joshi, Edward Hsu Physician Order Entry Associated with Greater Opioid Prescribing —John Ney, Allison P3.087 Effects of Education on Weathers, Brian Callaghan Symptom Recognition and Management of Pseudobulbar Affect: A Mixed-Methods P3.086 High resolution and high field Evaluation of Knowledge and Behavior diffusion MRI in the visual system of Changes of Clinicians and Patients —Anne primates — Osama Abdullah, Li Dai, Jacob

P3.088 Anterior horn cell (AHC)

involvement in autosomal recessive hereditary spastic paraplegia with thin corpus callosum (ARHSPTCC) patients with SPG 11 mutations. —Nouf Al-Faidi, Qurban Ali, Gulzar Karim, Khalil Kurdi, Haji Khan, Omar Wazzan, Youssef Al Said, Edward Cupler

Roc, Wendy Turell, Erik Pioro

P3.089 “Doctor, I can’t touch my cheek

with my tongue” —Vaibhav Goswami, Michael Tenner, Anila Thomas, Brij Ahluwalia-Singh

P3.090 Posterior Spinal Cord Infarction in a Patient with Moderate Degenerative Cervical Spondylosis —Danielle Stember, Robert Staudinger

Tuesday

HEADACHE: IMAGING, NEUROPHYSIOLOGY, AND RESEARCH METHODS

Study and Review of the Literature —Richard Removing Less CSF May Be Best —Simy

Following Epidural Blood Patch —Alison

P3.091 DEWS (DEep White matter

P3.097 Is cortical dysexcitability is the basis of palinopsia in migraine? —Jayantee

P3.108 Knocked Out: Concussion as

hyperintensity Segmentation framework): Fully automated pipeline for detecting small deep white matter hyperintensities in migraineurs —Mi-Ji Lee, Bo-yong Park, Hyujin Jo, Jihoon Cha, Chin-Sang Chung, Sung Tae Kim, Hyunjin Park

P3.092 WITHDRAWN P3.093 Vascular Wall Imaging in

Lewis, Armando Ruiz, Teshamae Monteith

Kalita, Usha Misra, Robin Bansal

P3.098 Clinical Characterization,

Repetitive Pattern Reversal Visual Evoked Potentials (rVEP), Transcranial Magnetic Stimulation (TMS) and Brain Imaging in Visual Snow —Fatma Gokcem Yildiz, Umur Turkyilmaz, Isin Unal-Cevik

P3.099 N=1 Statistical Approaches to examine Factors that Modify Headache Reversible Cerebral Vasoconstriction Syndrome- a 3-tesla Contrast-Enhanced MRI Severity in Chronic versus Episodic study —Chun-Yu Chen, Shih-Pin Chen, Jong-Ling patients —Ty Ridenour, Marina Vives-Mestres,

Parikh, Franchesca Fiorito Torres, Melissa Rayhill, Matthew McAdams, Michael Perloff

P3.102 Novel anti-neuronal antibodies in idiopathic intracranial hypertension patients —Erdem Tuzun, Güneş Altıokka Uzun,

Ece Erdag, Duygu Gezen-Ak, Erdinç Dursun, Cem Kucukali, Betul Baykan

P3.103 Correlation of Opening Pressure with Unilateral Versus Bilateral Venous Sinus Stenosis in Idiopathic Intracranial Hypertension (IIH) —Roman Kassa, Flavius Raslau, Douglas Lukins, Padmaja Sudhakar

P3.104 Intracranial hypertension and systemic lupus erythematosus —Sawsan

Daoud, nouha Bouzidi, Olfa Hdiji, Hanen Haj Kacem, salma sakka, Mariem Damak, Chokri Mhiri

Thaler, Anna Pace

a trigger for encephalopathic hemiplegic migraine. —Maria Gaughan, Jennifer Clarke, Daniel Healy

P3.109 Stroke-like image findings in sporadic hemiplegic migraine —Cristina

Sánchez-Vizcaíno Buendía, Noelia García Lax, Gabriel Valero López, Ester Carreon Guarnizo, Joaquín Zamarro Parra, Mariano Espinosa de Rueda Ruíz, Guillermo Parilla Reverter

P3.110 Familial Aphasic Migraine —Scott Woolf, Adil Iqbal, Sania Atta, Leah Harburg, Stephen Marks, Brij Ahluwalia-Singh

Fuh, Jiing-Feng Lirng, Yen-Feng Wang, Shuu-Jiun Wang

Gabriel Boucher, Alec Mian, Andrew Hershey

P3.094 Is diffusion restriction of the

Research Studies: The National Institute of Neurological Disorders and Stroke (NINDS) Headache Version 2.0 (V2.0) Common Data Elements (CDEs) —Sarah Tanveer, Sherita Alai,

P3.105 Intra-dural fluid collections in

Vestibular Migraine—Two New Subtypes of the Disorder —Steffen Naegel, Hsin-Chieh Chen,

in First-Visit Primary Headache Patients: A Prospective Multicenter Study —Byung-Su

THE LESS COMMON HEADACHES

Jik Park, Ho-Sung Ryu, Hanim Kwon, Mi Sun Kim, Joon Mo Koo, Kye Won Park, Sun J. Chung

Cheng, Tzu-Hsien Lai, Kuei-Hong Kuo, Siu-Pak Lee, Yen-Jun Lai

P3.096 Reversible Lesions of the Corpus

Cerebrospinal Fluid (CSF) Volume Removal for Idiopathic Intracranial Hypertension (IIH):

P3.107 Rare Cause of Explosive

P3.113 Cerebral Venous Sinus

optic disc head a new marker for Idiopathic Intracranial Hypertension? —Elanagan

Nagarajan, Manjamalai Sivaraman, Pradeep Bollu

P3.095 Neuroimaging Abnormalities Kim, Cho Soo-Jin

Callosum in Migraine with Aura: A Case

144 2018 AAN Annual Meeting

P3.100 Accelerating Headache Clinical

Joy Esterlitz, Michael Oshinsky

P3.101 Updated Results on

P3.111 Chronic and Primary Daily

spontaneous CSF leaks: The dural dissection H. Diener, Mark Obermann, Christoph Kleinschnitz, Dagny Holle theory —Monique Montenegro, Jeremy Cutsforth-Gregory P3.112 Headache in patients with P3.106 Sex-specific clinical features of isolated cortical vein thrombosis: Report of 9 spontaneous intracranial hypotension —Yun cases and review of the literature. —Yu-Chen

Headache: Iatrogenic Pneumocephalus

Thrombosis Presenting With Headache And

Papilledema Without Focal Neurological Deficits —Sai Sripada Koneru, Vijay Chandran,

P3.128 Fibromyalgia and Myositis in

P3.114 New Daily Persistent Headache

Malhi, Liseth Lavado, Salma Yousuf, Priyadarshee Patel, Anam Habib, Gull Mahvish, Ashish Kapoor, Urvish Patel

Sankar Gorthi, Aravind Prabhu

(NDPH) & OnabotulinumtoxinA Therapy — Ashhar Ali, Jennifer Kriegler, Stewart Tepper, Brinder Vij

P3.115 An Unusual Presentation

of Hemicrania Continua —Steven Yang,

Seyedhesamaldin Mostafavitoroghi, Annie Hsieh, Maria Diaz Rojas, Yan Zhang

P3.116 Unusual Presentation Of HaNDL Syndrome —Musab Ali, Boulenouar Mesraoua, Atlantic Dsouza, Hassan Alhussein, Lubna El Sheikh, Noha Mhjob, Gayane Melikyan, Hassan Jassim Al Hail, Dirk Deleu

Migraine: A Nationwide Study of Disability and Discharge outcome —Prutha Soni, Princy

P3.129 Productivity Loss and Indirect

Fanning, Michael Reed, Dawn Buse, Todd Schwedt, Richard Lipton, David Dodick

Headache Disorders in Kuwaiti Children and givers in resource constrained settings — Adolescents. —Samar Ahmed, Jasem Al-Hashel, Shruthi N M, Vishal Sondhi, Biswaroop Raed Alroughani

P3.130 Prevalence And Risk Factors

Dermitzakis, Jobst Rudolf, Michael Vikelis

Associated With Depression In Patients P3.144 Burden of Illness Among Treated With Chronic Headache Cross Sectional Migraine Patients with ≥4 Headache Days Study, In Aseer Region, Saudi Arabia —Hayfa in the Past Month —Lulu Lee, Jvawnna Bell, Timothy Fitzgerald, Joshua Cohen

P3.145 2017 Migraine in America

Symptoms and Treatment (MAST) Study: (HaNDL) presenting with Diffusion Restriction in Gender Differences in Treatment Patterns P3.131 Vitamin D deficiency in migraine — the Splenium of Corpus Callosum: Case report and Unmet Treatment Needs —Aftab Alam, Cho Soo-Jin, Tae-Jin Song, Min-Kyung Chu, and review of literature —Kunal Bhatia, Pradeep Jong-Hee Sohn, Sun Wha Lee, Jee Young Kim Richard Lipton, Sagar Munjal, Dawn Buse, Kristina Bollu, Navpreet Bains

P3.132 Development of a Claims-Based P3.118 Whole Body Cryotherapy Induced Algorithm for Use in Patients with Migraine P3.119 Cognitive and Hearing

to Identify Potentially Undiagnosed Chronic Migraine Patients —Jelena Pavlovic, Justin S.

Complaints in Veterans: Is Central Auditory Processing Disorder an Overlooked Disability? —Eliot Licht, Delia Karahalios, Kimberly Panizzon

Yu, Stephen Silberstein, Michael Reed, Steve H. Kawahara, Robert Cowan, Firas Dabbous, Karen Campbell, Anand R. Shewale, Riya Pulicharam, Jonathan W. Kowalski, Hema Viswanathan, Richard Lipton

P3.120 Cardiac Cephalalgia: A Deadly

P3.133 Medical Comorbidities of

Case Report —Matheus Pedro, Paulo Santos

P3.121 Third Cranial Nerve Palsy

Associated with an Attack of Cluster Headache —Jessica Coleman

Dawn Buse, Peter Goadsby

P3.134 The Cardiovascular Impact of (Never Smoker and No Parental Secondary Intravenous Dihydroergotamine for Pediatric Smoke Exposure as a Child): Results from the Headache Patients —Sara Fridinger, Christina Szperka United States Cluster Headache Survey — HEADACHE DIAGNOSIS, BURDEN AND CO-MORBIDITY

P3.123 Identifying Natural Subgroups of Migraine Based on Profiles of Comorbidities and Concomitant Conditions: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study —Richard Lipton,

P3.124 The Relationship between Pain, Psychiatric, and Endocrine/Neurological Comorbidities of Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study —Aubrey Manack

Headaches in Children with Celiac Disease —Grant Hom, Brian Hom, Barbara Kaplan, A. Rothner

P3.126 Migraine in Postural Orthostatic Tachycardia Syndrome (POTS) —Juliana

VanderPluym, Charlene Hoffman-Snyder, Julie Khoury, Brent Goodman

P3.127 Accuracy and safety of an

artificial intelligent system for nonacute headache diagnosis —Julian Acosta, Francisco Grimaldi, Francisco Dorr, Francisco Varela, Lucas Alessandro, Maria Goicochea, Diego Fernández Slezak, Mauricio Farez

headache: A population study —Jiyoung Kim,

Tae-Jin Song, Soo-Jin Cho, Won-Joo Kim, ChangHo Yoon, Kwang Yang, Min Kyung Chu

P3.147 Online Medical Education

Improves Knowledge of Both Risk Factors for Chronification and Clinical Trial Data in Migraine —Stacey Ullman, Thomas Finnegan,

Murinova, Daniel Krashin, Melissa Schorn

P3.149 Classification of cases with a Kledisa Shemsi, Edlira Shemsi, Ferid Domi

P3.138 Post-Traumatic vs Non-Traumatic Jaclene Dabbour, David Rosenberg Headaches: A Phenotypic Analysis —Andrea P3.153 An Investigation of Tracking

on Quality of Life and Costs Among People with Migraine with ≥4 Headache Days in the Past Month —Jvawnna Bell, Lulu Lee, Timothy Fitzgerald, Joshua Cohen

P3.140 Sleepy Brain in Pain; Prevalence of Sleep Problems in a University-Based Headache Clinic —Natalia Murinova, Daniel Krashin, Melissa Schorn, Sau Mui Chan-Goh, Flavia Consens

P3.141 Symptom Bothersomeness in

Migraine: Results from 2017 Migraine in America Symptoms and Treatment (MAST) Study —Sagar Munjal, Aftab Alam, Kristina

Neurology —Paul Fu, Babar Khokhar

P3.159 Using Data Analytics to Increase

Neurology Access With Existing Providers — Neil Holland, Kristina Barron, Megan Brosious, Trudi Dempsey, Teena Kubasti, Greg Strevig

P3.160 Barriers to Appropriate

Inpatient Stroke Code Activation: A Quality Improvement Survey —Chandler Gill, Stasia Rouse, Kalea Colletta, Saima Chaudhry, Stephen Yeung, Adriana Perilla, Michael Schneck, Sean Ruland, Matthew McCoyd

Modifying Therapies for Multiple Sclerosis in Medicare Part D —Daniel Hartung, Kirbee Johnston, Dennis Bourdette

P3.162 Factors Associated with

Outpatient Follow-up in Stroke Clinic after Discharge from a Comprehensive Stroke Center —Reema Butt, Mohammed Ismail, Daniel Miller, Shaneela Malik, Lonni Schultz

P3.163 Stroke Stat: Notification System for In-Hospital Acute Strokes —Jillian

Alderson, Neishay Ayub, Ka-wai Ho, Kathie Lin, Sandeep Kumar, Magdy Selim, Pushpa Narayanaswami

diagnosis of acute headache, to emergency P3.164 Characteristics of General division in Regional Hospital Durres, Albania. — Neurology Readmissions —Nina Kim, Sanjeev

Migraine and Medication-Overuse Headache PRACTICE, POLICY, AND ETHICS I in University-Based Headache Clinic —Pooja P3.150 Multimodal Communication Puvvadi, Melissa Schorn, Daniel Krashin, Natalia Enhances Family Centered Care in the Murinova Neurocritical Care Unit (NCCU) —Matthew P3.136 Improving Patient-Centeredness Jaffa, Tachira Tavarez, Taghi Ryder, Brigid Blaber, of Headache Questionnaires —Edlin Gonzales, Abbey Friets, Mary Ann Bautista, Melissa Motta Jessica Smith, Kenneth Nudelman, Sonja Potrebic, P3.151 Utilizing a Patient Contact Index Annette Langer-Gould to Determine Staffing of an Academic P3.137 Evaluation of Post-traumatic (PT) Neurology Department —Benjamin Greenberg, Emmitt Rathore, Debra Clamp, Jaya Trivedi Chronic Migraine (CM) in Veterans of OEF/ OIF Campaigns Using Serum Mass Profiling P3.152 Improving Warfarin Management to Distinguish CM from other PT Headaches Through Pharmacy Lead Dose Capping for by Identification of Peptide Changes in Patients ≥85 Years Old —Jonathan Falsetta, Serum —James Couch, Jay Hanas Elissa Dipasquale, Zachary Klein, Alan Mensch,

P3.139 The Impact of Headache Free Days

P3.158 Burnout and Vitality for Yale

P3.146 Insufficient sleep in tension-type P3.161 Trends in Coverage for Disease

P3.135 Diagnostic Delay of Chronic

Adams, Richard Lipton, Vincent Martin, Michael Reed, Kristina Fanning, Dawn Buse, Peter Goadsby Metti, Karen Schwab, Lisa Brenner, Wesley Cole, Ann Scher

P3.125 Frequency of Recurrent

Chakrabarty, Prashant Jauhari, Harsh Patel, Lokesh Saini, Jaya Shankar Kaushik, Rachana Dubey, Shefalli Gulati

Kothare, Harold Weinberg

P3.165 Optimization of Ambulatory

Neurology Clinics at an Academic Medical Center —Babar Khokhar

P3.166 Improving cost and laboratory utilization in Paraneoplastic Antibody Testing —Dana Vanino, Kelly Baldwin

P3.167 A Quality Improvement Project to Improve Trainee Compliance with Direct-toPharmacy Electronic Prescriptions —Shivika

Chandra, Kim Yen Thi Vu, Louise McCullough, Anjail Sharrief

P3.168 Progress Note Quality

Improvement Study: Results From a Resident and Faculty Survey —Carolyn Zyloney, Robert Thompson-Stone

P3.169 Implementation of Advanced Technology in the Setting of an Established Practice Provider (AAP) Practice Models in Neurology —Calli Cook Exercise Program for Individuals with Parkinson’s Disease —Sarah Ingersoll, Kenneth P3.170 Transitioning Neurology Hayashida, Jason Chen, Rushabh Modi, Kris Outpatients from a Tertiary Care Center Mendenhall, Daniel Togasaki to Primary Health Care Centers (PHCC). — P3.154 Trainee Responses to Hurricane Edward Cupler, Alanood Abdulfattah, Khadeejah Al-Hasani, Khalid Alqadi, Moira Abrahams, Bandar Harvey: Correlating Volunteerism with Rashwan, Manal Badawi, Ahmad Hassan, Sameer Burnout —Crystal Yeo, Gustavo Roman, Dottie Al-Kathiri, Rainavel Romano, Omar Wazzan, Mersinger, David Kusnerik, Shaylor Thomas, Trevor Youssef Al Said Burt, Timothy Boone, Suzanne Powell

P3.155 Improving access to sleep

medicine clinic services through the implementation of an econsult program —

P3.171 NA P3.172 NA

Asha Singh, Jon Billinger, Darren Malinoski

AAN.com/view/AM18 145

Tuesday

Kristina Fanning, Dawn Buse, Vincent Martin, Michael Reed, Aubrey Manack Adams, Peter Goadsby

Fanning, Michael Reed, Todd Schwedt, David Dodick

Migraine: Results from the Chronic Migraine David Dodick Epidemiology and Outcomes (CaMEO) P3.148 What do Headache Patients Study —Aubrey Manack Adams, Richard Lipton, Want? Patient Goals in Headache Medicine Vincent Martin, Michael Reed, Kristina Fanning, in a Tertiary Headache Center. —Natalia

P3.122 A Cluster Headache Phenotype

Todd Rozen

Neurodevelopmental Care: Initiatives to

P3.142 Prevalence and Burden of Primary empower health care professionals and care

P3.143 A Population Based Survey for Costs of Chronic Migraine and Episodic Headaches in Greece to Estimate Prevalence P3.157 Improving Patient Satisfaction Migraine in a Commercially-Insured and Treatment Preferences —Dimos Dimitrios By Implementing Existing Tools in EHR Using Population —Justin S. Yu, Emily Durden, William Mitsikostas, Chryssa Arvaniti, Theodoros Young, Oth Tran, Hema Viswanathan Lean Methodology —Anil Neelakantan Constantinidis, Nikolaos Fakas, Emmanouil

A Dhafer, Adel Ali Alhazzani, Abrar A BinAbbas, Ahmed Abouelyazid, Hanan A Albishi, Abdullah S P3.117 Syndrome of transient headache Alomari, Badr A Alfard, Ashwaq Z Abdulrahman, with neurological deficits and CSF lymphocytosis Walaa A Aldarwish

Reversible Cerebral Vasoconstriction Syndrome —David Atkins, Ryan Smith

P3.156 Comprehensive

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION III G IMAGING STUDIES IN AGING AND DEMENTIA

P3.173 Bilingualism and Age of

P3.184 Neurodegeneration: Prion-like

Behavior of Misfolded Proteins in the Syntactic Network —Belen Pascual, Quentin

Funk, Paolo Zanotti Fregonara, Elijah Rockers, Acquisition in Alzheimer Disease: A 18F-FDG Neha Pal, Meixiang Yu, Christof Karmonik, Bryan PET Study —Jean-Benoit Epiney, Mitsouko Spann, Gustavo Roman, Paul Schulz, Joseph van Assche, Giulia Frasca Polara, Perani Daniela, Masdeu Frederic Assal, Valentina Garibotto

P3.174 Amyloid and Hypertension Are Independently Associated with White Matter Injury Assessed by FLAIR and DTI MRI —Omar Al-Janabi, Christopher Brown, Ahmed Bahrani, Richard Murphy, Brian Gold, Donna Wilcock, Peter Nelson, Larry Goldstein, Charles Smith, Gregory Jicha

P3.175 Occipital and Cingulate

Hypometabolism is Significantly Under-reported and Probably Missed on 18-Fluorodeoxyglucose Positron Emission Tomography Scans of Patients with Lewy Body Dementia —Moath Hamed, Frank Schraml, Jeffrey Wilson, Marwan Sabbagh

P3.176 Quantitative dopaminergic

imaging identifies normal pressure hydrocephalus from its mimics —Gilles

Allali, Valentina Garibotto, Ismini Mainta, Nicolas Nicastro, Frederic Assal

P3.177 Multimodal MRI Staging

Improves Clinico-Imaging Correlations in sJCD. —Simone Sacco, Eduardo Caverzasi,

Matteo Paoletti, Adam Staffaroni, Isabel Allen, Gabriel Marx, Joel Kramer, Stefano Bastianello, Roland Henry, Howard Rosen, Michael Geschwind

P3.178 White matter microstructural

damage and cerebral atrophy in middle age. The longitudinal CARDIA MRI sub-study. — Justine Moonen, Nick Bryan, Guray Erus, Ilya Nasrallah, Pam Schreiner, Christos Davatzikos, Lenore Launer

P3.179 Automatic classification of

P3.185 Volume and Functional

Connectivity of the Ventral Tegmental Area as Early Markers of Alzheimer’s Disease — Matteo De Marco, Annalena Venneri

P3.186 The impact of localized gray

matter damage on connectivity: Posterior Cortical Atrophy study —Haya Glick-Shames, Yael Backner, Noa Raz, Netta Levin

P3.180 Distinct Spatial Distribution of

White Matter Hyperintensities Associated with Alzheimer’s Disease Pathology and Hypertension. —Omar Al-Janabi, Christopher

Tuesday

Brown, Ahmed Bahrani, Richard Murphy, Brian Gold, Peter Nelson, Donna Wilcock, Larry Goldstein, Charles Smith, Gregory Jicha

P3.181 MRI-derived markers of disease progression in early versus late PSP and CBS —Kimiko Domoto-Reilly, Daniel Peterson,

Shubir Dutt, Hilary Heuer, Phi Luong, Carmela Tartaglia, Irene Litvan, Scott McGinnis, Bradford Dickerson, John Kornak, Norbert Schuff, Gil Rabinovici, Bruce Miller, Anne Fagan, Kejal Kantarci, Alexander Pantelyat, Tatiana Foroud, Bradley Boeve, Howard Rosen, Adam Boxer

P3.182 Added Value of Multimodal

Structural MRI to the Clinical Diagnosis of Primary Progressive Aphasia Variants —

Federica Agosta, Elisa Canu, Francesca imperiale, Francesca Caso, Andrea Fontana, Giuseppe Magnani, Andrea Falini, Giancarlo Comi, Massimo Filippi

Kesayan, Kenneth Heilman

P3.199 Pure apraxia of speech

associated with infarction in premotor cortex —Riddhi Patira

P3.200 NA ACUTE STROKE IMAGING

P3.201 Average Time from CT to CTP

Completion is Long: What are we getting in return? —Umar Shariff, Ameer Hassan, Christina Sanchez, Ahmed Malik, Adnan Qureshi

P3.202 Role of Thin-sliced Reformatted

Patients: A Perfusion Study using Deep Learning —Yannan Yu, Danfeng Guo, Min Lou, David Liebeskind, Fabien Scalzo

P3.213 Magnetic Resonance

Angiography with Black Blood as Routine for Evaluate Cerebrovascular Disease —Hennan Teixeira, Christiane Monteiro Siqueira Campos, André Luiz Guimarães de Queiroz, Karlla Danielle Ferreira Lima, Victor Hugo Marussi, Alex Baeta

P3.214 Is Contrast Staining on Post-

thrombectomy CT Predictive of Final Stroke Volume? —Kristie Wang, Lawrence Chu, Benjamin Emanuel, May Kim-Tenser, Matthew Tenser, William Mack, Arun Amar, Sebina Bulic

CT Imaging for acute Ischemic Stroke Patients, do we need CT angiography before POST-STROKE MOOD, COGNITION, AND RECOVERY Metabolic Network Activity Associated with deciding for acute neurointervention? — Siddhart Mehta, Ashish Kulhari, Amrinder Singh, the Progression of Alzheimer’s Disease — P3.215 Diffuse Abnormal Cerebral Rafia Jawed, Sara Strauss, Spozhmy Panezai, Chris Tang, Michael Small, Paul Mattis, Amir Activation may Underlie Post-Stroke Jawad Kirmani Nazem, Phoebe Spetsieris, David Eidelberg Cognitive Dysfunction, or the “Minor Stroke P3.188 Longitudinal Cortical Thickness P3.203 Impact of Acute Interventions for Syndrome” —Elisabeth Marsh, Rafael Llinas, Ischemic Strokes on Infarcted Tissue Volume: Rodolfo Llinas Analysis in Alzheimer Disease. ADNI-Arg Cohort —Ismael Calandri, Ignacio Demey, Patricio Comparison of MRI Profiles —Michael P3.216 MIND Diet Slows Cognitive Gezalian, Jeremy Moretz, Walshe Izumigawa, Chrem Mendez, Maria Julieta Russo, Gabriela Shauna Cheung, Brian Cristiano, Laura Nist, Bryan Decline in Stroke Survivors —Laurel Cherian, Cohen, Ezequiel Surace, Horacio Martinetto, Federico Nahas, Maria Eugenia Martin, Paula Harris, Varela Yanina, Jorge Campos, Gustavo Sevlever, Silvia Vazquez, Ricardo Allegri

P3.189 Diffusion MRI Measures from

the Updated ADNI3 Protocol are Associated with Cognitive Impairment in the Elderly — Talia Nir, Sophia Thomopoulos, Neda Jahanshad, Paul Thompson

P3.190 White matter connectivity

differences between typical amnestic and variant non-amnestic individuals with earlyonset Alzheimer’s disease (EOAD) —Paul

Tsao, Paul Jacobson, Vincent Truong

P3.204 Comparing Safety and Efficacy

Yamin Wang, Keiko Fukuda, Sue Leurgans, Neelum Aggarwal, Martha Clare Morris

of Biplane versus Monoplane Angiography in P3.217 Motor Impairment and Lack of Hyperacute Neuroendovascular Therapy — Functional Independence as Predictors of Depression in Post-Stroke Patients —Sen Gregory Kurgansky, Igor Teslya, Ryan Bo, Jeffrey Farkas, Karthikeyan Arcot, Ambooj Tiwari, David Turkel-Parrella

P3.205 Choice of Pretreatment

Neuroimaging Impacts Clinical Outcomes Following Mechanical Thrombectomy —

Sitara Koneru, Shazli Khan, Jaclyn Mueller, Samar Sheriff, Syed Zaidi

Ninan, Nadege Gilles, Jeremy Weedon, Clotilde Balucani, Jonathan Singer, Susan Law, Steven Levine

P3.218 Prevalence and Factors

Associated with Depression in Young Argentinian Patients with Ischemic Stroke —

Anibal Chertcoff, Julieta Quiroga, Miguel Saucedo, Lucrecia Bandeo, Fatima Pantiu, Luciana Vanesa Thompson, Mario Mendez, Madelaine Daianu, P3.206 Pitfalls of CT Perfusion Imaging in Leon Cejas, Maria Pacha, Marcela Uribe Roca, Randy Desarzant, Rebecca Melrose, Elvira Jimenez Acute Ischemic Stroke: A Case Series —Rae Pablo Bonardo, Manuel Fernandez Pardal, Ricardo Reisin Bacharach, Muhammad Niazi, David Ermak

Brown, Nathan Johnson, Brian Gold

LANGUAGE AND LANGUAGE DISORDERS

P3.192 Longitudinal decline in the

concreteness of speech in semantic variant primary progressive aphasia (svPPA) —

Katheryn Cousins, Sharon Ash, Murray Grossman

P3.193 WITHDRAWN P3.194 Dysprosody markers in PPA — Naomi Nevler, Sharon Ash, David Irwin, Mark Liberman, Murray Grossman

P3.195 Cerebrospinal Fluid Biomarkers

of Likely Pathology in Primary Progressive Aphasia —Catherine Norise, Amy Halpin, David Irwin, Murray Grossman

P3.196 Investigating the use of high

frequency repetitive transcranial magnetic stimulation for primary progressive apraxia of speech —Danielle Shpiner, Dannaly Reyes-

Baerga, Katalina McInerney, Corneliu Luca, Alyssa Bautista, Joyce Gomes-Osman

P3.197 Clinicopathological Correlates

of Verbal Fluency in Parkinson’s Disease: A

P3.183 Assessing Test-Retest Reliability Pilot Study —Rasheda El-Nazer, Jonathan Artz,

of Phase Contrast MRI for Measuring Wencong Chen, Christine Belden, Charles Adler, Cerebrospinal Fluid Flow Dynamics in Thomas Beach, Jared Benge Alzheimer’s Disease —Ashwin Sakhare, Lisette P3.198 Unilateral Apraxic Agraphia Isenberg, Judy Pa without Ideomotor Apraxia in a patient with

146 2018 AAN Annual Meeting

callosal and frontal lobe lesions —Tigran

P3.187 Longitudinal Changes in

patients with Alzheimer’s disease (AD) and P3.191 Differential Susceptibility of Large-Scale Brain Networks to White mild cognitive impairment (MCI) who will convert to AD using deep neural networks — Matter Alterations in Aging —Christopher Silvia Basaia, Federica Agosta, Luca Wagner, Giuseppe Magnani, Massimo Filippi

Tuesday, April 24 11:30 a.m.–7:00 p.m.

P3.207 Inter-User Scoring Discrepancies P3.219 The Influence of Sleep Amongst Residents using The Alberta Stroke Program Early CT Score (ASPECTS) Shows Limited Use of this Scoring Tool without Formal Training. —Saman Zafar, Ylec Cardenas Castillo, Simon Castro, Lakshmi Leishangthem, Brooke Devenney-Cakir, Rakesh Ahuja, Aparna Prabhu

Derangement, Low Energy and Fatigue on Depression after Stroke —Pratik Bhattacharya, Phillip Kucab, Advait Mahulikar, Ramesh Madhavan

P3.220 Anxiety and Depression in

Patients Who Undergo a Cerebrovascular Procedure —Lauren Lombardo, Richard Shaw,

P3.208 Impact of Ultra-Rapid-Sequential Dorothea Altschul IV/Contrast on Renal Function and incidence P3.221 Beta Blockers do not Increase of CIN in a Comprehensive Stroke Center —

the Risk of Post-stroke Depression in a

Phillip Ye, Jennifer Frontera, Ryan Bo, Karthikeyan Arcot, Jeffrey Farkas, David Turkel-Parrella, Ambooj Predominantly Afro-Caribbean Population — Elizabeth McCuaig, Jeremy Weedon, Nadege Tiwari Gilles, Cindy Tsui, Lucy Tan, Jonathan Singer, P3.209 Flat- Panel Cone Beam Computed Susan Law, Steven Levine

Tomography is a NOT a Reliable Predictor for P3.222 Post-Traumatic Stress Disorder in Early Changes in Ischemic Stroke Patients functionally independent patients following with Large Vessel Occlusions (LVO) — a first-ever Ischemic Stroke/TIA —Marcos Amrinder Singh, Ashish Kulhari, Siddhart Mehta, Lange, Beltrami Larissa, Paula Marques, Francisco Briana DeCarvalho, Hemal Patel, Spozhmy Panezai, Germiniani, Francisco Jaime Barbosa, Rafael Jawad Kirmani Massuda, Viviane Zetola

P3.210 CTP Mismatch Imaging

Underestimates Tissue Viability in UltraEarly Large Artery Occlusion —James Frey, Carol Darbonne

P3.211 Diffusion And Perfusion

Mismatch Is Associated with Early Neurologic Deterioration in Single Small Subcortical Infarction —Si Baek Lee, Yoo Dong Won

P3.212 The Prediction of The

Hemorrhagic Transformation Locations After Reperfusion Therapy in Acute Stroke

P3.223 A Depression Screening Protocol for Patients With Acute Stroke: A Quality Improvement Project —Celia McIntosh

P3.224 Do Selected Stroke Risk Factors Predict Post-Stroke Fatigue in an AfroCarribean Population? —Cindy Tsui, Clotilde Balucani, Jeremy Weedon, Elizabeth McCuaig, Lucy Tan, Susan Law, Nadege Gilles, Jonathan Singer, Steven Levine

P3.225 Thalamic Atrophy Mediates the

Effects of Cerebral Small Vessel Disease on Gait Impairment —Ning Su, Xin-Yu Liang, Fei-Fei

Zhai, Lixin Zhou, Jun Ni, Ming Yao, Feng Tian, ShuYang Zhang, Zheng-Yu Jin, Li-Ying Cui, Gao-Lang Gong, Yi-Cheng Zhu

P3.239 Evaluation Times and Outcomes

P3.226 Consciousness disorders in

Alejandro Vargas, Laurel Cherian, James Conners, Sarah Song, Rima Dafer, Joshua Bock, Nicholas Osteraas

thalamic vascular lesions —Blas Couto, Guido

Vazquez, Carla Florencia Bolaño Diaz, Alejandro Thomson, Carlos Santiago Claverie, Francisco Klein

P3.227 Early tablet-assisted cognitive

rehabilitation for aneurysmal subarachnoid hemorrhage: Feasibility of a single-center randomized controlled trial —Bing Yu Chen,

P3.254 Unilateral Vocal Cord Paralysis in English versus Non-English Speaking associated with Ipsilateral Acute Cortical Patients Undergoing Telestroke Evaluation — Stroke: A Rare Case Presentation —Khalid

Associated with Aiming Neglect After Right Brain Stroke —Jonathan Thomas, Meghan Caulfield, A. Barrett

P3.229 Late Functional Recovery

After Lacunar Stroke: Implications For Rehabilitation Studies —Aravind Ganesh, Rose M Wharton, Sergei A Gutnikov, Peter Rothwell, on behalf of the Oxford Vascular Study

P3.230 Aphasia Rapid Test—

Quantification and assessment of Aphasia in Stroke —Harish Jayakumar, Balasubramanian Samivel, Manickvasagam Janarthanam, Shanmuga Sundaram N, Lakshmi Ranganathan, Krishnamoorthy Kuppusamy, Kaushik Gowthaman

P3.231 Prevalence of Cognitive

Impairment and Effects on Survival in the Mayo Clinic Florida Familial Cerebrovascular Diseases Registry —Kevin Barrett, Tasneem

Hasan, Thomas Brott, Elizabeth R. Lesser, David O. Hodge, James Meschia

STROKE KNOWLEDGE, BEHAVIOR, AND CULTURE

P3.232 Help-seeking delay in stroke increases mortality and hospital stay: Results from a developing country. —

Alejandro Gonzalez Aquines, Adolfo Cordero, Nicolás Escobedo-Zúñiga, Luis Ramirez, Alan Treviño-Herrera, Helda E Sanchez-Teran, Juan Gongora Rivera

Sawalha, Omar Hussein, Ahmed Abd-Elazim, Diana Gugger, Brin Freund, Peter Kaplan Greene-Chandos, Michel Torbey

P3.255 An Unexpected Imitator: HLH

P3.240 A 31-year old Postpartum

Tijil Agarwal, Rebecca Romero

Britton, Sara Hocker, Amy Crepeau

P3.256 Reversal of Fortune: Congenital

P3.274 EEG Predictors of Post-Stroke

Woman with Thunderclap Headache: A Case PCA Laterality is Detrimental to Infarct of Segmental Cerebral Vasoconstriction Volume —Kalea Colletta, Geeta Verma, Camilo Secondary to Pheochromocytoma —Stephen Gomez

Vasoconstriction Syndrome with Bilateral Intraocular Hemorrhage —Hae Young Baang,

P3.235 Health Literacy and Length of

Stay in Stroke —Wendy Tian, Lakshmi Warrior, Lisa Diep, Michael Kelly

P3.236 Hmong Stroke Knowledge

P3.275 Mapping the dynamics of heart

EEG AND IMAGING

Manmeet Kaur, Rabia Jamy, Margi Patel, Angela Hays Shapshak, Sandipan Pati

P3.259 Resident Competency and

Sachin Kedar, T. Scott Diesing

Interrater Agreements Using the ACNS Critical Care EEG Terminology —Joy Ding,

and Cognitive Impairments from ThalamicHypothalamic Stroke —Jessica Ng, Kasun

P3.265 Time to Detection of Seizures

P3.238 Primary Language Predicts

Outcomes in Acute Ischemic Stroke —Afra

rate variability and complexity changes with progressive focal status epilepticus. —

P3.276 Bilateral independent

periodic discharges are associated with

Josee Carpentier, Kristin McBain, Nicolas Gaspard, electrographic seizures and poor outcome: A case-control study —Gamaleldin Osman, Rahul P3.243 Stroke-like Symptoms following M. Westover, Tadeu Fantaneanu Rahangdale, Jeffrey Britton, Emily Gilmore, Hiba a Lumbar Epidural Block: A Rare Case Report P3.260 Improving Diagnostic Accuracy Haider, Stephen Hantus, Aline Herlopian, Sara of Pneumocephalus —Nicholas Lannen, in Epilepsy: Effect of Online Medical Hocker, Jong Lee, Benjamin Legros, Vineet Punia, Brandon Francis, Muhammad Farooq Nishi Rampal, Jerzy Szaflarski, Adam Wallace, M. Education on EEG Interpretation Among Westover, Lawrence Hirsch, Nicolas Gaspard P3.244 Painless Labor: A Case of Neurologists —Stacey Hughes, Thomas Progressive Myelopathy during Pregnancy — Finnegan, Selim Benbadis P3.277 Comparison of Ambulatory and Andrea Wasilewski, Tirisham Gyang, Lawrence Inpatient 24 hour EEG: A Value Analysis — P3.261 Utility of Inpatient EEG and Samkoff Sotiris Mitropanopoulos, Jeffrey Britton Role of Neurologic Input in Tertiary Care P3.245 Ruptured Anterior Spinal Artery Hospital —Bakhtier Nurmukhamedov, Vishal P3.278 A Case of Focal REM-Sleep of the Craniocervical Junction: Case Report Shah, Robert Beach Epilepsy Originating from the Occipital and Review —Lakshmi Leishangthem, Sudhakar P3.262 Testing and Turnaround Time for Lobe —Umar Shuaib, Mohammad Humayun, R. Satti Sharjeel Panjwani, Ajaz Sheikh Stat EEGs: How do we get faster? —Brian P3.246 Spinal Cord Infarction: Clinical Hanrahan, Eric Jackowiak, James Lee, Stephanie P3.279 Functional Connectivity Analysis and Imaging Insights from the Periprocedural Paolini, Anto Bagic, Alexandra Popescu on Scalp EEG for Identification of Deep Setting —Nicholas Zalewski, Alejandro P3.263 Analysis of EEG Use Utilizing Parenchymal Lesions —Jalyoung Joe, George Rabinstein, Karl Krecke, Robert Brown, Eelco Newman the National Inpatient Sample —Rebecca Wijdicks, Brian Weinshenker, Derrick Doolittle, Bernheimer, Seth O’Neal, Marissa Kellogg Eoin Flanagan P3.280 Mapping Cortical Connectivity P3.264 Survey of Neurologists Regarding Using Cortico-Cortical Evoked Potentials — P3.247 Pathological Crying Prior to the Onset of Pontine Ischemic Stroke —Eric Lee, the Use of Continuous EEG (cEEG) Monitoring Lawrence Crowther, Peter Brunner, Anthony in Children Presenting With Encephalopathy Ritaccio, Gerwin Schalk Bradley Jacobs, Thomas Pitts, Suraj Rajan Following Status Epilepticus (SE) —Asri P3.281 Spectral analysis of dynamic P3.248 First-order Horner’s Syndrome Yuliati, Amanda Weber Navarathna, Malveeka Sharma, Jose Romero

P3.249 Atypical ipsilateral Dejerine

Roussy syndrome following a left thalamic

Almallouhi, Marian Dale

with Continuous EEG (cEEG) Monitoring: The Correlation with Seizure Etiologies, Neurologic Status and EEG Findings —Ifrah Zawar, Stephen Hantus

P3.267 Efficacy of Simultaneous Scalp

P3.251 Frontal eye field ischemic stroke

and Intracranial EEG in Detecting Seizure Onset Zone —Ying Sun, Arun Antony, Jullie Pan,

Shaker, Abdallah Hamdallah, Blake Senay, Vivek Rai

P3.268 Electroencephalogram

functional connectivity between restingstate networks reveals information beyond static connectivity —Sharon Chiang, Emilian Vankov, Hsiang Yeh, Michele Guindani, Marina Vannucci, Zulfi Haneef, John Stern

P3.282 Involvement of Different

Networks in Mesial Temporal Lobe Epilepsy Subtypes Identified by Interictal EEG Source Analysis and Structural Neuroimaging —Luiz

Betting, Elaine Fujisao, Karen Alves, Thais Rezende

P3.283 Reduced Resting State

Functional Connectivity of the Hippocampi as a Biomarker of Temporal Lobe Epilepsy —

presenting with internuclear opthalmoplegia: Alexandra Urban, Joanna Fong, Naoir Zaher, Tanya Thomas Henry, Scott Burwell, Eric Waldron, Bryon Mueller, Jazmin Camchong, Kelvin Lim, Abhrajeet Case report and review of anatomy —Hussam Rath, Mark Richardson, Anto Bagic

P3.252 Rapid Revascularization of

Simultaneous Bilateral ICA Occlusions causing Coma —C. Frances Fan, David

Survey —Carol Droegemueller, Zong Xiong, Pakou Liebeskind, Jason Hinman, Charles Windon Xiong, Jodi Mueller-Hussein, Nour Eldin Hussein, P3.253 Typical Stroke Symptoms with Sidney VanDyke, Haitham Hussein Atypical Imaging: A case series of cortical ribboning on MRI representing acute ischemic P3.237 Language Barrier Does Not stroke —Muhammad Niazi, Harmanpreet Tiwana, Affect Acute Stroke Management and Cheran Elangovan, David Ermak Treatment —Noriko Anderson, Afra Janarious, Wengui Yu, Dana Stradling

Christine Smith, Leonardo Almeida, Anna Khanna, Maria Hella, Stephan Eisenschenk

Characteristics in Critical Ill Patients before Cardiac Arrest: A Small Case Series —Jian Xu, Wazim Mohamed, Aaron Desai, Maysaa Basha, Deepti Zutshi

P3.269 WITHDRAWN P3.270 Concordance of Focal

Electrographic Slowing with Structural Lesions on MRI —Syed Shabbir, Alexis Boro

P3.271 Heart Rate Variability as a Prognostic Marker Following Cardiac Arrest —Rahul Guha, Andrew Schomer

Roy

P3.284 The Role of Generalized Tonic-

Clonic Seizures and Partial Onset Seizures and the Effects of Antiepileptic Drugs on Retinal Architecture. —Samuel Lichtman-Mikol, Kalyan Yarraguntla, Melody Gilroy, Varun Chauhan, Elise Wiersma, Navid Seraji-Bozorgzad, Maysaa Basha, Deepti Zutshi, Aashit Shah

P3.285 Using Surface Electromyography to Differentiate between Generalized Tonic-Clonic Seizures and Psychogenic NonEpileptic Spells —Damon Cardenas, Jonathan Halford, Kristen Malloy, Luke Whitmire, Jose Cavazos

Janarious, Noriko Anderson, Wengui Yu

AAN.com/view/AM18 147

Tuesday

Gazi, Terri Hunter, Edward Miech, Linda Williams, Michael Lyerly

Seizure —Lesley Kaye, Zachary Newcomer,

P3.257 NA P3.258 NA

P3.266 Quantitative EEG Spectrograms: Symptom Onset and Emergency Department Venkataraman, Eric Mariuma Diagnostic efficacy in Intensive care and Arrival in Stroke Patients —Scott Le, Laurel P3.250 Acute Bilateral Apraxia of Eyelid Epilepsy Monitoring units and the common Copeland, John Zeber, I-Chia Liao, Leigh Allen, Closure (AEC) Following Bilateral Subcortical seizure mimickers. —Ajay Goenka, Alexis Boro Jared Benge, Jennifer Rasmussen Frontal Infarctions-Case Report —Eyad among Veterans with Acute Ischemic Stroke —Carolina Temple, Miles Cobia, Melissa

P3.273 Electroencephalography in West

Nile virus Neuroinvasive Disease —Angela Presenting as CNS Infarction —Hanna Blaney, Parsons, Marie Grill, Anteneh Feyissa, Jeffrey

P3.233 Factors Affecting Time Between ischemic stroke —Faddi Saleh Velez, Sandheep

P3.234 Reasons for Delayed Arrival

Etiology and Prognostic Value of Bilateral Independent Periodic Discharges —James

STROKE CASE REPORTS I

Hisham Aldhukair, Jonathan Cote, Julie Flinois, Tuan Hoang, Hao Cheng Shen, Chloe Xu, Morgane English, Deena Nasr Laverdure, Yi Tong, Emily Nolan, Ke Xuan Li, Leila P3.241 A Case of Fulminant Unilateral Cattelan, Christine Audi, Noemie La HayePerioperative RCVS —Lin Zhang, Sanjeev Caty, Vanessa Danielova Gueorguieva, Eugene Brailovski, Kourosh Lalavi, Lo Benjamin, Etienne De Taneja Villers-Sidani P3.242 Catastrophic Reversible Cerebral

P3.228 Anterior Striatal Lesions are

P3.272 Retrospective Analysis of the

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION III G P3.286 Anxiety and Depression

children with hemiplegic migraine. —Rachit Symptoms Disrupts Resting State Networks Patil, Rahul Nikam, Badal Jain, Vinay Kandula in Patients with Generalized Epilepsies — AUTISM AND DEVELOPMENTAL Danielle dos Santos Garcia, Mateus Nogueira, DISABILITIES Marina Alvim, Marina Polydoro, Akari Ishikawa, Tamires Zanão, Brunno de Campos, Lucas Lodi Montanher, Marcia Morita, Fernando Cendes, Clarissa Yasuda

P3.302 STARS: A Phase 2 Adult

Angelman Syndrome Clinical Trial: Randomized, Double-blind, Safety and

P3.287 Frontal Lobe Functions in Children Efficacy Study of Gaboxadol —Cesar Ochoawith Newly Diagnosed Temporal Lobe Epilepsy: Functional Magnetic Resonance Imaging —Temitayo Oyegbile, J VanMeter, William Gaillard, Bruce Hermann

P3.288 Status epilepticus: What do

peri-ictal changes in brain images mean? —

Alejandro Thomson, Guido Vazquez, Carla Bolaño, Blas Couto, Carlos Santiago Claverie, Diego Minarro, Guillermo Di Lorenzo, Alfredo Thomson

P3.289 Yield of Emergent Computed

Tomography in Epilepsy Patients Presenting with a Seizure —Kathryn Kvam, Vanja Douglas, William Whetstone, S. Josephson, John Betjemann

P3.290 Arterial spin labeling (ASL) MRI in a patient with non-convulsive status epilepticus (NCSE) —Jae Eun Lee, Pritikanta Paul, Mark Buehler, Xin Wang, Imran Ali

P3.291 NA P3.292 NA P3.293 NA P3.294 NA ACQUIRED BRAIN INJURY: STROKE, TRAUMATIC BRAIN INJURY

P3.295 The Influence of Presenting

Lubinoff, Logan Wink, Joseph Grieco, Jeannie Visootsak, Rebecca Burdine, Alexander Kolevzon, Ronald Thibert, Lynn Bird

P3.303 Comparison of Functional

Connectivity Abnormalities in Autism and Williams Syndrome —Julie Korenberg

Tuesday

Bridget MacDonald, Doris Trauner

P3.300 Reversible Cerebral

a novel mutation —Sireesha Chinthaparthi,

P3.315 Micronutrient Levels in Patients

Treatment of an Infantile Neuroaxonal Dystrophy Patient with a Novel Stabilized Polyunsaturated Fatty Acid Drug —Darius

Sacco, Don Bailey, Jeannie Visootsak, Raquel Cabo

With ADHD —Siddharth Gupta, Keith Pecor, Shreya Agarwal, Daniel Oh, Jeffrey Kornitzer

P3.316 Anatomic and Functional

Kimberly McDonald, Lamar Davis

P3.327 Case Report: Expanded Access

Adams, Janannaz Dastgir, Robert Molinari, Frederic Heerinckx

P3.328 Expanded Phenotypes of

Vanishing White Matter disease —Hitha CLINICAL AND BASIC SCIENCE OBSERVATIONS

Selena Chea, Patricia Lasutschinkow, Carole Samango-Sprouse

P3.306 MicroRNAs and Gene-

Predictors of Adult Outcomes —David

Heidrich, Stephany Nguyen, Keith Crenshaw, Drake Duane

P3.318 Cannabidiol Based Medical

Cannabis in Children with Autism- a Retrospective Feasibility Study —Adi Aran,

Environment Interactions in Autism: Prenatal Hanoch Cassuto, Asael Lubotzky Maternal Stress and the SERT Gene —David P3.319 A Literature Review of the Beversdorf, Ayten Shah, Janelle Noel-MacDonnell, Economic Burden of Fragile X Syndrome — Patrick Hecht, Bradley Ferguson, Zohreh Talebizadeh

Patricia Sacco, Melissa Raspa, Leslie Leahy, Raquel Cabo

P3.307 Healthcare and Medical Service

P3.320 EEG Endophenotypes in Autism

Utilization Among Patients With Angelman Syndrome By Molecular Subtype: Results From The AS-NHS Study —Raquel Cabo, Nasreen Khan, Wen-Hann Tan, Regina Tayang,

Spectrum Disorder —Jamie Capal, Paul Horn, Christopher Carosella, Elora Corbin, Patricia Manning-Courtney

P3.321 Prospective validation of

molecular subtype diagnostics for autism spectrum and neurodevelopmental disorders —Elizabeth Donley, Robert Burrier,

Joseph King, Alan Smith, Paul West, Lindsay Feuling, Michael Ludwig, DelRay Sugden, Brandon Smart, David Amaral

CHILD NEUROLOGY AND neonates: Size at birth and postnatal growth DEVELOPMENTAL NEUROLOGY: NEURODEGENERATIVE DISEASE predict neurodevelopmental outcomes — Thiviya Selvanathan, Vann Chau, Rollin Brant, Anne P3.322 LeukoSeq Whole Genome Synnes, Ruth Grunau, Steven Miller Sequencing Clinical Trial: An Interim P3.310 Profile of Children with Cerebral Analysis —Guy Helman, Omar Sherbini, Zachary Cross, Sarah Woidill, Asako Takanohashi, Holly Palsy and Congenital Malformations in Dubbs, Joseph Flores, Maren Bennett, Julia Canada —Marcel Severe, Pamela Ng, Maryam

P3.312 Social Functioning Mediates

ADHD Symptomatology and Mental Health Functioning in Neurotypical Children versus Children with Autism Spectrum Disorder or Williams Syndrome —Rowena Ng, Ursula

Vasoconstriction Syndrome: A novel mechanism for neurologic complications in Bellugi, Doris Trauner Schimke Immuno-osseus Dysplasia. —Darrah Haffner, Nancy Rollins, Michael Dowling P3.313 Effect of a Combination of Carnitine, Coenzyme Q10 and Alpha-Lipoic P3.301 Role of Arterial Spin Labelling Acid (MitoCocktail) on Mitochondrial Perfusion weighted MRI in evaluation of

148 2018 AAN Annual Meeting

in Fragile X Syndrome: Results of a Targeted Literature Review —Melissa Raspa, Patricia

P3.317 Tourette Syndrome: Childhood

disorder: The Relationship with Autism Spectrum Disorders (ASD), Developmental delay, and Testosterone —Andrea Gropman,

Michael Karras, Larry Goldstein, Ricki F Goldstein, Marc Wolfe, Muralimohan Palla, Robert Baumann, P3.311 Chandigarh Autism Spectrum Michael Dobbs Disorder Study: Prevalence in India —Priti Arun, Bir Singh Chavan

Outcomes with Neonatal EEG Activity —

P3.314 Clinical Unmet Needs and Burden with peripheral neuropathy associated with

P3.305 49,XXXXY, a rare genetic

Neonatal Stroke —Ana Albuja, Valeria Naranjo, Oskoui

P3.299 Predicting Perinatal Stroke

P3.325 WITHDRAWN P3.326 A case of Alexander disease

Amin, Nilesh Desai, Lisa Emrick

P3.309 Head circumference in preterm

P3.298 Inaccuracies In Coding In

Barash, Aric Orbach, Iris Grossman, Ralph Laufer, Michael Hayden

Estevez, Gerry Leisman, Philip Defina

Cristancho, Drew Streicher, Arastoo Vossough, James Treat, Daniel Licht, Jenna Streicher

Woodward, Helen Carlson, Adam Kirton

BDNF Expression in a Rett Syndrome Mouse Model —Michal Geva, Jennifer Dreymann, Steve

Hanoch Cassuto

Xun Zhang, Nicole Pigeon, Louise Koclas, Céline Lamarre, Francine Malouin, Carol L. Richards, Michael Shevell, Maryam Oskoui

Functional Connectivity in Hemiparetic Children With Perinatal Stroke —Kristine

Brigid Garvin, Shirish Damle, Kelleen Corrigan, James Connell, Diana Thao, Ignacio Valencia, Joseph Melvin, Divya Khurana, Mitzie Grant, Craig Newschaffer

Connectivity Relationship in Autistic Children —Yanin Machado, Mauricio Chinchilla, to stimulants effect in Autism Spectrum Disorder —Itai Berger, Julia Peled, Dorit Shmueli, Yazmina Machado, Calixto Machado, Mario

P3.296 Characterization of Features of

P3.297 Sensory-Motor Network

Function and Neurobehavioral Performance in Children with Autism Spectrum Disorder —Agustin Legido, Michael Goldenthal,

P3.304 Processing Speed as a marker

Characteristics on Outcomes in Moderate Lynn Bird to Severe Pediatric Traumatic Brain Injury: Penetrating versus Blunt Mechanisms —Ryan P3.308 A Portrait of Cerebral Palsy in Chae, Cynthia Austin, Nathan Evanson, Katrina Quebec Over a Decade : Birth years 1999Peariso 2010 —Aristides Hadjinicolaou, Pamela Ng, PHACE Syndrome on Fetal MRI and Natural History of Postnatal Management —Ana

Tuesday, April 24 11:30 a.m.–7:00 p.m.

P3.329 A Novel RMND1 knock-in Mouse Recapitulates Clinical and Biochemical Abnormalities Observed in Patients —Maria

J Sanchez-Quintero, Carlos Lopez Gomez, Catarina Quinzii Hirano

P3.330 Retinal Nerve Fiber Layer

(RNFL) and Ganglion Cell Inner Plexiform Layer (GCIPL) in Persistently Myelin Oligodendrocyte Glycoprotein Antibody Positive Youth —Stephanie Grover, Carmen

Yea, Tara Berenbaum, Danusha Nandamalavan, Renisha Iruthayanathan, Colin Wilbur, Fahad Albassam, Giulia Longoni, Arun Y. Reginald, Michael Wan, Fiona Costello, Julia O’Mahony, Douglas Arnold, Brenda Banwell, Amit Bar-Or, Ruth-Ann Marrie, Donald Mabbott, E. Ann Yeh

P3.331 Nervus Intermedius Neuralgia Caused By Craniofacial Fibrous Dysplasia In A Pediatric Patient: A Case Report And Literature Review —Philip Eye, Adam Lewis, David Dennison, Sarah Cantrell, Latanya Agurs

P3.332 Chemotherapy Exposure Disrupts the Gliogenic Microenvironment —Erin Gibson, Michelle Monje

P3.333 Isolated ophthalmoplegia as

presenting sign of pediatric Wernicke encephalopathy —Danielle Takacs, Ariel LyonsWarren

P3.334 Neonatal Dexamethasone

McEachern, Denise Perry, Nicole Ulrick, Johanna Schmidt, Amy Pizzino, Genevieve Bernard, Ryan Taft, Adeline Vanderver

Treatment Attenuates Hippocampal and Amygdaloid GPR30 Gene Expression in Adult Female Rats —Keiko Lo, Kowk-Tung Lu

P3.323 Pilot study of the use of

P3.335 A Patient with 4H Syndrome Who

Janus Kinase Inhibitor, Baricitinib, in the treatment of heritable interferonopathy Aicardi Goutières Syndrome —Adeline

Vanderver, Ulrick Nicole, Francesco Gavazzi, Asako Takanohashi, Thais Armangue, Jullie Rhee, Jamie Koh, Sarah Woidill, Justine Shults, Deborah Foerster, Raphaela Goldbach-Mansky, Laura Adang, Amy Waldman

P3.324 Pridopidine Treatment Recovers Gait Abnormalities and Rescues Impaired

Presents in Adulthood —Ozge Uygun, Tuncay Gunduz, Murat Kurtuncu, Mefkure Eraksoy

P3.336 PURA Syndrome and Myotonia: A Case Report and Review of the Literature — Steven Trau, Carolyn Pizoli

P3.337 Neurological manifestations of

X-linked ichthyosis: Case report and review of the literature —William Baek, Umut Aypar

P3.338 NA

Research Methodology ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P3.339 Autoimmune Cerebellitis as

as Neurology Residents —Saman Zafar, Ylec

P3.342 Massive Right-sided Ovarian

Darshan Pandya, Michael Goldberg, Linda Lewis

Cardenas Castillo, Lakshmi Leishangthem, Aparna Tumor as a Probable Cause of Left-sided Prabhu, Sridhara Yaddanapudi, David Roby, George Meralgia Paresthetica —Nikesh Bajaj Newman

P3.340 Amateur Fundus Photography

P3.341 Developing a First-of-its-Kind

with Various New Devices- Our Experience

Telemedicine Rotation for Neurology Residents —Mitra Afshari, Nicholas Galifianakis

MS AND CNS INFLAMMATORY DISEASE: NEUROIMAGING

Stephen Jones, Izlem Izbudak, Yvonne Lui, Lauren Krupp, Ellen Mowry, Carl DeMoor, Richard Rudick, James Williams, Elizabeth Fisher

a paraneoplastic syndrome in Ovarian Teratoma —Ashley Roque, MaryKay Pavol,

P3.345 Magnetic Resonance Imaging in Multiple Sclerosis associated Seizures —

Kalyan Yarraguntla, Shitiz Sriwastava, Rohit Marawar, Maysaa Basha, Deepti Zutshi, Evanthia Bernitsas

P3.346 Atrophied lesion volume: A

P3.355 MRI predictors of improvement

P3.348 Regional brain atrophy and its

Ivo Paunkoski, Deepa Ramasamy, Diego Silva, Ellen Carl, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman, Robert Zivadinov

P3.349 Great reduction of correlation

in multiple sclerosis patients may be sexspecific —Dejan Jakimovski, Robert Zivadinov,

clinical correlations in single MS patients at first visit —Alaleh Raji, Gerhard Winkler between global and regional brain volume and spinal cord volume in multiple sclerosis patients with severe disability —Manuela

interprofessional competency in opioidsparing acute pain management —Joseph

P3.357 Accelerated central atrophy

P3.351 Brain lesion segmentation and

Johannes Gregori, Luc Bracoud, Christian Cornelissen

P3.365 Cognitive impairment in Multiple

P3.352 Gray Matter Atrophy and

P3.359 Multiple sclerosis patients who

improve in their disability over time develop less brain atrophy compared to those who remain stable or progress —Emanuele

Ghione, Niels Bergsland, Michael Dwyer, Jesper Hagemeier, Dejan Jakimovski, Ivo Paunkoski, Deepa Ramasamy, Ellen Carl, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman, Robert Zivadinov

Valentina Poretto, Silvia Franciotta, Alice Riccardi, Monica Margoni, Davide Poggiali, Francesco Causin, Paolo Gallo

Microstructural White Matter Abnormalities Underlying Cognitive Impairment in Benign P3.361 Thalamic Atrophy and MS —Maria Rocca, Gianna Carla Riccitelli, Disability in Progressive Multiple Sclerosis Elisabetta Pagani, Marta Radaelli, Paolo Preziosa, Subgroups —Sean Tobyne, Andrew Russo, Giancarlo Comi, Andrea Falini, Massimo Filippi

P3.353 Disappearing Brainstem MRI Lesions in Multiple Sclerosis —Svetlana

Eckert, Bianca Weinstock-Guttman, Channa Kolb, David Hojnacki

P3.354 Comparison of Techniques for

Measurement of Brain Volume in Multiple Sclerosis Patients —Adrian Tsang, Carrie

Wager, Ricardo Corredor-Jerez, Mario J. Fartaria, Benedicte Marechal, Tobias Kober, Robert Bermel,

P3.374 INSPIRATION: Towards individual determination of NEDA 4—Qualitative visual determination of short term stable brain volumes from standardized MRI acquisition in daily clinical routine of MS patients —Achim Gass, Luc Bracoud, Johannes Gregori, Stefan Hoffmann, Christian Cornelissen

P3.375 Relationship between clinical Sclerosis: The contribution of cognitive reserve and regional gray matter volumes — manifestation of MS relapse and Gadolinium Alvino Bisecco, Gabriella Santangelo, Luigi Trojano, enhancing lesions in brain MRI —Lorena Renato Docimo, Rocco Capuano, Mattia Siciliano, Alessandro d’Ambrosio, Marida Della Corte, Simona Bonavita, Gioacchino Tedeschi, Antonio Gallo

Martín-Aguilar, Silvia Presas, José Vicente HervásGarcía, Anna Massuet-Vilamajo, Laia Grau-Lopez, Cristina Ramo

P3.366 Prospective multi-modal MRI

Tissue Damage in Chronic Active Lesions as Measured by Change in T1 HypoIntensity of Slowly Evolving Lesions in Patients With Primary Progressive Multiple Sclerosis —Colm Elliott, Jerry Wolinsky, Stephen

study to examine the effect of Fingolimod on tissue injury and repair in the brain in patients with relapsing remitting multiple sclerosis —Sara Razmjou, Fen Bao, Samuel

P3.376 Ocrelizumab May Reduce

Jesper Hagemeier, Niels Bergsland, Bianca Weinstock-Guttman, Channa Kolb, David Hojnacki, Lichtman-Mikol, Melody Gilroy, Kalyan Yarraguntla, Hauser, Ludwig Kappos, Frederik Barkhof, Fabian Model, Wei Wei, Corrado Bernasconi, Shibeshih Ralph Benedict, Michael Dwyer Rishi Sood, Carla Santiago-Martinez, Evanthia Belachew, Douglas Arnold Bernitsas, Navid Seraji-Bozorgzad

atrophy measurement in MS patients: Comparison between manual and automated methods —Hernán Chaves, Matías Varela, P3.360 Cerebellar cortical lesions Mercedes Serra, Emilia Osa Sanz, Nadia Stefanoff, selectively contribute to cognitive Iván Itzcovich, Jorge Correale, Diego Fernández dysfunction in early Multiple Sclerosis — Slezak, Mauricio Farez

Mendiratta, Sweta Patel, Michelle Bell

inhibitors and MRI outcomes in multiple sclerosis —Nicole Ziliotto, Francesco Bernardi, Dejan Jakimovski, Marcello Baroni, Giovanna Marchetti, Niels Bergsland, Bianca WeinstockGuttman, Paolo Zamboni, Murali Ramanathan, Robert Zivadinov

P3.369 The functional brain network

remains stable in natalizumab-treated multiple sclerosis patients: A one year study —Kim A Meijer, Oliver Wiebenga, Anand

JC Eijlers, Martijn D Steenwijk, Jeroen JG Geurts, Menno M Schoonheim

MS AND CNS INFLAMMATORY DISEASE: NEUROIMAGING: NOVEL TECHNIQUES

P3.377 Longitudinal change of myelin

water fraction (MWF) within chronic multiple sclerosis (MS) lesions —Sneha Pandya, Ulrike Kaunzner, Eric Morse, Thanh Nguyen, Nancy Nealon, Jai Perumal, Timothy Vartanian, Yi Wang, Susan Gauthier

P3.378 Double Inversion Recovery

Imaging MRI: A Good Tool to Identify Optic Neuritis Lesions in Multiple Sclerosis and Neuromyelitis Optica —Izumi Kawachi, Etsuji

Saji, Mariko Hokari, Akiko Yokoseki, Takahiro Wakasugi, Fumihiro Yanagimura, Osamu Onodera

P3.370 Evolution of New Lesions and its P3.379 Reduced Dynamism of Functional Temporal Patterns in Patients with Clinically Isolated Syndrome (CIS) Treated with Subcutaneous Interferon beta-1a (scIFNβ1a) —Hugo Vrenken, Marlieke de Vos, Marco

Connectivity Is Associated with Cognitive Impairment in Multiple Sclerosis Patients: A Dynamic Functional Connectivity Study in a Multi-Center Setting —Alessandro D’Ambrosio,

Maria Rocca, Paola Valsasina, Antonio Gallo, Battaglini, Gijs J. Nagtegaal, Bernardo De Almeida Nicola De Stefano, Debora Pareto, Frederik Teixeira, Kurt Marhardt, Nicola De Stefano, Barkhof, Olga Ciccarelli, Christian Enzinger, Robert Fox, Eric Klawiter Frederik Barkhof Gioacchino Tedeschi, Maria Laura Stromillo, Maria-Jesus Arevalo, Hanneke Hulst, Nils Muhlert, P3.362 Brain Volume Increase in Multiple P3.371 Brain Volume Loss in RRMS is Sclerosis Patients —Michaela Andelova, Jan Associated to Clinical Scores Irrespective of Marisa Koini, Massimo Filippi Krasensky, Niels Bergsland, Zdenek Seidl, Barbora Quantification Method —Jozef Magdic, Žiga P3.380 One Size Does Not Fit All: Benova, Eva Havrdova, Manuela Vaneckova, Dana Špiclin, Tanja Hojs Fabjan Large-scale neuronal network Functional Horakova, Tomas Uher ®

P3.363 Brain Activity Induced by

Psychological Stress Predicts Future Gray Matter Atrophy Accumulated in a Two-Year

P3.372 Use of LesionQuant to Measure Connectivity differs across Cognitive

Cerebral White Matter Lesion Distribution in Phenotype groups in Multiple Sclerosis — Neuromyelitis Optica and Relapsing Multiple Korhan Buyukturkoglu, David Parker, Qolamreza Razlighi, Christian Habeck, Claire Riley, Victoria Leavitt

AAN.com/view/AM18 149

Tuesday

Fuchs, Niels Bergsland, Deepa Ramasamy, Tomas Uher, Dana Horakova, Manuela Vaneckova, Eva Havrdova, Ralph Benedict, Robert Zivadinov, Michael Dwyer

(EEG) Tutorial Atlas as a Learning Tool for Neurology Residents —Rachael Benson, Anil

Sclerosis —Cameron L. Schubert, Enrique Antonia Meyer-Arndt, Janina Behrens, Katharina Alvarez, Justin Honce, Christopher Filley Wakonig, Michael Scheel, Alexander Brandt, Judith Bellmann-Strobl, John Dylan Haynes, Stefan P3.373 Brain atrophy staging of single MS patients with MRI at first visit —Alaleh Gold, Friedemann Paul Raji, Gerhard Winkler

Vaneckova, Michaela Andelova, Jan Krasensky, P3.358 Micro and Macrostructural Lukas Sobisek, Zdenek Seidl, Eliska Kusova, Tomas Limbic System Correlates of Comprehensive P3.367 Optic Neuritis Neuroimaging Uher, Eva Havrdova, Barbora Benova, Benedicte Characteristics Are Affected By Etiology — Cognitive Symptomatology in Multiple Marechal, Tobias Kober, Dana Horakova Sclerosis using Quantitative MRI and DTI — Casey Farin, Christopher Eckstein P3.350 Accelerated subcortical atrophy Zafer Keser, Khader Hasan, Benson Mwangi, Arash P3.368 Plasma levels of hemostasis Kamali, Kyan Younes, John Lincoln, Flavia Nelson following new lesion accrual in directly

connected tracts is significant and appears limited to the first year —Keith Carolus, Tom

P3.344 A Mobile Electroencephalogram

Period in MS Patients —Martin Weygandt, Lil-

during specific rehabilitation of information P3.364 INSPIRATION: An approach processing speed and attention in MS: A randomized trial against non-specific training to brain volume and quantitative lesion load assessments from standardized MRI with semi-ecological evaluation. —Ismail Koubiyr, Delphine Lamargue-Hamel, Mathilde acquisition in daily clinical routine of MS Deloire, Aurore Saubusse, Julie Charre-Morin, patients —Achim Gass, Stefan Hoffmann,

novel and robust imaging biomarker in multiple sclerosis for predicting disability Aurelie Ruet, Bruno Brochet progression —Robert Zivadinov, Niels Bergsland, P3.356 Whole Brain and Lateral Jesper Hagemeier, Deepa Ramasamy, Tomas Ventricular Volume Changes are associated Uher, Manuela Vaneckova, Eva Havrdova, Dana with Development of Disability Progression Horakova, Michael Dwyer in Multiple Sclerosis: Results from a LargeP3.347 Disability-Specific Atlases of Scale Clinical Routine 5-Year Observational Gray Matter Loss in Relapsing-Remitting Study —Emanuele Ghione, Michael Dwyer, Niels Multiple Sclerosis —Allan MacKenzie-Graham, Bergsland, Jesper Hagemeier, Dejan Jakimovski, Florian Kurth, Yuichiro Itoh, HeJing Wang, Michael Montag, Robert Elashoff, Rhonda Voskuhl

P3.343 Online education for

Nugent, Luis Buenaver, Marlis Gonzalez-Fernandez, Sharon Kozachik, Suzanne Nesbit, Beth Hogans

POSTER SESSIONS

g1 H

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION III G P3.381 Quantitative Magnetization

MS THERAPEUTICS Transfer Imaging in Multiple Sclerosis: A 3.0 IN DEVELOPMENT Tesla Clinical Study —Francesca Bagnato, Giulia P3.393 Phase 1 Trial of Intrathecal Franco, Nikita Thomas, Seth Smith, Junzhong Xu, Rituximab in Progressive MS Patients Richard Dortch with Evidence of Leptomeningeal Contrast P3.382 Column-specific demyelination Enhancement —Pavan Bhargava, Cassie Wicken, in Spinal Cord Normal Appearing White Matthew Smith, Irene Cortese, Daniel Reich, Peter Matter occurring in Multiple Sclerosis: A Calabresi, Ellen Mowry preliminary study using inhomogeneous P3.394 WITHDRAWN Magnetization Transfer and DTI —Henitsoa Rasoanandrianina, Bertrand Audoin, Manuel Taso, P3.395 Ozanimod (RPC1063) Reduces Olivier Girard, Guillaume Duhamel, Lauriane Pini, Plasma Levels of Neurofilament Light Chain Sarah Demortiere, Maxime Guye, Jean Philippe (NfL) in Patients With Relapsing Multiple Ranjeva, Jean Pelletier, Virginie Callot Sclerosis (RMS): Results From RADIANCE Part A, a Randomized, Placebo-Controlled, P3.383 Multi-compartment Spherical Phase 2 Study —Kristen Taylor Meadows, Brett Microscopic Diffusion Imaging Using Spherical Mean Techniques to Probe Axonal Skolnick, Paul Frohna, Richard Aranda, Harry Southworth, Gregory Opiteck Injury in Multiple Sclerosis —Francesca Bagnato, Giulia Franco, Nikita Thomas, Seth Smith, P3.396 Ozanimod Demonstrates Efficacy Richard Dortch, Junzhong Xu and Safety in a Multicenter, Randomized, Double-Blind, Double-Dummy, ActiveP3.384 Modulation of CorticoSubcortical Functional Connectivity Occurs Controlled Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM) —Giancarlo After Symptomatic Treatment of Fatigue Comi, Douglas Arnold, Bruce Cree, Ludwig Kappos, in Patients with Multiple Sclerosis —Maria Rocca, Paola Valsasina, Bruno Colombo, Paolo Preziosa, Vittorio Martinelli, Andrea Falini, Giancarlo Comi, Massimo Filippi

P3.385 Dynamic Functional Network

Connectivity in CIS Patients: A Longitudinal Study —Milagros Hidalgo de la Cruz, Paola

Tuesday, April 24 11:30 a.m.–7:00 p.m. P3.405 Rapid Improvement of Symptoms P3.416 Bayesian analysis of glatiramer after Fibrinolysis in a Patient with Multiple Sclerosis Exacerbation —Konstantin Balashov, Suhayl Dhib-Jalbut, Igor Rybinnik

P3.406 Comparison of Biodistribution

Following Subcutaneous and Intravenous Administration of a Novel Zirconium-89 Labeled Anti-CD20 Antibody Using Imaging —Mary-anne Migotto, Rajiv Bhalla, Karine Mardon, Jacqueline Orian, Gisbert Weckbecker, Rainer Kneuer, David Reutens

P3.407 Integrated Safety Analysis of

Infections during Periods of Grade 3 or 4 Lymphopenia in Patients Taking Cladribine Tablets 3.5mg/kg —Stuart Cook, Thomas Leist,

Giancarlo Comi, Xavier Montalban, Elke Sylvester, Christine Hicking, Fernando Dangond

P3.408 Predictors of an Opicinumab

Treatment Effect and Identification of an Efficacy Subpopulation: A Post hoc Analysis of the SYNERGY Study —Sarah Sheikh, Peter

P3.397 Efficacy and Safety of Tabalumab From A Phase 2 Multicenter Study Of

Filippi, Maria Rocca

Eric Nantz

P3.386 [F-18]PBR06 PET to assess

P3.398 Efficacy and Safety of 2 Doses

Ublituximab, A Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), In Patients With Relapsing Forms Of Multiple Sclerosis (RMS), Demonstrates Complete Elimination Of Gd-Enhancing Lesions —

Matilde Inglese, Maria Petracca, Sergio Cocozza,

Sibyl Wray, Michael Racke, Richard Shubin, Cary TSPO binding and its association with brain of Ponesimod (10 and 20 mg o.d.): Interim Twyman, Wendy Su, James Eubanks, Koby Mok, atrophy and disability in multiple sclerosis — Analysis of a Phase II Extension Trial in Tarun Singhal, Kelsey O’Connor, Shipra Dubey, Relapsing-remitting Multiple Sclerosis —Eva Michael Weiss, Edward Fox Anthony Belanger, Shelley Hurwitz, Renxin Chu, Havrdová, Anat Achiron, Patricia Coyle, Daniele P3.410 Clinical and Magnetic Resonance Shahamat Tauhid, Marie Kijewski, Marcelo DiCarli, D’Ambrosio, Juha-Pekka Eralinna, Brian Hennessy, Imaging Results From RADIANCE Part Howard Weiner, Rohit Bakshi Ewa Lindenstroem, Jan Lycke, Guillermo Izquierdo B, a Multicenter, Randomized, DoubleAyuso, Carlo Pozzilli, Mark Freedman P3.387 WITHDRAWN Blind, Phase 3 Trial of Ozanimod Versus P3.399 Safety, Tolerability and Intramuscular Interferon β-1a in Relapsing P3.388 Diagnostic Utility of FDG-PET Pharmacodynamics of Intravenous Multiple Sclerosis (RMS) —Jeffrey Cohen, in Neuro-sarcoidosis: A Case Report and Siponimod in Healthy Subjects —Kasra Giancarlo Comi, Krzysztof Selmaj, Amit Bar-Or, Review of the Literature —Yujie Wang, James Shakeri-Nejad, Anne Gardin, Cathy Gray, Srikanth Douglas Arnold, Lawrence Steinman, Hans-Peter Andrews, Annette Wundes

P3.389 Ultra-Small Superparamagnetic

Neelakantham, Swati Dumitras, Eric Legangneux

Hartung, Xavier Montalban, Eva Havrdova, Bruce Cree, James Sheffield, Kartik Raghupathi, Ludwig

P3.400 Personalised dosing of cladribine Kappos Iron Oxide (USPIO) Nanoparticle Enhanced for people with multiple sclerosis —Zhifeng High-Field Imaging of Neuro-inflammation — Mao, Cesar Alvarez-Gonzalez, Ozlem Yildiz, P3.411 Clinical Features and 7T

Tuesday

Michelle Sudyn, Ferdinand Schweser, Marilena Kimberley Allen-Philbey, Benjamin Turner, Preda, Venkatpavanni Punugu, Michelle Sveinsson, Sharmilee Gnananpavan, Monica Marta, Joela Robert Zivadinov, Suyog Pol Mathews, Gavin Giovannoni, David Baker, Klaus Schmierer P3.390 Natalizumab Treatment of

Multiple Sclerosis Leads to Diminished Microglial Activation in the Normal Appearing White Matter —Laura Airas,

Marcus Sucksdorff, Jouni Tuisku, Eero Rissanen

P3.391 Effect of teriflunomide on gray

Bergsland, Robert Zivadinov, Jesper Hagemeier, Ellen Carl, Channa Kolb, David Hojnacki, Bianca Weinstock-Guttman

P3.403 Treatment Optimization Using

a Multidimensional Decision Model (TIME Study): A Proof-of concept Study to P3.392 The role of Right Anterior Assess a Multidimensional Standardized White Matter area in Multiple SclerosisDocumentation Model to Optimize related fatigue: A Magnetic Resonance Management of Patients with Multiple Spectroscopy (MRS) Study —Shitiz Sriwastava, Sclerosis in Germany —Martin Stangel, Boris Kalyan Yarraguntla, Samuel Lichtman-Mikol, Sara Razmjou, Fen Bao, Rishi Sood, Navid SerajiBozorgzad, Evanthia Bernitsas

Kallmann, Ruth Schruefer, Iris Katharina Penner

P3.417 Longitudinal Assessment of

Retinal Structure of Patients with RelapsingRemitting Multiple Sclerosis on Glatiramer Acetate 40mg —Samuel Lichtman-Mikol, Melody Gilroy, Sara Razmjou, Carla SantiagoMartinez, Evanthia Bernitsas, Navid SerajiBozorgzad

NEUROINFLAMMATORY AND OTHER AUTOIMMUNE DISORDERS II

P3.418 Checkpoint Inhibitor-Induced

Central Nervous System Autoimmunity: A Case Series —Suma Shah, Anastasie Dunn-Pirio,

Matthew Luedke, Joel Morgenlander, Mark Skeen, Christopher Eckstein

P3.419 A Distinct Case of CLIPPERS with

Relapsing-Remitting Multiple Sclerosis Treated with Dimethyl Fumarate —Maria

Di Cristinzi, Lucia Moiola, Marco pisa, Francesca Sangalli, Gloria Dalla Costa, Marta Radaelli, Paolo Preziosa, Marzia Romeo, Filippo Martinelli Boneschi, Bruno Colombo, Federica Esposito, Vittorio Martinelli, Giancarlo Comi

P3.414 Efficacy and Safety of

Mitoxantrone Use in Aggressive Multiple Sclerosis —Marzena Pedrini, William Carroll, Allan Kermode

P3.420 Evaluating the Positive Predictive Value of Onconeural Antibody Testing in Patients with Suspected Paraneoplastic Neurologic Syndromes —Adrian Budhram, Liju Yang

P3.421 Polyneuritis Cranialis Associated With Franciscella Tularemia Infection —

Benzion Blech, Marie Grill, Kara Asbury, Mark Ross, Michael Christiansen, Robert Orenstein

P3.422 Amyloid Beta-Related Angiitis: A

Rare Cause of CNS Vasculitis —Zachery Rohm

P3.423 Multiple Autoantibody-Related Paraneoplastic Limbic Encephalitis with Complete Neurologic Recovery —Thomas Shoemaker, Scott Newsome

P3.424 NA P3.425 NA P3.426 NA P3.427 NA P3.428 NA ALS, SMA, AND OTHER NEUROMUSCULAR DISORDERS I

P3.429 Utility of Intrathecal Baclofen

Pump in Primary Lateral Sclerosis —Adeel Zubair, Matthew Raymond, Huned Patwa

P3.430 Successful Percutaneous

Gastrostomy Tube Placement with Fluoroscopy in ALS Patient Requiring 24/7 Ventilation —Senda Ajroud-Driss, Cosette Burian, John-Michael Li, Lisa Wolfe

P3.431 A Systematic Review of the

Blood-central Nervous System Barrier Pathology in ALS —Ario Mirian, Agessandro Abrahao, Serena Soleimani, Lorne Zinman

P3.432 Unreported Gene Mutation of

Episodic Ataxia —Abdallah Hamdallah, Hussam Shaker, Pascal Atanga, Paul Twydell

P3.433 Patient with MT-ATP 6 gene

mutation and NARP like disease —Yasushi Kisanuki, Yasmeen Rauf

P3.415 Defining Glatiramer Acetate:

P3.434 Spastic Dysarthria as a P3.404 Siponimod is a Functional Agonist The USA Definition of Sameness and the EU presenting sign of Stiff Person Syndrome — for the S1P5 Receptor —Marc Bigaud, Barbara Definition of Similarity —Sigal Melamed-Gal, Nuesslein-Hildesheim, Thi-Thanh-Thao Tran, Danilo Guerini

150 2018 AAN Annual Meeting

MRI Findings of Progressive Multifocal Leukoencephalopathy in the Setting of Extended Natalizumab Dosing: A Case Report —Laura Baldassari, Stephen Jones,

P3.401 Biotin—the forgotten Vitamin in Robert Fox MS ? —Gerhard D. Roth, Walter Maier-Janson, P3.412 WITHDRAWN Erich Scholz, Matthias Schmid P3.413 Prospective Observational P3.402 Absolute Bioavailability of Study in a Cohort of Patients Affected by

Single, Oral Dose of Siponimod in Healthy and white matter brain pathology in multiple Subjects —Anne Gardin, Kasra Shakerisclerosis using volumetric and diffusionNejad, Cathy Gray, Srikanth Neelakantham, Eric tensor imaging MRI measures —Niels Legangneux, Swati Dumitras

Robert Noble, Joshua Steinerman, Jessica Alexander, David Ladkani

Calabresi, Gavin Giovannoni, Raju Kapoor, Douglas predominant Spinal Cord Involvement — Maha Khan, Shitiz Sriwastava, Praveen Vemuri, Arnold, Yi Chai, Bing Zhu, Carmen CastrilloNavid Seraji-Bozorgzad Viguera, Aaron Deykin, Ih Chang

Krzysztof Selmaj, Amit Bar-Or, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva MS THERAPEUTICS I Havrdova, James Sheffield, Kartik Raghupathi, Jeffrey Cohen P3.409 Final MRI Results At 6 Months

in Patients with Relapsing-Remitting Valsasina, Sarlota Mesaros, Jelena Dackovic, Irena Multiple Sclerosis: A Randomized, DoubleBlind, Placebo-Controlled Study —Maria Silk, Dujmovic Basuroski, Jelena Drulovic, Massimo

acetate 40 mg/mL TIW treatment effect in reducing relapse rate —Ofra Barnett-Griness,

Samuel Giles, Amanda Persaud, Michael Pulley, Pippa Loupe, Iris Grossman, Benjamin Zeskind, Natalya Shneyder Vera Weinstein, Bracha Timan, Sarah Kolitz, Arthur Komlosh, Tal Hasson, Yousif Sahly

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m. MYOPATHY

P3.435 Efficacy and safety of

dichlorphenamide in adolescent patients with primary periodic paralysis —Emma Ciafaloni, Fredric Cohen, Robert Griggs

P3.448 Diagnostic Spectrum and

Treatment Outcomes of Granulomatous Myopathy —Reem Alhammad, Teerin Liewluck

P3.449 RNA-sequencing analysis of

muscle biopsy samples from patients with inclusion body myositis and those with

ALS I

P3.463 Neuromuscular Ultrasound to

Identify Deep Muscle Fasciculations in a Suspected Case of Amyotrophic Lateral Sclerosis (ALS) —Arjumond Khan, Arben Brahaj,

P3.436 Open Label Trial of Ranolazine for polymyositis —Chiseko Ikenaga, Akatsuki

Huned Patwa

Samantha LoRusso, David Kline, Amy Bartlett, Julie Agriesti, Miriam Freimer, Mark Rich, John Kissel, William Arnold

Lateral Sclerosis in Cinema and Television —

the Treatment of Paramyotonia Congenita — Kubota, Hiroyuki Ishiura, Hidetoshi Date, Shoji

P3.437 Circulatory Kv1.3+ cells in

patients with sIBM —Karissa J. Munoz, Ali H Mannaa, Jenna Kastenschmidt, Marie Wencel, Namita Goyal, S. Armando Villalta, Tahseen Mozaffar

P3.438 MRI prognostic outcome

Tsuji, Jun Goto, Jun Shimizu

P3.450 Variable penetrance of Andersen-

P3.440 A series of aggregated

randomized-controlled N-of-1 trials with mexiletine in non-dystrophic myotonia: Clinical trial results and validation of rare disease design —Bas Stunnenberg, Joost

Raaphorst, Hans Groenewoud, Jeffrey Statland, Robert Griggs, Willem Woertman, Dick Stegeman, Janneke Timmermans, Jaya Trivedi, Emma Matthews, Christiaan Saris, Bas Schouwenberg, Gea Drost, Baziel van Engelen, GertJan van der Wilt

P3.441 Sensitivity of IBM Criteria in

a Large Multicenter Cross-Sectional IBM Cohort —Sumiko Weir, Tahseen Mozaffar,

Matthew Wicklund, Jeffrey Statland, Mamatha Pasnoor, Omar Jawdat, Melanie Glenn, Bachir Estephan, Jonathan McKinnon, Sarita Said-Said, Richard Barohn, Mazen Dimachkie

P3.442 Muscle Biopsy and

Electromyography Correlation —Elie Naddaf,

Margherita Milone, William Litchy, Michelle Mauermann, Jayawant Mandrekar, Andrew Engel

P3.443 Willingness to Participate in

Natural History Studies amongst Sporadic Inclusion Body Myositis Patients —Veena Mathew, Marie Wencel, Namita Goyal, Robert Goldberg, Tahseen Mozaffar

David Avila

Tawil Syndrome in a Caucasian family with a P3.465 Hypersensitivity and rare missense KCJN2 mutation —Reem Deeb, Edaravone—Summary of Case Reports — Aravindhan Veerapandiyan, Alrabi Tawil, Simona Treidler

P3.451 Follow-up of clinical and MRI

changes in juvenile adult onset DM1 —Sigrid Baldanzi, Corrado Angelini, Francesca Bevilacqua,

in asymptomatic/paucisymptomatic Gabriele Siciliano HyperCKemia —Piar Marti, Nuria Muelas, Jorge P3.452 Response to Liver Transplant and Alberto Diaz-Manera, Juan Vilchez Padilla Riboflavin in MADD Myopathy —Elisabeth P3.439 Myopathies Presenting with Golden, Rahul Abhyankar, Kyle Womack, Jaya “dropped-head syndrome” —Reem Alhammad, Trivedi Elie Naddaf

P3.464 The Portrayal of Amyotrophic

P3.453 Necrotizing Inflammatory

Myopathy Following Immune Checkpoint Inhibitor Therapy Presenting With Progressive Upper Extremity Weakness — Pariwat Thaisetthawatkul, Rodney McComb

Laura Bower, Benjamin Shander, Alexander Kalin

TRANSCENDS SCHOLARS

P3.466 Saving the survivors of cardiac

arrest: Exploring novel mechanisms of secondary brain injury and improving accuracy of neuroprognostication —Carolina Barbosa Maciel

P3.467 Healthcare expenditure patterns among elderly with seizure in the United States: Medical Expenditure Panel Survey, 2003-2014 —Alain Lekoubou

P3.468 Should we do cardiac monitoring

in young adults with ischemic stroke? Analysis of the IMS Health database —Karen

P3.454 Subacute paresis in a 28-year-old Orjuela, Michelle Leppert, Sharon Poisson man with HIV —Yohei Harada, Neil Masangkay, P3.469 Taking Steps Backward to Move Murat Gokden, Reza Sadjadi

Forward: A Preliminary Feasibility Study in

P3.455 Individual N-of-1 Trial Salbutamol Stroke —Oluwole O. Awosika Versus Placebo as Attack Treatment in P3.470 Combining Neuroimaging and a Patient with Hyperkalemic Periodic Paralysis —Robyn Weijma, Esther Merkus, Bas van Vlijmen, Hans Groenewoud, Gert Jan van der Wilt, Baziel van Engelen, Joost Raaphorst, Christiaan Saris, Bas Stunnenberg

P3.456 Severe Necrotizing Myopathy Associated with Pembrolizumab for Urothelial Carcinoma —Chandler Gill, Ewa

Blood Biomarkers in Cerebrovascular Disease —Alexis N. Simpkins

P3.471 Understanding the Role of

Alzheimer Disease Pathology in Parkinson Disease: Focus on Language —Federico Rodriguez-Porcel

Borys, Ryan Jacobson

P3.457 Diminished Distal Finger Creases in Patients with Inclusion Body Myositis — Benjamin Koo, Leo Wang

P3.458 Role of microRNAs in lipid

storage myopathies. —Valentina Pegoraro, Corrado Angelini

P3.459 Correlation of MRI with

Sener, Jennifer Martinez-Thompson, Elliot Dimberg, Ruple Laughlin, Devon Rubin

P3.446 Feasibility and Validation of

Modified Oculobulbar Facial Respiratory Score (mOBFRS) in Sporadic Inclusion Body Myositis —Marie Wencel, Nadia Araujo, Lishi

Zhang, Eileen Medina, Tahseen Mozaffar, Namita Goyal

P3.447 Diagnoses in HyperCKemia:

Study from classical aproach to the use of new technologies (NGS). —Piar Marti, Nuria

Tuesday

Muscle Biopsy Findings in Critical Illness Myopathy —Edward Labin, Georgios Manousakis (Ilaris), an IL-1β Receptor antagonist, in the treatment of patients with sporadic Inclusion P3.460 Pulmonary-Sparing Anti-MDA5Body Myositis (sIBM) —Michail Kosmidis, Positive Dermatomyositis with Scleroderma Dimitrios Pikazis, Panayiotis Vlachoyiannopoulos, Overlap, Glomerulonephritis and Athanasios Tzioufas, Marinos Dalakas Cardiomyopathy —Cina Sasannejad, Marcus P3.445 Correlation of Electromyography Cimino, Luis Chui, Margaret Adler Findings to Muscle Biopsy Findings in P3.461 Anti-dopaminergic medication Patients with Suspected Myopathy —Ugur related myopathy causing respiratory muscle

P3.444 A pilot trial of Canakinumab

weakness without neuroleptic malignant syndrome —Yohei Harada, Murat Gokden, Tuhin Virmani, Vikki Stefans

P3.462 Acute necrotizing myopathy

associated with bronchiolitis obliterans with organizing pneumonia (BOOP) responding to treatment with rituximab and steroids. — Guru Ramaiah, Boyd Koffman, Kevin Litzenberg, Preeti Rao

Muelas, Immaculada Azorin, Teresa Jaijo, Jose Maria Millan, Juan Vilchez Padilla

AAN.com/view/AM18 151

POSTER SESSIONS

POSTER SESSION IV G NEUROLOGY PRACTICE AND OUTCOMES

P4.001 Autoencoder— a new method

Wednesday, April 25 11:30 a.m.–7:00 p.m.

case report and review of the literature. —

Amanda Persaud, Fatoumata Sakho, Sukhwinder Sandhu, Suparna Krishnaiengar MD

P4.011 Comparing brain structural and for keeping data privacy when analyzing videos of patients with motor dysfunction — perfusion MRI changes across ALS-FTD Marcus D`Souza, Matthew Johnson, Jonas Dorn, continuum —Dongchao Shen, Bo Hou, Bo Cui, C.E.P. Van Munster, Manuela Diederich, Christian Kamm, Saskia Steinheimer, Kristina Kravalis, Jacques Boisvert, Ian Ormesher, Lorcan Walsh, Abigail Sellen, Frank Dahlke, Bernard Uitdehaag, Ludwig Kappos

Hongfei Tai, Liying Cui, Mingsheng Liu, Jing Gao, Feng Feng

P4.002 Teleneurology Clinics for

Sanei Moghaddam, Guru Ramaiah, Mouhammad Jumaa, Syed Zaidi

Polyneuropathy: A Pilot Study —Andrew

Wilson, Nasheed Jamal, Moira Inkelas, Michael Ong

P4.003 Improving Outcomes in Inpatient Send-Out Studies —Michael Robers, Harlori

Disorders: A Systematic Review —Bas

Stunnenberg, Joost Berends, Robert Griggs, Jeffrey Statland, Gert Jan van der Wilt, Joost Raaphorst, Baziel van Engelen

P4.005 Hybrid Charting Improves

Documentation Compliance in a Comprehensive Stroke Center —Paul Wright, Danielle Gonsalves, Christina Paiva, Suzanne Pine, Shantel Coleman, Neeroopa Surendranath, Saeyoan Thirunavukkarasu

Encephalopathy Syndrome PRES Clinical Presentation and Epidemiology in Different south Asian Population —Faisal Ibrahim,

functional magnetic resonance imaging between Neurological and Liver-only affected Wilson’s Disease patients —

Keerthana Nalamada, Ayse Tinaz, Jagriti Arora, Ana Vives-Rodriguez, Todd Constable, Michael Schilsky, Daphne Robakis

P4.015 Semiquantitative Analyses

of Dopamine Transporter Imaging in the Patients with Idiopathic Normal Pressure Hydrocephalus (iNPH) —Nobutoshi Morimoto, Motonori Takamiya, Mizuki Morimoto

GENERAL NEUROLOGY: NEUROIMAGING

P4.016 An Atypical Presentation of

P4.006 DTI-Correlated Parkinsonism

Deirdre Donaldson

after Chronic Carbon Monoxide Poisoning —

Posterior Reversible Encephalopathy Syndrome —Melissa Martinez, Dinesh Jillella,

Eric Hirsch, Erica Glants, Tahir Sheikh, Daryl Duran, P4.017 Use of Proton Magnetic Resonance Spectroscopy (MRS) to Detect Ranga Krishna

P4.007 Bilateral Superior Ophthalmic Vein Dilatation as an Early Indicator of Increased Cranial Pressure —Erin Flynn,

Himanshi Suri, Jessica Stevens, Lynn Kataria

P4.008 Magnetic resonance

characteristic of Parkinson’s disease based on the presence of cognitive impairment — Farangis Doniyorova

P4.009 Hypobaric Exposure in Aircrew

Personnel: Possible Basis for Group Differences on Arterial Spin Labeling (ASL) —Michael Hossack, Timothy Fullam, John Sladky, Stephen McGuire

P4.010 Reversible splenial lesion

Wednesday

syndrome (RESLES) associated with Idiopathic Intracranial Hypertension: A rare

152 2018 AAN Annual Meeting

037–084

P4.013 Posterior Reversible

P4.014 A comparison of resting-state

Regional Differences in Absolute Neurometabolite Concentrations in Aircrew Personnel with Hypobaric Exposure —Timothy Fullam, John Sladky, Stephen McGuire

P4.018 Posterior Reversible

173–200

ePosters

085–090

Encephalopathy Syndrome (PRES) Secondary to Use of Axitinib in Renal Cell Cancer —Amin

Bains, Bill Jacobsen, Sana Aslam, Robert Jackson, Yasir Mohamed, Dirk Deleu, Gayane Melikyan, Boulenouar Mesraoua, Najib Murr Edward Chen, Jennifer Heim, Ganesh Murthy, Aaron Zigelbaum, Kerry Knievel

P4.004 N-of-1 Trials in Neurological

091–172

P4.012 Posterior Reversible

b1 g1 339–344 a1 ePosters

Poster Discussion

027–036

001–026

P4.020 Osmotic Demyelination

Syndrome in Liver Failure Patient Without Hyponatremia —Izabela Biesiada

259–294

295–338

345–428

429–480

Poster Session 4 A. General Neurology: 001 – 026

a1. Cerebrovascular Disease and Interventional Neurology Poster Discussion Session: 027 – 036 B. Movement Disorders: 037 – 084

b1. Cerebrovascular Disease and Interventional Neurology I ePoster Session: 085 – 090 C. D. E. F. G.

Headache; Neuro-oncology; Practice, Policy, and Ethics: 091 – 172 Aging, Dementia, Cognitive, and Behavioral Neurology: 173 – 200 Cerebrovascular Disease and Interventional Neurology: 201 – 258 Epilepsy/Clinical Neurophysiology (EEG): 259 – 294 Neuro Trauma, Critical Care, and Sports Neurology: 295 – 338

g1. Cerebrovascular Disease and Interventional Neurology II ePoster Session: 339 – 344 H. MS and CNS Inflammatory Disease: 345 – 428 I. Neuromuscular/Clinical Neurophysiology (EMG): 429 – 480

GENERAL NEUROLOGY: CASE REPORTS I

Encephalopathy Syndrome during Treatment with Lenvatinib —Jean Khoury, Pauline Funchain P4.021 Vitamin B6 Toxicity Revisited: A Case of Reversible Pyridoxine-associated P4.019 Examining the Spectrum of Neuropathy and Disequilibrium. —Rohitha Reversibles: Cerebral ischemia in PRES and Moudgal, Shahla Hosseini, Patricia Colapietro, RCVS —Ashley Pena, Cumara O’Carroll, Kristen Oluwole Awosika Steenerson, Amaal Starling

201–258

P4.022 Systemic Botulinum Toxicity in an Emery-Dreifuss Muscular Dystrophy Patient Secondary to a Botox Injection —Diviya Kaul, Hena Waseem, George Thomas, Elijah Stommel, Mary Feldman, Stephen Lee, Jeffrey Cohen

P4.023 An interesting case of

transient recurrent plegic events: Sprengel Deformity —Barbara Santos, Larissa Carvalho,

Vanessa Dinis, Kamilla Daveiro, Stephanie Queiroz

P4.024 Metastasis to the Conus

Medullaris and Cauda Equina Presenting with Primarily Motor Symptoms —Christeena Kurian, Rafia Shafqat, Jin Li

P4.025 “Right Insula: Maintaining

language and speech qualities”. A review of literature and a case report on Foreign Accent Syndrome. —Varun Chauhan, Richa

Tripathi, Hamidreza Saber, Navid Seraji-Bozorgzad

P4.026 NA

Cerebrovascular Disease and Interventional Neurology Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below.

Posters displayed 11:30 a.m.-5:30 p.m. • Data blitz 12:00 p.m.-12:50 p.m. • Presenters Stand by Posters 5:30p.m.-7:00 p.m. Data Blitz: 11:45 a.m.–11:50 a.m.

Data Blitz: 12:00 p.m.–12:05 p.m.

Data Blitz: 12:10 p.m.–12:15 p.m.

P4.027 What are the Molecular

P4.030 Prevalence and Risk Factor of

P4.032 Prevalence of Carotid Webs in

Mechanisms of WldS-Mediated Axon Protection in Stroke? —Jack Wang, Jason Hinman

Data Blitz: 11:50 a.m.–11:55 a.m.

P4.028 In vivo Electrical Stimulation

of Neural Stem Cells via Conductive Polymer Scaffold Improves Endogenous Repair Mechanisms of Stroke Recovery —

Large Perivascular Spaces in a PopulationBased MRI Study —Jiang-Tao Zhang, Si-Yu

Chen, Ming-Li Li, Jun Ni, Lixin Zhou, Ming Yao, Ding-Ding Zhang, Shu-Yang Zhang, Zheng-Yu Jin, Li-Ying Cui, Yi-Cheng Zhu

Data Blitz: 12:05 p.m.–12:10 p.m.

P4.031 Early Elevated Troponin

Levels after Ischemic Stroke Suggests a Cardioembolic Source —Andrew Chang,

Cryptogenic Stroke —Joel Nunez Gonzalez,

Payam Sajedi, Prashant Raghavan, Steven Kittner, Carolyn Cronin

Data Blitz: 12:25 p.m.–12:30 p.m.

P4.035 Seizures and the impact on

clinical outcomes at discharge in acute stroke patients from a large multicenter P4.033 Safety Outcomes of Thrombolysis FL-PR registry —Fanglin Zhang, Kefeng Wang, Chuanhui Dong, Kathy Fenelon, Carolina M. for Acute Ischemic Stroke in Patients with Gutierrez, Ralph Sacco, Tatjana Rundek, FL-PR History of Intracranial Hemorrhage —Stacy CReSD Investig and Collaborators Data Blitz: 12:15 p.m.–12:20 p.m.

Chu, Samuel Sommaruga, David Hwang, Jennifer Dearborn, Lauren Sansing, Branden Cord, Gargi Brittany Ricci, Grace B Russo, Mahesh Jayaraman, Samarth, Nils Petersen, Emily Gilmore, Joseph Schindler, Charles Matouk, Kevin Sheth, Guido Ryan A McTaggart, Morgan Hemendinger, Priya Data Blitz: 11:55 a.m.–12:00 p.m. Narwal, Katarina Dakay, Brian Mac Grory, Shawna Falcone P4.029 Bypassing Interhospital Transfers Cutting, Tina Burton, Christopher Song, Emile Data Blitz: 12:20 p.m.–12:25 p.m. Mehanna, Matthew Siket, Tracy E Madsen, for Large Vessel Occlusions in the Era of P4.034 Utilization, Outcomes and Safety Michael Reznik, Alexander Merkler, Michael Mobile Stroke Units —Lila Sheikhi, Payal Patel, of IV tPA for Acute Ischemic Stroke during Naresh Mullaguri, Pravin George, Andrew Reimer, Lerario, Hooman Kamel, Mitchell Elkind, Karen Furie, Shadi Yaghi pregnancy —Abhishek Lunagariya, Branko HuisaGabor Toth, Muhammad Hussain, Ken Uchino, Andrew Russman Byeongtaek Oh, Shang Song, Vivek Lam, Alexa Levinson, Paul George

Garate, Achint Patel, Zabeend Mahuwala, Vishal Jani, Thomas Hemmen

Data Blitz: 12:30 p.m.–12:35 p.m.

P4.036 Care and Outcome of Stroke

Patients with Language Barrier in a Busy Stroke Centre —Fatemeh Rezania, Angelos

Sharobeam, Elizabeth Mackey, Michael Seman, Christopher Neil, Tissa Wijeratne

HUNTINGTON’S DISEASE AND OTHER CHOREA

Sanjay Gandhi, Victor Abler, Brian Davis, Debra Irwin, Victor Sung

PARKINSON’S DISEASE: SURGICAL MANAGEMENT

P4.059 Long-term Outcomes with

P4.037 Frequency of Single Nucleotide

P4.045 Nitric Oxide as an Exercise

Polymorphisms (SNPs) rs362307 or rs362331 in Patients with Huntington’s Disease (HD): Results from a Prospective Observational Research Study —Daniel Claassen, Mary

Induced Mitochondrial Function Modulator in the CAG140 KI Huntington’s Mouse Model —Charles Caldwell, Enrique Cadenas,

P4.052 Five Year Outcomes of a

Zeilman, Edward Ofori, David Vaillancourt, Kelly

P4.038 Clinical manifestations of

Rojas, Gustavo Da Prat de Magahlaes, Javier Ziliani

Michael Barbe, Steven Gill, Alan Whone, Mauro Porta, Domenico Servello, Francois Alesch

Guillermo Moguel-Cobos

P4.047 Laughing and Dancing: A case

P4.053 Efficacy of Subthalamic Neural

the Effects of GPi DBS on Features of Dopamine Dysregulation Syndrome —Lenora

Mary-Ann Fares, Samuel Giles, Emil Gaitour, Natalya Shneyder

Bronte-Stewart, Muhammad Furqan Afzal, Anca Velisar, Chioma Anidi

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

Rescue Target Deep Brain Stimulation in Patients with Dystonia —Abigail Hatcher, Pam

Prospective, Multi-Center Trial Evaluating Foote, Michael Okun, Aparna Wagle-Shukla Deep Brain Stimulation with a New Multiple P4.060 Subcortical Atrophy Predicts Source, Constant-Current Rechargeable Michael Jakowec, Giselle Petzinger Motor Response in Idiopathic Parkinson’s System in Parkinson’s Disease —Lars Disease Patients with Pallidal (GPi) but not Edmondson, Ralf Reilmann, Nenad Svrzikapa, P4.046 Late onset Huntington’s disease Timmermann, Roshini Jain, Nic Van Dyck, Lilly Subthalamic (STN) Deep Brain Stimulation Kenneth Longo, Jaya Goyal, Serena Hung, Michael in an Argentinian cohort —Emilia Gatto, Martin Chen, Thomas Brucke, Fernando Seijo, Esther (DBS) —Moath Hamed, Francisco Ponce, Suarez San Martin, Veerle Visser-Vandewalle, Panzara Cesarini, Jose Luis Etcheverry, Natalia Gonzalez homozigote allele carriers in Huntington’s disease —Esther Cubo Delgado, Saul

Martinez-Horta, Maria Antonia Ramos-Arroyo, Cecilia Gil-Polo, Frederic Sampedro, Asuncion Martinez-Descalls, Sara Calvo, Katia LLano, Ignacio Muñoz-Siscart

report of Pseudobulbar Affect in Late Onset Huntington’s Disease —Amanda Persaud,

P4.039 Huntington Disease: The ‘typical’ P4.048 Loss of the Sigma-1 receptor phenotype for the commonest CAG repeat expansion in the ENROLL-HD study across varying functional levels —Florence Ching-Fen

disrupts pridopidine-induced gene expression —Jennifer Dreymann, Michal Geva,

Closed-loop Deep Brain Stimulation for Bradykinesia in Parkinson’s Disease —Helen

P4.054 Electrophysiologic Mapping of

Cortical Networks Activated by Dorsal vs. Ventral Subthalamic Nucleus Deep Brain Stimulation —Aarathi Minisandram, Kristen

Gandhi, Victor Abler, Kristen Bibeau, Daniel Claassen, Samuel Frank

eicosapentaenoic acid as a treatment for Huntington’s disease: A systematic review and meta-analysis of randomized clinical trials —Mohamed Fahmy Doheim, Sara Morsy,

Chang, Elizabeth McCusker, Clement Loy

Compliance, Satisfaction, and Patient Perception of Change in Huntington Disease Symptoms —Victor Sung, Ravi Iyer, Sanjay

P4.049 Efficacy and safety of ethyl-

P4.056 Real-World Outcomes Using

Florence Ching-Fen Chang, Elizabeth McCusker, Clement Loy

Deuschl, Roshini Jain, Heleen Scholtes, Alex Wang, Michael Barbe, Monica Pötter-Nerger, Andrea Kuehn, Jens Volkmann, Steffen Paschen, Jan Vesper

phenotype for the commonest CAG repeat expansion in the ENROLL- HD study —

P4.042 The Impact of Family History

on the Clinical Features of Huntington’s Disease —Danny Bega, Gabriel Kringlen, Lisa

P4.050 Experience of Individuals With Huntington Disease and Chorea —Eileen

Kinsley, Sharon Aufox, Gerald Rouleau

Mack Thorley, Ravi Iyer, Noelle Carlozzi, Paul Wicks, Chris Curran, Sanjay Gandhi, Victor Abler, Karen E. Anderson

P4.043 Niemann Pick Type C

P4.051 Evaluation of ataxia in patients

as Presentation of Huntington-Like Syndrome —Lucia Zavala, Nelida Garretto,

with Huntington’s Disease —Gustavo Franklin, Helio Afonso Teive, Francisco Branco Germiniani, Tomoko Arakaki, Sergio Rodriguez Quirofa, Dolores sibele milano, Giovanna Pavanelli, Nayra Lima, Moron, Patricia Vega, Nancy Medina, Marcelo Salmo Raskin, Gustavo Ribas Kauffman

P4.044 Healthcare Utilization and Costs for Huntington Disease Patients Prescribed Tetrabenazine —Karen E. Anderson, Ravi Iyer,

P4.062 The Effect of Short Pulse Width

Settings on the Therapeutic Window in Subthalamic Nucleus Deep Brain Stimulation for Parkinson’s disease —Viswas Dayal, Patricia Limousin, Thomas Foltynie

P4.063 Finding ways to decrease gait

and speech impairment in patients with chronic STN DBS for Parkinson’s disease —

in patients with Parkinson’s disease and Jessica Karl, Leonard Verhagen Metman substantial Action/Postural Tremor —Kamilia P4.064 RAD-PD: Registry for the Nozile-Firth, Vyas Viswanathan, Adolfo Ramirez Zamora, Kelly Foote, Michael Okun, Aparna Wagle- Advancement of DBS in Parkinson’s Disease —Joohi Jimenez-Shahed, Susan Shukla

P4.041 Huntington Disease: The ‘typical’ Samar Morsy Khalil, Mohamed Gomaa Kamel,

Doaa Saeed Mahmoud El-Basiony, Hossam Idrees Ahmed Hassan, Ahmed Abdelaziz Eisa, Cao Thi Anh Ngoc, Nguyen Phu Dang, Kenji Hirayama, Nguyen Tien Huy

Higginbotham, Stewart Factor

a Novel Directional Lead from a Registry of DBS for Parkinson’s Disease —Guenther

P4.057 STN vs. GPi deep brain

stimulation for tremor suppression in Parkinson’s disease: A systematic review and meta-analysis —Joshua Wong, James

Bressman, Michelle Burack, Elana Farace, James McInerney, James Kirk, Rachel Saunders-Pullman, Jason Schwalb, Ludy Shih, Meredith Spindler, Elena Moro, Michele York

P4.065 The mutual relationship of

bilateral subthalamic stimulation impact on the non-motor and motor symptoms in Parkinson’s disease: Open, prospective pilot study —Petr Kanovsky, Sandra Kurcova,

Jan Bardon, Marketa Vecerkova, Miroslav Vastik, Martin Nevrly, Katerina Mensikova, Tereza Bartonikova, Pavel Otruba, David Krahulik, Egon Cauraugh, Kwo Wei David Ho, Matthew Broderick, Kurca Adolfo Ramirez Zamora, Leonardo Almeida, Aparna Wagle-Shukla, Christina Wilson, Robertus De Bie, P4.066 Effect of Subthalamic NucleusDeep Brain Stimulation Surgery on Frances Weaver, Michael Okun Impulsivity in Parkinson’s Disease Patients — P4.058 Speech Side Effects from DBS: Abhinav Raina, Roopa Rajan, Gangadhara Sarma, Differential Effects of Target, Handedness, Syam Krishnan, K Krishnakumar, Asha Kishore and Hemisphere. —Adeel Memon, Manmeet Kaur, Jesse Faulk, Barton Guthrie, Harrison Walker

AAN.com/view/AM18 153

Wednesday

P4.040 Initial Deutetrabenazine

Jermaine Ross, Yoonjeong Cha, Rebecca Kusko, Kanoff, Emad Eskandar, Todd Herrington Renan Escalante-Chong, Benjamin Zeskind, Daphna Laifenfeld, Iris Grossman, Michael Hayden P4.055 Comparison of STN and GPi DBS

P4.061 A Case Series Analysis of

POSTER SESSIONS

POSTER SESSION IV G P4.067 Predicting Depression and

Anxiety Following DBS Implantation —Mary Flaherty, Carol Schramke, Timothy Leichliter

P4.068 DIRECT DBS: A Prospective,

Multi-center Clinical Study with Blinding for a Directional Deep Brain Stimulation (DBS) Lead —Frank Steigerwald, Jens Volkmann,

P4.072 Outcomes of a Prospective,

Multicenter International Registry of Deep Brain Stimulation —Guenther Deuschl, Roshini

Tam, Radha Bhavsar, Courtney Timms, Leonard Verhagen Metman, Deborah Hall, Karen Marder

MOVEMENT DISORDERS: TARDIVE DYSKINESIA

P4.070 Impact of Deep Brain Stimulation P4.074 Estimation of an MCID for AIMS on hospital and related outcomes in patients with comorbid Parkinson’s disease and Major Depressive Disorder: A Nationwide Inpatient Sample study —Rikinkumar Patel, Amit Chopra

P4.071 Sixty hertz subthalamic deep

brain stimulation improves freezing of gait with less attenuation of beta band power than 140Hz stimulation —Chioma Anidi,

Johanna O’Day, Muhammad Furqan Afzal, Judy Syrkin-Nikolau, Anca Velisar, Helen Bronte-Stewart

b1 C

P4.076 Long-Term Treatment With

Deutetrabenazine is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study —Robert Hauser, Hubert

Jain, Heleen Scholtes, Alex Wang, Steffen Paschen, Michael Barbe, Andrea Kuehn, Monica Pötter-Nerger, Jens Volkmann, Yen Tai, Jan Vesper Fernandez, David Stamler, Mat Davis, Stewart Factor, Joohi Jimenez-Shahed, William Ondo, L. P4.073 Health disparities and shortFredrik Jarskog, Scott W. Woods, Mark LeDoux, term outcomes analysis of a multiethnic David Shprecher, Karen E. Anderson

Cordula Matthies, Dalal Kirsch, Stephan Chabardes, Robertus De Bie, P.R. Schuurman, sample receiving deep brain stimulation for Elena Moro, Valérie Fraix, Sara Meoni, David Blum, Parkinson’s Disease at a tertiary referral Leon Juarez Paz, Kenny Wynants, Nic Van Dyck center —Daniel Garbin Di Luca, Juan Sebastian Diaz, Henry Moore, Carlos Singer, Bonnie Levin, P4.069 Interest in Genetic Testing in Iahn Cajigas, Jonathan Jagid, Corneliu Luca

Parkinson’s disease patients with Deep Brain Stimulation —Avram Fraint, Gian Pal, Eric

Wednesday, April 25 11:30 a.m.–7:00 p.m.

Total Score Change in Tardive Dyskinesia — Roger Kurlan, Mark Stacy, Khodayar Farahmand, Joshua Burke, Scott Siegert, Grace Liang

P4.077 Effect of Tardive Dyskinesia on

Quality of Life: Patient-reported Symptom Severity is Associated with Deficits in Physical, Mental, and Social Functioning —

Joseph McEvoy, Benjamin Carroll, Sanjay Gandhi, Avery Rizio, Stephen Maher, Mark Kosinski, Jakob Bjorner

Khodayar Farahmand, Sean Hinton, Grace Liang, Scott Siegert

P4.080 Cardiovascular Safety

Assessment of Deutetrabenazine in Healthy Volunteers and Implications for Patients With Huntington Disease or Tardive Dyskinesia —Donna Cox, Micha Levi, Laura Rabinovich-Guilatt, David Truong, David Stamler

P4.081 Tardive Dyskinesia Among

Patients Using Antipsychotic Medications in Customary Clinical Care in the United States —Anita Loughlin, Nancy Lin, Victor Abler, Benjamin Carroll

P4.082 A Case of Tardive Dyskinesia and Parkinsonism Following Use of Phentermine

P4.078 Effects of Long-Term Valbenazine for Weight Loss —Ryan Barmore, Christopher on Tardive Dyskinesia and Patient-Reported Outcomes: Results from the KINECT 4 Study —Stewart Factor, John Kane, Stephen

Marder, Robert Hauser, Khodayar Farahmand, Roland Jimenez, Joshua Burke, Scott Siegert, Deutetrabenazine for Tardive Dyskinesia in a Grace Liang 2-Year Open-Label Extension Study —Hubert P4.079 Short- and Long-term Effects Fernandez, David Stamler, Mat Davis, Stewart of Once-Daily Valbenazine on Tardive Factor, Robert Hauser, Joohi Jimenez-Shahed, William Ondo, L. Fredrik Jarskog, Scott W. Woods, Dyskinesia by Body Region —Cynthia Comella, Mark LeDoux, David Shprecher, Karen E. Anderson Carlos Singer, Stephanie Lessig, Joshua Burke,

P4.075 Confirmed Safety of

Hess, Nikolaus McFarland, Michael Okun

P4.083 RE-KINECT: A Prospective

Real-World Dyskinesia Screening Study and Registry in Patients Taking Antipsychotic Agents: Patient Demographics —Caroline

Tanner, Andrew Cutler, Stanley Caroff, William Lenderking, Karen Yeomans, Huda Shalhoub, Linda Ross, Charles Yonan

P4.084 NA

Cerebrovascular Disease and Interventional Neurology I ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P4.085 The FAST VAN Tool for

Priyank Khandelwal, Joshua Lukas, Kunakorn Atchaneeyasakul, Robert Starke, Eric Peterson, Dileep Yavagal

Michael Kelly, Kimberly Davy, Gary Hunter

P4.087 Support of New Triage Protocol

Identifying Large Vessel Occlusion in Acute Stroke —Sanchea Wasyliw, K. Ruth Whelan,

P4.086 Intra-arterial tPA administration

Among Acute Stroke Care Providers —David

during Mechanical Thrombectomy is associated with increased risk of Subarachnoid Hemorrhage. —Vasu Saini,

Anderson, Haitham Hussein

HEADACHE THERAPEUTICS

P4.095 The Impact of Fremanezumab

P4.091 Eptinezumab Reduced Migraine

Frequency, Duration, and Pain Intensity Through Week 24: Results From the Phase 3 PROMISE-1 Trial —Stephen Silberstein, Peter McAllister, Gary Berman, Roger Cady, Jeff Smith, David Biondi, Joe Hirman

P4.092 Eptinezumab Achieved

Wednesday

Meaningful Reductions in Migraine Activity Within 24 Hours That Were Sustained Through Week 12: Results From PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Phase 3 Trial —Timothy Smith, David Biondi, Gary Berman, Marshall Freeman, Joe Hirman, Eric Kassel

P4.093 Efficacy and Safety of 2 Dose

Regimens of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine —David Dodick, Ernesto Aycardi,

Marcelo Bigal, Paul Yeung, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma, Stephen Silberstein, Peter Goadsby

P4.094 Efficacy of Erenumab For the

P4.088 Design and Implementation of a

P4.090 SPAN-100 Designation as an

P4.089 Cervical Epidural Hematoma

Priyank Khandelwal, Kunakorn Atchaneeyasakul, Omar Alkhatib, Eric Peterson, Dileep Yavagal

Stephen Silberstein, Paul Yeung, Tricia Blankenbiller, Xiaoping Ning, Ronghua Yang, Yuju Ma, Ernesto Aycardi, Marcelo Bigal

P4.104 Efficacy of Fremanezumab

Catherine Legault, Shefali Dujari, Sam H Shen, Alexie M. Wagner, Gregory Albers, Eric Bernier, Patrice Callagy, Nirali Vora

mimicking Acute Ischemic Stroke: A better look at the imaging —Ary De Sousa

Early Predictor of 24-36 hour NIHSS in Patients with LVO Status-post Mechanical Thrombectomy. —Joshua Lukas, Vasu Saini,

Novel Acute Stroke Code for the Extended

on Headache-Related Disability in Patients with Episodic Migraine using the Migraine Disability Assessment —Paul Winner, Timothy Fitzgerald, Sanjay Gandhi, Paul Yeung, Joshua Cohen, Yuju Ma, Ernesto Aycardi

P4.096 Efficacy of Erenumab in Women

With and Without a History of MenstruallyRelated Migraine —Jelena Pavlovic, Koen

P4.100 Erenumab Safety Among

Migraine Patients Using Triptans or With Cardiovascular (CV) Risk Factors —Paul

Winner, Uwe Reuter, David Dodick, David Kudrow, Jacek Rozniecki, Fei Xue, Feng Zhang, Sunfa Cheng, Hernan Picard, Daniel Mikol

Paemeleire, Hartmut Gobel, Jo Bonner, Alan P4.101 Impact of Fremanezumab Rapoport, Feng Zhang, Hernan Picard, Daniel Mikol on the Number of Days with Use of

P4.097 Efficacy of Fremanezumab

Acute Headache Medications in Chronic Migraine —Ernesto Aycardi, Paul Yeung, Tricia

in Patients With Chronic Migraine and Blankenbiller, Melissa Grozinski-Wolff, Ronghua Comorbid Moderate to Moderately Severe Depression —Joshua Cohen, Paul Yeung, Ernesto Yang, Yuju Ma, Egilius Spierings, Marcelo Bigal Aycardi, Marcelo Bigal, Ronghua Yang, Kristen P4.102 Early Onset of Action with Bibeau, Maja Galic, Michael Seminerio, Richard Fremanezumab Versus Placebo for the Lipton, Dawn Buse Preventive Treatment of Chronic Migraine — Paul Yeung, Ernesto Aycardi, Marcelo Bigal, Tricia P4.098 Erenumab Immunogenicity: A Blankenbiller, Melissa Grozinski-Wolff, Ronghua Pooled Analysis of Phase 2 and Phase 3 Yang, Yuju Ma, Jan Brandes Migraine Prevention Clinical Trials —Bert Vargas, Amaal Starling, Stephen Silberstein, P4.103 Analysis of Blood Pressure Yanchen Zhou, Marie-Louise Trotman, Fei Xue, Following Short-Term and Long-Term Farhad Sahebkar-Moghaddam, Hernan Picard, Treatment with Erenumab —Stewart Tepper, Daniel Mikol

Treatment of Patients with Episodic Migraine P4.099 Efficacy Of Fremanezumab in with Aura —Peter McAllister, Julio Pascual, Lora Patients With Chronic Migraine With or McGill, Lawrence Newman, Cristina Tassorelli, Without Concomitant Use of Preventive Feng Zhang, Hernan Picard, Daniel Mikol Medication —Peter Goadsby, David Dodick,

154 2018 AAN Annual Meeting

Window of Endovascular Treatment —

Julio Pascual, Uwe Reuter, Hernan Picard, Frank Hong, Marie-Louise Trotman, Fei Xue, Daniel Mikol, Jan Klatt

in Patients With Chronic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA —Paul Yeung, Egilius

Spierings, Tricia Blankenbiller, Xiaoping Ning, Ronghua Yang, Yuju Ma, Marcelo Bigal, Ernesto Aycardi

P4.105 Efficacy of Erenumab for the

Treatment of Patients with Episodic Migraine with Depression and/or Anxiety —Stewart Tepper, Gregor Broessner, Dawn Buse, Todd Schwedt, Erik Strauss, Feng Zhang, Hernan Picard, Daniel Mikol

P4.106 Impact of Fremanezumab

on the Number of Days With Use of Acute Headache Medications in Episodic Migraine —Jan Brandes, Fumihiko Sakai, Paul

Yeung, Tricia Blankenbiller, Melissa GrozinskiWolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi, Marcelo Bigal

P4.107 Early Onset of Action with

Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine — Jan Brandes, Paul Yeung, Ernesto Aycardi, Marcelo Bigal, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma, MS

Young, John Rothrock, J. Lopez, Aubrey Manack Adams, Andrew Blumenfeld Azarci, Rachel Sobolev, Amanda Shallcross, Audrey Halpern, Thomas Berk, Naomi Simon, Scott P4.134 A Multicenter, Prospective, Powers, Richard Lipton, Elizabeth Seng

Migraine: A Pilot Study using Turk Prime —

P4.121 WITHDRAWN P4.122 Deep Brain Stimulation of the

Placebo-Controlled, Study Evaluating the Efficacy of DFN-02 (Nasal Spray of Sumatriptan 10 mg + Permeation Enhancer) in Migraine With or Without Aura —Sagar

P4.108 Repeat Infusions of Eptinezumab Observational Study —Mia Minen, Sarah Associated With Greater Migraine Reductions and Longer Migraine-Free Intervals: Results From the Phase 3 PROMISE-1 Trial —Egilius Spierings, Timothy Smith, Roger Cady, Eric Kassel, Joe Hirman

P4.109 The Impact of Fremanezumab

on Headache-Related Disability in Patients with Chronic Migraine Using the Headache Impact Test (HIT-6) —Paul Winner, Timothy Fitzgerald, Sanjay Gandhi, Paul P. Yeung, Joshua Cohen, Ronghua Yang, Yuju Ma, Ernesto Aycardi

P4.110 Efficacy of Fremanezumab in

Posterior Hypothalamus for the Treatment Chronic Cluster Headache: A Systematic Review —Nilson Nogueira Mendes Neto, Erich

Talamoni Fonoff, Sergio Adrian Fernandes Dantas, Marcelo Rodrigues Zacarkim, Levi Higino Jales Junior, Tatyana Vidal Mendes, Sebastiana Jayne Alves Vidal, Daniel Duarte Rolim, Jessika Thais da Silva Maia

Randomized, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of OnabotulinumtoxinA and Topiramate for Headache Prophylaxis in Adults with Chronic Migraine: The FORWARD Study —John

P4.135 Effectiveness of Intravenous

Dihydroergotamine for Pediatric Headache: Does Headache Diagnosis Matter? —Sara Fridinger, Christina Szperka

Rashmi Halker, Jessica Ailani

Egilius Spierings, Donald Kellerman, Pete Schmidt

P4.113 Achievement of Response with

P4.126 Effects of OnabotulinumtoxinA

Richard Lipton, Scott Powers, Mia Minen

Aycardi, Paul Yeung, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma

Pain within the First Week of Beginning Treatment in the Phase 2 Episodic Migraine Study —Marcelo Bigal, Ernesto Aycardi, Mirna

Silberstein

P4.115 The Impact of Fremanezumab on

R. Shewale, Rachel Halpern, Sally W. Wade, Eleena Koep, Hema Viswanathan

McDonald, Robert Noble, Pippa Loupe

Migraine-Specific Health-Related Quality of Life in Episodic Migraine —Richard Lipton, Sanjay Gandhi, Timothy Fitzgerald, Paul Yeung, Joshua Cohen, Yuju Ma, Ernesto Aycardi

P4.116 Analysis of Injection Site

Reactions across Four Placebo Controlled Trials of Erenumab for Migraine Prevention —Julio Pascual, David Doleüil,

Brendan Davies, Hernan Picard, Frank Hong, Feng Zhang, Fei Xue, Daniel Mikol, Jan Klatt

P4.117 The Impact of Fremanezumab on

Timothy Fitzgerald, Paul Yeung, Joshua Cohen, Ronghua Yang, Yuju Ma, Ernesto Aycardi

associated Extracranial Arterial Vasoconstriction and Stroke —Malveeka Sharma, Brian McGeeney, Carlos Kase, Hugo Javier Aparicio

P4.120 Factors Related to Migraine

Patients’ Decisions to Follow a Headache Specialist’s Recommendation for Migraine Behavioral Treatment: A Prospective

P4.137 The Role of Onabotulinum Toxin Type A in the Management of Chronic Non-Migraine Headaches —Cassie Jia, Fang Zhang, Scott Lucchese, Kristen Scheitler, Raghav Govindarajan

P4.138 The Feasibility of RELAXaHEAD

(A Smartphone Based Progressive Muscle Relaxation (PMR) Therapy and Electronic Diary Application) For Use in a Headache Center —Sarah Jinich, Thomas Berk, Sait Ashina,

Babcock, Vernon Rowe, John Hunter, Arlene O’Shea, Doug Schell, Dorsey Paul, James Barnett

P4.140 Hybrid High Cervical and Diagnosed Chronic Migraine Patients in a Occipital Nerve Stimulation for Chronic Large US Health Insurer’s Population —Anand Intractable Migraine —Chad Domangue, Lilly P4.128 The Efficacy of Transcranial Direct

P4.130 Evaluation of

IncobotulinumtoxinA as Prophylactic Treatment of Chronic Headache in Veterans —Amanda Vu, Keith Yuge, Leah

Loewenstein, Hyo-Jin Chae, Mary Wen, Frank Bertone, Sunita Dergalust

Lawrence Robbins, Aubrey Manack Adams, Stephen Silberstein

P4.132 Transcranial Magnetic

Stimulation (TMS) for Migraine Prevention in Adolescents: A Pilot Open-Label Study —

Samantha Irwin, William Qubty, Isabel Allen, Irene Patniyot, Peter Goadsby, Amy Gelfand

P4.133 Effects of OnabotulinumtoxinA

OnabotulinumtoxinA for the Symptomatic Treatment of Chronic Migraine: The REPOSE Study —Fayyaz Ahmed, Charly Gaul, Paolo Martelletti, Juan Garcia Monco Carra, Aubrey Manack Adams

P4.151 Menigeal Extravasation, Efficacy of Botulinum Toxin or Triptans are not specific for Pathophysiology of Migraine only —Zdravko Lackovic, Ivica Matak, Boris

Filipovic, Visnja Drinovac-Vlah, Lidija Bach-Rojecky

P4.152 American Headache Society

Survey about Urgent and Emergency Management of Headache Patients —Mia Minen, Emma Ortega, Richard Lipton, Robert Cowan

P4.153 The effect of regional anesthetic sphenopalatine ganglion block on selfreported pain in patients with intractable migraines —Dev Mehta, Megan Leary, Hussam

Yacoub, Mohammed El-hunjul, Hope Kincaid, John Castaldo

THERAPEUTICS IN NEUROONCOLOGY: FROM LASER ABLATION TO IMMUNOTHERAPY I

P4.154 Single-agent Dabrafenib

for Intracranial BRAFV600E-mutated Histiocytosis —Ankush Bhatia, Gary Ulaner,

Raajit Rampal, David M Hyman, Omar AbdelWahab, Benjamin Durham, Julio Hajdenberg, Chezi Ganzel, Eli Diamond

P4.155 Laser interstitial thermotherapy (LITT) for newly diagnosed and recurrent P4.141 Migraines relieved by apixaban, a glioblastoma: Safety, effectiveness and Chen, Kristen Lechleiter, Roshini Jain

case report —Michael Yang, Deborah Reed Current Stimulation in Patients with Medication P4.142 Erythromelalgia Secondary to Overuse Headaches Secondary to Chronic Verapamil —Ashhar Ali, A. Rothner Migraines —Naji Riachi, Anthony Mansour, Maher Salem, Christelle Khoury, Tony Sabbouh, P4.143 User Design and Experience Tarek Jabri, Georges Khazen, Rechdi Ahdab Preferences in a Novel Smartphone Application for Migraine Management: A P4.129 Visual Snow Syndrome Successfully Treated with Lamotrigine: Case Think Aloud Study of the RELAXaHEAD Application —Emma Ortega, Adama Jalloh, Mia Report. —Robert Fekete

P4.131 The Effects of Migraine Medications in Patients with OnabotulinumtoxinA Treatment on the Episodic Migraine in the STRIVE Phase 3 Chronic Migraine Comorbidities of Sleep and Trial of Erenumab for Migraine Prevention — Fatigue —Andrew Blumenfeld, Stewart Tepper,

P4.119 Case of Dihydroergotamine

William Young, Aubrey Manack Adams, John Rothrock

P4.127 Treatment Patterns for Newly

P4.118 Use of Acute Headache and

Uwe Reuter, Julio Pascual, Gregor Broessner, Yngve Hallstrom, Hernan Picard, Sunfa Cheng, Feng Zhang, Daniel Mikol, Jan Klatt

Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Headache Every Day: A COMPEL Subanalysis —J. Lopez, Andrew Blumenfeld,

P4.150 Real-Life Use of

Minen

P4.144 Sphenopalatine Ganglion

Block for the Treatment of Acute Migraine Headache —Mohamed Falah, Eman Al-Ghawi, Eslam Shosha, Ali Al-Hilly, Moiz Bakhiet

P4.145 Treatment Plans for Various

Neurologic Conditions Include the Use of Smartphone Applications: An observational study of the privacy issues related to commercial smartphone applications using headache applications as an example —Rose Sciortino, Eric Stieglitz, John Torous, Mia Minen

P4.146 A Case of Lamotrigine

association between time to initiation of chemotherapy post-procedure and outcome —Stefania Maraka, Dhiego Chaves De Alm Bastos, Barbara O’Brien, Diane D. Liu, Olga Starostina, Kristin Alfaro-Munoz, Rao Ganesh, John De Groot, Sujit Prabhu

P4.156 Combining Traditional Herbal

Medicines for the Treatment of Malignant Gliomas —Prateeksunder Pinchi, Amishi Taneja, Uday Kode, Prahlad Parajuli

P4.157 Correlating Radiographical and

Pathological Response to Immunotherapy in Primary Brain Tumors —Jessica Schulte, Peter Canoll, Angela Lignelli, Fabio Iwamoto

P4.158 Safety of Alteplase for Acute

Ischemic Stroke in Patients with Intracranial Neoplasms: An Institutional Experience — Sasmit Sarangi, Shadi Yaghi, Heinrich Elinzano

P4.159 Neurological Complications

of Immune Checkpoint Inhibitors: A case series —Sarah Mancone, Thomas Lycan, Tamjeed

Responsive Post-Stroke SUNA —Asad Rauf, Sofia Loucao, Melissa Cortez, Seniha Ozudogru

Ahmed, Andrew Dothard, Umit Topaloglu, William Petty, Roy Strowd

P4.147 Dead Ends in the History of

P4.160 CD38 Targeted Therapy in

Duarte

Sonikpreet, Paula Schiapparelli, Alak Manna, Aneel Paulus, Steven Rosenfeld, Asher ChananKhan, Alfredo Quinones-Hinojosa

Treatment of Headache —Noah Rosen, Robert

Treatment on Disability and Quality of Life in P4.148 Message Framing to Determine Patients with Chronic Migraine with Baseline Best Methods for Discussing Migraine Allodynia: A COMPEL Subanalysis —William Behavioral Treatments with Persons with

Glioblastoma : A Step Forward. —Dr

AAN.com/view/AM18 155

Wednesday

Migraine-Specific Health-Related Quality of Life and Overall Health Status in Chronic Migraine —Sanjay Gandhi, Richard Lipton,

P4.136 Effects of OnabotulinumtoxinA

Treatment on Chronic Migraine Comorbidities P4.139 Onabotulinum Toxin Serves as of Depression and Anxiety: Psychiatric an Effective Treatment for Chronic Daily Comorbidities Responder Analysis —Andrew Headache in Patients with Hypermobility Blumenfeld, Stewart Tepper, Lawrence Robbins, Spectrum Disorder —Kelsey Riggs, Lauren

P4.114 Fremanezumab Reduces Headache Aubrey Manack Adams, Dawn Buse, Stephen

P4.149 A Randomized, Double-Blind,

Rothrock, Aubrey Manack Adams, Esther Jo, Xiang Munjal, Elimor Brand-Schieber Zhao, Andrew Blumenfeld

Patients With Episodic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA — P4.123 Long-Term Safety and Tolerability David Kudrow, Fumihiko Sakai, Paul Yeung, Tricia of OnabotulinumtoxinA Treatment in Chronic Blankenbiller, Xiaoping Ning, Ronghua Yang, Yuju Migraine Patients: COMPEL Analysis by Ma, Ernesto Aycardi, Marcelo Bigal Treatment Cycle —Mitchell Brin, Paul Winner, Andrew Blumenfeld, Eric Eross, Amelia Orejudos, P4.111 Fremanezumab Decreases Aubrey Manack Adams Migraine Symptoms such as Nausea, Vomiting, Photophobia and Phonophobia and P4.124 Subjects with Episodic Migraine Reduces the Need for Acute Medications Treated with DFN-02 (Sumatriptan 10 mg in the First Week of Treatment in the HFEM + the permeation enhancer DDM) Report Study —Marcelo Bigal, Mirna McDonald, Ernesto Higher Treatment Satisfaction and Reduced Aycardi, Pippa Loupe, Robert Noble Functional Disability Compared with Placebo —Elimor Brand-Schieber, Sagar Munjal P4.112 Reversion of Patients With Chronic Migraine to an Episodic Migraine P4.125 Effectiveness and Safety of Classification With Fremanezumab a New Zolmitriptan Rapid Absorption Treatment —Joshua Cohen, Kristen Bibeau, Maja Microneedle Array (M207) for the Acute Galic, Michael Seminerio, Verena Ramirez Campos, Treatment of Migraine (The ZOTRIP Study) — Fremanezumab in the Treatment of Chronic Migraine —Paul Winner, Marcelo Bigal, Ernesto

Adama Jalloh, Olivia Begasse De Dhaem, Elizabeth Seng, Mia Minen

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION IV G P4.161 Neurologic Immune-related

Wednesday, April 25 11:30 a.m.–7:00 p.m.

NOVEL BIOMARKERS IN AGING AND Adverse Events Associated with Check-point DEMENTIA Inhibitors: A Case Study and Systematic P4.173 Choroid Plexus Volume Is Review of the Literature —Kelsey JusterAssociated with CSF Protein Levels in Switlyk, Nicholas Johnson Healthy and Diseased Individuals —Ehsan P4.162 Neurologic complications of Tadayon, Alvaro Pascual-Leone, Emiliano immune checkpoint inhibitors in cancer Santarnecchi patients —Michael Youssef, Karin Woodman P4.174 Cerebrospinal fluid α-synuclein P4.163 Durable response to bevacizumab as a potential biomarker for Alzheimer’s in adults with recurrent pilocytic disease —JieQiong Li, Jintai Yu, Lan Tan astrocytoma —Andrea Wasilewski, Nimish P4.175 CSF Cytokine Profiles Uniquely Mohile Identify Different Neurodegenerative Disorders —Umesh Gangishetti, J. Christina PRACTICE, POLICY, AND ETHICS II

P4.186 Peripheral Blood Markers of Cell

P4.164 Glioneuronal Growth of Spinal

P4.176 CSF neurofilament-light chain

Leilani Doty, Sudha Seshadri, Kenneth Heilman

Bruce Miller, Adam Boxer

Talisha Davis, Babak Baban, Anilkumar Pillai

Cord Following Intrathecal Stem Cell Transplant —Rahul Rahangdale, Mohammad

Ali, Susan Baser, Mary Flaherty, Cunfeng Pu, M.D., Ph.D., Sandeep Rana, Andrea Synowiec, Ruchi Wanchoo

Howard, Alexander Kollhoff, William Hu

Cycle Dysregulation are Associated with Alzheimer’s Disease Biomarkers —Jocelyn Argueta, Judy Pa

BIOMARKERS, BIOLOGY, PHYSIOLOGY

in Schizophrenia —Steven Vernino, Mindy Kim, Elena Ivleva, Elliott Gershon, Sarah Keedy, Carol Tamminga

P4.188 Autoimmune Encephalitis

Secondary to Neuronal Ganglionic Acetylcholine Receptor Antibodies —Alicia

and phosphorylated-tau predict disease P4.189 C3aR-dependent infiltrating progression in PSP —Julio Rojas -Martinez, Jee monocytes promote stress-induced Bang, Iryna Lobach, Richard Tsai, Gil Rabinovici, depressive behavior in mice —Tami Feng,

P4.177 Circulating Angiogenic Cell

Himali, Daniel Levy, Sarah Connor, Alexa Beiser, Paul Courchesne, Claudia Satizabal, Matthew

P4.170 Economic Impact of Older Age on Pase, Vasan Ramachandran, Sudha Seshadri the Initial Care of Patients with Acute Spine P4.181 Event Related Potentials as a Trauma —Julio Furlan, Michael Fehlings, B. Catharine Craven

P4.171 Assess the Implementation

of Stroke Performance Measures in the Acute-Care Setting at West LA VA Medical Center —Amy Huang, Melisa Kamali-Grigorian,

Wednesday

Shelly de Peralta, Mary Wen, Hyo-Jin Chae, Frank Bertone, Roi Wallis, Sunita Dergalust

P4.172 Sleep clinic follow up, co-

morbidities, mortality rates in patients screened high positive with STOP BANG Questionnaire —Sanath Kasi Reddy, Kalyan

Sajja, Kamalika Banerjee, Erin Smith, Sachin Kedar

Prognostic Measure: Predictive Value for Rate of Cognitive Decline in Patients with Mild Alzheimer’s Disease. —Marco Cecchi, Carl Sadowsky, Diana Michalczuk, Elizabeth Vassey

Hassan, Umar Shariff, Christina Sanchez, Ahmed Malik, Adnan Qureshi

ischemic stroke: Trends and predictors of utilization of thrombectomy using a national database —Michael Hamer, Sahil Gupta, Mina Lobbous, Frank Benesh, Angela Hays Shapshak

P4.203 Mechanical Thrombectomy with Roman Herzig, Dagmar Krajickova, Antonin Krajina, Eva Vitkova, Simona Haluskova, Oldrich Vysata, Pavla Cabelkova, Martin Valis

P4.204 Get with The Guideline on

Reducing Door-to-Reperfusion Time and Good Clinical Outcomes for Endovascular Reperfusion Therapy —Shuichi Suzuki, Jason

Meng, Ravi Patel, Li-Mei Lin, Kiarash Golshani, Hermelinda Abcede, Mohammad Shafie, Wengui Yu, Steven Cramer, Mark Fisher, Frank Hsu

P4.205 Readmission After Mechanical Thrombectomy for Acute Ischemic Stroke: A Nationwide Readmission Database Analysis —Preethi Ramchand, Dylan Thibault, James Crispo, Joshua Levine, Robert Hurst, Michael Mullen, Scott Kasner, Allison Wright Willis

P4.206 Emergent Carotid Stenting in

Acute Anterior Circulation Ischemic Stroke Due to Tandem Lesions Has Very Low Risk of Hemorrhage —Arpan Shrivastava, Richard W Crowley, Laurel Cherian, James Conners, Reneta Costa, Kathryn Ess, Nicholas Osteraas, Sarah Song, Alejandro Vargas, Rima Dafer

P4.207 Safety of endovascular

thrombectomy for M2 compared to M1 middle cerebral artery occlusion. —Asma

Arash Kamali, Zafer Keser, Larry Kramer, Paul Schulz

Moussaoui, Michael Chen, Renata Costa, Bichum Ouyang, Laurel Cherian, James Conners, Nicholas Osteraas, Sarah Song, Alejandro Vargas, Rima Dafer

P4.193 Neural correlates of self-

P4.208 Downstream Clot Fragment

Nair, Jane Allendorfer, Rodolphe Nenert, Amber Martin, Daniel Mirman, Jennifer Vannest, Jerzy Szaflarski

James Frey

generation and verbal memory performance during paired-associate learning —Sangeeta

P4.194 Application of Quantitative

P4.182 Diagnostic accuracy of biomarker MR Imaging Volumetrics to a Combined combinations in the A/T/N classification for Alzheimer’s disease —Patricio Chrem Mendez,

Number of Passes with a Stentreiver and Hemorrhagic Transformation? —Ameer

Stent-retrievers is Safe in Anticoagulated Parker, Sarah Rehl, Leila Saadatpour, Usama Tariq, Patients with Anterior Circulation Stroke —

Neurology —Jaya Trivedi, Pravin Khemani,

Todorov

P4.201 Is There a Correlation with

P4.187 Presence of NMDA-R Antibodies P4.202 Mechanical thrombectomy in

P4.190 Behavioral correlates of Attenuation and Senescence Correlates with cerebrospinal fluid concentrations of Worse Memory and Greater White Matter aminoacids and monoamine metabolites Debra Clamp, Kimberly Kelley, David Pool, Paula Lesion Burden in Older Adults —Daniel Nation, according to APOE-ε4 carrier status in Hardeman, Emmitt Rathore, Matthew Stowe, Alick Tan, Elissa McIntosh, Shubir Dutt, Jean Kim Siniscalchi, Padraig O’Suilleabhain, Steven dementia with Lewy bodies compared with Ho, Jung Jang, Belinda Yew, Kathleen Rodgers, Vernino, Benjamin Greenberg, Mark Goldberg Alzheimer’s dementia and cognitively healthy Katherine Chang, Aimee Gaubert, Anna Blanken people —Fabricio De Oliveira, Marjorie Miraldo, P4.166 Implementation of Protocols Eduardo Castro, Fernando Machado, Sandro P4.178 Peripheral Innate Immune to Mitigate Violence Within a Health Care Activation Correlates with Disease Severity Almeida, Sandro Matas, Paulo Bertolucci, Maria Setting for Patient and Healthcare Worker Naffah-Mazzacoratti in GRN Mutation Carriers —Peter Ljubenkov, Safety —Michael Goldberg, Paul Wright, Paige Mumford, Michael McGrath, Isabel Allen, Saeyoan Thirunavukkarasu, Richard Schwarz P4.191 Negative BOLD Response and Zachary Miller, Laura Mitic, Anna Karydas, Hilary Functional Connectivity in the Default P4.167 The State of Ethics Education in Heuer, Julio Rojas -Martinez, Ping Wang, Jane Mode Network are Representative Neurology Residencies —Douglas McAdams, Zhang, Adam Staffaroni, Yann Cobigo, Rodney Pearlman, Bruce Miller, Howie Rosen, Adam Boxer of Two Overlapping but Separate James Giordano Neurophysiological Processes —David Parker, P4.179 The association of plasma P4.168 High patient participation rate Qolamreza Razlighi neurofilament light chain and cognitive in Post-Stroke Depression screening at function in patients with Alzheimer disease P4.192 Quantitative Diffusion Tensor an Acute Stroke Center —Amanda Persaud, and Parkinson disease —Jong-Ling Fuh, Wei-Ju Tractography of the Superior Thalamic Loretta Schnepel, Fatoumata Sakho, Wayne Radiation and the Corticospinal tract in Lee, Shuu-Jiun Wang Hodges, Vicki Coppen, Michelle Prosje, Scott relation to Ventricular and Sulcal CSF Silliman P4.180 Circulating BNP and GDF15 and Volumes in Patients with Ventriculomegaly P4.169 Quality measure in teleneurology Risk of Incident Dementia: The Framingham Diagnosed with Normal Pressure consultations —Alexandre Todorov, Daniele Offspring Cohort —Emer McGrath, Jayandra Hydrocephalus —Kyan Younes, Khader Hasan, P4.165 Southwestern Access to

ENDOVASCULAR TREATMENT

Cognitive Neurology and Geropsychiatry Clinic Case Series —Somayeh Meysami, Cyrus

Migration During Endovascular Thrombectomy Adversely Affects Clinical Outcome —Carol Darbonne, Kristina Chapple,

P4.209 Isolated M2 Segment Occlusions: Should These Patients Receive Endovascular Therapy? —Anusha Boyanpally, Matthew Nardi, Vikas G. Patel, Molly Jacob

Ismael Calandri, Ignacio Demey, Lucia Pertierra, Raji, Verna Porter, Jamila Ahdidan, David Merrill Maria Russo, Ezequiel Surace, Horacio Martinetto, P4.195 Magnetic Resonance Jorge Campos, Silvia Vazquez, Gustavo Sevlever, Spectroscopy (MRS) predict cognitive Ricardo Allegri

P4.210 Assessing the Affect

P4.183 The Potential Role of Optical

Kurgansky, Phillip Ye, Ryan Bo, Jeffrey Farkas, Karthikeyan Arcot, David Turkel-Parrella, Ambooj Tiwari

outcomes in children after cardiac transplantation —Pilar Pichon, Barbara Coherence Tomography as a Marker of Holshouser, Vidhya Krishnamurthy, Stephen Disease Severity in Alzheimer’s Dementia — Ashwal, Richard Chinnock, Kiti Freier Roberto Santangelo, Giancarlo Comi, Giuseppe Magnani, Letizia Leocani

P4.196 Multitasking in Early Multiple

Cognitive Decline in MCI Patients —Xiaoyan

Roy Martin, Jerzy Szaflarski

of Clot Firmness on the Speed and Grade of Recanalization in Hyperacute Neuroendovascular Therapy —Gregory

P4.211 Safety and Effectiveness of Ticagrelor in Patients with Clopidogrel

Sclerosis —Christina Lewis, Gabrielle Pelle, P4.184 Aetiology of cognitive impairment Stephen Krieger, Victoria Leavitt, James Sumowski Resistance Undergoing Angioplasty, Stent or Flow Diverter Placement —Umar Shariff, in patients with inconclusive cerebrospinal Ameer Hassan, Adnan Qureshi fluid results for Alzheimer’s disease —Martin P4.197 Stress Perception Modulates Neural Response to Psychosocial Stress in Rakusa, Sofia Gak, Evgenija Modric P4.212 Incidence of Hemorrhage of Psychogenic Nonepileptic Seizures —Jane P4.185 CSF Neurogranin Levels Predict Allendorfer, Rodolphe Nenert, Kathleen Hernando, Combination IV tPA and Eptifibatide Therapy Sun, Alison Headley, Andres De Leon Benedetti, Chuanhui Dong, Steven Lang, Bonnie Levin, Tatjana Rundek, Christian Camargo, Clinton Wright, Henrik Zetterberg, Kaj Blennow, David Loewenstein

156 2018 AAN Annual Meeting

P4.198 NA P4.199 NA P4.200 NA

in Stroke Endovascular Thrombectomy — Ashik Shrestha, Phillip Ye, Ting Zhou, Ambooj Tiwari, David Turkel-Parrella, Jeffrey Farkas, Karthikeyan Arcot, Danielle Crotty

P4.213 Mechanical Thrombectomy

P4.227 DamAGE cONTrol: A novel tool in Acute Ischemic Stroke: A Regional for predicting outcomes after successful Comprehensive Stroke Center Experience — endovascular thrombectomy —David Ermak, Agnieszka Slowik, Dorota Wloch-Kopec, Joanna Chrzanowska-Wasko, Aleksandra Golenia, Antoni Ferens, Bartlomiej Lasocha, Wojciech Serednicki, Pawel Brzegowy, Tadeusz Popiela

P4.214 Direct aspiration (ADAPT) and

primary stent retriever thrombectomy for acute ischemic stroke: A systematic review of radiographic and clinical outcomes in 5441 patients —Christopher Primiani, Aquilla Turk, III, Italo Linfante, Elad Levy, Adnan Siddiqui, Maxim Mokin

Muhammad Niazi, Raymond Reichwein, Kevin Cockroft

Anterior Circulation Large Vessel Occlusion and Mild Symptoms. —Mohammad Anadani,

Sami Alkasab, Madison Hyer, Alejandro Spiotta, Raymond Turner, Jonathan Lena, Joseph Jamison, Mohammed Imran Chaudry

P4.229 Impact of Ictal Definition on

Reperfusion Outcomes in eLVO Cases —

Ryan Bo, Phillip Ye, Jeremy Liff, Jeffrey Farkas, Karthikeyan Arcot, David Turkel-Parrella, Ambooj Tiwari

Sohyun Boo, Amelia Adcock

TPA IN ACUTE ISCHEMIC STROKE

P4.216 Unrelenting Posterior Circulation

P4.230 Thrombolysis in Posterior TIAs Improved by Left Vertebral Angioplasty Circulation Stroke Patients is associated and Stenting —Ramita Dewan, Christopher with Prolonged Door to needle Time —Faisal Stack, John Cole

P4.217 Safety of Acute Intracranial

Stenting for treating Posterior Circulation Strokes in the Stentriever Era. —Siddhart Mehta, Ashish Kulhari, Amrinder Singh, Rafia Jawed, Spozhmy Panezai, Jawad Kirmani

P4.218 Dose and Time Dependence

of Eptifibitide Complications in Patients undergoing Neuroendovascular Therapy with and Without Hyperacute Stenting —

Ryan Bo, Ashik Shrestha, Ting Zhou, David TurkelParrella, Karthikeyan Arcot, Jeffrey Farkas, Ambooj Tiwari, Danielle Crotty

P4.219 Reasons and Outcomes of

Patients Who Do Not Receive Mechanical Thrombectomy for Acute Ischemic Stroke —

Ibrahim, Naveed Akhtar, Najib Murr, Saadat Kamran, Dirk Deleu, Ashfaq Shuaib

Alkuwaiti, Connie Bongiorno, Christopher Logue, Shailesh Male, Benjamin Miller, Rwoof Reshi, Kevin Engel, Victor Urrutia, Christopher Streib

P4.232 WITHDRAWN P4.233 Initial Presenting Stroke

Symptoms Impact Treatment Timeline Among Ischemic Stroke Patients —Elizabeth Baraban, Lindsay Lucas, Archit Bhatt

P4.234 Should Fibrinogen levels be

P4.220 Outcome of Distal Clot Migration Repeat Head Computed Tomography (CT) Ryan Bo, Jeremy Liff, Jeffrey Farkas, Karthikeyan Arcot, David Turkel-Parrella, Ambooj Tiwari

in Acute Ischemic Stroke Patients Treated with Intravenous (IV) Tissue Plasminogen Activator (tPA)? —Justine Milligan, Harleen Kaur, Christopher Newey

P4.221 Predictive Value of Procedure

P4.236 Ultra-early IV tPA for emergent

Reichwein, Kevin Cockroft, David Ermak

Donohue, Ken Uchino, Dolora Wisco

Duration in Outcomes After Endovascular Thrombectomy —Muhammad Niazi, Raymond

large vessel occlusion strokes improves clinical outcomes —Rodica Di Lorenzo, Megan

P4.222 Outcomes in Patients with Acute P4.237 Response of Intravenous Tissue Plasminogen Activator in Large Artery Atherosclerosis Stroke Etiology —Nidhi

Rybinnik, Kiwon Lee, Deviyani Mehta

Kasatwar, Lee Birnbaum

P4.223 Outcomes Of Mechanical

P4.238 A Comparative Study Of

Hussain Shallwani, Felix Chin, Adnan Siddiqui, Robert Sawyer, Kunal Vakharia, Hakeem Shakir, Elad Levy

Population Characteristics in Stroke Mimic vs Acute Stroke Receiving tPA —Muhammad Aman, Nidhi Kasatwar, Lee Birnbaum

Shazli Khan, Sitara Koneru, Syed Zaidi

P4.225 Does Intra-Arterial Therapy Help Patients with Mild Acute Ischemic Stroke: A 6-Year Look at Large Vessel Occlusions — Alessandro Orlando, Johnathan Davis, Judd Jensen, David Bar-Or

P4.226 Outcomes of Mechanical

Thrombectomy in Tandem ICA Occlusion — Omar Hussein, Khalid Sawalha, Dilip Singh, Randheer Yadav, Deepak Gulati

P4.243 Effect of Statins and Dose

Relation on Intracerebral Hemorrhage and Outcome after IV Thrombolysis for Acute Ischemic Stroke —Harshit Shah, Navdeep Lail,

Thrombolysis in Unusual Stroke Mimics —

Felipe Franco da Graca, Thiago Prado, Leo Gordiano Azevedo

P4.240 Anticoagulant Use Is Not

Associated With Higher Post tPA Hemorrhagic Conversion —Achint Patel,

Abhishek Lunagariya, Urvish Patel, Vishal Jani, Nandakumar Nagaraja, Branko Huisa-Garate, Thomas Hemmen

P4.241 Time Intervals of Symptomatic Intracereberal Hemorrhage (sICH) after Tissue Plasminogen Activator (rt-PA) Treatment —Patrick Chen, Brett Meyer, Karen Rapp, Thomas Hemmen, Royya Modir, Kunal

P4.259 Electroclinical and Historical

Features Related to Response to AEDs in Juvenile Myoclonic Epilepsy. —Iffat Ara

Suchita, Samiya Rashid, Charles Szabo, Lola Morgan, Kameel Karkar, Octavian Lie, Linda Leary, Caila Vaughn, Annemarie Crumlish, Robert Sawyer, Ishan Adhikari Ashkan Mowla

P4.244 WITHDRAWN P4.245 Mixed but Unused Doses of

Thrombolytic Therapy in Acute Ischemic Stroke: What is an Acceptable Rate for Wasted Drug? —Reid Taylor, Erika Prezas, Ameran Tooley, Alexander Schneider

P4.246 Imaging Characteristics of

Sumera Ali, Manoj Kumar

P4.247 Impact of Mock Code Stroke on

Door to Needle times —Tijil Agarwal, Andrew Slusher, Michael Palm, Lee Birnbaum

P4.260 Relationship between

Levetiracetam exposure and Psychogenic Non-Epileptic Seizures —Andrew Brown, Kalyan Yarraguntla, Rohit Marawar

P4.261 A Proof-of-Principle Quantitative EEG Study of an Oral, Potent and Selective T-Type Calcium Modulator in Healthy Volunteers —Spiridon Papapetropoulos, Stacey Boyer, Margaret Lee

P4.262 Tendencies in Antiepileptic Drugs use and polytherapy in a mexican General Hospital —Fernando Cortés-Enríquez, Ildefonso Rodriguez-Leyva, Adriana Patricia MartínezMayorga, Sandor Quintero-Aparicio, Fernando Alcides Lozano-Sánchez, Alejandro FloresSobrecueva

P4.263 Posterior Reversible Encephalopathy Syndrome in a Patient stroke thrombolysis delay from 70 to 31 Treated with Cisplatin/Pemetrexed —Chelsea minutes in Christchurch, demonstrating Zhu, Guru Ramaiah, Vicki Ramsey-Williams transferability with ‘real-world’ resources. — Erin Coleman, Sarah Wright, Deborah Mason, Jon P4.264 Combination AED Treatment Reimers, Roderick Duncan, Mary Griffiths, Michael With Clobazam in Patients With LennoxHurrell, David Dixon, Atte Meretoja, John Fink, Gastaut Syndrome: Post Hoc Analyses of the Teddy Wu CONTAIN Study —Steve Chung, Barry Gidal, Ole Michael Lemming, Meghana Karnik-Henry, P4.249 Impact on IV TPA Treatment Times Following RACE Score-Based Hospital Elizabeth Hackler, David Tworek, Salma Sayeed Protocol Implementation: Northwest Ohio P4.265 Pharmacometrics of Clobazam Experience —Jaclyn Mueller, Samar Sheriff, in Pediatrics: Population PK Modeling to Sitara Koneru, Shazli Khan, Syed Zaidi Predict Effective Clobazam Doses for Dravet Syndrome —Dwain Tolbert, Hui-May Chu, Ene Ette P4.250 Quality Improvement Initiative Reduces Door-to-Needle Time for P4.266 The PK/PD Basis for Clobazam Intravenous Thrombolysis —Demi Tran, Dana Use in Refractory Seizures: Is There a Stradling, Hermelinda Abcede, Mohammad Shafie, Need for Clobazam Dosage Reduction in Wengui Yu the Presence of Other Antiepileptic Drugs (AEDs)? —Dwain Tolbert, Pavel Klein, Barry P4.251 “Time Out Before Bolus” for Gidal, Hui-May Chu, Ene Ette Safe and Efficient Administration of IV tPA for Acute Ischemic Stroke —Sandhya Mehla, P4.267 Efficacy of Clobazam as Maria Zambrano, Muhammad Ahmed, Harshit Add-on AED in Partial Onset Seizures Shah, Ashkan Mowla Management —Aashit Shah, Kalyan Yarraguntla, P4.252 The Effectiveness of Combination Deepti Zutshi, Maysaa Basha, James Bathe Therapeutic Craniocerebral Hypothermia P4.268 Effect of Perampanel and and Trombolysis in Hyperacute Stroke Amantadine on Rat Model of Pilocarpinemanegment. —Irina Sharinova, Igor Stulin, Irina Induced Status Epilepticus: Evidence on P4.248 Helsinki Stroke model reduced

Kalenova, Oleg Shevelev, Sofya Ustinskaya, Nikita

P4.239 Under Pressure: A Case Series of Litvinov, Andrey Butrov, Vyacheslav Ardashev,

P4.224 Outcomes Following Mechanical Matias, Larissa Vilany, Wagner Avelar, Paula Thrombectomy in Nursing Home Residents —Samar Sheriff, Jaclyn Mueller,

ANTI-EPILEPTIC DRUGS AND EPILEPSY SURGERY

Sang-Hoon Kim, Kang-Ho Choi, Man Seok Park

Marina Petrova

P4.253 Intravenous Thrombolysis

Before Endovascular Treatment Leads to Higher Hospital Charges without Improving Outcomes —Ameer Hassan, Umar Shariff, Christina Sanchez, Ahmed Malik, Adnan Qureshi

P4.254 Intravenous Thrombolysis and

Endovascular Treatment in Chronically Anticoagulated Patients with Ischemic Stroke in the United States: Analysis of Nationwide Inpatient Sample from 2006 to 2014. —Ameer Hassan, Mohammad-Rauf Afzal, Omar Saeed, Saqib Chaudhry, Adnan Qureshi

Seizure Termination, Behavioral Alterations, Epileptogenesis and Neuronal Damage — Hanan Mohammad, Changiz Taghibiglou, Farzad Moien Afshari

P4.269 Topiramate induced reversible

hyperammonemic encephalopathy. —Jaime Shoup, Vishwanath Sagi

P4.270 Lack of pharmacokinetic

interaction of lacosamide on carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, topiramate and valproic acid in children and adolescents with epilepsy: Post-hoc analysis of a randomized, double-blind, placebocontrolled trial —Barbara Steinborn, Armel Stockis, Ying Zhang, Svetlana Dimova, Paul Martin

AAN.com/view/AM18 157

Wednesday

M2 Occlusions Undergoing Endovascular Reperfusion Therapy —James Lee, Igor

Thrombectomy in acute ischemic stroke patients with Large Vessel Occlusions and Low NIHSS —Haris Kamal, Muhammad Ahmed,

Thrombolysis —Joontae Kim, Bang-Hoon Cho,

P4.242 Clinical Implications of

Ischemic Stroke Patient Not Thrombolysed P4.231 Guideline-Based Intravenous tPA Due to Mild or Resolving Symptoms (“Too for Central Retinal Artery Occlusion: A Case Good To Treat”) and Findings associated with Series and Systematic Review —Mohammed Poor Outcomes —Lindsay Malatesta, Syed Ali,

monitored with IV-tPA? —Rafia Shafqat, Vaibhav Goswami, Christeena Kurian, Ervis Han Wang, Macym Rizvi, Trisha Dickey, Ciro Xhihani, Ramandeep Sahni Ramos Estebanez, Wei Xiong, Michael De Georgia, Cathy Sila, Anthony Furlan, Sophia Sundararajan P4.235 What is the Utility of a 24 Hour in the Setting of IV r-tPA and Stroke Endovascular Thrombectomy —Phillip Ye,

Serial Glucose Measurements in Acute

P4.255 NA P4.256 NA P4.257 NA P4.258 NA

P4.228 Long Term Functional Outcome of Ischemic Stroke Treated with Intravenous

P4.215 Rare Phenomenon of Limb-

Shaking TIA, Resolved with Intracranial Wingspan Stenting —Tamra Ranasinghe,

Agrawal, Branko Huisa-Garate, Lovella Hailey, Kevin Attenhofer, Abhishek Lunagariya, Pradeep Selvan, Dawn Meyer

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION IV G P4.271 Effect of Pharmaceutical

Formulation of Purified Cannabidiol (CBD) on Seizure Frequency and Severity is Independent of Drug-Drug Interactions with other Anti-Epileptic Drugs (AEDs) —Tyler Gaston, Gary Cutter, Yuliang Liu, Leslie Perry Grayson, E Bebin, Jerzy Szaflarski

P4.272 Safety and Pharmacokinetics

of Diazepam Buccal Soluble Film —Allen H

Heller, Stephen Wargacki, Cassie Jung, David J Wyatt, Mark Schobel

P4.273 Comparative Pharmacokinetics of

titer —Kushak Suchdev, Kalyan Yarraguntla, Mohammad Ibrahim, Aashit Shah

P4.287 Relevance of Serial Anti-GAD titers in relation to Seizure Frequency in Autoimmune Epilepsy (AIE): An Observational Study —Kalyan Yarraguntla,

Kushak Suchdev, Mohammad Ibrahim, Aashit Shah

P4.304 WITHDRAWN P4.305 Rapidly Resolving and

presenting at a tertiary care hospital, in Islamabad Pakistan —Faleha Zafar, Raja Shoaib,

Tara Becker, Tasneem Hasan, Lauren K. Ng Tucker, James Meschia, William Freeman

P4.320 A rare case of cyclophosphamide

Astrocytopathy underlies Autoimmune Epilepsy case-control study —Naillid Felipe, Sok Lee, Helena Lau, Ayshe Beesen, Melissa Mercado, in the setting of Multi-Organ Failure —Dina Dababneh, Derek Notch, Jafar Kafaie

Stephanie Zhang, Will Ross

wasim Tariq, Ehsanul Haq, Danish Hassan, Ibrahim

Contralateral Recurrent Subdural Hematoma Shamael in Disseminated Intravascular Coagulation —

P4.306 Predictors of acute respiratory P4.288 Glial Fibrillary Acidic Protein (GFAP) failure in acute ischemic stroke patients: A

P4.289 EpxEpilepsy: A SMS-Based Diazepam Buccal Soluble Film and Diazepam Intervention for Patients with Epilepsy — Rectal Gel —Allen H Heller, Stephen Wargacki, Rajat Duggirala, Sirui Ma, Robert Peters, Tracy Stalvey, David J Wyatt, Mark Schobel

Wednesday, April 25 11:30 a.m.–7:00 p.m.

Courtney Takahashi, Julie Shulman, Hugo Javier Aparicio, Thanh Nguyen, Jose Romero, Viken Babikian, David Greer, Anna Marisa CervantesArslanian

induced Posterior reversible encephalopathy syndrome (PRES). —Taha Nisar, Abdul Rahman Alchaki, Erin Feinstein

P4.321 Bilateral Dentate nuclei injury

after global cerebral hypoperfusion: A case report —Shashank Shekhar, Shreyas Gangadhara, Fouad Abuzeid, Christa O’hana Nobleza, Rebecca Sugg, Hartmut Uschmann

P4.322 Long-term functional outcome in P4.307 Potentially modifiable risk factors patients with acquired infections after acute

for long-term cognitive impairment after spinal cord injury. —Jan Schwab, Peter Martus, critical illness—a systematic review —Tarun Ralf Watzlawick, YuYing Chen, Michael DeVivo, of Nonconvulsive Status Epilepticus in Pediatric Epilepsy (DRE) in the Veteran Population — Singh, John O’Horo, Amra Sakusic, Rahul Kashyap, Marcel Kopp Patients with Angelman Syndrome —Lila Hyo-Jin Chae, Alexander Crossley, Leah Loewenstein, Ronald Petersen, Alejandro Rabinstein Worden, Olivia Grocott, Amanda Tourjee, Fonda Mary Porter, Frank Bertone, Sunita Dergalust P4.323 Early Mobilization in the ICU: Chan, Ronald Thibert P4.308 WITHDRAWN Assessing a Standardized Early Mobility P4.291 NA Protocol on Neurological Patients —Sandeep P4.275 Man’s Best Friend: A Survey of P4.309 In-Hospital Complications Walia, Simrit Sodhi, Doris Chen, Hugh Black Academic Neurologists and Subsequent Review P4.292 NA following acute neurological injuries — P4.293 NA of the Literature Exploring Seizure Dogs — Anantha Vellipuram, Rakesh Khatri, Mohtashim P4.324 Consent Rate For Organ Donation Christopher Stack, Ramita Dewan, Ana Sanchez Qureshi, Mohammad-Rauf Afzal, Ihtesham P4.294 NA After Brain Death: A Single Center’s Qureshi, Alberto Maud, Darine Kassar, Paisith Experience over 11.5 years —Mohammed P4.276 Medical Marijuana-receptivity NEUROCRITICAL CARE I Piriyawat, Salvador Cruz-Flores, Gustavo Rodriguez Kananeh, Paul Brady, Lisa Louchart, Lonni Schultz, and knowledge in a cohort of Hispanic Chandan Mehta, Mohammed Rehman, Stephan patients with Epilepsy —Laura Surillo Dahdah, P4.295 Impaired Dynamic Cerebral P4.310 GCS Predicts Survival and Ignacio Pita Garcia Discharge Disposition in Patients with Acute Mayer, Panayiotis Varelas Autoregulation is a Predictor of Worsening Cerebral Injury —Ross Hamilton, Hia Ghosh, Hepatic Encephalopathy Severity —Eric P4.325 Multidisciplinary Management P4.277 High Times? Prevalence and Jean Nickels, Franchesca Konig-Toro, Matthew Liotta, Leena Thomas, Katie LaHaye, Shyam Approach to Fulminant Hepatic Perceptions of Marijuana Use Among Kruppenbacher, Debra Roberts, Peter Kaplan, Prabhakaran, Farzaneh Sorond Encephalopathy in the Neurocritical Patients with Epilepsy —Ginette Moores, Gretchen Birbeck, Olga Selioutski Care Unit: A single-center experience — Andrew Lockey, Ahmed Attar P4.296 Plasma IL-6 Levels are P4.311 Improving Cytotoxic Edema With Mohammed Rehman, Chandan Mehta, Riad Independently Associated with Functional P4.278 Evaluation of Quality of life in Ramadan, Bradley Howell, Hussam Elkambergy, Outcome and Markers of Secondary Injury in Cerebral Fat Embolism Syndrome, From A patients treated with VNS —Victoria Grassi Nightmare To A Shiny Morning: Two Cases Stephan Mayer Spontaneous Intracerebral Hemorrhage — Bonamigo, Bruno Takeshita, Talita Perboni, Pedro Presentation —Furkan Yilmaz, Alok Patel, Tapan P4.326 Single or Dual Brain Death Audrey Leasure, Arthur Steinschneider, Guido Kowacs, Murilo Meneses, Samanta Rocha Kavi Falcone, Emily Gilmore, Lauren Sansing, Kevin Exams: Tertiary Hospital Experience Over P4.279 Knowledge of and Attitude Sheth 11.5 Years —Paul Brady, Mohammed Kananeh, P4.312 Race, Insurance and SocioToward Epilepsy Surgery Among Lisa Louchart, Chandan Mehta, Mohammed P4.297 Brain Tissue Oxygenation as an Economic Status Among Donors Versus Neurologists in Saudi Arabia — Bandar Nasser Rehman, Ariane Lewis, David Greer, Stephan Adjunctive Monitor for Determining Optimal Recipients In United States from years A Aljafen, Majed Alomar, Nawaf Abohamra, Mayer, Panayiotis Varelas Cerebral Perfusion Pressure in Subarachnoid 2011-14 —Ihtesham Qureshi, Mohtashim Mohammed Alanazy, Taim Muaygil Qureshi, Mohammad-Rauf Afzal, Rakesh Khatri, P4.327 Live Simulation for Emergency Hemorrhage Patients —Jenna Ford, Soojin Park, Alberto Maud, Darine Kassar, Paisith Piriyawat, Amelia Boehme, Murad Megjhani, Kalijah Terilli Neurology Life Support —Peggy White, CLINICAL EPILEPSY III

P4.274 Diazepam for Outpatient Treatment P4.290 Managing Drug Resistant

P4.280 Adoption of Responsive

Neurostimulation (RNS) at a typical level 4 Epilepsy Center —Angelica Rivera Cruz, Himali Jayakody, Selim Benbadis

P4.281 Saccadic Eye Movement

Abnormalities in Genetic Epilepsy —Saloua

Mrabet, Mouna Ben Djebara, Fatma Laatar, Amira Nasri, Imen Kacem, Amina Gargouri Ep Berrechid, Riadh Gouider

Wednesday

P4.282 Clinical Vignette: Limbic Encephalitis Presenting as Bilateral Epilepsia Partialis Continua —Vishal Mandge, James Castellano, Daryl McHugh, Mark Milstein, Alexis Boro

P4.283 Hospitalization Rate For

P4.298 IL-17F and IFN-beta May Predict Acute Clinical Course after Traumatic Brain Injury —Annie Chiu, Holly Hinson

P4.299 Intracranial Pressure (ICP)

Trajectories: A Novel Tool that may Inform Outcome and Mortality in Severe Traumatic Brain Injury —Ruchira Jha, Jonathan Elmer, Benjamin Zusman, Ava Puccio, David Okonkwo, Seo Young Park, Lori Shutter, Jessica Wallisch, Yvette Conley, Patrick Kochanek

P4.300 Risk Factors and Outcomes of

P4.285 Neuroimmune Mechanisms

Of Epilepsy As A Key To Pathogenetic Treatment Of The Disease —Rano Azizova, Maruf Salokhiddinov

P4.286 Role of other autoantibodies

in patients with autoimmune epilepsy in presence of elevated anti-GAD antibody

158 2018 AAN Annual Meeting

P4.313 Atypical Presentation of

Intracranial Hypotension Secondary to Hypothalamic Compromise —Ahmed

Abd Elazim, Omar Hussein, Khalid Sawalha, Mohammad Hamed, Michel Torbey

Amra Sakusic, Ognjen Gajic, Rahul Kashyap, Alejandro Rabinstein

Desaturation Is Associated with Ipsilateral Epileptiform Activity on Continuous EEG in Comatose Patients —Leah Dickstein, Batya

Christopher Robinson, Carolina Maciel, Marc-Alain Babi, Jennifer Munoz, Lars Beattie, Nicholas Maldonado, Teddy Youn, Chris Giordano, Katharina Busl

P4.328 Burnout and Resiliency Amongst Neurological Critical Care Unit Clinical Staff —Taylor Purvis, Brittany Powell, Gail Biba,

P4.314 Rituximab for treatment of

Deena Conti, Thomas Crowe, Heather Thomas, Juan Carhuapoma, John Probasco, Paula Teague, Deanna Saylor

John Liang, Syed Omar Shah

P4.329 A Single-Center Intervention

refractory fulminant acute disseminated encephalomyelitis (ADEM) —Jane Khalife,

Critically Ill Patients with Acute Brain Failure: P4.315 Delayed post-hypoxic A novel end point —Tarun Singh, John O’Horo, encephalopathy: A prognostic dilemma —

Epilepsy And Convulsion In Lagos, P4.301 Institutional Variability in Status Nigeria. —Oguntunde Olapeju, Mustapha Danesi, Epilepticus Management: Intubation Use and Oluwadamilola Ojo, Njide Okubadejo Implications for In-Hospital Mortality —Elan P4.284 Glucose and Seizure Guterman, James Burke, S. Josephson, John Betjemann Relationships in an Ambulatory Patient Where Both are Continuously Monitored — P4.302 Regional Cerebral Oxygen Kathryn Kinnear, Nicole Warner, Alan Haltiner, Alyssa Brandt, Michael Doherty

Anantha Vellipuram, Gustavo Rodriguez, Salvador Cruz-Flores

Bharathi Sundar, Meenakshi Sundaram Salvadeeswaran, Somalinga Nagendran Karthik, Pandi Suresh, Jude Vinoth, Sanjeevirajah Madhanrajah

P4.316 Metabotropic Glutamate

to Discontinue Postoperative Antibiotics after Spinal Fusion —Ariane Lewis, Jessica Lin, Herbert James, Anne Krok, Nicole Zeoli, Janine Healy, Tyler Lewis, Donato Pacione

P4.330 Neurologic Implications of

Increased ICP-Induced Thinning of the Ocular Sheath —Meagan Newell, Lauren East, Parth

Agrawal, Brittany Earnest, Ian M. Heger, Robert W.

Receptor Subtype 5 and Encephalitis —Caitlin Gibson, Matt Lyon Hof, Larry Burris

P4.317 A Cautionary Tale of Synthetic Marijuana Use —Lucy Zhang, Payal Patel, Dhimant Dani

P4.318 Aneurysmal Subarachnoid

Radzik, Eva Ritzl, Rohan Mathur, Wendy Ziai, Hemorrhage Complicated by Central Charles Hogue, Romergryko Geocadin, Ryan Healy, Neuronal Hyperventilation —Ahmed Abd Caitlin Palmisano, Vishank Shah, Lucia Rivera Lara Elazim, Omar Hussein, Mohammad Hamed, Khalid Sawalha, Michel Torbey, Diana Greene-Chandos P4.303 Neurologic Recovery after

Anoxic Brain Injury with Marked Diffusion P4.319 Clinical re-audit of intravenous Restriction —Paul Elsbernd, Tyler Koehn, Thomas recombinant tissue plasminogen activator Duginski (r-tPA) recipients in ischemic stroke patients

P4.331 Control of vascular risk factors

at baseline in Crest-2 —James Meschia, Kevin

Barrett, Gary Roubin, Donald Heck, Michael Jones, Lawrence Wechsler, Joseph Rapp, Tanya Turan, Bart Demaerschalk, Brajesh Lal, Jenifer Voeks, George Howard, Virginia Howard, Thomas Brott

P4.332 Serial Pupillometer Readings

Predicting Intracranial Pressure Crisis —Antje Giede-Jeppe, Julia Koehn, Stefan Gerner, Joji Kuramatsu, Hagen Huttner, Stefan Schwab

P4.333 Attitudes Towards Hospital

P4.334 The Significance of Contrast

Powell, Gail Biba, Deena Conti, Thomas Crowe, Heather Thomas, Juan Carhuapoma, John Probasco, Paula Teague, Deanna Saylor

Mohammad Hamed, Shraddha Mainali

Chaplains Among Neurological Critical Care Unit Clinical Staff —Taylor Purvis, Brittany

g1 H

Density of the Computed TomographyAngiographic Spot Sign: The Spot Sign Ratio —Omar Hussein, Khalid Sawalha,

to the Hospital EMR: Effects on Nursing Satisfaction and Patient Outcomes After Two Years. —Patrick Chen, Diem Kieu Tran, Jefferson Chen

P4.336 To study if levetiracetam (Lev) is

P4.335 The Development of a System for effective in reducing the incidence of early Direct Download of Pupillometer Information post traumatic seizures in 0-17 year old

children with closed head trauma —Brittany Taylor, Sarah Cobb, Kapil Arya

P4.337 Factors associated with code

status in acute neurologic illness —Kaitlyn Lillemoe, Aaron Lord, Jose Torres, Koto Ishida, Barry Czeisler, Ariane Lewis

P4.338 NA

Cerebrovascular Disease and Interventional Neurology II ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P4.339 Safety and Clinical outcomes

after Transverse Venous Sinus Stenting for Treatment of Idiopathic Intracranial Hypertension: Single Center Experience —

Ashish Kulhari, Siddhart Mehta, Rebekah Amarini, Spozhmy Panezai, Jawad Kirmani

in the setting of a left atrial myxoma with concomitant RCVS —Shane Stone, Eduardo Cortez-Garcia, Patrick Reynolds

P4.341 Case report: Artery of Percheron

P4.340 All Myxed Up- A Case Report:

infarction detected by CT perfusion imaging, prompting thrombolytic treatment with excellent outcome —Kiddy Ume, Matthew

PEDIATRIC MULTIPLE SCLEROSIS

P4.354 Evaluation of Teriflunomide in

Cardioembolic multivessel ischemic infarcts

P4.346 Anakinra(IL-1 blockade) Use in

Children with Suspected FIRES: A Single Institution Experience —Nikita Shukla, Sarah Risen, Jennifer Lee, Yi-Chen Lai, James Riviello, Eyal Muscal

P4.347 Effects of Childhood

SCLEROSIS

Comparison —Fatima Ismail, Eliza Gordon-Lipkin, P4.357 Cumulative Data from the Katherine Huether, Iain Blair, Miklós Szólics, Faisal European Interferon Beta Pregnancy Aziz, Taoufik Alsaadi, Jehan Suleiman, Nicoline Registry —Kerstin Hellwig, Yvonne Geissbuhler, Findings in Pediatric anti-MOG Ab Positive Patients —Cynthia Wang, Darrel Conger, Benjamin Greenberg

Treatment in Children with RRMS —Canan

P4.358 Disease activity and disability after Natalizumab (NTZ) withdrawal due to planning a pregnancy in women with multiple sclerosis —Nina Esters, Charlotte

P4.362 Pregnancy outcomes in patients with multiple sclerosis and exposure to branded glatiramer acetate during all three trimesters —Kerstin Hellwig, Orit Neudorfer,

Sigal Melamed-Gal, Peleg Baruch, Shahd Qassem

P4.363 Pregnancy Outcomes in

P4.364 Vitamin D and Postpartum

Amethyst Leimpeter, Kathleen Albers, Eric Kerezsi, Keeli McClearnen, Stephen Van Den Eeden, Annette Langer-Gould

P4.365 Parenthood and Multiple

Sclerosis: An explorative web-based study. —Luigi Lavorgna, Sabrina Esposito,

Roberta Lanzillo, Eleonora Cocco, Marinella Clerico, Giuseppe Fenu, Giovanna Borriello, Stefania De Mercanti, Jessica Frau, Rocco Capuano, Laura Rosa, Alice Laroni, Vincenzo Brescia Morra, Gioacchino Tedeschi, Simona Bonavita

Leigh Charvet

P4.367 Design of the Ocrelizumab

P4.352 Variation in Treatment

and Outcomes of Children With Acute Disseminated Encephalomyelitis —Craig

Press, Matthew Kirschen, Kerri LaRovere, Sarah Risen, Kristin Guilliams, Melissa Chung, Jennifer Griffith, Jennifer Lee, Katrina Peariso, Laurence Ducharme-Crevier, Samir Shah, Matthew Hall, Mark Wainwright

P4.353 Two Cases of Pediatric Multiple Sclerosis after Human Papillomavirus Vaccination —Ye Hu, Leticia Tornes, Robert Lopez-Alberola

Spicher, Sandra Thiel, Ralf Gold, Kerstin Hellwig

Vincent Damotte, Jeffrey Gelfand, Carolyn Bevan, Bruce Cree, Lynn Do, Ari Green, Stephen Hauser

P4.360 Interferon-β /glatiramer acetate

Maria Didden, Joanna Evershed, Monika Garas, Qing Wang, Kerstin Hellwig

P4.361 Pregnancy Outcomes in Patients With MS Treated With Teriflunomide: Clinical Study and Postmarketing Data —

P4.370 Effect of Pregnancy Loss on MS Disease Activity —Tamara Kaplan, Riley Bove,

Kristin Galetta, Brian Healy, Tanuja Chitnis, Maria Houtchens

P4.371 Teriflunomide (Aubagio®)

International Pregnancy Registry: Enrollment Update —Christine Lebrun-Freney, David Rog, Myriam Benamor, Stephanie Jurgensen, Philippe Truffinet, Angelo Ghezzi

P4.372 Design of a Multi-Source Post-

Marketing Study to Evaluate Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Who Were Exposed to Ocrelizumab During, or Within 6 Months Before, Pregnancy —Andrea Margulis, Elizabeth

Andrews, Sonia Hernández-Diaz, Melinda Magyari, Elena Rivero-Ferrer, Silvia Bader-Weder, Joanna Evershed, Monika Garas, Qing Wang, David Wormser

TOOLS AND OUTCOME MEASURES FOR MS TRIALS AND CLINICAL TRACKING

P4.373 An investigation into the

Justin Underwood, Karl Wissemann, Lori Fafard, Jared Srinivasan, Barbara Bumstead, Marijean Buhse, Myassar Zarif, Karen Blitz-Shabbir, Donald Morisky

P4.374 Factors Influencing Best Practices in Treating Multiple Sclerosis: Results from a Predictive Modeling Analysis —Jamie Reiter, Jan Perez, Sharon Tordoff, Whitney Faler

P4.375 Impact of Multiple Sclerosis P4.368 Risk of relapses during pregnancy Relapse Severity on Health Care Costs —

and post-partum period among multiple treatment during lactation in women with Multiple Sclerosis —Andrea Ciplea, Anna Stahl, sclerosis patients —Raed Alroughani, Saeed Sandra Thiel, Ralf Gold, Kerstin Hellwig

an Acute Top of the Basilar Artery Stroke —

Relationship between the Multiple Sclerosis Impact Scale (MSIS-29) and Predicted Technologies and Multiple Sclerosis Medication Adherence as Measured Relapses: A New Case Series, and Pooled Analyses of Existing Studies. —Kelsey Rankin, by the Morisky Medication Adherence Chao Zhao, Jorge Correale, Kerstin Hellwig, Laure Scale (MMAS-8) in People with Multiple Michel, David Laplaud, Tanuja Chitnis, Riley Bove Sclerosis —Zohra Hamid, Mark Gudesblatt,

P4.366 Assisted Reproductive

Pregnancy Registry to Assess Maternal, Fetal and Infant Outcomes in Women With Multiple Sclerosis Who Were Exposed to P4.351 Computerized Measurement of P4.359 Rituximab treatment before Processing Speed Predicts Cognitive Decline conception in women with multiple sclerosis Ocrelizumab During, or Within 6 Months Before, Pregnancy —David Wormser, Pierre and neuromyelitis optica: Case series and in Pediatric Onset Multiple Sclerosis — Engel, Kristen Hahn, Silvia Bader-Weder, Evasystematic review. —Riley Bove, Gitanjali , Michael Shaw, Ashley Clayton, Lauren Krupp, duman ilki, Mefkure Eraksoy

P4.344 Pourfour du Petit Syndrome in

Akhtar, Maya Zeineddine, Maryam Alowayesh, Yehya EL Kouzi, Samar Ahmed, Raed Behbehani, Samia Khoury, Jasem Al-Hashel, Bassem Yamout

P4.369 Pregnancy Outcome, Changes in

Lymphocyte Subsets in Peripheral Blood, and Sandra Vukusic, Patricia Coyle, Stephanie Plasma Osteopontin in Japanese Patients Jurgensen, Philippe Truffinet, Myriam Benamor, Elizabeth Poole, Jeffrey Chavin, Christina Chambers with Multiple Sclerosis after Assisted Reproductive Technology —Yuko Shimizu, Ryotaro Ikeguchi, Kazuo Kitagawa

Jacqueline Nicholas, Li Yunfeng, Maria Cecilia Vieira Da Silva, Huanxue Zhou, Ching-An Wang, Vivian Herrera

P4.376 Improved Clinical Detection of

Cerebellar Lesions in Multiple Sclerosis Patients —Oluwasheyi Ayeni, Stephen Krieger,

Rachel Brandstadter, Asaff Harel, Maria Petracca, Christina Lewis, Fred Lublin, Aaron Miller, Gabrielle Pelle, Alessio Pepe, Matilde Inglese, James Sumowski

AAN.com/view/AM18 159

Wednesday

P4.350 The Results of Fingolimod

Meritxell Sabidó Espin, David Appiah-Badu, Evra Köfüncü, Joachim Klinger, Peter Huppke, Asher Ornoy

EEG in Comatose Survivors of Cardiac Arrest —S Cooley, Gary Hunter

Bakhtier Nurmukhamedov, Aiga Rakhesh, Vishal Shah, Antonio Culebras

P4.355 The interplay of multiple sclerosis Multiple Sclerosis Relapses —Jessica Smith,

Badihian, Navid Manouchehri, Vahid Shaygan Anusha Yeshokumar, Michelle Fabian, Victoria Leavitt, Christina Lewis, Gabrielle Pelle, Mohamed- Nejad Mounir El Mendili, Amgad Droby, Matilde Inglese, P4.356 Low relapse risk under disease James Sumowski modifying treatment during ART in women with relapsing remitting multiple sclerosis — P4.348 Pediatric Multiple Sclerosis in Barbara Zurawski, Sandra Thiel, Ralf Gold, Kerstin the United Arab Emirates: Characteristics Hellwig From a Multi-Center Study and Global

P4.349 Optical Coherence Tomography

Mehmood Rashid

Skripchenko, Banu Anlar, Miqun Robinson, Rita Deng, Margaux Dupin, Philippe Truffinet, Stephanie the Ozanimod Nonclinical and Clinical Development Program —Denise Campagnolo, Jurgensen, Jeffrey Chavin, Ludwig Kappos Catherine Montero-Embalsado, Susan MeierDavis, Neil Minton PREGNANCY AND MULTIPLE

Socioeconomic Status on Neuroimaging and and menstrual cycle: Which one affects Functional Outcomes in Patients with MS — the other one? —Omid Mimosayyeb, Shervin

Schiess

distortions associated with the recovery from posterior reversible encephalopathy syndrome (PRES) —Payam Sadry, Irfan Sheikh,

Hileman, Vismay Thakkar, Sajjad Mueed

Children and Adolescents With Relapsing P4.345 Sub-acute Hemiplegia in a MS: TERIKIDS Phase 3 Study Design, Toddler: A Case Study in Anti-MOG Antibody Enrollment Update, and Baseline Data — Positive Tumefactive Demyelinating Tanuja Chitnis, Marc Tardieu, Brenda Banwell, Encephalitis —Jason Gill, Danielle Takacs, Kivilcim Gücüyener, Kumaran Deiva, Natalia Timothy Lotze

P4.342 Metamorphopsia and other visual P4.343 Continuous Bedside Subhairline

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION IV G P4.377 No Significant Genetic or

survey —Giovanna Borriello, Luigi Lavorgna, Sabrina Esposito, Rocco Capuano, Laura De Giglio, Transcriptomic Predictors of Severe and Prolonged Lymphopenia in MS Cases Treated Alessandra Logoteta, Gioacchino Tedeschi, Simona Bonavita with Dimethyl Fumarate —Paola Bronson, Dipen Sangurdekar, Michelle Penny P4.388 Comparing Benefit-Risk Profiles P4.378 Telemedicine Reduces Barriers to of Oral DMTs for Relapsing MS: A Likelihood Care for Patients with Multiple Sclerosis and of Help vs. Harm (LHH) Analysis. —Dimos Neuroinflammation —Riley Bove, Priya Garcha, Dimitrios Mitsikostas, Dimitrios Papadopoulos Carolyn Bevan, Elizabeth Crabtree-Hartman, Ari P4.389 Usefulness of the unification Green, Jeffrey Gelfand of the criterion for the evaluation of the P4.379 Driving Continuous Improvement functional system cerebral functions of the Expanded Disability Status Scale (EDSS) — of MS Care Quality—Initial Launch Experience from the First Continuous Quality Ricardo Alonso, Barbara Eizaguirre, SIlva Berenice, Cecilia Pita, Sandra Vanotti, Fernando Caceres, Improvement Research Learning Health Domingo Garcea System in Multiple Sclerosis —Brant Oliver, Terrie Livingston, Michelle Patel, Amy Hall, Randy P4.390 Patient Reported Disease Messier, Carolyn Schwarz Modifying Therapy Adherence in the Clinic: A P4.380 Overall Response Score: A Novel Reliable Metric? —Devon Conway, Maria Cecilia Vieira Da Silva, Nicholas Thompson, Kaila Parker, Disability Endpoint That Allows for the Integrated Assessment of Improvement and Xiangyi Meng, Robert Fox Worsening over Time in Patients with MS — P4.391 Predicting Falls in Multiple Ih Chang, Ludwig Kappos, Gavin Giovannoni, Peter Sclerosis: Are Electrophysiological Measures Calabresi, Alfred Sandrock, Yi Chai, Bing Zhu, more accurate than Clinical Measures? —

Wednesday, April 25 11:30 a.m.–7:00 p.m. P4.400 Multiple Sclerosis, Gait and

Digital Devices: A Comparison of Two FDA approved validated devices that provide multidimensional quantifiable gait parameters in People with Multiple Sclerosis (PwMS) —Mark Gudesblatt, Stacy Trebing, Christina Burke, Karl Wissemann, Myassar Zarif, Barbara Bumstead, Lori Fafard, Marijean Buhse, Karen Blitz-Shabbir

Lakshmi Ranganathan, Shunmugasundaram Kanthimathinathan, Sarala Govindarajan, Uma Maheswari E, Jawahar Marimuthu, R M Bhoopathy

P4.402 Delivering Education to

Patients with MS—a Survey of Canadian Neurologists —Olga Lekontseva, Penelope Smyth, Carol Hodgson

P4.403 Cognitive-Motor interaction in patients with multiple sclerosis —Barbara

P4.381 The Multiple Sclerosis Partners

P4.392 Multiple Sclerosis Treatment

Ellen Mowry, Lauren Krupp, Stephen Jones, Robert Naismith, Aaron Boster, Megan Hyland, Izlem Izbudak, Yvonne Lui, Carrie Hersh, Bjorn Tackenberg, Mar Tintoré, Alex Rovira, Xavier Montalban, Hagen Kitzler, Tjalf Ziemssen, Eunice Jung, Tatiana Plavina, Carl DeMoor, Elizabeth Fisher, Bernd Kieseier, Himanshu Pandya, James Williams, Richard Rudick

P4.382 FLOODLIGHT: Remote

Self-Monitoring Is Accepted by Patients and Provides Meaningful, Continuous Sensor-Based Outcomes Consistent With and Augmenting Conventional In-Clinic Measures —Xavier Montalban, Patricia Mulero,

Luciana Soledad Midaglia Fernandez, Jennifer Graves, Stephen Hauser, Laura Julian, Mike Baker, Jan Schadrack, Christian Gossens, Alf Scotland, Florian Lipsmeier, Gregoire Pointeau, Corrado Bernasconi, Shibeshih Belachew, Michael Lindemann

P4.383 Tool for Semi-Automated and

Reproducible Histological Analysis of Brain Tissue —Suyog Pol, Tommy Tsang, Michelle Sveinsson, Michelle Sudyn, Robert Zivadinov

P4.384 Long-term predictors of clinical

Wednesday

outcomes in patients with multiple sclerosis randomized to fingolimod 0.5 mg in the phase 3 FREEDOMS, FREEDOMS II and TRANSFORMS studies —Till Sprenger, Aaron Boster, Xiangyi Meng, Shannon Ritter, Daniela Piani Meier, Davorka Tomic, Diego Silva, Frederik Barkhof, Pavle Repovic

P4.385 Dynamic Visual Tests as a

Measure of Demyelination in the Visual System of Progressive MS Patients —Yael

Gudesblatt, Karl Wissemann, Myassar Zarif, Barbara Bumstead, Lori Fafard, Jared Srinivasan, Ilir Topalli, Jeffrey Wilken, Karen Blitz-Shabbir, Marijean Buhse, Glen Doniger

P4.393 Real-World Use of Wearable

Devices in a Large Multiple Sclerosis Cohort —Luca Foschini, Jennie Medin, Vladimir

Bezlyak, David Stuck, Diego Silva, Wei-Nchih Lee

P4.394 Overcoming Therapeutic

Inertia in Multiple Sclerosis care: A pilot Randomized Trial evaluating an Educational Intervention —Gustavo Saposnik, Jorge

Alejandro Maurino, Angel Sempere, Muhammad Mamdani, Maria Terzaghi, Christian Ruff, Philippe Tobler, Xavier Montalban

P4.395 Is Routine Renal US Indicated for

Daily Self-Report Fall Calendars Accurate? A Comparison with a Real-Time Body-Worn Self-Report Device in Multiple Sclerosis —

Nahian Chowdhury, Andrea Hildebrand, Jonathon Folsom, Peter Jacobs, Michelle Cameron

P4.405 A Preliminary Investigation into

the Relationship between the Multiple Sclerosis Walking Scale (MSWS-12) and an Objective Multi-dimensional Digital Gait Analysis —Mark Gudesblatt, Stacy Trebing, Christina Burke, Karl Wissemann, Myassar Zarif, Barbara Bumstead, Lori Fafard, Marijean Buhse, Karen Blitz-Shabbir

Fernanda Mendes, Samira Apóstolos-Pereira, Dagoberto Callegaro

P4.409 Psychological Resilience is

Katherine Heller

Gabrielle Pelle, Christina Lewis, James Sumowski

Linked to Lower Disability in Early Multiple Sclerosis —Sylvia Klineova, Michelle Fabian,

P4.398 Quantifying Cognitive Fatigue

P4.410 Response time for identifying shapes and textures with Interactive Sensory Digital Platform in patients with multiple sclerosis —Michal Greenberg-

Abrahami, David Magalashvili, Shay Menascu, Mark Dolev

P4.399 Performance on a digital resonance spectroscopy in differentiating neuropsychological test battery in individuals P4.411 Relation between Fatigue tumefactive demyelinating lesions from Severity Scale and Pupillary Indices in gliomas —Ryotaro Ikeguchi, Yuko Shimizu, Kayoko with relapsing remitting multiple sclerosis Patients with Multiple Sclerosis —Ye Hu, and healthy controls. Normative values. — Abe, Koichiro Abe, Takakazu Kawamata, Kazuo Kitagawa

P4.387 How an early diagnosis has

impacted on clinical practice in the last years in Italy: A web-based patient-centered

160 2018 AAN Annual Meeting

Daniel Sanchez, Maria Goldfeder, Pagani Cassara Fatima, Vladimiro Sinay, Teresa Torralva, Maria Roca, Diana Bruno

P4.415 Impaired Sexual Quality of Life in

Women with Neuromyelitis Optica Spectrum Disorder —Maureen Mealy, Michael Levy

P4.416 At-Home Transcranial Direct

Current Stimulation Benefits Depression and Cognition in Multiple Sclerosis: Two Case Reports —Ashley Clayton, Robert Charlson, Bryan Dobbs, Jonathan Howard, Lauren Krupp, Michael Shaw, Leigh Charvet

Quality of Life in Multiple Sclerosis —

Heidemarie Lex, Sara Weisenbach, Jacob Sloane, Sana Syed, Eva Rasky, Wolfgang Freidl

P4.418 Cognitive stimulation in patients with relapsing-remitting multiple sclerosis: Effects on cognition, quality of life and MR functional connectivity. —Riccardo Manca,

Micaela Mitolo, Basil Sharrack, Annalena Venneri

P4.419 The relationship between

memory and executive functions in relapsing remitting multiple sclerosis patients. —Maria Goldfeder, Diana Bruno, Pagani Cassara Fatima, Vladimiro Sinay, Maria Roca

P4.420 Analysis of Cognitive Impact on Evaluation of Brazilian Portuguese version Physical Disability in People with Multiple of Fatigue Severity Scale and Modified Sclerosis (PwMS) —Karl Wissemann, Mark Fatigue Impact Scale —Fernanda Dantas, Maria Gudesblatt, Zohra Hamid, Lori Fafard, Jared

Feasibility of Incorporating PhotoVoice into MS Mosaic —Fletcher Hartsell, Casey Farin,

P4.386 Usefulness of proton magnetic

Maria Luisa Martinez Ginés, Jose Manuel Garcia Dominguez, Lucía Forero, Daniel Prefasi, Jorge Maurino

P4.406 Fatigue in Multiple Sclerosis:

P4.397 MS PhotoMosaic: Evaluating

in Multiple Sclerosis using P300 Evoked

Samadzadeh, Roya Abolfazli, Siamak Najafinia, Christian Morcinek, Peter Rieckmann

P4.404 Are “Gold Standard” Prospective P4.417 Social-Emotional Aspects of

MS Patients? —Victoria Titoff, Igor Titoff, Thomas P4.407 Overview of the North American Registry for Care and Research in MS Scott (NARCRMS) —David Jones, June Halper, Lisa P4.396 TITRE: Dedicated Mobile Patton, Sarah Murphy, Kottil Rammohan Application for Drug Adverse Reactions P4.408 WITHDRAWN Reporting by Patients with Relapsing Remitting Multiple Sclerosis: A Multicenter Cluster-Randomized Controlled Trial —Gilles MS AND CNS INFLAMMATORY Defer, Florian Le Caignec, Sophie Fedrizzi, François DISEASE: QUALITY OF LIFE, SYMPTOMS, AND Montastruc, Damien Chevanne, Jean-Jacques SYMPTOMATIC THERAPY III Parienti, Laure Peyro Saint Paul

Backner, Panayiota Petrou, Noa Raz, Haya Shames, Potentials —Somasundaram Chinnadurai, Avathvadi Srinivasan, Lakshmi Ranganathan, Dimitrios Karussis, Netta Levin Bhanu Kesavamurthy

as a valuable tool to assess visual pathway function in Multiple Sclerosis: First results on potential association with fatigue —Sara

P4.414 Stigma in Multiple Sclerosis: Sclerosis: Correlation Between Objective and Revisiting the psychometric properties of Subjective Measures —Guhan Ramamurthy, the SSCI-8 questionnaire —Javier Ballesteros,

Eizaguirre, Angeles Merino, Cecilia Yastremiz, SIlva Berenice, Ricardo Alonso, Sandra Vanotti, Somasundaram Chinnadurai, Avathvadi Srinivasan, Domingo Garcea Bhanu Kesavamurthy, Lakshmi Ranganathan

Decisions: EDSS Independent Disease Impact/Reserve and the Use of Additional Milestones that Matter —Daniel Golan, Mark

P4.413 Quantitative manual pupillometry

P4.401 Cognitive Fatigue In Multiple

Carmen Castrillo-Viguera, Aaron Deykin, Sarah Sheikh

Advancing Technology and Health Solutions (MS PATHS) patient cohort —Robert Bermel,

Fabian, Victoria Leavitt, Christina Lewis, Gabrielle Pelle, Mounir El Mendili, Amgad Droby, Matilde Inglese, James Sumowski

Hong Jiang, Jianhua Wang, Byron Lam, Kottil Rammohan

Srinivasan, Barbara Bumstead, Marijean Buhse, Myassar Zarif, Karen Blitz-Shabbir, Cynthia Sullivan, Jeffrey Wilken

P4.421 The reduced version of the

Reading the mind in the eyes test. It’s utility in evaluating complex emotion recognition in relapsing remitting multiple sclerosis. — Milagros García, Daniel Sanchez, Katia Rosenbaum, Pagani Cassara Fatima, Vladimiro Sinay, Teresa Torralva, Maria Roca, Diana Bruno

P4.422 Higher Openness is related to

Higher Social Network Density in Persons with Multiple Sclerosis —Rebecca Straus

Farber, Amar Dhand, Seth Levin, Gabriella Tosto, Eva Gelernt, Victoria Leavitt

P4.423 Effect of Fampridine on the

Manual Functions of Patients with Multiple Sclerosis: Difference Between Cerebellar and Pyramidal Dysfunction —Serkan Ozakbas, Bilge Piri Cinar, Turhan Kahraman

P4.424 Predictors of Fatigue Severity in Multiple Sclerosis Patients —Zainab Alalawi, Kalyan Yarraguntla, Rishi Sood, Navid SerajiBozorgzad, Evanthia Bernitsas

P4.425 Observations of a Multiple

Sclerosis Patient-Centered Specialty Practice: Analysis of Depression Patterns — Eric Meninno, Terrie Livingston, Susan Stuart,

P4.412 Fatigue in early multiple sclerosis Sonya Powell, Alexis Carlson, Nasima Afsari, and the role of the caudate nucleus. —

Achillefs Ntranos, Stephen Krieger, Michelle

Michelle Patel, Tom Valuck, Pat Farmer, Carlo Tornatore

P4.426 Prevalence of Stigma in

Caribbean Hispanic patients with Multiple Sclerosis —Angelica Rivera Cruz, Janice Vargas, Valerie Wojna, Gishlaine Alfonso

P4.427 Quality Of Life Assessment

Among Multiple Sclerosis Patients , Saudi Arabia—Cross Sectional Study —Adel Ali

Alhazzani, Mohammed Alqahtani, Mohammed Alahmari, Mohannad Assiri, Noof Alamri, Leen Sarhan, Shahad Alkhashrami, abdullmgeed Asiri

P4.428 The relationship between

the ALS Japanese Severity Scale and Use over Time —Laura Bower, Benjamin Shander, Alexander Kalin

James Carroll, Darius Seidler, John Dessaint, Louis Patients —Brooke Lubinski, Monserrat DiazVaickus, Patricia Henegan, Tanya Butt, Angeline Abad, Justin Kwan Andrew, Elijah Stommel

P4.439 A New Grading Scale for

P4.450 Study Design and Preliminary

Phenotypic Diversity in Amyotrophic Lateral Results of Safety and Efficacy of Ranolazine Sclerosis/Frontotemporal Dementia —Yin Liu, for the Treatment of Amyotrophic Lateral Sclerosis —Anai Hamasaki, Mazen Dimachkie, Jeffrey Rosenfeld

P4.440 Graph Theory Network Analysis Distinguishes Regional Brain Changes in UMN-predominant ALS Patients With and Without Corticospinal Tract Hyperintensity —Erik Pioro, Venkateswaran

incidental learning and executive functions in relapsing remitting multiple sclerosis Rajagopalan patients. —Agostina Galiani, Diana Bruno, Pagani P4.441 Contribution of Rare Homozygous Cassara Fatima, Vladimiro Sinay, Maria Roca Variants in ALS in a Homogenous Population —Vivian Drory, Orly Goldstein, Merav ALS II

P4.429 Measuring Disease Progression in Amyotrophic Lateral Sclerosis: Correlations between Slow Vital Capacity and ALSFRS-R Measures of Respiratory Function —Carlayne Jackson, Mamede de

Kedmi, Mali Gana-Weiss, Beatrice Nefussy, Shir Twito, Yaara Feinmesser, Omri Nayshool, Avi OrrUrtreger

P4.442 Coactivation of TRPA1/TRPV1

Mamatha Pasnoor, Melanie Glenn, Omar Jawdat, Laura Herbelin, Duaa Jabari, Richard Barohn, Jeffrey Statland

ALS, SMA, AND OTHER NEUROMUSCULAR DISORDERS II

Kurt, Sevim Erdem-Ozdamar, Ersin Tan

P4.431 Low expression of mutant

subscore of ALSFRS-R? —Nimish Thakore,

Ubiquilin-2 exacerbates ALS/FTD features in a TDP-43 mouse model —Vincent Picher-

P4.444 How good is the respiratory Brittany Lapin, Erik Pioro

Ian Cheong, Gulin Oz, Malgorzata Marjanska, David Walk

P4.452 Reliability of Spinal Muscular

Atrophy Functional Rating Scale (SMAFRS) in Ambulatory Adults with Spinal Muscular Atrophy. —Bakri Elsheikh, Wendy King, William

Primary Lateral Sclerosis with Minor Electromyographic Abnormalities —Shivam

Mittal, William Hu, Keith Josephs, J. Ahlskog, Eric Sorenson, Anhar Hassan

P4.463 PLS in a Connecticut ALSA Datta, Kevin Felice

P4.464 Use of Ommaya Reservoir with a Thoracic Spinal Catheter for Intrathecal Delivery of Nusinersen in a Patient with Spinal Muscular Atrophy Type 2 —Arpita Lakhotia, Sonam Bhalla, Elizabeth Doll, Willam Gump

P4.465 Diseases that simulate

Amyotrophic lateral sclerosis: Clinical differences —Maria Constanza Segamarchi, Raul Rey, Gabriel Rodriguez

P4.454 Characterization of Later

Childhood/Adult Spinal Muscle Atrophy Patients and Their Transitions of Care within U.S. Hospitals —Jaanai Babb, Megan Teynor,

P4.432 The natural history of dysphagia

the survival of SOD1 G93A mice when administered after the onset of disease —

Andrea Calvo, Cristina Moglia, Stefania Cammarosano, Antonio Ilardi, Antonio Canosa, Enrica Bersano, Letizia Mazzini, Adriano Chio

Jill Dreyfus, Teresa Davis, Sandra Reyna, Michelle Hongquan Jiang, Ming Ren, Xiang Yin, Jing Wang, Patel, Terrie Livingston, Mehul Jhaveri Yan Qi, Honglin Feng P4.455 Phase Sensitive Inversion

P4.446 Overestimation of Renal Function Recovery (PSIR) spinal cord imaging as

Alterations in Amyotrophic Lateral Sclerosis Are Modulated by the Topology of the Anatomical Brain Connectome —Massimo

P4.462 Clinical Phenotypes of

Gerber, Christian Czech, Yumi Cleary, Margaret Chan, Stephan Nave, Ksenija Gorni, Omar Khwaja

P4.445 Guanabenz does not affect

P4.433 Structural Connectivity

Shah

Center: Retrospective study of progression Spectroscopy in ALS: Clinical Correlations — rate and clinical course in 46 patients —Neil

Martel, Jean-Pierre Julien

in ALS patients with bulbar and spinal onset —Umberto Manera, Fabrizio D’Ovidio,

(MUNIX) in Spinal Muscular Atrophy (SMA) —Jasmine Forte, Sumit Verma, Durga

P4.451 Longitudinal 7 Tesla MR

and its Potential Impact on Cramps, Spasms, Arnold, John Kissel Spasticity and Pain in Amyotrophic Lateral Carvalho, Angela Genge, Terry Heiman-Patterson, Sclerosis —Glenn Short, Brooke Hegarty, P4.453 Updated pharmacodynamic and Jeremy Shefner, Amy Wohltman, Andrew Wolff safety data from SUNFISH Part 1, a study Jennifer Szegda, David Golod, William McVicar, Thomas Wessel evaluating the oral SMN2 splicing modifier P4.430 Exploiting Integrated miRNAs RG7916 in patients with Type 2 or 3 spinal Analysis of Patient-derived iPSCs-Motor P4.443 The expression of epidermal muscular atrophy —Eugenio Mercuri, Giovanni Neurons to Develop a Molecular Therapy growth factor (EGF) and keratinocyte growth Baranello, Jan Kirschner, Laurent Servais, Nathalie for ALS —Mafalda Rizzuti, Monica Nizzardo, factor (KGF) in skin biopsy of amyotrophic Valentina Melzi, Giuseppe Filosa, Laura Dioni, Luca lateral sclerosis patients —Erdal Kurt, Can Ebru Goemans, Maria Carmela Pera, Anne Marquet, Gillian Armstrong, Heidemarie Kletzl, Marianne Calandriello, Martina Locatelli, Nereo Bresolin, Silvia Barabino, Giacomo Comi, Stefania Corti

P4.461 Motor Unit Number Index

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

by Creatinine-derived Estimated Glomerular Filtration Rate Correlates with the Loss of Appendicular Skeletal Muscle Index in Amyotrophic Lateral Sclerosis Patients —Yuji

a potential biomarker for Motor Neuron Disease —Nicholas Olney, Antje Bischof,

P4.447 C-Reactive Protein ( CRP ) is

P4.457 Long-term Outcome of Filgrastim

Howard Rosen, Eduardo Caverzasi, William Stern, Catherine Lomen-Hoerth, Bruce Miller, Roland Henry, Nico Papinutto

Saitoh, Masaki Kakizawa, Yuka Hama, Yohei Aoshima, Daiki Takewaki, Taiji Mukai, Tomoya P4.456 Results from the Cure SMA Filippi, Silvia Basaia, Nilo Riva, Edoardo Spinelli, Kawazoe, Asami Tasaki, Yuko Morimoto, Masayuki Newly Diagnosed Survey —Lisa Belter, Yuri Falzone, Adriano Chio, Andrea Falini, Giancarlo Miyazaki, Takashi Odo, Madoka Mori-Yoshimura, Rosangel Cruz, Jill Jarecki, Cynthia Jones, Sandra Comi, Federica Agosta Miho Murata, Yuji Takahashi Reyna, Kenneth Hobby

P4.434 Characterization of ALS patients

based on MIP & FVC at first visit —Keerthana

Kassar, Mohtashim Qureshi, Mohammad-Rauf Afzal, Anantha Vellipuram, Paisith Piriyawat, Ihtesham Qureshi, Mohammad Ghatali, Gustavo Rodriguez, Rakesh Khatri, Alberto Maud, Salvador Cruz-Flores

P4.436 Alterations in Hippo pathway

signaling as a mechanism of neuronal death in Amyotrophic Lateral Sclerosis —Ghazaleh Sadri-Vakili, Kaly Mueller, Eric Granucci, Amanda Dios, James Berry, Khashayar Vakili

P4.437 Successful Postmortem

Collection of Neurological Tissues: The National ALS Biorepository Experience —

Wendy Kaye, Laurie Wagner, Thor Stein, Thomas Bell, Ben Buehrer, Maureen Orr

P4.438 A Comparative Safety Analysis of the Edaravone Safety Profile Based on

Mohammed Sanjak, Elena Bravver, William Bockenek, Tiffany Williamson, Scott C Lindblom, William Dawson, Melissa Johnson, Nicole Lucas, Cynthia Lary, Lisa Ranzinger, Allison NewellSturdivant, Nicol Brandon, Scott Holsten, Amber Ward, Rachel Hillberry, Kathryn Wright, Nigel Rozario, Benjamin Brooks

P4.448 Frequency and Clinical

Characteristics of Mexican Patients with Vulpian-Bernhardt Syndrome —Juan Lopez, Guillermo Delgado-Garcia, Karina Carrillo-Loza, Edwin Vargas

P4.449 Identifying Aerosolized

(G-CSF) in ALS Patients —Siw Johannesen,

Tim-Henrik Bruun, Bettina Budeus, Sebastian Peters, Anne-Louise Meyer, Ines Kobor, Ohnmar Hsam, Anna Maria Wirth, Wilhelm SchulteMattler, Sabine Klatt, Ulrich Bogdahn

Wednesday

Significantly Higher in Amyotrophic Lateral Sclerosis (ALS) Patients on Non-Invasive Ventilation (NIV) and TracheostomyP4.435 Impact Of In-Hospital Mechanical Invasive Ventilation (TIV) Compared with ALS Patients at Intake Clinic Evaluation Ventilation On In-Hospital Outcomes Of Amyotropic Lateral Sclerosis (ALS) In United and Decreases Following Riluzole States: Analysis From Nationwide Inpatient Administration—Is CRP Potentially a Sample (NIS) Database (2011-2014) —Darine Biomarker for Treatment Responsiveness? — Akkineni, Ericka Simpson, Vanessa Holland, Leif Peterson

P4.458 ALS Dashboard—Cognitive,

Affect, Bulbar, Respiratory, Arm, Leg Staging Algorithm—Single Center Longitudinal Assessment —Benjamin Brooks, Elena Bravver, Urvi Desai, Mohammed Sanjak, William Bockenek, William Dawson, Scott C Lindblom, Benjamin Bringardner, Robert Taylor, Velma Langford, Melissa Johnson, Amy Lindville, Tiffany Williamson, Nicole Lucas, Cynthia Lary, Lisa Ranzinger, Allison Newell-Sturdivant, Rachel Hillberry, Kathryn Wright, Scott Holsten, Amber Ward, Nigel Rozario, Nicol Brandon

P4.459 Big Data Analytics for

Early Diagnosis of Amyotrophic Lateral Sclerosis —Tara Grabowsky, Oodaye Shukla, Manjula Kasoji, Chris Miller, Charlotte Merrill,

Wendy Agnese, Nazem Atassi Cyanobacteria as an Environmental Risk Factor for ALS using Human Bronchoalveolar P4.460 Application of Amyotrophic Lavage and Nasal Swab Specimens — Lateral Sclerosis Staging Systems in ALS Dominic Facciponte, Matthew Bough, Jacob Rauh,

AAN.com/view/AM18 161

POSTER SESSIONS

POSTER SESSION V NEURO-REHABILITATION

Thursday, April 26 11:30 a.m.–7:00 p.m.

P5.011 Physician’s Global Assessment of

Response to Repeated AbobotulinumtoxinA Injections in Adults with Lower Limb Transcranial Direct Current Stimulation Spasticity Post-Stroke or Traumatic Brain (RS-tDCS) Improves Parkinson’s Disease (PD) Injury —Alberto Esquenazi, Wuwei Feng, Symptomatology —Bryan Dobbs, Shashank Khashayar Dashtipour, Anthony Rodrigues, Claire

P5.001 Remotely-Supervised

Agarwal, Charles Feinberg, Natalie Pawlak, Michael Shaw, Milton Biagioni, Leigh Charvet

Vilain, Gustavo Suarez-Zambrano, Jean-Michel Gracies

091–172

P5.002 At-Home Tele-Monitored

P5.012 Safety of IncobotulinumtoxinA transcranial Direct Current Stimulation in Adult Spasticity: Results from a Pooled (tele-tDCS) Therapy for Fatigue in Parkinson’s Analysis of Randomized, Prospective, Clinical Disease —Kush Sharma, Daniella Mania, Studies —David Simpson, Michael Hast, Angelika

a randomized double-blind remotely supervised tDCS trial for symptomatic management in multiple sclerosis —Michael Shaw, Bryan Dobbs, Natalie Pawlak, Maria Palmeri, Lauren Krupp, Kathleen Sherman, Leigh Charvet

Robert Jech, François Constant Boyer, Pascal P5.004 Effects of Repetitive Transcranial Maisonobe, Jovita Balcaitiene

Magnetic Stimulation in Aphasic Stroke: A Randomized Double-blind Controlled Clinical Trial. —Federico Silva, Marlen Y Pachon Poveda, Alexander Pabon Moreno, Jose A Mendoza Sanchez, Luis A Lopez Romero, Ligia C Rueda Guzman, Juan S Parra Mendez, Yizel K Leon Vargas, Ramiro F Trillos Leal, Yuletzy Castellanos, Ronald G García Gomez

P5.005 Remotely-Supervised

Transcranial Direct Current Stimulation (RS-tDCS) is Feasible for 40 Treatment Sessions —Bryan Dobbs, Natalie Pawlak,

P5.014 Intrathecal Baclofen Therapy

Decreases Pain and Improves Quality of Life Compared to Conventional Medical Management in Severe Post-Stroke Spasticity: The SISTERS Study —Michael

Yochelson, Michael Creamer, Geoffrey Cloud, Peter Kossmehl, Gerard Francisco, Anthony Ward, Jorg Wissel, Mauro Zampolini, Meghann Loven, Abdallah Abouihia, Alessandra Calabrese, Leopold Saltuari

P5.015 Challenges and Strategies for

Implementing Interventions in a Statewide

Michael Shaw, Ashley Clayton, Kathleen Sherman, System-Based Pragmatic Trial —Barbara Lutz, Leigh Charvet Sylvia Coleman, Cheryl Bushnell, Pamela Duncan, Sabina Gesell P5.006 Spinal cord epidural

stimulation: Classifying movement using accelerometers —Nicholas Peterson, Bryan

P5.016 Modified Approach to Stroke

P5.007 Neofect Glove: Virtual Reality

MaryKay Pavol, Clare Bassile, Jacqueline Callender, Nancy Ferreira, Emma Harmon, Jennifer Lehman, Brittany Shinn, Nancy St. James, Joel Stein

Ladd, David Darrow

Device for Home Therapy in Stroke Survivors —Alay Parikh, Catherine Legault, Kara Flavin, Maarten Lansberg

Rehabilitation (MAStR)-Feasibility Study —

P5.017 Validation of the Spanish version

of the CAL scale in stroke patients —Maria Electromyographic Automated Rehabilitation Julieta Russo, Solange Louzao, Valeria Prodan, Technology (HEART) Project —Mingjian Zhang, Maria Marta Saavedra, Josefina Courtis, Lucas

P5.008 The Holographic

Shuyang Liu, M. Ehsan Hoque, Ania Busza

P5.009 Cortical Somatosensory

Responses after Botulinum Toxin Therapy of Post-Stroke Spasticity —Petr Hlustik, Tomas Veverka, Pavel Hok, Pavel Otruba, Jana Zapletalova, Alois Krobot, Petr Kanovsky

P5.010 Pooled Safety Analysis of

Randomized, Prospective Studies on IncobotulinumtoxinA for the Treatment of Cervical Dystonia, Blepharospasm, and Upper Limb Spasticity —David Simpson,

Thursday

Michael Hast, Angelika Hanschmann

037–084

P5.013 Effect on Voluntary Movements

of Simultaneous Upper and Lower Limb AbobotulinumtoxinA Injections in Conjunction with Guided Self-Rehabilitation Contracts in Adults with Spastic Hemiparesis: Methodology of the ENGAGE Study —Jean-Michel Gracies, Gerard Francisco,

Bonamico, Lisandro Olmos, Liliana Sabe, Ricardo Allegri

P5.018 Analysis of discharge functional outcomes & disposition locations following inpatient rehabilitation in Guillain-Barre Syndrome patients —David Kushner, Maite Maguregui, Stacy A. Thomashaw

ePosters

b1 g1 339–344 a1 ePosters

Poster Discussion

027–036

M Abdulghani, Mohamed Khaled, Tamer Roushdy, Dalia Maher

259–294

295–338

345–428

429–480

Poster Session 5 A. Neuro-rehabilitation: 001 – 026

a1. MS and CNS Inflammatory Disease Poster Discussion Session: 027 – 036 B. Movement Disorders: 037 – 084

b1. Infectious Disease and Global Health I ePoster Session: 085 – 090 C. D. E. F. G.

Infectious Disease; Global Health; Neuroepidemiology: 091 – 172 Aging, Dementia, Cognitive, and Behavioral Neurology: 173 – 200 Cerebrovascular Disease and Interventional Neurology: 201 – 258 Epilepsy/Clinical Neurophysiology (EEG): 259 – 294 History of Neurology; General Neurology: 295 – 338

g1. Infectious Disease and Global Health II ePoster Session: 339 – 344 H. MS and CNS Inflammatory Disease: 345 – 428 I. Neuromuscular/Clinical Neurophysiology (EMG): 429 – 480

P5.020 The efficacy of

acetylcholinesterase inhibitor on poststroke aphasia: A systemic review and metaanalayis of experimental studies —Ian Shih

P5.021 Anti-fibrotic approach and

P5.024 Amantadine Use in Post-

Concussive Headaches: An Exploratory Retrospective Review —Conor Ryan, Ivan

Carabenciov, Britta Bureau, F. Cutrer, Rodolfo Savica

P5.025 Compare serum Creatinine reactivation of neurogenesis by targeting the TGF-ß System —Sabrina Kuespert, Michael versus Renal 99mTc-DTPA scan determined Glomerular Filtration Rates in Veterans with Poellmann, Rosmarie Heydn, Eva Zitzelsperger, Sebastian Peters, Anne-Louise Meyer, Tim-Henrik Traumatic Spinal Cord Injury and Neurogenic Bruun, Ludwig Aigner, Ulrich Bogdahn bladder —Meheroz Rabadi P5.022 Taking Steps Backward to Move Forward: A Preliminary Feasibility Study in Stroke —Oluwole Awosika, Katie Krier, Emily

P5.019 A Predictive model for functional Wasik, Boyne Pierce, Kari Dunning, Daniel Woo, recovery of upper extremity after acute ischemic stroke —Nevine El Nahas, Hany Aref,

201–258

001–026

Brett Kissela

P5.023 Amelioration of left hand apraxia in a patient with callosal disconnection by use of mirror visual feedback therapy — Riddhi Patira

162 2018 AAN Annual Meeting

173–200

085–090

Shashank Agarwal, Leigh Charvet, Michael Shaw, Hanschmann Alberto Cucca, Hamzeh A Migdadi, Milton Biagioni

P5.003 Long term outcome from

P5.026 NA

MS and CNS Inflammatory Disease Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below.

Posters displayed 11:30 a.m.-5:30 p.m. • Data blitz 12:00 p.m.-12:50 p.m. • Presenters Stand by Posters 5:30p.m.-7:00 p.m. Data Blitz: 11:45 a.m.–11:50 a.m.

P5.027 Ozanimod (RPC1063) Preserves

Central Nervous System (CNS) Tissue in Rodents by Reducing Neuronal Breaks in Vivo and Modulating Astrocyte Activity in Vitro —Kristen Taylor Meadows, Mohd Waseem Akhtar, Morgan Brand, Christiane Villescaz, Bryan Clemons, Carlos Lopez, Samantha SawaBallweber, Kevin Dines, Gregory Opiteck, Fiona Scott, Julie Selkirk

Data Blitz: 11:50 a.m.–11:55 a.m.

P5.028 Multitasking is the Cognitive

Hagemeier, Dejan Jakimovski, Ivo Paunkoski, Deepa Ramasamy, Ellen Carl, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman, Robert Zivadinov

Data Blitz: 12:00 p.m.–12:05 p.m.

P5.030 Impacting The Natural History

of Multiple Sclerosis: A Report on the First Generation of Treated Patients —Thomas

Scott, Troy Desai, Chris Hackett, Edward Gettings, Teresa Hentosz, Wisam Elmalik, Carol Schramke

Data Blitz: 12:05 p.m.–12:10 p.m.

P5.031 Alemtuzumab Reduced MRI Ability Most Linked to Depression in Multiple Lesions and the Rate of Brain Volume Loss Sclerosis —Daniel Kurz, Michelle Fabian, in CARE-MS II Patients Switching From SC Gabrielle Pelle, Christina Lewis, Fred Lublin, Aaron IFNB-1a: 5-Year Follow-up (TOPAZ Study) — Miller, James Sumowski

Data Blitz: 11:55 a.m.–12:00 p.m.

P5.029 Aging is accelerating brain

atrophy in MS patients —Emanuele Ghione, Michael Dwyer, Niels Bergsland, Jesper

DYSTONIA: PHENOMENOLOGY AND THERAPEUTICS

P5.037 Outcomes of Week-24

Completers and Subjects Who Had FollowUp Beyond Week 24 After a Single Treatment of DaxibotulinumtoxinA for Injection (RT002): Results of a Phase 2, Open-Label (Level II), Dose Escalating Study in Isolated Cervical Dystonia —Joseph Jankovic, Daniel Truong, Atul Patel, Allison Brashear, Marian Evatt, Roman Rubio, Chad Oh, Daniel Snyder, Cynthia Comella

P5.038 Golfer’s Cramp: Quantitative

Method for Separating Golfers with a TaskSpecific Dystonia —Charles Adler, M’hamed Temkit, Debbie Crews, Troy McDaniel, Jennifer Tucker, Joseph Hentz, Christian Marquardt, Dale Abraham, John Caviness

P5.039 The Phenotype of ATP1A3+

Data Blitz: 12:10 p.m.–12:15 p.m.

after Fingolimod withdrawal due to planning Junctional Adhesion Molecule-A (JAM-A) a pregnancy in women with multiple controls cytokine and protease secretion, sclerosis —Spalmai Hemat, Maria Houtchens, T cell infiltration of the CNS and clinical Angela Vidal-Jordana, Michael Guger, Doriana disability during autoimmune attack —Sam Landi, Miguel D’Haeseleer, Pietro Annovazzi, Mar Tintoré, Sandra Thiel, Ralf Gold, Kerstin Hellwig

Data Blitz: 12:15 p.m.–12:20 p.m.

P5.033 WITHDRAWN Data Blitz: 12:20 p.m.–12:25 p.m.

P5.034 Progressive Motor Impairment

from a Critically Located Lesion in Highly Restricted CNS Demyelinating Sven Schippling, Daniel Pelletier, Michael Barnett, Disease —Mark Keegan, Timothy Kaufmann,

Data Blitz: 12:30 p.m.–12:35 p.m.

P5.036 Serum and CSF Neuroflament

Light Chain levels normalise following Bone Marrow Transplant in MS Patients —Simon

Thebault, Daniel Tessier, Iva Stonebridge, Vincent Tabard-Cossa, Mark Freedman

A single-centre case-controled study —Maja P5.052 Cervical Dystonia Patients Relja, Vladimir Miletic Treated with OnabotulinumtoxinA Report Improvements in Health-Related Quality P5.044 Validation of a Questionnaire of Life in a Multicentre, Prospective, for Distinguishing X-linked Dystonia Parkinsonism from XDP mimics —Jose Danilo Observational Study: POSTURe —Marc Diestro, Mark Willy Mondia, Mark Ang, Paul Matthew Pasco

P5.045 Comparison of

OnabotulinumtoxinA Utilization and Effectiveness Across Various Etiologies of Spasticity from the Adult Spasticity International Registry Study: ASPIRE —

Gerard Francisco, Daniel Bandari, Ganesh Bavikatte, Wolfgang Jost, Aleksej Zuzek, Joan Largent, Alberto Esquenazi

P5.046 Evolution of cervical dystonia

patterns in subjects new to botulinum toxin treatment —Richard Trosch, Vivay Peter Misra, Pascal Maisonobe, Savary Om

Petitclerc, Martin Cloutier, Meetu Bhogal, Goran Davidovic

P5.053 A case of levodopa responsive

rapid onset dystonia-parkinsonism. —Yeva Fernandez, Steven Frucht

P5.054 Mingo Supplemental Trial:

An Open-Label Prospective Randomized Controlled Trial in X-linked Dystonia Parkinsonism Patients in the Province of Capiz, Philippines —Patrick Acuna, Greta

Solinap, Jan Kristoper De Guzman, Mark Ang, Criscely L. Go

P5.055 Deep brain stimulation of the

P5.060 Body Region Response to

Pallidal Deep Brain Stimulation in Isolated Dystonia —Jennifer Choi, Laura Scorr

P5.061 Cervical dystonia and substance abuse —Abhimanyu Mahajan, Joseph Jankovic,

Laura Marsh, Achint Patel, H. Jinnah, Cynthia Comella, Richard Barbano, Joel Perlmutter, Neepa Patel

P5.062 Focal Task-Specific Dystonia

Affecting the Proximal Arm—An UnderRecognized Disorder? —Christine Stahl, Steven Frucht

P5.063 Acute and Reversible Sadness

Following Deep Brain Stimulation Targeting the Globus Pallidus Internus in Dystonia — Rohit Kesarwani, Tejas Sankar, Fang Ba

PARKINSON’S DISEASE: THERAPEUTICS II

P5.064 Extended-release (ER) formulations of aminoadamantanes as NMDA-receptor antagonists: Pharmacokinetic (PK) determinants of improved tolerability —Jack Nguyen, Timothy

Fultz, Charles Davis, Rajiv Patni, Elizabeth Brigham, Jonathon Holt, Greg Went

P5.065 Pimavanserin use in a movement

disorders clinic: A single center experience — Abhimanyu Mahajan, Bisena Bulica, Ayesha Ahmad, Patricia Kaminski, Peter LeWitt, Danette Taylor, Shana Krstevska, Neepa Patel

P5.066 A Long-term Study on

Effectiveness of Levodopa-carbidopa Intestinal Gel Treatment in Advanced Parkinson’s Disease Patients —Kallol

Chaudhuri, Angelo Antonini, Werner Poewe, David Standaert, Per Odin, Jorge Zamudio, Lars Bergmann

P5.067 ITI-214, A Novel

Phosphodiesterase Type I Inhibitor, For The Treatment Of Motor And Non-motor Symptoms Of Parkinson’s Disease —Robert Davis, Kimberly Vanover, Sharon Mates

AAN.com/view/AM18 163

Thursday

Horng, Candice Chapouly, Daivd Dai, Gareth John

Aaron Boster, Giancarlo Comi, Hans-Peter Hartung, Brian Weinshenker, Orhun Kantarci, William Schmalstieg, M. Paz Soldan, Eoin Flanagan Alex Rovira, Barry Singer, Anthony Traboulsee, David Margolin, Luke Chung, Nadia Daizadeh, Kunio Nakamura, Douglas Arnold

globus pallidus interna with microelectrode recording for Myoclonus-Dystonia (DYT-11): P5.047 Therapeutic benefits persist at Haq, Beverly Snively, Cynthia Suerken, Jared the end of one botulinum toxin injection cycle One year Outcome in Two Patients —Murat Gultekin, Halil Ulutabanca, Ahmet Selcuklu, Meral Cook, Charlotte Miller, Kathleen Sweadner, Laurie in cervical dystonia—results from a metaMirza, Yasin Temel, Ersoy Kocabicak Ozelius, Allison Brashear analysis of 1091 subjects —Vivay Peter Misra, Richard Trosch, Savary Om, Pascal Maisonobe P5.056 Which factors predict patient P5.040 In Vivo RNA Transcriptional / Translational Landscape in X-linked Dystonia P5.048 The Adult Spasticity International satisfaction with botulinum toxin treatment for cervical dystonia in routine practice? — - Parkinsonism (XDP/DYT3) Patient-Specific Registry (ASPIRE) Study: Real-World Tae Mo Chung, Carlo Colosimo, Vivay Peter Misra, Neuronal Cells —Anna Szekely, Ellen Penney, Treatment Utilization and Effectiveness of P. Charles, Pascal Maisonobe, Savary Om Jennifer Yang, Cristopher Bragg, Nutan Sharma, OnabotulinumtoxinA in Post-Stroke Patients Sherman Weissman P5.057 Deep brain stimulation: A Treated for Spasticity —Ganesh Bavikatte, Gerard Francisco, Daniel Bandari, Wolfgang Jost, Treatment Modality for Generalized Dystonia P5.041 Safety and Efficacy of Aleksej Zuzek, Joan Largent, Alberto Esquenazi Secondary to Anoxic Brain Injury in Adults — IncobotulinumtoxinA for the Treatment of Padmaja Vittal, Joshua M Rosenow, Mark Nolt, Blepharospasm in Botulinum Toxin-Naive P5.049 The Prevalence of Dystonic Jennifer Pallone, Martha T McGraw, Alison Subjects —Fernando Pagan, Andrzej Dekundy, Tremor and Tremor Associated with Dystonia Monette, Laura Guzman, Archana Shrivastava, Kati Sternberg, Dimos Dimitrios Mitsikostas in Patients with Cervical Dystonia —Lenka Michael Rezak Hvizdosova, Martin Nevrly, Pavel Otruba, Petr P5.042 Drivers of change in Toronto P5.058 Evaluation of DTI-Tractography Western Spasmodic Rating Scale (TWSTRS) Kanovsky Findings in Botulinum Neurotoxin Injected scores following botulinum toxin treatment: P5.050 Psychiatric Manifestations of Hemifacial Spasm Patients —Hakan Cavus, Impact of geographical region —Carlo Autosomal Dominant Dopa Responsive Pervin Iseri Colosimo, Vivay Peter Misra, P. Charles, Tae Mo Dystonia —Lindsey Neimand, Robert Ortega, Chung, Pascal Maisonobe, Savary Om Deborah Raymond, Gary Heiman, Susan Bressman, P5.059 Early onset tremulous dystonia-a Rachel Saunders-Pullman familial case and novel mutation —Mariam Al P5.043 Assessment of non-motor symptoms and cognitive functions in patients P5.051 Family structures in adult-onset Hussona, Eavan McGovern, David Webb, Michael Hutchinson, Sean O’Riordan with isolated adult-onset cervical dystonia focal Dystonia —Maryamnaz Zaribaf, H. Jinnah previously not treated with botulinum toxin: Rapid-Onset Dystonia-Parkinsonism (RDP) is Broader than Previously Defined. —Ihtsham

Data Blitz: 12:25 p.m.–12:30 p.m.

P5.032 Disease activity during pregnancy P5.035 Astrocyte-T cell signaling via

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION V

P5.068 A Phase 2a study of nilotinib in

Disease Clinical Trials. —Pinky Agarwal, patients with advanced and early Parkinson’s Sudeshna Ray, Daniel Burdick, Alida Griffith disease. Study design —Tanya Simuni, Brian P5.072 Improvement in Attention/ Fiske, Kalpana Merchant, Christopher Coffey, Helen Memory Domains in Advanced Parkinson’s Matthews, Richard Wyse, Patrik Brundin, Gary Disease Patients Treated with LevodopaRafaloff, David Simon, Michael Schwarzschild, carbidopa Intestinal Gel is Associated with David Weiner, Charles Venuto, Laura Trusso Better Quality of Life —David Standaert, Ramon P5.069 Movement Disorder Specialists’ Rodriguez, John Slevin, Coleen Hall, Maurizio Determination of Eligibility for Device Aided Facheris, Janet Benesh, Stephanie Dubow Treatment in Advanced Parkinson’s Disease: P5.073 Barriers to Adherence to Results from the OBSERVE-PD Study — Physical Therapy, Occupational therapy, and Alfonso Fasano, Klaus Seppi, Victor Fung, Juan Speech/Swallowing Therapy in Parkinson’s Carlos Parra, Lars Bergmann, Kavita Sail, Yash Disease —Gregory Vurture, Catherine Kulick, Jalundhwala, Koray Onuk

P5.070 Genomic analysis identifies new loci associated with motor complications in Parkinson’s disease —Sun J. Chung, Juyeon Kim, Kiju Kim, Mi-Jung Kim, Young Jin Kim, HoSung Ryu

Kathryn Montgomery, Melissa Nirenberg

P5.076 Modulating BDNF Activity

in Parkinson’s Disease: The Impact of Aerobic Exercise and Transcranial Magnetic Stimulation —Hamzeh A Migdadi, Hoau-Yan Wang, Shashank Agarwal, Kush Sharma, Alberto Cucca, Angelo Quartarone, Maria Ghilardi, Alessandro Di Rocco, Milton Biagioni

ATAXIAS II

on Activities of Daily Living and Motor Trials And Tribulations of The Limited English Symptoms of Parkinson’s Disease —Danielle Proficiency Patient Volunteer in Parkinson`s Larson, Danny Bega, Eric Johnson, Laura Slowey

genes in spinocerebellar ataxia type 3 —Shi-

Rui Gan, Ning Wang, Sheng-Han Kuo, Zhi-Ying Wu

P5.080 Beyond Whole-Exome

Sequencing: A Propos of Two Neurodegenerative Diseases. —Fabio

Nascimento, Salmo Raskin, Brunhilde Wirth, Helio Afonso Teive

P5.081 Ataxia with Oculomotor Apraxia 2 : Clinical and Genetic study of 17 of Spinocerebellar Ataxia Type 10 —Bernardo patients —Haifa Kharrat, Cyrine Jridi, Jihene Machado Dias Domingues, Adriana Moro, Salmo Raskin, Tetsuo Ashizawa, Helio Afonso Teive

P5.078 Feasibility of Arterial Spin

Labeling MR Imaging for Detecting Movement Therapy in Parkinson’s Disease — Cerebellar Hypoperfusion in Patients with Spinocerebellar Degeneration —Masamichi Kristi Michels, Erica Hornthal, Danny Bega

P5.075 Effects of Rock Steady Boxing

P5.079 Interplay of repeat expansion

P5.077 Clinical and Genetic Evaluation

P5.074 A Pilot Study on Dance/

P5.071 Clinical Research Participation:

b1 C

Thursday, April 26 11:30 a.m.–7:00 p.m.

Ikawa, Hirohiko Kimura, Yuki Kitazaki, Akiko Matsunaga, Koji Hayashi, Osamu Yamamura, Tadanori Hamano, Makoto Yoneda, Hidehiko Okazawa, Yasunari Nakamoto

Sassi, Fatma Nabli, Samir Blel, Faycal Hentati

P5.082 Quality of Life in Fragile

X-associated Tremor/Ataxia Syndrome (FXTAS) — Danielle Thorarson, Erin RobertsonDick, Bicham Ouyang, Bryan Bernard, Joan O’Keefe, Deborah Hall

P5.083 NA P5.084 NA

Infectious Disease and Global Health I ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P5.085 Neurons on Wheels (NOW)—

Severe Acidosis —Akanksha Sharma, Jenny Siv, P5.088 Epilepsy-related Injuries: A Neuroschistosomiasis —Paul Elsbernd, Kathryn Liz Schackmann, Arielle Davis Lago, Tatjana Calvano, John Sladky Bringing Neurologists Into Shelters for Case-control Study —Mamta Singh, Coral Stredny, Saloni Kapoor, Arunmozhimaran Elavarasi, Better Patient Care —Joy Ding, Wendy Muckle, P5.087 Polyarteritis Nodosa from P5.090 Gas-containing Cervical and V Sreenivas, Victor Patterson Christopher Skinner, Jeffery Turnbull Hepatitis B Infection Presenting with Thoracic Spinal Epidural abscess secondary P5.089 Complete Neurologic Recovery to Klebsiella Pneumonia infection —Annie P5.086 Invasive Mucormycosis in an Bilateral Basal Ganglia Strokes and Immunocompetent Non-Diabetic with Sensorimotor Neuropathy —Vincent Arnone, after Acute Cauda Equina Syndrome due to Hsieh, Maria Rojas, Steven Yang, Saman Zafar, Indira De Jesus-Alvelo

Shumaila Sultan

P5.097 Treatment practices and

P5.103 Neurosyphilis, Neither Gone

P5.110 MS and HIV: A case of MS-IRIS

Sankaranarayanan, Kameshwar Prasad, Garima Shukla, Parthiban Balasundaram

Héctor Sánchez-Rodríguez, Pedro A HernándezRodríguez, Beatriz Chávez-Luevanos, Ingrid Estrada-Bellman, Alejandro Marfil-Rivera

P5.111 Subacute ZIKA Virus encephalitis

Kumar, Jayantee Kalita

P5.098 Epidemiology, Outcomes and

P5.104 Clinical Features Of Seizures

Coccidioidomycosis: A descriptive 19-year experience at an endemic tertiary care center —Erin Okazaki, Chia-Chun Chiang, Akta

neurological intensive care unit —Johann

NEUROLOGIC INFECTIONS: TREATMENTS AND OUTCOMES

P5.091 Safety and efficacy of

fludrocortisone in treatment of cerebral salt wasting in tuberculous meningitis: a preliminary study —Usha Misra, Mritunjai

Persistent disease activity after 9 months of treatment in CNS tuberculosis- an ambispective cohort study —Muthukani

Nor Forgotten: A Retrospective Study From Northeast México. —Sergio Castillo-Torres,

associated with antiretroviral therapy initiation —Pria Anand, Deanna Saylor

in Rio de Janeiro. —Joao Marcos Ferreira,

Thursday

Pamela Passos dos Santos, Luiz Felipe Dantas Pagliarini, Pedro Macedo, Ivan Da Silva, Celso In Hiv Patients With Toxoplasma Hygino, Ana Carolina Andorinho, Caroline Amaral, Prognosis of Central Nervous System P5.092 Central Nervous System Infections in Singapore—preliminary results Encephalitis. —Annick Melanie Magnerou, Victor Pedro Moreira Filho, Camila Pupe, Osvaldo Manifestations of Mycoplasma Pneumoniae, from the Singapore Neurologic Infections Nascimento Sini, Halima Fidelie Schol Ngoungoure, Denahin Systematic Review of the Literature with Hinnoutondji Toffa, Mouhamadou Mansour Ndiaye Programme (SNIP) —Kevin Tan, Yvonne Chan, P5.112 Enteroviral T-Cell Encephalitis Regard to Pathogenosis and Treatment in Derek Soon, Humaira Shafi, Monica Chan, Say-Tat P5.105 Daclizumab, a Potential Exit Related to Immnuosupresive Therapy Adult Subjects, with First Case Report of Ooi, Jenny Low, October Sessions, Eng-Eong Ooi, Strategy in MS Patients at High Risk for Including Rituximab —Nicolas Garzo Caldas, Successful Treatment with Intravenous Lin-fa Wang, Angela Vincent, Limin Wijaya Sara Vila Bedmar, Sara Llamas, Juan Ruiz Morales, Natalizumab-Associated PML? —Tobias Immunoglobulin in an Adult —Pirouz Piran, Aurelio Hernandez Lain, Dolores Folgueira Lopez, Moser, Bsteh Christian, Mihael Varosanec, Peter P5.099 Development of Transverse Subin Mathew, Alex Linn, Mei Lu, Efrain Salgado Wipfler, Ferdinand Otto, Annemarie Pokorny, Julia Elena Ruiz-Beato, Claudia Rodríguez López, Luisa Myelitis after Vaccination, A CDC/FDA Panadés Oliveira, David Uriarte Perez de Urabayen, Feige, Zslot Nagy, Johann Sellner P5.093 Neurocysticercosis: A Spanish Vaccine Adverse Event Reporting System Alberto Villarejo Galende center experience —Luna Fuentes Rumi, Jose (VAERS) Study, 1985-2017. —Shreya Shah, P5.106 A case of Listeria Maria Cabrera Maqueda, Ester Carreon Guarnizo, Janaki Patel, Abdul Rahman Alchaki, Moamina P5.113 Central Nervous System Tuberculosis Rhombencephalitis: Emphasizing good Ana Esther Baidez Guerrero, Gabriel Valero López, Fakher Eddin, Nizar Souayah presenting as Acute Meningioencephalitis: A outcome with awareness and prompt Jose Diaz Perez, Estefania Garcia Molina, Jose Case series describing an under recognized treatment. —Vivek Yadala, Yu-Ting Chen, P5.100 Agitation in autoimmune and Meca Lallana, Rocio Hernandez-Clares infectious encephalitis: A comparative study Humaira Khan, Sen Sheng, Mai Vuong, Shirley Ong entity. —Irfan Shah, Ravouf Asimi, Mushtaq Wani, Bashir Sanaie, Mudasir Mushtaq P5.094 Central Nervous System of clinical course and management at the Sellner, Gayane Harutyunyan, Martin Dünser, Fabio Rossini, Markus Leitinger, Helmut Novak, Patel, Holenarasipur Vikram, Janis Blair, Marie Grill Wolfgang Aichhorn, Eugen Trinka, Larissa Hauer

P5.095 Acute Flaccid Myelitis: Treatment P5.101 Defining PML Spectrum

Outcomes From a Tertiary Referral Center — Disease —Lauren Reoma, Bryan Smith, Matthew Benjamin Greenberg, Patricia Plumb, Cynthia Wang Schindler, Daniel Reich, Avindra Nath, Irene Cortese

P5.096 Is Infection at Stroke Onset

Associated with Prognosis Following Acute Ischemic Stroke? —Hamidreza Saber, Mahsa Sadeghi, Azara Singh, Morad Nasseri, Kushak Suchdev, Mohammad Ibrahim, Wazim Mohamed

164 2018 AAN Annual Meeting

P5.102 Clinical characteristics of HIV

patients with acute stroke —Hemil Gonzalez,

Lakshmi Warrior, Fabian Sierra Morales, Danielle Rice, Lisa Diep, Michael Kelly

P5.107 Elevated CSF 14- 3- 3 and Tau and Negative RT Quic after ECT —Miriam

P5.114 Clinical Characteristics of

NEUROLOGIC INFECTIONS: UNUSUAL PRESENTATIONS

Ueda, Hideaki Shibata, Megumi Yamada, Yuichi Hayashi, Akio Kimura, Kenichi Ando, Takayoshi Shimohata

Freimer, Yasmeen Rauf

P5.108 Candida meningitis and

ventriculitis after IV brown heroin use: A case series. —Carolina Vivar, Kelly Baldwin

Persistent/ Intractable Hiccups Caused by VZV Infection —Nobuaki Yoshikura, Natsuko

P5.115 Lyme Disease Presenting with

Meningoradiculitis: A Case of Variant Bannwarth Syndrome —Monica Diaz, Sarah

P5.109 Concurrent Faciobrachial Diplegia Wesley and Diaphragmatic Weakness Caused by P5.116 Palatal Tremor and Hypertrophic Lyme Neuroborreliosis —Seyedali Hejazi, Taqi Zafar, Armin Maghsoudlou, Golshan Fahimi, Laura Simionescu

Olivary Degeneration after Listerial Rhombencephalitis —Seong-il Oh, Kyong Jin Shin

P5.117 IL6 and IL17 as inflammatory response in a case of Neurobrucellosis presenting as Leucoencephalopathy —

Mariem Kchaou, Mariem Belguith, khadija Bahrini, Mohamed jalleli, slim echebbi, Hela Jamoussi, Nadia Ben Ali, Mohamed Fredj, Ridha Barbouche

P5.118 Bilateral Spontaneous Subdural

Lima, Hennan Teixeira, Carmen Lucia Penteado Lancellotti, Leonardo Furtado Freitas, Alex Baeta

P5.149 Image studies in Zika Virus

P5.134 An interesting case of Nocardial

Luiz Felipe Dantas Pagliarini, Joao Marcos Ferreira, Pamela Passos dos Santos, Ana Carolina Andorinho, Eduardo Davidovich, Ivan Da Silva, Celso Hygino, Camila Pupe, Osvaldo Nascimento

brain abscess mimicking brain tumor in an immunocompetent patient. —Aiga Rakhesh,

Gobind Singh, Bakhtier Nurmukhamedov, Eufrosina Young

Hematomas in an HIV Patient with A Normal P5.135 Acute Streptococcal pneumoniae Platelet Count —Hisham Elkhider, Lindsay Meningoencephalitis Associated with a Malatesta, Shirley Ong, Mallory Smith, Atul Kothari Multitude of Vascular Complications —Sara Dawit, Marie Grill P5.119 HIV Related OpsoclonusMioclonus-Ataxia Syndrome As The Initial P5.136 A New Tick Palsy: Case of Neurological Presentation: A Case Report. — Guillian-Barre Syndrome Associated with Marlene Arbeu Reyes, Alicia Garmendia Rebolledo Lyme Disease —Mena Samaan, Anna Van P5.120 A Rare Case of Neuroborreliosis Venrooy, Claire Botros, Raghuveer Puttagunta Presenting with Intracranial Hypertension — P5.137 Myoclonic jerks as a unique Anvi Patel, Subhendu Rath, Sarah Meira Benchaya, clinical manifestation in a patient with Amre Nouh Murine Typhus —Ahmad Yusuf Solaiman, Hunaid Hasan, Neel Patel, Xiang Fang P5.121 Lemierre’s Syndrome Complicated by Epidural Abscess —Shoichi P5.138 A severe case of Shimamoto, John Liang, Shah Syed

P5.122 Tuberculous myopathy —Marco Julio Flores, Maria Alejandra Gonzalez Duarte

P5.123 Isolated abducens palsy from

neurological complications —Pedro Macedo,

brachial neuritis following Salmonella paratyphi bacteraemia —Aravindhan Baheerathan, Sabrina Kalam

P5.152 Viral encephalitis: What are the most common viruses in patient admitted to an University Hospital in the Tropics? —

Karylsa Torres Gomez, Valerie Wojna, Mariela Cuebas

P5.127 Starry Sky Image: Miliary

Neurotuberculomas without apparent Pulmonary Injury —Barbara Diniz, Yuri

metagenomic sequencing after 18 months of meningitis and spinal cord compromise —

GLOBAL HEALTH

Macedo, Joao Marcos Ferreira, Pedro Macedo, Karoline Medeiros, Guilherme Torezani, Leonardo Modenezi, Fabio Martins, Nathane Rezende, Camila Pupe, Osvaldo Nascimento

P5.128 Paroxysmal Singultus as the result of Brainstem Histoplasmosis —

Nicholas Metrus, Carlos Kamiya Matsuoka, Jennifer Johnson

P5.129 The Danger of Flying with

Acute Otitis Media, Which May Result in Gradenigo’s Syndrome —Lauren Spiegel, Lily Pham, Pitchaiah Mandava

P5.130 Vision impairment and

Woc-Colburn, Rod Foroozan, Jacob Mandel

P5.142 Neurosyphilis Mimicking

Disorders at an Outpatient Clinic in Addis Ababa, Ethiopia —Mehila Wuhib, Guta Zenebe,

P5.143 Cerebral Histoplasmosis: Relate of Case. —Nayme Monfredini, Andre Franzoi, Felipe Ibiapina dos Reis, Laura Parolin

P5.156 The Spectrum of Neurological James Johnston

P5.157 Head CT Findings at a Public

Hospital in Rural Haiti: Retrospective Analysis of 3614 CT Scans —Ioannis Valtis, Maggie Cochran, Louine Martineau, Bregenet Lamour, Jeffrey Mendel, Aaron Berkowitz

NEUROLOGICAL INFECTIONS: DIAGNOSTICS AND ANIMAL MODELS P5.158 Etiology and clinical profiles of pediatric encephalitis in Myanmar: A prospective study —Alyssa Smith, Robert P5.144 Brain Heme Oxygenase Antioxidant and Type I Interferon Responses Rudock, Cameron Crockett, Cho Thair, Ayemu Saan, Chaw Su Hlaing, Aye Mya Min Aye, Kyaw in Simian Immunodeficiency Virus (SIV)Linn, Soe Mar Infected Rhesus Macaques: A Model for Human Brain Responses to HIV —Maria Diaz P5.159 Perception of Functioning Ortiz, Rolando Garza, Fiorella Rossi, Ferzin Sethna, as a Potential Screening Modality for Michael R. Betts, Guido Silvestri, Dennis Kolson HIV-Associated Neurocognitive Disorder in Nigeria —Deidre Ammah, Jibreel Jumare, Walter P5.145 MRI Brain Abnormalities in Royal Acute Flaccid Myelitis: Characteristics and Differentiation from Acute Disseminated P5.160 Perinatal Case Fatality Rate Encephalomyelitis —Sarah Hopkins, Eliza in Cases of Congenital Zika Syndrome: A Gordon-Lipkin, Keith Van Haren, Jonathan Santoro, Cross-Sectional Study —Jessika Thais da Silva

P5.132 Longitudinally Extensive Spinal

P5.133 Atypical presentation of

Cytomegalovirus meningoencephalitis in a immunocompetent patient —André Luiz Guimarães Queiroz, Karlla Danielle Ferreira

P5.166 Pre-diagnostic branched

chain amino acids and the risk of ALS —

Kjetil Bjornevik, Eilis O’Reilly, Clary B. Clish, Larry Kolonel, Loic Le Marchand, Marjorie L. McCullough, Sabrina Paganoni, Michael Schwarzschild, Zhongli Zhang, JoAnn E. Manson, Alberto Ascherio

P5.167 Are ALS Motor Phenotypes

stochastic? —Adriano Chio, Fabrizio D’Ovidio,

Letizia Mazzini, Cristina Moglia, Umberto Manera, Enrica Bersano, Antonio Canosa, Gabriele Mora, Andrea Calvo

P5.168 Evaluating the completeness of

the National ALS Registry, United States — Wendy Kaye, Laurie Wagner, Ruoming Wu, Paul Mehta

P5.169 NA P5.170 NA P5.171 NA P5.172 NA COGNITIVE PHENOTYPES IN AGING AND DEMENTIA

P5.173 Machine-driven Classification of

Cognitive Profiles —Jordan Weiss, Eli Puterman, Aric Prather, David Rehkopf

P5.174 The Correlation Between

Reported Changes in Cognitive Functioning and Objective Performance on Cognitive Screening in English- and Spanish-speaking Patients —Reena Gottesman, Erica Weiss,

Ronda Facchini, Karen Valdesuso, Carlos Marquez, Jessica Zwerling

P5.175 Sleep Patterns In Patients At Risk For Alzheimer’s Disease May Be Related To Cognitive Performance and Amyloid Burden —Peter Yan, Ryan Thorpe, Olivia Scheyer, Aneela Rahman, Richard Isaacson

P5.148 HIV and Alzheimer’s Disease: Tat, P5.162 Telemedicine as a pivotal

Thinning Associated with Poorer Cognitive Performance Regardless of Amyloid Burden in Normal Elderly —Catherine Veilleux, Pénélope

Arachnoid Cyst Secondary to Chronic P5.147 Florence Foster Jenkins and Coccidioides immitis Meningitis —Tyler Koehn, Neurosyphilis in the 1940s —David Avila Jeffrey McClean, Anthony Frattalone

Rotem, Monique Breteler, Linda Valeri, David Sparrow, Marc Weisskopf

Maia, Sebastiana Jayne Alves Vidal, Tatyana Vidal Mendes, Maria Goretti Lins, Marcelo Rodrigues Zacarkim, Daniel Duarte Rolim, David M. Aronoff, Virus Leads to Neuroinvasive-Like Syndrome Angelle Desiree LaBeaud, Nilson Nogueira in Mice —Parminder Vig, Amber Paul, Dobrivoje Mendes Neto Stokic, A Leis, Fengwei Bai, Michael Garrett, P5.161 Developing a Child Neurology Mariper Lopez, Qingmei Shao Training Program in Cambodia: A Pilot

Laura Munoz-Arcos, Susan Matesanz, Carlos

P5.131 Atypical Presentation of Probable Pardo-Villamizar, Brenda Banwell Creutzfeldt-Jakob Disease Associated with P5.146 Chronic Exposure to West Nile Anti-Zic4 Antibody: Literature Review of Neuronal Antibodies in Creutzfeldt-Jakob Disease —Richard Salazar

Interaction with Uric Acid —Vy Nguyen, Ran

Beta-Amyloid, and Neprilysin —Tugba Ozturk, Jessica Howell, William Hu

P5.176 In-vivo mapping of

monoaminergic network disruption in Alzheimer’s disease: Implications for neuropsychiatric symptoms —Marco Bozzali,

Laura Serra, Marcello D’Amelio, Carlotta Di Domenico, Camillo Marra, Nicola Mercuri, Carlo Study —Brian Wong, Heng Nhoung, Pei Liu, Soma Caltagirone, Mara Cercignani Sahai-Srivastava P5.177 Alzheimer Signature of Cortical

part of rural neurology and migraine management. —Nawaz Hack, Claudio Osorio, Regine Reimers

Sévigny-Dupont, Marie-Maxime Lavallée, Maude Joanette, Jim Nikelski, Howard Chertkow, Sven Joubert, Kevin Whittingstall, Christian Bocti

AAN.com/view/AM18 165

Thursday

papilledema as the initial manifestation of neurosyphilis in a young immunocompetent patient —Doyle Yuan, Fabio Nascimento, Laila

Meya, Joseph DeRisi, Michael Wilson

Kuybu, Charoskhon Turabova, Catherine S. Chaudoir, Erik Burton

Horton, Shannon Graham, Reshma Punjani, Grete Wilt, Wendy Kaye, Kimberly Maginnis, Lauren Webb, Judy Richman, Richard Bedlack, Edward Tessaro, Paul Mehta

P5.165 Association of Lead Exposure P5.153 Candida dubliniensis identified by on Cognitive Decline due to Mediation and

Cardenas Castillo, Lakshmi Leishangthem, Saman Zafar, Sridhara Yaddanapudi, Aparna Prabhu

Sarcoidosis with CNS Involvement. —Okkes

Soma Sahai-Srivastava

NEUROEPIDEMIOLOGY: MOTOR profile and Validation of Thwaites Diagnostic NEURON DISEASE, COGNITIVE Criteria. —Sankar Gorthi, Reshma Susan, Aravind IMPAIRMENT, SLEEP II Prabhu, Vijay Chandran P5.164 A Spatial Analysis of P5.151 Evaluation of Adenosine Deaminase Amyotrophic Lateral Sclerosis (ALS) Cases in the United States and their Proximity to activity in CSF for diagnosis of Tuberculous Multidisciplinary ALS Clinics, 2013 —D. Kevin Meningitis —Abul Shoab, Mostafa Hosen

sinusitis related septic dural venous thrombosis P5.139 Optic Neuritis and Hemiparesis in P5.154 The International HIV Dementia invading Dorello’s canal. —Aparna Vaddiparti, Ninad Desai, Neil Datta, Stephen Conway a Previously Healthy Young Woman —Dulanji Scale as a screening tool for HAND in Uganda —Maria Molinaro, Deanna Saylor, Kuruppu, G Giuliari, Devin Mackay P5.124 Mysterious Meningitis: Recurrent Gertrude Nakigozi, Noeline Nakasujja, Kevin P5.140 A Rare Case of Creutzfeldtchemical meningitis due to ruptured Robertson, Ronald Gray, Maria Wawer, Ned Sacktor epidermoid cyst —Bhavesh Trikamji, Mark Morrow Jakob Disease with Elevated Anti-Thyroid Antibodies —Subhendu Rath, Yan Hou, Ilavarasy P5.155 Etiologies and Outcomes among P5.125 Streptococcus Pneumoniae Maran, Lawrence Bluth Non-Traumatic Spinal Cord Injuries in Uganda — Meningitis Presenting as Pseudo-subarachnoid Hemorrhage —Jared Yee, Laura Nist, Bryan Tsao, P5.141 An Intriguing Case of Unresolved Kisekka Musubire, David Boulware, Ana-Claire Meyer, Akshaya Ramesh, Debarko Banerji, David Post-Operative Pneumocephalus —Ylec Vincent Truong

P5.126 A rare case of parainfectious

Neurology Education and Engagement During Short-Term Global Health Initiatives —Brian Wong, Heng Nhoung, Pei Liu,

P5.150 Tubercular Meningitis—Clinical

Cytomegalovirus (CMV) meningoencephalitis Akshaya Ramesh, Debarko Banerji, Lilian Khan, Jonathan Blum, Gary Green, Joseph DeRisi, in an otherwise healthy immunocompetent Michael Wilson 2 month old male. —Whitney Gervelis, Jade Davis, Saurabh Singhal, John Christenson, Susan Conrad

P5.163 Using Social Media to Enhance

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION V P5.178 The relationship between

Mini-Mental State Examination (MMSE) & Alzheimer’s Disease Assessment Scalecognitive subscale (ADAS-cog) using real world data in US & Europe —Rezaul Khandker, Christopher Black, James Pike, Joseph Husbands, Baishali Ambegaonkar, Eddie Jones

P5.179 Picture Memory Impairment

Screen: Montefiore-Einstein Center for the Aging Brain Experience —Reena Gottesman,

Jessica Zwerling, Rubina Malik, Erica Weiss, Joe Verghese

P5.180 Identifying Cognitive Subtypes

of Mild-to-Moderate Alzheimer’s Disease Using the National Alzheimer’s Coordinating Center Uniform Dataset Neuropsychological Test Battery —Yuqi Qiu, Diane Jacobs, Karen Messer, David Salmon, Howard Feldman

P5.181 Measuring Sentence Production in Primary Progressive Aphasia —Elisa Canu,

Federica Agosta, Francesca imperiale, Pilar Maria Ferraro, Giuseppe Magnani, Giancarlo Comi, Stefano Cappa, Massimo Filippi

Disease Neuroimaging Initiative database — P5.204 Twelve versus twenty four Maria Julieta Russo, Gabriela Cohen, Jorge hour bed rest after acute ischemic stroke Campos, Ricardo Allegri reperfusion therapy —Brian Silver, Tariq Hamid, Mario Di Napoli, Reza Behrouz, Muhib Khan, P5.192 Trajectory of Memory Decline Gustavo Saposnik, Nils Henninger, Jo-Ann Sarafin, Differs in Hippocampal Sclerosis and Susan Martin, Shawna Cutting, Majaz Moonis, Alzheimer’s Disease —Denis Smirnov, Douglas Richard Goddeau, Adalia Jun-O’Connell, Ali Saad, Galasko, Lawrence Hansen, Steven Edland, David Salmon

P5.193 Simulation study on differences in Alzheimer Disease (AD) Cooperative Study-Preclinical Alzheimer Cognitive Composite (ADCS-PACC) Based on Longterm Clinical Outcomes —Anuraag Kansal, Sean Stern, Alexander Keenan

BEHAVIORAL AND COGNITIVE NEUROLOGY: OTHER II

Shadi Yaghi, Marcey Osgood, Raphael Carandang, Susanne Muehlschlegel, Wiley Hall, Corey Fehnel, Linda Wendell, Nicholas Potter, Bradford Thompson, James Gilchrist, Bruce Barton

Rossi, Ramon Rodriguez

P5.195 Cholinergic modulation targeting

Thursday

Wenyaw Chan, Eveleen Darby

Balasubramanian Samivel, Shanmuga Sundaram Natesan, Manickavasagam Janarthnam, Lakshmi Ranganathan

P5.189 Line Bisection and Trisection,

P5.202 Combined Antagonism of

Age and Accuracy —Zared Schwartz, John

Williamson, Damon Lamb, Dana Szeles, Kenneth Heilman

P5.190 Capturing Latency in Cognitive Symptoms for People with Significant Memory Concern —Ali Tafazzoli, Anuraag

Kansal, Josh Weng, Mira Krotneva, Jack Ishak

P5.191 Discriminability index as a

possible measure of Alzheimer’s disease progression validated using the Alzheimer’s

166 2018 AAN Annual Meeting

Vasopressin Receptor Subtypes with Conivaptan Attenuates Cerebral Edema Following Ischemic Stroke —Saeed Ansari,

Rashi Krishnan, Reza Bavarsad Shahripour, Payam Moein, Ali Kerro, Fnu Abhi Pandhi, Michael Waters, Vishunmurthy Hedna

Mannava, Sebastian Koch, Priyank Khandelwal, Dileep Yavagal, Amer Malik

P5.218 Large Artery Atherosclerosis

P5.206 Neurology Inpatient Services

P5.219 Transthyretin levels negatively

Saves Lives and Money —Ajal Dave, Kendra

Ischemic Stroke Diagnostic Evaluation and Secondary Prevention at Acute Stroke Ready Hospitals —Andrew Zhang, Mohammed Alkuwaiti, Jessica Jarnot, Sarah Engkjer, Angela Heyer, Carah Harper, Amy Reichert, David Anderson, Christopher Streib

P5.208 Adherence to the Clinical Practice Guidelines of the Stroke Society of the Philippines in the Management of Ischemic Stroke in young adults admitted in 3 tertiary hospitals in Bacolod City, Philippines from May to October 2010 —Beverly Baliguas

P5.209 Comparison of Length of

Stay and Discharge Disposition between Anticoagulants for Secondary Stroke Prevention in Atrial Fibrillation —Sanskriti

Mishra, Arpita Hazra, Kinsuk Chauhan, Michele Gribko, Rohan Arora

correlate with carotid carotid intima-media thickness and beta-stiffness index. —

Wojciech Ambrosius, Slawomir Michalak, Justyna Rosinska, Maria Lukasik, Wojciech Kozubski

P5.220 Carotid artery stenosis is

uncommon as a cause of stroke in Saudi population —Misealreem Shaheen, Areej

AlBelali, Muneera AlSaqabi, Raghad AlAskar, Raghad AlKanhal, Raghad AlTurki, Altaf Khan, Ismail Khatri

P5.221 Extracranial and Intracranial NonStenotic Carotid Atherosclerotic Plaques in ESUS Patients —Rajasumi Rajalingam, Shirin Jalini, Aleksandra Pikula

P5.222 Clinico-vascular Correlation In Carotid Stroke —Pratheep Kumar S, Lakshmi

Ranganathan, Balasubramanian Samivel, Thamilpavai Natarajan, Guhan Ramamurthy, Anto Nazarene, Christianne Sandhya Ravi Chandar, Moses Moorthy

P5.223 Prevalence and Outcomes

of Intracranial Hemodynamic Steal in Symptomatic Internal Carotid Artery Oral Anticoagulants after Cardioembolic Occlusions —Mukesh Kumar, Dheeraj Khurana, Stroke or TIA is Safe and Effective —Win Toe, Chirag Ahuja, N Khandelwal, Baljinder Singh,

P5.210 Early Initiation of Direct-acting Jennifer Trevino, Mark Bank

Manju Mohanty

P5.211 Prevalence of Microembolic

P5.224 Uric Acid Predicts Carotid

Signals in Patients with Cerebral Ischemic Events —Arth Srivastava, Jessica Lee, Richard Bernstein, Farzaneh Sorond

P5.212 Early Neurological Deterioration in Patients with Large Vessel Occlusion —

Plaque Stability, Cerebrovascular Events, Cardiovascular Events and Death in Patients Undergoing Carotid Endarterectomy — Valentina Nardi, Megha Prasad Frederick Meyer, Lilach O. Lerman, Amir Lerman

Hazem Shoirah, Amy Metry, Alexander Chartrain, Kambiz Nael, Tomoyoshi Shigematsu, Christopher Kellner, Thomas Oxley, Johanna Fifi, Reade De Leacy, J Mocco

P5.225 High-Sensitive C-Reactive Protein

P5.213 Optimal Systolic Blood Pressure

Prasad, Frederick Meyer, Lilach O. Lerman, Amir Lerman

P5.201 Prognostic Markers and Outcome Shareena Rahman, Gary Sherill, Christa Swisher

Progression Rate Used to Predict PostDiagnostic Change on Common Alzheimer’s Disease Outcome Measures —Valory Pavlik,

Recurrent Middle Cerebral Artery Acute Ischemic Strokes in a Young Patient —Sishir

Jun Ni, Ming-Li Li, Zheng-Yu Jin, Gao-Lang Gong, Shu-Yang Zhang, Li-Ying Cui, Yi-Cheng Zhu

Michael Malek-Ahmadi, Kathy O’Connor, Sharon Schofield, David Coon

P5.188 Validation of a Pre-Diagnostic

P5.217 Carotid Artery Web Causing

Saposnik, Rosemary Martino, Jimming Fang, Moira Kapral

P5.187 Trajectory and Variability

of Decompressive Hemicraniectomy in Malignant Middle Cerebral Artery Infarction —Kaushik Gowthaman,

Christopher Calder, Asad Ikram, Maryam Zulfiqar, Puja Mathur, Dinesh Jillella, Saif Bushnaq, Tobias Kulik, Joel Nunez Gonzalez, Atif Zafar

Modifies the Relationship between Kidney Function and Cerebral Small Vessel Disease —Dong-Hui Ao, Fei-Fei Zhai, Lixin Zhou,

Stubblefield, Trisha Cooper, Kiersten Espaillat, Heather Koons, Peter Konrad, John Fang, Howard Kirshner, Thomas Davis

Characterization of the Montreal Cognitive Assessment in Older Adults —Edward Zamrini, INPATIENT STROKE CARE

Database —Piotr Bzdyra, Fares Qeadan,

direct enteral tube placement and outcomes after acute stroke —Raed Joundi, Gustavo

P5.205 Association between timing of

P5.194 Neuropsychology, Criminalization Cagniart, Matthew Holtkamp in Frontotemporal Syndromes and Impaired P5.207 Variability in Inpatient Acute Sense of Agency —Michael Hoffmann, Fabian

medial prefrontal cortex leads to behavior P5.182 Effects of Age on the Spanish English deficit in interval timing task —Qiang Zhang, Neuropsychological Assessment Scale in Normal Benjamin De Corte, Dennis Jung, YoungCho Kim, Elderly and Autosomal Dominant Alzheimer’s Joel Geerling, Nandakumar Narayanan disease —John Ringman, Luis Medina, Helena Chui, P5.196 Depression, Fatigue, and Their Freddi Segal-Gidan Association with Post-Stroke Disability — P5.183 Performance on the Cognitive Lucy Tan, Jeremy Weedon, Cindy Tsui, Elizabeth Abilities Screening Instrument (CASI) among McCuaig, Nadege Gilles, Clotilde Balucani, Jonathan Singer, Susan Law, Steven Levine Spanish and English Speakers at-risk for Autosomal Dominant Alzheimer’s Disease — P5.197 Cognitive Change in Cognitively Lina M. D’Orazio, Luis Medina, John Ringman Intact Amyotrophic Lateral Sclerosis: Reliable Change Index in a population-based P5.184 Cognitive Functions After cohort. —Tom Burke, Marta Pinto Grau, Katie Serial CSF Tap Test In Probable and Lonergan, Peter Bede, Orla Hardiman, Niall Pender Possible Idiopathic Normal Pressure Hydrocephalus. —Samanta Rocha, Pedro P5.198 Longitudinal Predictors of Kowacs, Ricardo Krause, Luciana Pizzani, Ricardo Caregiver Burden in Amyotrophic Lateral Ramina, Helio Afonso Teive Sclerosis: A population-based cohort of P5.185 Visual Association Test: A brief cognitively intact patient-caregiver dyads. — Tom Burke, Orla Hardiman, Marta Pinto Grau, Katie cognitive tool and low cost alternative Lonergan, Katy Tobin, Anthony Staines, Miriam to biomarkers in predicting progression Galvin, Niall Pender of amnestic mild cognitive impairment to Alzheimer’s disease —Ratnavalli Ellajosyula, P5.199 Opportunities for Improved EndJwala Narayanan of-Life Care in Dementia with Lewy Bodies: Survey Results —Melissa Armstrong, Pamela P5.186 The Cortical Lesion Pattern Of Corsentino, Angela Taylor Dysexecutive Syndrome in MEMENTO cohort —Daniela Andriuta, Martine Roussel, P5.200 Protocolizing Work-up for Normal Carole Dufouil, Genevieve Chene, Clara Fischer, Pressure Hydrocephalus Improves Evaluation Chabha Azouani, Marie Chupin, Bruno Dubois, and Outcomes —Lealani Acosta, Kassandra Bruno Vellas, Florence Pasquier, Francois Tison, Frederic Blanc, Olivier Godefroy

Thursday, April 26 11:30 a.m.–7:00 p.m.

Goals after Successful Mechanical Thrombectomy for Patients with Large Vessel Occlusion Strokes —Ovais Inamullah, CEREBROVASCULAR DISEASE AND INTERVENTIONAL NEUROLOGY: LARGE ARTERY DISEASE: CAROTID, BASILAR, VERTEBRAL, INTRACRANIAL

Predicts Cerebrovascular and Cardiovascular Events in Patients Undergoing Carotid Endarterectomy —Valentina Nardi, Megha

P5.226 Non Invasive Imaging of

Vulnerable Plaques: An Institutional Experience —Lakshmi Ranganathan, Pratheep Kumar S, Thamilpavai Natarajan, Babu Peter Sathyanathan, K Kanmani, Guhan Ramamurthy

P5.227 Geometric characteristics of

Middle Cerebral Artery Atherosclerosis and Clinical Stroke: An Observational Study — Yannan Yu, Ming-Li Li, Yuyuan Xu, Harry Trieu,

P5.214 Power Motion Mode Transcranial Shan Gao, Feng Feng, David Liebeskind, Weihai Xu Doppler examination in Posterior Circulation P5.228 Enlarged Perivascular Spaces Strokes —Sivakumar M.R., Akshay Deepak, Deepak Arjundas, Shravan Sivakumar

P5.215 Utility of transcranial

in the Basal Ganglia are Independently Associated with Intracranial Atherosclerosis in the Elderly. —Victor Del Brutto, Robertino

Doppler(TCD) in the treatment and diagnosis Mera, Oscar Del Brutto Of Vertebral Basilar Insufficiency(VBI) — P5.203 Does 24-hour CT Scan Post P5.229 Factors Associated with ShortRichard Serano Thrombolysis Change Management in Acute term Outcome in Patients with Symptomatic Ischemic Stroke Patients? —Syed Ali, Sukumar P5.216 Outcome of Basilar Artery Severe Middle Cerebral Artery Stem Occlusion in Urban and Rural Centers: Gundapaneni, Krishna Nalleballe, Sanjeeva Stenosis —Liming Shu, Hongbin Chen, Wenjin Analysis of a National Cross-Sectional Onteddu Shang, Jiahui Liang, Su Xiao, Zhuhao Li, Hua Hong

P5.230 Stroke recurrence in symptomatic P5.244 Creation of a Dedicated

intracranial atherosclerotic disease in Neurovascular Discharge Follow-Up Clinic in Southern Brazil —Marcos Lange, Gustavo Ribas, Assessing Its Effect on 30 Day Readmission Valeria Scavasine, Francisco Branco Germiniani, Rates: A Quality Improvement Initiative — Renata Ducci, Danielle Mendes, Viviane Zetola, Norberto Cabral, Tatjana Rundek

Elizabeth Aradine, John Legge, Mariko Hanson, Matthew Baer, Ashley Snowden, R.N., Melissa Stacie Stevens, Ph.D., F.N.P., R.N., Kristina P5.231 The Association between Arterial Byrne, Gooch, R.N., Michael Oliver, R.N., Warren Felton, Tortuosity and Ischemic Stroke in Intracranial Daniel Falcao Atherosclerotic Disease —Dong-Ick Shin, Hoseong Han, Yeon-Su Lee, Jong-Keol Lee, Hyungsuk P5.245 Quality Improvement: Improving Lee Primary Care Follow-Up for Stroke/TIA —Muhammad Salim Khan, Gamaleldin P5.232 Extracranial carotid atherosclerotic Patients Osman, Abhimanyu Mahajan, Abdullah disease in context of middle cerebral artery Alshammaa, Mohammed Kananeh, Reema Butt, stenosis —Nada Elsaid, Ashraf El-Mitwalli, Tobias Walbert Mohammad Farrag, Mohamed Abdelsalam

P5.233 Vertebral Artery Origin Stent

Placement Using the Dual Lumen QureshiJiao Guidecatheter —Adnan Qureshi, Yabing Wang, Mohammad-Rauf Afzal, Liqun Jiao

STROKE CLINIC

P5.246 Predictors of Non-adherence to

P5.257 NA P5.258 NA ANTI-EPILEPTIC DRUGS

P5.259 Racial Influence on Antiepileptic Drug levels —Advait Mahulikar, Kalyan

Yarraguntla, Aashit Shah, Navid Seraji-Bozorgzad, Maysaa Basha

P5.260 Tolerability and efficacy of

adjunctive lacosamide in children and adolescents with focal seizures in context of presence or absence of sodium-channel blocking AEDs: Post-hoc analysis of a randomized, double-blind, placebo-controlled trial —Ingrid Scheffer, Ali Bozorg, Tony Daniels, Ying Zhang, Nancy Yuen, Svetlana Dimova

Post-Stroke Hospitalization Clinic FollowUp —Carolina Temple, Melissa Gazi, Toby Gropen, P5.261 Hallucinations as Adverse Event Michael Lyerly from Lacosamide: Three Case Series —Alok

P5.247 The association of office-based

provider visits with emergency department utilization among publicly insured stroke survivors. —Kinfe Bishu, Bruce Ovbiagele, Alain

Patel, James Noto, Dena Little, Melissa Carran

P5.262 Safety, Tolerability,

P5.270 Analysis of Psychiatric

Treatment-Emergent Adverse Events (TEAEs) in Two Phase III Conversion-toEslicarbazepine Acetate (ESL) Monotherapy Trials —Cynthia Harden, Jay Salpekar, David

Loring, Todd Grinnell, David Cantu, Hailong Cheng, David Blum

P5.271 Sodium and Thyroid Hormone

Levels During Phase III Trials of Adjunctive Eslicarbazepine Acetate (ESL), According to Concomitant Antiepileptic Drug (AED) Use —Eugen Trinka, Meriem Bensalem Owen,

Todd Grinnell, David Cantu, Joana Graça, Joana Moreira, Hailong Cheng, David Blum

P5.272 Incidence of Treatment-Emergent Adverse Events (TEAEs) According to Baseline Antiepileptic Drug (AED) Use: A Pooled Analysis of Data from Phase II/III Trials of Adjunctive Eslicarbazepine Acetate (ESL) in Children —Elaine Wirrell, Tobias Loddenkemper, Joan Conry, Todd Grinnell, David

Papapetropoulos

AAN.com/view/AM18 167

Thursday

Cantu, Helena Gama, Francisco Rocha, Yan Li, Pharmacokinetics and Pharmacodynamics P5.234 Electronic Decision Support for of Multiple Ascending Doses of TAK-935 in David Blum Improvement of Contemporary Therapy Lekoubou Looti Healthy Subjects —Shining Wang, Grace Cheng, P5.273 An Analysis of the Accuracy for Stroke prevention (EDICTS) —Seemant Tolga Uz, John Affinito and Utility of Automated Kit (AK) Assays P5.248 “Inflammatory Cerebral Chaturvedi, Adam Kelly, Shyam Prabhakaran, P5.263 Evaluation of pharmacodynamic in Quantifying Thyroid Hormone Levels in Gustavo Saposnik, Lilly Lee, Amer Malik, Christine Amyloid Angiopathy: Approach to Clinical Patients Taking Eslicarbazepine Acetate Diagnosis” —Grace Crotty, Kathleen McKee, effects of cholesterol 24-hydroxylase Boerman, Gayle Serlin Altaf Saadi, Andrew Young, Isaac H Solomon, inhibitor TAK-935 and its target engagement (ESL) —John Eddy, Todd Grinnell, Yan Li, David P5.235 Cerebral Microbleeds in a Stroke Jennifer Lyons Cantu, David Blum in animals —Tatsuki Koike, Maki Miyamoto, Prevention Clinic —A-Hyun Cho, Krunal Shah, Toshiya Nishi, Eiji Sunahara, Shigeo Hasegawa, P5.274 Evaluation of the Impact of David Floriolli, Annlia Paganini-Hill, Mark Fisher PRE-HOSPITAL, TELESTROKE, AND Sayuri Watanabe, Shuhei Ikeda, Tsuyoshi Potential Missing Seizure-diary Data on Ishii, Shinichi Kondo, Junzo Takahashi, Hideki ED-BASED STROKE CARE III P5.236 Tracking the Development of Primary Efficacy Outcomes in Phase III Hirabayashi, David Alagille, Olivier Barret, Gilles Risk Factors for Cerebrovascular Disease Studies of Adjunctive Eslicarbazepine P5.249 Predictors of good functional Tamagnan, Takanobu Kuroita After Pregnancy with Preeclampsia —Daniela outcome in patients treated with intravenous Acetate (ESL) for Partial-onset (Focal) Diego, Adriana Wong, Madeline Lederer, Desiree P5.264 Inhibition of Cholesterol Seizures —Hailong Cheng, Robert Tosiello, David thrombolysis via telestroke. —Tarun Girotra, Nguyen, Usha Verma, Seemant Chaturvedi 24-hydroxylase is a Novel Pharmacological Blum Shaun Ajinkya, Ellen Debenham, Christine Strategy for Epilepsy Treatment —Toshiya Holmstedt, Chirantan Banerjee P5.237 Does maternal age impact P5.275 Determination of the Minimal Nishi, Shinji Fujimoto, Shigeo Hasegawa, Sayuri development of vascular risk factors Clinically Important Difference (MCID) in P5.250 Observational study of a regional Watanabe, Shinichi Kondo following preeclampsia? —Desiree Nguyen, Seizure Frequency in Three Phase III Trials of inter-hospital telestroke network in the Adriana J. Wong, Daniela S. Diego, Madeline H. P5.265 Clinical Trial Simulations Adjunctive Eslicarbazepine Acetate (ESL) for thrombectomy era —Ricardo Varela, Gustavo Lederer, Seemant Chaturvedi Partial-onset (Focal) Seizures (POS) —Hailong Santo, Egidio Machado, Abilio Goncalves, Renato for Paediatric Dose Selection Using a Pharmacokinetic/Enzyme-Occupancy/ Cheng, Robert Tosiello, David Blum Saraiva, Dulcidia Sa, Ana Gomes, Nuno Costa, P5.238 Use of Vascular Preventative Pharmacodynamic Model of TAK-935, a Vítor Branco, Eugenia Andre, Joao SargentoMedications in Patients with OSA —Sarah P5.276 An Analysis of the Efficacy and Freitas, Antonio Gandra de Almeida, Regina Cholesterol 24S-hydroxylase Inhibitor — Marmol, Yee Cheng, Seemant Chaturvedi Pimentel, Fernando Gomes da Costa, Luis Cunha Thomas Wagner, Asif Paker, Mahnaz Asgharnejad, Tolerability of Eslicarbazepine Acetate (ESL) by Study Period in Two Phase III ConversionP5.239 Generic Clopidogrel: Has Axel Facius, Majid Vakilynejad P5.251 Demographics and Outcomes to-ESL Monotherapy Trials —Steve Chung, Substitution for Brand Name Plavix® Been P5.266 A Phase 1b/2a Study to Examine Amir Arain, Todd Grinnell, David Cantu, Hailong Between Telestroke and Routine Hospital Safe and Effective? —Francis Gengo, Erica Transfers in Acute Ischemic Stroke —Aashrai the Safety, Tolerability, Pharmacokinetics, Cheng, David Blum Westphal, Traci Aladeen, Kaitlin McCadden, Gudlavalleti, Sanam Anwer, Jennifer Schleier, and Pharmacodynamics of TAK-935 Michelle Rainka, Vernice Bates P5.277 Analysis of Cognitive Adverse Joshua Onyan, Michelle Vallelunga, Rahul as an Adjunctive Therapy in Subjects Events in Two Phase III Conversion-toP5.240 Antiplatelet Therapy as Primary Chandak, Julius Latorre with Developmental and/or Epileptic Eslicarbazepine Acetate (ESL) Monotherapy Prevention for Patients with Type 2 Diabetes Encephalopathies —Mahnaz Asgharnejad, Asif P5.252 Single-Center Retrospective Trials —Jay Salpekar, Cynthia Harden, David Mellitus: A Population-Based Study in Paker, Rengyi Xu, Deborah Lee Loring, Todd Grinnell, David Cantu, JungAh Jung, Taiwan —Yen-chung Chen, Yi-Chun Yeh, Yen-Yu Comparison of Prehospital Large Vessel Occlusion Tools —David Ermak, Muhammad David Blum P5.267 Safety, Tolerability, Chen Niazi, Kevin Cockroft, Raymond Reichwein Pharmacokinetics and Pharmacodynamics P5.278 Mechanism of Action of P5.241 TIA-Minor Stroke Outpatient of Single Ascending Doses of TAK-935 in Cenobamate: Preferential Inhibition of Pathway-Safety Implementation Study (TOP- P5.253 Assessing Accuracy in Nurse Healthy Subjects —Grace Cheng, Shining Wang, the Persistent Sodium Current —Michiko SAILS) —Lauren Dunn, Deanna Saylor, Stephanie Activated Stroke Codes in the Emergency Tolga Uz, John Affinito Nakamura, Hyewon Shin, Il-Sung Jang Figueroa, David Yousem, Mustapha Saheed, Victor Department —Kristin Miller, Rachel Forman, Deborah Lynch, Sarah Song, Rima Dafer, Nicholas P5.268 Analysis of Sodium Levels Urrutia P5.279 Cenobamate (YKP3089) in Osteraas, Laurel Cherian, James Conners and Hyponatremia Events in Trials of Photosensitive Patients: Proof of Principle — P5.242 Expansion of the Rapid-Access Eslicarbazepine Acetate (ESL) in Pediatric P5.254 Effective Endovascular Routing Dorothee Kasteleijn, Bree DiVentura, John Pollard, Transient Ischemic Attack (TIA) Clinic Patients (Aged 4-17 years) —Inna Vaisleib, within Stroke Systems of Care —Angela Gregory Krauss, Jacqueline French Referrals from Emergency Department Michael Duchowny, Todd Grinnell, David Cantu, Hawkins, Harold Morris, Karin Olds to Primary Care: Improving outcomes and P5.280 Pharmacokinetics of Cenobamate Mariana Vieira, Fabio Ikedo, Yan Li, David Blum reducing costs —Sarah Hermanson, Nirali Vora, P5.255 Stroke Related Education To (YKP3089): Results From Single and P5.269 Safety and Tolerability of Nancy Isenberg Emergency Department (ED) Staff—An Multiple Oral Rising-Dose Studies in Healthy Adjunctive Eslicarbazepine Acetate (ESL) Acute Stroke Care Quality Improvement Subjects —Laurent Vernillet, Marc Kamin P5.243 Use of a Transient Ischemic in Pediatric Patients (Aged 4-17 Years) with Attack (TIA) center decreased length of stay Initiative —Rohit Bhatia, Inder Puri, Deepti P5.281 CX-8998, a potent, selective Partial-Onset (Focal) Seizures (POS) —Mark Vibha, Mamta Singh, Padma Hadakasira, Praveen for ischemic stroke and TIA patients in a Mintz, Jesus Pina-Garza, Steven Wolf, Patricia T-type calcium channel antagonist Aggarwal, Kameshwar Prasad primary stroke center —Claire Carrazco, Tamara McGoldrick, Todd Grinnell, David Cantu, Raquel dose-dependently suppresses seizures Goodman, Richard Libman, Paul Wright, Jeffrey P5.256 How experts diagnose TIA: A Costa, Joana Moreira, Yan Li, Sergiusz Jozwiak, in the WAG/Rij genetic model of Katz systematic review —Tess Fitzpatrick, Sophia David Blum absence epilepsy. —Margaret Lee, Spiridon Gocan, Chu Qi Wang, Aline Bourgoin, Dariush Dowlatshahi, Grant Stotts, Michel Shamy

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION V

P5.282 A Phase 2a Study of CX-8998, an HISTORY OF NEUROLOGY Oral, Potent and Selective T-Type Calcium Modulator in Adolescents and Young Adults with Absence Epilepsy: Rationale for population and dose selection —Spiridon Papapetropoulos, Margaret Lee, Stacey Boyer, Mark Versavel

P5.283 Anti-Epileptic Monotherapy for

Elderly Patients with New-Onset Seizures, a Meta-Analysis —Bahar Beaver, Jake Torrison, Bichum Ouyang, Aditya Voruganti, Rebecca O’Dwyer

CLINICAL EPILEPSY IV

P5.284 Effect of Endovascular Treatment On Post Stroke Seizures. —Jaysingh Singh, Wolfgang Leesch, Lawrence leemis

Thursday, April 26 11:30 a.m.–7:00 p.m. P5.314 Between Weir Mitchell

and Autoimmunity: Donato AlarcónP5.295 History of Key Developments that Segovia’s Contribution to the Study of Led to Nerve Conduction Studies in Human Erythromelalgia —Guillermo Delgado-Garcia, Subjects —Edward Fine, Emily Langan Bruno Vidal

Parikh, Vineet Punia, Pravin George, Stephen Hantus

P5.287 Refractory Epilepsy Screening

Tool for Lennox-Gastaut Syndrome (RESTLGS): Improving the Detection of LGS in the Clinic —Steven Wolf, Danielle Boyce, David Tworek, Kathryn Davis, Heather Gatens, George Lai, Patricia McGoldrick, Bethany Thomas, Jesus Pina-Garza

P5.288 Clobazam Effect on Seizure

Control and Quality of life in children with refractory epilepsy —Leon Weinstock, Nitin

Agarwal, Joy Parrish, Zaheerud Cheema, Osman Farooq

P5.289 Efficacy and Tolerability of

Intravenous Levetiracetam as Monotherapy in Acute Seizure Management in Children —

Lessons from the past and challenges for the Application in Neurology and for Prevention future —Manon Auffret, Sophie Drapier, Marc of Burnout. —Sankar Bandyopadhyay Verin

P5.316 Neurophysiological Dreams P5.297 Kabbalah and the Frontal Lobe — in Georges Perec’s La Boutique obscure Jeffrey Kornitzer, Michael Akerman

(1973) —Guillermo Delgado-Garcia, Carolina

P5.298 The Life of Solomon Carter Fuller: Rodríguez-Návarez, Teresa Corona Vazquez, Bruno An African American Pioneer in Neurology — Vidal Ogechukwu Nwanegwo, Chantale Branson

P5.299 Brief History of Electrical Cortical Stimulation: A Journey in time from Volta to Penfield —Cigdem Isitan, Christopher Benjamin,

Islamic Scholars to the Progress of Neuroscience; Headache —Ola Alshaqi, Abdul Rahman Alchaki, Janaki Patel, Nizar Souayah

P5.302 The Influence of Neurology

and Neurologists in the Women’s Suffrage Movement —Eric Farbman

P5.303 Babinski’s Mexican Lost Legacy:

GENERAL NEUROLOGY

Carla Bolaño, Guido Vazquez, Blas Couto, Alejandro Thomson, Carlos Santiago Claverie, Alfredo Thomson

P5.304 Milestones of spinal imaging: Myelography in the pre-MRI era —Peter

Bede, Eoin Finegan, Rangariroyashe Chipika, Orla Hardiman

Incidence of Fatal Crashes: A Responsibility

Kazamel

P5.306 Enjolras Vampré: A pioneer of Clinical Neurology in South America — Roberto Prado, Philippe Macedo

P5.290 Mapping Musical Automatism:

nowadays little read essay of James P. of Hoxton Square, Shoreditch, London. —Ylmar

P5.307 Parkinsonian Advices or on a

Further insights from Epileptic HighFrequency Oscillations Analysis —James Rini, Correa Neto, Catarina Correa Juan Ochoa P5.308 Goodwyn’s Diving Reflex —Jose P5.291 Epilepsy After Stroke —Bouattour Vega Nadia, Farhat Nouha, Hadjkacem Hanen, Hdiji Olfa, P5.309 Jean-Martin Charcot’s influence Sakka Salma, Mariem Damak, Mhiri Chokri on Sigmund Freud’s career —Livia Oliveira, Helio Afonso Teive, Paula Marques, Francisco P5.292 NA Germiniani, Luciano De Paola P5.293 NA P5.310 Neurological References in Ernst P5.294 NA Cassirer’s The Phenomenology of Knowledge (1929) —Guillermo Delgado-Garcia, Carolina

Thursday

Rodríguez-Návarez, Teresa Corona Vazquez, Bruno Vidal

P5.311 Requiem For A Neurologist: The Funeral Rites Of Jean-Martin Charcot. —

for Carpal Tunnel Syndrome —Christopher Hawkes

P5.320 The role of Vitamin D in

treatment of Chronic Insomnia with Melatonin —Greta Sahakyan

Krishnamoorthy Kuppusamy, Sarala Govindarajan, Balasubramanian Samivel, Lakshmi Ranganathan, Shunmugasundharam kanthimathinathan, Thamilpavai Natarajan, Harish Jayakumar, Sindhuja Lakshminarasimhan

New Entity —Balasubramanian Samivel,

Georges Perec’s Cantatrix sopranica L. (1974) —Guillermo Delgado-Garcia, Carolina

Rodríguez-Návarez, Teresa Corona Vazquez, Bruno Vidal

P5.331 Rationale and Design for

a Multicenter, Double-blind, Placebo-

Safety of H.P. Acthar® Gel in the Treatment of Subjects with Amyotrophic Lateral Sclerosis —Susan Vanmeter, Patrice Becker, Enxu Zhao, Todd Levine

P5.332 WITHDRAWN P5.333 Double Dorsiflexion Sign (DDFS) tricks in the neurologist’s bag for assessing non-physiological weakness? —Reema Butt, Kavit Shah, Daniel Miller, Lonni Schultz

P5.334 Time Course of Onset of Phantom Pain in Male and Female Amputees —Talal

Aboud, Aman Deep, Jen Pryweller, Paul Pasquina, Jack Tsao

P5.335 Comparison of Metabolic

Profiles of Newer Second Generation Antipsychotics —Traci Aladeen, Emily

Lewandowski, Michelle Rainka, Jonathan Beecher, Francis Gengo, Horacio Capote

P5.336 Massive Ballooning of redundant myelin sheaths in DS —Julie Korenberg

P5.337 L-Methylfolate Calcium in Krishnamoorthy Kuppusamy, Lakshmi Adolescents and Children: A Retrospective Ranganathan, Harish Jayakumar, Shaik Fazale Ilahi, Bhanu Kesavamurthy, Chandramouleeswaran Analysis —Michelle Rainka, Traci Aladeen, Jacqueline Meaney, Francis Gengo, Horacio Venkatraman, Sarala Govindarajan Capote P5.323 Brain Plasticity after Spinal Cord

P5.338 NA Decompression in Cervical Spondylotic Myelopathy Patients Depends on Corticospinal Tract Integrity —Pavel Hok, Lumír Hrabálek, Petr Hlustik, Eva Cechakova, Tomáþ Wanek, Pavel Otruba, Miroslav Vaverka, Petr Kanovsky

P5.324 Serum Vitamin B12 Levels in

Subacute Combined Degeneration —Tracey Fan, Ifrah Zawar, Erik Pioro

P5.325 Persistent Postural-Perceptual

Dizziness (PPPD) and TBI —Britta Lynn Bureau, Jeffrey Staab, Rodolfo Savica

P5.326 The Effects of Venlafaxine vs

Gabapeptine in Fibromyalgia —Arjola Gabrani, Drini Dobi, Florida Dobi, Sesila Cibuku

P5.327 Post hoc analysis using PRO-

Paula Marques, Francisco Branco Germiniani, Helio ACT database to evaluate Repository Corticotropin Injection (H.P. Acthar® Gel) as a Afonso Teive, Livia Oliveira, Olivier Walusinski potential treatment for ALS —Susan Vanmeter, P5.312 The American Civil War and the Patrice Becker, Lester Mackey, Lilly Fang, Enxu Birth of American Neurology —Scott Rewinkel, Zhao Helmi Lutsep

P5.313 Imaginary Neuroscience in

Thomson, Maria Gonzalez Toledo, Macarena Gonzalez, Karim Haddad, Marcela Benitez, Valeria Descalzi, Mario Embon, Gabriel Gondolesi, Camila Bertone, Maria Roca, Diego Minarro

P5.319 Hawkes Sign: A Novel Office Test and Double Finger Tap Sign (DFTS): More

P5.305 The Split between Neurology and P5.322 Mercurial Channel Disease—A Psychiatry: Historical Overview —Mohamed

prospective study: Pre and post liver transplant evaluation of neurological complications and its clinical-neurocognitiveimaging correlate —Blas Couto, Alejandro

P5.317 Disease of Drivers Contributing to Controlled Study to Assess the Efficacy and

P5.321 Electrophysiological and The Case of Antonio A. Loaeza (18711947) —Guillermo Delgado-Garcia, Teresa Corona LANSS Pain Scale Score Relationship in Vazquez, Bruno Vidal Patients with Carpal Tunnel Syndrome —

Donald Barr, Zachary Pranske, Richard Castillo, Batool Kirmani

168 2018 AAN Annual Meeting

about cannabis in neurological diseases? —

P5.296 The many faces of apomorphine: P5.315 A Brief History of Mindfulness for P5.330 Preliminary findings of a

P5.285 Serial non-adherence in epilepsy Imran Quraishi, Dennis Spencer, Mhd Alkawadri Analysis Study —Byungkwan Hwang, Joongyeb clinics: An analysis of patient characteristics Lee, Sun-young Chung and resource utilization. —Huan Huynh, Imad P5.300 Neurology and the First Ladies — Teryn Nogles P5.318 Dry beriberi: A still existent and Najm, Vineet Punia treatable condition in Western world. — P5.301 The Contribution of Medieval P5.286 Incidence of EEG seizures in Andrea Loggini, Katherine Schwartz, Tao Xie patients with intraparenchymal hemorrhage re-veals a significant role for subcortical hemorrhages in epileptogenicity. —Prachi

P5.329 What do we think patients know

P5.328 Neurological complications after

liver transplant: A not only frequent but also disturbingly heterogeneous phenomenon. — Guido Vazquez, Carla Florencia Bolaño Diaz, Blas Couto, Alejandro Thomson, Carlos Santiago Claverie, Alfredo Thomson, Fernando Gruz, Valeria Ines Descalzi

g1 H

Infectious Disease and Global Health II ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P5.339 JC Virus Granule Cell

Neuronopathy as a Manifestation of the Immune Reconstitution Syndrome in Human Immunodeficiency Virus. —Khalil Husari, Peter Sguigna, Benjamin Greenberg

P5.340 A Rare Case of Herpes

Simplex Virus Type 2 Encephalitis in an

MS THERAPIES: MOA, SAFETY AND COMPLICATIONS

Macedo, Karoline Medeiros, Celso Hygino, Luiz Immunocompetent Adult —Melissa Cook, Tyler P5.342 A rare case of pertussis Felipe Dantas Pagliarini, Camila Pupe, Osvaldo Koehn, Daniel Simmons, Anthony Frattalone encephalopathy in an immunocompetent Nascimento adult —Andrew Filipowicz, Amartyadeb Goswami, P5.341 Syndromic categorization of Mehyar Mehrizi, Tom Hrisomalos P5.344 Of Competence and Compromise: acute central nervous system infections Developing Standards in the Treatment of may help clinicians rationalize use of P5.343 Peripheral Neuropathies in a Chronic Cryptococcal Meningitis in Nonneuroimaging —Kevin Tan, Tingwei Teo, Monica Tropical Country: An Image Approach — HIV-Infected Patients —Satabdi Hudson, Jesse Chan, James Sejvar, Tchoyoson Lim Frederico Prado, Barbara Diniz, Joao Marcos

P5.355 Delayed Onset of CD8+ T cell

Ferreira, Guilherme Torezani, Yuri Macedo, Pedro

Manikowski, Nicholas Marko, Andrew Conger, Stanley Martin, Na Tosha Gatson

Bryan Ceronie, Nicolas Dubuisson, Francesca

P5.375 Lymphomatoid Papulosis in a

Ammoscato, David Baker, Gavin Giovannoni, Klaus Leukoencephalitis After Bone Marrow Transplantation —Erin Balcom, William Branton, Schmierer P5.345 Real-world Strategies for Beste Edguer, Gregg Blevins, Elaine Yacyshyn, P5.366 Lymphocyte Decline and Management of Gastrointestinal Events Derek Emery, Frank van Landeghem, Christopher Reconstitution After Discontinuation in Patients Treated with Delayed-release Power in Patients With Severe, Prolonged Dimethyl Fumarate: EFFECT Gastrointestinal P5.356 Impact of disease-modifying Lymphopenia Treated With Delayed-Release Sub-study Results —Jinny Min, Jacob Sloane, treatments on the longitudinal evolution Dimethyl Fumarate —Robert Fox, Andrew Chan, Fang Fang, Catherine Miller, J. Theodore Phillips Ralf Gold, J. Theodore Phillips, Lili Yang, Shifang of anti-JCV antibody index in multiple P5.346 Can Personalized Natalizumab Liu, Spyridon Chalkias, Devangi Mehta, Catherine sclerosis —Harald Hegen, Janette Walde, Miller Dosing Mitigate PML Risk and Minimize Michael Auer, Gabriel Bsteh, Franziska Di Pauli, Disease Breakthrough? A Novel Assessment Florian Deisenhammer, Thomas Berger P5.367 Safety of Alemtuzumab After of Active Unbound Natalizumab —John Foley, Exposure to Chemotherapeutic Agents P5.357 Limited Impact of Long-term Pfeilsticker Jessica, Bradley Messmer in Patients with Multiple Sclerosis— Teriflunomide Treatment on Lymphocyte P5.347 Patient initiation of fingolimod Experience of a single MS center —Daniela Counts and Infection Rates in the Pooled Pimentel Maldonado, Oleg Yerokhin, Kerime treatment: Comparison of cardiac monitoring TEMSO and TOWER Core and Extension Ararat, Raffaella Umeton, Liesl Matzka, Carolina in-clinic and in the Gilenya@Home Trials —Aaron Miller, Giancarlo Comi, Myriam Ionete program —John Osborne, Jamie Weiss, Xiangyi Benamor, Philippe Truffinet, Karthinathan Meng, Brandon Brown Thangavelu, Matthew Mandel, Mark Freedman P5.368 Development of Tumefactive MS Lesions in association with Fingolimod: A P5.348 Relapses during high doses of P5.358 WITHDRAWN case series —Erica Utigard, Alexander Rae-Grant biotin in progressive multiple sclerosis: A P5.359 Successful treatment of multicase series —Pierre Branger, Nathalie Derache, P5.369 Impact of Immunodepleting drug resistant primary CNS vasculitis with Nizam Kassis, Elisabeth Maillart, Rana Assouad, Treatment with Alemtuzumab on the natalizumab —Paula Hardeman, Benjamin Gilles Defer Peripheral Treg Compartment in Patients Greenberg P5.349 The Middle Cerebellar Peduncle with Multiple Sclerosis —Juergen Haas, P5.360 Six year prospective Alexander Schwarz, Mirjam Korporal-Kuhnke, Sven Lesion in Natalizumab-Treated Multiple immunological study of Alemtuzumab Jarius, Sven Meuth, Brigitte Wildemann Sclerosis Patients: Think Twice Before treated patients: Focus on CD4+ T cell Assuming a Relapse —Ahmed Obeidat, P5.370 Effectiveness of Lymphocytesubsets —Marinella Clerico, Simona Rolla, Vasantham Annadurai, Aram Zabeti, Lawrence based Re-treatment Criteria in Minimizing Stefania De Mercanti, Valentina Bardina, Angele Goldstick the Incidence of Severe Sustained Cucci, Daniela Taverna, Eleonora Cocco, Anton P5.350 Autoimmune Hepatitis During Vladic, Mario Habek, Ivan Adamec, Pietro Osvaldo Lymphopenia during Treatment with Luigi Annovazzi, Dana Horakova, Luca Durelli Treatment of Multiple Sclerosis with Cladribine Tablets 3.5mg/kg —Stuart Cook, Giancarlo Comi, Gavin Giovannoni, Peter Alemtuzumab —Aaron Carlson, Nina Bozinov, P5.361 Characterization of the impact Lucas Kipp, Jeffrey Dunn, Christopher Lock

P5.351 Selective and Discontinuous

Reduction of B and T Lymphocytes and NK Cells in Patients with Early and Relapsing MS (ORACLE-MS, CLARITY and CLARITY Extension) after Administration of Cladribine Tablets —Olaf Stuve, Per Soerensen, Gavin Giovannoni, Thomas Leist, Yann Hyvert, Doris Damian, Ursula Boschert

Pneumonia following the Second Treatment Course of Alemtuzumab Infusion for Relapsing Remitting Multiple Sclerosis — Elizabeth Spurgeon, Justin Abbatemarco, Mary Rensel

P5.353 Fatal leukoencephalopathy in

a patient with multiple sclerosis following treatment with ocrelizumab —Robert Kadish,

Ranganath, Christof Seiler, Elena Vendrame, Mathieu Le Gars, Jason Fontenot, Sami Fam, Susan Holmes, Catherine Blish

P5.362 Clinical Trial and Post-marketing

Claudia Prada, Nicholas Everage, Sirisha Kalari, Spyridon Chalkias, Priya Singhal, Karen Smirnakis, Veronica Englishby

P5.363 Generation and Analysis of

P5.376 Lymphocyte Counts in Patients

Treated With Teriflunomide: Observations From Phase 3 Clinical Trials and the RealWorld Teri-PRO Study —Patricia Coyle, Aaron Miller, Ralf Gold, Patrick Vermersch, Bhupendra Khatri, Myriam Benamor, Jeffrey Chavin, Karthinathan Thangavelu, Giancarlo Comi

P5.377 Lack of Lymphopenia

Following First Phase of Treatment with Alemtuzumab —Joshua Stone, Jonathan Cahill, Syed Rizvi

P5.378 A longitudinal study of JC virus

serostatus stability among Multiple Sclerosis Patients —Raed Alroughani, Samar Ahmed, Raed Behbehani, Jasem Al-Hashel

P5.379 Does early tonsillectomy

decrease the risk of infection with JC virus. —Mirla Avila, Suhaireirene Suady, Sorleen Trevino

P5.380 Treatment of natalizumab-

induced PML with cidofovir or CMX001 (brincidofovir) and mirtazapine —Svetlana

Eckert, Bianca Weinstock-Guttman, Channa Kolb, David Hojnacki

MS AND CNS INFLAMMATORY DISEASE: ENCEPHALITIES AND ENCEPHALOPATHIES

P5.381 Two Sides of the NMDA Receptor

Autoimmune Encephalitis Spectrum: The Tip of the Iceberg? —Mayra Montalvo Perero,

P5.371 Rebound of disease activity after Jacques Reynolds, Jonathan Cahill, Bradford fingolimod (FTY) withdrawal: Can we predict Thompson it? —Julio Dotor García-Soto, Virginia Meca Lallana, Sonia Quintas, Jose A. Vivancos Mora

Reports Indicate No Increased Risk of Herpes P5.372 Screening patients for their Zoster in Patients Treated With Delayedimmunization status when transitioning release Dimethyl Fumarate —Jerome Hanna, to B-cell depleting therapy —Lakshman

Jayagopal, Gloria Von Geldern, Deb Cramer, Wendy Durand, Deborah Gallaro, Michael Persenaire, Gary Stobbe, Jennie Toro, Annette Wundes

P5.382 Post-Transplant Autoimmune

Encephalitis —Devon Cohen, Sebastian Lopez, Andrew McKeon, Sean Pittock, Anastasia Zekeridou, Barry Boilson, William Hogan, John Poterucha, Eoin Flanagan

P5.383 NINJA; Normal-appearing

Imaging-associated, Neuroimmunologically Justified, Autoimmune Encephalomyelitis —

Human T Cell Lines Responsive to Glatiramer P5.373 Herpes reactivation after Acetate —Peter Lipsky, Jeffrey Smith, Benjamin Fingolimod in MS patients: What happens A. Tjoa, Anne Lodge after drug use in real world? —Talyta Grippe,

Daiki Takewaki, Youwei Lin, Wakiro Sato, Hirohiko Ono, Masakazu Nakamura, Manabu Araki, Tomoko Okamoto, Yuji Takahashi, Yukio Kimura, Miho Ota, Noriko Sato, Takashi Yamamura

P5.364 Long-term Lymphocyte Counts in Natalia Cunha, Marta de Carvalho, Carlos

P5.384 Chronic Antibody-Negative

Patients with RRMS Treated with Cladribine David Robertson, Michael Sweeney Tablets 3.5 mg/kg: Total Lymphocytes, B-, P5.354 Neutropenia Following Treatment and T-cell Subsets —Per Soerensen, Fernando Dangond, Christine Hicking, Gavin Giovannoni with Rituximab for Multiple Sclerosis — Lindsay Horton, Robert Gross, John Corboy, P5.365 Memory B Cells: Toward a Enrique Alvarez Unified Therapeutic Target for Effective Immunotherapy in Multiple Sclerosis —

Rieckmann, Per Soerensen, Patrick Vermersch, Fernando Dangond, Christine Hicking

Ilena George, Meenal Kheterpal, Aaron Miller

Ana Carolina Aguilar, Denise Diniz Carneiro, Bernardo Tauil

Autoimmune Limbic Encephalitis: A Case Report —Trenton Tollefson, Andrew Smith,

P5.374 A Case of Progressive Multifocal Lawrence Samkoff Leukoencephalopathy in a Patient on Extended Interval Dose Natalizumab —Josef P5.385 Anti-NMDAR Encephalities: A Gutman, Lana Zhovtis Ryerson, Ilya Kister

Report of Eight Cases —Tsubasa Yuki, Ryo

Sugaya, Genya Watanabe, Kenichi Tsukita, Tetsuya Chiba, Emiko Kawasaki, Yasushi Suzuki

AAN.com/view/AM18 169

Thursday

P5.352 A Case of Severe Legionella

of daclizumab beta on circulating natural killer cells by mass cytometry —Thanmayi

37-year-old Woman with Relapsing Multiple Sclerosis Treated with Dimethyl Fumarate —

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m.

POSTER SESSIONS

POSTER SESSION V

P5.386 AMPA-R Limbic Encephalitis

P5.401 The Incidence and Prevalence of

Siddiqi

Cecilia Kelly, Andrew McKeon, Alfonso Lopez, Vanda Lennon, Avi Gadoth, Carin Smith, Sandra Bryant, Christopher Klein, Allen Aksamit, Michel Toledano, Bradley Boeve, Jan-Mendelt Tillema, Eoin Flanagan

associated with Systemic Lupus Erythematosus: A case report —Zoya Zaeem,

Autoimmune Encephalitis and a comparison to Infectious Encephalitis: A PopulationCollin Luk, Dustin Anderson, Gregg Blevins, Zaeem Based Study —Divyanshu Dubey, Sean Pittock,

P5.387 Clinical presentation and

treatment of autoimmune encephalitis: Single center cohort study of 47 cases. — Muhammad Affan, Sarah Madani, Gamaleldin Osman, Owais Alsrouji, Lonni Schultz, Mirela Cerghet

Thursday, April 26 11:30 a.m.–7:00 p.m. P5.415 A Case of Posterior Predominant

Leucoencephalopathy Secondary to Vitamin B12 Deficiency —David Vaughan, Noel Fanning, Aisling Ryan

P5.416 Case Report: Hypertrophic

Pachymeningitis (HP) from IgG4-RD (related disease—A rare presentation or its most common cause? —Karan Topiwala, Christopher

Catherine Lubetzki, Caroline Bensa, Olivier Gout, Claire Giannesini, Bruno Stankoff, David Brassat, Audrey Rico Lamy, Jean Pelletier, Bertrand Audoin

MUSCULAR DYSTROPHY

P5.429 Examining longitudinal functional changes in Dysferlinopathy: The JAIN Clinical Outcome Study —Linda Lowes,

disease in patients with common variable immunodeficiency —Jonathan Galli, Jon

P5.403 Brain FDG-PET in assessment Singhal, Shamik Bhattacharyya, Joshua Klein, Ivana Vodopivec, Janice Wong, Jennifer Lyons

Meredith James, Anna Mayhew, Lindsay Alfano, Marni Jacobs, Simone Spuler, Kristi J. Jones, John Day, Diana Bharucha-Goebel, Emmanuelle diagnostic keys for differentiating Susac Campana-Salort, Alan Pestronk, Maggie Walter, Syndrome and primary angiitis of central Carmen Paradas Lopez, Tanya Stojkovic, Madoka nervous system —Mariano Marrodan, Lucas Mori-Yoshimura, Elena Bravver, Elena Pegoraro, Alessandro, Victoria Fernandez, Junior Carnero, Jordi Diaz Manera, Tina Duong, Kristy Rose, Jerry Alejandro Kohler, Marcela Fiol, Sebastian Ameriso, Mendell, Kate Bushby, Volker Straub Jorge Correale

P5.389 GFAP antibody mediated

P5.404 Anti-GAD-65 associated

P5.418 Bagel Sign in neuro-Behσet’s

P5.388 Assessing neurological

Williams, John Greenlee, Adi Gundlapalli, Stacey Clardy

autoimmune meningo-encephalomyelitis— first reported fatal outcome in a healthy young patient —Raquel Fonseca, Sami Bajwa, Anthony Geraci, Fred Lado

P5.390 Clinical findings, IgG subclass,

and antibody effects in encephalitis associated with metabotropic glutamate receptor 5 (mGluR5) antibodies —Marianna

Spatola, Lidia Sabater, Jesús Planagumà, Takahiro Iizuka, Harald Pruss, Eugenia Martinez-Hernandez, Thais Armangue, Myrna Rosenfeld, Francesc Graus, Josep Dalmau

P5.391 A rare case of anti-NMDAR

encephalitis complicating pregnancy —

Sabrina Kalam, Aravindhan Baheerathan, Victoria Singh-Curry

P5.392 Effect of Rituximab on Seizure Burden in Patients with Rasmussen Encephalitis: A Case Series —Rachelle Herring, Mindl Messinger, Rohini Coorg

P5.402 Unique FDG-PET findings in

anti-LGI-1 encephalitis —Jennifer Lyons, Janice P5.417 Corpus Callosum lesions as Wong, Ivana Vodopivec, Tarun Singhal

of autoimmune encephalopathies —Tarun

Ghazala Perven

Yesim Ozguler, Serdal Ugurlu, Emire Seyahi, Naci Kocer, Civan Islak, Kejal Kantarci, Sabahattin Saip, Aksel Siva, Orhun Kantarci

the Treatment of Duchenne Muscular Dystrophy —Marco Passini, Li Gan, Jenna A.

P5.405 An Institutional Analysis of

P5.419 Glial fibrillary acidic protein

P5.431 A randomized, placebo-

Mark Jentoft, Orhun Kantarci

Wagner, Brenda Wong, Barry Byrne, H. Lee Sweeney, Leslie Jacobsen, Giridhar Tirucherai, Michael Rabbia, Jeppe Buchbjerg, Michelle Krishnan, Clifford Bechtold

Serum and CSF Autoantibodies to Aid in the Diagnosis of Limbic Encephalitis —George Culler, Stephen VanHaerents

P5.406 Unsual Case of Methadone

Induced Toxic Leukoencephalopathy —

Sharjeel Panjwani, Nurose Karim, Mohammad Humayun, Gretchen Tietjen

NEUROINFLAMMATORY AND OTHER AUTOIMMUNE DISORDERS III

(GFAP) autoimmunity in the setting of seropositive rheumatoid arthritis treated with etanercept —Kelsey Smith, Shreyasee

P5.420 Clinical Episode of Aseptic

Meningitis with Leptomeningeal Enhancement in Patient with Anti-MOG Antibodies —Sasmit Sarangi, Brian Wong, Jonathan Cahill

P5.421 Meningioma Mimicry: Biopsy

Nick Lukish, Michael Kilduff, Deanna Saylor, Scott Newsome

Mark-Victor Siwoski, Yunxia Wang

of Variant-Stiff Person Syndrome: A Case Series —Thomas Shoemaker, Salman Aljarallah,

Karan Topiwala, Anvi Patel, Neil Datta, Yan Zhang, Isaac Silverman

Lennon

P5.394 An Unusual Presentation of

Anti-NMDA Receptor Antibody Positive Encephalitis: Non-Epileptic Spells and A Splenial Lesion on Brain MRI —Alison Christy,

Paraneoplastic Neurologic Syndrome Developing in a Patient with Metastatic Merkel Cell Carcinoma During Immune Checkpoint Inhibitor Treatment —Bianca

P5.395 Nivolumab Induced Auto-

P5.410 Could neurological involvement

Rukmangadachar, Ali Choucair

Siva, Sinem Nihal Esatoglu, Ugur Uygunoglu, Yesim Ozguler, Gulen Hatemi, Melih Tutuncu, Sabahattin Saip, Melike Melikoglu, Izzet Fresko, Vedat Hamuryudan, Civan Islak, Hasan Yazici, Emire Seyahi

P5.409 Anti-CRMP5-Associated

Santomasso, Sandra D’Angelo

confirmed neurosarcoidosis presenting as multiple extra axial intracranial masses —

P5.422 Aseptic Meningitis as a

Ana Sofia Morgadinho

P5.397 N-Type Calcium Channel

Antibody Encephalitis Coexisting With Multiple Sclerosis —Michael Robers, Harlori

Thursday

Bains, Aimee Borazanci

P5.398 A Fatal Case of Adult-Onset

P5.411 Neuro-Sweet’s Syndrome, a

Diagnostic Conundrum —Kanita Beba, Grant

Adrian Hadiono, Peter Sguigna, Jeffrey Elliott

P5.423 Acute Hemorrhagic

Leukoencephalitis (AHLE): A Case Report With a Successful Outcome —Wejdan

Balubaid, Manal Badawi, Hindi Al Hindi, Zainalabedeen Jamjoom, Khalil Kurdi, Youssef Al Said, Omar Wazzan, Edward Cupler

P5.424 Clinical and Immunological

Investigation of Anti-Glutamic Acid Decarboxylase 65 Antibodies in Suspected Neurological Autoimmunity —Lei Liu, Jiawei MS THERAPEUTICS II

P5.425 Routine Laboratory Measures

in the Controlled-Treatment Period of Phase III Ocrelizumab Trials in Relapsing and Progressive Multiple Sclerosis —Jerry

Wolinsky, Ludwig Kappos, Xavier Montalban, Abadal, Kathryn Potter, Meredith Wicklund, Miguel Cathy Chognot, Harold Koendgen, Carrie Li, Ashish Chuquilin Arista Pradhan, Stephen Hauser

P5.412 Hypocupremia induced

P5.432 Impact on respiratory decline

resulting from idebenone treatment in patients with Duchenne muscular dystrophy (DMD): Results of Meta-analysis —John Karafilidis, Thomas Meier, Mika Leinonen, Gunnar Buyse

P5.433 Longitudinal Evaluation of

Disease Progression in Congenital Myotonic Manifestation of the Anti-MOG Syndrome — Dystrophy —Nicholas Johnson, Melissa

immune Encephalitis —Nidaullah Mian, Lokesh in Behçet’s Disease occur atypically? —Aksel Wang encephalitis —Mario Sousa, Francisco Sales,

Wood, Monica Yao, Nelsa L. Estrella, Christopher Treleaven, Bruce Wentworth, JS Charleston, Joseph V. Rutkowski, Gunnar J. Hanson

controlled, double-blind, Phase 1b/2 study of the novel anti-myostatin adnectin RG6206 (BMS-986089) in ambulatory boys with Amin, Lyell Jones, Daniel Lachance, Eoin Flanagan, Duchenne muscular dystrophy —Kathryn

P5.407 Defining the Clinical Spectrum

P5.408 Neurological Paraneoplastic presentations of Anti-Leucine-rich-Glioma- Autoimmunity and Small-Cell Lung Cancer: Inactivated 1(LGI -1) encephalitis—an Clinical and Serological Accompaniments — emerging cause of limbic encephalitis (LE) — Anastasia Zekeridou, Masoud Majed, Vanda

P5.396 A rare cause of limbic

P5.430 Development of PPMO for

Syndrome —Ugur Uygunoglu, Burcu Zeydan,

Progressive Encephalomyelitis with Rigidity and Myoclonus following West Nile Virus Encephalitis. —Jordan Loeb, Michelle Devine,

P5.393 A bout of confusion: Atypical

Anandam Hilde, Rebecca Marshall

Hampton, David Waitzman, Carl Boland

McIntyre, Melissa Dixon, Becky Crockett, Jerry Bounsanga, Man Hung, Craig Campbell

P5.434 Effects of Weakness of Orofacial Muscles on Swallowing and Communication in Facioscapulohumeral Muscular Dystrophy —Mattison Sills, Karlien Mul, Kiera Berggren, Melissa Currence, Ayla McCalley, Nicholas Johnson, Jeffrey Statland

P5.435 Motor Unit Control in Myotonic Dystrophy Type 1 —Trevor Moravec, Michael Lawless, Julie Agriesti, William Arnold

P5.436 Impact of Idebenone on rate of

respiratory function decline in Duchenne muscular dystrophy (DMD) —John Karafilidis, Mika Leinonen, Gunnar Buyse

P5.437 Neurodevelopmental needs

in young boys with Duchenne Muscular Dystrophy: Observations from the CINRG DMD Natural History Study —Mathula Thangarajh, Heather Gordish-Dressman, Paula Clemens

Acute Necrotizing Encephalitis Secondary to Encephalomyelopathy with CSF Oligoclonal Influenza A Virus —Varun Pulakanti, Neil Holland Bands —Anastasie Dunn-Pirio, Suma Shah, Mark Skeen P5.399 Comparison of Costs and Outcomes of Patients Presenting with a Rare P5.413 Ipilimumab Induced Auto-immune Brainstem Syndrome —Devin Prior, Nancy Hypophysitis —Nidaullah Mian, Lokesh

P5.426 Rationale and Design of the

Song, Vijay Renga

Rukmangadachar, Ali Choucair

P5.400 A spectrum of autoimmune

P5.414 Improvement of Stiff Person

Based Patient-Reported Electronic Diary in Rrms Patients With Disease Activity Despite Myotonic Dystrophy Type 1 —Jeffrey Statland, Second-Line Treatment —Pierre Durozard, On behalf of the Myotonic Dystrophy Clinical Re

encephalitis: A realistic and challenging diagnosis —Joao Marcos Ferreira, Barbara

Diniz, Karoline Medeiros, Yuri Macedo, Guilherme Torezani, Pedro Macedo, Diego Wedemann, Fernanda Herculano, Camila Pupe, Osvaldo Nascimento

170 2018 AAN Annual Meeting

Syndrome Symptoms During Pregnancy — Megan Esch, Scott Newsome

Traditional versus Early Aggressive Therapy for MS (TREAT-MS) Trial —Scott Newsome, Thomas Shoemaker, Sandra Cassard, Elizabeth Ogburn, Jerry Prince, Ellen Mowry

P5.427 WITHDRAWN P5.428 Rituximab As Rescue Therapy In

Adil Maarouf, Clémence Boutiere, Aurelie Ruet, Bruno Brochet, Sandra Vukusic, Clarisse CarraDalliere, Pierre Labauge, Guillaume Mathey, Marc Debouverie, Caroline Papeix, Elisabeth Maillart,

P5.438 Self-Reported Sleep Features

in Myotonic Dystrophies —Carolyn Savage,

Sheela Crasta, Katharine Hagerman, Jennifer Perez, Eileen Leary, Emmanuel Mignot, Jacinda Sampson, John Day

P5.439 An Interactive Telephone-

P5.440 A Novel Genotype and

Pathological Phenotype in a Patient with Myosin Heavy Chain 2A Myopathy —

POSTER SESSIONS

Stand-by time for this session is 5:30 p.m. to 7:00 p.m. Nicolas Madigan, Teerin Liewluck, Mohammad Alsharabati, Eric Sorenson, Andrew Engel, Margherita Milone

Impairment and Test-Retest Agreement over 3 Months —Katy Eichinger, Melissa Currence, Kieu Capron, Tina Duong, Richard Gee, Laura

Galen Joe, Wendy King, Donovan Lott, P5.441 Dysmetria in Myotonic Dystrophy Herbelin, On behalf of Myotonic Dystrophy Clinical Re type 1 —S Subramony, B Yacoubi, A CasamentoMoran, Donovan Lott, Evangelos Christou P5.456 Diagnostic Yield of a Next Generation Sequencing Panel for Muscular P5.442 Effects of MNK-1411 on

Inflammation and Muscle Function in the mdx Mouse Model —Dale Wright, Joseph

Randall, Prabha Sharma, Ben Zweifel, Rick Fitch

P5.443 Investigation of Ranolazine as

an Anti-myotonia Treatment in Myotonic Dystrophy Type 1 —Michael Lawless, William Arnold, Julie Agriesti, Trevor Moravec, Trevor Moravec, Trevor Moravec

P5.444 Electromechanical Delay During Goal-directed Movements in Myotonic Dystrophy type 1 (DM 1) —S Subramony, B Yacoubi, A Casamento-Moran, Donovan Lott, Evangelos Christou

Dystrophies and Hereditary Myopathies in Southern Brazil —Pablo Winckler, Bruna Cristine Chwal, Daniela Burguez, Bianca Madeira, Marcia Polese Bonato, Filippo Filippo Pinto e Vairo, Jonas Saute

P5.457 Case report: Hereditary

myopathy with early respiratory failure and ventricular tachycardia —Emily Grodinsky, Madhu Soni

P5.458 A Novel Mutation in Acid Alpha Glucosidase resulting in Late-Onset Pompe Disease —Eric Libell, Kymberly Gyure, Cheryl Smith

P5.445 Limb-girdle muscular dystrophy

ALS, SMA, AND OTHER 1D including a novel p.Phe100Ile (c.298T < NEUROMUSCULAR DISORDERS III A) mutation in DNAJB6 in three Koreans from two families —Woo-kyung Kim, Kitae Kim, P5.459 Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Young-Chul Choi Systematic Review and Meta-analysis. — P5.446 Phenotypic Heterogeneity in Mohamed Fahmy Doheim, Abdelrahman Elshafay, Limb-girdle Muscular Dystrophy Type 2L Mahmoud Attia Mohame Kassem, Mohammed Fathi ELdoadoa, Sarah Keturah Holloway, Israa (Anoctaminopathy) —Kamal Shouman, John Morren, Payam Soltanzadeh

P5.447 Accuracy of Online Diagnostic

Atia Elbestawi, Heba Abo-elghar, Kenji Hirayama, Nguyen Tien Huy

Assistants for Diagnosing Limb Girdle Muscular Dystrophies —Hamza Malek, Senda

P5.460 Positive cytosolic 5-nucleotidase

P5.448 Rhabdomyolysis and Fluctuating

P5.461 Guaiacol can be a drug-

Mark A Cipriani, Ruple Laughlin, Zhiyv Niu, Margherita Milone

Leonardo Solmesky, Miguel Weil, Hanoch Senderowitz, Alexander Lossos, Rafael Alvarez, Sergey Pampou, Pablo Escriba, Wyatt Yue, Orhan Akman

Ajroud-Driss

Asymptomatic HyperCKemia Associated with CACNA1S Variant —Charenya Anandan,

P5.449 Limb-girdle muscular dystrophy

type 2L—A case series from a tertiary center —Ricardo Varela, Mario Sousa, Anabela Matos, Argemiro Geraldo, Olinda Rebelo, Luís Negrão

P5.450 Limb-Girdle Muscular Dystrophy: A Perspective from Patients on What Matters Most —Michael Hunter, Anna

Hatzipolakis, Chad Heatwole, Nicholas Johnson

P5.451 Cardioembolic stroke in a

23-year-old man with elbow contracture, an unusual presentation of Emery Dreifuss Muscular Dystrophy (EDMD) —Bhaskar Roy,

1A antibodies in motor neuron disorders — Rami-james Assadi, Georgios Manousakis

candidate for treating Adult Polyglucosan Body Disease —Or Kakhlon, igor Ferreira,

P5.462 Longitudinal Clinical Assessment in Stiff Person Syndrome: Evidence of a Progressive and Disabling Disorder —Goran Rakocevic, Harry Alexopoulos, Marinos Dalakas

P5.463 Unrecognized Respiratory

Manifestations of Stiff Person Syndrome (SPS) —Anthony Allen, Goran Rakocevic,

Matthew Woodford, Katrina Pack, William Sexauer

P5.464 Urinary and Bowel Symptoms in

Adult Patients with Adrenoleukodystrophy — Pablo Gomery, Camille Corre, Florian Eichler

Elizabeth Raynor

P5.452 Clinical, pathological and

molecular characterization of a Limb-girdle muscular dystrophy type 2I(LGMD-2I) cohort —Mario Sousa, Ricardo Varela, Anabela

Thursday

Matos, Argemiro Geraldo, Olinda Rebelo, Luis Negrao

P5.453 Cumulative Motor Index (CMI)

in Duchenne Muscular Dystrophy (DMD) — Jenny Lin, Durga Shah, Courtney McCracken, Sumit Verma

P5.454 Phenotypic and muscle biopsy

features of patients with FKRP c.1387A>G founder mutation —Angela Lee, Karra Jones, Katherine Mathews, Steven Moore, Russell Butterfield, Nicholas Johnson, Chamindra Konersman, Jose Abdenur, Brent Beson

P5.455 Muscle Strength and Function

Measures in a Multicenter Study of Myotonic Dystrophy Type 1 (DM1): Baseline

AAN.com/view/AM18 171

POSTER SESSIONS

POSTER SESSION VI G GENERAL NEUROLOGY: VASCULAR NEUROLOGY

Friday, April 27 11:30 a.m.–5:30 p.m.

Pria Anand, Rohan Mathur, Taylor Haight, Jiaying Zhang

P6.010 A Multidisciplinary Team Factor Control and Physician Specialty in the Approach Improves Door to Groin Puncture Time for Endovascular Stroke Therapy in a Crest-2 Trial —Tanya Turan, James Meschia, Comprehensive Stroke Center —Paul Wright, Jenifer Voeks, Kevin Barrett, Robert Brown,

P6.001 Relationship Between Risk

Seemant Chaturvedi, Marc Chimowitz, Bart Demaerschalk, Prabhu Emmady, George Howard, Virginia Howard, John Huston, Michael Jones, Brajesh Lal, Ronald Lazar, Wesley Moore, Claudia Moy, Ana Roldan, Gary Roubin, Thomas Brott

Jeffrey Katz, Avi Setton, Saeyoan Thirunavukkarasu

P6.002 Cavernous malformation—A

GENERAL NEUROLOGY: CASE REPORTS II

rare complication of gamma knife surgery for Arterio-venous malformations —Nagaraj Sanchitha Honganur, Yathish Haralur, Laszlo Mechtler, Usha Holla

P6.003 Factors Influencing Stroke

091–172

P6.011 Hypoglossal Cranial Nerve Palsy: Unusual Microvascular Complication —

P6.004 Barriers to Meeting Time Goals

ePosters

037–084

P6.012 Wernicke Encephalopathy

Masquerading As A Right Middle Cerebral Artery Territory Infarction —Chi-Ying Lin, Ji-Yeoun Yoo, Amish Doshi, Rachel Colman

259–294

201–258

b1 g1 339–344 a1 ePosters

085–090

Priyanka Chilakamarri, Shamik Bhattacharyya

295–338

Poster Discussion

027–036

001–026

Awareness among Patients with Hypertension in a Tertiary Hospital of Nepal: P6.013 Neuroinvasiveness of West Nile A Cross-sectional Study —Sulochana Ghimire, Virus: A Case Report —Ketan Jhunjhunwala, Shakti Shrestha, Lekhjung Thapa

173–200

345–428

429–480

Poster Session 6

Yedatore Venkatesh

A. General Neurology: 001–026

P6.014 Sarcoid with Subacute

Confusion —Cassandra Cross, Meltiady Issa,

a1. Movement Disorders Poster Discussion Session: 027–036

Sushma Kola

B. Movement Disorders: 037–084

Droegemueller, Stephen Stanfield, Clarice Marsh, Ryan Bourdon, Zachary Stoecker, Aaron Burnett, Jodi Mueller-Hussein, Tiffany Robbe, Bhavani Kashyap, Lauren Erickson, Vesselina Pearsall, Leah Hanson

P6.015 Cerebral missile injury with

b1. Movement Disorders I ePoster Session: 085–090

P6.005 Performance of a New “Code

Due to Dalfampridine in a Patient with Relapsing-Remitting Multiple Sclerosis —

in Suspect Stroke Patients Receiving IV Thrombolysis —Haitham Hussein, Carol

Stroke” Process in Hospitalized Patients in a Comprehensive Stroke Center in Minnesota —Carol Droegemueller, Roberta

delayed diagnosis and minimal sequelae. —

P6.016 Convulsive Status Epilepticus Zeeshan Ali, Antoaneta Balabanov

Wagner, Bhavani Kashyap, Mitchell Clayton, Mary Fennig, Leah Hanson, Haitham Hussein

P6.017 A Unique Variant of a Partial

P6.006 Symptoms of a stroke: A diagnostic challenge. —Eliz Agopian

Timothy Fullam, Philippine Dana Peralta, Thomas Duginski

P6.007 Mimics of Spinal Dural

P6.018 Thyrotoxic Periodic Paralysis in

Arteriovenous Fistula and Spinal Arteriovenous Malformation —Patrick Chen, Shuichi Suzuki, Anton Hasso, Frank Hsu

C. D. E. F. G.

Saurabh Singhal, Amanda Croxton, Jade Davis, Laurence Walsh

g1. Movement Disorders II ePoster Session: 339–344 H. MS and CNS Inflammatory Disease: 345–428 I. Neuromuscular/Clinical Neurophysiology (EMG): 429–480

Brown-Séquard Syndrome as the Result of Thoracic Fibrocartilaginous Embolism —

a Patient of Somali Descent: Case Report & Review of Literature. —Marion Oliver, Vivek Rai, Blake Senay, Logan Kinney

Neuro-oncology: 091–172 Aging, Dementia, Cognitive, and Behavioral Neurology: 173–200 Cerebrovascular Disease and Interventional Neurology: 201–258 Epilepsy/Clinical Neurophysiology (EEG): 259–294 Neuro Trauma, Critical Care, and Sports Neurology: 295–338

alahmad, Antonio Perez, Bradley Williams, emer joyce

P6.021 Conservative management

P6.023 Clinical characterization of

Pramipexole induced edema and skin reaction in Parkinson Disease (PD) after one year of follow up —Natalia Rincon, Enrique

P6.008 A randomized Controlled trail of

P6.019 Creutzfeldt-Jakob Disease

of Aseptic Meningitis from Rupture of Brainstem Epidermoid Cyst —Yuan Kit

Sankar Gorthi, sitla prasad pathak, pawan dhull, Manoj Nair

Wiggins, Dinesh Jillella, Andrew Lin, Atif Zafar

P6.022 Transient Isolated Downbeating

laminectomy; a rare presentation and review of intracranial hypotension —Mark-Victor

Intrathecal Anesthesia —Kenneth Leung,

P6.025 Trigeminal Neuralgia Exacerbated

Granulocyte colony stimulating factor(GCSF) Presenting as Hashimoto’s Encephalopathy: intervention in acute Ischemic stroke (AIS) — A Challenge to the Diagnostician —Judea

P6.009 Reversible Cerebral

Vasoconstriction Syndrome Presenting as Third Cranial Nerve Palsy —Leah Dickstein,

Christopher Chua, Ellie Choi, Qasim Ahmed, Tseng Tsai Yeo, Wei Ping Kay Ng

P6.020 Severe Gabapentin Toxicity After Vertical Nystagmus as a Complication of Acute Kidney Injury in Hospitalized Patient with Acute Pain —Mohamad Alhoda Mohamad

Rajeev Motiwala

Urrea-Mendoza, Fredy Revilla

P6.024 Abducens palsy following lumbar Siwoski, Joseph Pleen, Colleen Lechtenberg

By Menstrual Cycle —Anita Mehta

P6.026 NA

Movement Disorders Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below.

Posters displayed 11:30 a.m.-5:30 p.m. • Data blitz 12:00 p.m.-12:50 p.m. • Presenters Stand by Posters 4:00 p.m.-5:30 p.m. Data Blitz: 11:45 a.m.–11:50 a.m.

P6.027 Levodopa-Carbidopa Intestinal

Disease Determined by Diffusion Tensor Imaging —Ergun Uc, Vincent Magnotta, Warren

Friday

Darling, Joel Bruss, Kevin Doerschug, Teri Gel (LCIG) in Deep Brain Stimulation (DBS) Thomsen, Joel Kline, Steven Anderson, Matthew Parkinson’s Patients. —Ahmad El Kouzi, Leonardo Rizzo, Michelle Voss, Jeffrey Dawson Almeida, Adolfo Ramirez Zamora, Pam Zeilman, Data Blitz: 12:00 p.m.–12:05 p.m. Matthew Barabas, Irene Malaty, Michael Okun

Data Blitz: 11:50 a.m.–11:55 a.m.

P6.028 ODM-104 and Optimized

Carbidopa Dose Show Beneficial Effect on Levodopa PK in Healthy Subjects —Johanna Tuunainen, Juha Ellmen, Mikko Vahteristo, Aila Holopainen, Denis Strugala

Data Blitz: 11:55 a.m.–12:00 p.m.

P6.029 Effects of Aerobic Exercise on the Cerebral White Matter in Parkinson’s

172 2018 AAN Annual Meeting

P6.030 A Dystonia-Related

Microstructural Topography Identified in Diffusion MRI —Koji Fujita, An Vo, Chris Tang, David Eidelberg

Data Blitz: 12:10 p.m.–12:15 p.m.

Data Blitz: 12:25 p.m.–12:30 p.m.

P6.032 Altered Serum Lysosomal

P6.035 A Family with Spinocerebellar

Ito, Sayuri Shima, Akihiro Ueda, Tatsuro Mutoh

Elaine Binkley, Jessica Rexach, Amy KnightJohnson, Pravin Khemani, Brent Fogel, Soma Das, Edwin Stone, Christopher Gomez

Hydrolase Activities in Parkinson’s Disease —Yoshiki Niimi, Yasuaki Mizutani, Shinji Data Blitz: 12:15 p.m.–12:20 p.m.

P6.033 Uniparental disomy causing

Myoclonus Dystonia Syndrome associated with Russell Silver Syndrome: A case report —Danielle Shpiner, Henry Moore Data Blitz: 12:20 p.m.–12:25 p.m.

Ataxia and Retinitis Pigmentosa Attributed to a Novel ELOVL4 Mutation —Changrui Xiao,

Data Blitz: 12:30 p.m.–12:35 p.m.

P6.036 Serial CSF Studies of Anti-GAD

Antibodies and GAD-IgG Intrathecal Synthesis in Stiff-Person Syndrome (SPS): Correlation with Disease Severity and P6.031 GABA Levels are Reduced in P6.034 Climbing fiber synaptic pathology Progression —Haralambos Alexopoulos, Sofia the Thalamus of Patients with Cervical Akrivou, Goran Rakocevic, Marinos Dalakas Dystonia —Christopher Groth, Mark Brown, Erika in essential tremor: Parallel evidence from both human and mouse models —Sheng-Han Shelton, Brian Berman Data Blitz: 12:05 p.m.–12:10 p.m.

Kuo, Phyllis Faust, Elan Louis, Ming-Kai Pan

FUNCTIONAL MOVEMENT DISORDERS AND OTHER HYPERKINETIC MOVEMENT DISORDERS

P6.049 Multidisciplinary Inpatient

P6.037 Hereditary Spastic Paraplegia:

P6.050 Clinical Characteristics of

Clinical & Genetic Characterization of the Alberta Cohort —Hammad Shaikh, Anil

Venkitachalam, Setareh Ashtiani, Aakash Shetty, Erica McKenzie, Ziv Gan-Or, Guy Rouleau, Oksana Suchowersky

P6.061 Whole Exome Sequencing in Rehabilitation for Functional Movement Essential Tremor —Isabel Alfradique-Dunham, Disorders —Aikaterini Kompoliti, Charles Hebert, Laurie Robak, Anita Kaw, Oluwafunmiso Ibunkun Jay Behel, Gian Pal, Alice Negron, Ravi Kasi

Functional Movement Disorders: A ClinicBased Study —Jung E Park

P6.051 Family with brain calcification

and SLC20A2 variant - possible anticipation —Takuya Konno, Patrick Blackburn,

Fagbongbe, Zeynep Coban Akdemir, Emily Young, James Lupski, Joseph Jankovic, Joshua Shulman

P6.073 Efficacy and Safety of BIIB092

in Patients with Progressive Supranuclear Palsy: PASSPORT Phase 2 Study Design —

Tien Dam, Adam Boxer, Lawrence Golbe, Günter Höglinger, Huw Morris, Irene Litvan, Jean Corvol, Anthony Lang, Tatsuhiko Yuasa, P6.062 Tremor Research Group Essential Christophe Clifford Bechtold, Michael Grundman, Irfan Qureshi

Tremor Rating Scale (TETRAS): Assessing Impact of Different Item Instructions — Crystal Yeo, William Ondo

P6.063 Orthostatic Tremor: Disease

P6.074 Correlation of the UMSARS-

II Motor Score to Commonly Affected Components of MSA-QoL in MSA Patients —Matthew Remz, Larry Brown, Elizabeth

P6.038 Astasia, Reach and Grasp Deficits Todd Rozen, Jay Van Gerpen, Owen Ross, Paldeep Impact and Progression —Nirosen Vijiaratnam, Kent, Giselle Huet, Steven Vernino, Pravin Khemani Darshana Siresena, Eldho Paul, Kelly Bertram, Following a Bilateral Medio-dorsal Pulvinar Atwal, Zbigniew Wszolek David Williams P6.075 Ethnicity-specific clinical and Lesion —Mathias Baehr, Peter Dechent, Melanie P6.052 Spasticity-related Involuntary neuroimaging characteristics in multiple Wilke P6.064 Improved Atypical Tremor Control Movements: A Cross-sectional Study — system atrophy —Hanim Kwon, Ho-Sung Ryu, After Deep Brain Stimulation Targeting The Hesham Abboud, Hubert Fernandez, Xin Xin Yu, P6.039 CAPN1: Novel mutations Yun Jik Park, Mi Sun Kim, Kye Won Park, Sung Reul expanding the phenotype of hereditary spastic paraparesis. —Aakash Shetty, Setareh Ashtiani, Ziv Gan-Or, Bart Van de Warrenburg, Tessa Wassenberg, Guy Rouleau, Oksana Suchowersky

P6.040 Two novel mutations in CP

associated with Aceruloplasminemia and basal ganglia cavitation —Giulietta Riboldi, Kara Anstett, Rajan Jain, Heather Lau, David Swope

P6.041 Psychosocial Profiles of

Functional Movement Disorder (FMD) Patients compared to General Neurology Patients —Alexandra Jacob, Abbey Roach,

Francois Bethoux

P6.053 Pseudoathetosis Including

Lingual Pseudoathetosis: Successful Treatment with Pregabalin —Nabil Biary,

Waleed Ahmed Khoja, Aisha Malik, Mohammad Kabiraj

MOVEMENT DISORDERS: ESSENTIAL AND OTHER TREMOR SYNDROMES

P6.054 A quantitative study of “empty

baskets” in essential tremor and cerebellar degenerative diseases —Elan Louis, Jong Seo Lee, Phyllis Faust

Megan Jablonski, Courtney Smith, Kathrin LaFaver

P6.055 An Innovative, Non-Intrusive

P6.042 Immunotherapy-responsive

Zhang, Daniel Eliahu, Gabriel Elkaim

chorea in a patient with antiphospholipid antibody syndrome and refractory Crohn’s disease: A case report —Neepa Patel, Gamaleldin Osman, Anza Memon

P6.043 WITHDRAWN P6.044 ATP13A2-Related Heriditary

System for the Diagnosis of Tremor. —Lin

Dentato-Rubro-Thalamic Tract —Shivika

Chandra, Valentin Laticevschi, Jessika Suescun, Albert Fenoy, Mya Schiess

P6.065 An Unusual Presentation of

Late-Onset Alexander Disease with Slow Orthostatic Tremor and a Novel GFAP Variant —Derek Stitt, Ralitza Gavrilova, Robert Watson Jr., Anhar Hassan

P6.066 Quantitative tremor analysis of

Holmes tremor: A case series —Anh-Thu Vu,

Richa Tripathi, Garrett Alexander, Stewart Factor

P6.067 Progression of Essential Tremor

Over Time Using Digital Spirography in Patients on Stable Medication Doses Compared to Untreated Patients —Katherine Longardner, Fatta Nahab

P6.056 Thalamic Deep Brain Stimulation ATYPICAL PARKINSONISM For Holmes Tremor —Erik Krause, Neha Prakash, Richard Bucholz, Pratap Chand

P6.057 Non-amnestic Cognitive

P6.068 The Effects of Amantadine on

P6.046 Refractory Myoclonus in

Lance Adams Syndrome Responding to Brivaracetam —Rahul Chandak, Aashrai Gudlavalleti, Karen Medin

P6.047 Breakdown of Affective-

Cognitive Network in Functional Dystonia — Elisa Canu, Federica Agosta, Alexandra Tomic, Nataþa Dragaþevic, Marina Svetel, Vladimir Kostic, Massimo Filippi

P6.048 Are There Two Different Forms

Fishman, W. Jeffrey Elias, Pejman Ghanouni, Ryder Singer, Elizabeth Coon Gwinn, Nir Lipsman, Michael Schwartz, Jin Chang, Takaomi Taira, Vibhor Krishna, Kazumichi Yamada, P6.070 Background pathology of Kieje Igase, G. Rees Cosgrove, Haruhiko Kishima, ‘corticobasal degeneration (CBD) mimics’ Michael Kaplitt, Travis Tierney, Howard Eisenberg -Japanese validation study of CBD (J-VAC study) —Takayoshi Shimohata, Ikuko Aiba, Mari P6.059 Repetitive Transcranial Yoshida, Yasuko Toyoshima, Shigeo Murayama, Magnetic Stimulation Therapy is a Potential Toshiki Uchihara, Tetsuaki Arai, Ichiro Yabe, Therapeutic Option for Primary Orthostatic Takafumi Hasegawa, Kazuko Hasegawa, Takeshi Tremor. —Wei Hu, Joseph Legacy, Amy Ferng, Ikeuchi, Masato Hasegawa, Takashi Komori, Koichi Aparna Wagle-Shukla Wakabayashi, Aya Tokumaru, Keita Sakurai, Kenji Nakashima P6.060 A Phase 2 Efficacy Study

of an Oral, Potent and Selective T-Type of Functional Dystonia? A Multimodal Brain Calcium (Cav3) Modulator in Essential Structural Imaging Study —Elisabetta Sarasso, Tremor Patients (T-CALM): Design and Federica Agosta, Alexandra Tomic, Nataþa Dragaþevic, Marina Svetel, Silvia Basaia, Andrea Dose Selection Rationale —Spiridon Fontana, Vladimir Kostic, Massimo Filippi

Papapetropoulos, Yuri Maricich, Margaret Lee, Stacey Boyer, Bruce Silver

P6.076 The Role of Neuro-

Ophthalmology in Atypical Parkinsonism: Clinical Findings on a Standardized Ocular Motor Exam —Meagan Seay, Andrea Lee, Steven Frucht, Janet Rucker

P6.077 A Prospective Clinical Cohort and Biorepository of Multiple System Atrophy (MSA). —Jiwoo Kim, Deepak Gupta, Christopher Liong, Thong Ma, Un Kang, Sheng-Han Kuo, Roy Alcalay, Miriam Sklerov

P6.078 The Role of Neuro-

Ophthalmology in Atypical Parkinsonism: Referral Patterns of Movement Disorders Specialists and Neuro-Ophthalmic Contribution to Diagnosis —Andrea Lee, Meagan Seay, Steven Frucht, Janet Rucker

P6.079 Parkinson Disease from long term

drug abuse: Meta-analysis of amphetamine/ the Progression of Progressive Supranuclear methamphetamine and Parkinson Disease — Palsy (PSP) —Amie Hiller, Charles Murchison, Richa Tripathi, Hamidreza Saber, Varun Chauhan,

Impairment in Essential Tremor (ET): Defining Jennifer Nichols, Joseph Quinn the Phenotype —Nikita Urval, Christina Palmese, Spastic Paraplegia (HSP) —Marium Jamil, P6.069 Multiple System Atrophy Vicki Shanker Abdul Siddiqui, Ann Sollinger, Joseph Ferrara Presenting as Motor Neuron Disease — P6.058 Neurologic Adverse Event Lauren Jackson, Renee Nelson, James Bower, P6.045 Phenomenology of Leg Profile of MRI-Guided Focused Ultrasound Joseph Matsumoto, Paola Sandroni, Eduardo Stereotypy Syndrome —Nicki Niemann, Joseph Thalamotomy for Essential Tremor —Paul Benarroch, Mariana Suarez, Phillip Low, Wolfgang Jankovic

Kim, Sun J. Chung

POSTER SESSIONS

Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.

P6.071 Brain MRI findings in

Woodhouse-Sakati Syndrome —Ali Abusrair, Saeed Bohlega, Fahad Al-Ajlan, Abdulaziz AlSemari, Bader Mohamed, Amaal AlDakheel

P6.072 Vocal cord “paralysis”: The First Sign in Multiple System Atrophy —Philip Tipton, Jay Van Gerpen

Kaushalendra Mani Tripathi, Stewart Factor

P6.080 Motor function impairment in chronic HIV is similar but less severe to that seen in Parkinson’s disease —Helen

Bronte-Stewart, Varsha Prabhakar, Talora Martin, Megan Trager, Anca Velisar, Mandy Koop, Eva Muller-Oehring, Kathleen Poston, Tilman Schulte

P6.081 The ‘Hot Cross Bun’ Sign is Not

Always Multiple System Atrophy: Etiologies of 10 Cases —Christopher Way, David Pettersson, Amie Hiller

P6.082 The Phonemic Verbal Fluency in Progressive Supranuclear Palsy (PSP) and Parkinson’s Disease (PD): Relation with Executive and Language Function Measure. —Sanjida Chowdhury

P6.083 Primary central nervous system

lymphoma presenting as Parkinsonism with atypical MRI findings and elevated 14-3-3 protein —Elanagan Nagarajan, Sushma Yerram, Pradeep Bollu, Joel Shenker

P6.084 NA

Friday

AAN.com/view/AM18 173

POSTER SESSIONS

POSTER SESSION VI G

Friday, April 27 11:30 a.m.–5:30 p.m.

Movement Disorders I ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P6.085 Is Benign Hereditary Chorea

Melissa Naylor, Charmaine Demanuele, Hao

Parnes, Hassaan Bashir, Joseph Jankovic

Bilal, Bryan Ho, Peter Bergethon, Michael Erb, Daniel Karlin

Really Benign? Brain-Lung-Thyroid Syndrome Zhang, Stephen Amato, Farhan Hameed, Paul Wacnik, Tairmae Kangaroo, Vibha Anand, Erhan Caused by NKX2-1 Mutations —Mered

P6.086 Wearable Inertial Sensor

P6.088 Levodopa Induced Dyskinesias

in Neurodegeneration with Brain Iron Accumulation due to a Heterozygous Mutation in C19orf12. —Daniel Savitt, Joseph Jankovic

Chrestian, Francois Gros-Louis, Guy Rouleau, Robert Laforce, Nicolas Dupre

P6.090 Associations of genetic variants in COMT, BDNF, SNCA, MAPT genes with cognitive impairment in Parkinson’s disease. —Konstantin Senkevich, Irina

Technology Produces Endpoints with Good Reliability in Healthy Volunteers and Can Detect Changes in Parkinson Disease Patients with Levodopa —Vesper Ramos,

P6.087 Changes in Cerebellar Nuclei Shreenath Rajendran, Mary Blue, Harvey Singer

Miliukhina, Valera Shadenkov, Elizaveta Gracheva, Beletskaya Maria, Daria Kulabukhova, Anton Beaudin, Leila Sellami, Gabrielle Houle, Christian Martel, Bastien Paré, Laurence Martineau, Nicolas Emelyanov, Sofya Pchelina

CASE BASED NEURO-ONCOLOGY: THE ART AND POWER OF CLINICAL OBSERVATION

literature —Dhiren Patel, Arunkumar Shah,

Trigeminal Nerve: Case Report —Mohamad

and Granule Layer in a Mouse Model of Stereotypies —Shannon Dean, Syed Ali,

Meher Ursekar

P6.103 Intra-axial CNS Involvement of P6.091 Glioblastoma Arising Within Sites Langerhans Cell Histiocytosis —Scott Turner, Syed Kazmi, Michel Lacroix of Encephalomalacia From Vascular brain injury: Two Novel Cases and a Review of the P6.104 Concurrent Leptomeningeal and Literature —Emily Ferenczi, Altaf Saadi, Shamik Parenchymal Brain Metastases in Primary Bhattacharyya, Aaron Berkowitz Invasive Ductal Cell Carcinoma of the P6.092 Anti-Ma2 Encephalitis: Beyond Breast —Armin Maghsoudlou, Seyedali Hejazi, Laura Simionescu Testicular Cancer—The Association with other Urogynecologic Tumors —Mario Altikes P6.105 Primary Leptomeningeal Hazzan, Herval Soares-Neto, Francine Gomes Medulloblastoma: A Rare Presentation —

P6.089 Phenotype and Cognitive Profile in ELOVL4-Associated SCA34 —Marie

Orabi, Julio Chalela, Cynthia Welsh, David Cachia

P6.117 Desmoplastic Medulloblastoma: A literature review and case report investigating most common clinical presentations in the adult —Jonathan Greco,

P6.128 Meningioma resection surgery

P6.118 Case Presentation Of CRPM5

P6.129 Patterns of Care in Recurrent

Encephalitis Secondary To A Thymoma. — Jessy Walia, Erin Feinstein

Thapa, Sushma Bellamkonda, Manmeet Ahluwalia

Caraballo-Cartagena, Yesenia Enriquez-Gonzales, Roberto Borrero, José Rodríguez, Patricia Pastor, David Blas-Boria

Survival on Vemurafenib Monotherapy in a Patient with Recurrent and Metastatic BRAF V600E Mutated Glioblastoma WHO Grade IV —Kanita Beba, Meggen Walsh, Anthony

Manifestation of Prostate Metastatic Disease: An Uncommon Diagnosis —Sonia

P6.093 WITHDRAWN P6.094 Spinal Leptomeningeal

P6.120 Angioimmunoblastic T-Cell P6.107 Leptomeningeal disease in a case Lymphoma with Central Nervous System

Dissemination as a Fatal Complication of Malignant Prolactinoma —Justine Cormier,

Adeniyi Fisayo, Joachim Baehring, Kevin Becker

Fazeel Siddiqui

of recurrent uveal melanoma —Sujan Teegala Reddy, Mary Frances McAleer, Sapna Patel

P6.108 Delayed Cerebral

Pseudoaneurysm Formation From

P6.095 Intravascular Lymphoma Involving Dissemination Of Atrial Myxoma —Ashley the CNS: A case report underscoring the importance of brain biopsy for progressive cerebrovascular disease —Cheran Elangovan,

Justin Lowe, Harmanpreet Tiwana, Muhammad Niazi, Charles Specht, Muhammad Ibrahimi, David Ermak

P6.096 Glioblastoma that Arises from Tumefactive Multiple Sclerosis —Jennifer Johnson, Nicholas Metrus, Carlos Kamiya Matsuoka

Roque, Joachim Baehring, Tara Kimbrough, Anita Huttner, Christopher Traner

Involvement Mimicking Acute Stroke — Nasima Shadbehr, Sung Cho

P6.121 Unsual Case of Ring Enhancing Multifocal Radiation Induced Necrosis — Nurose Karim, Sharjeel Panjwani, Alexis Vick, Gretchen Tietjen

Alshehri, Mohammad Ejaz, Ali Assiri

P6.110 Rapidly Progressive

lesion. —Fabio Nascimento, Peter Kan, Lydia Sharp, Jacob Mandel

P6.123 Melanoma and AMPA

Encephalitis- First Reported Case —Ali

Demyelinating Lesions in a patient with Daneshmand, Lance Pagliaro, Andrew McKeon, Intravascular B Cell Lymphoma: A Diagnostic Eelco Wijdicks, Sara Hocker Dilemma —Natasha Hameed, Pradeep P6.097 An Unusual Case of Histiocytosis P6.124 Capturing Capecitabine of the Central Nervous System involving the Kumbham, Betul Gundogdu Neurotoxicity: Delayed Clinical Leptomeninges —Bhumika Balgobin, Catherine P6.111 Cerebellar ataxia following Manifestations of Capecitabine-Related Austin, Lev Bangiyev , Agnes Kowalska allogenic stem cell transplant: A clinical Multifocal Leukoencephalopathy —John approach to a differential diagnosis — Greenert, Roohi Katyal, Sarah Sung P6.098 Neuropathy as an adverse effect of vascular endothelial growth factor Catherine Maurice P6.125 Primary CNS Posttransplant tyrosine kinase inhibitors, a meta-analysis of P6.112 CMV Colitis: A rare complication Lymphoproliferative Disease (PCNS-PTLD): randomized clinical trials —Bhaskar Roy, Avash in a LGI-1 antibody encephalitis patient Recognizing the Entity and Minimizing Das, Abhishek Maity, Aashish Gupta, Dhrubajyoti treated with Cellcept —Muhammad Amjad Toxicity in Renal Transplant Patients —Na Bandypadhyay Hameed, Sonja Chaparala, Tulika Ranjan

P6.099 CASPR2 Autoimmunity Preceding P6.113 Intravascular Lymphoma; the Diagnosis of Thyroid Cancer —Akanksha

a rare mimic of Acute Disseminating

Sharma, Sebastian Lopez, Andrew McKeon, Maciej Encephalomyelitis —Mina Lobbous, Mariam Mrugala Youssef, Sahil Gupta, Paula Warren

Friday

P6.100 Atypical Papillary Glioneuronal

P6.130 Eleven Month Progression Free

Yachnis, David Tran, Ashley Ghiaseddin

P6.131 Treatment at Academic Centers is Associated with Improved Survival in Patients with Low-grade Glioma —JayJiguang Zhu, Ping Zhu, Xianglin Du, Yoshua Esquenazi

P6.132 Botulinum Toxin as Prophylaxis

for Adverse Dermatologic Effects of Tumor-

P6.122 Spinal dural arteriovenous fistula Treatment Fields (TTF) —Julia Bucklan, Glen

P6.109 Primary Central Nervous System and concomitant intramedullary spinal Lymphoma Mimicking Tumefactive Multiple Sclerosis —Nourah Al-Hamdan, Ali Mohammed

Glioblastoma in the Era of Molecular Diagnosis —Ibrahim Migdady, Lu Dai, Bicky

P6.119 Cranial Nerve Palsies as a

Ankita Ghosh, John Slopis, Mary Kay Koenig

Cell Lymphoma —Shilpa Chaku, Nadeem Khan,

in elderly patients: An analysis of a national database —Mina Lobbous, Mariam Youssef,

Amanda Persaud, Natalya Shneyder, Scott Silliman Sahil Gupta, Angela Hays Shapshak

Barros Mendonça, Ana Pincerno Pouza, Roberta Arb Saba Rodrigues Pinto, Thiago De Araújo Gue Granjeia, Patrick Sampaio, Helton Oliveira, Sonia Magalhaes

P6.106 A Case of Intravascular Large B

THERAPEUTICS IN NEUROONCOLOGY: FROM LASER ABLATION TO IMMUNOTHERAPY II

Stevens, Dave Peereboom, Allison Vidimos, Susan Staugaitis

P6.133 Steroid-responsive Dementia with Immunotherapy for Metastatic Melanoma —Javier Gonzalez

P6.134 Acute stroke treated with tissue plasminogen activator in a patient with GBM —Archana Hinduja, Yasmeen Rauf

P6.135 A case of rare Papillary

Tumor of the Pineal Region (PTPR) with leptomeningeal metastases treated with Bevacizumab and Chemotherapy —Austin Momii, Mark Linskey, Xiao-Tang Kong, Daniela Bota, Jose Carrillo

P6.136 Two Cases of Pembrolizumab

Therapy for CNS lymphoma —Jerome Graber,

Tosha Gatson, Jeffrey Summers, Gino Mongelluzzo, Dan Moore, Raya Mawad Maria Bermudez, Joseph Vadakara, Leonard Gitter

P6.126 Immune Mediated Neuritis

P6.137 Hodgkin’s lymphoma presenting

as paraneoplastic rhombencephalitis: Do and Polyradiculopathy due to Checkpoint plasmapheresis and IVIG play a therapeutic Inhibitors —Rahul Chandak, Aashrai Gudlavalleti, role? —Tigran Kesayan, Xiyan Yi, Rebecca Hurst Awss Zidan

P6.114 Metastatic Melanoma presenting Tumor: A Neoplasm in Search of a Grade —J. as an Intraventricular non-bleeding Mass — P6.127 The Gray Area of Dueling Clay Goodman, Barrett Lawson, Jacob Cherian, Sana Somani, Rabia Jamy, Maron Rhodemarie Immunity: Clinical Challenges in Treating Shankar Gopinath P6.115 A Rare Presentation of Multiple Concurrent Multiple Sclerosis and Primary P6.101 Rare Malignant Transformation Myeloma Leptomeningeal Carcinomatosis — Brain Tumor —Muhammad Taimur Malik, Syed of an Epidermoid Cyst —Alexander Ou, Ryan Kazmi, Joseph Vadakara, Gino Mongelluzzo, Na Lalanthica Yogendran, Micah Etter, Harvey

NEURO-ONCOLOGY: GENES, BIOMARKERS, PATIENT CARE, AND OUTCOMES

Heslin, Agnes Kowalska, Patricia Coyle

Buchsbaum

P6.102 Lymphomatosis Cerebri: An

P6.116 Multi Cranial Neuropathy

Castillo Saavedra, Matthew Walker, Ryan Merrell

interesting case report and review of

174 2018 AAN Annual Meeting

Secondary To Primary Glioblastoma Of

Tosha Gatson

P6.138 Validation of a novel scoring

system to predict rapid meningioma growth —David Kamson, Carlen Yuen, Laura

P6.139 Elevated YKL-40 level in

P6.151 Clinical evaluation of fitness to

Solomon Ambe, Damir Nizamutdinov, Ndolembai Njesada, Ekokobe Fonkem

GuangRong Lu, Ping Zhu, Rong Shao, Leomar Ballester

Cristina Valencia Sanchez, Vanessa Góra, Steven Schild, Sujay Vora, Jonathan Ashman, Thomas Daniels, Michele Halyard, William Rule, Akanksha Sharma, Maciej Mrugala, Alyx Porter

P6.167 Leukopenia as a Possible

Cerebrospinal Fluid is Associated with Glioblastoma Recurrence —Jay-Jiguang Zhu,

P6.140 Neurocognitive Function and

drive in patients with brain metastases —

Biomarker for Overall Survival in Glioblastoma Patients Treated with Temozolomide —Ka-wai Ho, Eric Wong, Erik

P6.179 Optimizing the Gantenerumab

Phase 3 Dosing Regimen Through PK/PD Modeling and Clinical Trial Simulations —

Carsten Hofmann, Ronald Gieschke, Sylvie Retout, Smiljana Milosavljevic-Ristic, Nicola Voyle, Paul Delmar, Daniel Serafin

Uhlmann P6.180 The effect of social relationships Quality of Life in Stable Grade 2 and 3 Glioma P6.152 Gliomatosis Cerebri: Predispositions and Predictors of Behavior — Patients —Tracy Luks, Angela Jakary, Susan P6.168 A case series of thalamic gliomas and leisure activities in prevention of Motoric Chang, Sarah Nelson, Jennifer Clarke, Nancy Ann Fernando Santos Pinheiro, Na Tosha Gatson, Carlos Cognitive Risk Syndrome. —Emmeline Ayers, Kamiya Matsuoka, Gregory Fuller, Jeffrey Weinberg, harboring H3 K27M mutation —Divya Mella, Oberheim Bush, Nicholas Butowski, Jennie Taylor

P6.141 Prediction of Platelet-Derived

Growth Factor Receptor Alpha (PDGFRA) gene amplification for newly diagnosed glioblastoma patients with radiomic analysis on Apparent Diffusion Coefficient (ADC) maps —Stefania

Ivo Tremont, John De Groot, Monica Loghin

P6.153 Prospective Assessment of

End of Life Symptoms and Quality of Life in Glioblastoma —Tobias Walbert, Lonni Schultz,

Rahul Abhyankar, Edward Pan

Joe Verghese

P6.169 Retrospective Review of Surgical P6.181 Establishing digital biomarkers Tissue Sample Processing for Molecular Diagnosis of Gliomas at DHMC —Hena

Waseem, Sahyli Perez Parra, Angeline Andrew, Joel Phillips Daniel Calnan, Angela Lee, Erin D’Agostino, Lara Maraka, Aikaterini Kotrotsou, Srishti Abrol, Ahmed P6.154 A Neurologists Foray into Gamma Ronan Kunschner, Lananh Nguyen Hassan, Nabil Elshafeey, Olga Starostina, Kristin Knife: Lessons Learned from the first 50 P6.170 Undetected CSF and Low Serum Alfaro-Munoz, Rivka Colen, John De Groot cases: —Glen Stevens, Lilyana Angelov, Michael

for clinical trials. —Neil Thomas, Nora Mattek,

Thomas Riley, Phelps Witter, Christina Reynolds, Johanna Austin, Nicole Sharma, Jennifer Marcoe, Jeffrey Kaye

P6.182 Safety, Tolerability and

Pharmacokinetics of Crenezumab in Mildto-Moderate AD Patients Treated with Escalating Doses for up to 32.3 Months —

P6.142 LZTR1 mutations associated

Vogelbaum, Jenny Yu, Samuel Chao, John Suh, Gene Barnett, Gennady Neyman, Erin Murphy, Alireza Mohammadi

Epstein Barr Virus PCRs in EBV-Positive CNS Post Transplant Lymphoproliferative Disorder —Shreya Nayak, Islam Zaydan

Smith, Marlon Seijo, James Walker, Serkin Erdin, Vanessa Merker, Vijaya Ramesh, Wenli Cai, Gordon Harris, Miriam Bredella, James Gusella, Scott Plotkin

P6.155 The Development of

P6.171 The ENIGMA Cancer and

P6.143 Incidence trends, rates, and

Brian Andersen, Vaios Hatzoglou, Lisa DeAngelis

P6.156 WITHDRAWN P6.157 Effect of Health Disparities

Shiroishi, Vikash Gupta, Joshua Faskowitz, Bavrina A meta-analysis and systematic review Bigjahan, Steven Cen, Faisal Rashid, Darryl Hwang, assessing the current evidence based on Alexander Lerner, Orest Boyko, Chia-Shang Jason Liu, Meng Law, Paul Thompson, Neda Jahanshad prospective observational studies and randomized controlled trials —Wei Xu

with greater pain among patients with schwannomatosis —Justin Jordan, Miriam

ethnic variations of primary CNS tumors in Texas from 1995–2013. —Solomon Ambe,

Ventriculomegaly in Glioblastoma (GBM) Patients —Caroline Miranda, Alexandra Miller,

Chemotherapy Working Group and CancerRelated Cognitive Impairment —Mark

Kristopher Lyon, Damir Nizamutdinov, Ekokobe Fonkem on Overall Survival of Patients with P6.172 NA Glioblastoma —Jacob Mandel, Michael Youssef, P6.144 Refractory status epilepticus as Joo Yeon Nam, Jimin Wu, Diane D. Liu, Melissa CLINICAL TRIALS AND a predictor of tumor progression and poor THERAPEUTIC APPROACHES IN Bondy, John De Groot prognostic indicator —Dana Vanino, Cynthia NEURODEGENERATIVE DISEASES P6.158 Adult Pilocytic Astrocytoma: Correll, Na Tosha Gatson

P6.145 NF1 Associated Extra-Optic

Gliomas: The Importance of Age, Imaging, and Clinical Presentation Over Histology Alone —Marina Girgis, Fang-Chi Hsu, Adrian

Laxton, Stephen Tatter, Michael Chan, Christina Cramer, Glenn Lesser, Roy Strowd

P6.146 Assessing cerebral metabolic

activity of an Atkins-based diet using MR Spectroscopy—A feasibility study in glioma patients —Karisa Schreck, Adam Berrington, Bobbie Henry-Barron, Lindsay Blair, Adam Hartman, Eric Kossoff, Linda Easter, Christopher Whitlow, Fang-Chi Hsu, Mackenzie Cervenka, Jaishri Blakeley, Peter Barker, Roy Strowd

P6.147 Development and Validation

of Immunoassays for Paraneoplastic Neurological Disorders using a Parallel Nanoscale Microfluidic Analysis System —

Clinical Management and Prognostic Factors —Ovais Inamullah, John Kirkpatrick,

Patrick Healy, Eric Lipp, Margaret Johnson, David Ashley, Dina Randazzo, Henry Friedman, Katherine Peters

P6.159 Leptomeningeal dissemination

from low-grade neuroepithelial CNS tumors in adults: A 15-year experience —Philipp

Karschnia, Frank J. Barbiero, Michaela H. Schwaiblmair, Joseph M. Piepmeier, Anita Huttner, Kevin Becker, Robert K. Fulbright, Joachim Baehring

P6.160 Predictors of Early and Recurrent Seizure in Low-Grade Glioma —Jasmin

Jo, Kathryn Nevel, Ryan Sutyla, Mark Smolkin, Beatrice Lopes, David Schiff

P6.148 Molecular Classification of Glioblastoma in the Clinical Setting — Bernadette Kalman, Adam Nagy

P6.149 Ultra-High Gradient Diffusion

Barbara Wichtmann, Aapo Nummenmaa, Ovidiu Andronesi, Qiuyun Fan, Brian Nahed, William Curry, Daniel Cahill, Alexandra Golby, Tracy Batchelor, Jayashree Kalpathy-Cramer, Bruce Rosen, Elizabeth Gerstner

P6.150 Long-Term Outcomes of Adult

In Vivo and In Vitro Binding Properties of Crenezumab: Insights into Crenezumab’s Unique Mechanism of Action —William

Meilandt, Janice Maloney, Jose Imperio, Travis Bainbridge, Mike Reichelt, Danielle Mandikian, Yanmei Lu, James Ernst, Reina Fuji, Jasvinder Atwal

P6.175 Memantine Added to Background

Lorenzana-Mendoza

Ellison, John Edwards, Majid Kerolous

P6.162 Semi-Automated MRI

based profile for Alzheimer’s prevention:

P6.184 NSAID Use and the Prevention of

Alzheimer’s Disease: A Meta-Analysis —Xi Li, Flyn Kaida-Yip, Matthew Zabel

HEALTH CARE AND CAREGIVER ISSUES IN DEMENTIA

P6.185 Does Sleep Quality Moderate the Effect of Vitamin D Intake on Risk for Dementia? —Chen Zhao, Angeliki Tsapanou,

Jennifer Manly, Nicole Schupf, Adam Brickman, Yian Gu

baseline cognitive impairment and predicts in-hospital complexity —David Bissig, Charles DeCarli

P6.187 Characterization of Fall-Related

Injuries in Progressive Supranuclear Palsy —Susanna Kwok, Shoshannah Rubin, Dana McDermott, Bruce Miller

P6.188 Potential Resource Utilization

Benefits of Delaying the Progression of Mild Agronin, George Grossberg, Suzanne Hendrix, Noel Cognitive Impairment —Wan Tsong, Eddie

P6.176 Memantine ER and Donepezil

Treatment Maintains Cognitive Segmentation Workflow for Glioblastoma Improvements Versus Donepezil Treated by Tumor Treating Fields —Joshua Timmon, Edwin Lok, Pyay San, Kevin Bui, Eric Wong Monotherapy: Post Hoc Analyses From a Placebo-controlled Study in Patients with P6.163 Association of Reduced DNA Moderate-to-Severe Alzheimer’s Disease — Repair Gene Expression on Chromosome Alireza Atri, Jeffrey Cummings, Suzanne Hendrix, Arms 1p and 19q with Increased Noel Ellison, John Edwards Chemosensitivity in 1p19q Codeleted Lowergrade Gliomas —Natalie Neale, Lei Tang, Lu Deng, P6.177 Memantine With Cholinesterase Inhibitors Maintains Improvements of Harrison Bai, James Sun, Paul Zhang, Li Yang Psychiatric Symptoms vs Cholinesterase P6.164 Systemic staging in patients with Inhibitors Alone: Post Hoc Analyses From lymphomatous brain lesions —Rachna Malani, 3 Randomized, Double-blind, PlaceboAnkush Bhatia, Julia Wolfe, Christian Grommes controlled Studies in Patients With P6.165 CSF Lactate Dehydrogenase as a Alzheimer’s Disease —Jeffrey Cummings, prognostic marker in neoplastic meningitis — George Grossberg, Anton Porsteinsson, Suzanne Bernardo Cacho Diaz, Nydia Lorenzana-Mendoza,

P6.183 The construction of evidence-

P6.174 Characterization of the Selective P6.186 Brief cognitive screening detects

Cholinesterase-Inhibitors Reduces Agitation in Alzheimer’s Disease —Alireza Atri, Marc

Patients with Ependymoma —Zachary Vaslow, Sergio Valdes-Ferrer Katherine Peters, John Kirkpatrick, Frances P6.166 Incidence of Primary Brain and McSherry, James Herndon II, Eric Lipp, Margaret Central Nervous System Tumors Among Johnson, David Ashley, Annick DesJardins, Dina Hispanic Population in Texas 1995-2013 — Randazzo, Henry Friedman

Kramer, Suzanne Hendrix, Noel Ellison, Majid Kerolous

Helen Lin, Andres Schneider, Angelica Quartino, Tobias Bittner, Nan Hu, Jillian Smith, William Cho, Susanne Ostrowitzki

Hendrix, Noel Ellison, Majid Kerolous

P6.178 Memantine and Cholinesterase

Jones, James Pike, Daniel Bluff

P6.189 Changes in Depression Severity

Correlate with Quality of Life in Alzheimer Disease: A Longitudinal Study —Elizabeth Joe, Freddi Segal-Gidan, Lon Schneider, Helena Chui, John Ringman

P6.190 Sleep and Subjective Cognitive

Complaints in cognitively healthy older adults: Results from two cohorts —Angeliki

Tsapanou, Stephanie Cosentino, Yian Gu, Jennifer Manly, Adam Brickman, George Vlachos, Mary Yannakoulia, Mary Kosmidis, Efthimios Dardiotis, Georgios Hadjigeorgiou, Paraskevi Sakka, Yaakov Stern, Nikolaos Scarmeas

P6.191 Quality of Sleep Among

Caregivers of Alzheimer Disease Patients — Adel Ali Alhazzani, Mohammed Alqahtani, Turki Alyami, Ahmad Awwadh, Ahmad Alshbriqe, Mohammed alshomrani, Ossama Mostafa

Inhibitor Use in Alzheimer Disease Trials: Potential for Confounding by Indication —

Branko Huisa-Garate, Ronald Thomas, Shelia Jin, Tilman Oltersdorf, Curtis Taylor, Howard Feldman

AAN.com/view/AM18 175

Friday

MRI Reveals Distinct Microstructural Changes in Gliomas Before and After Radiation Therapy —Ina Ly, Susie Huang,

Improves Individual SIB Scores Compared With AChEI Alone: Post Hoc Analyses From a Randomized, Double-blind, Placebocontrolled Study —George Grossberg, Ken

P6.161 Clinical manifestations and

location of brain metastases as prognostic Urszula Trela, Keith Morneau, Brian Sansoucy, Amy markers. —Bernardo Cacho Diaz, Nydia Goldberger, Redon Xharja, Kelsie Twombly, Olivia Apiri, David Borowy, Emily Katzman, Beth Noyst, Pamela Loveland, Jamie Willis, Michael Jocson, Zhenyuan Wang, Sat Dev Batish, Nigel Clarke, Joseph Higgins

P6.173 Memantine ER With an AChEI

POSTER SESSIONS

Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.

POSTER SESSIONS

POSTER SESSION VI G P6.192 Correlates of Behavioral and

Psychological Symptoms of Dementia and impact on caregiver distress—A study from Eastern India —Adreesh Mukherjee,

Atanu Biswas, Arijit Roy, Samar Biswas, Goutam Gangopadhyay, Shyamal Das

Of Refractory Intracranial Hypertension Secondary To Extensive Cerebral Venous Thromboses. —Vijayaleskhmi Nair, Wyssem Ramdani, Elena Schmidt, Julius Latorre

P6.205 IV tPA Administration in Chronic Aortic Dissection —Soha Sadeghikhah,

Yosbelkys Martin Paez, Anna Khanna P6.193 WITHDRAWN P6.194 Factors Associated with Clinician P6.206 Bloodstream infection is

Adherence to Clinical Practice Guidelines for associated with infectious intracranial aneurysm in left ventricular assist device — the Diagnosis of Alzheimer’s Dementia —

Friday, April 27 11:30 a.m.–5:30 p.m. Report and Review of the Literature —Marion CEREBROVASCULAR AND CARDIAC Oliver, Vivek Rai, Todd Mulderink, Connor Greer DISEASE P6.221 Giant Carotid Pseudoaneurysm P6.236 Is Patent Foramen Ovale Amenable to Pipeline Stenting in a Patient in-rest a risk factor for Embolic strokes of with Ehlers-Danlos Type IV —Blake Senay, undetermined source? —Jamileh Chamma, Rohit Nallani, Paul Mazaris, Muhib Khan

P6.222 Embolic Stroke Due To

Thrombosed Left Subclavian Vein —Richard Jackson, Lily Chau, Adrian Marchidann

P6.223 Carotid Steal Syndrome

Ahmed Malik, Donald Cibula, Christopher Morley, Amy Sanders

Tiffany Lee, Sung Cho, Andrew Buletko, Jason Matthew

P6.195 Using digital biomarkers as

P6.207 Infectious Intracranial Aneurysm Kaur, Ramandeep Sahni, Stephen Marks During Cardiac Valve Repair —Cory Rice, Sung P6.224 May-Thurner Syndrome as a Cho, Lucy Zhang, Jean Khoury, Prateek Thatikunta,

objective measures of activity and effort related to caregiving. —Neil Thomas, Thomas Riley, Nora Mattek, Phelps Witter, Christina Reynolds, Johanna Austin, Nicole Sharma, Jennifer Marcoe, Jeffrey Kaye

Dolora Wisco, Muhammad Hussain, Ken Uchino

P6.208 Brain aneurysm associated with

BEHAVIORAL AND COGNITIVE NEUROLOGY: OTHER III

P6.197 The Prevalence of the Frontal

atrial myxoma. —Renan Coutinho, Mayara Haynes, Carolina Oliveira, Marco Lima

P6.225 Homocysteinuria due to

P6.198 Rapidly Progressive Dementia: Towards a Better Diagnostic Approach —

Mariano Marrodan, Lucas Alessandro, Mario Emiliano Ricciardi, Vanesa Nagel, Ricardo Allegri, Francisco Varela

P6.199 Impaired Clock Drawing Test

in Progressive Supranuclear Palsy and Corticobasal Syndrome: Differences from Alzheimer Disease —David Geldmacher,

cystathionine β-synthase deficiency

P6.209 Arteriovenous Fistula Presenting manifesting as Moyamoya disease and as Progressive Bifrontal Intracerebral Henoch-Schonlein Purpura —Rodica Di Hemorrhage —Benjamin Cox, Stephen Johnson, Lorenzo, Sung-Min Cho, Ken Uchino Eugene Scharf

Lobe Syndrome in a population-based P6.210 Distinct Presentation of Dural sample of 65 year olds: Preliminary Results AV Fistula as Primary Intraventricular from the Great-Age Study —Petronilla Battista, Hemorrhage Isolated in Cerebral Marco Piccininni, Orietta Barulli, Chiara Griseta, Aqueduct —Priyadarshee Patel, Premkumar Alessandra Grasso, Cristina Di dio, Roberta Stallone, Rosa Capozzo, Madia Lozupone, Rodolfo Sardone, Rosanna Tortelli, Francesco Panza, Giancarlo Logroscino

Cause of Embolic Stroke of Undetermined Source in a Young Patient: A Case Report — Andres De Leon Benedetti, Erika MarulandaLondono, Amer Malik

P6.196 Can Dementia Caregivers Define Graciani, Livia Afonso, Thiago Teixeira, Beatriz Dementia? —Joel Shenker, Gurtej Singh

Mimicking Subclavian Steal Phenomenon due to Innominate Artery Stenosis —Kavneet

Nattanmai Chandrasekaran, Kunal Bhatia, Elanagan Nagarajan

P6.211 CAMS Type II with Unusual

Involvement of Temporal Lobe —Tushar Bajaj, Syed Arsalan Akhter Zaidi, Rene Elkin

P6.213 Radiographic Efficacy of Middle

Meningeal Artery Embolization in Treatment

Age, Education, and Cognitive Impairment/ Diagnosis on Time to Complete Digital Cognitive Testing using the electronic SelfAdministered Gerocognitive Examination (eSAGE) —Douglas Scharre, Shu-Ing Chang, Haikady Nagaraja, Nicole Vrettos, Maria Kataki

STROKE CASE REPORTS II

P6.201 Intracerebral Hemorrhage

P6.214 Subclavian Steal Syndrome

secondary to Dialysis AVF treated with Balloon Mounted Stent —Shashank Agarwal, Patrick Kwon, George Selas, Jeffrey Farkas, Karthikeyan Arcot, Lisa Schwartz, Ambooj Tiwari

P6.215 Cavernous Sinus

Thrombophlebitis with secondary Vasculitis and Ischemic Stroke —Shahrzad Deliran, Lotte Sondag, Anton Meijer, Anil Tuladhar

Dinesh Jillella, Guangbin Xia

P6.228 A Case of Primary CNS Angiitis

Friday

176 2018 AAN Annual Meeting

in Diagnosis of MCA Dissection: A Case

Muhammad Taqi, Farzad Adl, Syed Quadri, Ajeet Sodhi, Martin Mortazavi

P6.240 Diagnosis Value of Prehospital

Biomarker of Ischemic Stroke in Ventricular Assist Device? —Catherine Hassett, Sung Min Cho, Cory Rice, Ken Uchino

P6.243 Cryptogenic Ischemic Stroke Patients with Left Atrial Enlargement are More Likely to Have Paroxysmal Atrial Fibrillation —Tracy Ander, Chelsey Mcpheeters,

Michael Christiansen, Cumara O’Carroll, Oana Dumitrascu

P6.231 Would you use new

oral anticoagulants (NOACs) for thromboprophylaxis in patients with an underlying hypercoagulable state? A literature review through a case report. —

Bhavika Kakadia, Rrita Daci, Giselle Suero-Abreu, Ryna Then

Assist Device Associated Ischemic Stroke — Catherine Hassett, Sung Min Cho, Cory Rice, Ken Uchino

Lauren Miller, Elizabeth Wise, Ruolan Liu, Jignesh Shah, Kerri Remmel, Wei Liu

P6.244 Comparison of Implantable

Loop Recorder and Event Monitors for Diagnosis of Atrial fibrillation in Patients with Cryptogenic Stroke —Smeer Salam, Noah Grose, Julie Mease, Muhammad Afzal, Archana Hinduja, Emile Daoud

P6.245 Risk of ischemic stroke

recurrence in patients with atrial fibrillation diagnosed after stroke —Luciano Sposato,

P6.232 Left Ventricular Non-Compaction: Joshua O. Cerasuolo, Lauren Cipriano, Jimming A Rare Cause of Stroke in the Young —

P6.217 Lateral Medullary Syndrome due Kauroon Darya, Monica Mejia-Acosta to Left Vertebral Artery Occlusion in a Boy Post Flexion Neck Injury —Abdulla Alawadhi, P6.234 Subdural hematoma secondary

P6.220 High Resolution Vessel Wall MRI

v/s Transesophageal Echocardiogram in Identification of Intracardiac Thrombus in Acute Ischemic Stroke Patients —Sajid Suriya,

Vision Loss Despite Aortic and Carotid Revascularization in Takayasu’s Arteritis —

P6.202 Thrombotic Therapy for

With Concomittant In-situ RTPA infusion And Systemic Anticoagulation In A Case

P6.239 Transthoracic Echocardiogram

P6.242 The Etiology of Left Ventricular

P6.233 Atrio-esophageal fistula

P6.204 Mechanical Thrombectomy

Robert Sawyer

Presenting as Longitudinally Extensive Transverse Myelitis —Frank Benesh, Amanda

Anabtawi, Dinesh Jillella, Christopher Calder

Fernando Torres, Kuo Chao, Marko Petrovic, Nazely Ashikian, Robert Arbuckle

Transesophageal Echocardiogram in Stroke in the Young —Muhammad Ahmed, Haris Kamal,

P6.241 Is Lactate Dehydrogenase level a

Unusual Stroke Mimic —Joshua Trujeque,

Mohammad Ridha, Supria Batra, Jennifer Collins, Jana Montgomery, Doreen Ho, Barbara Voetsch

Acute Stroke in Pratient with Refractory Epilepsy and an Implanted Responsive Christine Saint-Martin, Guillaume Sebire, Michael Neurostimulation Device with Intravenous Shevell Recombinant Tissue Plasminogen Activator —Heidi Henninger, Jane Morris, Diana P6.218 Traumatic Carotid Artery Dissection in Teenagers After Football Goodman, Barbara Jobst Injuries —Yvo Rodriguez-Linares, Surabhi Kaul, P6.203 Uncomplicated intravenous Gerson Suarez-Cedeno, Louise McCullough, Ritvij thrombolysis after lumbar puncture: A case Bowry report —Shashank Shekhar, Hebatalla Elhusseiny, P6.219 Recurrent Vertebral Arteries Christa O’hana Nobleza, Rebecca Sugg, Shreyas Dissection —Yuri Bronstein, Mitchell Danesh, Gangadhara

P6.238 Diagnostic Yield of

P6.227 Rheumatoid Meningitis: An

P6.216 A Case of Bilateral Globi Pallidi

Infarcts with Methamphetamine Use —Amir

Gary Gronseth

Sneha Jacob

after IV tPA for Stroke as Early Symptoms of ANCA-Associated Vasculitis —Neda

Zarghami, Daniel Anderson, Connie Pieper, Harold Adams

patients with Cryptogenic stroke and TIA with normal TTE: A systematic review and meta-analysis. —Shamik Shah, Yunxia Wang,

Electrocardiogram (ECG) vs Post Hospitalization 30-day Event Monitoring in Detecting Cardiac Arrhythmia in Ischemic Stroke Patients —Adrian Moritz, Iftekhar Ahmed

P6.230 Neurobrucellosis:Unusual Marissa Natelson Love, John Hammond, Giovanna of Chronic Subdural Hematoma —Nathan Pilonieta Farkas, Ryan Bo, Karthikeyan Arcot, Ambooj Tiwari, Cause of Stroke in a Young Patient —Walaa David Turkel-Parrella, George Selas, Jeffrey Farkas Mohammed, Mohamad Walid Al Sous P6.200 Influence of Digital Proficiency,

P6.237 Diagnostic yield of TEE in

Lady with Antiphospholipid Syndrome and Libman-Sacks Endocarditis —Amelia Adcock,

P6.226 Stroke Prevention in a Young

P6.212 A Case of Monocular Vision Loss Pennington, Kenneth Fallon, John Rinker in the Setting of Internal Carotid Artery P6.229 Irreversible and Severe Stenosis and Carotid-Cavernous Fistula. — Kishan Patel, Shannon White, Y. Jonathan Zhang, Richard Klucznik, Orlando Diaz-Daza, Rajan Gadhia

Valeria Scavasine, Gabriel Braga, Rodrigo Bazan, Viviane Zetola

Fang, Sebastian Fridman, Maryse Paquet, Gustavo Saposnik

P6.246 Heart - brain relationship: Cerebrovascular disease and its cardiac presenting with acute devastating strokes — impact —Guido Vazquez, Carlos Vigliano, Blas to spontaneous rupture of pseudoaneurysm of middle meningeal artery —Guru Ramaiah,

Syed Zaidi, Mouhammad Jumaa, Preeti Rao, Kevin Litzenberg

Couto, Alejandro Thomson, Alejandro Bertolotti, Roberto Favaloro, Juan Pablo Santili, Carla Florencia Bolaño Diaz, Francisco Klein

P6.247 WITHDRAWN P6.248 Atherosclerotic Risk Factor

Prevalence in Young Adults with Stroke and Acute Myocardial Infarction —Michelle Hemorrhage Complicating Venomous Leppert, James Burke, Jonathan Campbell, Snakebite in Nigeria: A Case Report —Aminat Timothy Bernard, Stefan Sillau, Michael Ho

P6.235 Intraparenchymal Intracerebral Kehinde Bakare, Kolawole Wahab, Omotoyosi Ilesanmi, Emmanuel Sanya

P6.249 Pre-existing Cardiac Thrombus

in Patient of Acute Ischemic Stroke with Large Vessel Occlusion —Sajid Suriya, M Asif

Taqi, Farzad Adl, Syed Quadri, Ajeet Sodhi, Martin Mortazavi

PRE-HOSPITAL, TELESTROKE, AND ED-BASED STROKE CARE IV

P6.250 Door In Door Out over Telestroke, two comprehensive stroke centers experience —Sami Alkasab, Danuel Snelgrove, Nancy Turner, Steve Warrs, Juanita Caudill, Christine Holmstedt, Jeffrey Switzer

P6.251 Evaluation of the Tele-Stroke Mimic Score (TM-Score) for Prehospital Distinction Between Stroke and Stroke Mimic Patients —Syed Ali, Frederik Geisler,

Martin Ebinger, Alexander Kunz, Michal Rozanski, Carolin Waldschmidt, Joachim Weber, Matthias Wendt, Benjamin Winter, Lee Schwamm, Heinrich Audebert

P6.253 Impact of the Implementation

P6.267 A Systematic Review of Seizures Shrestha, Li Wang, Huseyin Yuce, Joseph Zorzoli, R of Pooled Data from Four National Pharmacy and Epilepsy in Leukodystrophies —Royce Sumayo, Joseph Sirven

P6.268 Clinical Correlates of Negative Health Events in a Research Sample with Epilepsy —Neha Kumar, Kari Zimmermann, Hongyan Liu, Curtis Tatsuoka, Edna FuentesCasiano, Kristin Cassidy, Douglas Einstadter, Martha Sajatovic

P6.269 Association Between

Socioeconomic Variables and Seizure Frequency —Jaime Olivas, José Luis Gonzalez, Gerardo Padilla, Marco Diaz

P6.270 Psychosocial and Physiologic

Characteristics of Patients with Nonepileptic Events: A Retrospective Study of Rural Patients —Dipali Nemade, Paul Ferguson,

of an Extended Stroke Code Window on Stroke Code Volume and Yield —Lili Velickovic Sona Shah Ostojic, Danielle Wheelwright, Laura Stein, Steven P6.271 Knowledge, perceptions and Persaud, Stanley Tuhrim attitudes towards schoolchildren with P6.254 Importance of Awareness in epilepsy among school teachers in two Wake-Up Stroke —Shuichi Suzuki, Jason cities in south western Nigeria —Morenikeji Meng, Ravi Patel, Li-Mei Lin, Kiarash Golshani, Hermelinda Abcede, Mohammad Shafie, Wengui Yu, Steven Cramer, Mark Fisher, Frank Hsu

Komolafe, Taofiki Sunmonu, Olusegun Afolabi, Ayoade Adebiyi

P6.255 NA P6.256 NA P6.257 NA P6.258 NA

(BOI) of Lennox-Gastaut Syndrome (LGS) in the US —Tyler Story, Georgia Montouris, Susan

EPILEPSY: COMORBIDITIES, PSYCHOSOCIAL, HEALTH ECONOMICS, QUALITY

Funk, Timothy Saurer, Nancy Reaven

P6.273 Epilepsy: Transition from

Pediatric to Adult Care. Recommendations of the Ontario Epilepsy Implementation Task Force —Danielle Andrade, Anne Bassett,

Obstructive Sleep Apnea Using a Prompt in the Electronic Health Record in Adult Patients with Epilepsy. —Siddharth Gupta,

P6.274 Healthcare expenditure patterns among elderly with seizure in the United States: Medical Expenditure Panel Survey, 2003-2014. —Alain Lekoubou Looti, Kinfe Bishu,

Martha Mulvey, Aravindhan Veerapandiyan, Xue Ming Bruce Ovbiagele

P6.262 Muscle Tone in the Rapid Eye

P6.275 Preliminary Report of Movement Sleep of Persons with Epilepsy — Psychogenic Non-Epileptic Seizure Diagnosis Marcus Ng, Eleni Giannouli Among Veterans From 2004-2014 —Arjumond P6.263 Heart Rate Variability in Epilepsy: Khan, Nora Proops, Joshua Flaherty, Brenda Fenton, Mary Jo Pugh, Kei Cheung, Joseph Goulet, A Potential SUDEP Risk Biomarker —Ken Myers, Luis Bello-Espinosa, Joseph Symonds, Sameer Zuberi, Robin Clegg, Lynette Sadleir, Jeffrey Buchhalter, Ingrid Scheffer

P6.264 Antiepileptic Drugs and

Suicidality in Veterans with Epilepsy —

Shawniqua Williams, Rizwana Rehman, Gabriel Bucurescu

P6.265 Can volumes of cortical and

Carlos Millan, Anita Saporta, Ramses Ribot, Travis Stoub, Christin Bermudez, Merredith Lowe, Maria E Palomeque, Gustavo Rey, Enrique Serrano, Naymee Velez-Ruiz, Jonathan Jagid, Andres Kanner

P6.266 Assessment of Cognitive

Functioning In Patients with EpilepsyPreliminary Findings —Allison Hoynes, Nada

Alyousha, Monita Karmakar, Zayd Safadi, Anisha Maheshwari, Mary Haines, Imran Ali

O’Neal, Onur Baser, Li Wang, Joyce Cramer

Sara Golas, Jennifer Felsted, Joseph Dye, Jesse Fishman, Marjory Levey, Stephen Agboola

SPORTS NEUROLOGY

Cost of Care in an Integrated Healthcare System —Sujay Kakarmath, Mahesh Agarwal,

P6.281 The association between

P6.276 The Burden of Seizures in Adults with Tuberous Sclerosis Complex (TSC) and Epilepsy: Data from a Specialized Center in Netherlands —Bernard Zonnenberg, Wendela L.

de Ranitz-Greven, Raluca Ionescu-Ittu, Bruno Emond, Mei-Sheng Duh, Maureen Neary, Menno Vergeer

P6.294 NA

P6.295 Using Botox, biofeedback

and lifestyle modifications as therapy office-based provider visits and emergency for medication refractory post-traumatic department utilization among publicly headache (PTHA) in the military population insured epilepsy patients. —Kinfe Bishu, Bruce of Okinawa. —Nawaz Hack, Kathryn Eliasen Ovbiagele, Alain Lekoubou Looti

P6.282 Use of Templates in

Implementing AAN Epilepsy Quality Measurement Set in Neurology Resident Clinic —David Mao, Geetha Chari, Noa Sheikin, Katherine Mortati, Helen Valsamis

P6.283 Predictors of Clinically

Meaningful Improvements in Health-Related Quality of Life Among Adults With PartialOnset Epilepsy: A Pooled Analysis From Two Eslicarbazepine Acetate Monotherapy Trials —Joyce Cramer, Kathryn Anastassopoulos, Krithika Rajagopalan, David Blum

Depression and Anxiety Disorders in Veterans with Epilepsy: Can it be Prevented? —Mark Armanious, Maria Lopez, Rizwana Rehman, Andres Kanner

P6.296 Concussion and the Risk of

Suicide: A Systematic Review and MetaAnalysis —Matthew Burke, Michael Fralick,

Eric Sy, Adiba Hassan, Elizabeth Mostofsky, Todd Karsies

P6.297 Premorbid ADHD and Concussion in Pediatric Population —Megan Edwards,

Amanda Witt, Sara Dawson, Claire Harkey, Kevin Bui

P6.298 Value of Occupational Therapy in a Pediatric Concussion Clinic —Madison

Harris, Christopher Giza, Samia Rafeedie, Douglas Polster, Aliyah Snyder, Talin Babikian

P6.299 Amygdala Disconnection in

Pediatric Traumatic Brain Injury (TBI) —Kevin Bickart, Alexander Olsen, Emily Dennis, Talin Babikian, Robert Asarnow, Christopher Giza

P6.300 High Sensitivity C-Reactive

Protein: Potential Biomarker of Inflammation

P6.285 Suicidal Ideation among Epilepsy in Acute mTBI —Teena Shetty, Taylor Cogsil, Patients at a Sub-Saharan Health Facility in Calabar, Nigeria —Sidney Oparah, Uduak Williams, Kalu Idika

P6.286 Improving Antiepileptic

Medication Administration Time to Status Epilepticus Patients —Jennifer Haynes, Ivan

Cuesta Isabel, Ossama Khazaal, David Rahimian, Sarah Zubkov, Van Hellerslia

P6.287 Reduced Healthcare Costs

Among Clobazam-Treated Patients With Lennox-Gastaut Syndrome —John Stern,

Augustina Ogbonnaya, Ed Tuttle, Wendy Cheng, Georgia Montouris, Jesus Pina-Garza, Steven Kymes, Tasneem Lokhandwala, Francis Vekeman, Clement Francois

P6.288 Cognitive Burden of Seizures in Patients with Tuberous Sclerosis Complex (TSC) for Health-Related Quality of Life (HRQoL) and Functional Status —Bernard

Zonnenberg, Wendela L. de Ranitz-Greven, Raluca Ionescu-Ittu, Bruno Emond, Mei-Sheng Duh, Maureen Neary, Menno Vergeer

P6.289 Improving Epilepsy Care in Older

Adults in the Long-Term Care Setting: Effect of Online Medical Education on Risks and Recognition Among Neurologists —Piyali

Aashka Dalal, Kristin Halvorsen, Kelianne Cummings, Joseph T Nguyen

P6.301 Concussion Knowledge in

Nurses: Educating the front line —Philip

Rosenbaum, Mania Alexandrian, Nisha Batta, David McArthur, Meeryo Choe, Christopher Giza

P6.302 Distinct 6-Month Functional

Outcome Trajectories and Predictors after Traumatic Brain Injury —Raquel Gardner, Jing Cheng, Adam Ferguson, John Boscardin, Ross Zafonte, Geoffrey Manley

P6.303 Recovery Time, Risk Factors, and Volumetric Analysis in Acute mTBI —Teena

Shetty, Joseph T Nguyen, Taylor Cogsil, Apostolos Tsiouris, Sumit Niogi, Aashka Dalal, Kristin Halvorsen, Tianhao Zhang, Joseph Masdeu, Pratik Mukherjee, Luca Marinelli

P6.304 Chronic mTBI: Who is at Risk,

A Retrospective Analysis of mTBI Patients Presenting to the TBI Clinic at a Large Military Base —Aaron Daley, Ajal Dave, Matthew Blattner, Kendra Cagniart, Matthew Holtkamp

P6.305 Use of Event Related Potential Markers in Patients with Traumatic Brain

Chatterjee, Thomas Finnegan, Sheryl Haut, Ilo Leppik Injury —Tad Seifert, Marco Cecchi

P6.290 The Direct Cost Burden of Illness P6.306 Retinoid X Receptor Alpha (BOI) of Dravet Syndrome (DS) in the US —

Polymorphisms may Associate with Markers

stroke among adults with epilepsy in the United States: Medical Expenditure Panel Survey, 2003-2014. —Alain Lekoubou Looti,

P6.307 Never Say Never: Imaging in

Kinfe Bishu, Bruce Ovbiagele

Christopher Giza

P6.292 Epilepsy in Elderly: Prevalence

P6.308 Exertional Effects of

Anup Patel, Nancy Reaven, Susan Funk, Tyler Story, of Inflammation, Edema, and Outcome after TBI —Benjamin Zusman, Jordan Brooks, Ava P6.277 Use of Antiepileptic Drugs among Michael Chez Puccio, David Okonkwo, Yvette Conley, Patrick Patients with Tuberous Sclerosis Complex P6.291 Incremental expenditures of Kochanek, Ruchira Jha Related Epilepsy who Initiated an Oral mTOR

Inhibitor —Steven Sparagana, Darcy Krueger,

Jinlin Song, Elyse Swallow, Miranda Peeples, Mark Meiselbach, James Signorovitch, Qayyim Said, Ilia L Ferrusi, Michael Kohrman, Bruce Korf, Michael Wong

Concussion —Joshua Kamins, Meeryo Choe,

Neurocognitive Testing in Post-Acute Consolación Del Sur Municipality, A Door-To- Concussion Patients —Aliyah Snyder, Douglas Polster, Christopher Giza, Talin Babikian Door Survey —Juan Miguel Riol Lozano P6.309 Guided Physical Exertion in P6.293 Adherence with ExtendedSports-Related Concussion Patients — Release Oxcarbazepine (Oxtellar XR®) vs. Immediate-Release Oxcarbazepine: Analysis Michael Popovich, Andrea Almeida, Matthew

P6.278 Quality Measures in the Epilepsy and Etiologic in Urban Population of Monitoring Unit —Kristen Malloy, Damon Cardenas, Luke Whitmire, Jose Cavazos

P6.279 Impact of Medicaid antiepileptic drug formulary restrictions on health outcomes and costs —Jesse Fishman, Sulena

Lorincz, Andrew Sas

AAN.com/view/AM18 177

Friday

subcortical structures predict pre and post-laser ablation psychiatric symptoms in patients with temporal lobe epilepsy? —

Cynthia Brandt, Hamada Altalib

Claims Databases —Shannon Mendes, Welton

P6.280 Drivers of Epilepsy-related

P6.272 The Direct Cost Burden of Illness P6.284 Persistent Symptoms of

Eduard Bercovici, Felippe Borlot, Esther Bui, Peter Camfield, Guida Quaglia Clozza, Eyal Cohen, P6.259 Effect of Antiepileptic Drugs Timothy Gofine, Lisa Graves, Jon Greenaway, on Sexual and Reproductive Endocrine Beverly Guttman, Maya Guttman-Slater, Ayman Function in Men with Epilepsy —Parampeet Hassan, Megan Henze, Miriam Kaufman, Bernard S Kharbanda, Muneshwar Suryawanshi, Naresh Lawless, Hannah Lee, Lezlee Lindzon, Lysa Boissé Sachdeva, Manoj Goyal, Vivek Lal Lomax, Mary Pat McAndrews, Dolly Menna-Dack, Berge Minassian, Janice Mulligan, Rima Nabbout, P6.260 Artisanal “Hemp Extract” Tracy Nejm, Mary Secco, Laurene Sellers, Michelle Experience in Utah Epilepsy Cohort: Survey Shapiro, Marie Slegr, Rosie Smith, Peter Szatmari, Results —Carey Wilson, Taylor Shuman, Leeping Tao, Anastasia Vogt, Sharon Whiting, O. Matthew Sweney, Colin Van Orman, Francis Filloux Snead

P6.261 The Effects of Assessing

Faught, Joel Farley

POSTER SESSIONS

Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.

POSTER SESSIONS

POSTER SESSION VI G P6.310 The incidence of the Cavum

Friday, April 27 11:30 a.m.–5:30 p.m.

P6.317 Difference in pre-season Septum Pellucidum (CSP) in a population King-Devick (K-D) scores in Recreational vs exposed to Head Trauma —Ryan Hubbard, Ivan Competitive youth soccer players. —Bert

Neuro Intensive Care Unit —Aaron Desai, Jay

P6.330 Paroxysmal sympathetic

Carabenciov, Pieter Janssen, Michelle Mielke, Nicholas Wetjen, Rodolfo Savica

Vargas, ugo Bitussi, Kathleen Bell, Candice Osborne, Shannon Juengst, Cindy Dolezal

P6.311 Association of Neurocognitive

P6.318 Treating Prolonged Post-

intracerebral hemorrhage? —David Valentine,

P6.331 A Rare Case of Metastatic

and Neuropsychiatric Alterations with the Findings in Diffusion Tensor Imaging in pediatric patients with concussion: Pilot study. —Claudia Lizbeth Gomez Elias, Antonio

Bravo, Javier Allende Labastida, Guillermo Reyes Vaca, Cesar Guillermo Gonzalez, Jorge Luis Garcia Ramirez, Maria Elena Navarro, Cecilia Montoya Cabrera, Hector Hernandez Rodriguez

P6.312 Tonsillar Contusion Associated With Benign Tonsillar Ectopia Following Minor Head Trauma —Yonatan Serlin, Mony Benifla, Ilan Shelef

P6.313 Early Changes in Expression of

Inflammatory Pathways may play a role in Cerebral Hypoxia Following TBI —Benjamin Zusman, Ruchira Jha, Patrick Kochanek, David Okonkwo, Yvette Conley, Ava Puccio

P6.314 Case Series of Cervical Strain Mimicking Concussion in High School Athletes —Lisa Stropp, Kate Essad, Matthew McCarthy, Sandro Corti, Sean Rose, Jeffrey Kutcher

Concussion Symptoms in a Pediatric Patient with the Simultaneous Application of Cognitive Behavioral Therapy and Subthreshold Exercise: A Case Study —Sonal Singh, Douglas Polster, Meeryo Choe, Christopher Giza, Talin Babikian

P6.319 Assessing Clinical

Recommendations: Focus on Post-Traumatic Headaches —Emma Gregory, Ann Marie

P6.316 Measuring Postural Stability

in Adolescent Population at Baseline: The Balance Error Scoring System vs Sensory Evaluation Test —Zhe Wang, Sonal Singh,

g1 H

Briana Meyer, Philip Rosenbaum, David McArthur, Christopher Giza

Ariane Lewis

P6.325 Change in Practice Pattern in

Management of Aneurysmal Subarachnoid Hemorrhage During Hospitalization over a 5-year Period—A Single Center Perspective —Swathy Chandrashekhar, Danny

Samkutty, Joshua Santucci, Lance Ford, Kimberly Hollabaugh, Brad Bohnstedt, Bappaditya Ray

P6.326 Risk Factors for Mortality after

Drennon, Saafan Malik, Sean Sebasta, Scot Engel, Spontaneous Subarachnoid Hemorrhage and Adriana Rico, Conethra Burt-Kelley, Shandi Watts, External Validation of a Prediction Model — Daniel Beauchamp, Sidney Hinds Yasser B. Abulhasan, Najayeb Alabdulraheem, P6.320 Surfer’s Myelopathy in Pediatric Gabrielle Simoneau, Mark R. Angle, Jeanne population —Vijeta Shukla, Scott Kleppe, William Teitelbaum Walters

P6.321 Using an Eye Tracker as

an Assessment Tool for Concussion Diagnosis —Atefeh Katrahmani NEUROCRITICAL CARE II

P6.322 Characterization of Deep,

Supratentorial Intracerebral Hemorrhage in

P6.315 Clinical Evaluation of Concussion: the Ethnic/Racial Variations of ICH Study — Review of Current Guidelines and Practices —Mary Kelley

Kinariwala, Hamidreza Saber, Mohammad Ibrahim, hyperactivity with dystonia following Ellyse Probst-Simmons, Wazim Mohamed bilateral thalamic and cerebellar hemorrhage: A case report —Daniel Garbin Di P6.324 How does pre-existing Luca, Nathaniel Mohney, Mohan Kottapally hypertension affect patients with

P6.327 Initial Neutrophil-Lymphocyte Ratio Predicts Intracerebral Hemorrhage Outcomes at Discharge —Rashi Krishnan,

Georgios Tsivgoulis, Konark Malhotra, Jason Chang, Christopher Nickele, Daniel Hoit, Khalid Al Sherbini, Andrei Alexandrov, Adam Arthur, Lucas Elijovich, Nitin Goyal

P6.328 Healthcare-Associated

Infections after Spontaneous Subarachnoid Hemorrhage —Najayeb Alabdulraheem, Yasser

Audrey Leasure, Kevin Sheth, Mary Comeau, Chad B. Abulhasan, Ian Schiller, Susan Rachel, Nandini Aldridge, Anastasia Vashkevich, Jonathan Rosand, Dendukuri, Mark R. Angle, Charles Frenette Carl Langefeld, Charles Moomaw, Daniel Woo, Guido Falcone P6.329 Is Nimodipine Underutilized

P6.323 Fentanyl Associated Infection

Rates in Patients with Spontaneous Intracerebral Hemorrhage Admitted to the

In Patients Aneurysmal Subarachnoid Hemorrhage? —Arnavaz Hajizadeh Barfejani,

Sarah Clark, Alejandro Rabinstein, Eelco Wijdicks

Synovial Sarcoma Presenting as a Fatal Hemorrhagic Stroke —Kyle Carpenter

P6.332 Predictors of Worsening

Perihematomal Edema in Intracerebral Hemorrhage (ICH) —Mini Singh, Karen Albright, Angela Hays Shapshak

P6.333 Validating the Use of Prophylactic Antiepileptic Drugs in Patients with Subcortical Intracranial Hemorrhage in a Large Urban Hospital. —Rajanigandhi Hanumanthu, Anusha Boyanpally, Francisco Gomez, Matthew Sumicad, Machteld Hillen

P6.334 Bedside Ultrasonography of

the Inferior Vena Cava for Volume Status Assessment Following Aneurysmal Subarachnoid Hemorrhage —Mohammad

Hajighasemi-Ossareh, Roy Poblete, Sebina Bulic, Peggy Nguyen, May Kim-Tenser, Benjamin Emanuel

P6.335 Communication Priorities in

Spontaneous Intracerebral Hemorrhage (CPsICH): A Survey-based Study Incorporating Patient and Physician Perspectives —Jonathan Krett, Cally Martin,

Colleen Murphy, John Boyd, Nicole Chenier-Hogan, Phyllis Davis, Vivian Bethell, Albert Jin

P6.336 NA P6.337 NA P6.338 NA

Movement Disorders II ePoster Session Six semi-private viewing areas will allow for a more interactive and dynamic engagement and discussion with presenters. Look for six different E-posters each day! P6.339 SCA2 Presenting as Focal

Spears, Christopher Hess, Michael Okun, William Triggs, Leonardo Almeida

P6.342 Dysphagia in Patients with

B Rodrigues, Lauren M Byrne, Enrico de Vita, Eileanoir Johnson, Rachael Scahill, Edward Wild

Doyle, Stephen Reich

P6.341 In the eye of the beholder: a

Patterson, Erin Hastings, Jennifer Farmer, S Subramony

P6.344 Bilateral Facial Spasm following

Dystonia —Nan Cheng, James Gaul, Lauren

P6.340 Neuropathic Tremor Secondary to Chronic Immune Demyelinating Polyneuropathy with Robust Response to Intravenous Immune Globulin —Christopher

patient with catatonia found to have progressive encephalomyelitis with rigidity and myoclonus. —Natalie Witek, Anjali Gera, Charles Hebert, Cynthia Comella

Erica Marini, Tram Nguyen, Stacey Clardy, Melissa Cortez, L DeWitt, John Greenlee, Julia Klein, M. P6.345 Effects of Opicinumab on Patient- Paz Soldan, John Steffens, John Rose

MS THERAPEUTICS III

Reported Outcomes in Participants with Relapsing Multiple Sclerosis: A Post-Hoc Analysis of the Phase 2 SYNERGY Study —

Jennifer Petrillo, Stanley Cohan, Carmen CastrilloViguera, Ih Chang, Yi Chai, Sharon Chen, Bing Zhu

P6.348 Baseline cognitive function of

patients with relapsing remitting multiple sclerosis is associated with therapeutic response to Natalizumab —Daniel Golan,

Friday

Mark Gudesblatt, Karl Wissemann, Myassar Zarif, P6.346 Comparison of 12 month changes Barbara Bumstead, Lori Fafard, Cynthia Sullivan, Jeffrey Wilken, Karen Blitz-Shabbir, Marijean in Brain Volume among Long Term Users Buhse, Glen Doniger of Natalizumab versus Healthy Controls

in Multiple Sclerosis: Year one Analysis of a Two-Year Longitudinal Observational Study —Enrique Alvarez, Kavita Nair, Laura J

P6.349 A Real-Life Study of

Alemtuzumab: Impact of Previous Therapies and Washout Period on Disease Activity —

Weinkle, Jamie Craig, Brian Hoyt, Stefan Sillau, Francesco Sacca, Maria Pia Sormani, Alessio Eric Engebretson, Brittany Wedeman, John Corboy, Signori, Roberta Lanzillo, Damiano Baroncini, Pietro Timothy Vollmer, Justin Honce Annovazzi, Elisabetta Signoriello, Alice Laroni, P6.347 Dimethyl Fumarate in Relapsing Marco Capobianco, Arianna Sartori, Sara La Gioia, Giorgia Teresa Maniscalco, Cinzia Cordioli, Sarah Remitting Multiple Sclerosis: 24 Months Rasia, Marinella Clerico, Giuseppe Fenu, Eleonora Observations of the Effects of Dose Cocco, Jessica Frau Reduction on Lymphopenia —Ka-Ho Wong,

178 2018 AAN Annual Meeting

Friedreich’s Ataxia —Amir Besharat, Addie

Guillian-Barre Syndrome —Zain Guduru, Kapil

P6.343 Cerebrospinal fluid flow dynamics Sethi in Huntington’s disease using phase contrast MRI: A pilot cross-sectional study —Filipe

P6.350 Autologous Haematopoietic

P6.353 Safety and Efficacy of

Snowden, Sona Mistry, Helen Jessop, Simon Bell, Basil Sharrack

Svetlana Eckert, David Hojnacki, Robert Zivadinov, Ralph Benedict, Caila Vaughn, Bianca WeinstockGuttman

P6.351 Extended interval dosing

P6.354 Effect of Fingolimod 0.5 mg/

Stem Cell Transplantation in Treatment Naïve Patients with Rapidly Evolving Severe Multiple Sclerosis —Joyutpal Das, John

of natalizumab in MS; a New Zealand experience —Calvin Chan, Ronald Siu, Nick Mellsop, Jan Schepel

P6.352 Alemtuzumab treatment in

Multiple Sclerosis: Real clinical experience in the Northwest of Spain —Ana Lopez Real,

Ines Gonzalez, Eva Costa Arpin, Antonio Pato, Elena Alvarez Rodriguez, Ana Rodriguez Regal, Ana García-Pelayo Rodríguez, Maria Dolores Garcia Bargo, Miguel Angel Llaneza Gonzalez, Maria Rodriguez Rodriguez, Dulce Solar Sanchez, Agustin Oterino Duran, Joaquin Pena Martinez

Ocrelizumab in Multiple Sclerosis Patients with increased disability —Channa Kolb,

day vs Placebo on Two Newly Developed Expanded Disability Status Scale (EDSS) Subscales for Patients with RelapsingRemitting MS: EDSS Factor Analysis —Gary

Cutter, Florian Thomas, Nadia Tenenbaum, Xiangyi Meng

P6.355 Long-term follow up of treatment with interferon beta 1-b: A 23-year observational study in a single center cohort of 87 patients with multiple sclerosis — Helena Bulka, Ahmad Siddiqi, Lonni Schultz, Carol Freeman, Stanton Elias, Mirela Cerghet

P6.356 Real-World Experience with

Ocrelizumab —Brandon Moss, Erica Utigard,

Laura Baldassari, Jeffrey Cohen, Daniel Ontaneda

P6.357 Efficacy and Safety of

Alemtuzumab in Real World Italian Patients Switching from Natalizumab —Antonio Bertolotto, Marco Alfonso Narduc Capobianco, Maria Malentacchi, Dario Gned, Serena Martire, Simona Malucchi

P6.358 Supporting personalized

treatment decisions in relapsing remitting multiple sclerosis (RRMS) —Stefan Braune, Philip van Hoevell, Sarah Grimm, Anna Drewek, Elisabeth Stuehler, Matteo Tanadinia, Tjalf Ziemssen, Arnfin Bergmann, NeuroTransData Study Group

Betty Jean, Damien Galanaud, Laurent Pierot, Results from the EFFECT Study —Jonathan Gilles Edan, Pierre Clavelou, Frederic Sedel, Ayman Calkwood, Stanley Cohan, Andrew Chan, Ellen Tourbah, Isabelle Berry Lathi, Anneke Van Der Walt, Fan Wu, Jinny Min, Catherine Miller

P6.366 Durable Efficacy and Safety

With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Followup (TOPAZ Study) —Brian Steingo, Celia Oreja-

P6.374 Long-term Disability Outcomes

with Alemtuzumab Experience Durable Reductions in MRI Disease Activity and Slowing of Brain Volume Loss: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) —Daniel Pelletier, Anthony Traboulsee,

P6.375 Durable Reduction in MRI

Disease Activity and Slowing of Brain Volume Loss in Alemtuzumab-Treated Patients With Active RRMS: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) —Anthony Traboulsee, Douglas Arnold,

Michael Barnett, Giancarlo Comi, Christopher Michael Barnett, Giancarlo Comi, Jerome De Seze, LaGanke, Alex Rovira, Sven Schippling, David (extended-release) Phase IIa one-year study Alex Rovira, Sven Schippling, David Margolin, Luke Margolin, Maria Melanson, Nadia Daizadeh, Kunio in patients with Relapsing-remitting Multiple Chung, Nadia Daizadeh, Kunio Nakamura, Douglas Nakamura, Daniel Pelletier Sclerosis: Safety, tolerability and efficacy – Arnold P6.376 Durable Clinical Efficacy of NEDA Analysis —Ariel Miller, Laura Popper, Uri Alemtuzumab in Patients With Active Danon, Nadav Bleich Kimelman, Shai Rubnov, Ehud P6.368 Alemtuzumab Provides Durable Efficacy and Safety Over 5 Years After Marom, Joab Chapman, Alla Shifrin, Ronit Gilad, RRMS in the Absence of Continuous Switching From SC IFNB-1a: Follow-up of Dimitrios Karussis, Ron Milo, Chen Hoffmann, Treatment: 7-Year Follow-up of CARE-MS I Shlomo Flechter, Arnon Karni Patients From CARE-MS II (TOPAZ Study) — Patients (TOPAZ Study) —Patrick Vermersch, Bart Van Wijmeersch, Alexey Boyko, Simon P6.360 EVOLVE-MS-1: A Phase 3, Open- Broadley, David Brassat, Dominique Dive, R.M.M. Alasdair Coles, Alexey Boyko, Jerome De Seze, Hans-Peter Hartung, Eva Havrdova, Jihad Inshasi, Label, Long-Term Safety Study of ALKS 8700 Hupperts, Jan Lycke, Xavier Montalban, Basil Pamela McCombe, Xavier Montalban, Carlo in Relapsing-Remitting Multiple Sclerosis — Sharrack, Sibyl Wray, David Margolin, Luke Chung, Pozzilli, Krzysztof Selmaj, David Margolin, Maria Robert Naismith, Richard Leigh-Pemberton, David Nadia Daizadeh, Madalina Chirieac, Heinz Wiendl Melanson, Nadia Daizadeh, Claudio Rodriguez, Rezendes, Narinder Nangia, Boris Kandinov, Lisa P6.369 Durable Clinical Outcomes With Bart Van Wijmeersch von Moltke, Jerry Wolinsky

P6.359 Glatiramer Acetate Depot

P6.361 Analysis of 6-month Confirmed

Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) —Barry Singer, Raed Alroughani,

Disability Progression in RRMS Patients Treated with Subcutaneous Interferon beta1a —Schiffon Wong, Julie Aldridge, Robert Hettle, David Brassat, Simon Broadley, Hans-Peter Inderpreet Singh Khurana, Kashif Siddiqui

MS THERAPEUTICS: EXTENSION STUDIES

P6.362 Efficacy of Alemtuzumab in

Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: Results From the CARE-MS I Extension —Aaron Boster, Ann Bass, Regina Berkovich, Giancarlo Comi, Oscar Fernandez, Ho Jin Kim, Volker Limmroth, Jan Lycke, Richard Macdonell, Basil Sharrack, Anthony Traboulsee, Patrick Vermersch, Heinz Wiendl, Tjalf Ziemssen, Maria Melanson, Nadia Daizadeh, Barry Singer

P6.363 Efficacy of Alemtuzumab in

Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: Results From the CARE-MS II Extension —Barry Singer, Aaron Boster, Ann Bass, Regina Berkovich, Giancarlo Comi, Oscar Fernandez, Ho Jin Kim, Volker Limmroth, Jan Lycke, Richard Macdonell, Basil Sharrack, Patrick Vermersch, Heinz Wiendl, Tjalf Ziemssen, Maria Melanson, Nadia Daizadeh, Anthony Traboulsee

P6.364 Disability Improvement Is

P6.370 Baseline Characteristics of the

CHORDS Study Population: A Phase III Trial to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With RRMS Who Had Disease Activity With Prior DiseaseModifying Therapies —Anthony Reder, Robert Bermel, Bianca Weinstock-Guttman, Daniel Selchen, Thomas Leist, Gary Cutter, James Stankiewicz, Hanzhe Zheng, Bruno Musch, Csilla Csoboth, Jerry Wolinsky

P6.371 Effectiveness and safety of

fingolimod in Spanish Relapsing-Remitting Multiple Sclerosis patients in clinical practice (Fingoview study): Subanalysis of patients previously treated with first line injectable disease-modifying treatment —Marisa Martínez, Francisco Barrero, Eugenia Marzo, Javier Jose Mallada Frechin, Virginia Meca Lallana, Carmen Duran Herrera, Teresa Ayuso, Jose Meca Lallana, Sergio Martinez-Yelamos, Maria Jose Moreno Jimenez, Daniel Santos, Francisco Javier Ricart, Eli Garcia

P6.372 Evaluation of the Long-term

Treatment Effect of Teriflunomide on Cognitive Outcomes and Association With Brain Volume Change: Data From TEMSO and its Extension Study —Till Sprenger,

Raed Alroughani, Steven Bromley, Dominique Dive, Maria Pia Sormani, Jerry Wolinsky, Jens Würfel, Guillermo Izquierdo Ayuso, Ho Jin Kim, Jan Lycke, Karthinathan Thangavelu, Steven Cavalier, Matthew Mandel, Ludwig Kappos Richard Macdonell, Carlo Pozzilli, Basil Sharrack, Patrick Vermersch, Andreas Lysandropoulos, Luke P6.373 Real-world Effectiveness of Chung, Nadia Daizadeh, Heinz Wiendl

P6.365 MD1003 in Progressive Multiple Sclerosis: 24-Month Brain Volume Changes of the MS-SPI Trial —Douglas Arnold, Jean

Philippe Ranjeva, Jean Pelletier, Christian Barillot,

Delayed-release Dimethyl Fumarate in Relapsing-remitting Multiple Sclerosis Patients Who Are Treatment-naïve or Treated With Only One Prior Therapy: Final

P6.377 A Long-term Experience with

Fingolimod: Evaluation of Safety, Disability, and Treatment Satisfaction in Patients with Relapsing-Remitting Multiple Sclerosis — Nadia Tenenbaum, Jeffrey Cohen, Alit Bhatt, Ron Pimentel, Ludwig Kappos

P6.378 Long-term efficacy, safety, and

tolerability of three-times weekly dosing regimen of glatiramer acetate in relapsingremitting multiple sclerosis patients: 5-year results of the Glatiramer Acetate LowFrequency Administration (GALA) open-label extension study —Jessica Alexander, Hooman Beygi, Peter Feldman, Natalia Ashtamker

P6.379 Longer duration of natalizumab

exposure may lessen return of disease activity following a switch from natalizumab to an oral therapy: Modelling real-world data from relapsing-remitting multiple sclerosis (RRMS) patients in the TYSABRI® Observational Program (TOP) —Helmut Butzkueven, Heinz Wiendl, Maria Trojano, Ludwig Kappos, Timothy Spelman, Karen Rosales, Stephanie Licata, Pei-Ran Ho, Nolan Campbell

P6.385 Long-Term Efficacy of Early

Fingolimod Treatment in Young Adult Patients With Relapsing Multiple Sclerosis —Tanuja Chitnis, Diego Silva, Angelo

Ghezzi, Rolf Meinert, Dieter Haering, Daniela Pohl

P6.386 Peginterferon Beta-1a

Demonstrated Sustained Efficacy in Newly Diagnosed Relapsing Multiple Sclerosis (RMS) Patients Treated up to 4 Years: Subgroup Analysis of ATTAIN —Thomas Scott, Douglas Arnold, Jang Yun, Matthias Meergans, Maria Naylor

P6.387 Impact of the Presence of

Gadolinium-Enhancing (Gd+) Lesions at Baseline on No Evidence of Disease Activity (NEDA) Status in Patients Treated with Subcutaneous Interferon beta-1a (scIFNβ1a): A Post-hoc Analysis of REFLEXION —

Mark Freedman, Giancarlo Comi, Patricia Coyle, Julie Aldridge, Kurt Marhardt, Ludwig Kappos

P6.388 Long-Term Disease Control with Fingolimod in RRMS Patients With Active Disease —Eva Havrdova, Diego Silva, Ludwig Kappos, Rolf Meinert, Jeffrey Cohen, Virginia Devonshire

P6.389 Long-term Disability Outcomes in Patients Treated With Teriflunomide for up to 14 Years: Group- and Patient-Level Data From the Phase 2 Extension Study —Mark

Freedman, Amit Bar-Or, Myriam Benamor, Philippe Truffinet, Elizabeth Poole, Matthew Mandel, Marcelo Kremenchutzky

P6.390 WITHDRAWN P6.391 Long-term Efficacy and Safety Outcomes of Teriflunomide Treatment in TEMSO and TOWER —Jiwon Oh, Mark

Freedman, Myriam Benamor, Elizabeth Poole, Jeffrey Chavin, Giancarlo Comi

P6.392 Alemtuzumab Improves

Patient-reported Quality of Life Outcomes in Patients With Rapidly Evolving Severe Relapsing-remitting MS: Results From the CARE-MS I Extension Study —Rafael Arroyo

P6.380 Alemtuzumab Improves Patient-

Gonzalez, Jennifer Guo, Wei Zhang, Karthinathan Thangavelu, Luke Chung, Jungyoon Moon, Michael Keith, David Cella

Karthinathan Thangavelu, Luke Chung, Jungyoon Moon, Michael Keith, David Cella

Klotz, Michael Lang, Chrstoph Lassek, Stephan Schmidt, Bjorn Tackenberg, Christian Cornelissen

reported Quality of Life Outcomes in Patients With Relapsing-remitting Multiple Sclerosis: P6.393 PANGAEA: 5 years effectiveness of fingolimod in daily clinical practice —Tjalf Results From the CARE-MS I Extension Study —Rafael Arroyo, Jennifer Guo, Wei Zhang, Ziemssen, Holger Albrecht, Judith Haas, Luisa

P6.394 One- and two-year Annualized in a French cohort of patients with relapsing- Relapse Rate and NEDA-3 in Italian patients treated with fingolimod: Preliminary results remitting multiple sclerosis: TYSTEN cohort —Kevin Bigaut, Thibaut Fabacher, Nicolas from the GENIUS (FinGolimod Real World Collongues, Laurent Kremer, Marie-Celine Fleury, EvideNce Italian mUlticenter observational Study in Multiple Sclerosis) Study. — Jean-Claude Ongagna, Jerome De Seze P6.381 Long-term effect of natalizumab

P6.382 Delayed-release Dimethyl

Fumarate Demonstrates Long-term, Sustained Efficacy in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis followed for at least Eight-Years — Ralf Gold, Gavin Giovannoni, J. Theodore Phillips, Robert Fox, Lili Yang, Catherine Miller

Giancarlo Comi, Carlo Pozzilli, Vincenzo Brescia Morra, Antonio Bertolotto, Francesca Sangalli, Luca Prosperini, Antonio Carotenuto, Pietro Iaffaldano, Marco Alfonso Narduc Capobianco, Delia Colombo, Mihaela Nica, Alessandro Zullo, Maria Trojano

AAN.com/view/AM18 179

Friday

Observed in Each Functional System in Alemtuzumab-Treated Patients With Active RRMS: Results From CARE-MS II Extension —Samuel Hunter, Rany Aburashed,

Hartung, Eva Havrdova, Ho Jin Kim, Celia Oreja-Guevara, Carlo Pozzilli, Krzysztof Selmaj, Patrick Vermersch, Sibyl Wray, David Margolin, Luke Chung, Nadia Daizadeh, Madalina Chirieac, Alasdair Coles

functional systems (FS) in relapsingremitting multiple sclerosis (RRMS) patients treated with natalizumab in the TYSABRI® Observational Program (TOP) —Heinz Wiendl,

in Teriflunomide-Treated Patients in TEMSO Helmut Butzkueven, Ludwig Kappos, Timothy Spelman, Maria Trojano, Karen Rosales, Nolan and TOWER: An Analysis Utilizing the Topographical Model of MS —Stephen Krieger, Campbell, Pei-Ran Ho, Stephanie Licata Mark Freedman, Aaron Miller, Philippe Truffinet, K P6.384 WITHDRAWN

Guevara, Raed Alroughani, David Brassat, Alexey Boyko, Pamela McCombe, Bart Van Wijmeersch, David Margolin, Maria Melanson, Nadia Daizadeh, Thangavelu, Matthew Mandel, Fred Lublin Claudio Rodriguez, Patrick Vermersch

P6.367 Active RRMS Patients Treated

P6.383 Real-world improvement across

POSTER SESSIONS

Presenters Stand by Posters 4:00 p.m. to 5:30 p.m.

POSTER SESSIONS

POSTER SESSION VI G P6.395 Spanish Registry of patients

with Multiple Sclerosis (MS) treated with fingolimod (GILENYA Registry): Safety and effectiveness after four years. Patients without previous treatment subanalysis —

Jose Meca Lallana, Celia Oreja-Guevara, Delicias Munoz Garcia, Francisco Javier Olascoaga Urtaza, Antonio Pato, Lluis Ramio, Virginia Meca Lallana, Miguel Angel Hernandez Perez, Eugenia Marzo, Jose Alvarez-Cermeño, Alfredo Rodriguez Antiguedad, Xavier Montalban, Oscar Fernandez

P6.396 Treatment Satisfaction With

Teriflunomide in Patients Switching From a Prior Disease-Modifying Therapy: Results From the Phase 3 TENERE and Phase 4 Teri-PRO Clinical Trials —Patrick Vermersch,

Ralf Gold, Jose Meca Lallana, Karthinathan Thangavelu, Philippe Truffinet, Matthew Mandel, Steven Cavalier, Patricia Coyle

MS AND CNS INFLAMMATORY DISEASE: NEUROMYELITIS OPTICA AND RELATED DISORDERS

P6.397 Neuromyelitis Optica Spectrum Disorders with Aquaporin-4 and MyelinOligodendrocyte Glycoprotein Antibodies in Turkish Population: A Comparative Study —Egemen Idiman, Fethi Idiman, Mahmut

Kaya, Omercan Hasankoyoglu, Derya Kaya, Hatice Limoncu, Onur Bulut, Zekiye Altun

P6.398 Neuromyelitis Optica Mimicking Lateral Medulla Stroke —Lily Chau, Alison Baird, Craig Linden, Adrian Marchidann

P6.399 MRI Trident sign trumps

Aquaporin-4-IgG ELISA in discriminating Spinal Cord Sarcoidosis misdiagnosed as Neuromyelitis Optica Spectrum Disorder — Evan Jolliffe, Mark Keegan, Eoin Flanagan

P6.400 Axonal damage evolution in

multiple sclerosis and neuromyelitis optica spectrum disorder: Evaluation with optical coherence tomography —Letizia Leocani,

Francesco Ratti, Marco pisa, Simone Guerrieri, Marta Radaelli, Lucia Moiola, Vittorio Martinelli, Giancarlo Comi

P6.401 Neuromyelitis Optica spectrum

disorder and menstruation —Shervin Badihian, Navid Manouchehri, Omid Mirmosayyeb, Vahid Shaygan Nejad

P6.402 The Relationship Between

Carcinoma —Cigdem Isitan, Adeniyi Fisayo, Erin Longbrake

P6.407 Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: Analysis of the global NMOBase Registry —Ilya Kister, Tamar

Bacon, Vahid Shaygan Nejad, Eva Havrdova, Raed Alroughani, Murat Terzi, Ayse Altintas, Jyh Yung Hor, Talal Al-Harbi, Cavit Boz, Roberto Bergamaschi, Serkan Ozakbas, Diana Ferraro, Yara Fragoso, Guy Laureys, Aysun Soysal, Nastaran Majdinassab, Marco Onofrj, Eugenio Pucci, Ostoja (Steve) Vucic, Mark Slee, Jeannette Lechner-Scott, Juan Ignacio Rojas, Marcos Burgos, Tamara Castillo-Trivino, Allyson Reid, Zoe Rimler, Pamela McCombe, Franco Granella, Maria-Anna PolyzouKonsta, Michael Dreyer, Gerardo Iuliano, Allan Kermode, Cameron Shaw, Bianca WeinstockGuttman, Helmut Butzkueven

P6.408 Contributors to Long-Term

Disability in Patients with Neuromyelitis Optica Spectrum Disorder —Michael Levy,

Maureen Mealy, Sarah Mossburg, SU-Hyun Kim, Nadja Borisow, Reydmar Lopez, Juan Pablo Ospina, Michael Scheel, Anusha Yeshokumar, Jacqueline Palace, Jorge Andres Jimenez-Arango, Friedemann Paul, Ho Jin Kim

P6.409 The Mayo Clinic Glial

Autoimmunity Study: Glial autoantibody (AQP4/MOG/GFAP) serostatus in recurrent longitudinally extensive transverse myelitis —Jiraporn Jitprapaikulsan, Alfonso Lopez, Eoin Flanagan, James Fryer, Andrew McKeon, Jiao Yujuan, Brian Weinshenker, Masoud Majed, W. Tobin, Mark Keegan, Claudia Lucchinetti, Vanda Lennon, Jessica Sagen, Sean Pittock

P6.410 Sensitivity and specificity for NMO IgG assays in Australia and New Zealand —Kerri Prain, Patrick Waters, Laura

Clarke, ANZ NMO Collaboration, Angela Vincent, Simon Broadley

P6.411 Brain and spinal cord MRI

lesion criteria differentiate AQP4- and MOG-disease from MS —Catalina Bensi,

Alejandra Gonzalez, Anibal Chertcoff, Emilia Osa Sanz, Angeles Schteinschnaider, Jorge Correale, Mauricio Farez

P6.404 Obstetric Outcomes in Mexican

Patients with NMO-IgG (+) Neuromyelitis Optica —Guillermo Delgado-Garcia, Zoé Chávez,

Friday

Schachter, XinLi Du, Yang Tang

P6.406 Anti-CRMP5 Optic Neuropathy Associated with Oral Squamous-Cell

P6.432 Estimation of EQ5D Health Neuromyelitis Optica (NMO) in the Setting of Utilities from a Myasthenia Gravis Specific Acute HIV Infection —Mahsa Khayatkhoei, John Questionnaire —Carolina Barnett Tapia, Vera Lincoln

Bril, Ahmed Bayoumi

P6.417 Evaluation of idiopathic

P6.433 Readmission After Myasthenia

Eoin Flanagan, Mark Keegan

Dylan Thibault, James Crispo, Allison Wright Willis

transverse myelitis revealing specific myelopathy diagnoses —Nicholas Zalewski,

P6.434 Myasthenia Gravis: Pregnancy

George Hutton

Lucia Zavala, Victoria Fernandez, Luciana Melamud, Analisa Manin, Florencia Aguirre, Andres Villa

treated for Idiopathic Relapsing Transverse Myelitis —Viviana Orozco, Steven Dunham,

P6.419 Side effects of long-term

RTX treatment in NMOSD patients: Hypogammaglobulinemia and impairment of specific humoral immunity. —Antonio

Bertolotto, Andrea Marcinnò, Paola Valentino, Serena Martire, Maria Leto, Aurora Drago, Marco Alfonso Narduc Capobianco, Giancarlo Panzica, Fabiana Marnetto

P6.420 Characterization and Alternative Diagnoses in Patients with False-positive Aquaporin-4 Autoantibody Detection by Enzyme-Linked Immunosorbent Assay (ELISA) —Jon Williams, Lisa Peterson, Jaron

Steven Oberste, Mark Pallansch, James Sejvar, Janell Routh, Manisha Patel

Omercan Hasankoyoglu, Ahmet Onur Keskin, Nebahat Tasdemir, Zekiye Altun

Yang, Mitchell Miglis, Safwan Jaradeh, Srikanth Muppidi

P6.436 Effect of Coexisting Autoimmune

Disorders on Clinical Outcome in Myasthenia Gravis Patients: An Analysis from National Inpatient Database —Malik Adil, Mohammed Qureshi, Daniel Larriviere

P6.437 Myasthenia Gravis after

Vaccination in Adults the United States: A Report from the CDC/FDA Vaccine Adverse

Daniel

P6.439 B-cell depletion in late-onset

myasthenia gravis is safe and effective; Glycoprotein (MOG) Antibodies in a Patient a case series —Supreet Sahai, Hadi Maghzi, Richard Lewis with Ataxia, Diplopia, and an Enhancing Cerebellar Lesion —Josef Gutman, Mohammad P6.440 Myasthenia Gravis - Ice-Pack Fouladvand, Jafar Jafar, Rajan Jain, Ilya Kister Test Diagnostic Accuracy with MetaP6.423 Unique Presentation of acquired Analysis —Divya Arya, Owen Omoregie, Amit Longitudinally Extensive Transverse Myelitis Bhandari, Tushar Bajaj, Aiyi Zhang and GBS Overlap Syndrome following Tdap P6.441 Evolution of clinical outcome in Vaccination —Dharampreet Singh, Kelly Tisovic, thymectomy for Myasthenia Gravis —Jose Cara Harth

P6.424 Neuromyelitis Optica Spectrum

Maria Cabrera Maqueda, Carmen Garnés, Andres Arroyo Tristan, Francisco Martinez Garcia, Jose Meca Lallana, Rocio Hernandez Clares

P6.442 Elevation of Acetylcholine

Receptor Antibodies in association with Prolonged Clinical Deterioration in Postthymomectomy Myasthenia Gravis —Rejo

Cherian, Yuebing Li MD

P6.425 NA P6.426 NA P6.427 NA P6.428 NA

P6.443 Prednisone Side Effects are

Common and Associated with Unwillingness to Accept a Dose Increase: Survey Result from MGFA Registry —Ikjae Lee, Henry

MYASTHENIA GRAVIS

Kaminski, Michelle Feese, Tarrant McPherson, Gary Cutter

P6.429 The Frequency of LRP4

P6.444 Lambert-Eaton Myasthenia With

Autoantibodies in Serum Specimens Sent to a Clinical Laboratory for Myasthenia Gravis Testing —Sat Dev Batish, Brian Sansoucy, Amy Goldberger, Keith Morneau, Urszula Trela, Kelsey Gagnon, Altin Qeleshi, Marc Meservey, Jamie Willis, Emily Katzman, Beth Noyst, Diana Ngo, Joseph Higgins

P6.430 Pre-operative Management of

Myasthenia Gravis in Patients Undergoing Surgery —Tarun Singh, Francis Huttinger, Michael Brown, Lyell Jones

P6.431 MuSK (Muscle Specific Kinase) Positive Myasthenia: Grave Prognosis Or Undue Prejudice? —Priyanka Samal, Vinay Goyal, Mamta Singh, Padma Srivastava

180 2018 AAN Annual Meeting

Sleep and Fatigue: Are they related? —Ning

P6.422 Anti-Myelin Oligodendrocyte

Nathan Tagg, Stacey Clardy

Levels in Neuromyelitis Optica Spectrum Disorders with Aquaporin-4 and Multiple Sclerosis —Egemen Idiman, Derya Kaya,

P6.435 Myasthenia Symptom Burden,

Epidemiology and Clinical Characteristics, P6.438 Unusual electrodiagnostic United States, August 2014–August 2017 — feature in patient with severe Myasthenia Tracy Ayers, Adriana Lopez, Anita Kambhampati, Gravis —Karan Tarasaria, Subhendu Rath, Annie Adria Lee, Shannon Rogers, W. Allan Nix, M.

Cacciaguerra, Elisabetta Pagani, Marta Radaelli,

P6.415 Serum IL-27, IL-23 and IL-35

and Neonatal Complications in Argentina. —

Badger, M. Paz Soldan, John Greenlee, John Rose, Event Reporting System (1990-2017) —Nirav Stacey Clardy Sanghani, Rajanigandhi Hanumanthu, Shreya Shah, Nizar Souayah P6.421 Acute Flaccid Myelitis—

Prodromic Phase of Inflammatory Diseases Groshans, M. Paz Soldan, John Greenlee, John or a Distinct Inflammatory Condition? —Laura Rose, Noel Carlson, Sharon Austin, Sean Pittock,

Ju-Hong Min, Jin-Myoung Seok, Eun Bin Cho, Ho Jin Kim, Ha Young Shin, Byung-Jo Kim, Seol-Hee Baek, Hung Youl Seok, Sa-Yoon Kang, Oh-Hyun Kwon, Kwang-Kuk Kim, Young-Min Lim, Sang Soo Lee, Jeeyoung Oh, Eun Hee Sohn, So-Young Huh, Jong Kuk Kim, Byeol-A Yoon, Byoung Joon Kim

Gravis Discharge in a Nationally Representative Sample —Sujata Thawani,

P6.418 Long term outcomes of patients

Disorder (NMOSD) in Active Duty Service Members —Jon Williams, Jonathan Galli, Keith

Omar Isaac Castillo-García, Emmanuel Rodríguez- P6.414 Long term Mortality in Chávez, Marco Diaz, Sarah Vargas, Veronica Rivas, Neuromyelitis Optica Spectrum Disorder — Teresa Corona Vazquez, Jose Flores-Rivera Iris Marin Collazo, Brian Weinshenker, Zahra Nasr, P6.405 Neuromyelitis Optica Spectrum Alfonso Lopez

Disorders Presenting with Area Postrema and Acute Brainstem Syndromes with Concomitant Myasthenia Gravis —Jeffrey

P6.416 A Report of Seronegative

P6.412 Are Recurrent Myelitis a

Neuromyelitis Optica (NMO), Relapsing Vittorio Martinelli, Giancarlo Comi, Massimo Remitting Multiple Sclerosis (RRMS) And Filippi, Maria Rocca Systemic Autoimmunity. —Ashwaq Alshahrani, P6.413 The Analysis of Association Khalid Alqadi, Ahmed Hassan, Abdullah Alkutbi, Between the Disability and Multiple Mervat Al Reyo, Omar Wazzan, Youssef Al Said, Edward Cupler Autoantibodies in Neuromyelitis Optica Spectrum Disorder (NMOSD) —Hyelim Lee, P6.403 Unusual Presentation of Neuromyelitis Optica Spectrum Disorder (NMOSD) —Pritikanta Paul, Noor Pirzada

Friday, April 27 11:30 a.m.–5:30 p.m.

and Without Cancer: Clinical Characteristics and Long-term Survival —Shruti Raja, Vern Juel, Janice Massey, Lisa Hobson-Webb, Jeff Guptill, Karissa Gable, Donald Sanders

P6.445 Treatment Refractory Ocular

Symptoms in Myasthenia Gravis: Clinical and Therapeutic Profile —Bhavana Sharma,

Mamatha Pasnoor, Mazen Dimachkie, Richard Barohn, Omar Jawdat, Melanie Glenn, Constantine Farmakidis, Duaa Jabari

P6.446 Perioperative management of

myasthenia gravis patients undergoing general anesthesia, a survey from multiple institutions. —Sarah Madani, Bradley Howell, Kavita Grover

POSTER SESSIONS

Presenters Stand by Posters 4:00 p.m. to 5:30 p.m. P6.447 Disposition of Patients Diagnosed (1998-2014) —Janaki Patel, Shuja Sheikh, Abu with Myasthenia Gravis Crisis, a New York State Planning and Research Cooperation System Database Analysis (1998-2014) — Shuja Sheikh, Janaki Patel, Abu Nasar, Nizar Souayah

P6.448 Cognitive Biases at Bedside

Resulting in Diagnostic Error of Myasthenia Gravis —Natalie Kukulka, Shalvinder Seehra,

Rohit Gummi, Pradeep Bollu, Fang Zhang, Raghav Govindarajan

P6.449 An Atypical Presentation

of Congenital Myasthenic Syndrome Masquerading as Acquired Myasthenia Gravis —Tijil Agarwal, Michael Palm, Ratna Bhavaraju-Sanka, Carlayne Jackson

P6.450 Severe Exacerbation of

Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy —Dana

Cooper, Matthew Meriggioli, Philip Bonomi, Rabia Malik

P6.451 Description of a Myasthenia

Gravis population from a referral SouthAmerican center. —Valeria Alvarez, Valeria Lujan Salutto, Claudio Mazia

P6.452 3,4 DAP (FIRDAPSE) Improves

Progressive Dok-7 Congenital Myasthenic Syndrome (CMS) Weakness: Clinical Experience in Two Patients —Shoichi Shimamoto, Goran Rakocevic

P6.453 Fifty Years of Steroid Treatment of Myasthenia Gravis —Charles Cape

P6.454 Congenital Myasthenic

Syndrome with Tubular Aggregates and Agrin Mutations —Francis Huttinger, John DeWitt, Maria Martinez-Lage, Reza Sadjadi

P6.455 Myasthenia Gravis Therapeutic Intervention Charges Comparison. A New York State Planning and Research Cooperation System Database Analysis

Nasar, Nizar Souayah

P6.463 The Palmomental reflex Predicts Earlier Corticobulbar Involvement in ALS —

P6.456 Tacrolimus Inhibits Th1 and Th17

Noga Arwas, Ari Leshno, Marc Gotkine

Li, Melissa Russo, Janice Massey, Vern Juel, Lisa Hobson-Webb, James Howard, Manisha Chopra, Ashley Pifer, Kristina Balderson, Sommer Ebdlahad, Weibin Liu, Jeff Guptill, John Yi

Edaravone Controlled Clinical Trial Suggest Similar Rates of Decline in King’s Amyotrophic Lateral Sclerosis (ALS) Clinical Staging across Subgroups —Charlotte Merrill,

Responses in MuSK-MG Patients —Yingkai

P6.464 Post-hoc analyses of an

P6.457 Double Trouble: NXP2 mediated

Wendy Agnese, Joseph Palumbo, Gerry Oster,

dermatomyositis presenting in a patient with Rebecca Bornheimer, Ellen Dukes, Jean Hubble myasthenia gravis —Maria Gaughan, Laura P6.465 Ibudilast - Phosphodiesterase Nestor, Janice Redmond Type 4 Inhibitor - Bi-Modal Therapy with Riluzole in Early [ Not Requiring NonP6.458 Comparing the Effectiveness Invasive Ventilation ( NIV ) ] Cohort ( EC of IVIG and PLEX for Treatment of Neuromuscular Disorders —Ehtesham Khalid, ) and Advanced [ Requiring NIV ] ( ANC ) Amyotrophic Lateral Sclerosis ( ALS ) Christopher Lee, Peter Donofrio, Amanda Peltier Patients - Single-Center Adaptive Design P6.459 Effects of early nonsteroidal oral Six-Month Double-Blind ( DB ) - Placeboimmunomodulatory therapy in myasthenia Controlled Phase 1b/2a Epoch Followed gravis —Christine Lu, David Lucido, Stephen by Six-Month Open Label Extension ( OLE ) Scelsa, Daniel MacGowan Epoch, Washout ( WO ) and Post-Washout Epoch ( PWO ) - Final Report and Future ALS III Directions —Benjamin Brooks, Elena Bravver, P6.460 Racial and Ethnic Differences in Mohammed Sanjak, William Bockenek, Scott C Hospital Utilization, Life Saving Procedures Lindblom, Cynthia Lary, Lisa Ranzinger, Allison Newell-Sturdivant, Velma Langford, Scott Holsten, and Palliative Care Among Patients with Amber Ward, Rachel Hillberry, Kathryn Wright, Amyotrophic Lateral Sclerosis (ALS) —Darine Tiffany Williamson, Any Linville, Melissa Johnson, Kassar, Mohammad-Rauf Afzal, Mohtashim Qureshi, Anantha Vellipuram, Ihtesham Qureshi, Mohammad Ghatali, Gustavo Rodriguez, Paisith Piriyawat, Rakesh Khatri, Alberto Maud, Salvador Cruz-Flores

P6.461 Association between

Amyotrophic Lateral Sclerosis and Diabetes Mellitus Type I and II, a New York State Planning and Research Cooperation System Database Analysis (1998-2014) —Abu Nasar,

Nicole Lucas, Nicol Brandon, Joanna Dojillo, Kazuko Matsuda, Yuichi Iwaki, Donna Graves

P6.466 Clinical Course of Pathologically Confirmed Japanese Amyotrophic Lateral Sclerosis, a Retrospective Institute-based Study —Kiyonobu Komai, Chiho Ishida, Kazuya

Takahashi, Atsuro Tagami, Yuko Motozaki, Tokuhei Ikeda

Shuja Sheikh, Nizar Souayah

P6.462 The role of pre-morbid diabetes on developing ALS: A population-based study —Umberto Manera, Fabrizio D’Ovidio, Angelo D’Errico, Paolo Carnà, Andrea Calvo, Giuseppe Costa, Adriano Chio

Friday

AAN.com/view/AM18 181

Visit Booth #2023 at the 2018 AAN Annual Meeting to Learn More About Sunovion Medical Affairs and Our Areas of Research Focus Booth Dates/Times: Sun, April 22

11:30 am – 4:00 pm

mon, April 23

11:30 am – 6:00 pm

Tue, April 24

11:30 am – 4:00 pm

Wed, April 25

11:30 am – 3:00 pm

70TH ANNUAL MEETING EXHIBITORS Abbott AbbVie, Inc. ACADIA Pharmaceuticals Inc. Acorda Therapeutics, Inc. Actelion Pharmaceuticals Ltd ACTRIMS Adamas Pharma Advanced Brain Monitoring National ALS Registry Scientific Commercialization on behalf of Alder Alexion Pharmacueticals Allergan Allergan Medical Affairs Alnylam Pharmaceuticals, Inc. Alzheimer’s Association American Board of Psychiatry and Neurology American Headache Society American Heart/American Stroke Association Amgen/Novartis APDM Wearable Technologies AFTD and FTD Disorders Regsitry Aurora Health Care Bayer Bellin Health Benign Essential Blepharospasm Research Foundation, Inc. Biogen Biogen Medical Biohaven Pharmaceuticals BioMarin Pharmaceutical Boston Scientific BriovaRx Infusion Services CADWELL INDUSTRIES, INC. Cambridge University Press Cape Fear Valley Health Carolinas HealthCare System Catalyst Pharmaceuticals CEFALY Technology Celgene Corporation CEP America Child Neurology Foundation Children’s Hospital Los Angeles Clinical Neurology News.Com CNS Vital Signs COGNISION Cogstate Healthcare Community Health Systems CompHealth Coram / CVS Specialty infusion services Corinthian Health Services, Inc.

Corinthian Reference Lab CorTechs Labs CortiCare CSL Behring CuraScript SD Cytokinetics, Inc. DEMOS MEDICAL DENT Neuroscience Research Center (DNRC) DynaMed Plus/EBSCO Health Eisai Inc. electroCore, LLC Elsevier EMD Serono, Inc. eNeura, Inc. EUROIMMUN Every Body Fitness Frontiers GE Healthcare Genentech, A Member of the Roche Group General Sleep Glut1 Deficiency Foundation Great Lakes NeuroTechnologies Greenwich Biosciences, Inc. Hayes Locums HCA Healix Infusion Therapy Health Monitor Network Houston Methodist Impax Laboratories, Inc. Intermountain Healthcare International Essential Tremor Foundation International Parkinson and Movement Disorder Society (MDS) MS Care Connect Invitae Ionis Pharmaceuticals Ipsen Biopharmaceuticals, Inc. Jackson & Coker Jari Electrode Supply Johns Hopkins University Press KabaFusion Kaiser Permanente - Permanente Medical Groups King-Devick technologies, inc. KRONUS, Inc. LBDA Liftware Lilly LivaNova LocumTenens.com

Lundbeck Managing Epilepsy Well Network Mayo Clinic Mayo Medical Laboratories McGraw-Hill Education McKesson Specialty Health MEDDAY PHARMACEUTICALS MedLink Neurology Medscape Neurology Medtronic Merz Neurosciences Micromedical Technologies, Inc. Mitsubishi Tanabe Pharma America Medical Affairs Mitsubishi Tanabe Pharma America MNG Laboratories Moebius Syndrome Foundation Monteris Medical MotherToBaby Mount Sinai Health System MULTIGON INDUSTRIES,INC. Multiple Sclerosis Foundation Mylan Inc. National Ataxia Foundation National Headache Foundation National Institute of Neurological Disorders & Stroke Natus Neurology Navicent Health Neuro Central Neurocrine Biosciences Medical Affairs Neurocrine Biosciences, Inc. The Neurocritical Care Society Neurology Advisor NEUROLOGY REVIEWS Neurovirtual NIHON KOHDEN AMERICA, INC. NINDS CDE Project Northwell Health Novartis Pharmaceuticals Novocure Inc. Ochsner Health System OhioHealth Oxford University Press Parkview Health PeaceHealth Penn State Health Pfizer PHARNEXT Philips EGI Practical Neurology PracticeLink Prevea Health

Promius Pharma ProtoKinetics Gait Analysis Walkways Providence St Joseph Health Quadrant Biosciences Quest Diagnostics RDL Reference Laboratory Rimed USA, Inc. Riverside Healthcare RMS Medical Products RosmanSearch, Inc. Saint Luke’s Marion Bloch Neuroscience Institute Sanofi Genzyme Saol Therapeutics Sarepta Therapeutics SK life science Society of Vascular and Interventional Neurology Southeast Health Spectrum Health Clinical Neurosciences SpeechVive Springer Strongbridge Biopharma Sun Pharma Neurology Sunovion Sunovion Med Affairs Sunovion PD Supernus Pharmaceuticals, Inc. Tekscan, Inc. Teva CNS THE GUTHY-JACKSON CHARITABLE FOUNDATION OSF HealthCare Illinois Neurological Institute The JAMA Network The Michael J. Fox Foundation for Parkinson’s Research Defeat MSA & The MSA Shoe UBS Financial Services United Council for Neurologic Subspecialties University of Florida Health Upsher-Smith Laboratories, LLC US Bioservices US WorldMeds Variantyx Inc. Weatherby Healthcare Wolters Kluwer Yuma Regional Medical Center

*as of January 19, 2018

AAN.com/view/AM18 183

2018 AWARD RECIPIENTS The research we celebrate, with the recipients below, has generated paradigm-changing discoveries in epilepsy, fundamental insights in multiple sclerosis, and pioneering breakthroughs in pain, to name a few of the transformative advances conceived by these luminaries. We honor those researchers and pay tribute to all those who play a role in the search for cures for brain disease, from mentors to colleagues to those just starting out on their journey. The American Academy of Neurology thanks the American Brain Foundation for its philanthropic support of the American Academy of Neurology’s awards program.

ALLIANCE AWARDS: Founders Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance.

Recipient: Ezequiel Gleichgerrcht, MD Charleston, SC S9: Epilepsy/Clinical Neurophysiology (EEG) I Sunday, April 22, 3:30 p.m.

S. Weir Mitchell Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance.

Recipient: Eric C. Landsness, MD, PhD St. Louis, MO S17: Sleep Monday, April 23, 3:30 p.m.

AMERICAN ACADEMY OF NEUROLOGY PRESIDENT’S AWARD This award is given by the American Academy of Neurology President for outstanding service to the American Academy of Neurology and the profession of neurology.

Recipient: Lisa M. Shulman, MD, FAAN, Baltimore, MD

AMERICAN BRAIN FOUNDATION CHAIR’S AWARD Sponsored by the American Brain Foundation.

Recipient: Richard P. Essey, San Francisco, CA Wednesday, April 25, 6:00 p.m.

ASSOCIATION OF INDIAN NEUROLOGISTS IN AMERICA LIFETIME ACHIEVEMENT AWARD Sponsored by the American Brain Foundation.

Recipient: Vinay Chaudhry, MD, MBA, CPE, FRCP, FAAN Baltimore, MD Monday, April 23, 3:30 p.m.

AWARD FOR CREATIVE EXPRESSION OF HUMAN VALUES IN NEUROLOGY This award is sponsored by the Ethics, Law, and Humanities Committee, a joint committee of the American Academy of Neurology, the American Neurological Association, and the Child Neurology Society.

Recipient: Madaline B. Harrison, MD Charlottesville, VA The 9 o’clock Patient

184 2018 AAN Annual Meeting

A.B. BAKER AWARD FOR LIFETIME ACHIEVEMENT IN NEUROLOGIC EDUCATION Funded by an endowment created by matching funds from the A.B. Baker Family Trust and Novartis Pharmaceuticals.

Recipient: Steven Galetta, MD, FAAN New York, New York

COMMITMENT TO CURES AWARD Sponsored by the American Brain Foundation.

Recipient: DeMaurice Smith Executive Director, NFL Players Association Washington, DC

DREIFUSS-PENRY EPILEPSY AWARD Sponsored by the American Academy of Neurology and endowed by members of the American Academy of Neurology Epilepsy Section; Abbott Laboratories, Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Neuroscience; Ortho-McNeil Neurologics; Pfizer Inc; Shire US, Inc; and UCB Pharma.

Recipient: Kathryn A. Davis, MD, MS, FAES Philadelphia, PA S19: Epilepsy/Clinical Neurophysiology (EEG) II Monday, April 23, 3:30 p.m.

JOHN DYSTEL PRIZE FOR MULTIPLE SCLEROSIS RESEARCH Sponsored by the American Academy of Neurology and National Multiple Sclerosis Society and made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at the National Multiple Sclerosis Society.

Recipient: Frederik Barkhof, MD, PhD Amsterdam, Netherlands S8: Progressive MS Therapies and Age-Dependent Factors in MS Therapy Sunday, April 22, 3:30 p.m.

SHEILA ESSEY AWARD: AN AWARD FOR ALS RESEARCH Sponsored by the American Academy of Neurology, the American Brain Foundation and the ALS Association and supported through the philanthropy of the Essey Family and the ALS Association.

Recipient: Timothy M. Miller, MD, PhD Saint Louis, MO S25: Advances in Amyotrophic Lateral Sclerosis Tuesday, April 24, 3:30 p.m.

NORMAN GESCHWIND PRIZE IN BEHAVIORAL NEUROLOGY

LAWRENCE C. MCHENRY AWARD: AN AWARD FOR THE HISTORY OF NEUROLOGY

Sponsored by the American Academy of Neurology and endowed through Dr. Geschwind’s family, friends, and colleagues; Pfizer Inc; and the Society for Behavioral and Cognitive Neurology.

Sponsored by the American Academy of Neurology.

Recipient: Zachary Miller, MD San Francisco, CA S34: Behavioral and Cognitive Neurology Wednesday, April 25, 3:30 p.m.

WAYNE A. HENING SLEEP MEDICINE INVESTIGATOR AWARD Sponsored by the American Academy of Neurology and endowed by UCB, Inc., Lilly USA, Elite Home Medical & Respiratory, Inc., Raleigh Neurology Associates, and friends of Dr. Wayne A. Hening.

Recipient: Yo-El Ju, MD, MSCI Saint Louis, MO S17: Sleep Monday, April 23, 3:42 p.m.

INTERNATIONAL SCHOLARSHIP AWARD Sponsored by the American Academy of Neurology.

Recipients: Dr. Zemen Tadesse Abu Addis Ababa, Ethiopia Dr. Vafa Alakbarzade Plymouth, United Kingdom Dr. Fabiola De Marchi Novara, Italy Dr. Federico Eberbach Buenos Aires, Argentina Dr. Arunmozhimaran Elavarasi New Delhi, India Dr. Nada Abdelhameed Elsaid Mansoura, Egypt Dr. Clare Angeli Enriquez Manila, Phillipines Dr. Kaushik Gowthaman Chennai, India Dr. Chiseko Ikenaga Tokyo, Japan Dr. Mariano Marrodan Buenos Aires, Argentina

Dr. Sankaranarayanan Muthukani Tamilnadu, India Dr. Divya M. Radhakrishnan New Delhi, India Dr. Gerard Raimon M. Saranza Manila, Phillipines Dr. Elison Sarapura Lima, Peru Dr. Marianna Spatola Barcelona, Spain Dr. Irina Sharinova Moscow, Russia Dr. Chen-chen Tan Qingdao, China Dr. Joseph Kamtchum Tatuene Blantyre, Malawi Dr. Jiangtao Zhang Beijing, China Dr. Susanna M. Zuurbier Amsterdam, The Netherlands

MITCHELL B. MAX AWARD FOR NEUROPATHIC PAIN Sponsored by the American Academy of Neurology and endowed by the United States Cancer Pain Relief Committee, the Mayday Fund, and friends of Dr. Mitchell Max.

Recipient: David M. Simpson, MD, FAAN New York, NY S7: Pain and Palliative Care Sunday, April 22, 3:30 p.m.

Recipient: Bart TH Lutters, BSc Utrecht, Netherlands S39: History of Neurology Thursday, April 26, 1:00 p.m.

MEDICAL STUDENT ESSAY AWARDS: Sponsored by the American Academy of Neurology.

Extended Neuroscience Award Recipient: This award was not given for 2018

G. Milton Shy Award in Clinical Neurology Recipient: Benjamin Wissel Cincinnati, OH P2.468: Functional Neurological Disorders in Parkinson Disease Monday, April 23, 5:30 p.m.

Roland P. Mackay Award in Historical Aspects Recipient: Yi Tong Montreal, QC, Canada P2.469: Ghost in the Machine: Historical Aspects of Irreversible Brain Injury and Brain Death Monday, April 23, 5:30 p.m.

Saul R. Korey Award in Experimental Neurology Recipient: Kristen Martin Burlington, VT P2.470: Discovery of Novel Recessive Genes in a Consanguineous Cohort Using Genotype-phenotype Correlations Monday, April 23, 5:30 p.m.

MOVEMENT DISORDERS RESEARCH AWARD Sponsored by the American Academy of Neurology, the Parkinson’s Foundation, and the American Academy of Neurology Movement Disorders Section and endowed by the Parkinson’s Foundation.

Recipient: Irene Litvan, MD, FAAN La Jolla, CA S18: Movement Disorders: Ataxia and Tremor Monday, April 23, 3:30 p.m.

NEURO-ONCOLOGY INVESTIGATOR AWARD Sponsored by the American Academy of Neurology and supported by friends of Dr. Jerome Posner.

Recipient: Milan Chheda, MD Saint Louis, MO S23: Biologic and Clinical Discoveries in Neuro-oncology Tuesday, April 24, 1:00 p.m.

NEURO-ONCOLOGY SCIENTIFIC AWARD Sponsored by the American Academy of Neurology and supported by friends of Dr. WK Alfred Yung.

Recipient: Scott R. Plotkin, MD, PhD Boston, MA S23: Biologic and Clinical Discoveries in Neuro-oncology Tuesday, April 24, 1:12 p.m. AAN.com/view/AM18 185

2018 AWARD RECIPIENTS NEUROENDOCRINE RESEARCH AWARD Sponsored by the American Academy of Neurology and supported by friends of Dr. Andrew Herzog.

Recipient: Ellen M. Mowry, MD, FAAN Baltimore, MD Neuroendocrinology Section Meeting Wednesday, April 25, 8:15 a.m.

NEUROSCIENCE RESEARCH PRIZE Funded by the American Academy of Neurology.

Recipient: Alex Remnitz Armonk, NY P1.468: Behavioral Lateralization and Scototaxis Unaltered by Near Future Ocean Acidification Conditions in Poecilia Latipinna (Sailfin Molly) Sunday, April 22, 4:00 p.m. Recipient: Jackie Stochel Yorktown Heights, NY P1.469: Utilizing Drug Intervention to Inhibit Delayed Neuronal Death by Migrainous Spreading Depolarizations Sunday, April 22, 4:00 p.m. Recipient: Sarah Hoffman Ossining, NY P1.470: Exacerbated Alzheimer’s Disease Pathology in Female Hippocampus and Frontal Cortex of Tg6799 Mice and Humans Relative to Males Sunday, April 22,4:00 p.m.

CHILD NEUROLOGY NEUROSCIENCE RESEARCH PRIZE Sponsored by the American Academy of Neurology and the Child Neurology Society.

Recipient: Amy Shteyman Great Neck, NY The Language of Facial Expressions: A Neuroimaging Study on How a Smile is Generated and Perceived by Another Person Child Neurology Society Meeting

MICHAEL S. PESSIN STROKE LEADERSHIP PRIZE Sponsored by the American Academy of Neurology and endowed by Dr. Pessin’s family, friends, and colleagues.

Recipient: Glen Jickling, MD, MSC, FRCP(C) Edmonton, AB, Canada S10: Intracerebral and Subarachnoid Hemorrhage Sunday, April 22, 3:30 p.m.

PUBLIC LEADERSHIP IN NEUROLOGY AWARD Sponsored by the American Brain Foundation.

Recipient: Temple Grandin, Ph.D. Fort Collins, CO

186 2018 AAN Annual Meeting

MRIDHA SPIRIT OF NEUROLOGY HUMANITARIAN AWARD Sponsored by the American Brain Foundation and funded through the philanthropy of Dr. and Mrs. Mridha.

Recipient: Aaron L. Berkowitz, MD, PhD Boston, MA Global Health Section Meeting Tuesday, April 24, 12:00 p.m.

POTAMKIN PRIZE FOR RESEARCH IN PICK’S, ALZHEIMER’S, AND RELATED DISEASES Sponsored by the American Academy of Neurology and the American Brain Foundation and funded through the philanthropy of the Potamkin family.

Recipient: David A. Bennett, MD Chicago, IL S2: Clinical Trials and Therapeutic Approaches in Neurodegenerative Diseases Sunday, April 22, 1:00 p.m.

SAFETY AND QUALITY AWARD Sponsored by the American Academy of Neurology.

Recipient: Lily Grossmann, MD, Boston, MA Continuous Anesthesia Protocol for MRI and LP in Children Yi Li, MD, PhD, Worcester, MA Utilization of Ultrasound Guided Lumbar Puncture to Improve the Efficacy and Outcome in an Overweight Patient Population Michael Robers, MD, Phoenix, AZ Improving the Time for Physician Acknowledgement of Send out Labs Mauricio Villamar, MD, Lexington, KY Improvement in Time to Administration of SecondLine Antiseizure Medications After Implementation of an Inpatient Status Epilepticus Alert Protocol

IRWIN SCHATZ AWARD FOR AUTONOMIC DISORDERS Sponsored by the American Academy of Neurology and endowed by Lundbeck, Inc.

Recipient: David S. Goldstein, MD, PhD Bethesda, MD S12: Autonomic Disorders Monday, April 23, 1:00 p.m.

BRUCE S. SCHOENBERG INTERNATIONAL AWARD IN NEUROEPIDEMIOLOGY Sponsored by the American Academy of Neurology and endowed by GlaxoSmithKline, Inc.

Recipient: Fred Sarfo, MD, PhD Kumasi, Ghana S4: Neuroepidemiology: Neurodegeneration, Epilepsy, Cerebrovascular Disease Risks Sunday, April 22, 1:00 p.m.

SLEEP SCIENCE AWARD Sponsored by the American Academy of Neurology and the American Academy of Neurology Sleep Section and endowed by Cephalon, Inc.

Recipient: Bradley F. Boeve, MD Rochester, MN S17: Sleep Monday, April 23, 3:54 p.m.

JON STOLK AWARD IN MOVEMENT DISORDERS FOR YOUNG INVESTIGATORS Sponsored by the American Academy of Neurology and endowed by Kyowa Pharmaceutical, Inc., Lineberry Research, Quintiles, Dr. Dennis Gillings, and VelaPharma.

Recipient: Nandakumar Narayanan, MD, PhD Iowa City, IA S30: Movement Disorders: Dystonia, Chorea, and other Disorders Wednesday, April 25, 1:00 p.m.

H. RICHARD TYLER AWARD Sponsored by the American Academy of Neurology and the American Academy of Neurology History Section.

Recipient: Andrew J. Solomon, MD Burlington, VT History Section Meeting Monday, April 23, 12:00 p.m.

KENNETH M. VISTE JR., MD PATIENT ADVOCATE OF THE YEAR AWARD Sponsored by the American Academy of Neurology and endowed by gifts from Dr. Viste’s colleagues, friends and patients.

Recipient: Oleg Chernyshev, MD, PhD

HAROLD WOLFF-JOHN GRAHAM AWARD Sponsored by the American Academy of Neurology and endowed by Endo Pharmaceuticals.

Recipient: William R. Renthal, MD, PhD Boston, MA S43: Migraine Thursday, April 26, 3:30 p.m.

2018 RESEARCH PROGRAM RECIPIENTS CAREER DEVELOPMENT AWARD Funded by the American Academy of Neurology.

Recipient: Aasef Shaikh, PhD, MD Case Western Reserve University

NEUROSCIENCE RESEARCH TRAINING SCHOLARSHIP Funded by the American Academy of Neurology.

Recipients: Brett McCray, MD, PhD Johns Hopkins University Andrew Findlay, MD Washington University in St. Louis Marianna Spatola, MD Ragon Institute of MGH, MIT, and Harvard

CLINICAL RESEARCH TRAINING SCHOLARSHIP Funded by the American Academy of Neurology.

Recipient: Christopher Benjamin, PhD Yale New Haven Medical Center Matthew Bevers, PhD, MD Massachusetts General Hospital Brigham, Harvard Peter Kang, MD Washington University in St. Louis

PRACTICE RESEARCH TRAINING SCHOLARSHIP Funded by the American Academy of Neurology.

Recipient: Archana Patel, MD Children’s Hospital Boston

SUSAN S. SPENCER CLINICAL RESEARCH TRAINING SCHOLARSHIP Funded by the American Brain Foundation, the American Epilepsy Society, and the Epilepsy Foundation.

Recipient: Hiroki Nariai, MD UCLA Medical Center

CLINICIAN SCIENTIST DEVELOPMENT AWARD IN INTERVENTIONAL NEUROLOGY Funded the American Brain Foundation and the Society of Vascular and Interventional Neurology.

Recipient: Sunil Sheth, MD McGovern Medical School at the University of Texas Health Science Center

CLINICAL RESEARCH TRAINING SCHOLARSHIP IN PARKINSON’S DISEASE Funded by Lundbeck.

Recipient: Krithi Irmady, MD, PhD Clinical Scholar, Rockefeller University Movement Disorders Fellow, Columbia University

188 2018 AAN Annual Meeting

CLINICAL RESEARCH TRAINING SCHOLARSHIP IN NEUROMUSCULAR DISEASE Funded by the American Brain Foundation, and the Muscle Study Group.

Recipient: Davut Pehlivan, MD Baylor College of Medicine

CLINICAL RESEARCH TRAINING SCHOLARSHIPS IN DEMENTIA WITH LEWY BODIES Funded by the American Brain Foundation, and The Mary E. Groff Charitable Trust.

Recipient: Bhavana Patel, MD University of Florida College of Medicine

MCKNIGHT CLINICAL TRANSLATIONAL RESEARCH SCHOLARSHIP IN COGNITIVE AGING AND AGE-RELATED MEMORY LOSS Funded by the McKnight Brain Research Foundation.

Recipients: Brice McConnell, PhD, MD, University of Colorado Denver School of Medicine Kimberly Albert, PhD, Vanderbilt University Medical Center

CLINICAL RESEARCH TRAINING SCHOLARSHIP IN TOURETTE SYNDROME Funded by the American Brain Foundation and the Tourette Association of America.

Recipient: Wissam Georges Deeb, MD University of Florida College of Medicine

CLINICAL RESEARCH TRAINING SCHOLARSHIP IN MUSCULAR DYSTROPHY Funded by the American Brain Foundation and the Muscular Dystrophy Association.

Recipient: Kathrine Nicholson, MD Massachusetts General Hospital, Brigham, Harvard

CLINICAL RESEARCH TRAINING SCHOLARSHIP IN MULTIPLE SCLEROSIS Funded by Sanofi Genzyme and the American Academy of Neurology.

Recipient: Giulia Fadda, MD University of Pennsylvania

CLINICAL RESEARCH TRAINING SCHOLARSHIP IN ALS Funded by The ALS Association.

Recipient: Peter Creigh, MD University of Rochester

P L E A S E

J O I N

U S

A T

COMMITMENT TO

Please join us at Commitment to Cures, the American Brain Foundationâ&#x20AC;&#x2122;s signature annual fundraiser. The American Brain Foundationâ&#x20AC;&#x2122;s mission is to defeat brain disease by supporting research for all brain diseases.

For more information, please visit www.americanbrainfoundation.org/event/commitment2cures/

EXPERIENCE UNIQUE OPPORTUNITIES FOR STUDENTS, RESIDENTS, AND FELLOWS

The AAN Annual Meeting offers a unique experience for students, residents, and fellows with boundless opportunities to get exposure to a variety of interests and career disciplines, and network with leading neurologists and neurology professionals from around the world.

REGISTRATION

MARK YOUR CALENDAR!

FREE for Medical Students

Medical Student Digital Scavenger Hunt

Annual Meeting registration is FREE to medical students, graduate students, and PhD candidates who present a student ID card or are AAN members. Sign up for an AAN complimentary student membership at AAN.com/view/membership.

Saturday, April 21 – Wednesday, April 25, 2018

Every day, students can participate in this digital scavenger hunt by attending three events from a daily list and posting pictures to social media. The first three people to tweet or post will receive a prize.

Only $245 for Junior Residents and Junior Fellows

Young Investigator Program

Annual Meeting registration is only $245 (a more than $800 savings compared to nonmember neurologist registration!) before the March 29, 2018, early registration deadline. Gold Registration—Upgrade to Gold Registration to receive a copy of Annual Meeting On Demand. Some courses require pre-registration, may have a separate registration rate, and are subject to closure due to reaching maximum capacity.

VOLUNTEER OPPORTUNITIES Serve as a program monitor or a workshop volunteer and receive gratis registration. See page 198 » for full details.

Saturday, April 21 – Monday, April 23, 2018 Programming exclusively for young investigators: support your budding career in research with training, networking, and mentoring specifically for medical students and residents.

Medical Student Poster Hall Tour Sunday, April 22 – Friday, April 27, 2018

Students will be invited to sign up to tour the poster hall in a small group with a neurologist. This unique experience allows you to explore the various research topics with a very knowledgeable guide.

Medical Student Symposium: Careers in Neurology Sunday, April 22, 2018

LOOK FOR ANNUAL MEETING GUIDE AT www.aan.com/view/studentsRF

Futures in Research Luncheon

Monday, April 23, 2018, 12:00 p.m.–1:30 p.m. Brings together medical students, trainees, and junior faculty in neurology with leading clinician investigators to learn about a career in research. The program features presentations, a panel of contributors from various research backgrounds, and networking discussions on how to determine a type of career in research, select training programs, and identify funding opportunities. Attendees are invited to participate in Mentoring Sessions.

Faculty and Trainee Reception

Monday, April 23, 2018, 6:00 p.m.–9:00 p.m. Network with your peers and share ideas, honor award recipients during the award presentation, find information about residency programs or on pursuing fellowships and/or careers in neurology academics, research, or practice, and explore exhibits by private practice groups and recruiters/headhunters regarding job opportunities.

190 2018 AAN Annual Meeting

Run/Walk for Brain Research On your mark, get setâ&#x20AC;¦ help cure BRAIN DISEASE! Join your colleagues on Tuesday, April 24, 2018, at 6:30 a.m., for a friendly run/walk. All proceeds will help support brain research. Sign up for the Run/Walk at AAN.com/view/RunWalk18